[{"orgOrder":0,"company":"Pulmatrix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$100.2 million","upfrontCash":"$7.2 million","newsHeadline":"Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"PUR1800","moa":"p38 MAP kinase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0.10000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Pulmatrix \/ Johnson & Johnson Enterprise Innovation","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Antabio","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Pseudomonas elastase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Antabio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Antabio \/ CARB-X","highestDevelopmentStatusID":"1","companyTruncated":"Antabio \/ .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,800.0 million","upfrontCash":"$2,800.0 million","newsHeadline":"Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"BeiGene","amount2":2.7999999999999998,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":2.7999999999999998,"dosageForm":"Injection","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Balance Medical","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Continues NexoBrid\u2019s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Balance Medical","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Balance Medical \/ MediWound","highestDevelopmentStatusID":"10","companyTruncated":"Balance Me.."},{"orgOrder":0,"company":"Indivior","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Drinabant","moa":"CB1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Indivior","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Indivior \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Indivior \/.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$162.0 million","upfrontCash":"$3.0 million","newsHeadline":"Leap, BeiGene Ink Exclusive Antibody Alliance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Leap Therapeutics","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Black Diamond Therapeutics readies IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Mutabilis","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","amount":"$11.9 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings REPAIR Impact Fund Invests USD 12 Million in Mutabilis and IBT Vaccines and Provides Strategic Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Financing","leadProduct":"2G-Dabocins","moa":"Diazabicyclooctanes penicillin-binding proteins","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Mutabilis","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Mutabilis \/ Novo Holdings","highestDevelopmentStatusID":"2","companyTruncated":"Mutabilis .."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","amount":"$180.0 million","upfrontCash":"$9.0 million","newsHeadline":"GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoMimetics \/ Apollomics","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$2,550.0 million","upfrontCash":"$50.0 million","newsHeadline":"Merck Establishes Strategic Oncology Collaboration with Taiho and Astex","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Taiho Pharmaceutical","amount2":2.5499999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.5499999999999998,"dosageForm":"","sponsorNew":"Taiho Pharmaceutical \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Taiho Phar.."},{"orgOrder":0,"company":"NorthShore University HealthSystem","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eagle & NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion & Other Forms of Traumatic Brain Injury.","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"NorthShore University HealthSystem","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NorthShore University HealthSystem \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"NorthShore.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"$2.2 million","newsHeadline":"NanoViricides Receives Cash Infusion of $2.25 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"URUGUAY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"NV-HHV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"NanoViricides \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Yisheng Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The alliance is aimed at co-developing a combination therapy of YS-ON-001\/002 and Tavo-201\/203 for cancer treatment.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Tavo-201","moa":"CD4+ T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tavotek Biotherapeutics \/ Yisheng Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Bi.."},{"orgOrder":0,"company":"University of California","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"iPSC CAR NK cells","moa":"Chimeric antigen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Nocion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"PUR1800","moa":"p38 MAP kinase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pulmatrix \/ Nocion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"ImmuNext Inc","sponsor":"Curis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies \\n-","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Onvatilimab","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuNext Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmuNext Inc \/ Curis","highestDevelopmentStatusID":"6","companyTruncated":"ImmuNext I.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Announces Research Collaboration With CSL Behring","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$20.0 million","newsHeadline":"Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Cancer Research UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle\u00ae Immuno-oncology Candidate, BT7401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"BT7401","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"8","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Synaffix","sponsor":"Shanghai Miracogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody drug conjugate linker","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Synaffix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synaffix \/ Shanghai Miracogen","highestDevelopmentStatusID":"1","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Biosolution","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mundipharma, Biosolution to market CartiLife in South Korea","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mundipharma \/ Biosolution Co. Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"BioIntervene","sponsor":"MPM Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"MPM backs new biotech in the hunt for non-opioid painkiller","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"BIO-205","moa":"A3AR","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioIntervene","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"BioIntervene \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"BioInterve.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tarsus Pharmaceuticals Raises $60 Million in Series B Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"TP-03","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Topical","sponsorNew":"Tarsus Pharmaceuticals \/ Vivo Capital","highestDevelopmentStatusID":"9","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"PeriphaGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Candel Therapeutics acquires next-generation herpes drug development platform and manufacturing expertise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"rQNestin34.5","moa":"ICP34.5 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Candel Therapeutics \/ PeriphaGen, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Candel The.."},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TG01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Altavant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"OSP-101","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Altavant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Altavant Sciences \/ Altavant Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Altavant S.."},{"orgOrder":0,"company":"Xencor","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and Gilead Enter License Agreement for Use of XmAb\u00ae Antibody Technologies in Investigational Agents for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GS-9722","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ G.."},{"orgOrder":0,"company":"Certara","sponsor":"Galderma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Certara Partners with Galderma in Advancing Modeling and Simulation Technology to Attain FDA Approval of AKLIEF\u00ae Topical Acne Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Certara","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Certara \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Certara \/ .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF\/MEK Inhibitor CH5126766","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Verastem Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Serum Institute of India Private Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute and Aragen Bioscience Announce Collaboration on Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CHO-DG44","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aragen Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aragen Life Sciences \/ Serum Institute of India Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"Aragen Lif.."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$15.5 million","upfrontCash":"Undisclosed","newsHeadline":"Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent and Treat Serious Respiratory Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series C Financing","leadProduct":"AT-100","moa":"IL-8","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Airway Therapeutics","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"NorthSea Therapeutics","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"Icosabutate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NorthSea Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"NorthSea Therapeutics \/ venBio Partners","highestDevelopmentStatusID":"8","companyTruncated":"NorthSea T.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Kitov Pharma","pharmaFlowCategory":"D","amount":"$13.5 million","upfrontCash":"$13.5 million","newsHeadline":"Kitov Pharma Announces Closing of FameWave Acquisition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Kitov Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$69.0 million","upfrontCash":"Undisclosed","newsHeadline":"China\\'s Adagene bags $69M to advance lead immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series D Financing","leadProduct":"Adg106","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adagene Suzhou Limited","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Adagene Suzhou Limited \/ General Atlantic","highestDevelopmentStatusID":"6","companyTruncated":"Adagene Su.."},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerebral Therapeutics Completes $35 Million Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"Sodium Valproate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral T.."},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"$62.0 million","upfrontCash":"$15.0 million","newsHeadline":"Almirall enters into an option agreement to acquire Bioniz Therapeutics and to establish a broad research agreement to further expand its innovative pipeline in medical dermatology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"BNZ-1","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Bioniz Therapeutics \/ Almirall, S.A","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz The.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall and WuXi Biologics sign strategic collaboration agreement for multiple bispecific antibodies targeting dermatology diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibody","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Almirall, S.A","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"23andMe","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL-36 cytokine","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific Monoclonal Antibody","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"23andMe \/ Almirall, S.A","highestDevelopmentStatusID":"4","companyTruncated":"23andMe \/ .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Immunic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunic Exercises Option to License Daiichi\u2019s IMU-856","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IMU-856","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Immunic","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Avacta Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avacta, Daewoong Form Immunotherapy JV","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Avacta Group","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"ProBioGen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen inks next Commercial GlymaxX\u00ae License with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GlymaxX","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProBioGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProBioGen \/ Roche","highestDevelopmentStatusID":"1","companyTruncated":"ProBioGen .."},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec and BMS Expand IPSC Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Induced pluripotent stem cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Evotec","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Evotec \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Vickers Venture Partners","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Emergex completes \u00a38.4m Series A vaccines funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Set-point vaccines","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Emergex Vaccines Holding","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Emergex Vaccines Holding \/ Vickers Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Pfenex","sponsor":"Serum Institute of India Private Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL\u00ae, containing CRM197 produced in Pfenex Expression Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"CRM197","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfenex","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfenex \/ Serum Institute of India Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Pfenex \/ S.."},{"orgOrder":0,"company":"Rockefeller University","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Elipovimab","moa":"gp41","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Rockefeller University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rockefeller University \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Rockefelle.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","amount":"$71.5 million","upfrontCash":"Undisclosed","newsHeadline":"Infinity Pharmaceuticals Raises $20 Million Through an Innovative Non-Dilutive Asset-Backed Financing from BVF","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Financing","leadProduct":"Eganelisib","moa":"PI3K-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ BVF Partners L.P","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Enleofen Bio Pte","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"SINGAPORE","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Enx108A","moa":"IL-11","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Enleofen Bio Pte","amount2":1,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Enleofen Bio Pte \/ Boehringer Ingelheim","highestDevelopmentStatusID":"5","companyTruncated":"Enleofen B.."},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement Focused on Cell-Specific Delivery of Antisense Oligonucleotides","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Centyrins","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aro Biotherapeutics","amount2":1.3999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Aro Biotherapeutics \/ Ionis Pharmaceuticals, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Aro Biothe.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","amount":"$143.2 million","upfrontCash":"$11.1 million","newsHeadline":"Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA receptor A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Acacia Pharma","amount2":0.14000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.14000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals N.V.","highestDevelopmentStatusID":"10","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Abingworth","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jasper Therapeutics Announces Expansion of Series A Financing, Bringing Total Corporate Fundraising to More than $50 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"JSP191","moa":"CD117","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Jasper Therapeutics \/ Abingworth","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BTIG","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Matinas BioPharma Announces Proposed Public Offering of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"MAT9001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Matinas BioPharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Matinas BioPharma \/ BTIG","highestDevelopmentStatusID":"5","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptinyx Announces Proposed Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"NYX-2925","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"ArTara Therapeutics","sponsor":"Proteon Therapeutics","pharmaFlowCategory":"D","amount":"$42.5 million","upfrontCash":"Undisclosed","newsHeadline":"ArTara Therapeutics Completes Merger Transaction with Proteon Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Merger","leadProduct":"Penicillin G Potassium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ArTara Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"ArTara Therapeutics \/ Proteon Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"ArTara The.."},{"orgOrder":0,"company":"Sapphire Biotech","sponsor":"AXIM Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AXIM\u00ae Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Cannabinoid-like molecules","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sapphire Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapphire Biotech \/ AXIM Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"Sapphire B.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$507.0 million","upfrontCash":"$15.0 million","newsHeadline":"eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"eIF4E","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Effector Therapeutics","amount2":0.51000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.51000000000000001,"dosageForm":"","sponsorNew":"Effector Therapeutics \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Genethon","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genethon strengthens its collaboration with Sarepta Therapeutics for the development of the gene therapy product GNT0004 in Duchenne muscular dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"GNT0004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Genethon","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genethon \/ Sarepta Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Genethon \/.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Tucidinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HUYA Bioscience International \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$417.0 million","upfrontCash":"$45.0 million","newsHeadline":"Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ACT-709478","moa":"T-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Idorsia Pharmaceuticals","amount2":0.41999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"Oral","sponsorNew":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Alderaan Biotechnology","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"French Biotech Raises \u20ac19M to Hit Phase I with Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alderaan Biotechnology","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Alderaan Biotechnology \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Alderaan B.."},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Oxalate","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0.029999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Novome Biotechnologies \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Novome Bio.."},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Alta Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tyra Biosciences raises $50M to develop therapies targeting acquired resistance in oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tyra Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tyra Biosciences \/ Alta Partners","highestDevelopmentStatusID":"1","companyTruncated":"Tyra Biosc.."},{"orgOrder":0,"company":"BW Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BW Therapeutics Announces Opening Of Series A Round And Strategic Partnering Initiatives","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BW Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BW Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BW Therape.."},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"PACT Pharma Raises $75M in Oversubscribed Series C Financing to Develop Fully Personalized NeoTCR-T Cell Therapies for Patients with Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series C Financing","leadProduct":"NeoTCR-T cell","moa":"CD8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"PACT Pharma \/ Vida Ventures","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharm.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Gemphire Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroBo Pharmaceuticals to Focus on Advancing Clinical Stage Pipeline for Neurodegenerative Diseases lead drug candidate, lead drug candidate,","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Merger","leadProduct":"NB-01","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Gemphire Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Teoxane SA","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Teoxane SA","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Teoxane SA \/ Revance Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Teoxane SA.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Chinook Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Axitinib","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nektar Therapeutics \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Beijing Aosaikang Pharmaceutical","pharmaFlowCategory":"D","amount":"$62.8 million","upfrontCash":"$11.4 million","newsHeadline":"China licence agreement for Feraccru\/Accrufer","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Maltol","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Shield Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Shield Therapeutics \/ Beijing Aosaikang Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shield The.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Knight Partners With Debiopharm for the Commercialization of Trelstar\u00ae in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Debiopharm \/ Knight Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Eyevensys","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyevensys Closes $30M Series B Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"EYS606","moa":"TNF alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eyevensys","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Eyevensys \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"Eyevensys .."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"7","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Codexis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis and Nestl\u00e9 Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Codexis","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codexis \/ Nestle Health Science","highestDevelopmentStatusID":"2","companyTruncated":"Codexis \/ .."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"PB2452","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"NBE Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"NBE-Therapeutics Closes USD 22M Series C Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series C Financing","leadProduct":"NBE-002","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NBE Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"NBE Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"6","companyTruncated":"NBE Therap.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Lilly Announces Agreement to Acquire Dermira","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Amunix","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,540.0 million","upfrontCash":"$40.0 million","newsHeadline":"Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Polypeptides","moa":"scFvs","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Amunix","amount2":1.54,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.54,"dosageForm":"","sponsorNew":"Amunix \/ Roche","highestDevelopmentStatusID":"1","companyTruncated":"Amunix \/ R.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance\u00ae (palbociclib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"ZW25","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zymeworks \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IOV-3001","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Biose","sponsor":"Biomica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"BMC121","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biose","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biose \/ Biomica","highestDevelopmentStatusID":"4","companyTruncated":"Biose \/ Bi.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Oncologie","pharmaFlowCategory":"D","amount":"$306.0 million","upfrontCash":"$4.0 million","newsHeadline":"Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"DLL4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mereo BioPharma Group","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Oncologie","highestDevelopmentStatusID":"6","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kyverna Therapeutics Secures $25 Million Series A Funding","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"T cells therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$587.5 million","upfrontCash":"$17.5 million","newsHeadline":"Kyverna Therapeutics Enters into Strategic Collaboration with Gilead Sciences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"T cells therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kyverna Therapeutics","amount2":0.58999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kyverna Th.."},{"orgOrder":0,"company":"Qiagen","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qiagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qiagen \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Qiagen \/ A.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Enters into OmniAb\u00ae Platform License Agreement with Pandion Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ Pandion Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adare Pharmaceuticals and NLS Pharmaceutics Collaborate to Develop Mazindol Controlled Release (CR) for the Treatment of ADHD and Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Mazindol","moa":"MAO transporter","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Adare Pharma Solutions","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Adare Pharma Solutions \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Adare Phar.."},{"orgOrder":0,"company":"Crestone","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crestone, Inc. (Boulder) Secures CFF Funding for Preclinical Development of Novel Antibiotic to Treat NTM Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"MmpL3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crestone \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer\u2019s Disease in Collaboration With University of Pennsylvania","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Pennsylvania","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Pennsylvania \/ Eagle Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Codagenix Raises $20 Million in Series B Funding for Continued Development of RSV, Influenza and Oncolytic Virus Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"Respiratory syncytial virus vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codagenix","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Codagenix \/ Adjuvant Capital","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$750.0 million","newsHeadline":"MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MorphoSys","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"MorphoSys \/ Incyte","highestDevelopmentStatusID":"9","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","amount":"$331.0 million","upfrontCash":"$3.0 million","newsHeadline":"Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer\u2019s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate.","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0.33000000000000002,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Axsome Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coherus Acquires Commercial Rights for Avastin\u00ae Biosimilar in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Coherus BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$710.0 million","upfrontCash":"$75.0 million","newsHeadline":"Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer\u2019s Disease and Parkinson\u2019s Disease from Pfizer Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"PF-05251749","moa":"CK1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0.70999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.70999999999999996,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Apotex Inc","sponsor":"CHIESI USA INC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox\u00ae (deferiprone)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Deferiprone","moa":"Iron","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Apotex Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Apotex Inc \/ Chiesi Group","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Inc.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iovance Biotherapeutics to license certain TALEN technology from Cellectis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tumor infiltrating lymphocytes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"NCK AS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ NCK A\/S.","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"KinoPharma","sponsor":"Aska Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASKA Pharmaceutical Co., Ltd. and KinoPharma, Inc. Enter into Option Agreement for Treatment of Cervical Dysplasia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"RKP00156","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"KinoPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KinoPharma \/ ASKA Pharmaceutical Co.","highestDevelopmentStatusID":"6","companyTruncated":"KinoPharma.."},{"orgOrder":0,"company":"TAXIS Pharmaceuticals","sponsor":"Boston University","pharmaFlowCategory":"D","amount":"$14.6 million","upfrontCash":"$3.2 million","newsHeadline":"TAXIS Pharmaceuticals Announces CARB-X Award of $3.2 Million, With Potential for an Additional $11.4 Million, to Develop Efflux Pump Inhibitors (EPIs), a New Drug Class to Defeat Multi-Drug Resistant Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"TXA709","moa":"Efflux pump","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TAXIS Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"TAXIS Pharmaceuticals \/ Boston University","highestDevelopmentStatusID":"6","companyTruncated":"TAXIS Phar.."},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic\u00ae in India","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Rockwell Medical","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Rockwell Medical \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Rockwell M.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clinigen signs agreement with Iovance Biotherapeutics to supply Proleukin\u00ae (aldesleukin) for use in Tumor Infiltrating Lymphocyte (TIL) Clinical R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Aldesleukin","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinigen Group \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"V\u03b39V\u03b42 T cells based antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ ProBioGen AG","highestDevelopmentStatusID":"1","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"George Washington University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aprepitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"George Washington University","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"George Washington University \/ Hoth Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"George Was.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco","pharmaFlowCategory":"D","amount":"$113.0 million","upfrontCash":"$60.0 million","newsHeadline":"Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0.11,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"Health Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dalton Expands Cannabinoids Capabilities","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Dalton Pharma Services","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Dalton Pharma Services \/ Health Canada","highestDevelopmentStatusID":"12","companyTruncated":"Dalton Pha.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Bayer enter into acquisition agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Koate DVI","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ WuXi Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$10.2 million","upfrontCash":"Undisclosed","newsHeadline":"Phage Therapy Firm APT Lands DoD Contract for Antibiotic Alternative","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Phage-based therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Bonus BioGroup","pharmaFlowCategory":"D","amount":"$7.4 million","upfrontCash":"Undisclosed","newsHeadline":"Wize Pharma Executes Agreements for Strategic Transaction with Bonus BioGroup","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Wize Pharma","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Eye Drop","sponsorNew":"Wize Pharma \/ Bonus BioGroup","highestDevelopmentStatusID":"12","companyTruncated":"Wize Pharm.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"ArQule","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$2,700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Merck Completes Acquisition of ArQule","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"ARQ 531","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ArQule","amount2":2.7000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":2.7000000000000002,"dosageForm":"Oral","sponsorNew":"ArQule \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"ArQule \/ M.."},{"orgOrder":0,"company":"Evotec","sponsor":"OncoResponse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Just \u2013 Evotec Biologics announces product development and manufacturing agreement with OncoResponse","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"OR2805","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ OncoResponse","highestDevelopmentStatusID":"7","companyTruncated":"Evotec \/ O.."},{"orgOrder":0,"company":"Neon Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"$67.0 million","newsHeadline":"BioNTech to acquire Neon to strengthen global leadership position in T cell therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"NEO-STC-01","moa":"RAS neoantigen","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Neon Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Neon Therapeutics \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Neon Thera.."},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PANTHERx\u00ae Rare Pharmacy Selected by Blueprint Medicines Corporation to Distribute AYVAKIT\u2122 (avapritinib) for Genomically Defined Patient Population with Rare Cancer, GIST","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PANTHERx Rare Pharmacy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PANTHERx Rare Pharmacy \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"PANTHERx R.."},{"orgOrder":0,"company":"AgilVax","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"AgilVax Announces Expansion of Series A-1 Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Monoclonal antibody-based therapy","moa":"SLC7A11\/xCT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AgilVax","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"AgilVax \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AgilVax \/ .."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"TB Alliance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pretomanid","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ TB Alliance","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Revolution Med shoots for $100M+ IPO \u2014 and divulges some secrets about that Warp Drive buyout","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"Vociprotafib","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"China Medical System","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus inks pact with China Medical System to market Desidustat in Greater China","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Desidustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ China Medical System","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Seekyo","sponsor":"French Tech Seed","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"BIOTECH START-UP SEEKYO RAISES \u20ac800K WITH LEVERAGE FROM FRENCH TECH SEED FUND","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"SKY01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Seekyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seekyo \/ French Tech Seed","highestDevelopmentStatusID":"4","companyTruncated":"Seekyo \/ F.."},{"orgOrder":0,"company":"Betagenon","sponsor":"Ivy Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"China-Based Ivy Capital Invests in Betagenon\\'s Clinical Stage AMPK Activator Program","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"O304","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Betagenon","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betagenon \/ Ivy Capital","highestDevelopmentStatusID":"8","companyTruncated":"Betagenon .."},{"orgOrder":0,"company":"Contract Sales Organization","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Provides Update on its Commercialization Plan for its OTC DIN and NHP Product Programs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Triethanolamine Salicylate","moa":"COX-2","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Contract Sales Organization","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Contract Sales Organization \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Contract S.."},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Rumpus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinical Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Denovo Biopharma \/ Rumpus Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Bio.."},{"orgOrder":0,"company":"Ncardia","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Cardiomyocytes","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Ncardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ncardia \/ BlueRock Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Ncardia \/ .."},{"orgOrder":0,"company":"Seagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seattle Genetics Achieves Milestone Following European Commission Approval of Roche\u2019s Polivy\u00ae (Polatuzumab Vedotin)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ R.."},{"orgOrder":0,"company":"Inotrem","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Nangibotide","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Roche Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Entera Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma to Focus Commercial Efforts on Talicia\u00ae and Aemcolo\u00ae; Discontinuing Promotion of Legacy Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Termination","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Entera Health","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Xellia Pharmaceuticals ApS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen\u00ae (phenylephrine HCl) Co-Promotion Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Phenylephrine HCl","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Xellia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"HepaRegeniX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$12.2 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer, Novo-backed German biotech banks \u20ac11M in liver regeneration push","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Mapk4","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"HepaRegeniX","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"HepaRegeniX \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"1","companyTruncated":"HepaRegeni.."},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Merger","leadProduct":"Galacto-oligosaccharide","moa":"Lactase enzyme","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen","highestDevelopmentStatusID":"9","companyTruncated":"Ritter Pha.."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Won & Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Calidi Biotherapeutics raises funds from 2 Korean firms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Supernova 1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Won & Partners","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$200.0 million","newsHeadline":"PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":1,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":1,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Apexian Pharmaceuticals","sponsor":"Ocuphire Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"APX3330","moa":"Ref-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Apexian Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apexian Pharmaceuticals \/ Ocuphire Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Apexian Ph.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$279.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zymeworks Announces Pricing of $279.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"ZW25","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Zymeworks \/ J.P. Morgan Securities","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Armistice Capital","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Tetraphase Pharmaceuticals Announces $17.5 Million of Financings Priced At-the-Market","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Financing","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ Armistice Capital","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Boxcar PMJ","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immuneering Raises $20 Million in Oversubscribed Series A Funding","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"KRAS","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Immuneering Corporation","amount2":0.02,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Immuneering Corporation \/ Boxcar PMJ","highestDevelopmentStatusID":"1","companyTruncated":"Immuneerin.."},{"orgOrder":0,"company":"IGL Pharma","sponsor":"Q2Earth","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q2Earth Signs Exclusive Option Agreement to License Promising Drug to Treat Bone Cancer in Children","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Samarium Sm-153","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"IGL Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IGL Pharma \/ Q2Earth","highestDevelopmentStatusID":"1","companyTruncated":"IGL Pharma.."},{"orgOrder":0,"company":"Skysong Innovations","sponsor":"Sapphire Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AXIM\u00ae Biotechnologies Acquiree Sapphire Biotech, Inc. Signs License Agreement to Exclusively License Patent Rights in Cancer Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SBI-183","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Skysong Innovations","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Skysong Innovations \/ Sapphire Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Skysong In.."},{"orgOrder":0,"company":"Genmab","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genmab Announces 2019 Net Sales Figures for DARZALEX\u00ae (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ Janssen Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ J.."},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korean Investment Partners","pharmaFlowCategory":"D","amount":"$22.2 million","upfrontCash":"Undisclosed","newsHeadline":"PDC*line Pharma Raises \u20ac20 Million in Series B Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"PDC lung01","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDC*line Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"PDC*line Pharma \/ Korean Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"PDC*line P.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bellicum Enters Asset Purchase Agreement with MD Anderson","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Ro","sponsor":"Greenstone LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer\u2019s Greenstone and Digital Men\u2019s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra\u00ae (sildenafil citrate)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ro","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ro \/ Greenstone","highestDevelopmentStatusID":"12","companyTruncated":"Ro \/ Green.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Metoclopramide","moa":"5-HT4 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$72.5 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Ridinilazole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Summit Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Ionctura","sponsor":"INKEF Capital","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"iOnctura Raises EUR 15 Million in Series A Financing to Progress its Pipeline into Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"IOA-244","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Ionctura \/ INKEF Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Teva Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergan keeps Linzess generics out until 2029 with Teva settlement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Linaclotide","moa":"Guanylate cyclase?C","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan Aesthetics \/ Teva Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amgen Astellas Biopharma to Become a Wholly Owned Amgen Affiliate","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"DemeRx","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Financing","leadProduct":"Ibogaine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DemeRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DemeRx \/ ATAI Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"DemeRx \/ A.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Divestment","leadProduct":"Brazikumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ ASTRAZENECA","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Helsinn Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT\u00ae\/ALOXI\u00ae and AKYNZEO\u00ae in Russia and CIS region","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Fosnetupitant Chloride","moa":"Neurokinin 1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Berlin Chemie","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Berlin Chemie \/ Helsinn Group","highestDevelopmentStatusID":"12","companyTruncated":"Berlin Che.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"ATNAHS PHARMA UK LIMITED","pharmaFlowCategory":"D","amount":"$390.0 million","upfrontCash":"$350.0 million","newsHeadline":"AstraZeneca divests rights to established hypertension medicines","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Divestment","leadProduct":"Propranolol Hydrochloride","moa":"Adrenergic receptor beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.39000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.39000000000000001,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Atnahs Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Synthorx","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi announced today the successful completion of its acquisition of Synthorx, Inc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"THOR-707","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthorx","amount2":2.5,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2.5,"dosageForm":"","sponsorNew":"Synthorx \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Synthorx \/.."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Biotheus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TILT-123","moa":"TNF-alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Biotheus","highestDevelopmentStatusID":"6","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"Bill & Melinda Gates Medical Research Institute","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"M72\/AS01E","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bill & Melinda Gates Medical Research Institute","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bill & Melinda Gates Medical Research Institute \/ GlaxoSmithKline","highestDevelopmentStatusID":"8","companyTruncated":"Bill & Mel.."},{"orgOrder":0,"company":"National Comprehensive Cancer Network","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NCCN Oncology Research Program to Oversee Trials of the FGFR Inhibitor Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"National Comprehensive Cancer Network","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Comprehensive Cancer Network \/ Taiho Oncology","highestDevelopmentStatusID":"8","companyTruncated":"National C.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata\\'s Bacteriophage Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Financing","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$17.3 million","upfrontCash":"Undisclosed","newsHeadline":"Vascular Therapies Completes Upsized $17.3 Million Private Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Financing","leadProduct":"Sirolimus","moa":"T lymphocyte","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular T.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioPharmX And Timber Pharmaceuticals Announce Entry into Merger Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Timber Pharmaceuticals \/ Timber Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"BioLexis Pte. Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ BioLexis Pte. Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Cell Therapies","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kymriah\u00ae To Be Manufactured at Cell Therapies Pty Ltd, Marking Australia\u2019s First On-Shore Commercial Production of CAR T therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Cell Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cell Therapies \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Cell Thera.."},{"orgOrder":0,"company":"BravoVax","sponsor":"GeoVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BravoVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BravoVax \/ GeoVax","highestDevelopmentStatusID":"1","companyTruncated":"BravoVax \/.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX\u00ae (cabozantinib) for Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Exelixis \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"$343.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytRx Corporation","amount2":0.34000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"CytRx Corporation \/ ImmunityBio","highestDevelopmentStatusID":"6","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Parkinson\u2019s Foundation","sponsor":"Zelira Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zelira Therapeutics collaborates with Parkinson\\'s Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Cannabinoid-based Product","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Parkinson\u2019s Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Parkinson\u2019s Foundation \/ Zelira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Parkinson\u2019.."},{"orgOrder":0,"company":"Theraly Fibrosis","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Theraly Fibrosis Awarded $3.9 Million SBIR Phase II Grant to Support Development of TLY012 for Chronic Pancreatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"TLY012","moa":"DR5","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Theraly Fibrosis","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Theraly Fibrosis \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Theraly Fi.."},{"orgOrder":0,"company":"Locust Walk","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Brilacidin","moa":"PDE4","url1":"","url2":"","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Locust Walk","amount2":0,"therapeuticAreaNew":"Dental and Oral Health","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Locust Walk \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Locust Wal.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$201.0 million","upfrontCash":"Undisclosed","newsHeadline":"Versant Ventures Announces Successful IPO by Black Diamond Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Minister of Economy and Research","pharmaFlowCategory":"D","amount":"$16.4 million","upfrontCash":"Undisclosed","newsHeadline":"iTeos Therapeutics Awarded \u20ac15 Million in Non-Dilutive Funding by the Walloon Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"EOS-850","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Minister of Economy and Research","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Funding","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"BioCorRx","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Implant","sponsorNew":"BioCorRx \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JT to market CORECTIM in Japan to treat atopic dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Torii Pharmaceutical \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Torii Phar.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza Expands Partnership with Rocket Pharmaceuticals for Childhood Disorder Treatment","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"RP-L201","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Lonza","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"GeNeuro","sponsor":"Bryan, Garnier & Co","pharmaFlowCategory":"D","amount":"$19.3 million","upfrontCash":"Undisclosed","newsHeadline":"GeNeuro Announces Successful \u20ac17.5 Million Private Placement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Private Placement","leadProduct":"Temelimab","moa":"HERV-W","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"GeNeuro","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"GeNeuro \/ Bryan, Garnier & Co","highestDevelopmentStatusID":"8","companyTruncated":"GeNeuro \/ .."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"$330.0 million","newsHeadline":"Sandoz completes acquisition of Aspen\u2019s Japanese operations, strengthening its position in world\u2019s third largest market for generics and off-patent medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.44,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.44,"dosageForm":"Intravenous Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Onc-392","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Na\u00efve Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Itacitinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT211","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acura Pharmaceuticals Provides an Update on the Development of LTX-03","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydrocodone Bitartrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Acura Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acura Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Acura Phar.."},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadimastem reports positive ALS cell therapy results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AstroRx","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SGT-210","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Phase 2 Study of TJ202\/MOR202 in Multiple Myeloma in Mainland China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme reports positive arimoclomol data from open-label phase 2\/3 extension in Niemann-Pick disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RHB-106","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CK-3773274","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA\u2019s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"HBV immunogen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b\/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Fisogatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T\u2122 in Patients with Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-3006","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"IN10018","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New IND Per Year for the Next 5 Years","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TG4050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Escape Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESCAPE Bio Announces Excellent Safety and Tolerability in Phase 1 Study of Oral S1P5 Receptor Agonist ESB1609","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ESB1609","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Escape Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Escape Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Escape Bio.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Sirnaomics Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining Sintilimab and RNAi in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR\u2122 Therapy for Relapsed or Refractory T-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GC027","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Pharma Conducts Strategic Inlicensing of Clinical Phase Drug Candidate for Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces Plan for Global Phase III Head and Neck Cancer Registration Trial Along With Overall Development Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Carmell Therapeutics Receives IND Clearance for CT-101, Bone Healing Accelerant","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium Phosphate","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carmell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Th.."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dibuprenorphine-ethyl-ether","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS and University of Saskatchewan Partner to Conduct Cannabinoid-Based Research on Possible Treatment of Brain Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabis derivatives","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Significant Progress on LAM-001 and LAM-004 Programs","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AI Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therape.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis climbs as its drug beats Alexion's Soliris in phase 3","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Locus Biosciences initiates world\\'s first controlled clinical trial for a CRISPR enhanced bacteriophage therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"LBP-EC01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Locus Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Locus Bios.."},{"orgOrder":0,"company":"Invectys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I clinical trial results published for Invectys DNA Vaccine for Cancer using PharmaJet Needle-free injector","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"INVAC-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Invectys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Invectys \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Invectys \/.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Commences Phase 1 trial with AGEN1223","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AGEN1223","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Suzhou Connect Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201 \\nD","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Connect Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Suzhou Connect Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Con.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Astellas' sNDA for Expanded Indication of MYCAMINE for Invasive Candidiasis in Children Less Than 4 Months of Age","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Micafungin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Topical Ocular Formulation of Aerpio Pharmaceutical\u2019s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension in Phase 1b Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125\/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"PellePharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Patidegib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PellePharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PellePharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PellePharm.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota\u00ae Therapy for the Prevention of Recurrent C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach for Treatment of All Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ETX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Enterprise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterprise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enterprise.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b\/2a Clinical Trial in Allogeneic HCT Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribaxamase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Promethera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promethera\u00ae Announces Initiation of Phase 2b DHELIVER Study of HepaStem\u2122 in Patients with Acute-on-Chronic Liver Failure (ACLF)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"HepaStem","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Promethera Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Promethera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promethera.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp\\'s Ability to Treat Severe Fungal Infections in the Hospital Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis ligelizumab (QGE031) more effective than Xolair\u00ae at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ligelizumab","moa":"IgE\/Fc Epsilon RI pathway","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MBT5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Quetiapine Hemifumarate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OWP Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharma.."},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allysta Pharmaceuticals, Inc. Doses First Patient with ALY688 Ophthalmic Solution in Phase 1\/2a Dry Eye Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ALY688","moa":"Adiponectin receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Allysta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allysta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Allysta Ph.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-007","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Healios K.K","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healios K.K. to Highlight Its Novel Approach in Regenerative Medicine at the Upcoming 38th Annual J.P. Morgan Healthcare Conference and Biotech Showcase in San Francisco, CA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"HLCM051","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Healios K.K","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Healios K.K \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Healios K..."},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tideglusib","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AMO Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AMO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AMO Pharma.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1647","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac\u00ae Meets Primary and Secondary Endpoints","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sci-B-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-tolerated in Healthy Volunteers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Foralumab","moa":"CD3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Announces Initiation of New Clinical Trial With Evenamide in Patients With Schizophrenia, Following Approval of Plan By FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Evenamide","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Provides PR001 Program Update","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GEM103","moa":"Complement Factor H","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gemini The.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-450","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1\/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DTX301","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Announces First Patient Dosed in the REPAIR-MS Clinical Trial for the Treatment of Multiple Sclerosis with Lead Nanocatalytic Therapeutic, CNM-Au8","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich\u2019s ataxia (FA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redx Pharma nominates RXC007, a novel, orally active ROCK2 inhibitor as next drug development candidate in fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RXC007","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Redx Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis and AffaMed Therapeutics\u2019 Eculizumab Biosimilar Candidate Receives China IND Approval, Expanding the Ongoing Global Phase 3 Trial","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Eculizumab","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RhoVac Receives Approval in Germany and Belgium to Start Clinical Phase IIb Study in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostemsavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Pleural Effusions (MPE)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SCB-313","moa":"Apoptosis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone Skin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Staphylococcus epidermidis strain","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine, MV-012-968","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MV-012-968","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Meissa Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meissa Vaccines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Meissa Vac.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Presents Results From An Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-201","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pressurised Metered Dose Inhaler","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Entinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Bio\u2019s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences and Boston Children\\'s Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"IDE196","moa":"PKC","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics releases interim study data validating the safety of its ketamine depression drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Exebacase","moa":"Staphylococcus Aureus","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics (AKTX) Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Announces Strategic Priorities and Expected Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tamibarotene","moa":"RAR-alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-6231","moa":"PD-L1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Acceptance of Late-Breaking Abstract of KD025 for cGVHD at the 2020 TCT Meetings","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I\/II trial in AML Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous dendritic cell vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Genome & Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genome & Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & C.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1244","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Dova Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Dova Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dova Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dova Pharm.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura\u00ae in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"Celerion","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson\u2019s Disease and Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NPT520-34","moa":"SLC22A8","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neuropore Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neuropore Therapies \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Neuropore .."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics\\' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society\\'s Groundbreaking Beat Aml(R) Master Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Receives IND Clearance for Phase 1b\/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan\/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delcath Systems \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Sy.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"KIR3DL2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS\u00ae (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tagraxofusp","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemline T.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SPR206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neos Therapeutics Initiates and Completes Dosing in a Phase 1 Trial of NT0502 for the Treatment of Chronic Sialorrhea","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"N-Desethyloxybutynin","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Neos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Disintegrating Tablet","sponsorNew":"Neos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neos Thera.."},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r\/r AML and MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CYAD-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ N.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PBCAR269A","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ACN00177","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Kandy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NT-814","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Kandy Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kandy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kandy Ther.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Chikungunya virus-like particle","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-715","moa":"B Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpringWorks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Compass Pathways","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Compass Pathways \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita\u00ae (burosumab) for Tumor-Induced Osteomalacia (TIO)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Head-to-Head Phase 3 Data Show SKYRIZI\u2122 (risankizumab) Superior to Cosentyx\u00ae (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23 alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS\u00ae (ravulizumab) in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavapadon","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosomal protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenetic Biosciences (XBIO) Announces Publication of Data from Partner\\'s Phase 1\/2 Study Evaluating Program Leveraging Polyxen Platform Technology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SHP656","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Xenetic Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xenetic Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xenetic Bi.."},{"orgOrder":0,"company":"Kannalife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company\u2019s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"KLS-13019","moa":"mNCX-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kannalife","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kannalife \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kannalife .."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DNL201","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Therapeutics welcomes UK Regulatory Authority approval of Phase 2 clinical trial in critical limb ischaemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CYP-002","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Provides Update on One-Year ARDS Study Data","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem cell therapy","moa":"T cell","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613\u00ae? (devimistat) for Patients with Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda\u00ae in NSCLC Patients Progressing on Immune Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax and HMA Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvocidib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with Cellectis\u2019 New Allogeneic UCART123 Product Candidate for Relapsed\/Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"UCART123","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS\u2122 (KPI-121 0.25%) for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology\u2019s Rubraca\u00ae (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CART-TnMUC1-01","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb\u2019s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm\u00ae Phase 2a Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"buccal film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidea Technologies Utilizes GenScript\\'s Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SNP-7\/8a","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avidea Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avidea Technologies \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avidea Tec.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Granted Fast Track Designation for NanoFlu in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant quadrivalent seasonal influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New small molecule to treat Alzheimer\\'s disease and Dravet syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GNE-0723","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hanmi Pharma to develop innovative drugs for rare diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"HM15211","moa":"Glucagon\/GIP\/GLP-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringes","sponsorNew":"Hanmi Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Copper histidinate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Neuroptika","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NRO-1","moa":"Semaphorin-3A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuroptika \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika.."},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics announces that a common LAM-002 mechanism in cancer and neurodegenerative diseases shows antitumor activity in the clinic and hope for ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Apilimod mesylate","moa":"PIKfyve kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Kintai Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kintai Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kintai The.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Gains 29% In 5 Days, FLX475 Phase 2 Data Due In Q2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"FLX475","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Theranexus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theranexus Announces The Clinical Results Of Its Phase Ib Study Demonstrating The Extended Pharmacological Profile Of Its Drug\\n Candidate Thn201 Compared To Donepezil","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Donepezil","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Theranexus","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theranexus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Theranexus.."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest rockets on promising pancreatic cancer data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to Arena Pharmaceuticals\\' APD418 for Development in Decompensated Heart Failure Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"APD418","moa":"ADRB3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"OncoTartis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"International Research Collaboration Reveals Promising Drug Candidate for Treatment of Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"OT-82","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OncoTartis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"OncoTartis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoTartis.."},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51, a Multi-Kinase Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BTX-A51","moa":"CK1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"A3AR","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Umbralisib Developer Seeks FDA Approval In Marginal Zone Lymphoma and Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech\u2019s $220K Equity Investment","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Announces FDA IND Clearance for BBT-176, an EGFR TKI for NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-EGFR antibodies","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Presents Data from its SHP2 and Oncogenic RAS(ON) Programs at 6th AACR-IASLC International Joint Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RMC-4630","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Successfully Completes Required Genetic Toxicology Testing of Lead Drug Candidate NV-HHV-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NV-HHV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaryx Therapeutics Receives IND Approval for PLX-200 From the FDA for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-200","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Polaryx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polaryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polaryx Th.."},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TenNor Therapeutics Received FDA Orphan Drug Designation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TNP-2092","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TenNor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TenNor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TenNor The.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir\\'s Phase II Study of MIV-711 in Patients With Osteoarthritis Published in Annals of Internal Medicine","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-711","moa":"Cathepsin K","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces Acceptance by NMPA of IND Application of a Novel Humanized Claudin 18.2 Monoclonal Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lynparza regulatory submission granted Priority Review in US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J pushes to expand Imbruvica label after clinical success","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT-272","moa":"TDP-43","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Antimicrobial therapy","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999 \\nS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"OBI-999","moa":"Globo H glycolipid antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Trovagene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Announces First Patient Dosed in the RESCUE-ALS Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic, CNM-Au8","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces FDA Clearance of IND Application for its Lead Program in Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vallon Pharmaceuticals Presents Positive Data from Pilot Intranasal Human Abuse Study of Its Investigational Abuse Deterrent Stimulant, ADAIR, at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Vallon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Regorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Evoke Pharma\u2019s NDA Resubmission for Gimoti\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"5-HT4 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CUE-101","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Announces the Initiation of a Phase 1b\/2 Clinical Trial of CPI-613\u00ae (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NORWAY","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven\\'s Verdiperstat Receives FDA May Proceed Letter To Initiate Trial In Amyotrophic Lateral Sclerosis Conducted By The Healey Center For ALS At Mass General","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"JZP-258","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MET409","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Ther.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT\/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ra Pharmac.."},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LB Pharmaceuticals Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of LB-102, a Novel Benzamide for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmac.."},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintai Therapeutics Advances Anti-Obesity Agent KTX-0200 into IND-Enabling Studies Following Positive Preclinical Data Demonstrating Sustained Weight Loss and Improved Health Markers","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"KTX-0200","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Kintai Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kintai Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kintai The.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in Patients with Diabetic Macular Edema (DME) at Angiogenesis, Exudation, and Degeneration 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Updates to SLS-005 (trehalose) Programs for Europe and U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Neurotrope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer\\'s Disease Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope.."},{"orgOrder":0,"company":"Inhibitor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Itraconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibitor Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inhibitor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibitor .."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Rovatirelin","moa":"Thyrotropin releasing hormone receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Kissei Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pha.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TFC-1067","moa":"Tyrosinase activity","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Viloxazine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Supernus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Supernus P.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK\u2122 (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cad-1883","moa":"Calcium-sensitive potassium ion channel PAM","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BTRX-140","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BlackThorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn.."},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HLS Therapeutics Files New Drug Submission for PERSERIS\u00ae in Canada","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"HLS Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HLS Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"HLS Therap.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-702","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TNX-801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalent to Support DiaMedica Trial Using GPEx Technology","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DM199","moa":"Kallikrein-1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalent Pharma Solutions \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"LipoMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LipoMedix Announces Publication of Positive Phase 1 Data for Promitil\u00ae (PL-MLP) in Research Journal Investigational New Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Promitil","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix .."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia\/Lymphoma at Two Upcoming Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobomarsen","moa":"miR-155","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"gossamer bio announces data presentation at the 2020 crohn\u2019s & colitis congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer\\'s regorafenib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CS1001","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen\u2019s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC22","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ONO Announces Result from Phase III Clinical Study Evaluating Opdivo\u00ae (Nivolumab)\\nin Patients with Platinum-Refractory Advanced or Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Completes Dosing in Phase 1 Trial for New Oral Ulcerative Colitis Drug","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DB-020","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The First Patient Included in Australia in Isofol\\'s Phase 3 AGENT Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn\u2019s & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro models","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-101","moa":"CD28","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipidor Announces Positive Topline Results of AKP01 Phase III Clinical Study Using Calcipotriol Spray Against Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Announces Formal Acceptance of CNM-Au8 for HEALEY ALS Platform Trial as Center Receives FDA Approval to Proceed","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Asparagine, L-","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crescita Awarded Cannabis Research License from Health Canada","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinoid-based Product","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProtoKinetix Takes Delivery of GMP AAGP\u00ae PKX-001 Dedicated for Phase 1 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PKX-001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene downgrades late-stage study of PARP inhibitor in gastric cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamiparib","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"GABA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GABA Therapeutics commences phase I study of Etifoxine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Etifoxine","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"GABA Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"GABA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GABA Thera.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\\'s checkpoint inhibitor fails pivotal urothelial cancer trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces PDUFA Date for Intravenous Meloxicam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Influenza Challenge Study Published in Lancet Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"H1 influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology Presents Data on LONSURF\u00ae (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Trifluridine","moa":"DNA nucleic acid","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero to expand ongoing Phase IIa trial of AKR-001 for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AKR-001","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b\/2a Study of Hyleukin-7\u2122 (NT-I7) and KEYTRUDA\u00ae (Pembrolizumab) in Relapsed\/Refractory Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"NT-I7","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ficlatuzumab","moa":"HGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Epygenix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epygenix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX\u00ae2-73 (blarcamesine) Phase 2 Parkinson\u2019s Disease Dementia (PDD) Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka announces positive top-line results from clinical trials in Japan of\\nfremanezumab as a prophylactic treatment for migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Affiris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 trial with AFFITOPE PD01 in Early Parkinson\\'s Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"AUSTRIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PD01","moa":"Alpha-synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Affiris","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affiris \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affiris \/ .."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Acelarin","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Khondrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sonlicromanol","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion .."},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DNV3837","moa":"DNA topoisomerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SA.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Completes Enrollment in Anti-GBM","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Berg Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology Platform At ASCO-GI Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Nanosuspension for Intravenous Injection","sponsorNew":"Berg Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Healt.."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"1st clinical trial kicks off to test antibody-drug combination for HIV treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"CD24 binding site","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SRF617","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial of ORIC-101 in Combination with XTANDI\u00ae for the Treatment of Prostate Cancer in Collaboration with Astellas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"Vanilloid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow\u2019s Feet Lines Published in Dermatologic Surgery","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ N.."},{"orgOrder":0,"company":"Blueberry Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Terbinafine Hydrochloride","moa":"Squalene epoxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blueberry Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Blueberry Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blueberry .."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune Announces Presentation of CD24Fc Phase IIa Data and Phase III Clinical Trial Design at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CD24Fc","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer\\'s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antianxiety and Antidepressant Effects from a Single Dose of Psychedelic Drug Persist Years Later in Cancer Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NYU Grossman School of Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NYU Grossman School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NYU Grossm.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo to Present Next-Generation PARP Inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"OX401","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Update to Parkinson\u2019s Disease Program SLS-007","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SLS-007","moa":"Alpha-synuclein Non-Amyloid component","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte\\'s skin disease drug meets main goal in late-stage study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Present Positive Interim Data on Appili Therapeutics\u2019 ATI-1701 Biodefense Program at 2020 ASM Biothreats","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-5609, Its Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leronlimab Under Evaluation for Potential Treatment of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"Leukotriene receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Multiple neutralizing antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer nixes multiple Bavencio tests in recent clinical program dump","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PF 04518600","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Arrevus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrevus Receives FDA Qualified Infectious Disease Product (QIDP) Designation for the Treatment of Cystic Fibrosis Pulmonary Exacerbations","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Fusidate","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrevus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ .."},{"orgOrder":0,"company":"National Institutes of Health Clinical Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First human trial of monoclonal antibody to prevent malaria opens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mAb CIS43LS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"National Institutes of Health Clinical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health Clinical Center \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National I.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Orders More Rabeximod Substance and Confirms Timeline for the Phase IIb Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Vasopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ronopterin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"2019-nCoV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Results From Human PK Study Assessing Novel Ketorolac Formulations for Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketorolac Trometamol","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA\u2122 for Treatment of Relapsed Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Odyssey Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odyssey Group International and Prevacus Provide Development Update on its Potential Concussion and Nieman Picks Drug Candidates","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-002","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Odyssey Health","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Odyssey Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Odyssey He.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/.."},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emerald Health Pharmaceuticals Granted Orphan Designation in Europe for Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"EHP-102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Emerald Health Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Emerald He.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces Dosing of First Patient in CSPC\u2019s Chinese Study Evaluating COPIKTRA\u00ae (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Reports Positive Top-Line Preliminary Results in First Patient in Diverticulosis Pilot Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ACTR707","moa":"T cell receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Unum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Unum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Unum Thera.."},{"orgOrder":0,"company":"Geneos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GNOS-PV02","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Geneos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Geneos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Geneos The.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation for GLPG1690 in systemic sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Inarigivir","moa":"INFs","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spring Bank Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spring Ban.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tnx-801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Positive Phase I Study Results of Oral Octreotide using RaniPill\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"SSTR","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Thera.."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Itraconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dry Powder for Oral Inhalation","sponsorNew":"Pulmatrix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olipudase alfa","moa":"SMPD1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics\\' GMI-1359","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GMI-1359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company\u2019s Lead Investigational Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CVL-936","moa":"D3 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Announces FDA Acceptance of IND Application for FS120","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"FS120","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SNDX-5613","moa":"MLL1-Menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO3","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-134","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"QR-421a","moa":"USH2A protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"APR-246","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir has received notices of allowance in the EU and Japan for MIV-818 patent applications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvidia Therapeutics Announces Publication in Science Translational Medicine of Strategy for Lowering Triglycerides Using a Mimetic Peptide","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"D6PV","moa":"Apolipoprotein C-III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Corvidia Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvidia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Corvidia T.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"10153627","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates Seattle Genetics\u2019 Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP issues positive opinions for both bempedoic acid and the bempedoic acid \/ ezetimibe fixed dose combination tablet as treatments for hypercholesterolaemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ATP citrate lyase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Cardior Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CDR132L","moa":"miRNA-132","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cardior Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardior Ph.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ATP citrate lyase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex drops VX-961 to continue search for perfect pain drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"VX-961","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Loxicodegol","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tempest Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPST-1495 and Welcomes New Investors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TPST-1495","moa":"PGE2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tempest Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Th.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Forma Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 1701963","moa":"SOS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boehringer Ingelheim GmbH \/ FORMA Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Lilly Completes Acquisition of Dermira","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Immatics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"$50.0 million","newsHeadline":"GSK pays $50M for 2 solid tumor cell therapies from Immatics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Allogeneic T-cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immatics","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Immatics \/ GlaxoSmithKline","highestDevelopmentStatusID":"2","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"$473.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aimmune Announces $200 Million Equity Investment by Nestle","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Peanut (Arachis hypogaea) Allergen-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0.46999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"Oral Powder","sponsorNew":"Aimmune Therapeutics \/ Nestle Health Science","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$437.6 million","upfrontCash":"$27.6 million","newsHeadline":"Cellectis and Servier Expand Collaboration on UCART19 Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0.44,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.44,"dosageForm":"","sponsorNew":"Cellectis \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Xencor","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","amount":"$395.0 million","upfrontCash":"$10.0 million","newsHeadline":"Aimmune Licenses Worldwide Rights to Xencor\u2019s XmAb\u00ae7195","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"XmAb7195","moa":"IgE","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Xencor","amount2":0.40000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Xencor \/ Aimmune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ A.."},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","amount":"$375.0 million","upfrontCash":"$375.0 million","newsHeadline":"Assertio Announces Sale of NUCYNTA\u00ae Franchise to Collegium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Tapentadol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0.38,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"Assertio Therapeutics \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Assertio T.."},{"orgOrder":0,"company":"Oncodesign","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$363.3 million","upfrontCash":"$3.3 million","newsHeadline":"Oncodesign and Servier Reach a Key First Milestone","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"LRRK2 kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oncodesign","amount2":0.35999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Oncodesign \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Oncodesign.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Seagen","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"$5.0 million","newsHeadline":"Five Prime Grabs $5M lifeline in Seattle Genetics ADC deal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody-drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Five Prime Therapeutics","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Seattle Genetics","highestDevelopmentStatusID":"1","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Deciphera Pharmaceuticals Announces Closing of Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Ripretinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Passage Bio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gene Therapy Developer Passage Bio Files for $125M IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"PBGM01","moa":"Beta-galactosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0.13,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Passage Bio \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Orphazyme","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Arimoclomol","moa":"HSF-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"CytRx Corporation","amount2":0.12,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Capsule","sponsorNew":"CytRx Corporation \/ Orphazyme A\/S","highestDevelopmentStatusID":"10","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"ALX raises $105M for midphase trials of CD47 cancer drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series C Financing","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Vivo Capital","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"WPD Pharmaceuticals","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"WPD Pharmaceuticals Completed the Acquisition of Two Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Moleculin Biotech","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ WPD Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"CANbridge Pharmaceuticals Completes US$98 Million Series D Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series D Financing","leadProduct":"Idursulfase beta","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"Undisclosed","newsHeadline":"Spruce Biosciences Raises $88 Million in Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series B Financing","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"NEA-founded Imara pitches mid-stage alternative for $86M IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Un.."},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"$60.0 million","newsHeadline":"Valneva Announces New $85 Million Financing Arrangement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Financing","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$82.3 million","upfrontCash":"Undisclosed","newsHeadline":"ADMA Biologics Announces Proposed $75 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"$67.1 million","upfrontCash":"$5.1 million","newsHeadline":"VALBIOTIS inks Strategic Partnership With NESTL\u00c9 HEALTH SCIENCE","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"TOTUM-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0.070000000000000007,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Science","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Alladapt Immunotherapeutics","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alladapt Immunotherapeutics Secures $60 Million in Series C Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series C Financing","leadProduct":"ADP101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alladapt Immunotherapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Alladapt Immunotherapeutics \/ Gurnet Point Capital","highestDevelopmentStatusID":"7","companyTruncated":"Alladapt I.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$56.8 million","upfrontCash":"Undisclosed","newsHeadline":"Kezar Announces Closing of $56.8 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Elanco","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$55.0 million","newsHeadline":"Elanco Signs Agreement with Merck Animal Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Diclazuril","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elanco","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Elanco \/ Merck Animal Health","highestDevelopmentStatusID":"12","companyTruncated":"Elanco \/ M.."},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Syncona","pharmaFlowCategory":"D","amount":"$53.6 million","upfrontCash":"Undisclosed","newsHeadline":"OMass Therapeutics Announces \u00a327.5 M Extended Series A Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"OMass Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"OMass Therapeutics \/ Syncona","highestDevelopmentStatusID":"1","companyTruncated":"OMass Ther.."},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Israeli biotech NeoTX lands $45M series C for combo I-O cancer trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series C Financing","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"NeoTX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Ther.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"$22.0 million","newsHeadline":"BioCryst Submits Japanese NDA for Oral, Once Daily Berotralstat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Corbus Pharma Announces Proposed Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Lenabasum","moa":"CB2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sonoma bags $40M to push Tregs for autoimmune, neuro diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Series A Financing","leadProduct":"Treg therapy","moa":"T cell","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sonoma Biotherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sonoma Bio.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Sirtex Medical","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"$30.0 million","newsHeadline":"Sirtex Medical closes Strategic Transaction with OncoSec Medical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Sirtex","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Azafaros","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azafaros Completes EUR 25 Million Series A Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Series A Financing","leadProduct":"AZ-3102","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Azafaros","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Forbion","highestDevelopmentStatusID":"1","companyTruncated":"Azafaros \/.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Closes First $25 Million Securities Purchase Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tocagen and Forte Biosciences Announce Merger","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ ","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Cerecor","pharmaFlowCategory":"D","amount":"$22.1? million","upfrontCash":"Undisclosed","newsHeadline":"Cerecor and Aevi Genomic Medicine Complete Merger","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Rislenemdaz","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Aevi Genomic Medicine \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genom.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$21.7 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces Proposed Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0.02,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Guggenheim Securities","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"Undisclosed","newsHeadline":"MaaT Pharma Announces \u20ac18 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"MaaT Pharma \/ SymBiosis","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"PentixaPharm","sponsor":"ELSA Eckert Life Science Accelerator","pharmaFlowCategory":"D","amount":"$16.2 million","upfrontCash":"Undisclosed","newsHeadline":"PENTIXAPHARM Secures \u20ac 15 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Series A Financing","leadProduct":"Pentixafor","moa":"CXCR4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"PentixaPharm \/ ELSA Eckert Life Science Accelerator","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPha.."},{"orgOrder":0,"company":"MRM Health","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","amount":"$15.1 million","upfrontCash":"Undisclosed","newsHeadline":"DuPont Nutrition & Biosciences Enters into Collaboration","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Gut microbiome based therapeutics","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"MRM Health","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"MRM Health \/ DuPont","highestDevelopmentStatusID":"1","companyTruncated":"MRM Health.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Ocumension Therapeutics","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"$2.0 million","newsHeadline":"Ocumension inks $14M deal with EyePoint Pharma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Wanbury Limited","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore.","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Folic Acid","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Wanbury Limited","amount2":0.01,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Wanbury Limited \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Wanbury Li.."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Finnish Funding Agency for Innovation","pharmaFlowCategory":"D","amount":"$10.9 million","upfrontCash":"$1.2 million","newsHeadline":"Valo Therapeutics Announces New Funding for Immuno-Oncology Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"PeptiCRAd","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Valo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Valo Therapeutics \/ Finnish Funding Agency for Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","amount":"$10.2 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Pricing of Equity Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Financing","leadProduct":"ATI-2307","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aduro Biotech Announces Milestone Achieved under Merck Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"MK-5890","moa":"CD27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Chinook Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"$6.0 million","newsHeadline":"Can-Fite Granted Patent Allowance for Namodenoson in South Korea","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0.01,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Chong Kun Dang Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"CorMedix","sponsor":"New Jersey Economic Development Authority","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"$5.2 million","newsHeadline":"CorMedix Approved to Sell $5.5 Million of NOL Tax Benefits","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Taurolidine","moa":"TNF-alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Catheter Lock Solution","sponsorNew":"CorMedix \/ New Jersey Economic Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Stony Brook University","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Stony Brook University gets $4.2 million NCI grant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"ART26.12","moa":"FABP5","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Stony Brook University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stony Brook University \/ National Cancer Institute","highestDevelopmentStatusID":"2","companyTruncated":"Stony Broo.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","amount":"$3.8 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Therapeutics to Receive $1.0 Million Milestone Payment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Ridinilazole","moa":"Cell Division","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Summit Therapeutics \/ Eurofarma Laboratorios SA","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Bodor Laboratories","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"$1.0 million","newsHeadline":"Brickell Biotech Announces Settlement of Dispute with Bodor Labs","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Bodor Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Bodor Laboratories \/ Brickell Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Bodor Labo.."},{"orgOrder":0,"company":"Novan","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Novan Receives Phase 2 NIH Federal Grant of $1.0 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"WH602","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Novan \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Novan \/ Na.."},{"orgOrder":0,"company":"Equinox Science","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.0 million","newsHeadline":"EyePoint Pharmaceuticals inks License Agreement with Equinox Science","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Vorolanib","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Equinox Science","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Equinox Science \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Equinox Sc.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Innovation Fund Denmark","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Scandion Oncology receives DKK 5 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"SCO-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Innovation Fund Denmark","highestDevelopmentStatusID":"8","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Plex Pharmaceuticals Awarded $600,000 Phase I NIH SBIR Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Plex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plex Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"1","companyTruncated":"Plex Pharm.."},{"orgOrder":0,"company":"University College London","sponsor":"Cure Parkinson\u2019s Trust","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"UCL researchers test cough syrup drug for Parkinson\u2019s","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Ambroxol","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"University College London","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"University College London \/ Cure Parkinson\u2019s Trust","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"INmune Bio, Inc. Awarded $500,000 Grant","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"INmune Bio \/ ALS Association","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Neuropore Therapies Receives $500,000 Grant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"NPT1220-312","moa":"TLR2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuropore Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuropore Therapies \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Neuropore .."},{"orgOrder":0,"company":"Vabiotech","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Vietnam\u2019s Vingroup funds three coronavirus research projects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"VIETNAM","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vabiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vabiotech \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Vabiotech .."},{"orgOrder":0,"company":"Salzman Group","sponsor":"Kalytera Therapeutics","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Kalytera Announces New Payments Agreement with the Salzman Group","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Salzman Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Salzman Group \/ Kalytera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Salzman Gr.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"University of California, Irvine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics to Collaborate with University of California","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Neural stem cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ University of California, Irvine","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"AffyXell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avacta and Daewoong collaborate with AffyXell Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Stefin A","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ AffyXell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Seraph Research Institute","sponsor":"Enochian BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enochian Biosciences Acquires Exclusive License for Novel HVB B Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"ENOB-HB-01","moa":"HBV polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seraph Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seraph Research Institute \/ Enochian Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Seraph Res.."},{"orgOrder":0,"company":"Levena Biopharma","sponsor":"Navrogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Navrogen and Levena collaborate to Develop Antibody Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody drug conjugates","moa":"HIO","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Levena Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Levena Biopharma \/ Navrogen","highestDevelopmentStatusID":"4","companyTruncated":"Levena Bio.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Solarvest BioEnergy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma and Solarvest Enhance Commitment to CBD Research Project","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Cannabinoid","moa":"CB receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Solarvest BioEnergy","highestDevelopmentStatusID":"1","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theratechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theratechnologies Ink Agreements with General Hospital Massachusetts","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Theratechnologies","highestDevelopmentStatusID":"8","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Zeria Pharmaceutical","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kyowa Kirin Terminates ASACOL\u00ae deal with Zeria Pharmaceutical","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Mesalazine","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zeria Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zeria Pharmaceutical \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Zeria Phar.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioxytran Seeking Partners for Late Stage Treatment of Coronavirus","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"BXT-25","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bioxytran \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Protein Sciences Corporation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Diamyd enters agreement to facilitate transition of manufacturing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Diamyd","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Protein Sciences Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"CoreRx","sponsor":"JanOne","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JanOne strikes agreement with CoreRx","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"Vasodilator","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CoreRx","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CoreRx \/ JanOne","highestDevelopmentStatusID":"8","companyTruncated":"CoreRx \/ J.."},{"orgOrder":0,"company":"Curis","sponsor":"Aurigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curis and Aurigene Announce Amendment of Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"3-Aminopyrrolidine dihydrochloride","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Aurigene Discovery Technologies","highestDevelopmentStatusID":"9","companyTruncated":"Curis \/ Au.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Trefoil Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Trefoil Selects AGC Biologics as Lead Manufacturer of TTHX1114","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"TTHX1114","moa":"FGF-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"AGC Biologics \/ Trefoil Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Certara","sponsor":"Arvinas","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arvinas picks Certara for Its Targeted Protein Degradation Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Proteolysis targeting chimera","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Certara","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Certara \/ Arvinas","highestDevelopmentStatusID":"1","companyTruncated":"Certara \/ .."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla Medpro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Medpro Gets Distribution and Marketing Rights for Seroquel","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Cipla Medpro","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$761.0 million","upfrontCash":"$37.0 million","newsHeadline":"KalVista Pharma Provides Update on Diabetic Macular Edema Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Termination","leadProduct":"KVD001","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0.76000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.76000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"KalVista Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"J & J collaborates with U.S. Department of Health & Human Services","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Janssen Pharmaceutical K.K.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nippon Shinyaku inks new agreement for prostate cancer treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Nippon Shinyaku","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Nippon Shinyaku \/ Janssen Pharmaceutical K.K.","highestDevelopmentStatusID":"12","companyTruncated":"Nippon Shi.."},{"orgOrder":0,"company":"MAbSilico solutions","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Partners with MAbSilico","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Nivolumab","moa":"T-lymphocytes","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MAbSilico solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MAbSilico solutions \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"MAbSilico .."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Oxford Finance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syros Announces $60 Million Loan Facility with Oxford Finance LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Azacitidine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Oxford Finance","highestDevelopmentStatusID":"8","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Vitiprints","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LakePharma and NJ Bio to streamline antibody-drug conjugate services","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vitiprints","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vitiprints \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Vitiprints.."},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Synspira Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synspira Therapeutics and Cystic Fibrosis Foundation Sign Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"SNSP003","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fib.."},{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Norgine \/ Faes Farma S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ .."},{"orgOrder":0,"company":"myTomorrows","sponsor":"AiCuris Anti-infective Cures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AiCuris collaborates with myTomorrows","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Pritelivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"myTomorrows","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"myTomorrows \/ AiCuris Anti-infective Cures","highestDevelopmentStatusID":"8","companyTruncated":"myTomorrow.."},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novimmune unit nabs Takeda milestone payment for hemophilia work","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Light Chain Bioscience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Light Chain Bioscience \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Light Chai.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi joins forces with U.S. Department of Health for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"SARS vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ B.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vision Center Network of America","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals and Vision Center Network Ink Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vision Center Network of America","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"GenesisCare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noxopharm Alliance With GenesisCare","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Idronoxil","moa":"PMET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ GenesisCare","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Vectans Pharma","sponsor":"m8 Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"m8 Pharmaceuticals and Vectans Pharma Enter Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Miconazole","moa":"CYP50","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Vectans Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vectans Pharma \/ m8 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Vectans Ph.."},{"orgOrder":0,"company":"University of Rochester School of Medicine & Dentistry","sponsor":"Evgen Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evgen and Rochester University partner to advance SFX-01 trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"SFX-01","moa":"Nrf2","url1":"","url2":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of Rochester School of Medicine & Dentistry","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Royal DSM","sponsor":"Humanetics Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Acquires Manufacturing Assets for Radioprotectant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Royal DSM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Royal DSM \/ Humanetics Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Royal DSM .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Premier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Premier ProvideGx Program Partners with Pfizer","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"IBUTILIDE FUMARATE","moa":"hREG","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"ProMab Biotechnologies","sponsor":"Caribou Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Caribou Biosciences and ProMab Biotechnologies Inks Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"CB-011","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProMab Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMab Biotechnologies \/ Caribou Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"ProMab Bio.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioXcel Therapeutics Announces Proposed Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"GRCBDS","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Erytech Pharma Announces Strategic Supply Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Eryaspase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GRCBDS","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GRCBDS \/ Erytech Pharma","highestDevelopmentStatusID":"10","companyTruncated":"GRCBDS \/ E.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vifor Pharma and Fresenius Kabi create joint venture in China","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied DNA and Takis Biotech partner on coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Linear DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Applied DNA","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"Tianjin University","sponsor":"Beroni Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beroni Group teams up with Tianjin University for COVID-19 treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Nanobased antibody therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tianjin University \/ Beroni Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Un.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clover and GSK Announce Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 S-Trimer","moa":"S-Trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ GlaxoSmithKline","highestDevelopmentStatusID":"4","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Drug developer PolyPid to file for Wall Street IPO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Doxycycline","moa":"MMP7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.11,"dosageForm":"","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Virology laboratory, U.S","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovation Pharmaceuticals Submits Material Transfer Agreement to Study Lead Defensin Mimetic Brilacidin for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Brilacidin","moa":"Defensin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virology laboratory, U.S","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virology laboratory, U.S \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Virology l.."},{"orgOrder":0,"company":"Viatris","sponsor":"Beximco Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beximco To Distribute Mylan Product Portfolio In Bangladesh","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viatris \/ Beximco Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Medivir","sponsor":"Shijiazhuang Yuanmai Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear\u00ae in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aciclovir","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Medivir \/ Shijiazhuang Yuanmai Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$94.6 million","upfrontCash":"Undisclosed","newsHeadline":"ADMA Biologics Announces Closing of Full Exercise of Underwriters\u2019 Option","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Human Immune Globulin","moa":"Phagocytosis","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ADMA Biologics","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"12","companyTruncated":"ADMA Biolo.."},{"orgOrder":0,"company":"GSK","sponsor":"Suir Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STADA becomes a major Consumer Healthcare player by acquiring 15 well-established GSK brands","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Troxerutin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ STADA AG","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ STAD.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Paratek Announces License Grant to Almirall for SEYSARA\u00ae (sarecycline) for Greater China Region","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$6.2 million","upfrontCash":"$3.2 million","newsHeadline":"Aradigm Announces Entering into an Asset Purchase Agreement with Grifols, S.A.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aradigm","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Aradigm \/ Grifols","highestDevelopmentStatusID":"8","companyTruncated":"Aradigm \/ .."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Flerie Invest AB","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"KAHR Medical Raises $18 Million in Private Funding Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Atezolizumab","moa":"SIRP alpha\/41BBL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Kahr Medical \/ Flerie Invest AB","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"Peptilogics","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$12.1 million","upfrontCash":"Undisclosed","newsHeadline":"Peptilogics Announces CARB-X Funding to Accelerate Development of First-in-Class Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"DNDi","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"LXE408","moa":"Proteasome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"DNDi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"DNDi \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"DNDi \/ Nov.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Financing","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai and FUJI YAKUHIN Conclude License Agreement","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"Urate transporter","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Fuji Yakuhin \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuh.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Announces Pricing of $10 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"SACT-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptorum \/ Alliance Global Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arcus Biosciences and Taiho Pharmaceutical Announce Taiho\u2019s Exercise of an Exclusive License to Zimberelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AB154","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dialectic Therapeutics Receives $3 Million Seed Award for Product Development Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"DT2216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dialectic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dialectic Therapeutics \/ Cancer Prevention & Research Institute of Texas","highestDevelopmentStatusID":"5","companyTruncated":"Dialectic .."},{"orgOrder":0,"company":"Advanced BioDesign","sponsor":"Xerys Funds","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"Advanced BioDesign Raises Additional \u20ac9 Million From Xerys Funds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"ABD-3001","moa":"ALDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Advanced BioDesign","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Advanced BioDesign \/ Xerys Funds","highestDevelopmentStatusID":"4","companyTruncated":"Advanced B.."},{"orgOrder":0,"company":"Southern Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Research Collaboration with Southern Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Live modified horsepox virus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southern Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Southern Research \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Southern R.."},{"orgOrder":0,"company":"PvP Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$330.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda buys PvP in $330M deal to bag a 2nd celiac drug","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"TAK-062","moa":"Gluten","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"PvP Biologics","amount2":0.33000000000000002,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"PvP Biologics \/ Takeda","highestDevelopmentStatusID":"6","companyTruncated":"PvP Biolog.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma Pharma to commercialise Glenmark Pharma\u2019s new nasal spray Ryaltris in US","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Domainex","sponsor":"LUNAC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Domainex inks partnership with LUNAC Therapeutics to discover novel anticoagulant therapies","therapeuticArea":"Hematology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Protease","url1":"","url2":"","graph1":"Hematology","graph2":"Discovery","graph3":"Domainex","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Domainex \/ LUNAC Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Domainex \/.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$2,720.0 million","upfrontCash":"$350.0 million","newsHeadline":"Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"ST-501","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":2.7200000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.7200000000000002,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Soligenix","sponsor":"University of Hawai'i at Manoa","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Filovirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ University of Hawai\\'i at Manoa","highestDevelopmentStatusID":"1","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Abigo Medical AB","sponsor":"Essity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essity Acquires 75% of the Medical Solutions Company ABIGO Medical AB","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Dialkylcarbamoylchloride","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Abigo Medical AB","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Abigo Medical AB \/ Essity","highestDevelopmentStatusID":"12","companyTruncated":"Abigo Medi.."},{"orgOrder":0,"company":"MAKScientific","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MAKScientific","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAKScientific \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"10","companyTruncated":"MAKScienti.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Funding","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Exenatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"$30.0 million","newsHeadline":"Medexus expands US product portfolio by acquiring hematology asset IXINITY","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Recombinant coagulation factor IX","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aptevo Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Private Placement","leadProduct":"Defactinib","moa":"Focal adhesion kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Verastem Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Bioscience Announces Agreement with Mycenax Biotech for Production of Anti-VISTA Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"HMBD-002","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mycenax Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mycenax Biotech \/ Hummingbird Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Mycenax Bi.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Announces Publishes Two Manuscripts on Bempegaldesleukin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"INS1007","moa":"DPP-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces Study of Unituxin\u00ae (dinutuximab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"United The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Review Supplemental New Drug Application for RECARBRIO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Imipenem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Publishes Patient Benefit Results From A Pilot Clinical Study","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-3106","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Partner Updates on Phase 3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva to Present Results from its Phase IIa Odiparcil Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Odiparcil","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CorMedix Announces FDA Grant of Rolling Review of Neutrolin\u00ae NDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Taurolidine","moa":"TNF-alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Catheter Lock Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Completes 50% Patient Enrollment in Phase III RA Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Gains Japanese Dusquetide Patent Allowance in Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dusquetide","moa":"p62 protein","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Successfully Completes of Phase 1 AML Trial of Annamycin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Pharma Receives Issue Notification for a U.S. Patent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Immunitor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunitor publishes interim results from Phase III trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Hepcortespenlisimut-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunitor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunitor \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunitor .."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Presents Clinical Data from its Phase 1\/1b CPI-818 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CPI-818","moa":"Il-2 induced T-cell Kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Receives Formulation Patent Extending NCX 470 U.S","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCIB1 Investigational New Drug (IND) application approved","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SCIB1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scancell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Receives Fast Track Designation by U.S. FDA for ANAVEX\u00ae2-73","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharma Achieves Patient Screening Target for Zygel","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Receives FDA Breakthrough Therapy for Apabetalone","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon, Exscientia begin study of AI based OCD drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DSP-1181","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sumitomo Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Rebiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rebiotix Completes Enrollment for Pivotal Phase 3 Trial of RBX2660","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Rebiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics Advances GMI-1359 Program With Patent Issuance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GMI-1359","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immix Doses First Patient in USA in its Phase 1b\/2a Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Curcumin","moa":"STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immix Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biop.."},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trefoil Selects AGC Biologics as Lead Manufacturer of TTHX1114","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"TTHX1114","moa":"FGF-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Trefoil Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Trefoil Th.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB\\'s IRL790 Receives New Name `mesdopetam\\'","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emtora Presents Phase Ib Data in Low Grade Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emtora Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Bio.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys Initiates Expanded Access Program for Tafasitamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formycon Announce current Status of BLA Review of FYB201","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces First Patients Treated in Separate Phase 1b","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AV-GBM-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aivita Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"Alkahest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AKST4290","moa":"CCR3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alkahest","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkahest \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alkahest \/.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep to Present TACTI-002 Interim Data at German Cancer Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Desmetramadol is G-Protein Biased Opioid Receptor Agonist: Syntrix","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Desmetramadol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Syntrix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syntrix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Syntrix Ph.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Announces Publication of Abstracts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Inositec AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inositec\u2019s INS-3001 Reduces Cardiovascular Calcification","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"INS-3001","moa":"Vascular calcification","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Inositec AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inositec AG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inositec A.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Reports Interim Clinical Data on ARO-APOC3 and ARO-ANG3","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-APOC3","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ\u2122 Meets Primary and Key Secondary Endpoints","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences to Present KSI-301 Phase 1b Clinical Study Data","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIAID-sponsored Trial of M-001 Validates Previous Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"M-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Alector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alector Announces FDA Fast Track Designation Granted to AL101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AL101","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Gets FDA Clearance of IND Application for BXCL501","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Completes Patient Enrollment in Roluperidone Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Topline Data from Positive Phase 1 Trial with THR-687","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"THR-687","moa":"Pan-RGD integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foamix Announces Publication of Phase 3 Studies Evaluating FMX103","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pha.."},{"orgOrder":0,"company":"NeuroSense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroSense Receives Orphan Drug Designation for Amyotrophic","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroSense Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroSense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroSense.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Gets PDUFA Date Extension for NDA of Avapritinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SUNFISH Pivotal Results for Risdiplam Demonstrate Meaningful Benefit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PIC1-dPEG24","moa":"Complement C1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Provides Positive Update on Clinical Study of OpRegen\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cell","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ROR1 CAR-T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Presents Updated Data from MERECA Trial of Ilixadencel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Announces Positive Top-line Results from Trial of FINTEPLA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Gest U.S. FDA Acceptance of BLA for DAXI","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharma Gets IND Authorization for its Multiple Myeloma Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharm.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Publication Relating To Design Of Galactic-Hf","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Data for SRK-015","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-015","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeoVax Prepared to Advance GOVX-B11 HIV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GOVX-B11","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Presents Vopratelimab Predictive Biomarker Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"ICOS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Provides SB206 Program and Business Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Announces DSMB has Confirmed Initial Safety of GEN-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Commences Phase 3 Trial of AD04","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi brain-penetrant BTK inhibitor meets primary endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SAR442168","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Topline Results for Solanezumab from DIAN-TU Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Solanezumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche experimental drug flops in early Alzheimer\u2019s","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Priority Review for Kite\u2019s KTE-X19 BLA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KTE-X19","moa":"CD19","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Announces Significant Progress of SACT-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SACT-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Announces Further Positive Data For Its ALS-4","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"S-Trimer","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Provides Topline Results From Gantenerumab Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Receives Authorization from FDA To Begin Trial for INO-3107","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-3107","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Elorac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elorac to Present Naloxone Lotion Phase III Study Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elorac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Elorac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Elorac \/ N.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle, Astellas Announce Updated Results from PADCEV\u2122 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits to U.S. FDA for New DARZALEX\u00ae Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix Presents Key Clinical Data of Pegunigalsidase Alfa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Progresses in Prophylactic Vaccines Modality with CMV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1647","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Patient Enrolled in mRNA-3704 Phase II","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-3704","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Gets Fast Track Designation By U.S. FDA NBTXR3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Seurat Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seurat Therapeutics Shows Novel Mechanisms from Rat Migraine Model","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Insulin-Like-Growth-Factor-I 21-40","moa":"IGF-1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seurat Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seurat Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seurat The.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring\u2019s Plinabulin Activates Adaptive and Innate Immune System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review for Avalglucosidase Alfa, a Potential New Therapy for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Alkahest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AKST4290","moa":"CXCR3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alkahest","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkahest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Decision to Discontinue AB-452","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-452","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Unveils Results from Simplici-T1 Study of TTP399","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Updated Phase II Savolitinib \/ Imfinzi\u00ae Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Savolitinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven anxiety treatment fails late-stage study, shares fall 16%","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Troriluzole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KSQ Therapeutics Announces Discovery of Gene Targets to PD-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"CT-1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Safety, Efficacy and Durability Data","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Walter Reed Army Institute of Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Army Inches Closer To Develop Zika And Dengue Virus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MZ4","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Walter Reed Army Institute of Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Walter Reed Army Institute of Research \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Walter Ree.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz to initiate phase III clinical trial of centhaquine","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STP705 Gets Orphan Drug Designation By US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crescita Reports Topline Results from Two Pivotal Clinical Studies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX-101","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"T3D Begins Enrollment in PIONEER Phase 2 Trial of T3D-959","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"T3D-959 Sodium","moa":"PPAR delta\/gamma","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therap.."},{"orgOrder":0,"company":"DaVolterra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Da Volterra Reports Positive Top-line Results from DAV132 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DAV132","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"DaVolterra","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"DaVolterra \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DaVolterra.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics and Natera To Collaborate for ELI-002 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"mKRAS","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces MET Inhibitor Capmatinib (INC280), the First Potential Treatment for METex14 Mutated Advanced Non-small Cell Lung Cancer, Granted Priority FDA Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants New Drug Application and Priority Review for Ripretinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TriSalus Life Sciences Initiate Trial for Novel Delivery Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxaliplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"TriSalus Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TriSalus L.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WPD Pharma to Conduct Clinical Trials in Pediatric Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Reports Early Completion of Patient Enrollment in TLC590 Phase II","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allena Pharmaceuticals Announces Streamlined Design for URIROX-2","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Reloxaliase","moa":"Oxalate","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pha.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Receives the EMA PRIME Designation for Viralym-M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Viralym-M","moa":"T lymphocyte","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Positive Preliminary, Preclinical Data","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Anandamide","moa":"CB1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Initiates First-in-Human Study of ATI-2173","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-2173","moa":"HBV polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Review of NDA for Oral ASTX727 or oral C-DEC Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cedazuridine","moa":"Cytidine deaminase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XTANDI Improves Overall Survival in Phase III PROSPER Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PRIVIGEN Granted Orphan-Drug Designation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Rho D Immune Globulin","moa":"IgG","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RGLS4326","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Partner Receives Canadian Patent For Treatment of Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Angiopoietin-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Trovagene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga\u00ae-Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Trovagene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trovagene .."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Riptide Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Riptide Bioscience Announces Discovery of Novel Immune Checkpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Riptide Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Riptide Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Riptide Bi.."},{"orgOrder":0,"company":"ImmunogenX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Latiglutenase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ImmunogenX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunogenX \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunogenX.."},{"orgOrder":0,"company":"Atreca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca Announces First Patient Dosed in Phase 1b Clinical Trial of ATRC-101 in Patients with Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ATRC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ N.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay\u00ae for Treatment up to 52 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"EuMentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EuMentis Therapeutics Inc to Focus on Developing New Therapy to Treat High Value Neurodevelopmental and Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"EM-036","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"EuMentis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EuMentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EuMentis T.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Announces Presentations on JR-141 and JR-162 at the 16th Annual WORLDSymposium 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"JR-141","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Apamistamab-I-131","moa":"CD45","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Data Presentations at the Congress of the European Crohn\u2019s and Colitis Organisation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Announces Publication of Olutasidenib\u2019s Molecular Design and Potential Utility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces Updated Survival Data in Phase 1\/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-PSA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"PDE4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Delayed Release Tablet","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b\/2 Clinical Trial of Ciforadenant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scynexis completes patient enrollment for women\u2019s health phase 3 study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Provides Regulatory Update For COR388 Development Program In Alzheimer\u2019S Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Soligenix \\\"Fast Track\\\" Designation for RiVax\u00ae in the Prevention of Ricin Poisoning","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ricin toxin","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Sanifit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SNF472","moa":"Calcification","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sanifit","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polatuzumab Vedotin Achieved Primary Endpoint in the Japanese study for Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"Cyclophilin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces Publication of Phase 1b\/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx Announces IRB Approval to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Interim Data from STARDUST Study Show 2\/3rd of Patients Achieved Clinical Remission After Two Doses of STELARA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sihuan Pharmaceutical Accelerates Product Expansion in Digestive System and Liver Related Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Anaprazole sodium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sihuan Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sihuan Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sihuan Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Active Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the ?4?7 Integrin","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Advances Development of CAN04 Through Successful Production Scale Up","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nidanilimab","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Reveals 1-year Data for Novel Subcutaneous Formulation of Infliximab in Crohn\u2019s disease and Ulcerative colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files for Additional Indications of Tecentriq and Avastin for the Treatment of Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Announces Latest Data for LENVIMA\u00ae in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recardio Completes Interim Analysis of Phase 2 in AMI","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb announces updated results from phase 3 CheckMate -214 study of Opdivo plus Yervoy versus sunitinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis\\' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC40","moa":"TR-Beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Reveals Data In Renal Cell Carcinoma From an Ongoing Trial Of Sitravatinib In Combination With Nivolumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"TYRO3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Zelira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zelira Therapeutics Meets Primary Endpoints for Phase (1b\/2a) Medicinal Cannabis Trial for Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ZLT-101","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I\/ Phase II","graph3":"Zelira Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zelira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zelira The.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The First Patient Included in Japan in Isofol\\'s Phase 3 AGENT Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1220","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Announces Results From Study to Evaluate Efficacy of Elamipretide","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo\u00ae in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabiralizumab","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Five Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Arrevus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrevus Receives FDA Orphan Drug Designation for ARV-1801 (sodium fusidate)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Fusidate","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrevus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmac.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology\u2019s ALX148 Receives Two Fast Track Designations from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces First Subject Treated in Phase 1\/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"SNP3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life .."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Exploring Lead Defensin Mimetic Drug Candidate Brilacidin as Potential Novel Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Defensin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation for Retrotope\u2019s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta\u2019s Precision Oncology Research in EBV+ Cancers Highlighted at 16th Annual UCSD Moores Cancer Center Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"Leukotriene receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts BioCryst\u2019s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Camsirubicin","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Initiates Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion gets approval to add new sites to Phase II trial of SENS-401","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China approves first anti-viral drug against coronavirus Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Favilavir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang H.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Huntington\\'s disease drug, RG6042 gets Japanese orphan drug designation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tominersen","moa":"mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Aurigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurigene announces dose administration in first patient study for phase II study of psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AUR101","moa":"RAR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aurigene","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurigene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aurigene \/.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV\u2122 in Combination with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-101","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PL9643","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Ribomic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"FGF-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ribomic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ .."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemomAb Ltd. Announces Issuance of Composition of Matter Patent for CM-101 and Reinforces its IP Portfolio","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Reveals Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet Primary Endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio Therapeutics to Discuss Novel Lymph Node Vaccine Targeting Seven Key mKRAS Mutations at RAS","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1?I in a Model of Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SK1-I","moa":"Sphingosine Kinase 1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzo Biochem \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Bioch.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Genentech\u2019s Tecentriq Monotherapy as First-line Treatment of Advanced Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-Fibrotic Activity of Hepion Pharmaceuticals\u2019 CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"resTORbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"resTORbio Announces Interim Results for Phase 1b\/2a Trial of RTB101 in Patients with Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RTB101","moa":"TORC1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"resTORbio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"resTORbio .."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals\\' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Provides Update Regarding ZIMHI","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CoImmune Announces FDA Approval of its IND Application to Conduct a Phase 2b Clinical Trial with CMN-001 in Advanced RCC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CMN-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"Ergosterol","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Kowa Research Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kowa Achieves Goal Of Randomizing 10,000 Patients Into Landmark \\\"PROMINENT\\\" Cardiovascular Outcomes Study Of K-877 (Pemafibrate)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Pemafibrate","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Research Institute","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Research Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Resea.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIDDS: Second patient treated in the Phase I study, NZ-DTX-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"National C.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation and Rare Pediatric Disease Designation for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"Pyruvate kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Results from Phase 2 Study of Investigational Therapy Nemolizumab for Moderate to Severe Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-456","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Completes Enrollment in its Phase I\/II Trial to Evaluate Trappsol\u00ae Cyclo\u2122 for Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac for Advanced Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DPX-Survivac","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Study of CAPLYTA\u2122 (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science announces positive top-line Phase 2B\/3 results for oral masitinib in progressive forms of multiple sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"NoNO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NoNO Inc. Reports Groundbreaking Results from the Phase 3 ESCAPE-NA1 Study of the Peptide, Nerinetide, in Acute Ischemic Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nerinetide","moa":"PSD-95","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NoNO","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NoNO \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NoNO \/ Not.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed With Artery Infusion of Transgene\u2019s Oncolytic Virus TG6002 for Colorectal Cancer With Liver Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"TG6002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intrahepatic Artery Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces Positive Clinical Data in Ongoing Phase 1\/2 ADXS-503 Trial in NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CK-3773274","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Announces Phase 1\/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb\\'s Opdivo\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PH10","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breath Therapeutics, a Zambon Company, Initiates BOSTON-3 and BOSTON-4, Two Additional Clinical Studies for the Treatment of Bronchiolitis Obliterans Syndrome (BOS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WPD Pharmaceuticals\\' STAT3 Inhibitor Received FDA Approval of IND Status in Pediatric Brain Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"WPD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"Polyphor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyphor announces progress of the Phase III immuno-oncology program with balixafortide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polyphor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Polyphor \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DYV-700","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Dyve Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosc.."},{"orgOrder":0,"company":"Mannin Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mannin Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mannin Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mannin Res.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"HBM9161","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Iodine-131 apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Adrenomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Adrecizumab","moa":"Adrenomedullin receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed .."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise aims to develop coronavirus vaccine and drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech announces new direction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"ReNeuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReNeuron Announces Positive Long-term Data in Retinal Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"hRPC stem cell","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"ReNeuron","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReNeuron \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ReNeuron \/.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Approval for the Phase Ib\/II Clinical Trial of APG-1387 in Combination with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-1387","moa":"Apoptosis protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA accepts GSK\\'s sNDA for Zejula for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"Il-2 mutein","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Announces Research Publication Showing Markedly Enhanced Pain Relief of Second Pipeline Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ATB-352","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants \u2018breakthrough\u2019 status to antibiotic alternative as ContraFect rushes to join fight against superbug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Presents Updated Phase 1b\/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AU-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Conditioning Clinical Candidate MGTA-117 Demonstrates Broad Tolerability and High Therapeutic Index in Non-human Primates","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-117","moa":"CD117","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Institute of Human Virology and OncoImmune Launch Clinical Trial to Lessen Effects of HIV Later in Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CD24Fc","moa":"G\/10-associated SHP1 signaling","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fosun Kite\u2019s New Drug Application (NDA) Filing For Axicabtagene Ciloleucel Accepted For Review By China NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Fosun Kite Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fosun Kite Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Kite.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study of Aldafermin in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldafermin","moa":"Bile acid synthesis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX\u00ae2-73 (blarcamesine) in Multiple Sclerosis (MS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Announces INCREASE Study Of Tyvaso\u00ae Meets Primary And All Secondary Endpoints","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United The.."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering ATI-2173","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-2173","moa":"HBV polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Nymox Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nymox Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nymox Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nymox Phar.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Regulatory Path Forward for TLANDO\u2122 Resubmission","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Enhances its Intellectual Property Estate for CBP-307","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Sustained-Release Implant","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR 2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Announces Breakthrough Data from DeCidE1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax\u2019 Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant quadrivalent seasonal influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Pipeline Highlighted in Oral Presentations at the Annual Angiogenesis and Macula Society Meetings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefepime","moa":"Beta lactamase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Allecra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Allecra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allecra Th.."},{"orgOrder":0,"company":"Herantis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CDNF","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Herantis Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral infusion","sponsorNew":"Herantis Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Herantis P.."},{"orgOrder":0,"company":"Excel Diagnostics and Nuclear Oncology Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Excel Nuclear Oncology Center initiates the first Lu-177 DOTATOC PRRT clinical trial for the PUT-Neuroendocrine Tumors, in U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"177Lu-DOTATOC","moa":"SSTR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Excel Diagnostics and Nuclear Oncology Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excel Diagnostics and Nuclear Oncology Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Excel Diag.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetuximab","moa":"IRS1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol-Myers Squibb Advances CytomX Therapeutics\u2019 Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986249","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SB 11285","moa":"STING pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Ban.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Ionctura","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3K? Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"IOA-244","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionctura \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp gene","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Colesevelam Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Completion of Enrollment in its Extension Protocol to the Phase I Trial to Evaluate Trappsol Cyclo","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE Phase I\/II Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Includes First Patient in U.S. Phase 1\/2 Clinical Trial of ABX196 to Treat Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ABX196","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Strengthens its Commitment to Cystic Fibrosis Through Reallocating Resources","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Omburtamab","moa":"Beta\/gamma radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod in FSHD","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Completes Enrollment of Subjects in AXA1665-002 Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Pyoderma Gangraenosum","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"MRT5005","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel\u2122 in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ZYN002","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APEIRON\u2019s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRIA","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"APN01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R\/R AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of KAN-101 in Celiac Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Receives FDA IND Approval for Phase 2 Clinical Trial and Orphan Drug Designation for Anti-PD-L1 mAB","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"HBM9167","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Inflazome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inflazome\u2019s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Somalix","moa":"NLRP3","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Announces the Initiation of a Phase 3 Clinical Trial of D-PLEX100 for Sternal Wound Infection Post-cardiac Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation for Debiopharm\\'s Novel Chemo-Radio Sensitizer Debio 1143","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide in Combination With Anti-PD-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine\u2019s 36th Annual Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioDeliver.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"OX401","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fifth and Final Site Announced for BrainStorm\u2019s Progressive Multiple Sclerosis Phase 2 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors cell","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1\/2 ADXS-503 Trial in NSCLC at I\/O 360\u00b0 Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Neurimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"NI006","moa":"Transthyretin amyloid","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Presents Blinded Interim Data from the VISIONARY-MS Phase 2 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nonprofit drug development company starts GoFundMe for emergency funds to treat coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"EIDD-2801","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Drug Innovation Ventures at Emory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Innovation Ventures at Emory \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Drug Innov.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"BGB-3245","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Therapeutics Initiates Phase 1\/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"EOS-448","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage rethinks SAGE-217 program after phase 3 failure","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara to present at Transplantation & Cellular Therapy 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Rezafungin","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead starts 2 late-stage studies for coronavirus drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa gets RMAT designation for new CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CD30 CAR-T","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Ther.."},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll P.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Announces Enrollment of Last Patient in Phase 2B Dose-ranging, Efficacy Study of Lead Drug, ATB-346","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA in Combination with Low-Dose Cytarabine in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUYA Bioscience International\u00ae Announces the Successful Completion of Phase 1 Trial of HBI-3000","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulcardine sulfate","moa":"Fast sodium current","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RhoVac receives FDA approval in the US for the start of its Phase IIb clinical trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Respivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Respivant Sciences Supports International Rare Disease Day Through Awareness Activities","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Cromoglicate","moa":"Mast Cell","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respivant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Respivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Respivant .."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug Vision Presents Preclinical Results for GB-401","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"GB-401","moa":"ADRB","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda: Subcutaneous Formulation Of Vedolizumab Receives Positive CHMP Opinion","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hanmi\u2019s anti-NASH drug candidate set to become \u2018game changer\u2019 in global pharmaceutical market","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringes","sponsorNew":"Hanmi Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"Beijing Advaccine Biotechnology","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beijing Advaccine Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beijing Advaccine Biotechnology \/ Inovio Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Beijing Ad.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Celularity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Celularity ","highestDevelopmentStatusID":"1","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"CureVac","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"$8.3 million","newsHeadline":"CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"CureVac \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Pharmaceuticals Starts Clinical Trial of Anti-viral Drug\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Galidesivir","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"nCoV nanoviricide drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Tongji University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Hospital to Develop mRNA Vaccine Targeting the 2019-nCoV in 40 Days","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tongji University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tongji University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tongji Uni.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Announces Expanded Collaboration with HHS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibodie","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"4","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Pasteur Institute","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","amount":"$0.3 million ","upfrontCash":"Undisclosed","newsHeadline":"Pasteur Institute receives grant for Research on epidemiological characteristics and severe acute respiratory syndrome coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"2019-nCoV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pasteur Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pasteur Institute \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Pasteur In.."},{"orgOrder":0,"company":"CSL","sponsor":"University of Queensland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Collaborates With University of Queensland for Treatment of COVID-19 \n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Squalene API","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CSL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSL \/ University of Queensland","highestDevelopmentStatusID":"4","companyTruncated":"CSL \/ Univ.."},{"orgOrder":0,"company":"Advent","sponsor":"The Jenner Institute, Oxford University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Advent","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Advent \/ The Jenner Institute, Oxford University","highestDevelopmentStatusID":"6","companyTruncated":"Advent \/ T.."},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"rVaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Israel Institute for Biological Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Dyadic International","highestDevelopmentStatusID":"1","companyTruncated":"Israel Ins.."},{"orgOrder":0,"company":"Kansas State University Research Foundation","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma licences coronavirus drug candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kansas State University Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kansas State University Research Foundation \/ Cocrystal Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Kansas Sta.."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Beijing ZhonghuaInvestment Fund Management","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"$1.0 million","newsHeadline":"Chinese companies contract Generex for Covid-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"CD4 T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Generex Biotechnology \/ Beijing ZhonghuaInvestment Fund Management","highestDevelopmentStatusID":"1","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"iBio","sponsor":"CC-Pharming","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Plant derived vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ CC-Pharming","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ CC-.."},{"orgOrder":0,"company":"GSK","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":""},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM for organ failure in COVID-19 Patients ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tongji Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tongji Hospital \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tongji Hos.."},{"orgOrder":0,"company":"Bone Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation\n","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"rhNELL-1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Bone Biologics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bone Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bone Biolo.."},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinese official says Fujifilm\u2019s Favipiravir could treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm Toyama Chemical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Toyama Chemical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm T.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China approves use of Roche arthritis drug for some Covid-19 patients\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi, Regeneron Begin Global Kevzara Clinical Trial Program In Patients With Severe Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla ready with repurposed HIV drug to combat coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiwan firm teams up with US to develop Covid-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"TAIWAN","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medigen Vaccine Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigen Vaccine Biologics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Medigen Va.."},{"orgOrder":0,"company":"AntiCancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AntiCancer Inc. to Target Its Oral Recombinant Methioninase Against 2019-nCoV Coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Methioninase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer.."},{"orgOrder":0,"company":"Tulane University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tulane University launches new, primate-based coronavirus research program for vaccine aid","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tulane University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tulane University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tulane Uni.."},{"orgOrder":0,"company":"Forty Seven","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$4,900.0 million","upfrontCash":"$4,900.0 million","newsHeadline":"Gilead to Acquire Forty Seven for $4.9 Billion\r\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Magrolimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forty Seven","amount2":4.9000000000000004,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":4.9000000000000004,"dosageForm":"","sponsorNew":"Forty Seven \/ Gilead ","highestDevelopmentStatusID":"8","companyTruncated":"Forty Seve.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"STCube ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and STCube Enter into Development and Manufacturing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"STT-003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ STCube ","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Takeda Ventures","pharmaFlowCategory":"D","amount":"$100.5 million","upfrontCash":"Undisclosed","newsHeadline":"Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"XTX201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xilio Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Xilio Therapeutics \/ Takeda Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Xilio Ther.."},{"orgOrder":0,"company":"ITM","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ITM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ITM \/ Endocyte ","highestDevelopmentStatusID":"10","companyTruncated":"ITM \/ Endo.."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied DNA Sciences Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA\u2122 Vaccine Candidates Designed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Linear DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Applied DNA Sciences ","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"Immunocore","sponsor":"General Atlantic","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunocore Secures $130 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"MAGE-A4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Immunocore \/ General Atlantic","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Otsuka Chemical Co Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$90.0 million","newsHeadline":"Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Otsuka ","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Hypera Pharma","pharmaFlowCategory":"D","amount":"$825.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda agrees to divest select OTC and Non core assets in Latin America to Hypera Pharma for $825 million USD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Divestment","leadProduct":"Caffeine","moa":"Adenosine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.82999999999999996,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Hypera S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Maxim Merchant Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lipidio Pharmaceuticals Launches with First Close of Series A Financing","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"GDD3898","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Ph.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series C Financing","leadProduct":"Bexotegrast","moa":"AlphaVbeta1 integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Novartis ","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"NIH","pharmaFlowCategory":"D","amount":"$4.6 million","upfrontCash":"Undisclosed","newsHeadline":"NanoSurface Biomedical Awarded $1.9M in Funding from NIH","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Human iPSC-derived cardiac tissues","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoSurface Biomedical \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurfac.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Rockefeller University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.7 million","newsHeadline":"Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"10-1074","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Rockefeller University","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Pacylex Pharmaceuticals","sponsor":"Canadian angel investors","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Pacylex Raises US $3.9 Million To Advance New Cancer Therapy PCLX-001 Towards Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"PCLX-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Pacylex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacylex Pharmaceuticals \/ Canadian angel investors","highestDevelopmentStatusID":"5","companyTruncated":"Pacylex Ph.."},{"orgOrder":0,"company":"Alopexx Oncology","sponsor":"Beijing Shenogen Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DI-LEU16-IL2","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alopexx Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alopexx Oncology \/ Beijing Shenogen Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Alopexx On.."},{"orgOrder":0,"company":"Amunix","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amunix Raises $73 Million in Series A Financing Led by Omega Funds","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"AMX-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Amunix \/ Omega Funds","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ O.."},{"orgOrder":0,"company":"Moffitt Cancer Center ","sponsor":"DeMelle","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DeMelle OncoPharma Licenses Clinical-Stage Technology from Moffitt Cancer Center for New Targeted Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Farnesyl-Di-Methyl-Chromanol","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moffitt Cancer Center ","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moffitt Cancer Center \/ DeMelle","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Ca.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$94.0 million","upfrontCash":"Undisclosed","newsHeadline":"Royalty pharma acquires royalties on Entyvio from Massachusetts General Hospital","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Massachusetts General Hospital","amount2":0.089999999999999997,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Massachusetts General Hospital \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Miami Miller School of Medicine","sponsor":"Heat Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heat Biologics Announces Research Collaboration with University of Miami ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"gp-96 based COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Miami Miller School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Miami Miller School of Medicine \/ Heat Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Miami Mill.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Iliad Research and Trading","pharmaFlowCategory":"D","amount":"$0.4 million ","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Iliad Research and Trading","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Nichi-Iko Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ONO and Nichi-Iko Enter into Licensing Agreement and Technical Collaboration for Limaprost Alfadex Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Limaprost Alfadex","moa":"PGE2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Nichi-Iko Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Servier Canada","pharmaFlowCategory":"D","amount":"$410.0 million ","upfrontCash":"$27.6 million","newsHeadline":"Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0.40999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Cellectis \/ Servier ","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"Cinclus Pharma","sponsor":"Fourth Swedish National Pension Fund","pharmaFlowCategory":"D","amount":"$25.6 million","upfrontCash":"Undisclosed","newsHeadline":"Cinclus Pharma Raises SEK 250 Million for the Continued Development of a Novel Treatment Against Gastroesophageal Reflux Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Linaprazan","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Cinclus Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Cinclus Pharma \/ Fourth Swedish National Pension Fund","highestDevelopmentStatusID":"8","companyTruncated":"Cinclus Ph.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Mount Sinai Health System","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"$84.0 million","newsHeadline":"Advanz Pharma Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Alprostadil","moa":"EP1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0.10000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Abbhi Investments","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Autologous MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Abbhi Investments","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Therapeutics and Shionogi Announce Expanded Alliance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Zatolmilast","moa":"PDE4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi ","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Ther.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lyra Therapeutics wants a $58M IPO\n","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Hong Kong Teson Pharma","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"$3.0 million","newsHeadline":"Correvio Partners with Hong Kong Teson Pharma Limited","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Correvio Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Correvio Pharma \/ Hong Kong Teson Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Correvio P.."},{"orgOrder":0,"company":"Heartseed","sponsor":"Itochu Chemical Frontier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Allogeneic iPSC-derived cardiomyocytes","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Heartseed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"Heartseed \/ Itochu Chemical Frontier","highestDevelopmentStatusID":"6","companyTruncated":"Heartseed .."},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GT Biopharma and Cytovance Biologics Announce Collaboration for the treatment of coronavirus infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"OXS-3550","moa":"CD16","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cytovance Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Cytovance .."},{"orgOrder":0,"company":"Novavax","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Signs Development and Manufacturing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Emergent BioSolutions","highestDevelopmentStatusID":"6","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"J&J partner Legend plans IPO to fund CAR-T pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Atomwise","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","amount":"$1,080.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atomwise, Bridge Biotherapeutics pen $1B deal for AI-devised molecules","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Pellino protein","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Atomwise","amount2":1.0800000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.0800000000000001,"dosageForm":"","sponsorNew":"Atomwise \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/.."},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sinopharm Capital","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"China's GenFleet banks $58M for cancer, autoimmune pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"GFH018","moa":"TGF-beta receptor 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"GenFleet Therapeutics \/ Sinopharm Capital","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet T.."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3SBio ","pharmaFlowCategory":"D","amount":"$23.8 million","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ 3SBio ","highestDevelopmentStatusID":"5","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inovio files for $50 million offering amid Covid-19 vaccine hunt","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"XOMA","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zydus Cadila inks licensing pact with XOMA Corp","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Interleukin-2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"XOMA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XOMA \/ Zydus Cadila","highestDevelopmentStatusID":"1","companyTruncated":"XOMA \/ Zyd.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"European Health Authorities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie Partnering with Global Authorities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ European Health Authorities","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Menlo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Merger","leadProduct":"Serlopitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foamix Pharmaceuticals \/ Menlo Therapeutics ","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pha.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 1\/2 oncology biotech Zentalis Pharmaceuticals files for a $100 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Palbociclib","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"The Australian Research and Development Tax Incentive","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"OncoSec Receives $850,000 from The Australian R&D Tax Incentive Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ The Australian Research and Development Tax Incentive","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ IDEAYA Biosciences ","highestDevelopmentStatusID":"1","companyTruncated":"Cancer Res.."},{"orgOrder":0,"company":"GSK","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Angelini Pharma Acquires ThermaCare\u00ae From GSK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Camphor","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Angelini Pharma","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Ange.."},{"orgOrder":0,"company":"Burke Therapeutics","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Burke Therapeutics, LLC Signs Exclusive US Marketing and Supply Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Burke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Burke Therapeutics \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Burke Ther.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Venture Partners","pharmaFlowCategory":"D","amount":"$78.5 million","upfrontCash":"Undisclosed","newsHeadline":"Silverback Therapeutics Raises $78.5 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Silverback Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Biosight","sponsor":"Israel Biotech Fund ","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series C Financing","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.02,"dosageForm":"","sponsorNew":"Biosight \/ Israel Biotech Fund ","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Ocumension Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.3 million","newsHeadline":"Nicox to Receive \u20ac15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Ocumension Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Biotechnology Value Fund","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kymera Therapeutics Announces $102 Million Series C Financing\n","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"IRAK4","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Biotechnology Value Fund","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Lilly to Co-develop Antibody Therapies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Eli Lilly ","highestDevelopmentStatusID":"1","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Tyligand Bioscience","sponsor":"Context Therapeutics ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tyligand Bioscience and Context Therapeutics Sign Development Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Onapristone","moa":"PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tyligand Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyligand Bioscience \/ Context Therapeutics ","highestDevelopmentStatusID":"8","companyTruncated":"Tyligand B.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces $2.75 Million Registered Direct Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Raises $75 Million Series B+ Venture Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Nona Biosciences \/ SK Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Psagot Investment House","pharmaFlowCategory":"D","amount":"$43.7 million","upfrontCash":"Undisclosed","newsHeadline":"Protalix BioTherapeutics Announces $43.7 Million in Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Pegunigalsidase alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Protalix BioTherapeutics \/ Psagot Investment House","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Zelluna Immunotherapy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zelluna Immunotherapy collaborates with Karolinska Institutet","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"TCR based Natural Killer cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Karolinska Institutet","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Karolinska Institutet \/ Zelluna Immunotherapy","highestDevelopmentStatusID":"2","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"EXUMA Biotech","sponsor":"MSD Partners","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"F1 Oncology Changes Name To EXUMA Biotech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"CAR-T cells therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"EXUMA Biotech","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"EXUMA Biotech \/ MSD Partners","highestDevelopmentStatusID":"1","companyTruncated":"EXUMA Biot.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"TZLS-501","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ ThinkEquity","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$75.2 million","upfrontCash":"Undisclosed","newsHeadline":"A biotech tests Wall Street's roiled waters and comes away with a $75M IPO haul","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Un.."},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biogen and Vir Biotechnology to Collaborate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ V.."},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute of India, Novavax to develop and commercialise malaria vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Matrix-M vaccine adjuvant","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"8","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"IP Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kuur Therapeutics Launches to Develop and Commercialize \u201cOff-the-shelf\u201d CAR-NKT Cell Therapies\r\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"CMD-501","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kuur Therapeutics \/ IP Group","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Thera.."},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson ","highestDevelopmentStatusID":"4","companyTruncated":"Beth Israe.."},{"orgOrder":0,"company":"Lewis Katz School of Medicine","sponsor":"Can-Fite BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lewis Katz School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lewis Katz School of Medicine \/ Can-Fite","highestDevelopmentStatusID":"4","companyTruncated":"Lewis Katz.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"siRNAs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"University of Saskatchewan","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Saskatoon research lab gets $200,000 to find COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Saskatchewan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Saskatchewan \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"The EU Horizon 2020 consortium","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ExpreS2ion Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 consortium","highestDevelopmentStatusID":"1","companyTruncated":"ExpreS2ion.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Aprinoia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics expands presence in Greater China Region with CDO partnership for Alzheimer's candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Anti-tau monoclonal antibody","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Aprinoia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"$26.9 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Assertio Therapeutics Agrees to Merge with Zyla Life Sciences ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Merger","leadProduct":"Gabapentin","moa":"CaV Channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assertio Therapeutics \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Assertio T.."},{"orgOrder":0,"company":"The Peter Doherty Institute","sponsor":"Jack Ma Foundation","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Doherty Institute awarded AU$3.2 million to accelerate a vaccine for COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Peter Doherty Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Peter Doherty Institute \/ Jack Ma Foundation","highestDevelopmentStatusID":"1","companyTruncated":"The Peter .."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Duke-NUS Medical School ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics and Duke-NUS Medical School Partner to develop a coronavirus (COVID-19) vaccine using STARR Technology\u2122\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Starr RNA","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Duke-NUS Medical School ","highestDevelopmentStatusID":"2","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"University of Texas Medical Branch","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Texas Medical Branch","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Texas Medical Branch \/ Moleculin Biotech","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Vaxxas","sponsor":"Bill & Melinda Gates Foundation ","pharmaFlowCategory":"D","amount":"$5.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Measles vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxas","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vaxxas \/ Bill & Melinda Gates Foundation ","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxas \/ B.."},{"orgOrder":0,"company":"Ribomic","sponsor":"AJU Pharma","pharmaFlowCategory":"D","amount":"$6.0 million ","upfrontCash":"Undisclosed","newsHeadline":"RIBOMIC Enters License Agreement with AJU Pharma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RBM-007","moa":"FGF-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ribomic","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"Ribomic \/ AJU Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ .."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","amount":"$45.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Eureka Therapeutics Completes $45 Million Series E Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series E Financing","leadProduct":"ET140202","moa":"Alpha-fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Eureka Therapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"7","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Canada Pension Plan Investment Board ","pharmaFlowCategory":"D","amount":"$80.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sigilon Therapeutics Announces $80.3 Million Series B Financing to Advance","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"SIG-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sigilon Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Sigilon Therapeutics \/ Canada Pension Plan Investment Board ","highestDevelopmentStatusID":"5","companyTruncated":"Sigilon Th.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$21.4 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OSE-127","moa":"IL-7R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"OSE Immunotherapeutics SA","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Servier","highestDevelopmentStatusID":"8","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Bloom Science","sponsor":"ALS Association","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"The ALS Association Awards Bloom Science for Novel Microbiota-based Therapies\r\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"BL-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bloom Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bloom Science \/ ALS Association","highestDevelopmentStatusID":"4","companyTruncated":"Bloom Scie.."},{"orgOrder":0,"company":"Immatics","sponsor":"Arya Sciences Acquisition Corp","pharmaFlowCategory":"D","amount":"$252.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immatics Announces Business Combination with Arya Sciences Acquisition Corp\r\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"T cell immunotherapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0.25,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Immatics \/ Arya Sciences Acquisition Corp","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Griffith University","sponsor":"Luina Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luina Bio, Griffith University team up to develop coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Griffith University \/ Luina Bio","highestDevelopmentStatusID":"1","companyTruncated":"Griffith U.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$5.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Binimetinib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ IDEAYA Biosciences ","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"NewCo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FORMA Therapeutics Announces Divestiture of Select Hit Discovery Capabilities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Divestment","leadProduct":"FT-4202","moa":"RBC pyruvate kinase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ NewCo","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Meridian IT","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon Partners With Meridian IT to Fast Track Drug Manufacturing for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Meridian IT","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meridian IT \/ Mateon Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Meridian I.."},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Dechra Pharmaceuticals Manufacturing","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$43.0 million","newsHeadline":"Kindred Biosciences Announces Mirataz\u00ae (mirtazapine transdermal ointment) Transaction","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Divestment","leadProduct":"Mirtazapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Kindred Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kindred Biosciences \/ Dechra Pharmaceuticals PLC","highestDevelopmentStatusID":"12","companyTruncated":"Kindred Bi.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"$180.0 million ","upfrontCash":"$135.0 million ","newsHeadline":"BioNTech and Fosun to Develop mRNA Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0.17999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"BioNTech \/ Fosun Pharma ","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Institute of Chemical Technology","sponsor":"Lasa Supergenerics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lasa partners with ICT to develop Favipiravir therapy for COVID 19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Chemical Technology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Institute of Chemical Technology \/ Lasa SuperGenerics","highestDevelopmentStatusID":"1","companyTruncated":"Institute .."},{"orgOrder":0,"company":"Binex","sponsor":"Genexine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genexine, Binex to co-develop coronavirus vaccine GX-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Binex","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Binex \/ Genexine","highestDevelopmentStatusID":"1","companyTruncated":"Binex \/ Ge.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer, BioNTech to Co-Develop Potential COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Institute of Microbiology of the Chinese Academy of Sciences ","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences Announces Co-Development Agreement with IMCAS ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Microbiology of the Chinese Academy of Sciences ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institute of Microbiology of the Chinese Academy of Sciences \/ Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Institute .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Arcadia Consumer Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcadia Consumer Healthcare Acquires Iconic Over-the-Counter Anti-Diarrheal Medicine Kaopectate\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Bismuth Subsalicylate","moa":"COX","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Arcadia Consumer Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$289.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chinese cancer drugs developer InnoCare raises US$289 million after Hong Kong IPO is nearly 300 times oversubscribed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Orelabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0.28999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare P.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Partners with U.S. Government on Major Product Donation to Fight Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"Heme polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ U.S. Government","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"NineteenGale Therapeutics","sponsor":"Cyclica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroTheryX Partners with Cyclica to Launch NineteenGale Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Cannabinoid-based product","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NineteenGale Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NineteenGale Therapeutics \/ Cyclica","highestDevelopmentStatusID":"1","companyTruncated":"NineteenGa.."},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$4.9 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI collaborates with Institut Pasteur to develop COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institut Pasteur \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"Institut P.."},{"orgOrder":0,"company":"University of Georgia","sponsor":"EpiVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpiVax partners with UGA researcher on Covid-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia \/ EpiVax ","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Generex Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Li-Key peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ Generex Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ G.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"RoosterBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RoosterBio, Senti Biosciences Partner on Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human mesenchymal stem\/stromal cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ RoosterBio","highestDevelopmentStatusID":"1","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Nice & Green S.A","pharmaFlowCategory":"D","amount":"$21.2 million","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Moberg Pharma \/ Nice & Green S.A","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Biological E","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz acquires US distribution rights to two key hospital injectable medicines, reinforcing strategic focus on key growth segment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Daptomycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biological E \/ Sandoz ","highestDevelopmentStatusID":"12","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Announces Agreement to Joint Development for a Self-Assembling Vaccine (SAV)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Self-assembling vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"$0.2 million","newsHeadline":"CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WPD Pharmaceuticals \/ CNS Pharmaceuticals ","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"BELLUS Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"adMare BioInnovations","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"adMare BioInnovations \/ Bellus Health ","highestDevelopmentStatusID":"8","companyTruncated":"adMare Bio.."},{"orgOrder":0,"company":"Ubix Therapeutics","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoImmuneTech Enters into Exclusive License Agreement with Ubix Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NT-I7","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ubix Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ubix Therapeutics \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"Ubix Thera.."},{"orgOrder":0,"company":"Inceptua Group","sponsor":"Oxurion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"LUXEMBOURG","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ocriplasmin","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Inceptua Group","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inceptua Group \/ Oxurion ","highestDevelopmentStatusID":"12","companyTruncated":"Inceptua G.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$105.1 million ","upfrontCash":"Undisclosed","newsHeadline":"AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer\u2122 Tau Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"ACI3024","moa":"Tau aggregates","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AC Immune","amount2":0.11,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"AC Immune \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Lipigon ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"Antisense oligonucleotide therapies","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Secarna Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Lipigon ","highestDevelopmentStatusID":"1","companyTruncated":"Secarna Ph.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Astellas ","pharmaFlowCategory":"D","amount":"$1,600.0 million","upfrontCash":"$80.0 million","newsHeadline":"CytomX Therapeutics and Astellas Announce Strategic Collaboration ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"T-cell bispecific antibodies","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"CytomX Therapeutics","amount2":1.6000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.6000000000000001,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Astellas ","highestDevelopmentStatusID":"2","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"University of Georgia","sponsor":"CEL-SCI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Immunotherapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia \/ CEL-SCI","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Cascade Chemistry","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Appoints U.S. Company for cGMP Manufacturing of NP-120 (Ifenprodil) for COVID-19 Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cascade Chemistry","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cascade Chemistry \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Cascade Ch.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GDA-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Phase 2a Study of Cancer Vaccine Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-1901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improved Progression-Free Survival ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Announces Completed Enrollment in the ONCOS-102","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NORWAY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"GMCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Announces First Participant Trial of Wholly-Owned Lymphedema LYT-100","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Breakthrough Therapy Designation for Genentech\u2019s Esbriet pirfenidone","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genentech \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sihuan Announces Clinical Research of Favipiravir, Co-Developed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pha.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Positive Feedback from FDA on its Pivotal Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Announces Biomarker Data Showing EDP1815","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unum Implements Strategic Restructuring to Prioritize Efforts on BOXR1030","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BOXR1030","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Unum Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Unum Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Unum Thera.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Presents Positive Data From the Completed Phase Ia Study With MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Troxacitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Trofinetide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1647","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomic Therapeutics Announces Completion of Pre-IND Meeting with US FDA for ITI-1001, a Vaccine for the Treatment of GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ITI-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Phase 1\/2 Study of ARO-HSD ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-HSD","moa":"HSD17B13","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emerald Health Pharmaceuticals Receives Fast Track Designation from US FDA for EHP-101 in the Treatment of Systemic Sclerosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"EHP-101","moa":"PPAR gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Emerald He.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rare Pediatric Disease Designation to Stealth BioTherapeutics for Elamipretide for the Treatment of Barth Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First patient in treatment for RhoVac's clinical phase II study in Finland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001V","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial ","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OTX-TKI","moa":"TYK","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Ocular Therapeutix \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"MAX BioPharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAX BioPharma Announces Key Update to its Liver Fibrosis Program ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxy210","moa":"TGF beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"MAX BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAX BioPharma \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"MAX BioPha.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Preclinical Data For AMG 594 Presented At The Keystone Symposium On Heart Failure. ","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AMG 594","moa":"Cardiac Troponin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BT-001","moa":"CTLA4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"BioArctic AB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ban2401","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BioArctic AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioArctic AB \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"BioArctic .."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First patient treated with CRISPR medicine in phase 1\/2 trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AGN-151587","moa":"CEP290","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in AVITA Medical\u2019s Pivotal Study Evaluating RECELL\u00ae System for Pediatric Scald Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous regenerative epidermal cells","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Avita Medical","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avita Medical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avita Medi.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda begins development of COVID-19 plasma therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TAK-888","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision First Patient Enrolled for Phase II Part I Clinical Trial for ABV-1505 ","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Announces Allowance of New European Patent Covering Seclidemstat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Acelarin","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Reldesemtiv","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"MetaBlok","moa":"DPEP1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Receives Orphan Drug Designation for Umbralisib ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta\/CK1 epsilon","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"9","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Eleusis","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eleusis Announces Long Lasting Antidepressant-Like Effects of Psychedelics When Compared to Ketamine in Animals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Eleusis","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Eleusis \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Eleusis \/ .."},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhimeng Biopharma Announces the First-in-Human Dosing in Phase I Clinical Trial of ZM-H1505R ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ZM-H1505R","moa":"Capsid fromation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shanghai Zhimeng Biopharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Z.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"HDP","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology Expands Patent Portfolio for its Novel Versamune\u00ae Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"CD8 positive T lymphocyte stimulant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals completes enrollment in registrational trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Grindeks AS","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grindeks has successfully completed the Phase 1 Clinical Study of Its New Investigational Medicinal Product Methyl-GBB","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"LATVIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyl-GBB","moa":"GBBH","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Grindeks AS","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Grindeks AS \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Grindeks A.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Debio 0123","moa":"WEE1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Debiopharm \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Dynacure","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynacure Announces First Patient Dosed in Phase 1 \/ 2 'UNITE-CNM' Study of DYN101","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DYN101","moa":"Dynamin 2 expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Proof Of Concept Trial In PNH Patients With Oral Factor D Inhibitor, BCX9930","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals Announces First Patient Treated In Third And Final Dose Cohort Of Actimab-A Clag-M ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Announces Issuance of U.S. Patent for Use of PEDMARK\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals to Present Data from an Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-201","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Trial of Ionis Huntington\u2019s Disease Drug Halted After Side Effects","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tominersen","moa":"Huntingtin mRNA antisense","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"AJ Vaccines","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AJ Vaccines To Develop Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AJ Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AJ Vaccines \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"AJ Vaccine.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck & WEHI discover novel class of Candidate Anti Malaria Agents","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"WM382","moa":"Plasmepsins IX\/X","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Roskamp Institute","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study shows Nilvadipine slows early-stage Alzheimer\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nilvadipine","moa":"L-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Roskamp Institute","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Roskamp Institute \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Roskamp In.."},{"orgOrder":0,"company":"GEMoaB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GEMoaB Announces First Patient Apheresed in a Phase IA Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"UniCAR-T-CD123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GEMoaB \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ N.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Clearances for Three Phase Ib\/II Clinical Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare presents positive 48-week data from phase III study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CEL-SCI \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharma Announces Significant Results in STRIDE 3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE-083","moa":"GDF8","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA announce Rare Pediatric Disease Designation for Trofinetide","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Trofinetide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Neuraly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NLY01","moa":"GLP1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuraly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraly \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraly \/ .."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen, Tracon discontinue development of eye drug after mid-stage trial failure","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Carotuximab","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Santen Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Reports Preliminary Data from Phase II Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Acelarin","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Signs Agreement with the FDA on its Planned Pivotal Phase 3 Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IPH5201","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixazomib Citrate","moa":"Proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Liver Cancer Patient Dosed in the MIV-818 Phase Ib Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Troxacitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Plans to Develop MN-166 (ibudilast)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Regional Biocontainment Lab to Begin Testing of Brilacidin Against Coronavirus (COVID-19) Next Week","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Defensin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable ","highestDevelopmentStatusID":"5","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treatment With Gilead\u2019s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Vesatolimod","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilead Sciences \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Receives FDA Fast Track Designation For DARE-BV1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Airway Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Airway The.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Life Sciences Developing TZLS-501 as Treatment for Coronavirus Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TZLS-501","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tiziana Life Sciences \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Interim Clinical Data Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Updates On STARS Study FDA Interaction","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarizotan","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"MedDay Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedDay Reports Top-Line Data from Phase III Trial \u201cSPI2\u201d","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Biotin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"MedDay Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MedDay Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"MedDay Pha.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Announces Durable Virus Control of SHIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"N-803","moa":"IL-15","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Presents 96-week DISCOVER Trial Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences Announce ASN008 Achieves Positive Results","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ASN008","moa":"NaV Channel","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Asana BioSciences \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Provides Update on Opaganib (Yeliva\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"RedHill Biopharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH\/NAFLD","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Elobixibat","moa":"IBAT","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Pharma announces new data on ex-vivo FC21","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgrastim","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA grants Fast Track designation to Jardiance\u00ae\r\n","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progress of the Small Sample Clinical Trial of Ganovo\u00ae and Ritonavir Combination Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Danoprevir","moa":"NS3\/4A protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable ","highestDevelopmentStatusID":"11","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Attacking drug-resistant tumors with Sierra\u2019s struggling CHK1 blocker","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SRA737","moa":"Chk1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"GSK \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and EMD Serono bail on study of avelumab in head and neck cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Johns Hopkins Center for Health Security","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Potential universal flu vaccine shows efficacy in clinical trial\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Flu-v vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Johns Hopkins Center for Health Security","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johns Hopkins Center for Health Security \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopk.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem and Charit\u00e9 University of Medicine Berlin Join Forces Targeting COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for Coronavirus Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-HIG","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Engage Therapeutics reports positive results from Phase 2 study of Staccato alprazolam for epileptic seizures\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Alprazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Engage Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Engage The.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Five Prime Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemarituzumab","moa":"FGFR2B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Five Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Five Prime Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Five Prime.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Lattice Biologics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Amniotic fluid supplement","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lattice Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lattice Biologics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Lattice Bi.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Azasetron","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Not Applicable ","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen\u2019s Lenzilumab as a Potential Therapeutic for Lung Damage Arising From Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Beroni Group","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beroni Group Advances Research and Development of Medical Solution for Coronavirus (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beroni Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beroni Group \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Beroni Gro.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon launches antiviral programme focused on Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OT-101","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Launches Program to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Biotron","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biotron\u2019s Compound BIT036 as an antiviral for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cinnamoylguanidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biotron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biotron \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Biotron \/ .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"XPhyto","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XPhyto Therapeutics Initiates Infectious Disease Programs\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"XPhyto","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"XPhyto \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"XPhyto \/ N.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt explores iNO as potential Covid-19 therapy\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nascent Biotech Investigation Drug Product, Pritumumab, to be Studied as a Therapeutic agent against Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Pritumumab","moa":"Vimentin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nascent Biotech \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Bi.."},{"orgOrder":0,"company":"ImmuneMed, Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmuneMed tests new drug candidate VSF on COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Virus suppressing factor","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuneMed, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneMed, Inc \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"ImmuneMed,.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cansino Biologics and Institute Of Biotechnology, Academy Of Military Medical Sciences Developing Novel Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeoVax Labs \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Gain Trial in Alzheimer\u2019s Disease Has Reached Enrollment Milestone of 300 Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COR388","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cediranib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research Institute","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH clinical trial of investigational vaccine for COVID-19 begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Kaiser Permanente Washington Health Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kaiser Permanente Washington Health Research Institute \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Kaiser Per.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"Focal adhesion kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Pharma to Present Late Breaking Abstract at the AAT-AD\/PD Conference (Advances in Alzheimer's and Parkinson's Therapies)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the FDA for Voclosporin","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pilot testing of potential COVID-19 vaccine progresses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Stemirna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stemirna Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Stemirna T.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Initiator Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiator Pharma reports positive data from IPED2015 Phase IIa trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IPED2015","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Initiator Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Initiator Pharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Initiator .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Berotralstat (BCX7353) Significantly Reduced Use of Acute On-Demand Medicine in HAE Patients in APeX-2","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces Acceptance of sNDA Submission of ZEJULA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Announces Submission of Request for Type B Meeting with FDA to Discuss Trial Design for ENVASARC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Launches XRx-101, A New Program to Treat Coronavirus COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1\/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Celavet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celavet Inc. Plans Submission of Equine Tendinitis Study to FDA\u2019s Center for Veterinary Medicine ","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OK100 stem cell","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Celavet","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celavet \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Celavet \/ .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson says no evidence HIV drug works against coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Darunavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar reports positive results for Aplidin\u00ae against coronavirus HCoV-229E\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"VEGFA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Greffex","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greffex completes COVID-19 vaccine, prepares for FDA animal testing\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Greffex","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Greffex \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Greffex \/ .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release Syndrome in COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TJM2","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-Corona (COVID-19) IgG product","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"Kamada \/ N.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Completes Rolling Submission of New Drug Application to the FDA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Announces Important Advances in Novel COVID-19 Antibody Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Virus neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet publishes papers from studies of Takeda\u2019s dengue vaccine candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TAK-003","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"SignPath Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SignPath Pharma to Focus on Coronavirus Disease (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Curcumin","moa":"PPAR gamma","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SignPath Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SignPath Pharma \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"SignPath P.."},{"orgOrder":0,"company":"Avivagen","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avivagen Accelerates Plans for Commercial Launch of Its OxC-Beta\u2122 Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Beta Carotene","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avivagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avivagen \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Avivagen \/.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epinephrine Nasal Spray Demonstrates Bioequivalent Exposure","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Safely Completes Expanded Dosing of METABLOK","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva announces completion of patient visits for Phase IIb clinical study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces Publication of Positive TAVO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pneumagen Leverages its Novel Glycan Approach","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Carbohydrate binding modules","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pneumagen \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"Cellenkos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellenkos, Focuses on the Development of Cell-theray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CK0801","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cellenkos","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellenkos \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces First Patient Dosed in Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine Hydrochloride","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Reports Positive Study Results for ET-101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Topiramate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences\u2019 ALPN-101 Receives FDA Orphan Drug Designations","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-101","moa":"CD28","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"VIB","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VIB achieves important milestone in the development of a COVID-19 drug\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody-based drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VIB \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"VIB \/ Not .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie\/Roche\u2019s Venclexta fails in confirmatory AML trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Walter Reed Army Institute of Research","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Storied Army institute developing COVID-19 diagnostic test, vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Protein vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Walter Reed Army Institute of Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Walter Reed Army Institute of Research \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Walter Ree.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB provides an update on Phase 2b padsevonil safety and efficacy study in epilepsy (ARISE)\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Padsevonil","moa":"GABA receptor A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage to run 3 new studies to save once-failed depression drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposa\n","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluri \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhejiang Hisun Pharmaceutical Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang H.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"WEG232","moa":"Substance P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharma Publishes Phase 2 Study Data in Major Peer-reviewed Journal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis announces NEJM publication of three pivotal trials ","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody for COVID-19 Treatment","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Gimsilumab","moa":"GCSF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Roivant Sciences \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Binimetinib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder ","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Initiates Phase III Clinical Trial of Actemra in Hospitalized Patients With Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entos Pharmaceuticals Is Developing a DNA Vaccine Against COVID-19 Using Its Fusogenix Nanomedicine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Fusogenix DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Receives Orphan Drug Designation From FDA for DCR-A1AT ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DCR-A1AT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EUSA Pharma and Papa Giovanni XXIII Hospital to Initiate an Observational Case-control Study of Siltuximab in COVID-19 ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eusa Pharma \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharm.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for SARS-CoV-2 ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ii-Key peptide vaccine","moa":"CD4 T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generex Biotechnology \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable ","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"20vPnC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alstr\u00f6m Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable ","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nelipepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen to start trial of SNG001 in COVID-19 imminently","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona completes its six months double blind Phase 2a trial of Tesomet in hypothalamic obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharnext Receives Promising Innovative Medicine Designation for PXT3003 ","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 ","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sunitinib","moa":"FLT3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"CalciMedica \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Novotech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novotech Wins Cro Contract For Komipharm Coronavirus Covid-19 Clinical Trial In South Korea\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Panaphix","moa":"Cytokine","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novotech \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Novotech \/.."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-clinical Models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Linear DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie\u2019s HIV drug combo shows no benefit in Covid-19 trial\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Leads Coronavirus Vaccine Charge","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"QED Therapeutics begins patient dosing in ph3 and ph 2 trials of Infigratinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"QED Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"QED Therap.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Dupixent rival makes the grade in phase 3\u2014again","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Accelerates Completion Of Advance-1 Phase 2\/3 Trial Of Axs-05 In Alzheimer's Disease Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics To Announce Baseline Characteristics From Galactic-Hf During ACC.20\/WCC","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BX001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aqualung Therapeutics Advances Its Investigational Monoclonal Antibody into IND-Enabling Studies ","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Aqualung Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aqualung Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"5","companyTruncated":"Aqualung T.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Develops STI-4398 For Potential Prevention And Treatment Of SARS-COV-2 Coronavirus Disease (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-4398","moa":"Spike protein S1 domain","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Harvard Apparatus Regenerative Technology","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan\u2122 Esophageal Implant","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cellspan Esophageal Implant","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Harvard Apparatus Regenerative Technology","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harvard Apparatus Regenerative Technology \/ Not Applicable ","highestDevelopmentStatusID":"5","companyTruncated":"Harvard Ap.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's CanSino pushes coronavirus vaccine into clinical testing as Moderna kicks off trial\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CanSino Biologics \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BARDA: Athersys\u2019 Cell Therapy \u201cHighly Relevant\u201d for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep\u2019s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"iBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iBio Developing Proprietary COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 Virus-Like Particle","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Not.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ponesimod","moa":"S1PR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared IND for IMS001 ","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IMS001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AgeX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Phase IIa Study with IRL752 is Published in Movement Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IRL752","moa":"5-HT7 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migrain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces First Patient Dosed in the Global Phase Ib\/II Clinical Study ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Gel","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL\u2122","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ATP citrate lyase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical development plans for SCO-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SCO-101","moa":"VRAC complex","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinese Center for Drug Evaluation (CDE) Cleared Taletrectinib IND ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Inc. Announces Positive Safety Profile of Its Drug Trappsol\u00ae Cyclo","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PLN-1474","moa":"Integrin Alpha5beta1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pliant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VTP-800","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"PATH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Funded Nipah virus vaccine candidate first to reach Phase 1 clinical trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"HeV-sG-V","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PATH","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PATH \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PATH \/ Not.."},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DPPC","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novus Therapeutics, Inc \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Novus Ther.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Developing New Drug for Pulmonary Fibrosis Caused by COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ology Bioservices, Vanderbilt University Medical Center to Develop, Manufacture Monoclonal Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities LLC","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ JMP Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Decheng Capital","pharmaFlowCategory":"D","amount":"$123.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series C Financing","leadProduct":"Sotigalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Decheng Capital","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","amount":"$7.7 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Increases Previously Announced Bought Deal to $7.7 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"Interleukin 2","moa":"T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Aegis Capital Corp","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer Asset","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"FAZ053","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Laekna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"TAC01-HER2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Triumvira Immunologics","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia, Inc. Announces Closing of Approximately $6.0 Million Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Private Placement","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Alvotech","sponsor":"DKSH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and DKSH partner to bring key biosimilar to Asia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"IVIX","sponsor":"Ovoca Bio","pharmaFlowCategory":"D","amount":"$11.1 million","upfrontCash":"Undisclosed","newsHeadline":"Ovoca Bio plc: Acquisition of Remaining Minority Shareholding in IVIX LLC","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"RUSSIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Acquisition","leadProduct":"BP-101","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"IVIX","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"IVIX \/ Ovoca Bio","highestDevelopmentStatusID":"10","companyTruncated":"IVIX \/ Ovo.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","amount":"$10.2 million","upfrontCash":"Undisclosed","newsHeadline":"VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Fasedienol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-Licensing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Debio 0228","moa":"CA IX","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"3B Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"3B Pharmaceuticals \/ Debiopharm","highestDevelopmentStatusID":"2","companyTruncated":"3B Pharmac.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Unitaid","pharmaFlowCategory":"D","amount":"$6.4 million","upfrontCash":"Undisclosed","newsHeadline":"MedinCell Receives $ 6.4 Million Grant From Unitaid to Fight Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MedinCell","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Unitaid","highestDevelopmentStatusID":"4","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Avectas","sponsor":"Vycellix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vycellix and Avectas Announce Collaboration to Advance Next-Generation Solutions for Cell & Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"VY-M","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avectas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avectas \/ Vycellix","highestDevelopmentStatusID":"1","companyTruncated":"Avectas \/ .."},{"orgOrder":0,"company":"Regenacy Pharmaceuticals","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regenacy Pharmaceuticals Raises $30 Million in Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"Ricolinostat","moa":"HDAC6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Regenacy Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Regenacy Pharmaceuticals \/ Cobro Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Regenacy P.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alnylam Pharmaceuticals and Gen Sign Distribution Agreement ","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Gen","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Xencor","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend\u2122 XmAb\u00ae Antibody Technology in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Xencor \/ V.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Alector","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-SIRP-alpha antibody","moa":"SIRP alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Alector","highestDevelopmentStatusID":"4","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"SkylineDx","sponsor":"BioInvent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SkylineDx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SkylineDx \/ BioInvent","highestDevelopmentStatusID":"6","companyTruncated":"SkylineDx .."},{"orgOrder":0,"company":"ViralClear Pharmaceuticals","sponsor":"NeuroClear","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Merimepodib","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ViralClear Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ViralClear Pharmaceuticals \/ NeuroClear","highestDevelopmentStatusID":"1","companyTruncated":"ViralClear.."},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Castle Creek Biosciences Announces $75 Million Investment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"10","companyTruncated":"Castle Cre.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"JDRF T1D","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ JDRF T1D","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire.."},{"orgOrder":0,"company":"SutroVax","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series D Financing","leadProduct":"SVX-24","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"SutroVax","amount2":0.11,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"SutroVax \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"SutroVax \/.."},{"orgOrder":0,"company":"CG Oncology","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$10.0 million","newsHeadline":"CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CG0070","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CG Oncology","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"CG Oncology \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"CG Oncolog.."},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"MPM Capital","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"mRNA-mediated protein replacement therapies","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"ReCode Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ReCode Therapeutics \/ MPM Capital","highestDevelopmentStatusID":"1","companyTruncated":"ReCode The.."},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Akers Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Coronvirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Premas Biotech \/ Akers Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Premas Bio.."},{"orgOrder":0,"company":"iBio","sponsor":"AzarGen Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio Supporting AzarGen Biotechnologies\u2019 Development of a Rituximab Biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ AzarGen Biotechnologies","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Aza.."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$20.0 million","newsHeadline":"Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oasmia Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ T.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bold Therapeutics Seeks Collaborators for Rapid Development of BOLD-100; Lead Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"BOLD-100","moa":"GPCR 78","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Alphamab Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"KN026","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Alphamab Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Rising Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Minnesota \/ Rising Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$3.5 million","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi\u00ae Sprinkle","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diurnal Group","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Kitasato Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.5 million","newsHeadline":"Daiichi Sankyo, Kitasato Pharma to terminate sales cooperation for Influenza HA Vaccine \u201cDaiichi Sankyo\u201d in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Vaccine","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Influenza HA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Kitasato Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AmMax Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LifeMax Launches AmMax Bio Following The License Of Worldwide Rights to a Clinical Stage Orphan Asset From Amgen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AMG 820","moa":"CSF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ AmMax Bio","highestDevelopmentStatusID":"7","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"TJD5","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"University of Alabama","sponsor":"Altimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Alabama","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Alabama \/ Altimmune","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19 and Landmark Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Isoprene Pharmaceuticals","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Retinamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Isoprene Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isoprene Pharmaceuticals \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Isoprene P.."},{"orgOrder":0,"company":"Covar Pharmaceuticals","sponsor":"Aptorum","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"SACT-COV19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Covar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Covar Pharmaceuticals \/ Aptorum Group","highestDevelopmentStatusID":"1","companyTruncated":"Covar Phar.."},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"Undisclosed","newsHeadline":"AM-Pharma Increases Funding To \u20ac163m For Phase-Iii Trial Of Recap In Sa-Aki","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Ilofotase alfa","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Cowen Healthcare Investments","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma .."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"CureDuchenne Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Oligonucleotide linked antibody","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ CureDuchenne Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"National Research Council of Canada","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Announces Collaboration with the National Research Council of Canada to Develop Pan-Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Pan-coronavirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Research Council of Canada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Research Council of Canada \/ VBI Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"National R.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M adjuvant","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor for Coronavirus Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Cumberland Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Cumberland.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Lee's Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Windtree Enters into Agreement with Lee's Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Lucinactant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Lee's Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Evotec","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Ildong to collaborate with development projects on INDiGO platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"IDG-16177","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Ildong","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ I.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Vaccinex Announces up to $16.5 Million in Equity Financing Agreements","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Keystone Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"$40.0 million","newsHeadline":"Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Gedeon Richter","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CX-2029","moa":"CD71","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Karolinska Institutet","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cobra Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ Karolinska Institutet","highestDevelopmentStatusID":"4","companyTruncated":"Cobra Biol.."},{"orgOrder":0,"company":"Coalition for Epidemic Preparedness Innovations","sponsor":"U.K Government","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"UK boosts support for CEPI to spur COVID-19 vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"NORWAY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Coalition for Epidemic Preparedness Innovations","amount2":0.27000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Coalition for Epidemic Preparedness Innovations \/ U.K Government","highestDevelopmentStatusID":"1","companyTruncated":"Coalition .."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Vinnova","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Vinnova","highestDevelopmentStatusID":"8","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford BioTherapeutics (OBT) Announces Second Oncology Drug Candidate Selected to Advance into Formal IND Enabling Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Novavax","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Vaxart","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent Biosolutions Signs Development And Manufacturing Agreement With Vaxart","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Recombinant vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emergent BioSolutions \/ Vaxart","highestDevelopmentStatusID":"4","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$50.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Oncology biotech Ayala Pharmaceuticals files for a $50 million IPO\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Public Offering","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"U.S. Army Medical Research and Development Command","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pentagon Strikes Deal With Biotech Firm to Make Coronavirus Drug Available to Troops\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax\u2019 NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant hemagglutinin protein nanoparticle influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CS12192","moa":"JAK3\/JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shenzhen C.."},{"orgOrder":0,"company":"OncoQuest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"Mucin-16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoQuest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoQuest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoQuest .."},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"CD4 T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"eTheRNA immunotherapies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"eTheRNA immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"eTheRNA im.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProtoKinetix Ready to Ship AAGP\u00ae to the University of Alberta for the Continuation of Phase 1 Human Trials","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX-629","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Data for SRK-015 at the Muscular Dystrophy Association Clinical and Scientific Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-015","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"LB1148","moa":"Serine protease","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Initiation of Investigator-Sponsored Phase 1\/2 Study of AVB-500","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Clinical Candidate Apabetalone Featured As A Potential Covid-19 Treatment In Recent Publication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1\/2 Study (O-12-M1)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SCO-101","moa":"VRAC complex","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"Valneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VLA1553","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio Receives FDA Fast Track Designation for Niemann-Pick Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Receives Fast Track Designation for IPI-549 in Combination with the Checkpoint Inhibitor Opdivo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Danoprevir","moa":"NS3\/4A protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIDDS announces positive preclinical data for NanoZolid\u00ae-TLR9 agonist project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NZ-TLR9","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vopec gets NOC & test license from DCGI to develop new cancer drug that offers therapeutic option for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vopec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vopec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Vopec Phar.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China clears Taletrectinib IND, issues clinical trial authorizations","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology to test COVID-19 antibody 'in the summer'","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Technologies Receives Rare Pediatric Disease Designation from FDA for OT-58","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OT-58","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orphan Technologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Tec.."},{"orgOrder":0,"company":"Inflazome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inzomelid completes Phase I studies and shows positive results in the treatment of Cryopyrin-Associated Periodic Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Inzomelid","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome .."},{"orgOrder":0,"company":"Qurient","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qurient Announces Publication in New England Journal of Medicine of Phase 2 Data for Telacebec","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Telacebec","moa":"Cytochrome bc1 complex","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Qurient","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qurient \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qurient \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants Orphan Drug Designation to AlloVir\u2019s Viralym-M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Viralym-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief therapeutics and NeuroRx File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innocoll P.."},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"APR-OD031","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"APR Applied Pharma Research","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"APR Applied Pharma Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"APR Applie.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VGX-3100","moa":"HPV-16\/HPV-18 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyripharm Biopharmaceuticals Is in the Development Stage of a Novel Integrated Theranostic Approach for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed ","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-CB1 antagonist analogues","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vyripharm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Vyripharm .."},{"orgOrder":0,"company":"EpiVax Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-PD-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"EpiVax Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax Onc.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP-305","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"BioDuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioDuro Initiates Effort to Develop COVID-19 Nanobody Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Nanobody","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioDuro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioDuro \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"BioDuro \/ .."},{"orgOrder":0,"company":"Decibel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex binder","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Decibel Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Transtympanic Injection","sponsorNew":"Decibel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Decibel Th.."},{"orgOrder":0,"company":"Bio-Pharm Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"JBPOS0101","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Bio-Pharm Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bio-Pharm Solutions \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Pharm .."},{"orgOrder":0,"company":"National Tsing Hua University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiwan focuses on BNCT for cancer treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Undisclosed ","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Boron Neutron Capture Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"National Tsing Hua University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Tsing Hua University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"National T.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Positive Preliminary Phase 1a\/1b Clinical Trial Results for AB-729","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-729","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Translate Bio Provides MRT5005 Program Updates","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"MRT5005","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Composition of Matter Patent in China Expands ONC201\u2019s Global Coverage","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Pharmaceuticals Provides Update on Impact of COVID-19","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Linaclotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Submits New Drug Application for ISTURISA\u00ae in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharma Publishes study in Antimicrobial Agents and Chemotherapy Journal showing Positive Preclinical Results for Mino-Lok","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Announces Initiation of BDC-1001 Clinical Trial in Patients with HER2-Expressed Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BDC-1001","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mylan and Lupin Announce Positive CHMP Opinion for Nepexto\u00ae, Biosimilar Etanercept","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenScript ProBio Congratulates XlifeSciences on the Start of TAEST16001 Early Phase Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue L.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"HGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck reports headline results from phase IIa AMBLED study of foliglurax in Parkinson\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Foliglurax","moa":"Metabotropic glutamate receptor type 4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Submits Phase III Protocol Synopsis to FDA for Lenzilumab for Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Completes Phase I Study on Gimsilumab for ARDS in COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Gimsilumab","moa":"GCSF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA\u00ae (ozanimod)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP backs Sanofi\u2019s myeloma drug Sarclisa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Genentech\u2019s New Drug Application for Xofluza for the Treatment of Influenza in Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Difamilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Soticlestat","moa":"CH24H","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Relapsed\/Refractory B-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals\u2019 Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease\r\n","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Announces American College Of Cardiology Presentation Of Positive Phase 3 Evinacumab Results","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Evinacumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen jumps into COVID-19 arena with polyclonal antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant anti-coronavirus 19 hyperimmune gammaglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACC: Bayer, Merck's vericiguat leads meeting with phase 3 data","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome reports late-stage depression trial defeat, shares wilt","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupropion Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SEL120","moa":"CDK8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics Launches Program to Evaluate ST266 in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine and Ongoing Business and Clinical Operations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2 spike protein inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX-471","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals To Move Forward With A PCS499 Phase 3 Trial After A Successful FDA Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PCS499","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa P.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1536","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Outcomes Of Mesoblast\u2019s Cell Therapy In End-Stage Ischemic Heart Failure Presented","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Revascor","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Transendocardial Injection","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Receives Orphan Drug Designation from FDA for Toripalimab-Axitinib Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar delays CB4211 Phase 1b Study for NASH and Obesity","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CB4211","moa":"Insulin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilonacept","moa":"IL-1 beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"IMVT-1401","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Completes Patient Dosing in Phase 2a DME Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck announces phase IIa study results of Lu AG06466 in adults with Tourette Syndrome\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Droplet Microfluidic Screening and Sequencing Can Vastly Expand the Universe of New Antibody Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data on Sagimet's Lead Candidate TVB-2640 to be Presented at EASL ILC 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Announces Positive New Data Validating the INTASYL Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ME-401","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Announces Favorable Topline Results From Investigative Formulation of Rifaximin SSD IR","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Immediate Release Soluble Solid Dispersion Tablet","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"AKR-001","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Hard Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Discovery and Pharmahungary Report Positive Early-Stage Results for Novel Micro-RNA Therapeutic","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"miRNA-125b","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Horizon Discovery Group","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Horizon Discovery Group \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Horizon Di.."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"Mimetogen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavilermide","moa":"TrkA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mimetogen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mimetogen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mimetogen .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Receives Positive CHMP Opinion for ADCETRIS in Combination with Cyclophosphamide, Doxorubicin and Prednisone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application for Anti-BCMA CAR T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionomics and MSD Scientists Publish Preclinical Findings for BNC375 in Peer-Reviewed Journal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BNC375","moa":"Nicotinic alpha-7 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Bionomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bionomics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Positive Findings From an Interim Analysis in the Phase 1\/2 trial of QR-421","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"QR-421a","moa":"USH2A protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002\/RG7935) in Parkinson's Disease to be Presented at AAT-AD\/PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement factor C5a","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocardia Announces Positive DSMB Recommendation To Continue Phase 3 Pivotal CardiAMP Heart Failure Study As Planned","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Provides Comment on Impact of Vascepa\u00ae Patent Litigation on MAT9001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 pentaenoic acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primmune Therapeutics Announces the Selection of PRTX007 for COVID-19 and Oncology Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Primmune Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts IND Application for CRISPR\/Cas9-Based Sickle Cell Disease Therapeutic Candidate","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OTQ923","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics Announces Arthur DeCillis, MD as Acting Chief Medical Officer to Support CBX-12\u2019s Entry into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Exatecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Commencement of Retreatment of Patient Under GTB-3550 TriKE therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science announces that FDA clears masitinib IND in Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulopenem","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"HMPL-453","moa":"FGFR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Study Data for Gilead\u2019s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GS-6207","moa":"HIV capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GM-CSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Launches Novel I-Cell\u2122 COVID-19 Cellular Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-6991","moa":"Spike protein S1 domain","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Biocad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIOCAD started working on mRNA vaccine against coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-COV-2 mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Biocad","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biocad \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Biocad \/ N.."},{"orgOrder":0,"company":"Open Orphan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Open Orphan\u2019s Cathal Friel on firm\u2019s \u201cmilestone\u201d human coronavirus challenge study (ORPH)\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OC43 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Open Orphan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Open Orphan \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Open Orpha.."},{"orgOrder":0,"company":"Fillmed Laboratories","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crescita Signs Exclusive Distribution Agreement with FILLMED","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Fillmed Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fillmed Laboratories \/ Crescita Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Fillmed La.."},{"orgOrder":0,"company":"Murdoch Children\u2019s Research Institute ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Murdoch Children\u2019s Research Institute to trial preventative vaccine for COVID-19 healthcare workers\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Murdoch Children\u2019s Research Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Murdoch Children\u2019s Research Institute \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Murdoch Ch.."},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Partners with Neuronasal Inc. to Develop Novel Treatment for mild Traumatic Brain Injury (mTBI)","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Neuronasal","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"intranasal","sponsorNew":"Neuronasal \/ ATAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Neuronasal.."},{"orgOrder":0,"company":"Auditus","sponsor":"Oblato","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oblato Biotech Company Acquires Hearing Loss Drug","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Auditus","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Auditus \/ Oblato","highestDevelopmentStatusID":"8","companyTruncated":"Auditus \/ .."},{"orgOrder":0,"company":"AnGes","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anges to develop coronavirus vaccine with Osaka University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AnGes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnGes \/ Not Applicable ","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ No.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila looks to expedite Covid-19 vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces Initiation of Coronavirus Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Coronavirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codagenix partners Serum Institute of India on Covid-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Live-attenuated vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Codagenix ","highestDevelopmentStatusID":"1","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Grifols International","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-SARS-CoV-2 hyperimmune globulin therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoPrecise introduces PolyTope mAb therapy to tackle coronavirus pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Medicago","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago Announces Production of a Viable Vaccine Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Virus-Like Particle","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicago \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medical firms accelerate coronavirus vaccine research, clinical trials expected in late April","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Kangtai Biological Products \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shenzhen K.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baricitinib emerges as potential treatment for new coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Amarillo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as Defense Against Coronavirus\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon-alpha","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Amarillo Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amarillo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Amarillo B.."},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellular Biomedicine Group Announces Q4 and Full Year 2019 Financial Results and Recent Operational Progress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal stem cell exosomes","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cellular Biomedicine Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellular B.."},{"orgOrder":0,"company":"Novacell","sponsor":"AD Korea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novacell, AD Korea Corona 19 treatment joint development MOU","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"Heptameric peptide FPR2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novacell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novacell \/ AD Korea","highestDevelopmentStatusID":"4","companyTruncated":"Novacell \/.."},{"orgOrder":0,"company":"Texas A&M University System laboratories","sponsor":"iBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio Announces Advancement of COVID-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"IBIO-200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Texas A&M University System laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Texas A&M University System laboratories \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"Texas A&M .."},{"orgOrder":0,"company":"Generation Bio","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generation Bio and Vir Biotechnology Ink Research Pact to Leverage Scalable Non-Viral Gene Therapy Platform for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generation Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Generation Bio \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Generation.."},{"orgOrder":0,"company":"The University of Hong Kong","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI partners with HKU for COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"HONG KONG","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Hong Kong","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Hong Kong \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Fudan University","sponsor":"RNACure Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Towards an effective mRNA vaccine against 2019-nCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fudan University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fudan University \/ RNACure Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Fudan Univ.."},{"orgOrder":0,"company":"International Vaccine Institute","sponsor":"Sumagen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sumagen teams up with IVI to develop COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Viral vaccine vector","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"International Vaccine Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"International Vaccine Institute \/ Sumagen","highestDevelopmentStatusID":"4","companyTruncated":"Internatio.."},{"orgOrder":0,"company":"Cellivery","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellivery, iCP-NI 'Corona 19' Primate Treatment Efficacy Verification Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"iCP-NI","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cellivery","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellivery \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellivery .."},{"orgOrder":0,"company":"ISR","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISR Starts Vaccine Development For Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Corona vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ISR","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISR \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ISR \/ Not .."},{"orgOrder":0,"company":"Distributed Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Doctor Featured In Netflix's Pandemic Believes He Has Found A 'Cure' For Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibodies","moa":"S-protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Distributed Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Distributed Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Distribute.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus Drug Development Update From Nanoviricides","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside A Startup\u2019s Pivot To Have AI Fight Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"HONG KONG","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Insilico Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Insilico M.."},{"orgOrder":0,"company":"G+FLAS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G+FLAS Life Sciences Readying Animal Testing Of Coronavirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunogenic recombinant vaccine","moa":"S-protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"G+FLAS Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"G+FLAS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"G+FLAS Lif.."},{"orgOrder":0,"company":"ReiThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"After The USA And Australia, The First Pre-Clinical Animal Tests Are Also Carried Out In Italy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ReiThera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReiThera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ReiThera \/.."},{"orgOrder":0,"company":"Max Planck Institute for Infection Biology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"German Scientists Test TB Vaccine Against Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VPM1002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Max Planck Institute for Infection Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Max Planck Institute for Infection Biology \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus Study To Look At Using Gout Drug To Prevent Lung Complications And Deaths From Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Qilu Hospital of Shandong University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bevacizumab For The Treatment Of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Qilu Hospital of Shandong University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qilu Hospital of Shandong University \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Qilu Hospi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Trials Asthma Drug Alvesco To Fight COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Statement On SOLIRIS\u00ae (Eculizumab) And COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Eculizumab","moa":"Complement C5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melatonin? Stem Cells? Researchers Step Up With Unconventional Approaches To COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"Melatonin receptor type 1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland .."},{"orgOrder":0,"company":"VERO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VERO Biotech Announces First Patient With COVID-19 Infection Complicating Pulmonary Hypertension Treated With GENOSYL\u00ae DS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VERO Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"VERO Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"VERO Biote.."},{"orgOrder":0,"company":"German Primate Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japanese Encephalitis Drug May Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Camostat","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Primate Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"German Primate Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"German Pri.."},{"orgOrder":0,"company":"University of Tokyo ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nafamostat Inhibits SARS-Cov-2 Infection, Preventing COVID-19 Transmission","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Tokyo ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Tokyo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gemvax & Kael Expands GV1001 Patent To Cover COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Peptide","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tertomotide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GemVax & KAEL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GemVax & K.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Submits Letter Of Intent For A Clinical Trial Application For A Phase II Study In Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"C21","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Panoptes Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Viennese Biotech Company Panoptes Pharma Gmbh Has A Promising Active Ingredient Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PP-OO1","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panoptes Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panoptes Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Panoptes P.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel tests coronavirus vaccine prototype on rodents at defense lab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Israel Institute for Biological Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Israel Ins.."},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Ridgeback ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emory's DRIVE, Ridgeback partnering for drug vs coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"EIDD-2801","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Drug Innovation Ventures at Emory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Innovation Ventures at Emory \/ Ridgeback ","highestDevelopmentStatusID":"4","companyTruncated":"Drug Innov.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pandion Raises $80 Million Series B to Advance Autoimmune Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"PT101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"Novellus","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS in COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novellus \/ Citius","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/.."},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"MindMed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Acquires Exclusive License to Eight Clinical Trials of LSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University Hospital Basel","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"University Hospital Basel \/ MindMed","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Ethris","sponsor":"Neurimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurimmune and Ethris Enter Collaboration to Rapidly Develop Inhaled mRNA-based Antibody Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"NI007","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Neurimmune","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ N.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Sonnet BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Holdings Announces Merger Closing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Merger","leadProduct":"Atexakin Alfa","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Sonnet BioTherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Seikagaku","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Diclofenac conjugated sodium hyaluronate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seikagaku \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku .."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"iTeos Therapeutics Closes $125 Million Series B2 Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"EOS-850","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$285.0 million","upfrontCash":"$20.0 million","newsHeadline":"Paratek Pharmaceuticals Announces Initiation of Funding from BARDA ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0.28999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.28999999999999998,"dosageForm":"Oral","sponsorNew":"Paratek Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"HK Tainuo","pharmaFlowCategory":"D","amount":"$42.5 million","upfrontCash":"$10.0 million","newsHeadline":"Flexion Therapeutics Announces ZILRETTA\u00ae License Agreement and Provides Business Update Amid Coronavirus Pandemic","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Omadacycline","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Flexion Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Steroid","amount2New":0.040000000000000001,"dosageForm":"Intra-articular Injection","sponsorNew":"Flexion Therapeutics \/ HK Tainuo","highestDevelopmentStatusID":"12","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"$67.5 million","upfrontCash":"$52.5 million","newsHeadline":"AZ licences Movantik rights to RedHill","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Divestment","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0.070000000000000007,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Diamond Light Source","sponsor":"Exscientia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exscientia forms UK-US partnership to screen possible Covid-19 drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Anti-viral drugs","moa":"3CLpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Diamond Light Source","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diamond Light Source \/ Exscientia","highestDevelopmentStatusID":"1","companyTruncated":"Diamond Li.."},{"orgOrder":0,"company":"Soleo Health","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soleo Health Selected by Grifols as Limited Drug Distribution Partner for XEMBIFY\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Immune globulin human-klhw","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Soleo Health","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Grifols","highestDevelopmentStatusID":"12","companyTruncated":"Soleo Heal.."},{"orgOrder":0,"company":"Aspen Neuroscience","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aspen Neuroscience Announces $70 Million Series A Financing to Advance First Autologous Neuron Replacement Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"ANPD001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Aspen Neuroscience","amount2":0.070000000000000007,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Aspen Neuroscience \/ OrbiMed","highestDevelopmentStatusID":"5","companyTruncated":"Aspen Neur.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Human neutralizing antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Adaptive Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptive Biotechnologies \/ Amgen","highestDevelopmentStatusID":"2","companyTruncated":"Adaptive B.."},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":2.2999999999999998,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":2.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmac.."},{"orgOrder":0,"company":"Curzion Pharmaceuticals","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$45.0 million","newsHeadline":"Horizon Therapeutics Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"HZN-825","moa":"LyLPAR1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Curzion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curzion Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Curzion Ph.."},{"orgOrder":0,"company":"Vaccine and Immunotherapy Center","sponsor":"Voltron Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Voltron Therapeutics Enters into Sponsored Research Agreement with The Vaccine & Immunotherapy Center for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Self-Assembling Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaccine and Immunotherapy Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaccine and Immunotherapy Center \/ Voltron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Vaccine an.."},{"orgOrder":0,"company":"Dynacure","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$54.6 million","upfrontCash":"Undisclosed","newsHeadline":"Dynacure Announces \u20ac50M ($55M) Series C Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series C Financing","leadProduct":"DYN101","moa":"Dynamin 2 protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Dynacure \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Savara","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Savara Obtains Global Rights to Develop and Commercialize Apulmiq","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Grifols International \/ Savara","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"University of Wisconsin\u2013Madison","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UW\u2013Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CoroFlu vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Wisconsin\u2013Madison","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Wisconsin\u2013Madison \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BCMA antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Kite","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$14.5 million","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Partners with U.S. Government to Expedite Development of Plasma-Derived Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"COVID-Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$165.2 million","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Pharmaceuticals Announces Pricing Of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"RemeGen Completes USD $100 Million Plus in Funding\n","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Telitacicept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"RemeGen \/ Lilly Asia Ventures","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"BioArdis","sponsor":"Shenogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shenogen enters into an Exclusive License with BioArdis to Develop and Commercialize Novel FGFR4 Kinase Inhibitor for Asian Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BIO-1262","moa":"FGFR4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BioArdis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioArdis \/ Shenogen","highestDevelopmentStatusID":"10","companyTruncated":"BioArdis \/.."},{"orgOrder":0,"company":"XBiotech","sponsor":"BioBridge Global","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Human antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ BioBridge Global","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Autologous MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Oncology Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Kalos's Anti-Cancer Drug in Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"KTH-222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kalos Therapeutics \/ Oncology Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Ther.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":" BARDA","pharmaFlowCategory":"D","amount":"$7.2 million","upfrontCash":"Undisclosed","newsHeadline":"BARDA, Department Of Defense, And SAb Biotherapeutics To Partner To Develop A Novel COVID-19 Therapeutic\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK and Vir Biotechnology enter collaboration to find coronavirus solutions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-viral antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vir Biotechnology","amount2":0.25,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ GlaxoSmithKline","highestDevelopmentStatusID":"1","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Second Genome","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,538.0 million","upfrontCash":"$38.0 million","newsHeadline":"Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Second Genome","amount2":1.54,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":1.54,"dosageForm":"","sponsorNew":"Second Genome \/ Gilead Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Second Gen.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Shenzhen Smoore Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech and Shenzhen Smoore Technology Enter Agreement to Research Utilizing Smoore Inhalation Delivery Device","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aim ImmunoTech \/ Shenzhen Smoore Technology","highestDevelopmentStatusID":"4","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"D","amount":"$6.6 million","upfrontCash":"$6.6 million","newsHeadline":"Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Belinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Onxeo","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Onxeo \/ Acrotech Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Onxeo \/ Ac.."},{"orgOrder":0,"company":"Suzhou Ribo","sponsor":"Capital Venture Capital Fund ","pharmaFlowCategory":"D","amount":"$66.0 million","upfrontCash":"Undisclosed","newsHeadline":"Suzhou Ribo Life Science Completes $66 Million C Round for siRNA Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series C Financing","leadProduct":"RB-RQ007","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Suzhou Ribo","amount2":0.070000000000000007,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Suzhou Ribo \/ Capital Venture Capital Fund ","highestDevelopmentStatusID":"4","companyTruncated":"Suzhou Rib.."},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$14.5 million","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech Announces the National Cancer Institute\u2019s Award of $14.54M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Pa.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"U.S. Food & Drug Administration ","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"$0.5 million","newsHeadline":"Timber Pharmaceuticals Announces Award of Second Tranche of FDA Orphan Products Clinical Trials Grant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Timber Pharmaceuticals \/ U.S. Food & Drug Administration ","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"PCORI","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"DCRI To Trial Hydroxychloroquine To Prevent Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Duke Clinical Research Institute \/ PCORI","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clini.."},{"orgOrder":0,"company":"GB Sciences","sponsor":"Wellcana Plus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GB Sciences Completes and Achieves Milestone in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Cannabinoid-containing complex","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"GB Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GB Sciences \/ Wellcana Plus","highestDevelopmentStatusID":"4","companyTruncated":"GB Science.."},{"orgOrder":0,"company":"GSK","sponsor":"Xiamen Innovax Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK allies with Innovax for COVID-19 vaccine R&D project","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"AS03","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Xiamen Innovax Biotech ","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Xiam.."},{"orgOrder":0,"company":"Trovagene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trovagene Announces Acceptance of P 1b\/2 KRAS-Mutated Metastatic Colorectal Cancer Trial Abstract at the 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene .."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Regeneron Launch Second Kevzara Trial Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Announces Positive Topline Data for New Development Program - Etrasimod Controlled-Release (CR)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGenesis Files Expanded Patent Coverage for its Fibroblast Cell Therapy to treat Coronavirus (COVID-19) ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fibroblast cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zymeworks Announces First Patient Dosed in Phase 1b\/2 Trial of ZW25","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ZW25","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zymeworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu)-lilotomab satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Henlius Biotech Announces Results Of Phase 1 Clinical Trial Of Anti-EGFR Monoclonal Antibody Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HLX07","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra Pharmaceuticals Delays Recruitment In Donesta Phase III Clinical Programme","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt and Novoteris Receive Clearance from to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I\/II Clinical Study of ONC201 Begins in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia to study the effect of interferon beta-1a in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"FINLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Clinical Trial of Tedopi OSE Immunotherapeutics Announces Positive Top-Line Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tedopi","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fda Accepts Mesoblast\u2019s Biologics Licence Application For Ryoncil\u2122 And Agrees To Priority Review","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharm.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento forms alliance for preclinical testing of Covid-19 drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda receives CHMP positive opinion for ADCETRIS in combination with CHP in the treatment large-scale anaplastic lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab Vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Announces Two Phase 3 Randomised Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Receives Data Supporting Brilacidin\u2019s Direct Inhibition of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional patients treated in LIDDS clinical study NZ-DTX-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV- Pembrolizumab Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Biotherapeutics Announces Positive Topline Results from Phase 1b\/2a Clinical Trial of AB-2004 for Autism Spectrum Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-2004","moa":"Microbiome","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apeiron Biologics gets regulatory approvals for Phase II Covid-19 trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"APN01","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Bi.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn seeks approval to trial leronlimab for severe Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genfit says Covid-19 may not significantly delay NASH trial readout","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ N.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Announces the Initiation of ODYSSEY for Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication Describes Mechanism of Action for T?4 in Corneal Wound Healing and Regeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces IND and Investigator-Initiated Studies of AT-001 in Critical COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Grapiprant","moa":"Aldose reductase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Momenta Provides Corporate Update Amid COVID-19 Pandemic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ofranergene obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon Therapeutics Team Publishes Article On The Positive Clinical Study Results For Ot-101 Against Recalcitrant Resistant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF-beta 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Emergency IND Use of Humanigen's Lenzilumab For Compassionate Use In COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ennaid Therapeutics Announces Development of ENU200, A New Antiviral Therapeutic for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ENU200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ennaid Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ennaid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ennaid The.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Pharma Today Presented Key Preclinical Data on its Novel Cognitive Enhancer at the AAT-AD\/PD Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar has submitted a Phase II clinical trial of Aplidin for the treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"eEF1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ansun Biopharma Announces Positive Results from Investigator-Initiated Trial of Novel COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sialidase L","moa":"Sialic acid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ansun Biopharm \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biop.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Completes Phase-3 Clinical Study Of A Billion-Dollar Asthma Generic\n","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces Fast Track Designation from FDA for Zimura\u00ae for the Treatment of Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD\/PD 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CYPRUS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AADvac1","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Axon Neuroscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection\/Injectable","sponsorNew":"Axon Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axon Neuro.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 of coronavirus vaccine human trials may begin in spring, Moderna chairman says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun BioPharma Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s portfolio company Umecrine Cognition announces results from a phase 2a clinical study of golexanolone","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Golexanolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Karolinska Development AB","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karolinska Development AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents Efficacy Data From its Two Vafidemstat Clinical Trials in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"resTORbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"resTORbio Announces Delay of its Ongoing Phase 1b\/2a trial of RTB101 ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RTB101","moa":"TORC1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"resTORbio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"resTORbio .."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TJM2","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"GC007g","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Filing of FDA Pre-IND Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Files Request with FDA for Preliminary Meeting for Breakthrough Therapy Designation for Leronlimab for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Scripps Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clues to COVID-19 coronavirus\u2019s vulnerability emerge from an antibody against SARS\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Scripps Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Scripps Re.."},{"orgOrder":0,"company":"Izana Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initiation Of Two-Centre Compassionate Study Involving Namilumab In The Treatment Of Rapidly Worsening COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Namilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Izana Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Izana Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Izana Bios.."},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hope Biosciences Receives FDA Approval to Commence First Stem Cell Clinical Trial for Protection Against COVID-19\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Adipose-derived mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hope Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hope Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Biosc.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Rutgers Cancer Institute ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial For Drug Combination To Treat Coronavirus Is Fast-Tracked By Rutgers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved ","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rutgers Cancer Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rutgers Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rutgers Ca.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"SynAct Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRIEF-Synact Pharma Applies For Patent For Ap1189 Within Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AP1189","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SynAct Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SynAct Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SynAct Pha.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Provides COVID-19 Business Update","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces ASCENT Study to be Stopped for Compelling Efficacy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Serlopitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Menlo Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menlo Ther.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Celebrates Migraine PhIII Win, Shifting Eyes Toward A Pair Of Q4 Submissions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"LFB","sponsor":"HEMA Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LFB Announces FDA Approval of SEVENFACT for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eptacog Alfa","moa":"Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"LFB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LFB \/ HEMA Biologics","highestDevelopmentStatusID":"12","companyTruncated":"LFB \/ HEMA.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Simultaneously Publishes Two Phase 3 Studies Detailing Comprehensive Efficacy and Safety of TREMFYA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"OxThera AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact\u00ae in Patients With Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxalobacter formigenes","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"OxThera AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OxThera AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OxThera AB.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boston Biomedical Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-3654","moa":"PIM kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COM902","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bryn Pharma Presents Data Demonstrating Comparable Pharmacokinetic and Pharmacodynamic Effects of Intranasal Epinephrine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Bryn Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bryn Pharm.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Presents New Istaroxime Phase 2b Study Analysis at the American College of Cardiology (ACC) Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Istaroxime","moa":"SERCA2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR202","moa":"CD38","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion Announces European Commission Approval of the NUSTENDI Tablet for Hypercholesterolemia and Mixed Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Clinical Progress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Endoxifen","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheimer\u2019s Trial Screening Data Links High Amyloid Levels With Early Stage Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Solanezumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intelgenx Announces Adjusted Versafilm\u00ae Business Strategy, Next Steps For Rizaport\u00ae Versafilm\u00ae Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio Pharma confirms Type B Meeting date with FDA on HCC01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision Conducts Site Monitoring Visit for Phase II Part I Clinical Trial for ABV-1505","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Announces Investigational New Drug Application Amendment for HST 001","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Yiviva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yiviva Announces Dosing of First Patient in Phase 2b Study of First-Line YIV-906 Plus Sorafenib Combination Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Yiviva","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yiviva \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Yiviva \/ N.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Announces Pivotal Phase 3 Study Design for MarzAA in Individuals with Hemophilia A or B with Inhibitors","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Activated Marzeptacog Alfa","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Announces Positive Results In Dose-Finding Pediatric Study Of Macimorelin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Macimorelin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Ze.."},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Premas Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Premas Biotech \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Premas Bio.."},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Millendo Therapeutics Announces Topline Results for Pivotal Phase 2b Study of Livoletide\r\n","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Livoletide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Millendo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Millendo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Millendo T.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy: Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ABI-H0731","moa":"HBV core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Providence Cancer Institute","sponsor":"OncoSec Immunotherapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec's CORVax12","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Tavokinogene Telseplasmid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Providence Cancer Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Providence Cancer Institute \/ OncoSec","highestDevelopmentStatusID":"6","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Applied Biology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Biology to Launch COVID-19 Drug Discovery Platform based on Breakthrough Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Androgens","moa":"TMPRSS2 expression","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan BioScience Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Nolasiban","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ObsEva \/ Yuyuan BioScience Technology","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Y.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Farmitalia ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Signs LSA for Commercialization of Myring\u2122 in Italy, the Third Biggest Worldwide Market","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Mithra Pharmaceuticals \/ Farmitalia ","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Acquires Commercial Rights for Oral Contraceptive Zoely \n","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Theramex ","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Afaxys Pharma","sponsor":"TherapeuticsMD ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD and Afaxys Enter Into Agreement","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved ","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Afaxys Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Afaxys Pharma \/ TherapeuticsMD ","highestDevelopmentStatusID":"12","companyTruncated":"Afaxys Pha.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Gets 88% One-Year Response Rate with Relugolix ","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SJX-653","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Polysulfated glycosaminoglycan","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Regulatory Submission for Tanezumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tanezumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics Reports Safety Results from KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Symphogen \/ Servier ","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen .."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics, Pharmabcine Partner to Develop & Manufacture PMC-402 Pipeline to Treat Oncology And Neovascular Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"PMC-402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ PharmAbcine ","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Advent Life Sciences","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Amphista Therapeutics Raises $7.5m Series A Round to Advance Targeted Protein Degradation Assets in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Amphista Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Amphista Therapeutics \/ Advent Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Amphista T.."},{"orgOrder":0,"company":"GAIA Vaccine Foundation","sponsor":"EpiVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpiVax Partners with GAIA Vaccine Foundation to Make COVID-19 Vaccine License Free to Developing Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"EPV-CoV19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GAIA Vaccine Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GAIA Vaccine Foundation \/ EpiVax","highestDevelopmentStatusID":"4","companyTruncated":"GAIA Vacci.."},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Medison","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpha Tau Medical Announces Exclusive Distribution Arrangement With Medison Canada for Breakthrough Cancer Treatment Alpha DaRT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Radium-224","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Medison","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau .."},{"orgOrder":0,"company":"Cove","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC\u2122 ODT","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cove","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Cove \/ Biohaven","highestDevelopmentStatusID":"12","companyTruncated":"Cove \/ Bio.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.7 million","upfrontCash":"Undisclosed","newsHeadline":"Idera Pharmaceuticals Announces Private Placement of up to $20.7 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Prostate Cancer Clinical Trial Consortium","sponsor":"CellCentric","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellcentric Signs Deal for Clinical Trial Expansion into the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"CCS1477","moa":"p300\/CBP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prostate Cancer Clinical Trial Consortium","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prostate Cancer Clinical Trial Consortium \/ CellCentric","highestDevelopmentStatusID":"7","companyTruncated":"Prostate C.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"University of Georgia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals Announces R&D Collaboration with the University of Georgia for a Universal Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ University of Georgia","highestDevelopmentStatusID":"1","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoImmuneTech Announces Clinical Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Nivolumab","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Cardiothoracic Surgical Trials Network","sponsor":"Mesoblast","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mesoblast Partners With The Cardiothoracic Surgical Trials Network","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiothoracic Surgical Trials Network","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiothoracic Surgical Trials Network \/ Mesoblast Limited","highestDevelopmentStatusID":"9","companyTruncated":"Cardiothor.."},{"orgOrder":0,"company":"Celularity","sponsor":"Lung Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Lung Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Nucleic acid vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"EpiVax \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ I.."},{"orgOrder":0,"company":"SuperTrans Medical","sponsor":"Mediforum Pharm","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Korean firm invests $2M in SuperTrans Medical","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antibiotics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SuperTrans Medical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SuperTrans Medical \/ Mediforum Pharm","highestDevelopmentStatusID":"1","companyTruncated":"SuperTrans.."},{"orgOrder":0,"company":"Infectious Disease Research Institute","sponsor":"iBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"IBIO-200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Infectious Disease Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Infectious Disease Research Institute \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"Infectious.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"$362.0 million","upfrontCash":"Undisclosed","newsHeadline":"Samsung Inks $362M Deal To Boost Vir's COVID-19 Antibody Output","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0.35999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Viroclinics Biosciences","sponsor":"University of Queensland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"International Partnership Progresses UQ COVID-19 Vaccine Project","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Viroclinics Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Viroclinics Biosciences \/ University of Queensland","highestDevelopmentStatusID":"4","companyTruncated":"Viroclinic.."},{"orgOrder":0,"company":"East China Normal University","sponsor":"ImmuneCyte Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ThermoGenesis Announces Its ImmuneCyte Joint Venture Acquires Key Technologies to Develop Therapeutics for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Monoclonal antibody drug conjugates","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"East China Normal University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"East China Normal University \/ ImmuneCyte Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"East China.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo, Mitsubishi UFJ Capital & Nagoya Institute of Technology Collaborate","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"GtCCR4","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Mitsubishi UFJ Capital","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Allocetra","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Seagull Biosolutions","sponsor":"The Union science and technology ministry\n of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pune Firm First in India to Get Govt Funding for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"INDIA","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Active virosome vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Seagull Biosolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seagull Biosolutions \/ The Union science and technology ministry\n of India","highestDevelopmentStatusID":"1","companyTruncated":"Seagull Bi.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"$30.0 million","newsHeadline":"Zai Lab Targets Blood Cancers In Deal With Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"REGN1979","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly Begins Clinical Testing of Therapies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Macromoltek","sponsor":"Cytovia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics and Macromoltek to Develop Dual-Acting Natural Killer Immunotherapy Against SARS Cov2 (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Natural killer immunotherapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Macromoltek","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Macromoltek \/ Cytovia","highestDevelopmentStatusID":"1","companyTruncated":"Macromolte.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"CSL Behring","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ CSL Behring","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"University of Illinois","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanda Pharmaceuticals Inc. and The University of Illinois Announce Partnership to Identify Novel Antivirals Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antiviral drugs","moa":"Cathepsin-L","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Illinois","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Illinois \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Increases Focus on Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1015","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Cullgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullgen Announces Publication of Small Molecule BRAF Protein Degraders in Journal of Medicinal Chemistry","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Cullgen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cullgen \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Cullgen \/ .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seneca Biopharma Announces Update on Phase II Clinical Trial Underway in China for the Treatment of Ischemic Stroke\r\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NSI-566","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Grants Merck Patent For CRISPR-Chrom Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Lamellar Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lamellasome COVID-19 therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lamellar Biomedical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lamellar Biomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lamellar B.."},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polaryx Therapeutics Receives IND Approval From the FDA to Study PLX-200 ","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-200","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Polaryx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polaryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polaryx Th.."},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupus Therapeutics Developing a Study Focused On Lupus Patients And COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lupus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lupus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lupus Ther.."},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EmphyCorp N115 Reducing the Rate and Spread of COVID-19 with Nasal Nitric Oxide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Pyruvate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EmphyCorp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"EmphyCorp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"EmphyCorp .."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Announces Approval for the Phase Ib\/II Clinical Study of Bcl-2 Inhibitor APG-2575","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Completes Rolling Submission of New Drug Application to the U.S.FDA and Submits Marketing Authorization Application","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"InGeneron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous adipose-derived regenerative cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"InGeneron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"InGeneron \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"InGeneron .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Showcases Strategic Focus on WHIM Syndrome During 2020 Analyst Day Webinar","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PMN310","moa":"Amyloid beta oligomer","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Provides Update on Development Projects CAN04 and CAN10","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leading BioSciences Sees Potential for Its Drug LB1148 to Treat Multiple Organ Dysfunction Syndrome in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Provides Operational and Financial Update","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces Pipeline Progress Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BT1718","moa":"MMP-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Provides Update in Response to COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Dosing of First Patient in Phase 1\/2a Clinical Trial of PBCAR20A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Delivers Virtual Presentation at the Advances in Alzheimer\u2019s and Parkinson\u2019s Therapies AAT-AD\/PD\u2122 Focus Meeting 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Announces Data on Potent Anti-Tumor Activity of FS120 Published in Cancer Immunology Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FS120","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves BRAFTOVI in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"LUNAR-COV19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19 ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TZLS-501","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WPD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Pharma Files First Investigational New Drug Application with The U.S. FDA for Natural Killer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"K-NK002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial of Hydroxychloroquine, a Potential Therapy For COVID-19, Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Provides an Update on Oral Paclitaxel FDA Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Provides Statement Regarding COVID-19 Pandemic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Advances Battle Against Covid-19 On Multiple Fronts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm Announces the Start of a Phase II Clinical Trial of its Influenza Antiviral Drug \"Avigan\u00ae Tablet\" for COVID-19 ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"University of Utah Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Utah Health and Intermountain Healthcare Launch Two COVID-19 Clinical Trials to Test Effectiveness of Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Utah Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Utah Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Commences Next Phase of VNLG-152 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axon Neuroscience Has a Promising Peptide Vaccine Against COVID-19 in Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CYPRUS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Axon Neuroscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axon Neuroscience \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axon Neuro.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TD-0903","moa":"JAK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo Plus Yervoy\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FirstWave Bio to Initiate Phase 2a\/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Highlights Positive Impacts of Centhaquine on COVID-19 Patients.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Netarsudil Mesylate","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Galidesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"EicOsis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EC5026","moa":"sEH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EicOsis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ .."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PHA121 Shows Clinically Relevant Activity in a Translational in Vivo Model","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PHA121","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Business Update Related to COVID-19 Pandemic","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 \u201cHELP Study\u201d of Levosimendan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"Calcium sensitizer\/K-ATP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of the American Academy of Neurology Publishes ProMIS Neurosciences\u2019 Abstracts on Novel Antibody Candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"ProMIS Neurosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProMIS Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ProMIS Neu.."},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chromocell Makes Chromovert Technology and Novel Compounds Available to Support COVID-19 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ENaC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chromocell Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chromocell Corporation \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Chromocell.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1\/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-ENaC","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas Announces Acceptance of XOSPATA\u00ae (gilteritinib) for Regulatory Review in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Updates Corporate Progress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Olinciguat","moa":"sGC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MAP2K1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Starts Ph III Trial of Actemra for COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Sesderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesderma Labs Produces Lactyferrin to Counter the COVID-19 Strain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Genistein","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sesderma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sesderma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sesderma \/.."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Feinstein Institutes to Collect COVID-19 Patient Plasma, Research Antibodies Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasma therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Phase III ADAURA Trial will be Unblinded Early After Overwhelming Efficacy in the Adjuvant Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Swissx Labs AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swissx Labs Calls for Trials of Anti-Viral Naja Venom Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Naja Venom","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Swissx Labs AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Swissx Labs AG \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Swissx Lab.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell to Present TruUCAR\u2122 GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"GC027","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Announces Closing of Enrollment in its Phase 1b\/2a NASH Trial ","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"ProLynx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ProLynx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ .."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-810","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidivarin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharm.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics Announces MHRA Clearance to Begin Human Testing of EIDD-2801 in the UK for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EIDD-2801","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Independent Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ARV-110","moa":"Androgen receptor degradation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Applied Biology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Biology to License Intellectual Property Rights to a Novel Cannabinoid Based Therapy Under Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Antengene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ATG-019","moa":"PAK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Bcl-2 antisense oligonucleotide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NC318","moa":"Siglec-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Receives IND Approval for its HIV Drug ASC09F","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC09","moa":"HIV protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FTX-6058","moa":"HBG 1\/2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Kerecis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Evaluating Kerecis Omega3 Viruxide Spray for the Treatment of COVID-19 Patient\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ICELAND","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega3 Viruxide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerecis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Kerecis \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kerecis \/ .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zavegepant HCl","moa":"CGRP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Joins Battle Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Coronavirus Vaccine Designed to Meet a Global Demand\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Coravax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Thomas Jefferson University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thomas Jefferson University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Thomas Jef.."},{"orgOrder":0,"company":"Fiocruz research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fiocruz Investigates the Action of Anti-Retrovirals Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BRAZIL","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Atazanavir","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Fiocruz research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fiocruz research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fiocruz re.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 \n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse\u00ae Inhaled Nitric Oxide Therapy\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Antiviral Drug Heading Into Clinical Trials Offers Hope For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EIDD-2801","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of North Carolina \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Investigating Potential COVID-19 Treatment\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Ossianix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ossianix is Responding to the COVID-19 Pandemic by Developing Therapeutic Single Domain VNAR Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VNAR antibodies","moa":"Transferrin receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ossianix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ossianix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ossianix \/.."},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tarveda Therapeutics Provides Update on Proposed Merger with Organovo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Termination","leadProduct":"Locnartecan","moa":"Topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tarveda Therapeutics \/ Organovo","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Th.."},{"orgOrder":0,"company":"Griffith University","sponsor":"Indian Immunologicals Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"India, Australia Partner to Develop Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Live Attenuated SARS \u2013 CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Griffith University \/ Indian Immunologicals Limited","highestDevelopmentStatusID":"1","companyTruncated":"Griffith U.."},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Montreal Heart Institute (MHI) Research Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NYU Grossman School of Medicine Partners with Montreal Heart Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NYU Grossman School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"NYU Grossman School of Medicine \/ Montreal Heart Institute (MHI) Research Center","highestDevelopmentStatusID":"10","companyTruncated":"NYU Grossm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Circassia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Circassia To Terminate AstraZeneca Deal And Transfer Assets","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Termination","leadProduct":"Aclidinium Bromide","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Aerosol Powder","sponsorNew":"AstraZeneca \/ Circassia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Abandons Deal for Takeda's Tachosil Surgical Patch","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Termination","leadProduct":"Human fibrinogen","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.40000000000000002,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Johnson & Johnson","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Morningside Venture","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Stealth Biotherapeutics Announces $20 Million Financing to Advance Development of Elamipretide and Pipeline","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"SBT-272","moa":"TDP-43","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Morningside Venture","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"M. Arkin Dermatology Ltd","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Termination","leadProduct":"RX-5902","moa":"Phosphorylated-p68","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Rexahn Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Sets Back Review Date for Roche\u2019s SMA Drug by 3 Months","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NSI-566","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia\u2019s UQ Covid-19 Vaccine Candidate Advances to Preclinical Tests","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Queensland \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Begins Efforts to Identify Antibodies Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Coronavirus-neutralising antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Provides Update on ONWARD(TM) Phase 3 Pivotal Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Antibodies that Modulate TGF-\u03b2 Activation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-181","moa":"TGF-beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Academia Sinica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiwan\u2019s Academia Sinica Finds Powerful Inhibitor to Fight Wuhan Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Academia Sinica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Academia Sinica \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Academia S.."},{"orgOrder":0,"company":"Shanghai Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinese Scientists Determine COVID-19 Protease Structure for Quickened Drug Identification","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shanghai Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Institute \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Shanghai I.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Fast-Tracks Phase 1 Testing of Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteostasis Therapeutics Announces Completion of Scientific Advice Meeting with the Dutch Medicines Evaluation Board","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dirocaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene\u2019s Tislelizumab gets Chinese Approval to Treat Locally Advanced\/metastatic Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Investigational New Drug Application For Mesoblast To Use Remestemcel-L In Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Ziphius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziphius Therapeutics Announces Acceleration of mRNA Based Vaccine Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ZIP-1642","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ziphius Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ziphius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ziphius Th.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$682.5 million","upfrontCash":"$100.0 million","newsHeadline":"MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ME-401","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0.68000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Kyowa Kirin Co.","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intensity Therapeutics Signs Clinical Collaboration Agreement with Bristol Myers Squibb for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Bristol Myers Squibb \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and Gsk to Join Forces in Unprecedented Vaccine Collaboration to Fight Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"S-protein COVID-19 antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ GlaxoSmithKline","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"HaNK","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Institut Pasteur Korea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNION Therapeutics Launches COVID-19 Program in Collaboration With Institut Pasteur Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Union Therapeutics \/ Institut Pasteur Korea","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Tamir Biotechnology","sponsor":"Orgenesis","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis to Acquire Tamir Biotechnology for Broad Spectrum Antiviral Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Ranpirnase","moa":"tRNA hydrolytic enzyme","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Tamir Biotechnology","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Tamir Biotechnology \/ Orgenesis","highestDevelopmentStatusID":"7","companyTruncated":"Tamir Biot.."},{"orgOrder":0,"company":"Cerevance","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gates, GV Chip into $45M Round for CNS biotech Cerevance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"CVN424","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Cerevance \/ Google Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance .."},{"orgOrder":0,"company":"Undisclosed","sponsor":"AIkido Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIkido Pharma Executes Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Anti-viral drugs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ AIkido Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"Applied BioMath","sponsor":"OncoMyx Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied BioMath Announces Collaboration with OncoMyx Therapeutics for Systems Pharmacology Modeling in Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Myxoma virus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied BioMath \/ OncoMyx Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galapagos and Ryvu Announce Research Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"POLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ Galapagos NV","highestDevelopmentStatusID":"2","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"TScan Announces Collaboration with Novartis on the Discovery and Development of Novel T Cell Receptor Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TCR-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Novartis","highestDevelopmentStatusID":"2","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Athersys","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$50.1 million","upfrontCash":"Undisclosed","newsHeadline":"Athersys Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"MultiStem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Athersys \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"mRNA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"1","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Halix BV","sponsor":"University\u2019s Jenner Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HALIX Enters Collaboration with the University of Oxford for GMP Manufacturing of a COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Halix BV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Halix BV \/ University\u2019s Jenner Institute","highestDevelopmentStatusID":"7","companyTruncated":"Halix BV \/.."},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ginkgo Bioworks","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ginkgo Bioworks \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"Ginkgo Bio.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Ori Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ori Biotech, Achilles Therapeutics Partner to Test Novel Cell Therapy Manufacturing Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Tumour-derived T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achilles Therapeutics \/ Ori Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Jenner Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Supports Jenner Institute to Reach First Milestone in Covid-19 Vaccine Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Jenner Institute","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"$570.0 million","upfrontCash":"$40.0 million","newsHeadline":"LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"FB825","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0.56999999999999995,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"Intravenous Infusion","sponsorNew":"Oneness Biotech \/ LEO Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Bi.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck, Samsung Join Newly Crowded Market for Herceptin Biosimilars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"University of Ottawa","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bold Therapeutics and the University of Ottawa Initiate Research Partnership to Study BOLD-100 in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"BOLD-100","moa":"GPCR 78","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ University of Ottawa","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FairJourney Biologics and Iontas Announce Partnership in Search for SARS-CoV-2 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Iontas \/ F.."},{"orgOrder":0,"company":"Northwell Health","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia\n","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Northwell Health \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Northwell .."},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Sensory Cloud","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pulmatrix and Sensory Cloud Announce Partnership to Develop Potential Nasal Prophylactic and Anticontagion Product for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"PUR 003","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pulmatrix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Pulmatrix \/ Sensory Cloud","highestDevelopmentStatusID":"1","companyTruncated":"Pulmatrix .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Enters into Partnership with Medison Pharma to Distribute NURTEC\u2122 ODT In Israel","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Advances Therapeutic for COVID-19 in Partnership with Department of Defense and BARDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","amount":"$407.3 million","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences and Iksuda Enter into a Multi-Target Research Collaboration and License Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody drug conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"LegoChem Biosciences","amount2":0.40999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Iksuda Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Kubota Vision Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"VAP-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leo Pharma \/ Kubota Vision Inc","highestDevelopmentStatusID":"2","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics and National Cancer Institute Collaborate to Study ELI-002 Mutant KRAS Targeting Mechanism","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ELI-002","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ Elicio Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National C.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Sinovac Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus (COVID-19) Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Sinovac Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Soligenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CoVaccine HT","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BTG Specialty Pharmaceuticals \/ Soligenix","highestDevelopmentStatusID":"1","companyTruncated":"BTG Specia.."},{"orgOrder":0,"company":"Immunovant","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$139.4 million","upfrontCash":"Undisclosed","newsHeadline":"Immunovant Announces Closing of $139.4 Million Public Offering","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"IMVT-1401","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0.14000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"NeuroBo Pharmaceuticals Announces Closing of $7.5 Million Registered Direct Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"NB-01","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"Napo EU","sponsor":"Atlas Sciences","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NP-500","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Napo EU \/ Atlas Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ .."},{"orgOrder":0,"company":"Dilafor AB","sponsor":"Liverpool University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dilafor Initiates Collaboration with Liverpool University to Study the Effect of Tafoxiparin on SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Tafoxiparin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dilafor AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dilafor AB \/ Liverpool University","highestDevelopmentStatusID":"4","companyTruncated":"Dilafor AB.."},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"V-Capital","pharmaFlowCategory":"D","amount":"$25.4 million","upfrontCash":"Undisclosed","newsHeadline":"V-Capital Leads $25M New Round In Ocular Drug Developer Cloudbreak Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"CBT-001","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Cloudbreak Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Ophthalmic Solution","sponsorNew":"Cloudbreak Therapeutics \/ V-Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cloudbreak.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"Clinical Stage Oncology Biotech Lantern Pharma Files for a $29 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Irofulven","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$483.0 million","upfrontCash":"Undisclosed","newsHeadline":"BARDA Promises $483M to Shepherd COVID-19 Vaccine To Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0.47999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Edesa Biotech","pharmaFlowCategory":"D","amount":"$372.0 million","upfrontCash":"Undisclosed","newsHeadline":"Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NI-0101","moa":"TLR4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Light Chain Bioscience","amount2":0.37,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.37,"dosageForm":"","sponsorNew":"Light Chain Bioscience \/ Edesa Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Light Chai.."},{"orgOrder":0,"company":"CB Therapeutics","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CB Therapeutics Enters into Collaboration Agreement with Cleveland Clinic for the Manufacture of Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CB Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CB Therapeutics \/ Cleveland Clinic","highestDevelopmentStatusID":"1","companyTruncated":"CB Therape.."},{"orgOrder":0,"company":"OntoChem","sponsor":"Anixa Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anixa Biosciences and OntoChem Announce Collaboration to Develop Novel COVID-19 Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antiviral drugs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OntoChem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OntoChem \/ Anixa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"OntoChem \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CUE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Cue Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Kitov Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho Co, Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$6.4 million","newsHeadline":"Biofrontera AG Enters Into Exclusive License Agreement with Maruho Co., Ltd.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho Co, Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Biofronter.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Biotech ORIC Pharmaceuticals Sets Terms for $75 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Bell Potter Securities","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Paradigm Biopharmaceuticals has Significant Clarity on Development Pathway for Zilusol","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Pentosan Polysulfate Sodium","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Paradigm Biopharmaceuticals \/ Bell Potter Securities","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$214.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerus Expands BARDA Funding by Additional $14M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Intercept treated Red Blood Cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0.20999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Cerus Corporation \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corp.."},{"orgOrder":0,"company":"Delpharm Group","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Delpharm Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Delpharm Group \/ AzurRx BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Delpharm G.."},{"orgOrder":0,"company":"SIRS Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIRS Therapeutics to Develop FX06 for Treatment Of ARDS in COVID-19 Patients in Collaboration with F4 Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"FX06","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIRS Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SIRS Therapeutics \/ Wellington Partners","highestDevelopmentStatusID":"1","companyTruncated":"SIRS Thera.."},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody recruiting molecule","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Green Cross Lab Cell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Green Cross Lab Cell \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Green Cros.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zegocractin","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Initial Data Shows Improvement In Covid-19 With Redhill\u2019s Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Begins Clinical Study in Canada Evaluating Virazole in Combo with Standard of Care Therapy for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribavirin","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multiverse Investment Fund Announces Portfolio Company\u2019s Commencement of Clinical Trials to Treat ARDS Caused by Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic umbilical cord-derived mesenchymal stromal cell","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Orbsen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orbsen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Orbsen The.."},{"orgOrder":0,"company":"Ligandal","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligandal Proposes \u2018Antidote\u2019 to COVID-19 Using Robot-like Peptide Scaffolds\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Peptide-based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ligandal","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ligandal \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ligandal \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Initiates CALAVI Clinical Trial With Calquence Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SNDX-5613","moa":"MLL1-Menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Reports Promising Progress in Phase I\/lla Trial of Lead Program BI-1206 in Combination with Rituximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RBN-2397","moa":"PARP7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON to Present Latest Clinical Data From the NOX-A12 \/ Keytruda\u00ae Combination Trial in Colorectal and Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Epirium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epirium Bio Receives FDA Orphan-Drug Designation for EB 002 for the Treatment of Duchenne and Becker Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Epirium","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Epirium \/ .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX-629","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grid Therapeutics Announces FDA Approval of IND Application for GT103","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"GT103","moa":"CFH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Thera.."},{"orgOrder":0,"company":"LifeMax Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LifeMax Receives Fast Track Designation For LM-030 for the Treatment of Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"LM-030","moa":"KLK7\/ELA2","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"LifeMax Laboratories","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"LifeMax Laboratories \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"LifeMax La.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"Transthyretin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1893","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"KD Pharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KD Pharma Group & SLA Pharma Initiate Clinical Trial For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"KD Pharma Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"KD Pharma Group \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"KD Pharma .."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MBT2","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trypsinogen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Receipt of Final Meeting Minutes from FDA Following Pre-NDA Meeting for KD025 for the Treatment of Cgvhd","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"7HP349","moa":"Integrin alpha4\/beta1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVM Biotechnology has FDA Approval for Clinical Trials for Promising New Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Gets FDA Approval to Study Multistem Therapy for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Healios K.K","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healios to Enroll COVID-19 Patients in Phase II Off-the-Shelf Cell Therapy Program for ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HLCM051","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Healios K.K","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Healios K.K \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Healios K..."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayne Pharma Submits New Drug Application for E4\/DRSP to the FDA","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Doses First Patient in Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Gimsilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to RemeGen's Telitacicept as a Treatment for Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Synthon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthon Biopharmaceuticals Relaunches as Byondis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"(vic-) trastuzumab duocarmazine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Synthon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Synthon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Synthon Ph.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TOTUM-070","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Receives FDA Orphan Drug Designation for FT-4202 for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AG013","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Mouth Rinse","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA Ships COVID-19 LinearDNA\u2122 Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Linear DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Clinical Trial of HBM916","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Orphan Drug Designation for TransCon\u2122 hGH as Treatment for Growth Hormone Deficiency in the US","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Advances Cell Line Development for IMP761","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"IMP761","moa":"LAG-3","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1\/2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Initiation of Humanigen\u2019s Phase III Study of Lenzilumab in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PPP003","moa":"CB receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Khondrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Khondrion Highlights Potential Role Of Inflammatory Lipid Modulator Prostaglandin E2 In COVID-19 Disease And Proposes Potential Treatment Pathway With Sonlicromanol","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Khondrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Khondrion .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated with Leronlimab in Phase 2b\/3 Trial for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ansun Biopharma Enrolls First Patient in Proof of Concept Trial of DAS181 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sialidase L","moa":"Sialic acid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biop.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SMC Accepts Janssen\u2019s Ulcerative Colitis Drug Stelara for NHS Use","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"Il-12","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayo Clinic Preparing to Commence Phase II FDA Clinical Trial for the Treatment of COVID-19 with Vicromax\u2122\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Announces PV-10\u00ae Liver Cancer Presentation in ePoster Gallery of Society of Interventional Radiology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Rose Bengal Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus .."},{"orgOrder":0,"company":"Enterin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterin to Conduct a Randomized Phase 1\/2a Study in Hospitalized Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COV-ENT-1","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enterin","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Enterin \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enterin \/ .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Initiation of Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi\u00ae) as a Treatment for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Launching Brukinsa Trial In Later-Stage COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to Present Phase 2 Detailed Results of its Brain-Penetrant BTK Inhibitor in Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SAR442168","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Denies Clarus's Oral Testosterone Ester Citizen Petition","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MD Anderson Research Freeze Stops Production of Bellicum Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"18-Methoxycoronaridine","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"TissueTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TissueTech Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. Food and Drug Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TTAX02","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"TissueTech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TissueTech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"TissueTech.."},{"orgOrder":0,"company":"SciTech Development","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SciTech Development, LLC Submits COVID-19 Treatment with Proven Antiviral Activity to U.S. Health & Human Services (HHS)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SciTech Development","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SciTech De.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Advances Cobitolimod Further Towards Phase III Following Successful Interactions With FDA and EMA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alphamab Oncology Received U.S. FDA IND Approval to Initiate A Phase II Clinical Trial of KN046 For NSCLC in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN-EB3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Novel Mechanism of Action for FS118 and the Potential to Overcome PD-(L)1 Resistance Published in Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FS118","moa":"LAG3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Announces Laboratory Test Results of RYANODEX Against Coronavirus SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med's Surufatinib Bags US Fast Track Designations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starpharma to Develop COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Astodrimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus On Go to Start U.S. Studies of CAR T Candidate for ALL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO1","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New COVID-19 Clinical Trial Supported by Octapharma USA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH AFRICA","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrotope Initiates Project to Test RT001 in an Animal Model of Lung Damage to Protect Against COVID-19 Impact","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RT001","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Iodine-131 apamistamab","moa":"Ionising radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Receives its 4th FDA Orphan Drug Designation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0203","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Appoints Steering Committee of Leading Acute Myeloid Leukemia Experts for Its Ongoing Phase 3 REGAL Clinical Trial in AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Cancer Research Highlights Potent Antitumor Activity of Repotrectinib in Treatment Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Announces SFDA (Saudi Food & Drug Authority) Accepts Endari\u00ae Priority Review Request","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1\/2A Study of AFM24","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM24","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Preps Phase 3 Study of Ultomiris in Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BMS' Opdivo-Yervoy Combo Helps Mesothelioma Patients Live Longer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Lands PhIII Kidney Cancer Win With Bristol Myers in Their Hunt For $4 Billion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"University of Southampton","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Researchers to Trial Covid-19 Vaccine and Plasma Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Southampton","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Southampton \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"University.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Received IND Clearance from FDA for Initiating Clinical Trials for its Novel Monoclonal Antibody TST001","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Genome & Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Anti-Cancer Microbiome Therapeutic Receives FDA IND Clearance in Asia","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genome & Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & C.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NW Bio to Discuss Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia's Rival to Merck's Insomnia Drug Clears Phase 3 Test","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Announces Clearance of IND to Initiate Phase I\/II Study for First-in-Class PRGN-2009 AdenoVerse\u2122 Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-2009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BAY 1905254","moa":"ILDR2 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Updates Clinical Development and Operations Activities During the COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Begins Phase II COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx-4DP0004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Positive Topline Results From a Study of Its Novel Formulation of Diazepam Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology to Discuss Clinical Data from Investigator-initiated RAF\/MEK and FAK Combination Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First COVID-19 Patient Treated Using Stemedica Ischemia-Tolerant Allogeneic Mesenchymal Bone Marrow Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ischemic-tolerant mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemedica Cell Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Stemedica Cell Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Stemedica .."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon\u2122 PTH","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EOS-850","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis and Partner Announce Enrollment Completion of Global Phase 3 GENERATION HD1 Study for Huntington's Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tominersen","moa":"HTT protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GoldenBiotech Antroquinonol Selected as Potential Drug in Global Solicitation of Covid-19 Pneumonia Treament Projects\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Antroquinonol","moa":"Nrf -2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Golden Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Golden Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Golden Bio.."},{"orgOrder":0,"company":"Yale University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"$100,000 Gift Speeds Exploration of Sobetirome as COVID-19 Treatment\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sobetirome","moa":"TRb1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Yale University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yale University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Yale Unive.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces Coronavirus Vaccine Program\nTargeting At-Risk Elderly ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"7HP349","moa":"Alpha4Beta1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF Patients\n","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Dirocaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Accelerates Development of COVID-19 Antiviral Treatment and Aims to Launch Rapid Self-testing Kit","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA and EMA Accept Applications for Roche\u2019s OCREVUS (Ocrelizumab) shorter 2-hour infusion time","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ocrelizumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Porton Biopharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Porton Biopharma Limited Licenses Erwinase\u00ae to Clinigen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Asparaginase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Porton Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Solution","sponsorNew":"Porton Biopharma \/ Clinigen","highestDevelopmentStatusID":"12","companyTruncated":"Porton Bio.."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensysce, a California Based Biotech Company With a Mission to Solve the Opioid Crisis, Exploring a Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"NIAID","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Upamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"RedHill Biopharma \/ NIAID","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"Inovio Gets Grant to Partner with IVI and KNIH for Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Arrakis Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"$190.0 million","newsHeadline":"Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RNA targeted small molecule","moa":"RNA","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Arrakis Therapeutics","amount2":0.19,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Arrakis Therapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Arrakis Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"FSIO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI\u00ae and SYMDEKO\u00ae for Eligible Cystic Fibrosis Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Lumacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ FSIO","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sangamo taps Mogrify for off-the-shelf CAR-Treg project","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CAR-Treg cell therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mogrify","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mogrify \/ Sangamo","highestDevelopmentStatusID":"1","companyTruncated":"Mogrify \/ .."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Targovax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antigen peptides","moa":"CD8","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Valo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valo Therapeutics \/ Targovax ","highestDevelopmentStatusID":"1","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"Liechti Laboratory","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed in Collaboration with Liechti Laboratory Develops LSD Neutralizer Technology to Shorten and Stop LSD Trips\n","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Liechti Laboratory","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Liechti Laboratory \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Liechti La.."},{"orgOrder":0,"company":"Ewha Womans University ","sponsor":"SOM Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOM Biotech Announces the In Vitro Confirmation of Three Drug Candidates for COVID-19 in Collaboration with the Ewha Womans University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ewha Womans University ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ewha Womans University \/ SOM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Ewha Woman.."},{"orgOrder":0,"company":"Linical","sponsor":"Alpha Cognition","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Linical and Alpha Cognition Announce Strategic Partnership to Position Alpha-1062 for Approval in the U.S and Japan Alzheimer's Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Alpha-1062","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Linical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linical \/ Alpha Cognition","highestDevelopmentStatusID":"6","companyTruncated":"Linical \/ .."},{"orgOrder":0,"company":"MigVax","sponsor":"OurCrowd ","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"OurCrowd Leads $12 Million Investment Round in Israeli COVID-19 Vaccine Company MigVax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Financing","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MigVax","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"MigVax \/ OurCrowd ","highestDevelopmentStatusID":"1","companyTruncated":"MigVax \/ O.."},{"orgOrder":0,"company":"oNKo-innate","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"NK cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"oNKo-innate","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"oNKo-innate \/ Gilead","highestDevelopmentStatusID":"2","companyTruncated":"oNKo-innat.."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Children\u2019s Research Holdings","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReAlta Life Sciences Closes $14 Million Series A2 Financing to Support Transition into a Clinical Organization","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"RLS-0071","moa":"Complement","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"ReAlta Life Sciences","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ReAlta Life Sciences \/ Children\u2019s Research Holdings","highestDevelopmentStatusID":"8","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Medical University of Vienna","sponsor":"Viravaxx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Viravaxx AG, Medical University of Vienna launch project for an integrated platform for immune diagnosis and vaccination for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRIA","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Vienna","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medical University of Vienna \/ Viravaxx","highestDevelopmentStatusID":"1","companyTruncated":"Medical Un.."},{"orgOrder":0,"company":"Pathogen and Microbiome Institute ","sponsor":"Oncology Venture","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture to Test Activity of Its PARP Inhibitor, 2X-121, as a Potential Therapy for Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Stenoparib","moa":"PARP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pathogen and Microbiome Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pathogen and Microbiome Institute \/ Oncology Venture","highestDevelopmentStatusID":"4","companyTruncated":"Pathogen a.."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","amount":"$698.0 million","upfrontCash":"$20.0 million","newsHeadline":"Oasmia Receives Upfront Payment of 20 M USD from Elevar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oasmia Pharmaceutical","amount2":0.69999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Oasmia Pharmaceutical \/ Elevar Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Memgen","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Memgen Announces Exclusive License Agreements With Moffitt Cancer Center to Develop Innovative Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"MEM-288","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memgen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memgen \/ Moffitt Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Memgen \/ M.."},{"orgOrder":0,"company":"Population Health Research Institute ","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Population Health Research Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Population Health Research Institute \/ Bayer ","highestDevelopmentStatusID":"10","companyTruncated":"Population.."},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$475.0 million","upfrontCash":"$25.0 million","newsHeadline":"Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"NV-5138","moa":"mTORC1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Navitor Pharmaceuticals","amount2":0.47999999999999998,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Oral","sponsorNew":"Navitor Pharmaceuticals \/ Supernus","highestDevelopmentStatusID":"6","companyTruncated":"Navitor Ph.."},{"orgOrder":0,"company":"Bugworks","sponsor":"University of Tokyo Edge Capital","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Bugworks Raises US$7.5M From a Global Investment Syndicate to Combat the Global Challenge Posed by Deadly Bacterial Superbugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"GYROX-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bugworks","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Bugworks \/ University of Tokyo Edge Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bugworks \/.."},{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Ablexis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 S1 antibodies","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Berkeley Lights","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Berkeley Lights \/ Ablexis","highestDevelopmentStatusID":"4","companyTruncated":"Berkeley L.."},{"orgOrder":0,"company":"Cara Care","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cara Care Announces Collaboration With Consumer Healthcare Business Unit of Sanofi Germany for Digestive Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Hyoscine Butyl Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Cara Care","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cara Care \/ Sanofi ","highestDevelopmentStatusID":"12","companyTruncated":"Cara Care .."},{"orgOrder":0,"company":"QIMR Berghofer Medical Research Institute","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute ink License Agreement on Novel Bispecific Target Combinations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"EMB-01","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"QIMR Berghofer Medical Research Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QIMR Berghofer Medical Research Institute \/ EpimAb Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"QIMR Bergh.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$27.3 million","upfrontCash":"Undisclosed","newsHeadline":"Ology Bioservices to Adapt Veroplex\u00ae Cell Platform for Rapid Response to Viral Threats for Department of Defense","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Private Placement","leadProduct":"Sulbactam","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"OncoQuest","sponsor":"Dual Industrial","pharmaFlowCategory":"D","amount":"$375 million","upfrontCash":"Undisclosed","newsHeadline":"Dual Industrial to Buy OncoQuest's immunotherapy Drug Portfolio and Commit to fund Oregovomab Phase 3 Clinical Trial ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Divestment","leadProduct":"Oregovomab","moa":"Mucin-16","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"OncoQuest \/ Dual Industrial","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest .."},{"orgOrder":0,"company":"Affinivax","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"MAPS Pneumococcal vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Affinivax","amount2":0.12,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Affinivax \/ Viking Global Investors","highestDevelopmentStatusID":"8","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"BrainVectis","sponsor":"AskBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"BV-CYP01","moa":"CYP46A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"BrainVectis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BrainVectis \/ AskBio","highestDevelopmentStatusID":"4","companyTruncated":"BrainVecti.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bio Launches Stock Purchase Agreement for $15M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Divestment","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dar\u00e9 Bioscience","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"Intravaginal","sponsorNew":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"CMIC Holdings","sponsor":"FUJIFILM Toyama Chemical ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMIC Group Supports Clinical Trials and Manufacturing of Influenza Antiviral Drug \u201cAvigan\u00ae Tablet\u201d ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CMIC Holdings","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CMIC Holdings \/ FUJIFILM Toyama Chemical ","highestDevelopmentStatusID":"10","companyTruncated":"CMIC Holdi.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Valneva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"TLR9","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Valneva SE","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Pharmaceutical Services Selected by Lundbeck To Provide VYEPTI\u2122 (eptinezumab-jjmr) ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Orsini Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"University Hospital Institute ","sponsor":"Pharnext","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharnext, UHI to Evaluate Repurposed Drugs Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University Hospital Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University Hospital Institute \/ Pharnext","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"ProThera Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProThera Biologics and Takeda Enter Licensing Agreement to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Plasma-derived Inter-alpha Inhibitor Proteins therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"ProThera Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProThera Biologics \/ Takeda ","highestDevelopmentStatusID":"4","companyTruncated":"ProThera B.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Altium Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces Pricing of $15 Million Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Altium Capital","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"HLB","pharmaFlowCategory":"D","amount":"$61.3 million","upfrontCash":"Undisclosed","newsHeadline":"Immunomic Therapeutics Announces Close of $61.3M Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Dendritic cell vaccine therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunomic Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ HLB","highestDevelopmentStatusID":"8","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Atlas Special Opportunities","pharmaFlowCategory":"D","amount":"$15.4 Million","upfrontCash":"Undisclosed","newsHeadline":"NOXXON Secures Financing of up to \u20ac 14.2 Million Through Convertible Bonds From Atlas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Emapticap pegol","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"TME Pharma \/ Atlas Special Opportunities","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Accent Therapeutics","sponsor":"EcoR1 Capital ","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Accent Therapeutics nabs $63M for RNA cancer push","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"METTL3","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Accent Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Accent Therapeutics \/ EcoR1 Capital ","highestDevelopmentStatusID":"1","companyTruncated":"Accent The.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Cutia Therapeutics","pharmaFlowCategory":"D","amount":"$11.0 million ","upfrontCash":"$10.0 million","newsHeadline":"Menlo Therapeutics and Cutia Therapeutics ink License Agreement for AMZEEQ\u2122 and Approved Topical Minocycline Products in Greater China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Foamix Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Cutia Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Foamix Pha.."},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hansoh Pharma and NiKang Therapeutics Enter into a Partnership for a Novel Treatment for Anti-Viral Diseases in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"NKT-1992","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NiKang Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"NiKang Therapeutics \/ Jiangsu Hansoh Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"NiKang The.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"ORIC pulls off $120M Wall Street debut, eclipsing $86M goal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Senhwa Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Senhwa Biosciences, NIH to develop COVID-19 drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Senhwa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Rasna Therapeutics","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"$0.1 million","newsHeadline":"Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D from Rasna Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Dactinomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Rasna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rasna Therapeutics \/ Tiziana Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Rasna Ther.."},{"orgOrder":0,"company":"Akshaya Bio","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovance Biologics and Akshaya Bio Collaborate to Develop Therapeutics for Treatment of Coronavirus and Hepatitis B Virus Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Akshaya Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akshaya Bio \/ Cytovance Biologics ","highestDevelopmentStatusID":"6","companyTruncated":"Akshaya Bi.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$31.6 million","upfrontCash":"Undisclosed","newsHeadline":"Actinium Pharmaceuticals Closes of $31.6 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Apamistamab-I-131","moa":"BC8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ H.C. Wainwright","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"State of North Dakota ","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoPrecise Awarded Grant Focused on Coronavirus and Other Emerging Pathogens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Monocloncal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ State of North Dakota ","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"TRACON Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TRACON Retains Global Rights to TRC253 Following Completion of a Phase 1\/2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TRC253","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Johnson & Johnson Innovative Medicine \/ TRACON Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"ReiThera","sponsor":"Univercells","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Adenoviral vector-based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ReiThera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReiThera \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"ReiThera \/.."},{"orgOrder":0,"company":"The University of Dundee","sponsor":"Insmed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Brensocatib to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Brensocatib","moa":"DPP-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Dundee","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The University of Dundee \/ Insmed Incorporated ","highestDevelopmentStatusID":"1","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Institute for Systems Biology","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck joins Seattle Effort to Uncover COVID-19's Molecular Works","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute for Systems Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institute for Systems Biology \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Institute .."},{"orgOrder":0,"company":"Rome Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rome Therapeutics debuts with $50M and Rosana Kapeller as CEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Rome Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Rome Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Rome Thera.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$100.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Aeglea BioTherapeutics Announces Proposed Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Norwest Venture Partners","pharmaFlowCategory":"D","amount":"$35.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"Pirfenidone","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Avalyn Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Avalyn Pharma \/ Norwest Venture Partners","highestDevelopmentStatusID":"9","companyTruncated":"Avalyn Pha.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomedics Announces Proposed Public Offering Of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kamada and Kedrion Biopharma Join Hands to Develop, Manufacture and Distribute Plasma Based Anti-SARS-CoV-2 Polyclonal IgG Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-SARS-CoV-2 polyclonal immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Kedrion Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Kamada \/ K.."},{"orgOrder":0,"company":"Crestone","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crestone, Inc. Secures NIH Funding for Preclinical Development of Novel Antibiotic CRS3123 to Treat H. pylori Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"CRS3123","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crestone \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"CSHL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat in COVID-19-related Acute Respiratory Distress Syndrome ","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Lonodelestat","moa":"Human neutrophil elastase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Santhera Pharmaceuticals \/ CSHL","highestDevelopmentStatusID":"1","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Secures up to $25 Million in Convertible Note Financing","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Genpharm Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC\u2122 ODT in the Middle East","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Genpharm Services","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Lausanne University Hospital","sponsor":"Prokarium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prokarium Signs an Exclusive Option Agreement with the Lausanne University Hospital for the Treatment of Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Salmonella Typhi Ty21a","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lausanne University Hospital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Lausanne University Hospital \/ Prokarium","highestDevelopmentStatusID":"4","companyTruncated":"Lausanne U.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics Closes $2.0 Million Private Placement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","amount":"$57.5 million","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Hepatitis B vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VBI Vaccines","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Raymond James & Associates","highestDevelopmentStatusID":"10","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Imperial College London","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TriLink BioTechn & Imperial College London collaborate to produce saRNA for COVID-19 vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Self-amplifying RNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TriLink BioTechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TriLink BioTechnologies \/ Imperial College London","highestDevelopmentStatusID":"8","companyTruncated":"TriLink Bi.."},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$34.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim VC backs Actym Therapeutics for $34 million Series A Financing ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"Salmonella Typhimurium Attenuated Cancer Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Actym Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Actym Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"4","companyTruncated":"Actym Ther.."},{"orgOrder":0,"company":"NYC Health + Hospitals\/Metropolitan","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atossa Therapeutics Contracts with NYC Health + Hospitals\/Metropolitan for COVID-19 HOPE Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NYC Health + Hospitals\/Metropolitan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NYC Health + Hospitals\/Metropolitan \/ Atossa Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"NYC Health.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"CEPI Announces COVID-19 Vaccine Development Partnership With Clover Biopharmaceuticals\u2019 Australian Subsidiary","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 S-Trimer","moa":"S-Trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Merger","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen","highestDevelopmentStatusID":"10","companyTruncated":"Ritter Pha.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ADC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Denovo Biopharma To Acquire Tocagen's Entire Replicating Gene Therapy Platform and Related Assets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Vocimagene amiretrorepvec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forte Biosciences \/ Denovo Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Entos Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Epivax and Entos Pharmaceuticals to develop DNA-based vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"Fusogenix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ Entos Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ E.."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"GARDP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections With Limited Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Cefepime","moa":"Peptidoglycan synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"VenatoRx Pharmaceuticals \/ GARDP","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Quotient Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"4","companyTruncated":"Quotient S.."},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$530.0 million ","upfrontCash":"$300.0 million","newsHeadline":"Supernus to Acquire CNS Portfolio from US WorldMeds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"US WorldMeds","amount2":0.53000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"US WorldMe.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"CAD-9303","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.040000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Cowen Healthcare Investments","highestDevelopmentStatusID":"6","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"resTORbio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Merger","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ resTORbio","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Almac Group","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Taps Almac in Neurodegenerative Drug Discovery Deal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"DUBs","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Almac Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Almac Group \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Almac Grou.."},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune\u00ae-Based Anti-Cancer Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"PDS0103","moa":"Mucin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Cancer Institute \/ PDS Biotechnology Corporation","highestDevelopmentStatusID":"4","companyTruncated":"National C.."},{"orgOrder":0,"company":"Atreca","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"IgM antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ BeiGene","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ B.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$101.3 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Oxford University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca Strikes Deal With Oxford University to Mass Produce Experimental COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Oxford University","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$308.0 million","upfrontCash":"$130.0 million","newsHeadline":"Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"VLA15","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0.31,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"BioAge Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioAge Signs Exclusive License Agreement with Taisho to Develop and Commercialize Taisho\u2019s Phase 1 HIF-PH Inhibitor to Treat Aging","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BGE-117","moa":"HIF-PHI","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Taisho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taisho Pharmaceutical \/ BioAge Labs","highestDevelopmentStatusID":"6","companyTruncated":"Taisho Pha.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Immedica Pharma AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.1 million","newsHeadline":"PharmaMar Inks Pact with Immedica Pharma to market lurbinectedin in Eastern Europe and Other Territories ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Immedica Pharma AB","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Trio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"TRIObody drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Trio Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aravive","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Aravive Collaborate to Develop Novel Antibodies Targeting Cancer and Fibrosis Using the WuXiBody\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"CTGF","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Aravive","highestDevelopmentStatusID":"2","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Bixink Therapeutics","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX\u00ae (neratinib) in South Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Bixink Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Prometrika","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prometrika and Karyopharm Partner in Global COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Prometrika","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prometrika \/ Karyopharm","highestDevelopmentStatusID":"8","companyTruncated":"Prometrika.."},{"orgOrder":0,"company":"Wistar Institute","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wistar and Batavia Collaborate to Manufacture Rubella Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"RA 27\/3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Wistar Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wistar Institute \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"12","companyTruncated":"Wistar Ins.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaccitech and Oxford University Enter Partnership with AstraZeneca To develop and Distribute COVID-19 vaccine candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Vaccitech","highestDevelopmentStatusID":"1","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mallinckrodt to Fund Nitric Oxide Therapy Trial in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Massachusetts General Hospital \/ Mallinckrodt","highestDevelopmentStatusID":"1","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Mycenax Biotech","sponsor":"Gedeon Richter","pharmaFlowCategory":"D","amount":"$19.5 million","upfrontCash":"$3.0 million","newsHeadline":"Richter and Mycenax Entered into an Asset Purchase Agreement of Biosimilar Tocilizumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Mycenax Biotech","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Injection","sponsorNew":"Mycenax Biotech \/ Gedeon Richter","highestDevelopmentStatusID":"6","companyTruncated":"Mycenax Bi.."},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"RDD Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovate Biopharmaceuticals and RDD Pharma Merge to Form 9 Meters Biopharma","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Merger","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Innovate Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovate Biopharmaceuticals \/ RDD Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Innovate B.."},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclacel Pharmaceuticals Inks Collaboration With University of Edinburgh to Study CDK Inhibitors in COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Fadraciclib","moa":"CDK2","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Edinburgh \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics Expands Existing License Agreement with Luxna Biotech Inc ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antisense oligonucleotide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Luxna Biotech \/ Aligos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biot.."},{"orgOrder":0,"company":"University of Maryland","sponsor":"AIkido Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIkido Pharma Executes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antiviral drugs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"University of Maryland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Maryland \/ AIkido Pharma","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Xortx Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus \/ COVID-19 Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ XORTX Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Bausch + Lomb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearside Biomedical Revises NDA Resubmission Timeline and XIPERE\u2122 Commercial Partnership with Bausch Health","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Bausch + Lomb","highestDevelopmentStatusID":"12","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Sino Biological","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeoVax and Sino Biological Establish Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant proteins","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sino Biological","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sino Biological \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"Sino Biolo.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"The Department of Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Department of Biotechnology approves funding for 3 companies for developing COVID-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ The Department of Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"University of Georgia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Georgia\u2019s Covid-19 vaccine shows promise in test models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"Viral spike glycoprotein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Another PhIII win in hand, Cara aims straight for priority review of 'breakthrough' pruritus drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces First Patient Dosed in Phase 1b\/2a Study of Anti-FcRn Batoclimab to Treat Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Circularity Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New COVID-19 Clinical Trial Announced To Treat over 90% Of Patients With Underlying Medical Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Deoxyhemoglobin vasodilator","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Circularity Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Circularity Healthcare \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Circularit.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Anandamide","moa":"Complement C3","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Pharmaceuticals Announces US FDA Grants 67Cu-SARTATE\u2122 Orphan Drug Designation for Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"67Cu-Sartate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bonus Biogroup Initiates Preclinical Study for Treatment of Respiratory Distress in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Activated mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bonus BioGroup \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioG.."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NB-02","moa":"AChE","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroBo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuroBo Ph.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring Announces Results from Three Analyses of Hizentra\u00ae in Primary Immunodeficiency (PI)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarveda Therapeutics to Present Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Locnartecan","moa":"HSP90","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tarveda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Th.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Preclinical Data Demonstrating Antitumor Activity of a Potent and Selective Inhibitor of CBP\/p300","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-6876","moa":"CBP\/p300","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scynexis' New Antifungal Delivers in Yeast Infection Phase 3","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MK-7110","moa":"TLR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Reports Positive Topline Results from Phase 2 Trial of Tesomet in Hypothalamic Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"twoXAR Pharmaceuticals Presents Preclinical Data Demonstrating Positive Safety and Tolerability of Two Novel Lupus Drug Leads","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TXR-711","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"twoXAR Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pha.."},{"orgOrder":0,"company":"Asarina Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asarina Pharma Reports Topline Results from Phase Iib Study in PMDD","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Asarina Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Asarina Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asarina Ph.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic's IMU-838 Demonstrate Preclinical Activity Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"WindMIL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial to Treat Patients with Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Marrow-Infiltrating lymphocytes","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"WindMIL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WindMIL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WindMIL Th.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Submits New Drug Application to the FDA for Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal of Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HB-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Enrollment of First Patient in Phase 1\/2b Study of ARQ-252 in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ARQ-252","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dalcinonacog alfa","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Reports Encouraging Results from Use of RUCONEST\u00ae in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Conestat alfa","moa":"C1 esterase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acquist Therapeutics Expands Patent Portfolio for Novel Small Molecules, Receives Fourth U.S. Composition Patent","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ACQT1127","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Acquist Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acquist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Acquist Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kymriah\u00ae Receives FDA Regenerative Medicine Advanced Therapy Designation in Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisagenlecleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Data Showing Jakavi\u00ae (Ruxolitinib) More Effective Than Best Available Therapy in Acute Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q BioMed \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data in Hand, Ono\/Takeda to Seek 1st-Line RCC Nod for Opdivo\/Cabometyx Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"AntiCancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AntiCancer Inc. Establishes Subsidiary CoronaCure to Develop Its Novel Therapeutic for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Methioninase","moa":"Methionine","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Tot Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin) Meets Primary Endpoint in Phase III Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Tot Biopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tot Biopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tot Biopha.."},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nascent Biotech Provides Update on its Antibody Therapy for COVID-19 and also Human Brain Cancer Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pritumumab","moa":"Vimentin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nascent Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Bi.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b\/3 Multinational Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vixarelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AFYX Therapeutics Achieves Primary Endpoint in Phase 2b Trial of Rivelin-CLO in Patients with Oral Lichen Planus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AFYX Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Patch","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AFYX Thera.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Gains Accelerated US Approval for Trodelvy in Previously-Treated Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Presents New Data from the GARNET Study Revealing Potential of Dostarlimab to Treat Recurrent or Advanced Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Agastiya Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agastiya Biotech Proceeding with Drug Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AB001","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Agastiya Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agastiya Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Agastiya B.."},{"orgOrder":0,"company":"Acquist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomarck Announces, Phase 2a Clinical Trial Results of BIO-11006 for Acute Respiratory Distress Syndrome (ARDS)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO-11006","moa":"MARCKS protein","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Acquist Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Acquist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acquist Th.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Highlight Clinical Data on Vitrakvi\u00ae (larotrectinib) and Research on Investigational AhR Inhibitor at AACR 2020 Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BAY2416964","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Trial of Metablok to Stop Lung and Kidney Inflammation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CLBS119","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Publication Evaluating Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial of CPI-613\u00ae ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX\u00ae2-73 (blarcamesine) in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Presentation of New Phase IIIb ANJESO\u2122 Data at the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Publication of Comprehensive Review of Oliceridine Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Announces Publication Demonstrating PET Scan Results of Higher Dose Naloxone in Monkeys","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SRF388","moa":"IL-27","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"University Hospitals Geneva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swiss Hospitals Launch Drug Trial to Prevent Covid-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospitals Geneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University Hospitals Geneva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WPD Pharmaceuticals\u2019 Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"POLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Lynparza shows further promise in prostate cancer study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xbrane Biopharma Plans to Continue Phase III Trial of its Xlucane\u00ae (Ranibizumab) Biosimilar Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Xbrane Biopharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Xbrane Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xbrane Bio.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics, Voltron Therapeutics & HaloVax Announce Selection of First of Virus Targeting Peptides in Development of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Self-Assembling Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Three New Phexxi\u2122 or Presentation at 2020 ACOG","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Announces That Data Safety Monitoring Board Validates NOX-A12 Dose Escalation in Phase 1\/2 Brain Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from the Second Phase III SAkuraStar Study for Chugai\u2019s Satralizumab in Neuromyelitis Optica Spectrum Disorder ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Initiate ESCAPE, Phase II Clinical Trial to Test Efficacy of Vafidemstat in Severely Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical receives Japanese patent for intralymphatic administration of diabetes vaccine Diamyd","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"rhGAD65","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharma receives South Korean regulatory approval to begin phase 2 COVID-19 study of Ifenprodil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Tecentriq, on top of targeted drugs, stalls melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Ipsen","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MD Anderson and Ipsen Advance New Therapy with Potential Benefit for Underserved Patients with Lung and Ovarian Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"IPN60090","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Pads Case for Convenient Keytruda Dosing with New Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Pits Fast-Rising Farxiga Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"NEC Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEC Publishes Design Blueprints for SARS-Cov-2 Vaccines Using its Artificial Intelligence Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NEC Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NEC Corporation \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NEC Corpor.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi, Regeneron Tout Libtayo's First Lung Cancer Win","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Syndax data broach 'undruggable' leukemia mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SNDX-5613","moa":"MLL1-Menin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Green Valley to Start US Trials of Algae-Based Alzheimer\u2019s Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium oligomannate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Green Valley Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Green Valley Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Green Vall.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tecentriq\/Xtandi Combo Fails to Show OS Benefit, Halting Roche's PD-L1 Push into Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202\/MOR202 in r\/r Multiple Myeloma in Mainland China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR202","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Carmell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium Phosphate","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Carmell Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Carmell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Carmell Th.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical Presents Updates from Ongoing Ovarian Cancer and Glioblastoma Clinical Studies at 2020 AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AV-GBM-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aivita Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Announces Drug Candidate as Potential Therapy for Managing Cytokine Release Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 ","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxorubicin peptide conjugate","moa":"Sortilin receptor 1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301 for Post-Operative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Funapide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Flexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat ARDS in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Romark","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Romark Initiates Phase 3 Clinical Trials Of NT-300 For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Romark \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ N.."},{"orgOrder":0,"company":"Rgenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-104","moa":"Liver X receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rgenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rgenix \/ N.."},{"orgOrder":0,"company":"Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biopharma Starts Clinical Trials on Possible Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"High affinity immunoglobulin gamma Fc receptor I","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection","sponsorNew":"Biopharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Biopharma .."},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hua Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hua Medici.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE\u00ae Technology For Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Present Data from Study Highlighting Clinical Activity of RAF\/MEK and FAK Combination in KRAS Mutant Tumors ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyneuron Receives Approval to Begin Clinical Study With PN-1007 in Anti-MAG Neuropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PN-1007","moa":"MAG IgM","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polyneuron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1b\/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer Presented at the AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"Sema4D","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg\/30mL (1mg\/mL) Multiple Dose Vial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib for Treatment of NSCLC Patients ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Mobocertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN217","moa":"CTLs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italfarmaco Provides Update on Advanced-Stage Clinical Development Program with Givinostat in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Givinostat","moa":"HDAC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Italfarmaco S.p.A","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Italfarmac.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Therapeutics Gets Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells to Treat Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CAR-BCMA T cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar Gets Spanish Medicines Agency Authorization for APLICOV-PC Clinical Trial With Aplidin\u00ae for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"eEF1A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pneumagen Ltd Announces Positive Anti-Viral Activity for Novel Glycan Approach in Preventing Coronavirus (COVID-19) Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Carbohydrate binding modules","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pneumagen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Part 2 of FIREFISH Shows Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sovateltide Significantly Improved Clinical Outcome in Patients with Acute Cerebral Ischemic Stroke When Compared to Standard of Care","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NC-MSCs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Trial of Libtayo\u00ae as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A new FDA Fast Track designation for Zambon","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zambon Group SpA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Gro.."},{"orgOrder":0,"company":"Epsilogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epsilogen Limited Announces Interim phase 1 MOv18 IgE data presented at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MOv18 IgE","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epsilogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen .."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ORIC-533","moa":"CD73","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2\/3 Trial in Alzheimer\u2019s Disease Agitation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valo Therapeutics to Support Development of a Pan - Coronavirus Vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19-adenovirus vector-based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Valo Thera.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio's Bemcentinib to Be Fast-tracked as Potential Treatment for COVID-19 Through New National UK Government Clinical Trial Initiative","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Trovagene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Trovagene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trovagene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Trovagene .."},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioEclipse Receives FDA Clearance of Investigational New Drug Application for CRX100","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CRX100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces Results from Phase 3 VOYAGER Trial of Avapritinib vs Regorafenib in Advanced Gastrointestinal Stromal Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Plans COVID-19 Testing for Ilaris","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-456","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Announces Positive Preclinical Antitumor Activity and Safety of FS222 Published in Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FS222","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics to Present New Preclinical Data from Its CRISPR\/Cas9 Programs at the American Society of Gene and Cell Therapy Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NTLA-5001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Allows Trial to Proceed for Retrotope\u2019s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics to Present Preclinical Findings Supporting TurboCAR\u2122 Technology at the ASGCT Virtual 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-605","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1\/2 trial of COVID-19 vaccine candidates in Germany","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AE37 Peptide","moa":"Helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences Announces Publication of Potent In Vitro Activity of KBP-7072 Against Acinetobacter baumannii","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-7072","moa":"Protein synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"KBP Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"R-Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cromos Pharma Supports R-Pharm to Initiate Global Program to Test Two of its Leading Candidates in Patients with Severe COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Olokizumab","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"R-Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"R-Pharm \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"R-Pharm \/ .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Positive Phase II TACTI-002 Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Avdoralimab Phase Ii Clinical Trial in Covid-19 Patients with Severe Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avdoralimab","moa":"C5a receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Initiates Phase 2 Study of BXCL701 in Combination with PD-1 Inhibitor to Treat Emergent Neuroendocrine Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Talabostat Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Reports Analysis from Phase 1b Geographic Atrophy Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiTAA-specific T cells","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen Announces US FDA Clearance of IND Application to Initiate Phase II Clinical Trial in Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Disitamab vedotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Announces First Patient Enrolled in AEROSURF\u00ae Bridging Study for the Treatment of Respiratory Distress Syndrome","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucinactant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Hard Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Grants Orphan Drug Designation to Amylyx Pharmaceuticals\u2019 AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Defibrotide Sodium","moa":"Plasminogen","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MGD013","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CX-2029","moa":"CD71","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Troxacitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Sprint Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sprint Bioscience Publishes Scientific Study With New Positive Data from the Vps34 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SB02024","moa":"Vps34","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sprint Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sprint Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sprint Bio.."},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"SK1-I","moa":"Sphingosine kinase 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzo Biochem \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Bioch.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces Acceptance of Oral Paclitaxel Phase II Study in Angiosarcoma Abstract at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Data to be Presented at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Publishes Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Receives Approval to Conduct Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis ","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Initiates IND-Enabling Activities For EDIT-201, An Allogeneic NK Cell Medicine For The Treatment Of Solid Tumor Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-321","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PL9643","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix To Highlight New Data Across Its Portfolio Of Products At Digestive Disease Week 2020 Virtual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark to conduct trials in India for potential COVID-19 drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compelling Data on Mechanism of Action for GlycoMimetics\u2019 Late-stage Clinical Candidate Uproleselan Published in Nature Communications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion Biotechnology Successfully Completes Phase I Clinical Study of 0b-002h Topical Gel for HIV Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"0B-002","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calcimedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical Covid-19 Pneumonia on High-Flow Oxygen Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CM4620-IE","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data From EMD Serono at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lixte Biotechnology\u2019s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-100","moa":"PP2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biot.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Initiates Same Day Dosing Clinical Trial for ROLONTIS\u00ae (eflapegrastim)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GM-CSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson\u2019s and Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ZN-d5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Neon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NEO-PTC-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Neon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neon Thera.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b\/3 NASH-RX Protocol in NASH Cirrhosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"NKMax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKMax America To Present Data from its Natural Killer Cell Immunotherapy Clinical Program at the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ No.."},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILC Seeks \u00a34m to Help Advance COVID-19 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alpha 14","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ILC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ILC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ILC Therap.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan intends to screen NVN1000 against viruses including SARS-CoV-2\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus explores the biologicals route to treat novel Coronavirus\nwith long-acting Interferon alpha-2b","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon alpha-2b","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular partners Launch Anti-COVID-19 Therapeutic Program Bolstering DARPin Proteins Multi-Target Binding to Neutralize SARS-CoV-2 Viruses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DARPin","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Partners \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scancell Kicks Off COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"T cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scancell \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Indian Institute of Science ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IISc, start-up developing vaccine for Covid-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"Viral spike glycoprotein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Indian Institute of Science ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indian Institute of Science \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Indian Ins.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics and Servier to Present Results from Phase 1 Alpha Study of Allo-501 Allocar T\u2122 Therapy ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-501","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron and Sanofi Provide Update on U.S. Phase 2\/3 Adaptive-Designed Trial Of Kevzara\u00ae (Sarilumab) In Hospitalized Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"ThermoGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ThermoGenesis and ImmuneCyte Joint Venture Developing Several Convalescent Plasma and Antibody Therapeutic Approaches Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Monoclonal antibody drug candidate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ThermoGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ThermoGenesis \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ThermoGene.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen delays Alzheimer's drug filing plans, shares fall\r\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition, Inc. Receives FDA\/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpha-1062","moa":"AchE","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Arthritis Drug Tocilizumab Shows Promise in Covid-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Royal Melbourne Hospital ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australian Researchers Launch ASCOT Study for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Royal Melbourne Hospital ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Royal Melbourne Hospital \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Royal Melb.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biontech And Pfizer to Commence First Clinical Trial of Covid-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis\n","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Viriom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Elsulfavirine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viriom \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ N.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announced Results of Interim Analysis for RECOVERY Study of Tonmya ","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$270.4 million ","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Curadev Sign Research Collaboration and License Agreement to Develop novel STING Antagonists Across Indications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Curadev Pharma Private Limited","amount2":0.27000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Curadev Pharma Private Limited \/ Bayer","highestDevelopmentStatusID":"2","companyTruncated":"Curadev Ph.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cstone Submits New Drug Application for the Targeted Therapy Avapritinib In Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"AdaptVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adaptvac Signs Agreement with AGC Biologics to Develop & Produce COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"SARS-CoV-2 capsid-Virus Like Particle vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ AdaptVac","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Compass Pathways","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Compass Raises $80M to Take Magic Mushroom Drug Toward Phase 3","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0.080000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Compass Pathways \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pa.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19 Related Delays in RhoVac AB Ongoing Phase IIb-study are Expected to be Managed With Existing Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin to Host Investor Conference Call to Discuss COVID-19 Potential for Drug Candidate ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kalos Therapeutics Announces Progress in Covid-19 Preventative & Therapeutic Approaches","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KTH-222","moa":"Mapk","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kalos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Ther.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Gets NMPA Acceptance of its New Drug Application in Mainland China for Avapritinib in Two Gastrointestinal Stromal Tumor Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces U.S. FDA Filing Acceptance of New Drug Application for Terlipressin to Treat Hepatorenal Syndrome Type 1","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health to Present Somatrogon Phase 3 Pediatric Trial Results at ENDO Online 2020","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Achilles Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achilles Therapeutics to Present a Manufacturing Update at the virtual 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Clonal neoantigen T cells","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Achilles Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Achilles Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Achilles T.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Completes Enrollment for the INSIGHT-004 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Corporation Provides Update on Its Phase 2 PASADENA Study of Prasinezumab (PRX002\/RG7935) in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma Announces First Subject Dosed In Phase 1 Study of TD-0903","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TD-0903","moa":"JAK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Underway to Examine the Planned Use of BTG Pharmaceutical's Voraxaze\u00ae with Methotrexate in CNS Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BTG Specialty Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specia.."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Redx Pharma Provides Update on Its Phase 1\/2a Clinical Trial of RXC004","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RXC004","moa":"Porcupine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Redx Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Redx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSig Subsidiary ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR\u2019s Zotatifi Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Receptor Tyrosine Kinase-Driven Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Zotatifin","moa":"eIF4A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Results of Phase 3 Clinical Trial of DEXTENZA\u00ae for the Treatment of Ocular Itching in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Grants Positive Opinion for Janssen Pharmaceutical's DARZALEX\u00ae Subcutaneous Formulation for Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Presents Session on Repurposing Niclosamide for COVID-19 Treatment at AAPS Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Limited Begins Enrollment of Phase 2\/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna\u2019s Vaccine (mRNA-1273) Against Novel Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lonza Group \/ Moderna","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$459.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunomedics Announces Closing Of Public Offering Of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0.46000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"Immunomedics \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"ValiRx","sponsor":"Undisclosed ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ValiRx Signs Drug Transfer Agreement With Japanese Pharma Firm","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"VAL301","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"ValiRx","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ValiRx \/ Undisclosed ","highestDevelopmentStatusID":"4","companyTruncated":"ValiRx \/ U.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"$175.6 million","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Gets Funding for Drug Discovery Technology That Identifies Antibodies for Potential Use in drugs to treat and prevent COVID-19.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0.17999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"AbCellera \/ Government of Canada","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$677.0 million","upfrontCash":"$677.0 million","newsHeadline":"Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"EEF2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Menarini ","highestDevelopmentStatusID":"12","companyTruncated":"Stemline T.."},{"orgOrder":0,"company":"Transgene","sponsor":"Vaxxel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxxel Buys Transgene\u2019s Cell Line to Develop New Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"DuckCelt-T17","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Vaxxel","highestDevelopmentStatusID":"1","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Noachis Terra","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 Vaccine Candidate Utilizing \u201cSpike Protein\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"TerraCoV2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Noachis Terra","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noachis Terra \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Noachis Te.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Arcturus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Intralytix","sponsor":"NIAID","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Shigella bacteriophage therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Intralytix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intralytix \/ NIAID","highestDevelopmentStatusID":"7","companyTruncated":"Intralytix.."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Marinomed Receives FFG Funding to Research SARS-Cov-2 Therapy Based On Carragelose\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Carragelose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Marinomed Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Marinomed Biotech \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"1","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Mabpharm","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Collaborates with Mabpharm On Development and Commercialization of Ace-Mab\u2122 to Potentially Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ACE-MAB","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mabpharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mabpharm \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mabpharm \/.."},{"orgOrder":0,"company":"Nuritas","sponsor":"Advanced Computing in Europe","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nuritas Leverages AI Platform to Identify Therapeutic Peptides for the Treatment of COVID-19\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Peptides","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nuritas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuritas \/ Advanced Computing in Europe","highestDevelopmentStatusID":"2","companyTruncated":"Nuritas \/ .."},{"orgOrder":0,"company":"Kansas State University Research Foundation","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation for Coronavirus Antiviral Compounds\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antiviral drugs","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kansas State University Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kansas State University Research Foundation \/ Cocrystal Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Kansas Sta.."},{"orgOrder":0,"company":"KemPharm","sponsor":"Corium","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital After NDA Filing for Potential New ADHD Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"KemPharm \/ Gurnet Point Capital ","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioInvent Signs Manufacturing Agreement With US Cell Therapy Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kubota Vision Completes Enrollment in the Emixustat Phase 3 Clinical Trial in Patients with Stargardt Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pierre Fabre receives Positive CHMP Opinion for BRAFTOVI\u00ae in Combination with Cetuximab for Treatment of BRAFV600E-mutant Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Encorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pierre Fabre","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pierre Fabre \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pierre Fab.."},{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UC San Diego to Assess Hypertension Drug Ramipril for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ramipril","moa":"ACE","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Publication of Preclinical Study of EC-18 in Gouty Arthritis in Frontiers in Immunology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar\u2019s Abstract for ATS 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MBT2","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Priority Review Bristol Myers Squibb\u2019s Application for CC-486 for Maintenance Treatment of Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Re-purposes Ifenprodil Drug Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinigen Demonstrates IL-2 Plays Role in Emerging TIL Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Announces Positive Topline Results From its Phase 3 Study of Single-Dose Solosec\u00ae (secnidazole) for the Treatment of Trichomoniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Oxford and Sound Pharmaceuticals Complete Phase 2 Bipolar Disorder Study with SPI-1005","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's Core Drug Candidate HQP1351 Granted Orphan Drug Designation by the US FDA ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HQP1351","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics to Present at Maxim Group\u2019s Infectious Disease Virtual Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-2307","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS\u2122 for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Reports Top-Line Results From Its STARS Study Evaluating Sarizotan in Patients With Rett Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarizotan","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Receives Priority Medicines Designation from European Medicines Agency for Sotatercept in Pulmonary Arterial Hypertension","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Announces Appointment of Rekha Hemrajani to Board of Directors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"SIRPalpha-CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fulvestrant","moa":"Estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Updates Timing for Top-Line Results From Completed Phase 2B Dose-Ranging, Efficacy Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Inositec AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INS-3001","moa":"Vascular calcification","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Inositec AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inositec AG \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inositec A.."},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TCR\u00b2 Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TC-210","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TCR2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Thera.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia IND Application for CAN04 Approved by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nidanilimab","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarametyx Biosciences Launches With an Ambitious Strategy to Address Life-threatening Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CMTX-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clarametyx Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarametyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clarametyx.."},{"orgOrder":0,"company":"CARE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARE Conducting Clinical Trials For Primary & Secondary Prophylaxis to Reduce COVID-19 Hospitalization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Imiquimod","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CARE","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARE \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"CARE \/ Not.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data from Assembly Biosciences\u2019 Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ABI-M201","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspargo Laboratories Announces Successful Completion of Pre-IND Meeting with FDA on Sildenafil Oral Spray to Treat Erectile Dysfunction","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces Upcoming Presentations on MDNA55 at the ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL First-in-class MOSPD2 Antibodies Show Potential for Treatment for CNS Inflammation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-601","moa":"MOSPD2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI\u2019s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine to Treat Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto Presents GB0139 Preclinical and Clinical Data on Anti-Fibrotic Activity as Online Experimental Biology 2020 Poster","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GB0139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Interim Results from an Open-Label Extension Study of Antolimab in Eosinophilic Gastritis and\/or Eosinophilic Duodenitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Antolimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Expert Review of Data Supports the Potential of XF-73 to Address Antimicrobial Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"Siglec-8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Peginterferon Lambda","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"EvergreenHealth ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EvergreenHealth Prepares for 2nd Arm of Clinical Trial After Getting Promising Results for Remdesivir as Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EvergreenHealth ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EvergreenHealth \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EvergreenH.."},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Premas Biotech to Develop Vaccine Against COVID-19 Based on Multi-Antigenic Approach","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant triple antigen vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Premas Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Premas Bio.."},{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of California to Assess Whether Hypertension Drug May Reduce COVID-19 Severity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam, Vir Plan Year-End Trial of New Rnai COVID-19 Antiviral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-2703","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces That ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"Utrecht University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Utrecht University, Erasmus Medical Center and Harbour BioMed Report Discovery of Antibody that Blocks Novel Coronavirus Infection in Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Human monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Utrecht University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Utrecht University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Utrecht Un.."},{"orgOrder":0,"company":"Bioxytran","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BXT-10","moa":"Galectin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bioxytran","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioxytran \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioxytran .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi, Eli Lilly Agree to Co-develop JS016 Antibodies Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"JS016","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Viriom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viriom Initiates Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VM1500A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Viriom \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ N.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma BAGS MHRA Nod for Covd-19 Trial in Record Time","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics Announces FDA Release of IND Order for Ntx-001, A New Approach For Treating Patients With Peripheral Nerve Injuries","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts IND Application of ATyr Pharma on Phase 2 Study For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"Neuropilin-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"University of Colorado Denver","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Colorado Doctors Test Anti-blood Clot Treatment on COVID-19 Patients, Optimistic About Results So Far","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Alteplase","moa":"Plasminogen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Colorado Denver","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Colorado Denver \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak to Present New Preclinical Data on EngEx therapeutic candidates at the American Society of Gene and Cell Therapy Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"EngEx therapeutic candidates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Potential New Antiretroviral drug Developed at UNMC for HIV Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiretroviral drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Nebraska Medical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Nebraska Medical Center \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals Announces Final Clinical Safety And Efficacy Data From Illuminate-204 Trial In Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus DMCC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CERUS Announces the Acquisition of Laboratori Derivati Organici SpA (LDO) by Opocrin SpA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Heparin Sodium","moa":"Factor IIa","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Laboratori Derivati Organici","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Laboratori Derivati Organici \/ Cerus DMCC","highestDevelopmentStatusID":"1","companyTruncated":"Laboratori.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Details Early Responses to Tils in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation in EU for MIV-818 to Treat Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First novel COVID-19 vaccine candidate commences animal testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Government of United Kingdom","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imperial College London gets UK funding for Covid-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Self-amplifying RNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Imperial College London","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Imperial College London \/ Government of United Kingdom","highestDevelopmentStatusID":"4","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"CSL Behring","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"University City Science Center inks partnership with CSL Behring","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Chemokine-derived antifibrotic peptides","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Pittsburgh To Begin Work on Novel Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine Candidate Shows Immune Response in Early Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PittCoVacc","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"University of Pittsburgh \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Eli Lilly Announce NMPA Acceptance of Supplemental New Drug Application for Sintilimab in Combination with ALIMTA and Platinum","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Genfa Medica","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements with Genfa Medica","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Genfa Medica","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Genfa Medica \/ MediWound","highestDevelopmentStatusID":"12","companyTruncated":"Genfa Medi.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Imophoron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imophoron Develops COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Imophoron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imophoron \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Imophoron .."},{"orgOrder":0,"company":"Censa Pharmaceuticals","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","amount":"$366.0 million","upfrontCash":"$10.0 million","newsHeadline":"PTC Therapeutics to Acquire Censa Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Sepiapterin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Censa Pharmaceuticals","amount2":0.37,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.37,"dosageForm":"Oral","sponsorNew":"Censa Pharmaceuticals \/ PTC Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Censa Phar.."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ventus Uncloaks with $60M to Target the Innate immune System","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IL-1B","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Ventus Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Ventus The.."},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Dr. Daniel Carter","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Using Novel Nanoparticle Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NSP-10 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Predictive Oncology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Predictive Oncology \/ Dr. Daniel Carter","highestDevelopmentStatusID":"6","companyTruncated":"Predictive.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Inks Manufacturing Deal with Faron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Faron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bausch + Lomb Licenses Exclusive Rights from STADA and Xbrane to a Biosimilar Candidate for Lucentis in the United States and Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"STADA Arzneimittel \/ BAUSCH + LOMB","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"CaaMTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CaaMTech Collaborates With National Institutes of Health to Research Psychedelics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"National Institute on Drug Abuse","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Drug Abuse \/ CaaMTech","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"$5.0 million","newsHeadline":"BetterLife Pharma Enters into a Licensing Agreement with Altum Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AntiCovir","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Mediolanum Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mediolanum Farmaceutici Acquires the French Company ElsaLys Biotech to Develop Next Generation Immuno-oncology Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Inolimomab","moa":"IL-2 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ElsaLys Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElsaLys Biotech \/ Mediolanum Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"ElsaLys Bi.."},{"orgOrder":0,"company":"VIDO-InterVac","sponsor":"ZYUS Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ZYUS Collaborates with USask\u2019s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Plant based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIDO-InterVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VIDO-InterVac \/ ZYUS Life Sciences ","highestDevelopmentStatusID":"1","companyTruncated":"VIDO-Inter.."},{"orgOrder":0,"company":"AI VIVO","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AI VIVO Seeks Collaboration Partners to Progress Top-ranked COVID-19 Therapeutic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"PTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AI VIVO","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AI VIVO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AI VIVO \/ .."},{"orgOrder":0,"company":"Iontas","sponsor":"Inotrem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets with Inotrem","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"TREM-1","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ Inotrem","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ I.."},{"orgOrder":0,"company":"Defence Materials Technology Centre","sponsor":"Certara","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Certara and DMTC Announce Research Collaboration to Study Preventative Use of Chloroquine in Health Care Workers at High Risk of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Chloroquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Defence Materials Technology Centre","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Defence Materials Technology Centre \/ Certara","highestDevelopmentStatusID":"11","companyTruncated":"Defence Ma.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Commonwealth of Pennsylvania","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Noveome Biotherapeutics Receives $4 Million Grant From Commonwealth of Pennsylvania","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noveome Biotherapeutics \/ Commonwealth of Pennsylvania","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"University of Alberta","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Inks Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TNX-1810","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"University of Alberta","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Alberta \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"University.."},{"orgOrder":0,"company":"jCyte","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","amount":"$252.0 million","upfrontCash":"$50.0 million ","newsHeadline":"jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Santen Pharmaceutical","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"jCell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0.25,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.25,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Santen Pharmaceutical ","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Sa.."},{"orgOrder":0,"company":"Mount Sinai Health System","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento ventures into COVID-19 with Mount Sinai antibody pact","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVI-SHIELD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mount Sinai Health System","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mount Sinai Health System \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Mount Sina.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"NYIP","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"NOXXON Announces Capital Increase of \u20ac 5.5 Million by Private Placement to Further Develop Its Business","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Private Placement","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ NYIP","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"IDBiologics","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanderbilt University Medical Center and IDBiologics Ally in Race to Develop Breakthrough Medicines for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IDBiologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IDBiologics \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"2","companyTruncated":"IDBiologic.."},{"orgOrder":0,"company":"Columbia University","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ONCOlogues","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Fortress Biotech ","highestDevelopmentStatusID":"1","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Cities","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Third Rock-backed biotech Pliant Therapeutics files for an $86 million IPO","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"PLN-74809","moa":"Alpha5Beta1 Integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pliant Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Cities","highestDevelopmentStatusID":"8","companyTruncated":"Pliant The.."},{"orgOrder":0,"company":"ABL Bio","sponsor":"Themis Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Themis Collaborates with ABL Europe to Manufacture its SARS-Cov-2 Vaccine Candidate in France","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ABL Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABL Bio \/ Themis","highestDevelopmentStatusID":"1","companyTruncated":"ABL Bio \/ .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$85.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Pricing of $85.3 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical\u2019s Favipiravir ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Toyama Chemical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fujifilm Toyama Chemical \/ Appili Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm T.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Megapharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and Megapharm sign a licensing agreement for lurbinectedin in Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Megapharm","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$45.0 million","newsHeadline":"Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ACT-709478","moa":"T-type calcium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Idorsia Pharmaceuticals","amount2":0.40999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"Idorsia Pharmaceuticals \/ Neurocrine Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"National Center for Advancing Translational Sciences","sponsor":"Acer Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Emetine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Center for Advancing Translational Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Center for Advancing Translational Sciences \/ Acer ","highestDevelopmentStatusID":"9","companyTruncated":"National C.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Business Finland","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Faron receives grant from Business Finland","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Faron Pharmaceuticals \/ Business Finland","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inhibitory Effect of Innovation Pharmaceuticals\u2019 Brilacidin on SARS-CoV-2 (COVID-19) in Primary Human Immune Cells to be Studied at Leading Public Health Research Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Terminated Distribution and Commercialization Agreement of its SYMJEPI Products with Sandoz","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Termination","leadProduct":"Epinephrine","moa":"Adrenergic alpha\/beta","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Sandoz ","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI with US WorldMeds","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Stabilitech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$7.2 million","upfrontCash":"Undisclosed","newsHeadline":"Stabilitech Biopharma joins race to develop COVID-19 vaccine delivering unique double immunity using self-administered capsules\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"OraPro-COVID-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Stabilitech Biopharma","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Stabilitech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Stabilitec.."},{"orgOrder":0,"company":"DongWha Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DongWha Pharm to Kick Off Trials for Virus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DW2008","moa":"TIGIT","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DongWha Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DongWha Pharm \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"DongWha Ph.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"5 Fluorouracil","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Gets USFDA Nod For Flucytosine Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluocytosine","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis, Incyte will Test Jakafi in 2nd COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG's Leukemia Combo Clears Phase 3, Aims for 2020 Filing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to Enroll Thousands for its Coronavirus Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Propeller Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis\u2019 asthma triple heads CHMP\u2019s latest meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Propeller Health","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Antabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ANT3310","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Antabio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antabio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antabio \/ .."},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I\/II Peritoneal Trial is Accepted at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LPCN 1148","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure to Present AST-008 Updates at 2020 AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AST-008","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BT5528","moa":"Ephrin type A receptor 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Te.."},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Starts Phase II Study of ArtemiC to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ArtemiC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MGC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharma.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the ECCMID Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rezafungin","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"NuCana","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Acelarin","moa":"DNA polymerase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"NuCana","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NuCana \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NuCana \/ N.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Reports Positive Clinical Results from VERU-111 Phase 1b\/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial of Oral Tebipenem HBr vs Intravenous Ertapenem for Complicated UTI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia in Adult Patients on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Organicell Flow","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Composition of Matter Patent Allowance Extends Protection for Berotralstat in U.S. Market by Four Years to 2039","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion Announces Publication of ANG-3777 Phase 2 Results in the Scientific Journal Transplantation","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck\u2019s RECARBRIO Vs Piperacillin and Tazobactam in HABP\/VABP ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Imipenem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tyvyt (Sintilimab Injection) Combined with Gemzar (Gemcitabine for Injection) and Platinum Chemotherapy Met the Predefined Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Positive Top-Line Results From Otezla\u00ae (apremilast) Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Actemra studies against COVID-19 could be done this month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche flashes new 16-week bispecific AMD data, setting eyes on pair of PhIII trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at the ASCO20 Virtual Scientific Program Reflects Genentech\u2019s Commitment to Accelerating Progress in Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP-305","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OpRegen","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Desmoglein 3 Chimeric AutoAntibody Receptor T cells","moa":"B Cell","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Rebiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rebiotix and Ferring Announce World\u2019s First Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Rebiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics studies Aviptadil for Covid-19-related ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Bio-Pharma Provides PPP003 Inflammatory Cytokine Reduction Drug Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioP.."},{"orgOrder":0,"company":"Mainz University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Identify Potential Active Substances Against Coronavirus by Running Supercomputer Simulations","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Simeprevir","moa":"HCV proteases\/NS3-4A serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mainz University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mainz University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mainz Univ.."},{"orgOrder":0,"company":"Translational Genomics Research Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TGen and HonorHealth trial atovaquone plus azithromycin for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atovaquone","moa":"Cytochrome b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Translational Genomics Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Translational Genomics Research Institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Translatio.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants MIV-818 Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-EGFR antibodies","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexion Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant Glioma from FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Saposin C-dioleoylphosphatidylserine","moa":"Spingomyelinase catalysis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pha.."},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sj\u00f6gren's Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Wize Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Wize Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Wize Pharm.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Presentation of Results From Its Phase 2 (SKYGGN) Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipidor Presents Updated Project Plan - Initiates Phase III study of AKP02 in-House","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB.."},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HighTide Therapeutics Announces Positive Topline Results From Phase 2a Study of HTD1801 in NASH Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HTD1801","moa":"Lipid","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"HighTide Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HighTide Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HighTide T.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AST-VAC2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Submits SNDA for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2+ Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rising Pharmaceuticals & Laurus Labs to Support Phase 2 Clinical Trial of Hydroxychloroquine for COVID-19 Prophylaxis in Cancer Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK to Test Experimental Drug to Treat Pneumonia from COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Otilimab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1\/2 Trial of Lead Candidate ST101 in Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Pulmotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PARI Nebulizer Used in New Study with Pulmotect's Inhaled PUL-042 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Oligodeoxynucleotide","moa":"TLR2\/6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Pulmotect \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect .."},{"orgOrder":0,"company":"Lundquist Institute ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH-Sponsored COVID-19 Clinical Trial Begins at The Lundquist Institute","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lundquist Institute ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lundquist Institute \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist .."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Gets Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CM4620-IE","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data At The ASCO20 Virtual Scientific Program Reflects Roche\u2019s Commitment to Accelerating Progress in Cancer Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Announces Dosing of First Patient in Phase 1\/2 Trial of RTX-240","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-240","moa":"4-1BB ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Announces Scientific Progress with Orexin Agonist Program in Conjunction With Spin-off Companies Orexia and Inexia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Grou.."},{"orgOrder":0,"company":"Columbia University Irving Medical Center ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hydroxychloroquine Fails to Show Benefit In Covid-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Columbia University Irving Medical Center ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Columbia University Irving Medical Center \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Keck Medicine ","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keck Medicine to Launch Clinical Trial for Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Keck Medicine ","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Keck Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Keck Medic.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai, A*STAR to Develop Therapeutic Ab Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Synthetic human antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers at LSTM Demonstrate a Novel Way to Treat Snakebite","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimercaprol","moa":"Heavy metal","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Liverpool School of Tropical Medicine","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Liverpool School of Tropical Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Liverpool .."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Gaboxadol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives U.S. FDA Approval for Retevmo\u2122 (selpercatinib), the First Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Selpercatinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fexuprazan","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LYNPARZA\u00ae (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda to Begin Trial Against Virus in Summer with Global Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasma-derived therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio to Present Updated Results from Pivotal Phase 2 Karmma Study Of Ide-Cel In Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Presents Positive Additional Results From A Phase 2a Study Of Golexanolone","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Golexanolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Umecrine Cognition \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine C.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Novant Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novant Health Initiates Phase 2b\/3 Trial with CytoDyn\u2019s Leronlimab for Severely and Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Novant Health","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gastric-Cancer Drug Designated Breakthrough by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics Announces Topline Results from the BRIDGE Phase III Open-Label Trial of Pegunigalsidase Alfa in Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genfit Delivers Latest NASH Drug Failure","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ N.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 To Present New Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Hong Kong Baptist University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HKBU-led Research Team Develops Novel Anti-viral Targeted Drug for Nasopharyngeal Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"HONG KONG","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Peptide drug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hong Kong Baptist University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hong Kong Baptist University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hong Kong .."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Pharma Highlights Results from Recent Clinical Reports and Studies on use of Interferon","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion\u2122 for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Radium-223","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triple Drug Combination Shows Promise in Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Hong Kong","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"University of Hong Kong \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Reports Continued Progress Advancing HS-110","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Successful Completion of Immuno-Oncology Study Safety Phase","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Inc\u2019s INB03 Inhibits Cell Migration, Tumor Growth in Pre-clinical Models of Trastuzumab-Resistant HER2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INB03","moa":"TNF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"TolerogenixX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MIC-Lx","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TolerogenixX","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TolerogenixX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tolerogeni.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Announces Filing of IND for Phase 2\/3 Clinical Trial of Inhaled RLF-100 Targeting Early COVID-19 Lung Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Introduces 3-in-1 Inhaler Therapy for COPD in India, Promising Reduction in Risk of Severe Attacks and Improvement in Lung Function","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strongbridge Biopharma plc Announces Completion of Enrollment of Phase 3 LOGICS Study for RECORLEV for Endogenous Cushing\u2019s Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbrid.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Successful Type B Meeting with FDA for Pivotal Study of Envafolimab in Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Chronic Pruritus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Receives US FDA IND Approval to Initiate Phase 1b\/2a Trial of HST 001 in Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Tiburio Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiburio Announces Publication of Preclinical TBR-760 Data in Non-Functioning Pituitary Adenoma in Journal of the Endocrine Society","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TBR-760","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tiburio Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tiburio Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tiburio In.."},{"orgOrder":0,"company":"HJB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HJB & Mabspace Biosciences' Develop, Mfg Agreement for Novel Humanized Claudin1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized Claudin18.2 monoclonal antibody","moa":"Claudin 18.2","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HJB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HJB \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HJB \/ Not .."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen's Swiss Facility Ready to Help Boost Aducanumab Rollout","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Eyes 'Early Summer' Start for Phase 3 COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fox Chase Researchers Examine Role of Pembrolizumab in Treating Patients With Metastatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Fox Chase Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fox Chase Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Fox Chase .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac\u2019s PiCoVacc Experimental Vaccine Shows Promise in Monkeys Infected with SARS-CoV-2\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PiCoVacc","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AVA-Trap","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces First Quarter 2020 Financial Results and Provides Corporate Update ","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-2901","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"University of Waterloo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Waterloo developing DNA-based COVID-19 vaccine\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"University of Waterloo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"University of Waterloo \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Verndari","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid-19 Vaccine with Patch Delivery Technology Enters Preclinical Testing at Uc Davis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VaxiPatch COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verndari","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dermal Patch","sponsorNew":"Verndari \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Verndari \/.."},{"orgOrder":0,"company":"Rochester Clinical Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical trials for COVID-19 vaccine to begin in Rochester","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rochester Clinical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rochester Clinical Research \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Rochester .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Three Research Sites to Lead Clinical Trial of I-Mab\u2019s of TJM2 to Counter COVID-19\u2019s Deadly Cytokine Storm\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TJM2","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Pulmotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Houston Researchers Test Lung Inhalant That Could Protect Healthcare Workers From COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Oligodeoxynucleotide","moa":"TLR2\/6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Pulmotect \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar announces the initiation of a study of lurbinectedin in combination with immunotherapy ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar, Jazz Pharma Announce FDA Acceptance and Priority Review of NDA for Lurbinectedin in Relapsed Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rafael Pharmaceuticals Announces Collaboration to Evaluate the Effects of CPI-613\u00ae in Combination with Azacitidine and Venetoclax","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$8.3 million ","upfrontCash":"Undisclosed","newsHeadline":"Weill Cornell Medicine secured funding HIV and HPV Prevention","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Recombinant Human Papillomavirus 9-valent Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Weill Cornell Medicine","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Weill Cornell Medicine \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Weill Corn.."},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento and Smartpharm to collaborate to develop novel gene-encoded antibody vaccine intended to protect against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Gene encoded antibody vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SmartPharm Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SmartPharm Therapeutics \/ Sorrento","highestDevelopmentStatusID":"1","companyTruncated":"SmartPharm.."},{"orgOrder":0,"company":"DiNAQOR AG","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DiNA-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DiNAQOR AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DiNAQOR AG \/ BioMarin Pharmaceutical ","highestDevelopmentStatusID":"5","companyTruncated":"DiNAQOR AG.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Unveils New Strategic Plan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics to Present New Data on GeneRide\u2122 Platform and Next Generation Capsid Development Program at ASGCT 2020\r\n","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"SUO-CTC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Discovery Brings Bladder Cancer Patients Hope","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nadofaragene firadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"SUO-CTC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"SUO-CTC \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"SUO-CTC \/ .."},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senti Biosciences to Present on Gene Circuit-Based Therapies at the 2020 ASGCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SENTI-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Senti Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senti Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senti Bios.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA offers CRISPR, Vertex drug program VIP status for its comeback play","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"University of Texas Medical Branch","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"U.S., Chinese institutions work on vaccine against new coronavirus, says expert","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ University of Texas Medical Branch","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"These Texas doctors are working on a vaccine for the coronavirus\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"AlloVir","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AlloVir, Baylor ally to develop COVID-19 T-cell therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"ALVR106","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ AlloVir","highestDevelopmentStatusID":"4","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylor College Researchers Study BCG Vaccine for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"Kings College London","sponsor":"Epsilogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Epsilogen Licences Experimental Ige Antibody from KCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"MOv18 IgE","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kings College London","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kings College London \/ Epsilogen","highestDevelopmentStatusID":"6","companyTruncated":"Kings Coll.."},{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New study identifies drugs that are safe to use in COVID-19 treatment\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kings College London \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Kings Coll.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion\u2019s SEP-363856 for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ulotaront","moa":"TAAR1","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"$510.0 million","upfrontCash":"$60.0 million","newsHeadline":"Esperion Announces Agreement with Otsuka Pharmaceutical for Development and\r\nCommercialization of NEXLETOL and NEXLIZET\u2122 Tablets in Japan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Bempedoic Acid","moa":"ATP synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0.51000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.51000000000000001,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayurvedic Drug Zingivir-H Gets Approval for Clinical Trial to Treat COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Undisclosed","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Zingivir-H","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pankajakasthuri Herbal Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pankajakasthuri Herbal Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pankajakas.."},{"orgOrder":0,"company":"MIGAL Research Institute","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israeli Researchers Near Covid-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"MIGAL Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MIGAL Research Institute \/ Not Applicable ","highestDevelopmentStatusID":"2","companyTruncated":"MIGAL Rese.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Regains Global Rights to Brazikumab From Allergan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Termination","leadProduct":"Brazikumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"NanoTx Therapeutics","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","amount":"$137.2 million","upfrontCash":"$0.4 million","newsHeadline":"Plus Therapeutics Announces Closing of Agreement to License Novel Oncology Platform with NanoTx Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NanoTx Therapeutics","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"NanoTx Therapeutics \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NanoTx The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Dose First Participants in The U.S. As Part of Global Covid-19 mRNA Vaccine Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces Initiation of Patient Dosing in Phase 1 Proof-of-Concept Immuno-Oncology Trial of SRK-181","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-181","moa":"TGF-beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CB5064 analogs","moa":"Apelin receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Neurokinin 1 receptor positive mesenchymal stem cell","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takis Vaccines Neutralize SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flagship-Backed Evelo Biosciences Joins Covid-19 Hunt With Proposal for Bacteria Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data of Gencaro for Atrial Fibrillation in Heart Failure Featured in Three Presentations at 2020 Heart Rhythm Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucindolol Hydrochloride","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EAACI 2020 Annual Congress Has Accepted AB Science's Phase 3 Study Results with Masitinib in Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Clears Pluristem\u2019s IND Application for Phase II COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"CaroGen","sponsor":"Yale University School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CaroGen and Yale Scientists Team to Develop a COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 recombinant vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CaroGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CaroGen \/ Yale University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"CaroGen \/ .."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$3,100.0 million","upfrontCash":"$50.0 million","newsHeadline":"Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"iPSC-derived CAR-NK cells immunotherapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":3.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.1000000000000001,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"Symvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Symvivo to Start Safety Analysis of a COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"bacTRL-Spike","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ .."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Gynial","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Pharmaceuticals and Gynial Sign Commercialization Agreement for Myring\u2122 in Switzerland","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Etonogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Mithra Pharmaceuticals \/ Gynial","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Citi and Jefferies","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cancer Biotech Ayala Pharmaceuticals Prices Upsized US IPO at $15 midpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Ayala Pharmaceuticals \/ Citi and Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Novavax","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$388.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Inks $388M Deal With CEPI to Fund Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0.39000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.39000000000000001,"dosageForm":"","sponsorNew":"Novavax \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0.20000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Bluebird Bio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$17.2 million","upfrontCash":"Undisclosed","newsHeadline":"Inovio Receives CEPI Funding to Expand Manufacturing of COVID-19 DNA Vaccine INO-4800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Launches with over $100 Million to Advance Pipeline of High Impact Therapies for Brain Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Adimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adimmune May Start COVID-19 Vaccine Clinical Trials in August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adimmune \/.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio Announces Initiation of Clinical Program Targeting Soluble TNF to Prevent Complications of Cytokine Storm Caused by COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical trial in COVID-19 patients tests anti-inflammatory drug developed 25 years ago at Scripps Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"IC14","moa":"CD14","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Implicit Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Implicit Bioscience \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Implicit B.."},{"orgOrder":0,"company":"Ipsen","sponsor":"University of Montreal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Enters into an Option Agreement with IRICoR and University of Montreal for A Discovery-stage Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ University of Montreal","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Un.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"INOVIO Receives New $5 Million Grant to Accelerate Scale Up of Smart Delivery Device for Its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"VGX-3100","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inovio Coronavirus Vaccine Trial Starts In Philadelphia, Kansas City","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Maastricht University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Maastricht University","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Montreal Heart Institute Colcorona Receives Grant from the COVID-19 Therapeutics Accelerator to Study Cheap, Readily Available Drug","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi to Start a Clinical Study to Evaluate Whether Anakinra and Emapalumab May Relieve Complications Associated with Severe COVID-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Cardiff University","sponsor":"Ervaxx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ervaxx and Cardiff University Enter Collaboration to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"T cells clone","moa":"MHC-I","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cardiff University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiff University \/ Ervaxx","highestDevelopmentStatusID":"1","companyTruncated":"Cardiff Un.."},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Skyhawk Therapeutics Expands its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Skyhawk Therapeutics","amount2":0.59999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Skyhawk Th.."},{"orgOrder":0,"company":"Stimunity","sponsor":"Portage Biotech","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Portage Makes Additional Investment in Stimunity S.A.S","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"STI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Stimunity","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Stimunity \/ Portage Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Stimunity .."},{"orgOrder":0,"company":"Cipla","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Inks Voluntary Licensing Agreements With Multiple Companies for Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cipla \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Gi.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Gossamer Bio","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"$15.0 million","newsHeadline":"Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease Product Candidate GB004","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GB004","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Aerpio Pharmaceuticals","amount2":0.11,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Aerpio Pharmaceuticals \/ Gossamer","highestDevelopmentStatusID":"6","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Singota Solutions","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Singota Solutions Collaborates with Noveome Biotherapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Singota Solutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Singota Solutions \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Singota So.."},{"orgOrder":0,"company":"Travecta Therapeutics","sponsor":"TKS1","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Travecta Therapeutics Secures $15 Million in Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"TVT-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Travecta Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Travecta Therapeutics \/ TKS1","highestDevelopmentStatusID":"1","companyTruncated":"Travecta T.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Entinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Citigroup","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Virbac","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Animal Health to Acquire U.S. Rights to SENTINEL\u00ae Brand of Combination Parasiticides for Companion Animals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Milbemycin Oxime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Virbac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virbac \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Virbac \/ M.."},{"orgOrder":0,"company":"Alivexis","sponsor":"SBI Investments","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Modulus Discovery Closes $25.5M USD Series B","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alivexis","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Alivexis \/ SBI Investments","highestDevelopmentStatusID":"2","companyTruncated":"Alivexis \/.."},{"orgOrder":0,"company":"Abveris","sponsor":"Nkarta","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse\u00ae on the Berkeley Lights Beacon\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Abveris","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abveris \/ Nkarta","highestDevelopmentStatusID":"2","companyTruncated":"Abveris \/ .."},{"orgOrder":0,"company":"Manhattan BioSolutions","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"$0.1 million","newsHeadline":"Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Recombinant Mycobacterium Bovis Bacillus Calmette-Guerin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manhattan BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Manhattan BioSolutions \/ Nascent Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Manhattan .."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Gree Group","pharmaFlowCategory":"D","amount":"$232.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kintor Pharmaceutical Raises $1.8b IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Oral","sponsorNew":"Kintor Pharmaceutical \/ Gree Group","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Neovii","sponsor":"Tel Aviv University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TAU and Neovii Team Up to Develop Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Neovii","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neovii \/ Tel Aviv University","highestDevelopmentStatusID":"1","companyTruncated":"Neovii \/ T.."},{"orgOrder":0,"company":"Exyte","sponsor":"Univercells","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exyte and Univercells Combine Forces for Rapid Deployment of Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exyte","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exyte \/ Univercells Technologies","highestDevelopmentStatusID":"1","companyTruncated":"Exyte \/ Un.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"PoC Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cardiff Oncology Ink Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Onvansertib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiff Oncology \/ PoC Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"QurAlis","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"QurAlis Nabs $42M Funding Round for ALS, Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"Stem cell therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"QurAlis \/ Polaris Partners","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Ennaid Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"ENU200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Ennaid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"ReiThera","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$215.5 million","upfrontCash":"Undisclosed","newsHeadline":"BARDA Provides the Sabin Vaccine Institute With an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ChAd3-SUDV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReiThera","amount2":0.22,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"ReiThera \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"ReiThera \/.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$73.3 million","upfrontCash":"Undisclosed","newsHeadline":"Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Rilonacept","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Oasis Capital","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter Accounts Receivable Purchase Agreement with Oasis Capital, LLC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Jaguar Health \/ Oasis Capital","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"CytoAgents","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoAgents \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents.."},{"orgOrder":0,"company":"Creapharm","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Enters into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Trial Drug Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Creapharm","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Creapharm \/ AzurRx","highestDevelopmentStatusID":"8","companyTruncated":"Creapharm .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocytes","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0.089999999999999997,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Innovation Fund Denmark","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Danish Team of Researchers to Test Treatment of Critically Ill Patients Suffering from COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rigshospitalet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rigshospitalet \/ Innovation Fund Denmark","highestDevelopmentStatusID":"1","companyTruncated":"Rigshospit.."},{"orgOrder":0,"company":"Almac Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almac Discovery Enters Into Licensing Agreement for the Development & Commercialisation of ALM301","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ALM301","moa":"Akt kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Almac Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Almac Group \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Almac Grou.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$153.0 million","upfrontCash":"Undisclosed","newsHeadline":"TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Legend Biotech Aims for $100 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"JNJ-4528","moa":"T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Legend Biotech","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Immunai","sponsor":"Viola Group","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunai Raises $20M with an Immunology Focus","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"CAR-T cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunai","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Immunai \/ Viola Group","highestDevelopmentStatusID":"1","companyTruncated":"Immunai \/ .."},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Flu Lab","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Greenlight Biosciences Raises $17M Financing Round to Accelerate Large-Scale Manufacturing of Future COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Financing","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GreenLight Biosciences","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"GreenLight Biosciences \/ Flu Lab","highestDevelopmentStatusID":"1","companyTruncated":"GreenLight.."},{"orgOrder":0,"company":"Exvastat","sponsor":"Innovative Medicines Initiative","pharmaFlowCategory":"D","amount":"$3.9 million","upfrontCash":"Undisclosed","newsHeadline":"Exvastat Wins 3.6m Euro Grant For COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Imatinib Mesylate","moa":"PTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exvastat","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exvastat \/ Innovative Medicines Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Exvastat \/.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Baillie Gifford","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Announces Closing of $98.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Baillie Gifford","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Halozyme To Receive $15 Million Milestone Payment From Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Halozyme Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Halozyme Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Moksha8","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Exclusive Promotion Rights to Moksha8, Deepening Strategic Presence in Latin America for CNS Business","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Moksha8","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recursion Enters Into Global Licensing Agreement with Takeda to Develop TAK-733 in Hereditary Cancer Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tak-733","moa":"MEK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Recursion","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Enters License Pact for its Antibody Engineering Technologies with Eli Lilly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$81.3 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca Gets Funding And Manufacturing Boost For UK Vaccine Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Temasek","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"SQZ Biotech Snags $65M To Push Cancer Vaccine, Break Into Infectious Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series D Financing","leadProduct":"Atezolizumab","moa":"CD8 T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ Temasek","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$1,437.5 million","upfrontCash":"Undisclosed","newsHeadline":"Moderna Plans to Raise $1.25 Billion in a Secondary Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":1.4399999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.4399999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Neurotrope","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Merger","leadProduct":"Avanafil","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Neurotrope","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pha.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"BioPharmX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Timber Pharmaceuticals Announces Merger Closing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Timber Pharmaceuticals \/ BioPharmX","highestDevelopmentStatusID":"8","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"PLX Pharma","sponsor":"Park West Asset Management","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Financing","leadProduct":"Aspirin","moa":"COX","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PLX Pharma","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Liquid Capsule","sponsorNew":"PLX Pharma \/ Park West Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"PLX Pharma.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"MD Anderson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovent Biologics and MD Anderson Enter a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT in Rare Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Sintilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ MD Anderson","highestDevelopmentStatusID":"7","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Chelexa Biosciences","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antimicrobial therapy","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Chelexa Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chelexa Biosciences \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Chelexa Bi.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"J. P. Morgan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clovis Oncology Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Clovis Oncology \/ J. P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$60.1 million","upfrontCash":"Undisclosed","newsHeadline":"Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters\u2019 Option","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0.059999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Axcella Health \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"GB001","moa":"Prostaglandin D2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Gossamer Bio \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Panobinostat lactate","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Midatech Pharma \/ H.C. Wainwright","highestDevelopmentStatusID":"6","companyTruncated":"Midatech P.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$240.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kintor Pharmaceuticals Completes $240 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0.23999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.23999999999999999,"dosageForm":"Oral","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rallybio Scores $145M, Unveils Lead Rare Disease Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"RLYB211","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0.14999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Rallybio \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"Five Leaf Labs","sponsor":"Cannaworx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pressure BioSciences Pending Merger Partner Cannaworx, Inc. Announces Letter of Intent to Acquire Five Leaf Labs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Phytocannabinoid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Five Leaf Labs","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Five Leaf Labs \/ Cannaworx","highestDevelopmentStatusID":"12","companyTruncated":"Five Leaf .."},{"orgOrder":0,"company":"HintMD","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revance Announces Agreement to Acquire HintMD and its Proprietary Fintech Platform for Aesthetic Practices","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"DaxibotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"HintMD","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"HintMD \/ Revance Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"HintMD \/ R.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"DLA Piper","pharmaFlowCategory":"D","amount":"$483.3 million","upfrontCash":"Undisclosed","newsHeadline":"DLA Piper Advises Immunomedics in its US$483 Million Follow-On Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0.47999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"","sponsorNew":"Immunomedics \/ DLA Piper","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Abnova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmajet and Abnova Partner to Develop and Deliver COVID-19 Mrna Vaccine Using Needle-Free Injection Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection\n","sponsorNew":"PharmaJet \/ Abnova","highestDevelopmentStatusID":"1","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Therapix Biosciences","sponsor":"Evero","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Therapix Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapix Biosciences \/ Evero","highestDevelopmentStatusID":"8","companyTruncated":"Therapix B.."},{"orgOrder":0,"company":"Duchesnay","sponsor":"Plushcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Duchesnay Usa & Plushcare Announce a New Partnership to Facilitate Access to Healthcare for Menopausal Women Through Telemedicine","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Ospemifene","moa":"Estrogen receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Duchesnay","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duchesnay \/ Plushcare","highestDevelopmentStatusID":"12","companyTruncated":"Duchesnay .."},{"orgOrder":0,"company":"Vibalogics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vibalogics Announces Collaboration to Provide Additional Clinical Trial Material for COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vibalogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vibalogics \/ Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"Vibalogics.."},{"orgOrder":0,"company":"Genocea","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genocea Announces Material Transfer and License Option Agreement with Shionogi for Proprietary GEN-003 HSV-2 Antigens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GEN-003","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Shionogi","highestDevelopmentStatusID":"1","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Cue Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"Undisclosed","newsHeadline":"With Bucks From Pfizer Added To Their New Round, Amplyx Steers a Tricky Course Through PhII and a Global Pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series C Financing","leadProduct":"Fosmanogepix","moa":"Gwt1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Bio, Thomas Jefferson varsity to pursue Covid-19 vaccine candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Deactivated rabies vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Thomas Jefferson University","highestDevelopmentStatusID":"4","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"CytoDyn","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn and Mexican NIH to Assess Leronlimab for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"National I.."},{"orgOrder":0,"company":"Atomwise","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"IL-6 Signalling Pathway","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/.."},{"orgOrder":0,"company":"IQVIA","sponsor":"Walter and Eliza Hall Institute of Medical Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IQVIA Collaborates with Australian Medical Research Institute on COVID-19 Study to Support Frontline Healthcare Workers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"IQVIA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IQVIA \/ Walter and Eliza Hall Institute of Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"IQVIA \/ Wa.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$341.0 million","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Successfully Completes the Offering of New Shares Thereby Securing Funding for the Company\u2019s Growth Plan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Aprocitentan","moa":"Endothelin receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0.34000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.34000000000000002,"dosageForm":"","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617 in Combination with KEYTRUDA in Solid Tumor Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Strongbridge Biopharma plc Announces $30 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Strongbrid.."},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Assertio Completed Merger with Zyla Life Sciences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Merger","leadProduct":"Diclofenac Potassium","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Assertio Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assertio Therapeutics \/ Assertio Holdings","highestDevelopmentStatusID":"12","companyTruncated":"Assertio T.."},{"orgOrder":0,"company":"Celonic","sponsor":"Airway Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Airway Therapeutics and Celonic Group Collaborate to Produce AT-100 as Promising New Candidate for Coronavirus","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"AT-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Celonic","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celonic \/ Airway Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Celonic \/ .."},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Vaxart","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kindred Biosciences Announces COVID-19 Vaccine Manufacturing Agreement with Vaxart","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kindred Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kindred Biosciences \/ Vaxart","highestDevelopmentStatusID":"4","companyTruncated":"Kindred Bi.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Laidlaw & Company","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CanSino, Precision NanoSystems to co-develop COVID-19 RNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 mRNA-LNP vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision NanoSystems \/ CanSino Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Precision .."},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"S.R. One","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"Undisclosed","newsHeadline":"SR One fuels HotSpot's $65M B round to fund allosteric R&D","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"PKC theta","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HotSpot Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"HotSpot Therapeutics \/ S.R. One","highestDevelopmentStatusID":"2","companyTruncated":"HotSpot Th.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Takara Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"Plasmid DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Takara Bio","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Synlogic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synlogic Announces Termination of AbbVie Collaboration Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Termination","leadProduct":"Synthetic Biotic medicines","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synlogic \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Mizuho Securities USA LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ Mizuho Securities USA LLC","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Medison Pharma","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and NDA Acceptance for BTK Inhibitor BRUKINSA\u2122 (zanubrutinib) in Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Medison Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medison Pharma \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Medison Ph.."},{"orgOrder":0,"company":"Celularity","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kleo Pharmaceuticals and Celularity Team-up to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody recruiting molecule","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Advantech Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Advantech Capital","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medexus Provides an Update on the IXINITY\u00ae Acquisition and its Overall Business in the COVID-19 Environment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Recombinant coagulation factor IX","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus","highestDevelopmentStatusID":"12","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","amount":"$20.2 million","upfrontCash":"Undisclosed","newsHeadline":"Windtree Therapeutics Announces Closing of $23 Million Public Offering Including Full Exercise of Over-Allotment Option","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Sinapultide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Windtree Therapeutics","amount2":0.02,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Lyophilized Powder","sponsorNew":"Windtree Therapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"4","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Valence Life Sciences","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series C Financing","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Valence Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Funding Secured For UK Clinical Trial in Children With Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Vincristine Sulfate","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"University of Birmingham","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Birmingham \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellect Biotechnology's ApoGraft\u2122 to Empower Cellular Treatment of COVID-19 Related Pulmonary Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"ApoGraft treated stem cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Cellect Biotechnology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellect Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cellect Bi.."},{"orgOrder":0,"company":"Purdue University","sponsor":"Gibson Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gibson Oncology Expands its Scientific Advisory Board for Novel Oncology cMYC Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Azaindenoisoquinolines","moa":"cMYC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Purdue University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purdue University \/ Gibson Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Purdue Uni.."},{"orgOrder":0,"company":"Romanian National Institute of Infectious Diseases","sponsor":"CervoMed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Diffusion Pharma and Romanian National Institute of Infectious Diseases Join Hands to Expand Clinical Trial Program of TSC for COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"ROMANIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Romanian National Institute of Infectious Diseases","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Romanian National Institute of Infectious Diseases \/ Diffusion Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Romanian N.."},{"orgOrder":0,"company":"ACEA Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Acquired Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Abivertinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ACEA Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ACEA Therapeutics \/ Sorrento","highestDevelopmentStatusID":"10","companyTruncated":"ACEA Thera.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$231.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK Partners with Samsung Biologics to Secure Additional Manufacturing Capacity for Innovative Biopharmaceutical Portfolio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Belimumab","moa":"TNFSF13B","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Samsung Biologics","amount2":0.23000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Biologics \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Millicent Pharma Limited","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"$20.0 million","newsHeadline":"AMAG Pharmaceuticals Completes Sale of its Rights to Intrarosa\u00ae to Millicent Pharma for up to $125 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Divestment","leadProduct":"Prasterone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Hormone","amount2New":0.13,"dosageForm":"Intravaginal","sponsorNew":"AMAG Pharmaceuticals \/ Millicent Pharma Limited","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rigel Looking for Collaboration with Research Institutes to Investigate Potential Of TAVALISSE to Treat Severe COVID-19 Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Shanghai Henlius Biotech Says Entered Cooperation Agreement With Sanyou Biopharmaceuticals & Shanghai Zj Bio-Tech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Antibody drug conjugate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanyou Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Sanyou Bio.."},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinese Scientist Unite Together to Tackle With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"CAStem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Chinese Academy of Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinese Academy of Sciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chinese Ac.."},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Zhifei Longcom Biopharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zhifei Inks Exclusive CAS Tie-Up to Make First Vaccine for New Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chinese Academy of Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chinese Academy of Sciences \/ Zhifei Longcom Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Chinese Ac.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"Korea\u2019s SK Bioscience Gets $3.6 M Funding from Gates Foundation for COVID Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SK Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","amount":"$225.5 million","upfrontCash":"$10.0 million","newsHeadline":"Affibody and Inmagene Announce Strategic Partnership to Develop ABY-035","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"ABY-035","moa":"IL-17","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0.23000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Affibody \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","amount":"$215.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series D Financing","leadProduct":"AT-527","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0.22,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial Testing Antiviral Remdesivir Plus Anti-Inflammatory Drug Baricitinib for COVID-19 Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrthoTrophix Presents More Evidence on TPX-100 for Disease Modification in Knee Osteoarthritis in a New Abstract Published in a Journal","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TPX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"OrthoTrophix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTroph.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MaaT033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Sarclisa Cuts Death Risk In Mutiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Initiates Phase 3 Clinical Trials on Favipiravir to Check Efficacy on COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipal's Clinical Trials Using Arthritis Drug Tocilizumab Get Nod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences to Start P2 Trial Of Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"YD Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"YD Life Science Proves Efficacy Of Diabetic Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YD Life Science","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"YD Life Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"YD Life Sc.."},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport\u00ae Achieved High Levels of Satisfaction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AbobotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Convenes Virtual KOL Meeting to Discuss the State of Chronic Cough Treatment and the BLU-5937 Program","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces the Approval of TUKYSA in Switzerland for the Treatment of Patients with Metastatic HER2-Positive Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel to Treat Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-104","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Therapeutics Reports Progress on CRISPR\/Cas9 AML Cancer Therapy Using Cell Engineering Process at the 23rd ASGCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NTLA-5001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Announces New Data Validating and Enhancing its PM21 K-NK-Cell Platform Presented Today at the ASGCT Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"K-NK002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Principia Announces AAD Late Breaker Research Presentation of its Pemphigus Phase 2 Part B Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Recommends Wider Compassionate Use of Remdesivir in Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Files PCT Patent Application for Neuroprotection in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Announces Publication of a Driving Study Demonstrating the Effects of Tolperisone","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"Stanford Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stanford Medicine Researchers Trial Interferon-Lambda for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon-lambda","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Stanford Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stanford Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Stanford M.."},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Positive Top-Line Results for Two Comparative Studies for AVT02, a Proposed Biosimilar to HUMIRA\u00ae (Adalimumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna's Potential Coronavirus Vaccine Gains FDA's 'Fast Track' Status","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Launches Covid-19 Trial to Study Drugs for Elderly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Expects to Launch Clinical Trials Of Covid-19 Vaccine in July","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Assessing Use of Tick Molecule for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Evasins","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1\/2 Clinical Trial in China for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TJD5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pracinostat","moa":"pan-HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Polynoma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polynoma Presenting Final Analysis of MAVIS Phase III Part B1 Data of Its Investigational Melanoma Vaccine, Seviprotimut-L, at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Seviprotimut-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Showcases Oncology Pipeline At ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Receives First Regulatory Approval from BfArM to Initiate a Phase 2 Clinical Trial of IMU-838, in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RDIF and ChemRar Announce First Interim Results of Clinical Trials of Favipiravir Drug's Effectiveness in Coronavirus Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"RUSSIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roivant Provides Updates for Pivotal BREATHE Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Gimsilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Roivant Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Roivant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Roivant Sc.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Betterlife Pharma Announces Interferon Alpha-2b Covid-19 News Regarding its Emergence as a Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bexion Pharmaceuticals Presenting BXQ-350 Data at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BXQ-350","moa":"Spingomyelinase catalysis","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pha.."},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbor Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for AR19","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Phar.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC41","moa":"TR-Beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYVYT ORIENT-2 Study Met its Primary Endpoint in the Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion Ditches Once-Rejected ADHD, Binge Eating Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasotraline","moa":"MAO transporter","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Macrogenics Chief Scott Koenig Details the Upbeat Cancer Drug Data from 2 Programs That Drove a Big Spike in their Share Price","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MGD013","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present Trials in Progress Poster for BT5528 at the 2020 American Society of Clinical Oncology Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BT5528","moa":"Ephrin type A receptor 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Shares Initial Data from FORWARD II Testing Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarveda Therapeutics Reports Complete Data from Phase 1 Portion of Phase 1\/2a Study of PEN-866 to be Presented at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Locnartecan","moa":"HSP90","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tarveda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tarveda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarveda Th.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb\u00ae20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"XmAb20717","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo + Yervoy Improves Overall Survival vs. Chemotherapy Alone in First-Line Metastatic Non-Small Cell Lung Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DM199","moa":"KLK1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces Publication Describing Underlying Biology Behind Sotatercept\u2019s Potential as a Novel Therapy in PAH","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Xiling Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scimount Announces FDA Approval of SMP-100's IND Application for the Treatment of Irritable Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SMP-100","moa":"5-HT3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Xiling Lab","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Xiling Lab \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Xiling Lab.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO3","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines to Present Data Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea to Present Long-term Follow-up Data from GEN-009 Neoantigen Vaccine at Virtual ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Atreca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atreca Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATRC-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ N.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced CKD at ASCO 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex to Present Results from CLASSICAL-Lung Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"SEMA4D","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma at the ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vorasidenib","moa":"IDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at ASCO 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1536","moa":"NaPi2b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society of Clinical Oncology 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Inks Agreement with FDA on Resubmission of the Application for HETLIOZ to Treat Patients with Smith-Magenis Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Gets FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"DCprime","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DCprime Extends International Roll-out of DCP-001 Into the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DCP-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"DCprime","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DCprime \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DCprime \/ .."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oasmia Announces Outcome of Strategic Review to Deliver Long-Term, Profitable Growth as a Specialty Pharma Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Oasmia Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Genkyotex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genkyotex Receives Approval From the French Medicines Agency (ANSM) to Initiate a Phase 1 Clinical Study With High-dose Setanaxib","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Setanaxib","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Genkyotex","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genkyotex \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genkyotex .."},{"orgOrder":0,"company":"Viela Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VIB7734","moa":"IL-7","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Viela Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viela Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viela Bio .."},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReGenTree Announces Efficacy Results of the Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree .."},{"orgOrder":0,"company":"Veloce BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halodine\u00ae Nasal and Oral Antiseptics Show Rapid Antiviral Activity Against SARS-CoV-2 (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Povidone-Iodine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veloce BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veloce BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Veloce Bio.."},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem Life Sciences Innovation Center Announces Data from Phase I Study of its Ulcerative Colitis Treatment LC51-0255","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LC51-0255","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"LG Chem","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"LG Chem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"20-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA Abstract","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves ADCETRIS for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Presents Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at American Urological Association Annual Meeting","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Reports Publication of International Patent Application for Treatment of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Shares Clinical Data From Exploratory Study Confirming Delivery of FX-322 to the Cochlea","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"SIRPalpha-CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intratumoral Suspension","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACTG Initiates Clinical Trial to Evaluate Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"The AIDS Clinical Trials Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The AIDS Clinical Trials Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"The AIDS C.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at ASCO 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc To Develop Emergency and Conventional Covid-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"Killer T-Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics Announces FDA has Granted Fast Track Designation to NTX-001 Clinical Development Program","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Therapeutics Announces Abstracts Regarding Phase 1\/2 Study of SEL120 and SEL24\/MEN1703 Accepted for Presentation at 25th EHA Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvocidib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CLBS16","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intracoronary Injection","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaxCyte to Present Poster Presentation on MCY-M11","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MCY-M11","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 004","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Cellectar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CLR 131","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar .."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Provides Updates on BLU-5937","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oasmia Pharmaceutical Announces Poster Presentation at American Society of Clinical Oncology 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oasmia Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Oasmia Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda China Announces ADCETRIS\u00ae (Brentuximab Vedotin) ss Approved for the Treatment of Adult Patients with CD30-Positive Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brentuximab vedotin","moa":"TNF-8 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immupharma\u2019s Efforts in the Fight Against Covid-19 with Lupuzor\u2122 and Ureka","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IPP-201101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmuPharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ImmuPharma.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics to Present First Efficacy & Safety Data From Its Lead Program CBX-12 and Data From CBX-13 at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Alphale-Exatecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Data to be Presented at the EHA25 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Epcoritamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy Between Merimepodib and Remdesivir Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Helix BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Helix BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Helix BioP.."},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SRF231","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surface Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface On.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Shares FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Presentation of Positive Clinical Data for Envafolimab in MSI-H\/dMMR Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1\/2 ADXS-503 Trial in NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Constellation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constellat.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Survival Data from Phase 2 Lung Cancer Trial Accepted for Presentation at 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"T-Cell mediated immune response","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r\/r DLBCL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pevonedistat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Reports Provides Update on Cytisinicline Development Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"Nicotinic receptor alpha4\/beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Says Coronavirus Treatment Trial Using Recovered Patients' Blood Could Start in July","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TAK-888","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor - RBN-2397 - and its Discovery Platform at AACR 2020 Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RBN-2397","moa":"PARP7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Ther.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Upcoming Poster Presentation of Phase 1\/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-1901","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Announces Abstracts Selected for Presentation at the American Association for Cancer Research, AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HFB301001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"U3-1402","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure to Present Clinical Data at AACR 2020 Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AST-008","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Presents New Preclinical Data Demonstrating Potential of EngEx\u2122 Engineered Exosomes to Drive New Class of Molecular Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"exoVACC","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Announces Pre-IND Submission to USFDA for Piclidenoson to Treat COVID-19 Infected Patients with Moderate-to-Severe Symptoms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avacta Develops SARS-COV-2 Neutralising Affimer Reagents with Therapeutic Potential for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-COV-2 Neutralising Affimers","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene and BioInvent Present Preclinical Data Demonstrating BT-001\u2019s Powerful Activity Against Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BT-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor With Robust In Vivo Activity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Syntekabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"STB-C017","moa":"Indoleamine 2,3-dioxygenase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Syntekabio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syntekabio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Syntekabio.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Presentations on TLANDO\u2122 at AUA Virtual Experience 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vividion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vividion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vividion T.."},{"orgOrder":0,"company":"GEMoaB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming AACR Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"UniCAR-T-CD123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GEMoaB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ N.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Provides Update on Pivotal Phase 3 FLASH Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ\/11 Tumors and Preclinical MAT2A Synthetic Lethality Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IDE196","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma to Present Six Abstracts at 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-3526","moa":"MCL-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"VSY Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Drug to Treat COVID-19, TR-C 19 is Now Ready for Human Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TR-C 19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VSY Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VSY Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VSY Biotec.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271 at AACR Virtual Annual Meeting II 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA2271","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitomycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IMGN151","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formycon Announces Update On Biosimilar Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leading BioSciences Receives IND Clearance for Phase 2 COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer\u2019s Disease Does Not Meet Primary Endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics to Present First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"ICOS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T\u2122 at the AACR Virtual Annual Meeting II in June 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-3005","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Presents Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells to Develop Engineered Cell Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TH1902","moa":"Sortilin","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharmaceuticals to Present Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharm.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNF-1 beta","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the 25th EHA Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ME-401","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BI1029539","moa":"Microsomal prostaglandin E synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Gesynta Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gesynta Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gesynta Ph.."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine Consortium Develops COVID-19 Vaccine for Human Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Brinton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brinton Pharmato Launch Favipiravir, a Promising Drug for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brinton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Brinton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Brinton Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Data Show Moderna Covid-19 Vaccine Generates Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Seeks Ethics Approval for Covid-19 Trials in Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCLA Researchers to Study Prostate Cancer Drug for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Degarelix Acetate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Study finds Convalescent Plasma Safe for Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Convalescent plasma","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mayo Clinic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clini.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viiv HIV Prevention Trial Stopped Early on Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca\u2019s Bevespi Aerosphere approved in China for patients with COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Hong Kong Baptist University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HKBU Discovers New Treatment for Nasopharyngeal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"HONG KONG","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-Epstein-Barr virus drug","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hong Kong Baptist University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hong Kong Baptist University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Hong Kong .."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi to Develop Prophylactic Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Prophylactic recombinant protein vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mezzion Pharma's Udenafil Improved Ventricular Function Measured by Myocardial Performance Index in adolescents with SVHD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Udenafil","moa":"PDE5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Ph.."},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIPAC Oncology Announces Presentation of Data from Phase 1\/2a Study of LiPax in Patients with Highly Recurrent Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"LIPAC Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Onco.."},{"orgOrder":0,"company":"Mercaptor Discoveries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mercaptor Discoveries Uses its Proprietary Neurotherapeutic Platform to Develop Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Capton based drug","moa":"COX-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mercaptor Discoveries","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mercaptor Discoveries \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mercaptor .."},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subjects Dosed in JHL's Phase I Clinical Study of a Denosumab Biosimilar","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biolo.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Tobacco Files Supplemental New Drug Application for Use of Riona to Treat Adult Patients with Iron Deficiency Anemia in Japan","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC\u2122 ODT with 25 Presentations on the 2020 AAN Virtual Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-101","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Amivantamab","moa":"CTLs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Therapeutics Receives IND Clearance from the US FDA for CT041 CLDN18.2-CAR-T Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized anti-claudin18.2 autologous Chimeric Antigen Receptor T Cells","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Abcore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abcore Announces a Panel of Patent Pending Functional Single Domain Antibodies for Use as Therapeutic Candidates for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Single domain antibodies","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Abcore","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abcore \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Abcore \/ N.."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BM-Allo.MSC","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rising Pharmaceuticals to Support Global Clinical Trial Conducted by the CROWN Collaborative","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Chloroquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Washington.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Reports Additional Findings from Successful Phase II NASH Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva\u2019s Latest Research on Odiparcil\u2019s Mechanism of Action Published in Leading Peer-Reviewed Scientific Journal PLOS ONE","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Odiparcil","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Positive Feedback from The EMA on its Pivotal Trial Design for Trappsol Cyclo for Niemann-Pick Disease Type C1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CCX140","moa":"CCR2 receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears the IND Application to Enable the Phase II Trial of ViralClear\u2019s Merimepodib to Treat Advanced COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triphase Accelerator and Catalent Biologics Share Interim Results of a Dose Escalation Phase 1 Clinical Trial of TRPH-222","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TRPH-222","moa":"CD22","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Triphase Accelerator \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Triphase A.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson to Share Information on Clinical Data to be Presented at the ASCO and the Janssen Oncology Strategy and Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Teclistamab","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Doses First Chinese Patient in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Durlobactam","moa":"Beta-lactamases A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Provides Recent Updates From Phase 3 SPIRIT 2 and Phase 3 SPIRIT 1 study in women with endometriosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-729","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"TYRO3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liproca Phase II b Study Results Indicate Cancer Control","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"2-Hydroxyflutamide","moa":"Testosterone congener","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mgb-BP-3","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"MGB Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopha.."},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SELLAS Establishes Independent Data Monitoring Committee for Pivotal Phase 3 REGAL Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sellas Life Sciences Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sellas Life Sciences Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sellas Lif.."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HIV Prevention Trials Network Finds Cabotegravir Linked With Prevention of HIV Infection in Cisgender Men and Transgender Women","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Baseline Demographics Data from the SRK-015 TOPAZ Trial at the American Academy of Neurology Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-015","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces Enrollment of First Patient in ESCAPE: a Phase II Clinical Trial With Vafidemstat In Severely Ill COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"Il-6","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Hard Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Outcomes of Recardio's Dutogliptin Published in the British Journal of Pharmacology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Treats First Patients in Pivotal JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Highlights Findings in Abstract Accepted at OARSI 2020 and Published in Osteoarthritis and Cartilage","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Results From the ProCID Study of Efficacy and Safety of 3 Different Dosages of Panzyga in Patients with CIDP Presented at AAN 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Normal Human Immunoglobulin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"TASK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Africa BCG Booster Trials Seek Low-Cost Weapon Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SOUTH AFRICA","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TASK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"TASK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TASK \/ Not.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Tecentriq nabs solo OK in first-line lung cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy for Treatment of Progeria and Progeroid Laminopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonafarnib","moa":"Ftase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-1454","moa":"PK M1\/M2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosmanogepix","moa":"Gwt1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TauRx Reveals Study Results That Offer New Hope for Treatment of Patients With Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Ther.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 and EAN Virtual Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Presentation of Update on Phase 1\/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Expands Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus \/ COVID-19 Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA\u2122 to Reverse Cancer Resistance to PARPi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces Its Joint Venture, Aleor Dermaceuticals Receives USFDA Approval for Clobetasol Propionate Shampoo, 0.05%","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Ph.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRIEF-Dynavax Says Intend To Provide Update On Early-Stage Collaborations Regarding Potential Development Of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 adjuvanted vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces Publication of TIBSOVO\u00ae Phase 3 Data in The Lancet Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals\u2019 Brilacidin Reduces Viral Titer of SARS-CoV-2 by 75 percent After Only 1 Hour of Preincubation In Vitro Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Hillstream BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Salinomycin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Hillstream BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hillstream BioPharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Hillstream.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Pulmotect","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"St. Elizabeth Healthcare Partners with CTI and Pulmotect Becoming First Hospital Site for Phase-2 Clinical Trial Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Oligodeoxynucleotide","moa":"TLR2\/6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmotect","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Pulmotect \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmotect .."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals' CRV431 the First Cyclophilin Inhibitor to Advance to Phase 2 Trial for NASH Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CRV431","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Receives FDA IND Authorization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm Shares Fall After Report Avigan Not Showing Clear Efficacy in Some Coronavirus Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in Preclinical COVID-19 Model","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Activated mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bonus BioGroup \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioG.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron Announces Presentations on REBLOZYL at ASCO 2020 and EHA 2020 Virtual Annual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept-aamt","moa":"TGF beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"STING pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Ban.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NRP2 Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa\u00ae (Idebenone) in Duchenne Muscular Dystrophy (DMD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO as a Treatment for Patients with Multiple Myeloma After","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OBI-3424","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OBI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OBI Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OBI Pharma.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aripiprazole Lauroxil","moa":"5-HT1A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Normal Immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics\u2019 Abstract (#3016) Selected for Oral Presentation as Part of a Poster Discussion Session at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte and MorphoSys Announce the Validation of the European Marketing Authorization Application for Tafasitamab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenalidomide","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics to Advance ADX-1612 to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX-1612","moa":"HSP90","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FT538","moa":"CD16","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brensocatib","moa":"DPP-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug AT-H201","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-coronavirus drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Doses First Patient In Pivotal Phase 3 Respect Trial Of Rezafungin In Patients Undergoing Allogeneic Blood And Marrow Transplantation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rezafungin","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"D2 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Evoke Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Progenabiome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Progenabiome Begins Hydroxychloroquine Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Progenabiome","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Progenabiome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Progenabio.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGenesis Reports COVID-19 Breakthrough Using Fibroblast Cell Therapy (Pre-Clinical Trial Phase)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PneumoBlast","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Completes Pre-IND Meeting with FDA on Epoladerm","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pha.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107\/HyLeukin-7\u2122 in Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 ASCP Virtual Annual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATL1102","moa":"CD49d","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Clears Appili Therapeutics\u2019 Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2 spike protein inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Supports Trial to Investigate the Effects of VASCEPA\u00ae (icosapent ethyl) in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Announces Plans for Imetelstat Phase 3 Clinical Trial in Myelofibrosis and Other Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellect Biotechnology Plans to Examine Therapeutic Effects of Stem Cells to Reduce Pulmonary Manifestations Caused by COVID-19 Infection","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ApoGraft","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cellect Biotechnology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellect Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellect Bi.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study of BioAegis\u2019 Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat + Exemestane in HR+, HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Entinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pha.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Alethia Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-16B5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alethia Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alethia Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alethia Bi.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR at ASCP 2020 Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences\u2019 KBP-5074 Appears Well Tolerated in a single dose PK Study in severe CKD patients with and without hemodialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"Sumitovant Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitovant Biopharma's Family of Companies Achieve Multiple Clinical and Corporate Milestones","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Sumitovant Biopharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitovant Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sumitovant.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Antolimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Strongly Recommends CalciMedica to Move to a Blinded Placebo-controlled Trial with Auxora\u2122 in Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Montefiore and Albert Einstein College Are First to Test A Promising Drug for the Treatment of Severe Lung Inflammation in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NovaLead Pharma to Conduct Clinical Trials for Repurposed Drug for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NLP21","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NovaLead Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead P.."},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Group Receives FDA Approval for Ferriprox\u00ae (deferiprone) twice-a-day tablets","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deferiprone","moa":"Iron","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chiesi Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Gro.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics To Present Data on Multiple Immunomodulation Approaches with KRYSTEXXA at the EULAR 2020","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Kancera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kancera Applies for a Phase II Study with KAND567 in COVID-19 Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KAND567","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kancera","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kancera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kancera \/ .."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Announces Presentations During Upcoming Scientific Conferences","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvelle Therapeutics Announces Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Th.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX\u00ae3-71 (AF710B)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AF710B","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bozitinib","moa":"c-MET Type 1b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apollomics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion Announces U.S. FDA Approval of KYNMOBI Sublingual Film for the Treatment of Parkinson\u2019s Disease OFF Episodes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Reports Additional Safety Data of Satralizumab in NMOSD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Evobrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin+Nivolumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Takeda\u2019s ALUNBRIG as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Brigatinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Axial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Axial Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axial Ther.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Shares Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First human trial of COVID-19 Vaccine from CanSino Biologic finds its Safe and Induces Rapid Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Adenovirus vector based SARS-CoV-2 vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's COVID-19 Vaccine Enters Phase 2\/3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"University.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Beijing Institute of Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First COVID-19 Vaccine Human Trial Finds ft is Safe, Induces Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Beijing Institute of Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Beijing Institute of Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing In.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo, Sarah Cannon Research Institute begin phase 1 trial of DS-6157 in patients with advanced gastrointestinal stromal tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DS-6157","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces FDA Acceptance of NDA for the Dasiglucagon Hypopal rescue Pen for Treatment of Severe Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RDIF and ChemRar Launch Final Stage of Favipiravir Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Russian Direct Investment Fund \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Provides Update on COVID-19 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"BioCorRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BioCorRx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"BioCorRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCorRx \/.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme\u2019s Arimoclomol Receives US Fast Track Designation in Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"HSF-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Announces U.S. FDA Acceptance of IND Application to Conduct Phase 1\/2 Clinical Trial of NT219 in Variety of Advanced Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NT219","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Harpoon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harpoon Therapeutics to Present Interim Clinical Data for TriTAC\u00ae HPN424 at the ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HPN424","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Harpoon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Harpoon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Harpoon Th.."},{"orgOrder":0,"company":"Samumed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samumed","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Samumed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samumed \/ .."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi\u2019s Regulatory Submission for Pegfilgrastim Biosimilar Accepted for Review By EMA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mithra and Searchlight Pharma Announce Filing of New Drug Submission for Estelle\u00ae in Canada","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mithra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Finds Over 80% Of Patients with Spasticity And Cervical Dystonia Treated With Botulinum Toxin-A Experience Symptom Recurrence","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novalead to Start Trial on Anti- Parasitic Drug for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"NovaLead Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead P.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Submits IND Application with U.S. FDA for Multinational Phase 2b\/3 Human Study to Evaluate Ifenprodil for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deltyba\u00ae (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Delamanid","moa":"H37Rv","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Outcomes Using RYONCIL in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Novaremed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novaremed Submits IND to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NRD135S.E1","moa":"Lyn kinase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Novaremed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novaremed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novaremed .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI939","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Is Beginning Clinical Trials Of Its Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NVX\u2011CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo Linked With Survival of 85% of Newly Diagnosed Glioblastoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"WT1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac\u00b4s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"ImmunSYS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunSYS Announces Upcoming Presentation at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cryosurgical tumor cell lysis","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunSYS","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunSYS \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunSYS \/.."},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Birmingham to Launch CATALYST Trial for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Birmingham","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Birmingham \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Aarhus University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers IN Denmark Testing if Senicapoc Drug Can Reduce Lung Damage In Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Senicapoc","moa":"Intermediate conductance calcium-activated potassium channel protein 4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aarhus University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aarhus University \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aarhus Uni.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves First Covid-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Inactivated COVID-19 Vaccine Enters 2nd-Phase Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Massachusetts Eye and Ear and Massachusetts General Hospital Advancing Novel Experimental Gene-based COVID-19 Vaccine, AAVCOVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Massachusetts General Hospital \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"OncoGenerix USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncogen Researchers Propose Personalized Vaccinomics Strategy for the Novel China Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OncoGenerix USA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoGenerix USA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoGeneri.."},{"orgOrder":0,"company":"German Center for Infection Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trials For SARS-Cov-2 Vaccine Set to Start September","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Center for Infection Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"German Center for Infection Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"German Cen.."},{"orgOrder":0,"company":"German Center for Infection Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Development of a New Antiviral Agent Against SARS-Cov-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RHCDS-13b","moa":"Alpha-ketoamide protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"German Center for Infection Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"German Center for Infection Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"German Cen.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BPI-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Flow Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flow Pharma Announces Start of Pre-Clinical Efficacy Study for FlowVax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"FlowVax COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Flow Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Flow Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Flow Pharm.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Approval of Veklury\u00ae (remdesivir) in Japan for Patients With Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USFDA Postponds Intercept's NDA Application Meeting for Obeticholic Acid","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOBI Announces Results From Pivotal Phase 2\/3 Study of Emapalumab in Patients With Primary HLH Published in New England Journal of Medicine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapalumab","moa":"INF gamma","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOBI's Anakinra Found to Decrease Covid-19 Symptoms in a Small Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Shares Preclinical Efficacy Data on Telotristat Ethyl\u2019s Antiproliferative Effects Against Various Cancer Cell Lines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Telotristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PTR-01","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX to Present Data at the American Society of Clinical Oncology Virtual Scientific Program Featuring its Novel Probody Platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CX-2029","moa":"CD71","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TTI-622","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treatment Potential of LPCN 1144 Demonstrated in a Pre-Clinical NASH and Hepatic Fibrosis Model","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"LPCN 1144","moa":"Homeostasis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ENOB-HV-01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals Welcomes Swissmedic Approval of Carbetocin Ferring for the Prevention of Postpartum Haemorrhage in All Births","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Purdue University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Purdue-Developed Nanomaterial Significantly Enhances Potential COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Purdue University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purdue University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Purdue Uni.."},{"orgOrder":0,"company":"Osel Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osel\u2019s LACTIN-V Phase 2b Bacterial Vaginosis Study Published in the New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lactin-V","moa":"Hydrogen Peroxide","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osel Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Osel Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osel Pharm.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARAMIS Phase III Data to be Presented at ASCO 2020 Reveals Nubeqa Linked with Improved Overall Survival in Non-Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma to Present New Efficacy Data for Monalizumab in Combination with Cetuximab in Head and Neck cancer at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med to Highlight Clinical Data on Lead Products at the Upcoming ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Savolitinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Gets Priority FDA Review for Sutimlimab Product","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sutimlimab","moa":"Complement C1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals Announces New Clinical Data Published on Menopur\u00ae in a Predicted High Responder Population","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Menotropins","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates to Present New Data on its Engineered Toxin Bodies at the AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MT-6402","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faron Pharmaceuticals Reports Harmful Association of Gucocorticoids in Interferon Beta-1a Treated Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19: AIIMS Bhopal Claims Good Results in Drug Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mycobacterium w","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Cadila Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pha.."},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repurposed Drug Helps Obese Mice Lose Weight, Improve Metabolic Function","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulfiram","moa":"Aldehyde dehydrogenase","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Aging \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Phase 3 Trial of Ranibizumab Biosimilar Candidate, SB11 to Treat Namd Meets Primary Endpoints","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"NellOne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nellone Therapeutics Files Provisional Patent Application for NELL1 to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NELL1","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NellOne Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NellOne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NellOne Th.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Begins Phase 1b\/2 Study of HTX-034 to Treat Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Virginia Commonwealth University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virginia Commonwealth University \/ Hoth Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Virginia C.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Highlights Scientific Innovation and Advances in its Growing Oncology Portfolio at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Frozen Liquid","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme and GACI Global Initiate Study to Understand Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics to Present Preclinical Data from Lead ImmunoTAC Candidate, SBT6050, at Upcoming ASCO and AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera's Qinlock Becomes the First Drug to get FDA Approval for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STI-1499, a Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability to Completely Inhibit In Vitro Virus Infection In Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-1499","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Delcath Systems Prices $22M Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Melphalan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.02,"dosageForm":"","sponsorNew":"Delcath Systems \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Sy.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Approves Optune\u00ae for the Treatment of Newly Diagnosed and Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Optune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"K S Kim International","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MGC Signs Multi-Country Distribution Agreement for Anti-Infective Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"ArtemiC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"K S Kim International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"K S Kim International \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"K S Kim In.."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inflammatory Disease Biotech Applied Molecular Transport Files for a $100 Million IPO","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"AMT-101","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0.10000000000000001,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"CDR Life","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$494.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody fragment-based therapeutics","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"CDR Life","amount2":0.48999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"CDR Life \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"CDR Life \/.."},{"orgOrder":0,"company":"NanoMab Technology","sponsor":"University Hospital Aachen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NanoMab and University Hospital Aachen to Start a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"NM-02","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab Technology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoMab Technology \/ University Hospital Aachen","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab Te.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$31.3 million","upfrontCash":"Undisclosed","newsHeadline":"Orion Receives Total of EUR 28 Mllion Milestones From Bayer For Sales of Darolutamide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Biotechnology \/ Bayer","highestDevelopmentStatusID":"10","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Tybourne Capital Management","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Tybourne Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Day One Biopharmaceuticals","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Day One Bags $60m to Change Cancer Care and Acquires Takeda\u2019s Rights to Develop and Commercialize DAY101 Worldwide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"Tovorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Day One Biopharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Day One Biopharmaceuticals \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Day One Bi.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"M-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Key Oncologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and Key Oncologics Have Signed an Exclusive Agreement to Commercialize Yondelis\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Key Oncologics","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas' PROTAC\u00ae Protein Degrader ARV-110 Shows Promise in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ARV-110","moa":"Androgen receptor degradation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Oakwood Laboratories","sponsor":"Flow Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flow Pharma Announces Strategic Partnership with Oakwood Labs for GMP Manufacturing of FlowVax COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"FlowVax COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oakwood Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oakwood Laboratories \/ Flow Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Oakwood La.."},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"IAVI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI and Batavia Biosciences Announce Collaboration on VSV-vector Based Epidemic Preparedness Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"VSV\u2206G-SARS-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Batavia Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Batavia Bioscience \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"Batavia Bi.."},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna Pharmaceuticals Enters into Cooperation with Guangzhou\u2019s Sun Yat-sen University to Develop a Treatment for SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Antisense oligonucleotides","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Sun Yat-sen University","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Ph.."},{"orgOrder":0,"company":"Proteona","sponsor":"Flinders University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Proteona\u2019s ESCAPE\u2122 platform selected for SARS-CoV-2 vaccine characterization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Proteona","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Proteona \/ Flinders University","highestDevelopmentStatusID":"1","companyTruncated":"Proteona \/.."},{"orgOrder":0,"company":"Adjuvance Technologies","sponsor":"NIH","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Adjuvance Technologies Announces NIH Funding for COVID-19 Vaccine Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"TQL1055","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adjuvance Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adjuvance Technologies \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"Adjuvance .."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals Presents Edasalonexent, A Potential Foundational Therapy For Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minoryx Therapeutics Doses First Patient With Leriglitazone In Registration-Enabling Cald Nexus Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Leriglitazone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Minoryx Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Minoryx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Minoryx Th.."},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spruce Biosciences Announces Launch of CAHstudy.com to Initiate Screening of Patients for CAH Clinical Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Bio.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"V\u03b39V\u03b42 T cells based antibodies","moa":"5 Gamma 9V Delta 2 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpha Cognition Inc. Announces Granted EU Patents and Orphan Drug Designation for Its Progranulin Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpha-602","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Alpha Cognition","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpha Cogn.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's CAR-T Shows 100% Response Rate In Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"JNJ-4528","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Final Guidance Backs Pfizer's Lorviqua","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lorlatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Revives Eritorian as a Possible COVID-19 Treatment, Plans to Launch an International Collaborative Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Eritoran","moa":"TLR4\/MD-2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Latest Data from Oncology Pipeline at ASCO 2020, including KEYTRUDA + LENVIMA Investigational Combination Therapy & HALAVEN","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics to Report Results from Phase 1\/2 Trial with MultiTAA-Specific T Cell Therapy in Pancreatic Adenocarcinoma at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiTAA-Specific T Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to Showcase Oncology Portfolio and Innovative Pipeline at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AGENT-797","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Society of Clinical Oncology Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed\/Refractory Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-501","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with DMD Treated with Lead Candidate CAP-1002","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CAP-1002","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk\u2019s First Semaglutide Obesity Trial Hits The Mark","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SY-5609","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"HHMI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Trial to Test Treatment that Targets Overactive Immune Response to COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HHMI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HHMI \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HHMI \/ Not.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia's Mavacamten Met Primary and Secondary Endpoints in Phase 3 EXPLORER Clinical Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphista Therapeutics Appoints Leading Protein Degradation Pioneer, Ian Churcher as CSO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Amphista Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amphista Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Amphista T.."},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$525.0million","upfrontCash":"$10.0 million","newsHeadline":"ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Vanderbilt University","amount2":0.53000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"","sponsorNew":"Vanderbilt University \/ ACADIA Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Vanderbilt.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's ENHERTU\u00ae Granted Orphan Drug Designation in the U.S. for Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Poxel","sponsor":"JMP Securities LLC","pharmaFlowCategory":"D","amount":"$19.4 million","upfrontCash":"Undisclosed","newsHeadline":"Poxel Successfully Raises \u20ac17.7 Million in a Capital Increase","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Poxel \/ JMP Securities LLC","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ JM.."},{"orgOrder":0,"company":"George Mason University","sponsor":"Emergex Vaccines Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex Signs Agreement with George Mason Univeristy for Highly Pathogenic RNA Virus Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Set-point vaccines","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"George Mason University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"George Mason University \/ Emergex","highestDevelopmentStatusID":"1","companyTruncated":"George Mas.."},{"orgOrder":0,"company":"Purdue University","sponsor":"Gibson Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gibson Oncology Gains Commercial Rights to New Anti-Cancer Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Azaindenoisoquinolines","moa":"cMYC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Purdue University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Purdue University \/ Gibson Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Purdue Uni.."},{"orgOrder":0,"company":"University of Montreal","sponsor":"Medigene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medigene, IRICoR and Universit\u00e9 de Montr\u00e9al Sign Collaboration and Exclusive Licensing Option on Novel Cancer Antigens","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"T Cell receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Montreal","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Montreal \/ Medigene AG","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"UCI Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCI Health launches therapeutic clinical trial for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UCI Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"UCI Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCI Health.."},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Licenses Patent Rights for bacterial Vaccine Development","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Streptococcus Pneumoniae vaccine","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"St. Jude Children","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"St. Jude Children \/ Blue Water Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"St. Jude C.."},{"orgOrder":0,"company":"UCI Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCI Health to Initiate Drug Clinical Trial to Treat Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"UCI Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UCI Health \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"UCI Health.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-527","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody-Based therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Epacadostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Epacadostat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"AmideBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Orphan Drug Designation to Amidebio's Glucagon Analog for the Treatment of Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-G023","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"AmideBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/.."},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Therapeutics Becomes a Wholly Owned Subsidiary of Shionogi","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Zatolmilast","moa":"PDE4","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tetra Therapeutics \/ Shionogi","highestDevelopmentStatusID":"8","companyTruncated":"Tetra Ther.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ridgeback Biotherapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$3,065 million","upfrontCash":"$65.0 million","newsHeadline":"Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Repare Therapeutics","amount2":3.0699999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.0699999999999998,"dosageForm":"","sponsorNew":"Repare Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$10.2 million","upfrontCash":"Undisclosed","newsHeadline":"NanoViricides Completes $10.2 Million Registered Direct Offering Funds to Accelerate COVID-19 Drug Program and HerpeCide Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"NV-HHV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NanoViricides","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"NanoViricides \/ Maxim Group LLC","highestDevelopmentStatusID":"5","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"SeraNovo","sponsor":"Carna Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SeraNovo Enters into a Second License Agreement with Carna Biosciences for Development of Oral Formulation of Carna\u2019s Kinase Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"SeraNovo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"SeraNovo \/ Carna Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"SeraNovo \/.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Hutchison China MediTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Hutchison China MediTech Limited","highestDevelopmentStatusID":"1","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Alvaxa Biosciences","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensei Biotherapeutics Completes Acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Nanobodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Alvaxa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvaxa Biosciences \/ Sensei Biotherapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Alvaxa Bio.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$175.0 million","newsHeadline":"Gilead Sciences and Arcus Biosciences Ink Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"AB154","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":2,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Yimiao Shenzhou Pharmaceutical","sponsor":"EdiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boya Series and Yimiao China Announced that They will Jointly Develop Allogeneic CAR-T Therapy For Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Allogeneic CAR-T therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yimiao Shenzhou Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yimiao Shenzhou Pharmaceutical \/ EdiGene","highestDevelopmentStatusID":"1","companyTruncated":"Yimiao She.."},{"orgOrder":0,"company":"AbCellera","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Closes $105 Million Series B Financing to Further Advance World-Leading Antibody Drug Discovery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"AbCellera \/ OrbiMed","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Brill International S.L","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe for its Microdacyn60\u00ae Eye Care","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Sonoma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sonoma Pharmaceuticals \/ Brill International S.L","highestDevelopmentStatusID":"12","companyTruncated":"Sonoma Pha.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Syntone Ventures LLC","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Private Placement","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Syntone Ventures LLC","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Shanghai Cell Therapy Group","sponsor":"Baize Plan Fund","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"Shanghai Cell Therapy Group Ink Collaboration with USC to Improve Ex Vivo Expansion of Hematopoietic Stem Cells for Clinical Applications","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Hematopoietic stem cells","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Shanghai Cell Therapy Group","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Cell Therapy Group \/ Baize Plan Fund","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai C.."},{"orgOrder":0,"company":"Conatus Pharmaceuticals","sponsor":"Histogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Conatus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Conatus Pharmaceuticals \/ Histogen","highestDevelopmentStatusID":"6","companyTruncated":"Conatus Ph.."},{"orgOrder":0,"company":"Correvio Pharma","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"$76.0 million","newsHeadline":"Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Vernakalant Hydrochloride","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Correvio Pharma","amount2":0.080000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Correvio Pharma \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Correvio P.."},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ajinomoto Bio-Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto .."},{"orgOrder":0,"company":"Nuformix","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VistaGen and Nuformix agree to develop cocrystalline forms of AV-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"4-Chlorokynurenine","moa":"NMDA","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Nuformix","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuformix \/ VistaGen","highestDevelopmentStatusID":"4","companyTruncated":"Nuformix \/.."},{"orgOrder":0,"company":"Microbion","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$17.1 million","upfrontCash":"Undisclosed","newsHeadline":"Microbion Gets $17.1 M from CARB-X and Cystic Fibrosis Foundation to Develop Inhaled Antimicrobial for Chronic Respiratory Infections in CF","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Pravibismane","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0.02,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Microbion \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aerpio Pharmaceuticals and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for I-SPY COVID Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Razuprotafib","moa":"PTP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"Methamphetamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"University Hospital Basel","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University Hospital Basel \/ Mind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SYN-020","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ Synthetic Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Massachuse.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$80.5 million","upfrontCash":"Undisclosed","newsHeadline":"Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Cowen","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo and Syneos Health\u00ae Form Strategic Coalition for Development of Daiichi Sankyo\u2019s ADC Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Syneos Health \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Hea.."},{"orgOrder":0,"company":"University of Toronto","sponsor":"Virna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virna Therapeutics and University of Toronto Announce Licensing of Neutralizing Monoclonal Antibodies to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SARS-CoV-2 neutralizing antibodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Toronto","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Toronto \/ Virna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck, Baylor College of Medicine Extend Collaboration to Advance Manufacturing Platform to Fight COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"CoV RBD219-N1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"WP1244","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CNS Pharmaceuticals \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Vaxxas","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Vaxxas","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Vaxxas \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Vaxxas \/ M.."},{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Kerry Murphy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Financing","leadProduct":"KCC2","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Axonis Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axonis Therapeutics \/ Kerry Murphy","highestDevelopmentStatusID":"2","companyTruncated":"Axonis The.."},{"orgOrder":0,"company":"Southwest Research Institute","sponsor":"Henry M. Jackson Foundation","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"SwRI Awarded $1.9 Million Contract to Develop Treatment for COVID-19 in Collaboration with DOD","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Antiviral drug therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southwest Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Southwest Research Institute \/ Henry M. Jackson Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Southwest .."},{"orgOrder":0,"company":"Octapharma","sponsor":"Norton Heart & Vascular Institute in Louisvill","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Octapharma USA & BioMatrix Support Research Focused on COVID-19 & Myocardial Dysfunction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Immune globulin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Norton Heart & Vascular Institute in Louisvill","highestDevelopmentStatusID":"1","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the NIH for the Treatment of Patients with Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"RefleXion Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck\u2019s KEYTRUDA\u00ae for Certain Late-Stage Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ RefleXion Medical","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Medac","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fresenius Kabi Enters Marketing Agreement For Biosimilar Product","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Medac","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medac \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"Medac \/ Fr.."},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck to Acquire Themis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Themis Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Themis Bioscience \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Themis Bio.."},{"orgOrder":0,"company":"CordenPharma","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Extends Lipid Supply For Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CordenPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CordenPharma \/ Moderna","highestDevelopmentStatusID":"8","companyTruncated":"CordenPhar.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"$0.2 million","newsHeadline":"CNS Provides Update on Development Agreement for WP1122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WPD Pharmaceuticals \/ CNS Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"Pneumagen","sponsor":"Thairm Bio","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pneumagen Announces \u00a34m Fundraising and Commits to Clinical Trial Development for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"Carbohydrate binding modules","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pneumagen","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Pneumagen \/ Thairm Bio","highestDevelopmentStatusID":"4","companyTruncated":"Pneumagen .."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Zafgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Merger","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Larimar Therapeutics \/ Zafgen","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Sernova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and Sernova to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Recombinant pluripotent stem cell-derived pancreatic islet beta cells","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ Sernova","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical Oncology Biotech Repare Therapeutics Files for a $100 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"RP-3500","moa":"ATR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Stempeutics","sponsor":"Novumcella","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stempeutics Inks Pact with Novumcella for Development Co-Operation of Stempeucel to Treat CLI Due to Buerger\u2019s Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Bone marrow-derived allogeneic mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Stempeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stempeutics \/ Novumcella","highestDevelopmentStatusID":"12","companyTruncated":"Stempeutic.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for Manufacture of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ Astrazeneca","highestDevelopmentStatusID":"9","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"The National Cancer Center Japan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical Establishes Illuminox\u2122 Alliance Institutes to Accelerate Development of Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"ASP-1929","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ The National Cancer Center Japan","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Me.."},{"orgOrder":0,"company":"Genprex","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Oncoprex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Marinus Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Genexine","sponsor":"PT Kalbe Farma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kalbe to Start COVID-19 Vaccine Trial with S. Korean Pharma Firm","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ PT Kalbe Farma","highestDevelopmentStatusID":"4","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Arrevus","sponsor":"NIH","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Arrevus Receives Dual Awards from NIH and Department of Defense for Development of ARV-1502","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ARV-1502","moa":"DnaK protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Arrevus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrevus \/ NIH","highestDevelopmentStatusID":"4","companyTruncated":"Arrevus \/ .."},{"orgOrder":0,"company":"Icagen","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$274.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces Icagen\u2019s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Icagen","amount2":0.27000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Icagen \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Icagen \/ R.."},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ V.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"DS-1062","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Surrozen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen\u2019s Novel Wnt Activating Antibodies","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Wnt Activating Antibodies","moa":"WNT signalling pathway","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Surrozen","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Argenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argenx Announces Positive Topline Phase 3 ADAPT Trial Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Argenx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Argenx \/ N.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark to Commence Another New Phase 3 Clinical Trial on a Combination of Two Anti-Viral Drugs Favipiravir and Umifenovir for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Announces German Regulatory Approval of ABX464 Covid-19 Phase 2b\/3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emgality\u00ae Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Announces Dosing of First Patient with Fourth Immtac\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IMC-F106C","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegzilarginase","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Adds to Its Trove of Positive Data for Multiple Myeloma Contender as Rivals Continue to Command the Spotlight","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali\u00ae Shows Survival Benefit In HR+\/HER2 Advanced Breast Cancer With Consistent Results In Patients With More Aggressive Disease","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen to Start Trial of SNG001 in COVID-19 Imminently","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TJM2","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Presents Data from Phase 1 Study of MSB2311 in Pre-treated Advanced Solid Tumors and Select Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MSB2311","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Remdesivir Preliminary Results From NIAID Trial Published","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"SaNOtize","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SaNOtize Enrolls First Patient In Phase II Trial of Nitric Oxide Releasing Solution for Prevention and to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SaNOtize","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"SaNOtize \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SaNOtize \/.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Provides Update on Coronavirus Drug Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves VESIcare LS\u2122 (solifenacin succinate) Oral Suspension for Pediatric Patients","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Solifenacin Succinate","moa":"Muscarinic M2 receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Announces Orphan Drug Designation Granted for Pravibismane Suspension for Inhalation by US FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pravibismane","moa":"Microbial bioenergetic","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microbion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaled Suspension","sponsorNew":"Microbion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbion .."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Methadone","moa":"NMDA","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Releases CBN Preclinical Results in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Publication of Data from Ongoing COMBAT\/KEYNOTE-202 Clinical Trial in Nature Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Kantum Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kantum Pharma Highlights New Research Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KB-1801","moa":"P2Y14 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Kantum Pharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kantum Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kantum Pha.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Announces Rare Pediatric Disease Designation for ATR-12 for the Treatment of Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATR-12","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Azitra","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ N.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts for Review Fresenius Kabi\u2019s BLA Submission for Pegfilgrastim Biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces Launch of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b\/2 Study of ALRN-6924","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves New Pediatric Formulation of SIRTURO\u00ae (bedaquiline) as Part of Combination Therapy","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bedaquiline","moa":"ATP synthase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with IBS-D","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Linaclotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review of Nucala for Patients with Hypereosinophilic Syndrome","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals to Present Trial in Progress Poster at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menlo Therapeutics Announces Covered Status for AMZEEQ\u00ae (minocycline) topical foam, 4%, on Additional Commercial Formulary","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Menlo Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menlo Ther.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-3434","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Organicell Flow","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aqualung Therapeutics Gets NIH Approval to Advance to IND-Enabling Studies for Development of Novel Antibody for ARDS and the Critically Ill","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aqualung Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung T.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Announces Abstracts Selected for Publication at the 2020 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meitheal Pharmaceuticals Announces Launch of Enoxaparin Sodium Injection, USP in the United States","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Meitheal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Meitheal P.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Announces New Recommendations for Rubraca\u00ae (rucaparib) Tablets in Updated NCCN Guidelines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OP-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Clinical Data to be Presented at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Theraly Fibrosis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theraly Fibrosis Granted US Orphan Drug Designation for TLY012 for Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TLY012","moa":"DR5","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Theraly Fibrosis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Theraly Fibrosis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theraly Fi.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma to Present at Jefferies Virtual Global Healthcare Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NDX-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Rallybio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rallybio Further Broadens Drug Development Capabilities with Addition of R\u00f3is\u00edn Armstrong, PhD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RLYB211","moa":"HPA-1a","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Rallybio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rallybio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rallybio \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Tests Diabetes Drug Farxiga for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche initiates Phase III Clinical Trial of Actemra\/RoActemra Plus Remdesivir in Hospitalised Patients with Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Advances LYT-100 for Treatment of Serious Respiratory Complications that Persist Following Resolution of COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deupirfenidone","moa":"IL-6\/TNF-alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces FDA Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Treatment of KRAS-Mutated Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Lyon Sud Hospital Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avelumab Appears to be Effective in Preventing Relapse in Women With GTT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lyon Sud Hospital Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyon Sud Hospital Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyon Sud H.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Reports Positive Phase 3 BOSTON Data at the American Society of Clinical Oncology 2020 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CERC-002","moa":"LIGHT","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora\u2122 in Patients with Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"resTORbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dactolisib","moa":"TORC1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"resTORbio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"resTORbio .."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYR Pharmaceuticals Receives Positive CHMP Opinion For HEPCLUDEX\u00ae (bulevirtide)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Bulevirtide","moa":"HDV receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MYR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MYR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MYR Pharma.."},{"orgOrder":0,"company":"MedStar Washington Hospital Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Development of Drug Resistance in Colon Cancer Patients Contributed to Failure of Oxaliplatin-based HIPEC PRODIGE 7 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxaliplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MedStar Washington Hospital Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MedStar Washington Hospital Center \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MedStar Wa.."},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphivena Presents Data from First-in-Human Study of AMV564 in Solid Tumor Patients at the ASCO Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AMV564","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Announces Updated Results of ENHANCE 1, Investigating HALAVEN plus KEYTRUDA in Patients with Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Eribulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Highlights Innovative Oncology Portfolio and Pipeline of Oral, Biologic and Cell Therapies Through ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"JNJ-4528","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New England Journal of Medicine Publishes Primary Analysis of VISION Data for Tepotinib in Advanced NSCLC with METex14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tepotinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Presents Findings from Clinical Studies Evaluating TP-1287 and TP-3654 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-1287","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE\u00ae (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1\/2 Study of GB1275","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GB1275","moa":"CD11b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Response and Translational Data from DeCidE1, Phase 2 Study of DPX-Survivac Immunotherapy in Advanced Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD8+ T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Pharmaceuticals Presents Data from Phase 1b\/2 Study of Rebastinib and Paclitaxel Combo in Advanced Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Rebastinib","moa":"ABL1 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May Cause Treatment Resistance in Patients with METex14-altered NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"MET","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foundation Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Rgenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-202","moa":"SLC6a8\/CKB pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenix \/ N.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SY-5609","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Gets Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO for Preventive Treatment for Hereditary Angioedema Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Reports Results from Exploratory Analyses of HER2CLIMB for TUKYSA in Brain Metastases Patients With HER2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Alteogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-P7","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alteogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alteogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"IO-202","moa":"LILRB4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Talaris\u2019 Phase 2 Study of FCR001 in Living Donor Kidney Transplant Recipients to be Presented at ATC Virtual Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FCR001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ENHERTU Improved Tumor Response Rate and Overall Survival in HER2-positive Metastatic Gastric Cancer in Phase II DESTINY-Gastric01 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics Presents Data Supporting Clinical Activity of SBT6050 as a Single Agent and in Combination with Trastuzumab for HER2-Expressing Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead's Magrolimab and Azacitidine Combo Shows Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Yescarta\u00ae (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig\u00ae for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ponatinib","moa":"Bcr\/Abl fusion protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces Phase 1b\/2 DEDUCTIVE Study of FOTIVDA in Combination with IMFINZI Advances to Phase 2","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Receives Positive CHMP Opinion for Janssen\u2019s Investigational Preventive Ebola Vaccine Regimen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.ZEBOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"NKMax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ No.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion to Present Results from Multiple Preclinical and Health Economic Studies at the American Transplant Congress Virtual Meeting","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Treos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treos Bio Reports Positive Final Results of Phase I\/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PolyPEPI1018","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Treos Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Treos Bio .."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Final Results of GENUINE Phase 3 Study Testing Ublituximab + Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Vorasidenib","moa":"IDH1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NC318","moa":"Siglec-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TPX-0046","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Announces New Data Related To Its K-NK Cell Therapy Platform Presented today at the ASCO 2020 Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TTI-622","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Announces Approval of the REVocan Study by Regulatory Authorities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Highlights Updated Envafolimab Results in MSI-H\/dMMR Colorectal Cancer and Results from Clinical Trial of Opdivo and Yervoy Combination Therapy in Undifferentiated Pleomorphic Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiTAA-Specific T Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Show First-Line Triplet Regimen of Pembrolizumab, Herzuma\u00ae and Chemotherapy are Effective in Treatment of HER2+ Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents Novel Supportive Phase I Data at ASCO for its CTLA-4 x OX40 Bispecific Drug Candidate ATOR-1015","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1015","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"American Society of Clinical Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TAPUR Study Shows Encouraging Results for Olaparib in BRCA-Mutated Advanced Prostate and Pancreatic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"American Society of Clinical Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"American Society of Clinical Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American S.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoceutics to Present Additional Data at ASCO Showing Clinical Benefit from ONC201 for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelcitoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Zhongnan Hospital of Wuhan University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Effects of Dipyridamole on COVID-19 Patients With Coagulation Dysfunction 2 Coagulation Dysfunction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Dipyridamole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhongnan Hospital of Wuhan University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhongnan Hospital of Wuhan University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhongnan H.."},{"orgOrder":0,"company":"Apeptico","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"APEPTICO supplies SOLNATIDE Investigational Medicinal Product to the Medical University Vienna for the assessment of efficacy in COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Solnatide","moa":"Sodium channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeptico","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apeptico \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeptico \/.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Submits BLA to U.S. Food and Drug Administration for Pegunigalsidase Alfa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MesenCure","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Transfusion","sponsorNew":"Bonus BioGroup \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioG.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Launches ENHERTU\u00ae in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Evofem Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Evofem Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"1","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Vaxine","sponsor":"Medytox","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxine and Medytox partner on Covid-19 vaccine development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"COVAX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxine \/ Medytox Inc","highestDevelopmentStatusID":"4","companyTruncated":"Vaxine \/ M.."},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIkido Pharma Announces Publication of Results from Sponsored Research at Wake Forest University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KPC34","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkido Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alkido Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alkido Pha.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Report Positive Topline Results from the NORA Phase 3 Study of ZEJULA\u00ae as Maintenance Therapy Platinum-sensitive, Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ATR-002","moa":"SARS-CoV-2 replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XTANDI\u00ae (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"NKTR-358","moa":"IL-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GC027","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMFINZI Plus Tremelimumab Demonstrated Promising Clinical Activity and Tolerability in Patients With Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces Poster Presentations at EULAR 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-101","moa":"ICOS","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Evofem Biosciences' Phexxi\u2122 (Lactic acid, Citric acid and Potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"QED Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"QED Therap.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Presents Updated Long-term Safety, Immunogenicity and Durability Data from GEN-009 Neoantigen Vaccine Phase 1\/2a Trial Part A","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"CX-2029","moa":"CD71","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CytomX Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytomX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CytomX The.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"OrPro Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrPro Therapeutics Advances a New Inhalation Treatment Approach for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP100S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OrPro Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"OrPro Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OrPro Ther.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology Announces Presentation of Data for Futibatinib in Advanced Intrahepatic Cholangiocarcinoma at 2020 ASCO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following Bunionectomy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eFFECTOR\u2019s Tomivosertib Shows Positive Phase 2 Results in Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tomivosertib","moa":"Mapk 1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Effector Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Effector T.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiwan Approves Gilead's Remdesivir to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Lilly to Collaborate with Duke Clinical Research Institute on a Trial Examining Jardiance's Effects Following an Acute Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Duke Clinical Research Institute \/ Boehringer Ingelheim","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clini.."},{"orgOrder":0,"company":"IAVI","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"rVSV\u0394G-SARS-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IAVI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAVI \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"IAVI \/ BAR.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"CLBS12","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences Completes $100 Million Series C Financing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series C Financing","leadProduct":"Antibody-Oligonucleotide Conjugates","moa":"DMPK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Avidity Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"ADX-914","moa":"IL-7R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Q32 Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ Tavotek Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Genmab \/ T.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Initiates Phase 1\/2 Study of APL-9 in Patients with Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"APL-9","moa":"Complement C3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Announces Start of Clinical Trial to Evaluate Leukine in Respiratory Illness in Patients with COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"ProSciento","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nimacimab","moa":"CB1","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Skye Bioscience \/ ProSciento","highestDevelopmentStatusID":"8","companyTruncated":"Skye Biosc.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL\u2011CEBPA in Combination with Sorafenib in Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"CCAAT\/-binding protein alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Releases Takeda From Commitment to Divest Shire\u2019s Pipeline Compound SHP647","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ontamalimab","moa":"Mucosal addressin Cell adhesion molecule-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Humanetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanetics Corporation to Present Clinical Trial Results at the Annual Meeting of the American Society for Radiation Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Humanetics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Files Patent for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I\/II Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Hana Pharm","sponsor":"Bold Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bold Therapeutics Executes Option Agreement for Exclusive Development and Commercialization Rights to BOLD-100 in South Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hana Pharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hana Pharm \/ Bold Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Hana Pharm.."},{"orgOrder":0,"company":"Chimeron Bio","sponsor":"Mason University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chimeron Bio and George Mason University Partner to Develop a Coronavirus Vaccine using ChaESARTM Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Self-amplifying RNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chimeron Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chimeron Bio \/ Mason University","highestDevelopmentStatusID":"4","companyTruncated":"Chimeron B.."},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Palvella Therapeutics","pharmaFlowCategory":"D","amount":"$3.0 milion","upfrontCash":"$2.0 milion","newsHeadline":"Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"Sirolimus","moa":"mTOR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Ligand Pharmaceuticals \/ Palvella Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ligand Pha.."},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"$20.0 million","newsHeadline":"SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SCD-044","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"SPARC","amount2":0.14999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"SPARC \/ Sun Pharma","highestDevelopmentStatusID":"8","companyTruncated":"SPARC \/ Su.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Together with Partner Astellas, Reports Final Prosper Results Show Xtandi Extends Overall Survival In Men With Non-Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Montefiore Health System","sponsor":"NIH","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montefiore Health System","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Montefiore Health System \/ NIH","highestDevelopmentStatusID":"10","companyTruncated":"Montefiore.."},{"orgOrder":0,"company":"McMaster University","sponsor":"Ceapro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop Inhalable Therapeutic for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"Yeast beta-glucans","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"McMaster University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"McMaster University \/ Ceapro","highestDevelopmentStatusID":"4","companyTruncated":"McMaster U.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Receives Positive CHMP Opinion For A Third Nintedanib Indication In Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Issues Positive Opinion to Extend Invokana Indication to Reflect Improved Renal Outcomes in Diabetic Kidney and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Napp Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napp Pharmaceuticals \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Napp Pharm.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2020 Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Unveils Interim Data from OPTIC Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Translational Data Supports DPX-Survivac Mechanism of Action","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DPX-Survivac","moa":"Survivin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Reports Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"saRNA","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Mina Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Mina Thera.."},{"orgOrder":0,"company":"Harvard Stem Cell Institute","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Muscular Dystrophy Collaboration Aims to Correct Muscle Stem Cells\u2019 DNA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CRISPR\/Cas9 genome","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Harvard Stem Cell Institute","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harvard Stem Cell Institute \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Harvard St.."},{"orgOrder":0,"company":"NHS England","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis, NHS England team up in 'world-first' access agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"NHS England","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NHS England \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"NHS Englan.."},{"orgOrder":0,"company":"Vigene Bioscience","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ASC Therapeutics and Vigene Announce Long-Term Strategic Partnership for Gene Therapy Development and Manufacturing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Viral vector gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vigene Bioscience","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vigene Bioscience \/ ASC Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Vigene Bio.."},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"AnGes","pharmaFlowCategory":"D","amount":"$61.0 million","upfrontCash":"Undisclosed","newsHeadline":"Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series B Financing","leadProduct":"OMNI nuclease","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Emendo Biotherapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Emendo Biotherapeutics \/ AnGes","highestDevelopmentStatusID":"1","companyTruncated":"Emendo Bio.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-001","moa":"MUt transgene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"BMN 307","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Axovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Announces Positive 12 Month Data on Axo-Lenti-PD and Provide Updates on Gene Therapy Pipeline Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Axovant","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Axovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axovant \/ .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"Pan-kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aruvant Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sc.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1\/2 Clinical Trials in Achromatopsia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Adeno-associated virus-based gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"AKCEA-ANGPTL3-LRx","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Ther.."},{"orgOrder":0,"company":"Arrevus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"GJB2 Gene Therapy","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Arrevus","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrevus \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arrevus \/ .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-102","moa":"Gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"siRNA","moa":"mRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sirnaomics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Ikarovec","sponsor":"UKI2S","pharmaFlowCategory":"D","amount":"$3.2 million","upfrontCash":"Undisclosed","newsHeadline":"Ophthalmic gene therapy company launches with \u00a32.5m seed cash","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Funding","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ikarovec \/ UKI2S","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Urovant Sciences Announces Results from URO-902 Phase 1 Trials","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"URO-902","moa":"Maxi-K protein expression","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Urovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces Clinical Data Presentation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"AskBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AskBio Reveals First Patient Dosed in Phase 1 AAV Gene Therapy Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"NAN-101","moa":"PP1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"AskBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AskBio \/ N.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex to Focus Its Clinical Efforts on Oncoprex with Osimertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Erlotinib","moa":"Pan-kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"FerGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FerGene to Present Bladder Cancer Data at 2020 ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nadofaragene firadenovec","moa":"INF alpha 2b","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"FerGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"FerGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FerGene \/ .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Presents Initial Data for Cystinosis Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-04","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics Provides Update on FDA Review of LB-001 NDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-001","moa":"Methylmalonyl-CoA mutase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Provides Research Update for CTX120","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline presents data on its AAV-based gene therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics\u2019 PR001 Gets Orphan Drug Designation By FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Initiates Clinical Trial in McArdle Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"REN001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Completes Enrollment in the Two Highest Dose Groups of its Ongoing Phase 1\/2 Clinical Trial for X-Linked Retinitis Pigmentosa","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AGTC-501","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L102","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Receives FDA Fast Track Designation for LYS-SAF302 Gene Therapy in MPS IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Olenasufligene Relduparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI\u2019s 15th Annual Huntington\u2019s Disease Therapeutics Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrastriatal Injection","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Akouos","sponsor":"Pivotal bioVenture Partners","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Akouos Closes $105 Million Series B Financing","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.11,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Akouos \/ Pivotal bioVenture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ P.."},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Horama SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HORAMA Signs Exclusive License Agreement with Leiden University Medical Center","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"HORA-001","moa":"CRB1 gene","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leiden University Medical Center \/ Horama SA","highestDevelopmentStatusID":"1","companyTruncated":"Leiden Uni.."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AskBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of North Carolina \/ AskBio","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Partners with Vanderbilt University Medical Center for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Synthetic genes","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"The Invus Group","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Closes $170 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"Cell and gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"ElevateBio \/ The Invus Group","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$7.0 million","newsHeadline":"REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV\u00ae Technology Platform","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Gene Therapy-AAV8","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenxbio \/ Ultragenyx","highestDevelopmentStatusID":"1","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$2,080.0 million","upfrontCash":"$60.0 million","newsHeadline":"Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases ","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Small interfering RNA","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":2.0800000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.0800000000000001,"dosageForm":"","sponsorNew":"Silence Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Silence Th.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Announces Investigational New Drug Application Active for PR006","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PR006","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson\u2019s Disease with GBA1 mutations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Gene Therapy Publishes Preclinical Data of Ocugen\u2019s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NR2E3-AAV","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 Phase III Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"NG-641","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Akamis Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline receives Orphan Drug Designation from the European Commission","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer to Host Free Webinar on Pfizer\u2019s Advancement to Phase III Gene Therapy Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PF-06939926","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Homology Medicines Announces Peer-Reviewed Publication Of HMI-102 Investigational Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"HMI-102","moa":"PAH gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology M.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Advances RNAi Approaches to Target Highly Conserved Regions of Coronavirus RNAs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"siRNAs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion\u2019s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 in Hemophilia B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Provides Initial Observations From PHYOX 3 Trial of Nedosiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics to Present at AAT-AD\/PD Focus Meeting 2020: Advances in Alzheimer\u2019s and Parkinson\u2019s Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sofinnova Telethon Fund Backs Naldini's Gene Therapy Biotech","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"1","companyTruncated":"Genespire .."},{"orgOrder":0,"company":"Myosana Therapeutics","sponsor":"CureDuchenne Ventures","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne Ventures","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Non-viral gene therapy","moa":"Dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Myosana Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Myosana Therapeutics \/ CureDuchenne Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Myosana Th.."},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Pharmaceuticals and Affinia Therapeutics Set Up Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"AAV capsid-gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Affinia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Affinia Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Affinia Th.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"PBM Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Announce $30 Million Seed Financing and Strategic Partnership with the UT Southwestern Gene Therapy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Financing","leadProduct":"TGTX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Taysha Gene Therapies","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ PBM Capital","highestDevelopmentStatusID":"5","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$17.3 million","upfrontCash":"Undisclosed","newsHeadline":"Genespire Secures \u20ac16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"1","companyTruncated":"Genespire .."},{"orgOrder":0,"company":"UT Southwestern","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Inks an Unrivaled Alliance with the UT Southwestern Gene Therapy Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Partnership","leadProduct":"AAV gene therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"UT Southwestern","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UT Southwestern \/ Taysha Gene Therapies","highestDevelopmentStatusID":"1","companyTruncated":"UT Southwe.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Provides Update on the RESTORE-1 Parkinson\u2019s Disease Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VY-AADC","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cobra Biologics successfully completes key milestone in CombiGene\u2019s epilepsy project","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"CG01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biol.."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian Biosciences Announces Scientific Presentations at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Gene-modified cellular therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kolon Tissuegene Announces Plans To Resume US Phase III Clinical Trial For TG-C","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TissueGene-C","moa":"Chondrocytes","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon TissueGene","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Kolon TissueGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kolon Tiss.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I\/II Trial of GS030","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"GS030","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Receives Advanced Therapy Medicinal Product Classification from EMA for MB-107 Lentiviral Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-107","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regenxbio Announces Additional Positive Long-Term and Interim Phase I\/Iia Trial Update for RGX-314 for the Treatment of Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-201","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Announces Upcoming Oral and Poster Presentations at the American Society of Gene and Cell Therapy Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"4D-310","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"PR001","moa":"GBA1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Eight Presentations Across Gene Therapy Portfolio at the ASGCT 23rd Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$225.0 million","upfrontCash":"$125.0 million","newsHeadline":"Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ultragenyx Pharmaceutical","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Daiichi Sankyo","highestDevelopmentStatusID":"3","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"QVT","pharmaFlowCategory":"D","amount":"$80.5 million","upfrontCash":"Undisclosed","newsHeadline":"Kriya Therapeutics announces $80 million Series A financing to advance gene therapies for highly prevalent serious diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"KT-A112","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Kriya Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Kriya Therapeutics \/ QVT","highestDevelopmentStatusID":"1","companyTruncated":"Kriya Ther.."},{"orgOrder":0,"company":"SR-Tiget","sponsor":"Genespire","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genespire and SR-Tiget Announce Alliance for the Development of Transformative Gene Therapies for Genetic Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"MicroRNA-regulated lentiviral vectors","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"SR-Tiget","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SR-Tiget \/ Genespire","highestDevelopmentStatusID":"1","companyTruncated":"SR-Tiget \/.."},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Funding","leadProduct":"siRNAs","moa":"MSUT2 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"DTx Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DTx Pharma \/ Alzheimer's Association","highestDevelopmentStatusID":"4","companyTruncated":"DTx Pharma.."},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Affinia Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Affinia Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"1","companyTruncated":"Affinia Th.."},{"orgOrder":0,"company":"Coda Biotherapeutics","sponsor":"Facial Pain Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CODA Biotherapeutics Announces Research Collaboration With The Facial Pain Research Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"AAV vectors","moa":"Ligand gated ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coda Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Coda Biotherapeutics \/ Facial Pain Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Coda Bioth.."},{"orgOrder":0,"company":"Hitachi Chemicals","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma ink Clinical and Commercial Manufacturing Pact with Bluebird Bio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"LentiGlobin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Hitachi Chemicals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hitachi Chemicals \/ Bluebird bio","highestDevelopmentStatusID":"7","companyTruncated":"Hitachi Ch.."},{"orgOrder":0,"company":"Axplora","sponsor":"Lysogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novasep and Lysogene Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"LYS-GM101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Axplora","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axplora \/ Lysogene","highestDevelopmentStatusID":"6","companyTruncated":"Axplora \/ .."},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AskBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AskBio and UNC Team Up to Develop Angelman Syndrome Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AAV gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"University of North Carolina","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of North Carolina \/ AskBio","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Toshiba Corporation","sponsor":"Shinshu University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shinshu University, Toshiba Develop Tumor-Tropic Liposome Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Liposome vector based gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Toshiba Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toshiba Corporation \/ Shinshu University","highestDevelopmentStatusID":"1","companyTruncated":"Toshiba Co.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Teams With Mass. Eye & Ear to Join Coronavirus Vaccine Chase","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"AAVCOVID","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Phoenix Nest","sponsor":"Cure Sanfilippo Foundation","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Cure Sanfilippo Grants $380,000 to Type C Gene Therapy Development","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"AAV-TT","moa":"HGSNAT gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Phoenix Nest","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phoenix Nest \/ Cure Sanfilippo Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Ne.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAVrh8-HexA\/HexB","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathalamic Infusion","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Provides Update regarding SGT-001 Phase I\/II Clinical Hold on IGNITE DMD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenaya Therapeutics to Present Preclinical Data at 2020 Annual Meeting of the American Society of Gene & Cell Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-Gene Therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tenaya Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya The.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics Announces Presentations at ASGCT and ARVO Annual Meetings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics's Preclinical Data reveal In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TANGO antisense oligonucleotides","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyne Therapeutics Demonstrates FORCE\u2122 Platform\u2019s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FORCE-M23D","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Presents Positive Updates on FA and LAD-I Gene Therapy Programs at the 23rd ASGCT Annual Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L201","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyno Therapeutics Announces Presentations at 2020 American Society of Gene and Cell Therapy Conference","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Synthetic AAV capsids Proteins","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Dyno Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dyno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Dyno Thera.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Presents Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PBKR03","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection\n","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1\/2 Study of DTX301 Gene Therapy OTC Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"DTX301","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Presents Data on MGTA-145 at The Annual Meeting of American Society of Gene and Cell Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Self-delivering RNAi compounds","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Shares Positive Interim Results from Phase 1\/2 Trial of KB105 in TGM1-related Autosomal Recessive Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KB105","moa":"Transglutaminase 1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s New Phase 1b Results of Gene Therapy in Ambulatory Boys with DMD Support Advancement into Pivotal Phase 3 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PF-06939926","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avexis Receives EC Approval and Activates \u201cDay One\u201d Access Program for Zolgensma\u00ae, the only Gene Therapy for Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Onasemnogene abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"3 Hemophilia B Patients Report Uniqure's AMT-060 Gene Therapy Gave Them Normalcy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV5-hFIX","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gene Therapy Shows Promise in Mouse Model of Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ETX101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Encoded Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Encoded Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Encoded Th.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Shares Positive Preclinical Data With Scientific Evidence for its Ongoing Clinical Program in X-Linked Retinitis Pigmentosa Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PBGM01","moa":"Beta-galactosidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Wins Conditional EU Approval for Gene Therapy Zolgensma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Onasemnogene abeparvovec-xioi","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Agrees to Phase 1 Trial of ET3, Gene Therapy for Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ET3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Expression Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Expression Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Expression.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"SLS-004","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Provides 4 Years of Clinical Data from Ongoing Phase 1\/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO\u2122 and Its Electroporation Gene Delivery System","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Passage Bio","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Passage Bio Adds More Programs, Tech and Time to UPENN Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"University of Pennsylvania \/ Passage Bio","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Provides Update on Preclinical Experiment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"VXL-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxil Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Tel Aviv Medical Center","sponsor":"Vaxil Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxil Announces Collaboration Agreement With The Tel Aviv Sourasky Medical Center","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Peptide based COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tel Aviv Medical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tel Aviv Medical Center \/ Vaxil bio","highestDevelopmentStatusID":"4","companyTruncated":"Tel Aviv M.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Tel Aviv Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Announces the Identification of a Potential Corona Virus Vaccine and Provides an Update in the Previously Announced Debt Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxil Bio \/ Tel Aviv Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Reports New Responses in Esophagogastric Junction, Lung, and Head and Neck Cancers Using its SPEAR T-cells Targeting MAGE-A4","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Therapeutics Provides Clinical Update on its Allogeneic Platforms ADP-A2M4CD8, ADP-A2M4 and ADP-A2AFP at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4CD8","moa":"MAGE-A4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$897.5 million","upfrontCash":"$50.0 million","newsHeadline":"Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"T cell based therapy","moa":"T-cell receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adaptimmune Therapeutics","amount2":0.90000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.90000000000000002,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Opinion for Orphan Drug Designation for ADP-A2M4 in EU for Treatment of Soft Tissue Sarcoma from EMA' Committee","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and Clover Biopharmaceuticals Announce Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 S-Trimer","moa":"S-Trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Clover Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jacobio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"JAB-3068","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Jacobio","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"REGENERON","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$70.0 million","newsHeadline":"Regeneron and Intellia Therapeutics Expand Collaboration to Develop Crispr\/Cas9-Based Treatments","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"CRISPR\/Cas9 based gene therapy","moa":"Factor IX gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ REGENERON","highestDevelopmentStatusID":"4","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi Biosciences and Merck Announce Collaboration to Explore Promising New Composition Treatment for Head and Neck Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Merck","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Biotheus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alligator Bioscience's Collaboration With Biotheus Inc. Proceeds and Second Payment is Received","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Immune-activating antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Biotheus","highestDevelopmentStatusID":"1","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Ragon Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codiak BioSciences Collaborates with Ragon Institute to Evaluate the exoVACC\u2122 Vaccine Platform in SARS-CoV-2 and HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"exoVACC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Ragon Institute","highestDevelopmentStatusID":"2","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Aposense","pharmaFlowCategory":"D","amount":"$127.5 million","upfrontCash":"Undisclosed","newsHeadline":"Processa Pharmaceuticals Has Entered into an Agreement with Aposense, to License in the Next Generation Irinotecan Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Processa Pharmaceuticals","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Aposense","highestDevelopmentStatusID":"1","companyTruncated":"Processa P.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$35.6 million","upfrontCash":"Undisclosed","newsHeadline":"Kaleido Biosciences Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"KB109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"ARCA Biopharma Announces $9.4 Million Registered Direct Offering","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0.01,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"JMP Securities","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Secures $50 Million Credit Facility","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ JMP Securities","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Live modified horsepox virus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Aduro Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"ImStem Biotechnology","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent for Investigational MSC Candidate IMS001 for COVID-19 and ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IMS001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImStem Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImStem Biotechnology \/ AgeX","highestDevelopmentStatusID":"1","companyTruncated":"ImStem Bio.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Personalis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sarepta Therapeutics \/ Personalis","highestDevelopmentStatusID":"1","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"MigVax","sponsor":"OurCrowd","pharmaFlowCategory":"D","amount":"$100.0 Million","upfrontCash":"Undisclosed","newsHeadline":"OurCrowd Launches $100 Million Pandemic Innovation Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"MigVax-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MigVax","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"MigVax \/ OurCrowd","highestDevelopmentStatusID":"1","companyTruncated":"MigVax \/ O.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Trevena","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Trevena","highestDevelopmentStatusID":"6","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"EpiVax","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc and EpiVax Team up in Development of COVID-19 Emerging Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"OMV-peptide vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ I.."},{"orgOrder":0,"company":"Genor Biopharma","sponsor":"Hillhouse","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hillhouse Leads $160M Round for Chinese Antibody Maker Genor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Genolimzumab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genor Biopharma","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"Genor Biopharma \/ Hillhouse","highestDevelopmentStatusID":"8","companyTruncated":"Genor Biop.."},{"orgOrder":0,"company":"Edith Wolfson Medical Center","sponsor":"Orgenesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis to Collaborate with The Edith Wolfson Medical Center to Conduct Clinical Study Using Orgenesis\u2019 Proprietary POCare Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Tumor infiltrating lymphocytes","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Edith Wolfson Medical Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Edith Wolfson Medical Center \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Edith Wolf.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alvogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroquel\u00ae and Seroquel XR\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Alvogen Korea","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"NodThera","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"NodThera Announces Close of $55 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"NT-0167","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"NodThera","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"NodThera \/ Novo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"NodThera \/.."},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Seroba Life Sciences","pharmaFlowCategory":"D","amount":"$8.3 million","upfrontCash":"Undisclosed","newsHeadline":"Shorla Nabs $8.3M to Bring Improved Cancer Meds to the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"SH-105","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Shorla Oncology","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Shorla Oncology \/ Seroba Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Shorla Onc.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Exeltis Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Distribution Agreement in Key EU Territories for Orphan Drug NaMuscla\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lupin Ltd \/ Exeltis Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"CoV RBD219-N1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Baylor College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Selects AGC Biologics to Manufacture Matrix-M\u2122 Adjuvant for Novel COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M adjuvant","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Katana Pharmaceuticals","sponsor":"March of Dimes","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Katana Pharmaceuticals Gets $1.05 M Grant to Support the Development of a Novel Non-Opioid Treatment for Neonatal Abstinence Syndrome","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Non-opioid drug","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Katana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Katana Pharmaceuticals \/ March of Dimes","highestDevelopmentStatusID":"1","companyTruncated":"Katana Pha.."},{"orgOrder":0,"company":"Mediar Therapeutics","sponsor":"Distributed Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Distributed Bio Partners With Mediar Therapeutics, Inc.","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Neutralizing antibodies","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"Mediar Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mediar Therapeutics \/ Distributed Bio","highestDevelopmentStatusID":"2","companyTruncated":"Mediar The.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Pharmaceuticals Announces Intention to Launch an Initial Public Offering on Euronext Brussels","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Paracetamol","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Aqualung Therapeutics Gets $2.3 M NIH Fast-Track Award To Develop Novel Therapeutic Antibody For Patients With Radiation-Induced Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"ALT-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aqualung Therapeutics \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung T.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"San Diego Top Doctor Collaborates with Therapeutic Solutions International to Report QuadraMune\u2122 Immune Boosting Data in Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Pterostilbene","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Concept Life Sciences","sponsor":"AstronauTx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstronauTx Announces an Alliance With Concept Life Sciences to Accelerate the Identification of Novel Therapies For Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Astrocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Concept Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Concept Life Sciences \/ AstronauTx","highestDevelopmentStatusID":"2","companyTruncated":"Concept Li.."},{"orgOrder":0,"company":"American Porphyria Foundation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"American Porphyria Foundation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Porphyria Foundation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"American P.."},{"orgOrder":0,"company":"Duchenne research","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"$1M Gene Therapy Research Grant Launched by PPMD, Duchenne UK","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Gene therapy","moa":"DMD gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Duchenne research","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Duchenne research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Duchenne r.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Morningside Venture","pharmaFlowCategory":"D","amount":"$62.5 million","upfrontCash":"Undisclosed","newsHeadline":"Prilenia Therapeutics Raises $62.5M to Fund Late Stage Trials In HD and ALS","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Morningside Venture","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"AntiCovir","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Sulopenem","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Athira Pharma Closes $85 Million Series B Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"NDX-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Perceptive Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1\/2 Clinical Trial of INOVIO's INO-4800 in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Seoul National University Hospital \/ INOVIO","highestDevelopmentStatusID":"6","companyTruncated":"Seoul Nati.."},{"orgOrder":0,"company":"Leidos","sponsor":"Targovax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Microbially derived peptides","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Leidos","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leidos \/ Targovax","highestDevelopmentStatusID":"1","companyTruncated":"Leidos \/ T.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"U.S FDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aldeyra Therapeutics Reaches Agreement with the US FDA for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ U.S FDA","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Servier Completes the Acquisition of Symphogen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Symphogen \/ Sevier","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen .."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mereo BioPharma Announces Completion of $70 Million Private Placement and Plans to Develop Etigilimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Private Placement","leadProduct":"Etigilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Janchor Partners","pharmaFlowCategory":"D","amount":"$310.0 million","upfrontCash":"Undisclosed","newsHeadline":"Everest Medicines Completes US$310 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Everest Medicines","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"Intravenous Injection","sponsorNew":"Everest Medicines \/ Janchor Partners","highestDevelopmentStatusID":"1","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"CSL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Queensland \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$270\u202c.0 million","upfrontCash":"$125.0 million","newsHeadline":"UCB Acquires Engage Therapeutics for Staccato\u00ae Alprazolam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Alprazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.27000000000000002,"dosageForm":"Inhalation","sponsorNew":"Engage Therapeutics \/ UCB","highestDevelopmentStatusID":"10","companyTruncated":"Engage The.."},{"orgOrder":0,"company":"VIVEbiotech","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VIVEbiotech Collaborates with Xyphos Biosciences for Clinical Development Support Of Convertible CAR-T\u2122 Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"convertible CAR-T cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"VIVEbiotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VIVEbiotech \/ Xyphos Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"VIVEbiotec.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"Santhera Receives Financing Commitment of up to CHF 20 Million from Fund Managed by Highbridge Capital Management","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Reading Scientific Services","sponsor":"Ethypharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ethypharm and RSSL Fast-Track Medicine for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Fentanyl","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Reading Scientific Services","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reading Scientific Services \/ Ethypharm","highestDevelopmentStatusID":"1","companyTruncated":"Reading Sc.."},{"orgOrder":0,"company":"PolyPeptide Group","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PolyPeptide Group Partners with Novavax on COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"PolyPeptide Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PolyPeptide Group \/ Novavax","highestDevelopmentStatusID":"6","companyTruncated":"PolyPeptid.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Join Hands to Develop Antibody Therapy to Prevent and Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ AbbVie","highestDevelopmentStatusID":"1","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"DLA Piper","pharmaFlowCategory":"D","amount":"$604.0 million","upfrontCash":"Undisclosed","newsHeadline":"DLA Piper Advises Iovance Biotherapeutics in its US$604 million Common Stock Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Lifileucel","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ DLA Piper","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Columbus Venture\nPartners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Artax Biopharma Announces Series B Financing Extension to Advance First-in-Class Autoimmune Disease Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artax Biopharma \/ Columbus Venture\nPartners","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"Espero BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Espero BioPharma, Inc. Expands Collaboration Effort for Tecarfarin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin K","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Espero BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Espero BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Espero Bio.."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"MPM Capital","pharmaFlowCategory":"D","amount":"$98.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cullinan Oncology Completes $98.5 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"VK-2019","moa":"EBNA1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Cullinan Therapeutics \/ MPM Capital","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Novavax","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Gets US Defense Funding For Its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Novavax \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kadmon Raises $50 Million in Gross Proceeds Through Its at-the-Market Facility","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ U.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","amount":"$58.0 million","upfrontCash":"Undisclosed","newsHeadline":"Surgical Infection Biotech PolyPid Refiles for a $58 Million IPO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"MMP-8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Akouos","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hearing loss biotech Akouos files for a $100 million IPO","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"AK-OTOF","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Akouos","amount2":0.10000000000000001,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Akouos \/ BofA Securities","highestDevelopmentStatusID":"5","companyTruncated":"Akouos \/ B.."},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda","pharmaFlowCategory":"D","amount":"$227.0 million","upfrontCash":"$5.0 million","newsHeadline":"LegoChem Biosciences and Iksuda Enter Licensing Agreement for Antibody Drug Conjugate Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"LCB73","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"LegoChem Biosciences","amount2":0.23000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"LegoChem Biosciences \/ Iksuda","highestDevelopmentStatusID":"4","companyTruncated":"LegoChem B.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"National Centre for Research and Development","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"Ryvu Therapeutics to Receive NCRD Grant to Develop Targeted Immuno-Oncology Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"SEL120","moa":"CDK8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ryvu Therapeutics \/ National Centre for Research and Development","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Plexxikon","sponsor":"Novellus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Plixorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plexxikon \/ Novellus","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon .."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$14.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bharat Bio Consortium Gets $14m Grant for Chikungunya Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"BBV87","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bharat Biotech","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bharat Biotech \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Termination","leadProduct":"JTX-8064","moa":"LILRB2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Scandion Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement to Explore Combination Therapies for Chemotherapy and Immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Mitazalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Scandion Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Delos Psyche Research Group","sponsor":"New Wave Holdings Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Wave Holdings Corp Provides Funding for LSD Research Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Delos Psyche Research Group","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Delos Psyche Research Group \/ New Wave Holdings Corp","highestDevelopmentStatusID":"1","companyTruncated":"Delos Psyc.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GCAR Selects DelMar Pharmas' VAL-083 to Participate in GBM AGILE Study In Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Brown University","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Brown University Award of $3.4M includes funds for IND and First Clinical Trial of ONC212","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"ONC212","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Brown University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brown University \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Brown Univ.."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Rottapharm Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.3 million","newsHeadline":"Rottapharm Biotech and Takis Enter an Agreement for the Co-Development of the Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-eVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Takis Biotech \/ Rottapharm Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"GE Healthcare Inc","sponsor":"Entos Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytiva and Entos Pharmaceuticals work together to accelerate development of COVID19 vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Covigenix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GE Healthcare Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GE Healthcare Inc \/ Entos Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"GE Healthc.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$25.0 million","newsHeadline":"Revance and Mylan to Advance Development Program for Biosimilar to BOTOX\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OnabotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revance Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Mylan","highestDevelopmentStatusID":"1","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Begins First Human Tests of an Antibody Drug Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Korea's Celltrion Aims to Start In-Human COVID-19 Drug Trial in July","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 antiviral antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum's Future Looks Uncertain, After Lead Antibiotic Fails Consecutive Pivotal Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulopenem","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Submits NDA to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Plans Covid-19 Clinical Trial Program Launch","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Taltz Outpaces Novartis' Cosentyx with 4th FDA Approval","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe's NSAID Alternative Curbs Arthritis Pain in Phase 2","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minerva Neurosciences\u2019 Roluperidone Fails In Phase III Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Roluperidone","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Minerva Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma to Trial Nafamostat for Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"ChemRar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia Grants Temporary Approval for Avifavir to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ChemRar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ChemRar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ChemRar \/ .."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Announces Positive Results From OCEAN Study Between Melflufen & Pomalidomide In Patients With RRMM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces Results From INSIGHT-004 Phase I study Of EFTI In Combo With Avelumabto Treat Solid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen to Discontinue Phase 3 oGVHD Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RNA Gene Therapy Seen to Effectively Treat Hemophilia A Mouse Model","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FVIII mRNA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Seattle Children\u2019s Research Institute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seattle Children\u2019s Research Institute \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Seattle Ch.."},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivet\u2019s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VTX-803","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Ther.."},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-129","moa":"CFTR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Proteostasis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proteostasis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Proteostas.."},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camurus Announces Submission of Request for Final Approval of Brixadi\u2122 for the Treatment of Opioid Use Disorder in the US","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Initiates Rolling Submission Of New Drug Application For Arimoclomol With FDA in Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Longeveron Mesenchymal Stem Cells","moa":"VEGF","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Announces U.S. Availability of DAYVIGO\u00ae (lemborexant) CIV, a New Treatment Option for Adults With Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemborexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Gets FDA Clearance of IND Application for Phase 1\/2 Triple Combination Study of COM701 with Opdivo and TIGIT Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SYNB1891","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Receives Chinese Regulatory Approval to Begin Seamless Phase 2\/3 Clinical Trial of HBM9161 in Graves\u2019 Ophthalmopathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Gets FDA Acceptance for Filing of an NDA for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Biomarck Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO-11006","moa":"MARCKS protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biomarck Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Biomarck Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomarck P.."},{"orgOrder":0,"company":"Novus Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DPPC","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Novus Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Novus Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novus Ther.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Shionogi\u2019s sNDA with Priority Review for FETROJA\u00ae for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefiderocol","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OpRegen RPE Cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Vault Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus Vaccine Development Underway by Vault Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vault Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vault Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vault Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BRILINTA Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Sapphire Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AXIM\u00ae Biotechnologies Begins Pre-Clinical Pharmacokinetic Animal Drug Studies on its Cancer Drug Compound SPX-1009","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SPX-1009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AXIM Biotechnologies \/ Sapphire Biotech","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biote.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Announces Completion of ReveraGen\u2019s Long-Term Extension Study with Vamorolone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum\u2019s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Gets U.S. FDA Acceptance of Biologics License Application for Danyelza\u2122 in Neuroblastoma for Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Cellenkos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellenkos Gets FDA Clearance to Initiate Phase 1 Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells for COVID-19 Associated ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cord Blood-Derived T-Regulatory Cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellenkos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos .."},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ N.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Launches Clinical Trial of T-COVIDTM, Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"T-COVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology (ASCO) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Nanosuspension for Intravenous Injection","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Remestemcel-L Improves Respiratory and Functional Outcomes in Patients With Inflammatory Lung Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ\u2122 (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Reports Interim Results from Phase 1b\/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EnGeneIC Announces Acceptance of Abstract to the Annual Meeting of the American Society of Clinical Oncology 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"E-EDV-D682","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnGeneIC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnGeneIC \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"EnGeneIC \/.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok\u00ae Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk To Present New Data at the 80th Annual American Diabetes Association Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Phase 3 Data in Atopic Dermatitis and Plaque Psoriasis at the American Academy of Dermatology Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/.."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences Announces Topline Results from Phase 2b Study of Oral JAK\/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gusacitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Announces Topline Results from Pivotal Phase 3 True North Trial Evaluating Zeposia in Patients with Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases Announces First European Launch of Isturisa\u00ae (osilodrostat)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics and NeuroRx Enrolls First Patients with RLF- 100 in Phase 2b\/3 Clinical Trial in Patients with COVID-19 ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Issued European Patent for Method of Treating Alzheimer\u2019s Disease with ANVS401","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Menlo Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menlo Ther.."},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Safety and Efficacy Results from Part I of MATINS Study Presented in Poster at ASCO20 Virtual","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Faron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Phar.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Stem cell gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals Reports Data From and Planned Continuation of the ILLUMINATE-206 Trial for Micro-Satellite Stable Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Present Additional Efficacy Clinical Data From ALICE Phase IIa Trial with Iadademstat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Sarclisa\u00ae (isatuximab) for Adults with Relapsed And Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarclisa Combination Therapy Demonstrated Superior Progression Free Survival and Clinically Meaningful Depth of Response In Relapsed Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Begins Enrollment in Phase 1b\/2a Trial of HST 001 to Treat Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Complexa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Complexa Completes Patient Enrollment in Phase 2 FIRSTx Trial Evaluating CXA-10 in Focal Segmental Glomerulosclerosis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CXA-10","moa":"Nrf2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Complexa","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complexa \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Complexa \/.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 1\/2 Study of HPK1 Inhibitor, CFI-402411","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-402411","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Gets Approval for BRUKINSA in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia and Two more Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Provides Status Update in the Portfolio Projects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"Trophoblast glycoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax\u00ae-L for Glioblastoma Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals Invited to Present Seclidemstat Data at Pediatric Oncology Subcommittee of the FDA Advisory Committee Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Memgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memgen Announces Research to Be Presented at 2020 American Association of Cancer Research (AACR) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MEM-288","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memgen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memgen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Memgen \/ N.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NurOwn","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Alize\u0301 Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alize Pharma 3 Announces Rebranding to Amolyt Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Alize\u0301 Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alize\u0301 Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alize\u0301 Pha.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Jay Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMERI Holdings Amalgamation Partner Jay Pharma Reports IRB Approval For Testing Proprietary CBD Formulation In Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jay Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Jay Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jay Pharma.."},{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kings College London Launches Trial Investigating the Effectiveness of Ibuprofen in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibuprofen","moa":"COX","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Kings College London \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Kings Coll.."},{"orgOrder":0,"company":"RenovoRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RenovoRx Announces Orphan Drug Designation Granted for Treating Bile Duct Cancer with Intra-Arterial Gemcitabine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gemcitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"RenovoRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-arterial","sponsorNew":"RenovoRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RenovoRx \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Presents New Data Across Continuum of Care from its Broad Renal Portfolio at ERA-EDTA 2020 Virtual Congress","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New First-in-Class Phase 3 TREMFYA\u00ae (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 52","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel to Present Four Posters Highlighting IRAK1\/4 Inhibitor at the EULAR 2020 E-Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibafloxacin","moa":"IL-1 receptor-associated Kinase-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Files Pre-CTA Meeting Request with Health Canada and Update on IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follicum Re-Starts phase II Study With FOL-005 for Stimulation of Hair Growth and Expands the Number of Study Centres","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FOL-005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Follicum A.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Publication Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Provides Data Update from MISSION Study of KZR-616","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Shares New Data for Olumiant\u00ae in Rheumatoid Arthritis and Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented on KRYSTEXXA Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Announces Publication of the Phase 1 Clinical Trial Results for ATI-450","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-450","moa":"Mapk2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Hidradenitis Suppurativa and Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Initiates Patient Recruitment for AK002 Registrational Studies","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Presented at EULAR and ERA-EDTA Congresses","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH to Test One-Dose Antibiotic for the Prevention of Maternal and Infant Sepsis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spring Bank Advances IV SB 11285 Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SB 11285","moa":"STING pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Ban.."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinomed Expands into Italy and Broadens its Portfolio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Carrageenan API","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Marinomed Biotech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Throat Sprays","sponsorNew":"Marinomed Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Provides Updates Regarding Phase 2b Study of PTI-125","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune\u2019s Ongoing Registration-Directed Clinical Trials with RP1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RP1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Advancement of Oliceridine Clinical Development in China by Jiangsu Nhwa Pharmaceutical Co.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maverick Therapeutics Announces Pipeline Updates for its Conditionally Active T Cell Engaging COBRA\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick T.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Long-Term Data from RINVOQ Phase 3 Studies in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LSD","moa":"5-HT2B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Announces Positive Data From Clinical Study with ACD856","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Reports Veyonda\u2019s Potential in Late-Stage Cancer at ASCO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Caspase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Presents Preclinical Data on Novel Dual BAFF\/APRIL Inhibitory Domains for B cell Mediated Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-30x","moa":"BAFF","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Concludes Successful Meeting with EMA for Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Memo Therapeutics AG Identifies Potent SARS-CoV-2-Neutralizing Antibodies From the Blood of Recovered COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2-neutralizing antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Memo Thera.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elixirgen Therapeutics Concludes pre-IND Meeting with FDA for its COVID-19 Vaccine Candidate EXG-5003","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elixirgen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Elixirgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elixirgen .."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-601","moa":"MOSPD2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Gets Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b\/3 ANAVEX\u00ae2-73","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BIIB059","moa":"Blood dendritic cell antigen 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Announces Important Updates on AAVance Phase 2\/3 Clinical Trial with LYS-SAF302 in MPS IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Olenasufligene Relduparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento COVIDTRAP\u2122(STI-4398) Demonstrates in Preclinical Studies its Ability to Completely Inhibit SARS-CoV-2 Viral Infection In Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-4398","moa":"Spike protein S1 domain","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair\u00ae Breezhaler\u00ae (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Imipenem","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Publication of Results From Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViralClear adds St. David's HealthCare in Austin to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CD45-ADC","moa":"CD45","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Vericiguat for Marketing Authorization in the EU and Japan for the Treatment Of Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Adamas Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamas Announces FDA Filing Acceptance of sNDA to Modify Indication Statement for Gocovri","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amantadine Hydrochloride","moa":"MMP-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Adamas Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Adamas Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamas Pha.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts PharmaEssentia\u2019s Application for Ropeginterferon Alfa-2b to Treat Polythycemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"IFNAR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"PharmaEssentia \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Phase IIb\/III Study in Parkinson's disease to Target Good ON","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Shares Breadth of Innovative New Data from Rheumatology Portfolio for EULAR 2020 E-Congress","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Submission to Expand Clinical Sites in European AML Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Reports Weight Loss of 14.9% (16.9% if taken as intended) in STEP 1 trial","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Polyneuron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polyneuron\u2019s PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PN-1007","moa":"IgM","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Polyneuron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Polyneuron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Polyneuron.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-810","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces Publications in Peer-Reviewed Journals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta to Share Clinical Update from SRP-9003 Gene Therapy Trial for Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SRP-9003","moa":"Gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Initiates Phase II clinical Trial on AQCH, A Phytopharmaceutical Drug, As Potential Treatment for COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aqueous extract of Cocculus Hirsutus","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO\u00ae (lanadelumab) in Reducing Hereditary Angioedema Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Hosts Virtual R&D Event Providing Updates on Clinical Programmes in Oncology and COVID-19","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FOIPAN\u00ae Tablets, a Protease Enzyme Inhibitor, ONO Has Started Clinical Studies for Novel Coronavirus Infection (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Camostat","moa":"Proteinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine Trial Data Being Presented at Virtual EHA Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex\u2019s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-0159","moa":"Tyrosine kinase KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"AiCuris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiCuris Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir to Treat HSV Infections in Immunocompromised Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pritelivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AiCuris","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiCuris \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AiCuris \/ .."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Bukwang Pharmaceutical Co., Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leukavir, an Antiviral Agent for Bukwang Pharm, Confirmed the Effect on New Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Clevudine","moa":"Protein P","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bukwang Pharmaceutical Co., Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bukwang Pharmaceutical Co., Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bukwang Ph.."},{"orgOrder":0,"company":"University Hospitals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UH to Launch Clinical Trial in the Fight to Protect Clinicians Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetylpyridinium Chloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University Hospitals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University Hospitals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Beech Tree Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beech Tree Labs is Developing a Potential Antiviral Therapy to Fight COVID-19 Pandemic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Thimerosal","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Beech Tree Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Sublingual Drop","sponsorNew":"Beech Tree Labs \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Beech Tree.."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eleva's Drug Candidate to Be Examined for Use in COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant factor H","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Receives U.S. FDA Approval to Design a Phase 2a Clinical Trial To Treat Patients With Suspected or Confirmed Covid-19 Diagnosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Pharmaceuticals Announces that the US FDA Grants Rare Pediatric Disease Designation to 67Cu-SARTATE to Treat Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"67Cu-SARTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"Virginia Tech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virginia Tech Drug Researcher Develops \u2018Fat Burning\u2019 Molecule That has Implications for Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BAM 15","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Virginia Tech","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virginia Tech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virginia T.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"SanBio","sponsor":"Ocumension","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"$6.0 million","newsHeadline":"Sanbio and Ocumension Ink Pact For Research, Development of Innovative Stem Cell Therapies for Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Agreement","leadProduct":"SB623","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"SanBio","amount2":0.070000000000000007,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"SanBio \/ Ocumension","highestDevelopmentStatusID":"4","companyTruncated":"SanBio \/ O.."},{"orgOrder":0,"company":"Promedior","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"$390.0 million","newsHeadline":"Promedior Announces Completion of Acquisition by Roche","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"PRM-151","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Promedior","amount2":1.3999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Promedior \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Promedior .."},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Avion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmuPharma provides an update on the Avion Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Agreement","leadProduct":"Rigerimod","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"ImmuPharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ImmuPharma \/ Avion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"ImmuPharma.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Duchenne UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catabasis Pharmaceuticals \/ Duchenne UK","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Oppenheimer & Co.","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Public Offering","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"Catabasis Pharmaceuticals \/ Oppenheimer & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lyra Therapeutics Completes $30 Million Series C Financing","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Series C Financing","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Achillion","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$930.0 million","upfrontCash":"$930.0 million","newsHeadline":"Alexion Completes Acquisition of Achillion","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Danicopan","moa":"Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Achillion","amount2":0.93000000000000005,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.93000000000000005,"dosageForm":"Oral","sponsorNew":"Achillion \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Achillion .."},{"orgOrder":0,"company":"Histogen","sponsor":"Conatus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$135.1 million","upfrontCash":"Undisclosed","newsHeadline":"Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Histogen","amount2":0.14000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Conatus Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Quench Bio","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Quench Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Quench Bio \/ RA Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Quench Bio.."},{"orgOrder":0,"company":"Genentech","sponsor":"Ningbo NewBay Medical Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ningbo NewBay Medical Technology Co., Ltd. Announces a License Agreement with Genentech","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GDC-0570","moa":"Pan-PIM","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Ningbo NewBay Medical Technology","highestDevelopmentStatusID":"4","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Transcell Oncologics","sponsor":"L2P Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"L2P Research (Former AJES Life Sciences, LLC) and Transcell Oncologics, LLC Announce Partnership to Provide High Quality Hu-CB-CD34 and Hu-PBMC to Generate Humanized Mouse Models for Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Trans HSC (CD34+)","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Transcell Oncologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcell Oncologics \/ L2P Research","highestDevelopmentStatusID":"4","companyTruncated":"Transcell .."},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"SK Holdings, Heritas Capital, SEEDS Enterprise","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Closes Extended Series B Funding Round of $25M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series B Financing","leadProduct":"HMBD-001","moa":"HER3 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hummingbird Bioscience","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Hummingbird Bioscience \/ SK Holdings, Heritas Capital, SEEDS Enterprise","highestDevelopmentStatusID":"4","companyTruncated":"Hummingbir.."},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TWiB Receives Canada Health Approval for AC-1101 Phase 1 CTA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TWi Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotec.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Citigroup Global Markets","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sweden's Calliditas Seeks $75M IPO Haul to Bring Its Oral Steroid to Patients with an Orphan Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.080000000000000002,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0.080000000000000002,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Citigroup Global Markets","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Calliditas Therapeutics Prices its Initial Public Offering on The Nasdaq Global Select Market in the United States","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.089999999999999997,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0.089999999999999997,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Provides a Corporate Business Update in the Context of the COVID-19 Pandemic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Forge Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$190.5 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec partner Forge enters into collaboration with Roche to develop novel antibiotic","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Antibiotics","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Forge Therapeutics, Inc","amount2":0.19,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.19,"dosageForm":"","sponsorNew":"Forge Therapeutics, Inc \/ Roche","highestDevelopmentStatusID":"4","companyTruncated":"Forge Ther.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$882.0 million","upfrontCash":"$44.0 million","newsHeadline":"Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Protein therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Evox Therapeutics","amount2":0.88,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.88,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Takeda","highestDevelopmentStatusID":"4","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"$0.4 million","newsHeadline":"Propanc Biopharma Enters Into a $3 Million Financing with Institutional Investor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Financing","leadProduct":"Trypsinogen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Propanc Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Propanc Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Propanc Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford\u2019s Potential New Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Proteona","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Neutralizing antibody therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Proteona","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi To Present Oncology Strategy, Provide Update On Portfolio And Emerging Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ofranergene obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NKTR-358","moa":"IL-2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-3745","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"NKMax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKMax America Receives FDA Clearance of IND for Phase I\/2a Trial of SNK01 in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced\/Metastatic HER2- or EGFR- Expressing Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SNK01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NKMax \/ No.."},{"orgOrder":0,"company":"iBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iBio Announces Second COVID-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IBIO-201","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"iBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"iBio \/ Not.."},{"orgOrder":0,"company":"Rigenerand","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigenerand Receives Regulatory Approval for Gene Therapy Production","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RR001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rigenerand","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rigenerand \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rigenerand.."},{"orgOrder":0,"company":"Baylx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BAYLX,INC. Received US FDA Clearance of IND Application for Cord Tissue Mesenchymal Stem Cells","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BX-U001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Baylx","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ No.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Receives Positive CHMP Opinion for Janssen\u2019s Investigational Preventive Ebola Vaccine Regimen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.ZEBOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Doses First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JS016","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's RINVOQ Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA in RA Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Anvisa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anvisa Publishes Clinical Study Of Potential Vaccine Against Covid-19 Authorized","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"BRAZIL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anvisa","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anvisa \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anvisa \/ N.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Showcases Positive 1-Year Data and Budget Impact Analysis for Novel Subcutaneous Formulation of Infliximab for RA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Follica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follica Announces Positive Feedback From End of Phase 2 Meeting With FDA for Its Lead Program to Treat Male Androgenetic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Follica","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Follica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Follica \/ .."},{"orgOrder":0,"company":"Dimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Remap-Cap Platform Trial Protocol to Include Dmx-200 in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DMX-200","moa":"CCR2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Dimerix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dimerix \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Dimerix \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Preliminary Results of the Anti-PD-1\/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI318","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Devotes New York Facility To COVID-19 Cocktail Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Bionomics","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bionomics Announces Financing Led by Apeiron Investment Group Ltd","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"BNC210","moa":"nAChR Alpha7","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionomics","amount2":0.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Liquid Suspension","sponsorNew":"Bionomics \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Bionomics .."},{"orgOrder":0,"company":"Inventage Lab","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Partners with Inventage to Expand Long-Acting Injection Biz","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"Leuprolide Acetate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Inventage Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inventage Lab \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Inventage .."},{"orgOrder":0,"company":"Octapharma","sponsor":"University of California San Diego School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Octapharma USA Extends Funding for COVID-19 Study Following Positive Preliminary Research Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ University of California San Diego School of Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Introduces GEN-011, a Transformational T cell Therapy Designed to Improve on Current Limitations of TIL Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI310","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Receives Marketing Authorization for Lyfaquin\u2122 (centhaquine) from Indian Regulatory Agency","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology to Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Futibatinib","moa":"FGFR1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"HSBC","pharmaFlowCategory":"D","amount":"$11.1 million","upfrontCash":"Undisclosed","newsHeadline":"Nanobiotix Secures \u20ac10M in Non-Dilutive Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Nanobiotix","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ HSBC","highestDevelopmentStatusID":"9","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Microbiotica","sponsor":"Cancer Research UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Ipilimumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Microbiotica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microbiotica \/ Cancer Research UK","highestDevelopmentStatusID":"1","companyTruncated":"Microbioti.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Vaccines Manufacturing and Innovation Centre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Vaccines Manufacturing and Innovation Centre","highestDevelopmentStatusID":"9","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"HitGen","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Evotec SE Enter Into Drug Discovery Research Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Evotec SE","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ E.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$46.7 million","upfrontCash":"Undisclosed","newsHeadline":"Kezar Announces Pricing of a Public Offering of $46.7 Million of Common Stock and Pre-Funded Warrants","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$75.8 million","upfrontCash":"Undisclosed","newsHeadline":"Cognition Therapeutics Gets $75.8 M NIA Grant for Phase 2 Study of CT1812 in Collaboration with the Alzheimer\u2019s Clinical Trials Consortium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"CT1812","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Returns Rights to Gene Therapies to Oxford Biomedica","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SAR422459","moa":"ABCR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"AiCuris","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"$220.0 million","newsHeadline":"Royalty Pharma Acquires Partial Royalty Interest On Prevymis\u2122 (Letermovir) From Aicuris Anti-Infective Cures Gmbh","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Letermovir","moa":"DNA terminase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"AiCuris","amount2":0.22,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"","sponsorNew":"AiCuris \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"AiCuris \/ .."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Docetaxel","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Vitaeris","sponsor":"CSL","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Behring to Acquire Biotech Company Vitaeris","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Clazakizumab","moa":"IL-6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Vitaeris","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vitaeris \/ CSL","highestDevelopmentStatusID":"10","companyTruncated":"Vitaeris \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"The University of Tokyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The University of Tokyo, RIKEN, Nichi-Iko & Daiichi Sankyo Ink Collaborative R&D on Nafamostat Inhalation Formulation to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ The University of Tokyo","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Aerami","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Signs Agreement with Aerami Therapeutics Inc","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Imatinib Mesylate","moa":"PTK","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Aerami","highestDevelopmentStatusID":"5","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,230\u202c.0 million","upfrontCash":"$20.0 million","newsHeadline":"Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"RNA interference","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":1.23,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.23,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"A2A Pharmaceuticals Collaborates With LAXAI Life Sciences to Co-develop SARS-CoV-2 Main Proteases Inhibitors for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"LAXAI Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LAXAI Life Sciences \/ Laxai Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"LAXAI Life.."},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"EMD Serono","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prime Therapeutics and EMD Serono Ink Value-Based Agreement on MAVENCLAD\u00ae (Cladribine) Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Cladribine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Prime Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prime Therapeutics \/ EMD Serono","highestDevelopmentStatusID":"12","companyTruncated":"Prime Ther.."},{"orgOrder":0,"company":"University of Massachusetts Medical School","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CANbridge Pharmaceuticals Enters Into Rare Disease Gene Therapy Research Agreement With UMass Medical School","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Massachusetts Medical School","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Massachusetts Medical School \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"ABX-002","moa":"TR-Beta","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Autobahn Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Autobahn Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Autobahn T.."},{"orgOrder":0,"company":"IGY Life Sciences","sponsor":"MMS Holdings","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IGY Life Sciences Partners with MMS Holdings to Develop Novel COVID-19 Antibody Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"IgY-110","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IGY Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"IGY Life Sciences \/ MMS Holdings","highestDevelopmentStatusID":"4","companyTruncated":"IGY Life S.."},{"orgOrder":0,"company":"Staidson Biopharma","sponsor":"Pivotal","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Staidson and Pivotal are Collaborating in the Conduct of a Clinical Trial in Europe in Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"BDB-001","moa":"C5a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Staidson Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Staidson Biopharma \/ Pivotal","highestDevelopmentStatusID":"8","companyTruncated":"Staidson B.."},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"SAKK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Docetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oasmia Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ SAKK","highestDevelopmentStatusID":"6","companyTruncated":"Oasmia Pha.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$308.0 million","upfrontCash":"$130.0 million","newsHeadline":"Valneva Announces HSR Clearance for Lyme Vaccine Collaboration with Pfizer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.31,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Sass & Larsen ApS","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture Acquires Full Control of Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Dovitinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Oncology Venture","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Oncology Venture \/ Sass & Larsen ApS","highestDevelopmentStatusID":"10","companyTruncated":"Oncology V.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Phase 2 Clinical Trial of LSD for \"Suicide Headaches\" Begins Treating Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"Serotonergic","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Supernus Completes Acquisition of CNS Portfolio from US WorldMeds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"US WorldMeds","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"US WorldMeds \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"US WorldMe.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bioiberica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strategic Distribution Between Bayer Animal Health and Bioiberica in the International Companion Animal Health Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Chondroitin Sulfate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Bioiberica","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Ceek Womens Health","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Marketing Agreement With Ceek for Women's Health Products to Improve OB\/GYN and Patient Exam Experience","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Ceek Womens Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ceek Womens Health \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Ceek Women.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Lyvgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lyvgen Announces Clinical Trial Collaboration With MSD","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"LVGN6051","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Lyvgen","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar\u00ae for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Triptorelin Pamoate","moa":"GnRH analog","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Debiopharm \/ Verity Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"UbiVac","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UbiVac Announces Clinical Trial Collaboration with Bristol Myers Squibb on Combination Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"BMS-986178","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"UbiVac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UbiVac \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"UbiVac \/ B.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"$10.0 million","newsHeadline":"Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"IBAT","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Albireo Pharma","amount2":0.11,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antibe Therapeutics Announces $25 Million Bought Deal Unit Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Otenaproxesul","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"8","companyTruncated":"Antibe The.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkmate Pharmaceuticals Secures $85 Million in Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"Vidutolimod","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Checkmate Pharmaceuticals","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Checkmate Pharmaceuticals \/ Longitude Capital","highestDevelopmentStatusID":"6","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"Neurotrope","sponsor":"BryoLogyx Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Neurotrope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ BryoLogyx","highestDevelopmentStatusID":"5","companyTruncated":"Neurotrope.."},{"orgOrder":0,"company":"NeuroPharma","sponsor":"Mydecine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group to Acquire NeuroPharm Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"NeuroPharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeuroPharma \/ Mydecine","highestDevelopmentStatusID":"1","companyTruncated":"NeuroPharm.."},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Refana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panacea Biotech to Partner with US Firm Refana for COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panacea Biotec Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panacea Biotec Limited \/ Refana","highestDevelopmentStatusID":"4","companyTruncated":"Panacea Bi.."},{"orgOrder":0,"company":"Adgero Biopharmaceuticals","sponsor":"Minakem (formerly Delmar Chemicals)","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adgero Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adgero Biopharmaceuticals \/ DelMar","highestDevelopmentStatusID":"8","companyTruncated":"Adgero Bio.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmabcine Execute an Agreement with Thermo Fisher for the Development and Manufacturing Of Pmc-309","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"PMC-309","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ PharmAbcine","highestDevelopmentStatusID":"4","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Institut Pasteur Shanghai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alphamab Oncology \/ Institut Pasteur Shanghai","highestDevelopmentStatusID":"1","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$677.0 million","upfrontCash":"$677.0 million","newsHeadline":"Menarini Group Completes Acquisition of Stemline Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"EEF2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.68000000000000005,"dosageForm":"","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"12","companyTruncated":"Stemline T.."},{"orgOrder":0,"company":"Tanabe Research Laboratories","sponsor":"Adagene Suzhou Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adagene Announces Strategic Collaboration Agreement with Tanabe Research Laboratories","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Masked antibody drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tanabe Research Laboratories","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tanabe Research Laboratories \/ Adagene","highestDevelopmentStatusID":"1","companyTruncated":"Tanabe Res.."},{"orgOrder":0,"company":"Greene Street Pharmaceuticals","sponsor":"VerdePharmHealth","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VerdePharmHealth Signs Exclusive Partnership Agreement with Greene Street Pharmaceuticals for Cannabidiol Transdermal Patch","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Greene Street Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Greene Street Pharmaceuticals \/ VerdePharmHealth","highestDevelopmentStatusID":"4","companyTruncated":"Greene Str.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$25.0 Million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"CR-CP Life Science Fund","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"JW Therapeutics, Today Announced the Completion of a US$100 Million Series B Round Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"JWCAR029","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"JW Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"JW Therapeutics \/ CR-CP Life Science Fund","highestDevelopmentStatusID":"8","companyTruncated":"JW Therape.."},{"orgOrder":0,"company":"Corvidia Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"$725.0 million","newsHeadline":"Novo Nordisk to Acquire Corvidia Therapeutics to Expand Cardiovascular Presence","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Ziltivekimab","moa":"IL-6","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Corvidia Therapeutics","amount2":2.1000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"Corvidia Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Corvidia T.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"University of Louisville","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville to Develop AS1411 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qualigen Therapeutics \/ University of Louisville","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institute of Health","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chrysalis BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chrysalis BioTherapeutics \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"Chrysalis .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Institut of Butantan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Inactivated vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Institut of Butantan","highestDevelopmentStatusID":"4","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Collaborations on Dupixent\u00ae (dupilumab) Highlighted During Sanofi R&D Investor Event","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Egle Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Tumor-infiltrating Treg","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Egle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Egle Therapeutics \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Egle Thera.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Pharma Updates Shareholders on its Proposed Acquisition of Altum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"AntiCovir","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$87.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca ties up with Emergent BioSolutions to Make COVID-19 Vaccine in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Emergent BioSolutions","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Anthos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza Partners with Anthos Therapeutics for Thrombosis Treatment","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Factor XI","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene-editing therapies","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Verve Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Verve Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"4","companyTruncated":"Verve Ther.."},{"orgOrder":0,"company":"Stanford University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Acquires Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumes License of TNX-1900","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Oxytocin","moa":"CGRP","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Stanford University \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Stanford U.."},{"orgOrder":0,"company":"Intas Pharmaceuticals","sponsor":"Naari","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Naari Completes Acquisition of ANDAs from Intas Pharmaceuticals","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Intas Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intas Pharmaceuticals \/ Naari","highestDevelopmentStatusID":"12","companyTruncated":"Intas Phar.."},{"orgOrder":0,"company":"City of Hope","sponsor":"Scopus BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scopus BioPharma Licenses Novel Immuno-Oncology Gene Therapy Drug from City of Hope, a Cancer Center in Los Angeles, California","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CpG-STAT3siRNA","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Scopus BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"U.S. Regional Biocontainment Laboratory","sponsor":"Innovation Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Innovation Pharma Collaborating with Regional Biocontainment Lab on Grant Application to Study Brilacidin as Pan-Coronavirus Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"U.S. Regional Biocontainment Laboratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"U.S. Regional Biocontainment Laboratory \/ Innovation Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"U.S. Regio.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Spirig Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Signs LSA for Commercialization of Tibelia\u00ae in Liechtenstein and Switzerland","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tibolone","moa":"Sulphatase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mithra Pharmaceuticals \/ Spirig Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"LSP","pharmaFlowCategory":"D","amount":"$38.1 million","upfrontCash":"Undisclosed","newsHeadline":"eTheRNA Nabs \u20ac34M For mRNA Vaccine Including COVID-19 Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"SARS-CoV-2 mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"eTheRNA immunotherapies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"eTheRNA immunotherapies \/ LSP","highestDevelopmentStatusID":"1","companyTruncated":"eTheRNA im.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$118.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shattuck Labs Announces Closing of $118 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"SL-172154","moa":"CD47\/SIRPalpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Shattuck Labs \/ Redmile Group","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Forte Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Forte Biosciences, Inc. Announces Closing of Merger With Tocagen","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Tocagen","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"$278.0 million","upfrontCash":"$266.0 million","newsHeadline":"Takeda to Divest Select APAC Assets to Celltrion for $278M","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Celltrion","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Mapi Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mapi Pharma, Mylan Expand MS Alliance","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Glatiramer Acetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mapi Pharma","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Intramuscular Injection","sponsorNew":"Mapi Pharma \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Mapi Pharm.."},{"orgOrder":0,"company":"Schreiner MediPharm","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teva Partners with Schreiner MediPharm for Novel Adrenaline Injector Label","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Schreiner MediPharm","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Prefilled Syringe for Injection","sponsorNew":"Schreiner MediPharm \/ TEVA","highestDevelopmentStatusID":"12","companyTruncated":"Schreiner .."},{"orgOrder":0,"company":"Atum Bio","sponsor":"Phylex BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATUM and Phylex BioSciences Collaborate to Accelerate the Development of a Universal SARS Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"VLP based coronavirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Atum Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atum Bio \/ Phylex BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Atum Bio \/.."},{"orgOrder":0,"company":"Vernalis","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Vernalis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vernalis \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Vernalis \/.."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$130.4 million","upfrontCash":"Undisclosed","newsHeadline":"Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"CDX-3379","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"Celldex Therapeutics \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","amount":"$71.1 million","upfrontCash":"Undisclosed","newsHeadline":"Vedanta Biosciences Announces Series C Financing and Data from Two Phase 1 Studies of VE202","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"VE202","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ JSR","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"Champignon","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Champignon Identifies Synthetic Ketamine and Psilocybin\/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dalriada Drug Discovery","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dalriada Drug Discovery \/ Champignon","highestDevelopmentStatusID":"4","companyTruncated":"Dalriada D.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"academia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advancing our Discovery of Novel Coronavirus-Neutralising Antibodies Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ academia","highestDevelopmentStatusID":"4","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Autotelic BIO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon Announces Achievement of Milestone Under Licensing of OT-101\/IL-2 Combination to Autotelic BIO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Autotelic BIO","highestDevelopmentStatusID":"4","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Spanish Ministry of Science and Innovation","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"ORYZON Initiates a New Project to Explore the Efficacy of Vafidemstat in the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Vafidemstat","moa":"LSD1A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Spanish Ministry of Science and Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ JPEO-CBRND","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Magenta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Magenta's Technology Attracts Another Gene Therapy Developer Beam Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"MGTA-117","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Beam Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beam Therapeutics \/ Magenta Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Beam Thera.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted at ENDO 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IDE397","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Leap Healthcare Collaborative Announces the Selection of Sanofi's SAR439859 as the oral SERD Backbone Agent in the Endocrine Optimization Pilot Study of the I-SPY 2 TRIAL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ' Calquence Showed Promising Clinical Improvement in Majority of Hospitalised COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine from China's Sinopharm Clears Animal Tests","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BBIBP-CorV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JS016","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Serums to assess sepsis drug Ulinastatin for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Urinastatin","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Serums & Vaccines ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Ser.."},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Positive Preliminary Preclinical Data From Its Otoferlin Gene Therapy Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OTOF-GT","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Sensorion","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sensorion \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sensorion .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex to Present at the MoneyShow June Virtual Event","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Oncoprex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"NaV Channel","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology Conditions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"13-cis-RAMBA Retinamides","moa":"MNK1\/2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Brensocatib","moa":"DPP-1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces \u201cAtuzaginstat\u201d Selected as First-in-Class Nonproprietary Name for COR388","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Completes Patient Enrollment for Long-Term Safety Study of Tapinarof in Adult Patients with Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlgoTherapeutix Announces Orphan Drug Designation Granted by FDA for ATX01 in Erythromelalgia","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amitriptyline","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AlgoTherapeutix","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"AlgoTherapeutix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlgoTherap.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Announces Plans to Seek Expanded Labeling for Oxbryta\u00ae (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ardelyx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Announces a Phase 2 Study Result of tenapanor (KHK7791) for Hemodialysis Patients with Hyperphosphatemia in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Kirin \/ Ardelyx","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) Multiple-Dose Vial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma's Rivastigmine Transdermal Patch Receives Market Approval in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivastigmine","moa":"AChE\/BChE","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Peg L asparaginase","moa":"Amino acid metabolism","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Erytech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Erytech Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Erytech Ph.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Receives Positive Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"Serotonin transporter","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno's Drug Misses Key Goal in Prader-Willi Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Participation in ENDO Online 2020","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Completes Enrollment of Low-Dose Cohort in Phase 1\/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I Patients with GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-AAV-GM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CASI Pharmaceuticals Announces Submission of Clinical Trial Application to Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CID-103","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CASI Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharm.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Announces Dosing of First Patient in Phase 1\/2a Clinical Trial of PBCAR269A for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Announces FDA Clearance of Investigational New Drug (IND) Application for PTX-35","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTX-35","moa":"TNFRSF25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Provides Clinical Update of its Phase 1 Trial of ALPN-101 in Healthy Volunteers at the EULAR E-Congress 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-101","moa":"CD28\/ICOS","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ENOB-HV-01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enochian BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enochian BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enochian B.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Present Data on AT-001 for the Treatment of Diabetic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Grapiprant","moa":"Aldose reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Provides Corporate Update and Unveils New Preclinical Allogeneic NK Cell Therapy Pipeline Candidates at BIO Digital 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironshore to Present a Dose Conversion Poster at the 2020 American Society of Clinical Psychopharmacology Virtual Scientific Poster Session","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Ironshore Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Ironshore Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ironshore .."},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Virtual Presentation of Phase 1\/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sepofarsen","moa":"CEP290","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"ProQR Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ProQR Ther.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dalcinonacog alfa","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gaboxadol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Starts Enrolment in Pamrevlumab Trial for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamrevlumab","moa":"CTGF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Finds Niclosamide Effective Against Covid-19 in Animal Tests","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Proglumide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis and FDA QIDP Designation for Multiple Fungal Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Olorofim","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Subsidiary Orpheris Announces Completion of Phase 1 Study of OP-101 Subcutaneous Formulation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OP-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BT051","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Bacainn Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bacainn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bacainn Th.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Announces Issuance of U.S. Patent for Bifunctional Molecules Derived from TALON\u2122 Platform","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PT101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-CLEC-1 monoclonal antibody","moa":"CLEC-1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK begins US test of experimental drug for pneumonia caused by COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Otilimab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Phase I Clinical Data for Investigational Agent FT-4202 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-4202","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"NanOlogy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac\u00ae in Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NanOlogy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Powder for Suspension","sponsorNew":"NanOlogy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NanOlogy \/.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMG 510","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Amgen","highestDevelopmentStatusID":"7","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces Dosing of First Patient in a Phase 1\/2 Study of Selinexor in Combination with Standard of Care Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health Announces Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody\u2122 ISAC Technology and its Lead Development Candidate, BDC-1001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BDC-1001","moa":"TLR7\/8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic Gets FDA Clearance for CALVID-1 Trial in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring\u2019s PROTECTIVE-2 Phase 2 Trial for Chemotherapy-Induced Neutropenia Shows Positive Results in Chemotherapy Optimization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arecor announces oral presentation of the first phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ N.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rucaparib Camsylate","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson to Begin Human Trials for Coronavirus Vaccine in Late July, Earlier than Expected","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Announces Data on Different Dosing Regimens of Ferric Citrate for Iron Deficiency Anemia Presented","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CI-8993","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2\/3 Study with Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DMT310","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"Dermata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Th.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Receives Rare Pediatric Disease Designation for RZ358","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Linnaeus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"University of Florida","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UF Health researchers developing COVID-19 vaccine using gene therapy technique","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Florida","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Florida \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Tychan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Temasek-backed Tychan to Start Human Trials Next Week for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TY027","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tychan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tychan \/ N.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science to Present Results from AB8939 Preclinical Program in Acute Myeloid Leukemia at EHA 2020 Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AB8939","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform and Bifunctional Therapy Targeting PD-1 and IL-7 For Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BiCKI-IL-7","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Opdivo for the Treatment of Patients with Advanced ESCC After Prior Fluoropyrimidine- and Platinum-based Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Risperidone","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra The.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Disease Activity in Phase 2a Study of Patients with Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ABBV-3373","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Pharnext","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharnext Provides Regulatory and Clinical Update on PXT3003 Phase III Study for the Treatment of Charcot-Marie-Tooth Type 1A","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Marzeptacog alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca to Showcase Leadership in Treating Type 2 Diabetes and Cardiorenal Complications at ADA 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two Science Publications Highlight Potential of REGN-COV2 Anti-Viral Antibody Cocktail to Protect Against SARS-CoV-2 Escape Mutants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Initiate CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols Starts Production of its Hyperimmune Immunoglobulin as a Potential Passive Immune Therapy Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-SARS-CoV-2 hyperimmune globulin therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Launches Trials of COVID-19 Antibody \u201cCocktail\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Pfizer\u2019s Oncology Supportive Care Biosimilar, NYVEPRIA\u2122 (pegfilgrastim-apgf)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Starts Clinical Trial Evaluating Leukine\u00ae in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sargramostim","moa":"GM-CSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces European Medicines Agency Acceptance of Marketing Authorization Application for tralokinumab to Treat Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Real-World Data of Terlipressin in Hospitalized Patients in U.K. with Hepatorenal Syndrome Type 1 (HRS-1) Published in Alimentary Pharmacology and Therapeutics","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Starts Large-Scale Trial of Tirzepatide In Diabetic Heart Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World's First iLDC Enabling ADC Drug Receives IND Clearance by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GQ1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantu.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVM Biotechnology Awarded SBIR Phase I Grant from National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oblique Therapeutics AB has Identified a Potentially Important Epitope for Generation of SARS-CoV-2 antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oblique Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Th.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Provides Update on Preliminary Data for Bomedemstat at the 2020 Virtual EHA Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Reports Data from Pivotal Phase 2 Clinical Trial and Phase 1\/2 Combination Clinical Trial of Loncastuximab Tesirine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomic Therapeutics to Present at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ITI-3000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent \u03b1- and \u03b2-Thalassemia in Phase 2 Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitapivat","moa":"PKR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Constellation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelabresib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Constellation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Constellation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constellat.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Pivotal Data Demonstrate Superiority of Apellis\u2019 Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO1","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Presents Updated Data on Novel CD20xCD3 Bispecific Cancer Immunotherapy Glofitamab In Heavily Pre-Treated Non-Hodgkin Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Glofitamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Decision to Develop Vaccine in Japan for Novel Corona Virus Infection (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukaemia in Two Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"KTX-201","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech files provisional patent application for Ampligen as treatment for COVID-19 induced fatigue","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-H201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antisense Therapeutics Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATL1102","moa":"CD49d","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense .."},{"orgOrder":0,"company":"BioVie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVie Advances the BIV201 Clinical Program and Prefilled Syringe","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Continuous Infusion","sponsorNew":"BioVie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ N.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s ML Bio Solutions Dosed First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribitol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b\/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Trial for Paltusotine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a\/1b Study of TSC in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Presents New Late-Breaking Data Showing SKYRIZI Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX\u00ae at 52 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Risankizumab-rzaa","moa":"IL-23 alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara\u00ae at Week 16 in Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly and Dermira Present New Positive Lebrikizumab Phase 2b Clinical Data","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Dermira","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"ZZ Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZZ Biotech Announces FDA Fast Track Designation for Stroke Program","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"3K3A-APC","moa":"Tissue plasminogen","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ZZ Biotech","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ZZ Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ZZ Biotech.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for Potential Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-301","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Presents Early Phase 1a\/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Presents Results From French Phase Ib\/II Clinical Trial of APR-246 and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO in Multiple Myeloma as a First-Line Maintenance Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixazomib Citrate","moa":"Proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TG-1701","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvocidib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defects","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Announces Results from 2 New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum Contagiosum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AU-011","moa":"HSPGs","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aura Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Aura Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aura Biosc.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Betibeglogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Clinical and Preclinical Data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SRK-015","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TJ-CD4B","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Reports Findings From Janssen's Phase 3 Andromeda Study Evaluating Daratumumab Utilizing ENHANZE In Light-Chain Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VENCLEXTA\u00ae\/VENCLYXTO Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Na\u00efve Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"Bcl-2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AHS Posters for Lundbeck\u2019s VYEPTI in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"University of Sydney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australian Clot-Busting Drug Holds Hope for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-clotting drug","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Sydney","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Sydney \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib in Combination With Keytruda\u00ae in NSCLC Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"Tyrosine-protein kinase receptor UFO","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Investigational, Once-Weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-Daily Insulin Glargine U100 In Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Presents Clinical and Non-Clinical Evidence for Dasiglucagon Rescue Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MK-7110","moa":"TLR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Presents Data on Simplici-T1 Study Supporting the Role of TTP399 as an Oral Adjunctive Therapy for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Solasia Pharma KK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Darinaparsin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Solasia Pharma KK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Solasia Pharma KK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Solasia Ph.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio to Announce Zimura\u00ae 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Momenta Clears a PhII Hurdle on Nipo But One Big Rival Remains Well in the Lead in this Packed Field","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA approves ViiV Healthcare\u2019s Tivicay to treat HIV in children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Four Patients Given Higher AXO-Lenti-PD Dose in Gene Therapy Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dapagliflozin May Help Reduce Onset of Type 2 Diabetes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"Insulin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Domp\u00e9 Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ladarixin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farm.."},{"orgOrder":0,"company":"Cirius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented at the 2020 ADA Scientific Sessions Show that Patients Treated with Cirius Therapeutics' MSDC-0602K Improved Insulin Handling","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MSDC-0602K","moa":"Mitochondrial pyruvate carrier","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Cirius Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cirius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cirius The.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 AHS Virtual Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Emerging Oncology Pipeline Highlighted at the AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Amcenestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt to Present Phase 3 StrataGraft\u00ae Regenerative Skin Tissue Clinical Trial Results","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"StrataGraft skin tissue","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Completion of Enrollment in the PEGASUS Trial of AMX0035 in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Present Results from Head-to-Head PK Comparison Study of Jivi\u00ae Vs Adynovate\u00ae in Late-Breaker Presentation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Antihemophilic factor recombinant PEGylated-aucl","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Lyophilized Powder for Solution for Intravenous","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Reports Notice of Allowance for a US Patent Application Covering Use of Thykamine for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Thylakoid extract","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Devonian H.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alpine Immune Sciences Announces ALPN-202 Poster Presentation at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Davoceticept","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Extends Clinical Development Program for Finerenone with Phase III trial in Heart Failure and Preserved Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives FDA Orphan Drug Designation for NT-I7 for the Treatment of Progressive Multifocal Leukoencephalopathy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Micro\u2122 Glucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Diasome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diasome Reports Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diasome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diasome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Diasome Ph.."},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zentalis Pharmaceuticals to Present Preclinical Data on ZN-c5 at the Upcoming AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ZN-c5","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis P.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imperial to Begin First Human Trials of New COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Receives Regulatory Approval to Initiate COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EB05","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Phathom Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phathom Pharmaceuticals Provides Clinical Trial Status Update","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vonoprazan Fumarate","moa":"P-CAB","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Phathom Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phathom Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Phathom Ph.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ402","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Data Continues to Show Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed\/Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ManKind Presents Positive Original Analyses of Afrezza\u00ae Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Ph.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Pharmaceuticals Reports Results of the Mars study, a Phase 2a Study of the Efficacy and Safety of TP-03 to Treat Demodex Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-03","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EOS-448","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Treos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PolyPEPI-SCoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Treos Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio .."},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Pharma Submits Application for Additional Dosage and Administration of 5-HT3 Receptor Antagonist Aloxi\u00ae for Pediatric Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Palonosetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Taiho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Phar.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva\u2019s Lanifibranor Meets Primary & Key Secondary Endpoints in the Phase IIb NATIVE Clinical Trial In Non-Alcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Provides Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment of Chronic Fatigue Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Medicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Medicure","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicure \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Medicure \/.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Update on Clinical Trials and Development Programs","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Announces Full Commercial Launch of ANJESO\u2122 and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics Announces Start of AT-007 Pediatric Galactosemia Study; Releases Additional 40mg\/kg Data from Adult Galactosemia Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Govorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dalcinonacog alfa","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunovion Announces Health Canada Approval of KYNMOBI\u2122 Soluble Film for the Treatment of Parkinson\u2019s Disease OFF Episodes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apomorphine Hydrochloride","moa":"D2\/D3\/D4\/D5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Sunovion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SRP-9001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Receives FDA IND Clearance to Initiate a Phase 1\/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T\u00ae for HER2+ Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-603","moa":"MyD88\/CD40","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Files IND Application for GEN-011, a T cell Therapy Designed to Improve on Current Limitations of TIL Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOTIO to Present New Preclinical Data on IL-15 Superagonist, SO-C101, at the 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"IL-15 alpha receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cy.."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine, \u201cHyleukin-7 (GX-I7), US clinical trial approval for COVID-19 treatment for mild patients\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HyLeukin-7","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"CN Bio","sponsor":"Cambridge University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CN Bio and Cambridge University Identify Novel Regulatory Pathway Driving NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"CN Bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CN Bio \/ Cambridge University","highestDevelopmentStatusID":"1","companyTruncated":"CN Bio \/ C.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG.APV-527","moa":"5T4 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bryn Pharma Publishes Positive Results from Its Intranasal Epinephrine Preclinical Study Program In Three Peer-Reviewed Scientific Journals","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bryn Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharm.."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"$55.0 million","newsHeadline":"Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Merger","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Spinal Muscular Atrophy (SMA)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Launches PhIII JAK Study, Aiming for the First Drug to Lower Mortality in Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"British Heart Foundation","sponsor":"Imperial College London","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"British Heart Foundation Researchers to Test Promising Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"British Heart Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"British Heart Foundation \/ Imperial College London","highestDevelopmentStatusID":"6","companyTruncated":"British He.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayo Clinic Study of Humanigen\u2019s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Dosses First Patient with FT596","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"FT516","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta's SRP-9003 Gene Therapy for LGMD2E Shows Benefits After 1 Year","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SRP-9003","moa":"Gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Grants Orphan Drug Designation to Nippon Shinyaku's viltolarsen (NS-065\/NCNP-01)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Nippon Shinyaku","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nippon Shinyaku \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nippon Shi.."},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Magenta Reports Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MGTA-145","moa":"CXCR2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Magenta Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Magenta Th.."},{"orgOrder":0,"company":"L.E.A.F. Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"L.E.A.F. Pharmaceuticals Lead Investigational Product for Lung and Colorectal Cancers, LEAF-1401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gamma L-pentaglutamated pemetrexed","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"L.E.A.F. Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"L.E.A.F. Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"L.E.A.F. P.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories enters into a Licensing Agreement with Gilead Sciences for Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$822.0 million","upfrontCash":"Undisclosed","newsHeadline":"SK Biopharmaceuticals Emerges from Pandemic Delays with Pitch for $822M IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.81999999999999995,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.81999999999999995,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA\u2122 for the Middle East and North Africa region","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tildrakizumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Announces License to Commercialize Tempol","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tempol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Matrix Biomed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Matrix Biomed \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Matrix Bio.."},{"orgOrder":0,"company":"UCLA","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"UCLA Receives Nearly $14 million from NIH to Investigate Gene Therapy to Combat HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"CAR-T therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"UCLA \/ National Institution of Health","highestDevelopmentStatusID":"1","companyTruncated":"UCLA \/ Nat.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi To Present Phase 3 Results of Avalglucosidase Alfa in Patients with Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Topline Results from Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MVA-BN-WEV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PH-762","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sound Pharma Advances Pivotal Phase 3 Clinical Trials in Meniere's Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn announces FDA acceptance of IND application for TAS0953\/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HM06","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Ad.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Merck\u2019s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi to present growth opportunities and development strategy for Dupixent\u00ae (dupilumab) in type 2 inflammatory diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Presents Preliminary Phase 1 Results of ALX148 in Combination with Rituximab in Relapsed or Refractory Non-Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"SIRPalpha-CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in\nMolecular Genetics and Metabolism Reports","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Show Near Elimination of Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1\/2 Clinical Study of bluebird bio\u2019s LentiGlobin\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LentiGlobin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of ADHD in Adult Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Centanafadine","moa":"Serotonin uptake","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"International Vaccine Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INOVIO, IVI to Start Ph 1\/2 Trials of COVID-19 Vaccine in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ International Vaccine Institute","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Spicona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Partners with Spicona for COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"VLP based COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Spicona","highestDevelopmentStatusID":"1","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Lycia Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lycia uncloaks with $50M to Tackle Protein Degradation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Lysosome targeting chimeras","moa":"Apolipoprotein-E4","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Lycia Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Lycia Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Lycia Ther.."},{"orgOrder":0,"company":"Genmab","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$3,900.0 million","upfrontCash":"$750.0 million","newsHeadline":"AbbVie and Genmab Announce Broad Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Epcoritamab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":3.8999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.8999999999999999,"dosageForm":"","sponsorNew":"Genmab \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"BioNTech","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$112.3 million","upfrontCash":"Undisclosed","newsHeadline":"European Investment Bank to provide BioNTech with up to \u20ac100 M in debt financing for COVID-19 vaccine development and manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.11,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Successfully Develops \u201cChange History\u201d for its Clinical Trial Product for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CypCaps","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer with TAVO\u2122 and KEYTRUDA\u00ae Plus Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Izana Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Izana Bioscience\u2019s Drug Enters UK Covid-19 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Namilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Izana Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Izana Bioscience \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Izana Bios.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"INKmune","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivipansel","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Ona Therapeutics","sponsor":"Fund+","pharmaFlowCategory":"D","amount":"$33.6 million","upfrontCash":"Undisclosed","newsHeadline":"Fund+ Announces Investment in Ona Therapeutics EUR30 Million Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ona Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ona Therapeutics \/ Fund+","highestDevelopmentStatusID":"4","companyTruncated":"Ona Therap.."},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Perceptive Advisors and Cobro Ventures","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Transcription factor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"C4 Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"C4 Therapeutics \/ Perceptive Advisors and Cobro Ventures","highestDevelopmentStatusID":"4","companyTruncated":"C4 Therape.."},{"orgOrder":0,"company":"Pluristyx","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"ESI human embryonic stem cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Pluristyx","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pluristyx \/ AgeX Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pluristyx .."},{"orgOrder":0,"company":"Ichor Medical Systems","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation Delivery Technology for ITI-1001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ITI-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ichor Medical Systems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ichor Medical Systems \/ Immunomic Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ichor Medi.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$2,015.0 million","upfrontCash":"$120.0 million","newsHeadline":"Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"TAK-831","moa":"DAAO","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":2.02,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":2.02,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"4D Molecular Therapeutics Raises $75 Million in Series C Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"4D-310","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"4D Molecular Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Lifeline Ventures","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Secures Over EUR 6 million to Advance Cancer Immunotherapies Into Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"TILT-123","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Lifeline Ventures","highestDevelopmentStatusID":"6","companyTruncated":"TILT Bioth.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$100.0 million","newsHeadline":"Glaxosmithkline Pens $120M Upfront Cancer Pact with Ideaya","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"IDE397","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ GlaxoSmithKline","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Valneva","sponsor":"Batavia Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Batavia Biosciences to Partner with Valneva Sweden AB for Polio Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Inactivated polio vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Batavia Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Saiba AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Saiba AG and AGC Biologics Enter COVID-19 Vaccine Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Virus-like particle vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Saiba AG","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Armata Pharmaceuticals Gets $15 Million Award from the U.S. DoD to Develop Bacteriophage Therapy to Treat S. aureus Bacteremia Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"AP-SA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Actinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Iodine-131 apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Actinium pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ H.C. Wainwright","highestDevelopmentStatusID":"10","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"IDE397","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cobra Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Cobra Biol.."},{"orgOrder":0,"company":"LGC Group GB","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"OLX301D","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"LGC Group GB","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LGC Group GB \/ OliX Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"LGC Group .."},{"orgOrder":0,"company":"NTC","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Levofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"NTC","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NTC \/ Taro Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"NTC \/ Taro.."},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ubiquigent Continues Drug Discovery Collaboration With Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ubiquigent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ubiquigent \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Ubiquigent.."},{"orgOrder":0,"company":"Lassen Therapeutics","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics to Treat Fibrosis and Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"LASN01","moa":"IL-11 receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lassen Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Lassen Therapeutics \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"Lassen The.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$44.6 million","upfrontCash":"Undisclosed","newsHeadline":"AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Tivozanib","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ SVB Leerink","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Southern Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix and Southern Research to Study Immune Responses to Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"TNX-1800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Southern Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Percutaneous","sponsorNew":"Southern Research \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Southern R.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lightspeed Venture","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orca Bio Raises $192m to Support Cell Therapies Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series D Financing","leadProduct":"TRGFT-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Bio","amount2":0.29999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Orca Bio \/ Lightspeed Venture","highestDevelopmentStatusID":"7","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Farmacore Biotechnology","sponsor":"MCTIC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PDS Biotech and Farmacore Partner to Develop Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"PDS0204","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Farmacore Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Farmacore Biotechnology \/ MCTIC","highestDevelopmentStatusID":"4","companyTruncated":"Farmacore .."},{"orgOrder":0,"company":"Cipla","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche Pharma India Expands Partnership with Cipla to Improve Access to Key Oncology Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ Ro.."},{"orgOrder":0,"company":"Entero Healthcare Solutions","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche Pharma India Partners with Entero Healthcare Solutions to Improve Access to Nephrology Medicines","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Entero Healthcare Solutions","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Entero Healthcare Solutions \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Entero Hea.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$95.7 million","upfrontCash":"Undisclosed","newsHeadline":"Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0.10000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Sirnaomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirnaomics and Precision NanoSystems Have Formed a Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Precision NanoSystems","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision NanoSystems \/ Sirnaomics","highestDevelopmentStatusID":"8","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"ISA Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration With Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ ISA Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"ALK","sponsor":"Otonomy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO\u00ae, the First and Only Single-Dose Treatment for Acute Otitis Externa","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"ALK","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"ALK \/ Otonomy","highestDevelopmentStatusID":"12","companyTruncated":"ALK \/ Oton.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"George Washington University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"WEG232","moa":"Substance P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ George Washington University","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Nan Fung Life Sciences","pharmaFlowCategory":"D","amount":"$32.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engrail Therapeutics Raises $32 Million in Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"ENX-101","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Engrail Therapeutics \/ Nan Fung Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Th.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"Rexahn and Ocuphire Enter into Definitive Merger Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Merger","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Rexahn","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$13.9 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"MVA-BN Filo vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bavarian Nordic \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"Themis Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Completes Acquisition of Themis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Themis Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Themis Bioscience \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Themis Bio.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$865\u202c.0 million","upfrontCash":"$60.0 million","newsHeadline":"Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ALPN-101","moa":"ICOS","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.87,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.87,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"Renovion","sponsor":"White Rock Capital Management","pharmaFlowCategory":"D","amount":"$8.1 million","upfrontCash":"Undisclosed","newsHeadline":"Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"Approved","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"ARINA-1","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Renovion","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Renovion \/ White Rock Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"Achilles Vaccines","sponsor":"The EU Malaria Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Italy to Be First Beneficiary of EU Malaria Fund: Siena-Based Achilles Vaccines srl to Receive Financing to Fight Malaria and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Malaria vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Achilles Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achilles Vaccines \/ The EU Malaria Fund","highestDevelopmentStatusID":"1","companyTruncated":"Achilles V.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Termination","leadProduct":"ABI-M201","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Assembly Biosciences \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Urovant Sciences","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Urovant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Urovant Sc.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical oncology biotech Nkarta files for a $100 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Acalabrutinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acerta Pharma \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pha.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"BioSig Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent to Partner with ViralClear for Oral COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ BioSig Technologies","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Civica Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kaiser Permanente Joins Forces with Civica Rx to Improve Availability and\nAffordability of Essential Generic Medications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaiser Permanente Washington Health Research \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Kaiser Per.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Halozyme to Receive $10 Million Milestone Payment From Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Halozyme Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Agenus","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"$35.0 million","newsHeadline":"Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ B.."},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vizient Announces Novaplus Enhanced Supply Agreement with Pfizer for Six Essential Medications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Vizient","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vizient \/ Pfizer","highestDevelopmentStatusID":"1","companyTruncated":"Vizient \/ .."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Minerva Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Minerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"huMNC2-CAR44 CAR T cells","moa":"MUC1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Tasmanian Alkaloids Pty Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tanner Pharma \/ Tasman Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pha.."},{"orgOrder":0,"company":"Orgenesis","sponsor":"Leidos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Ranpirnase","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Orgenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orgenesis \/ Leidos","highestDevelopmentStatusID":"4","companyTruncated":"Orgenesis .."},{"orgOrder":0,"company":"Intravacc","sponsor":"Wageningen Bioveterinary Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc Partners With Wageningen Bioveterinary Research and Utrecht University to Develop an Intranasal COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Intravacc \/ Wageningen Bioveterinary Research","highestDevelopmentStatusID":"1","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology biotech Poseida Therapeutics refiles for a $115 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"P-BCMA-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Poseida Therapeutics, Inc","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi\u2019s Investigational Enzyme Replacement Therapy Improves Critical Manifestations of Late-Onset Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak to Present New Preclinical Data on exoASO\u2122-STAT6 and exoASO-C\/EBP\u03b2 at the AACR 2020 Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"exoASO-STAT6","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India's Serum Institute to Play Pivotal Role in COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VPM1002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Codagenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codagenix Announces the Synthesis and Preliminary Safety of Scalable, Live-attenuated Vaccine Candidate Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-005","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Codagenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codagenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Codagenix .."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Reports Additional Analysis of Lenzilumab in Severe and Critical COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Singapore Scientists to Start Human Trials of COVID-19 Vaccine in August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SINGAPORE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Duke-NUS Medical School","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Duke-NUS Medical School \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Duke-NUS M.."},{"orgOrder":0,"company":"JW Pharmaceutical Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JW Pharmaceutical to Repurpose Targeted Oncology Drug as COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CWP291","moa":"Wnt\/Beta-Catenin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"JW Pharmaceutical Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JW Pharmaceutical Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"JW Pharmac.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces the Initiation of a Phase 2\/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Emvododstat","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phanes Therapeutics Reveals a New Bispecific Antibody Technology Platform at BIO Digital 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Phanes Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phanes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Phanes The.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Confirmatory In Vitro Analysis of WP1122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex\u2122 Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Oncoprex","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Vyome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyome Therapeutics Announces Positive Results in Phase 2 Trial of VB-1953 for Moderate to Severe Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-1953","moa":"TLR\/MD2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Vyome Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vyome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vyome Ther.."},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senju Pharmaceutical Launches New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"SENJU PHAR.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Added to Russell Indexes and Provides Phase 2b Study Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTI-125","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Affibody","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affibody Announces Positive Top-Line Data from Phase 2 Proof-of-Concept Trial of ABY-035 in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ABY-035","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Affibody","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves First Treatment for Adult Onset Still\u2019s Disease, a Severe and Rare Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX\u00ae2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bionic Sight Doses First Patient in a Phase 1\/2 Trial of a New Investigational Treatment for Blindness caused by Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BS01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bionic Sight \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sig.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Presents NURTEC Clinical and Pharmacoeconomic Data at the American Headache Society Virtual Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB Published Phase I\/II Clinical Trial Results of Ilixadencel in Gastrointestinal Stromal Tumors in Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Dosed First Patient in Phase II Clinical Study of IAP Antagonist APG-1387 in Combination with Entecavir for Chronic Hep B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-1387","moa":"Apoptosis protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Enrolled First Patient in Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of M.S","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics to Present Tomorrow at 2020 Raymond James Human Health Innovation Conference","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Oncology to Highlight Rubraca\u00ae (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucitanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer\u2019s Patient","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Rare Diseases: Isturisa\u00ae (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing\u2019s Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Receives FDA Fast Track Designation for ONIVYDE as a First-Line Combination Treatment for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1\/2A Study of AFM24","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM24","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Gets Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Verzenio Shows up Ibrance, Hitting its Goal in Early Breast Cancer After Pfizer's Drug Faltered","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Disitamab vedotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Provides Additional Data from Ongoing Phase 1\/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kangpu Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kangpu Bio.."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AKR-001","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"AriBio","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AriBio Announces Completion of Enrollment in Phase 2 Alzheimer\u2019s Study with AR1001","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"CREB pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ SK Chemicals","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ S.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-450","moa":"Mapk2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Completes Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA in Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Provides Clinical Update on ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Exebacase","moa":"Cell wall peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Reports Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II\/III Trial of IFX-1 in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement factor C5a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Presented Results from Preclinical Studies of TNX-1700 in a Poster at the AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TNX-1700","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Pfizer\u2019s Steglatrotm Meets Primary Endpoint in VERTIS CV Trial for Type 2 Diabetes and Atherosclerotic Cardiovascular Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ertugliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Rheumatoid Arthritis Drug Fails to Help COVID-19 Patients in Italian Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Sangamo Announce Updated Phase 1\/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events in 3e13 Vg\/Kg Cohort After Sb-525 Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Giroctocogene fitelparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Receives Rare Pediatric Disease Designation From U.S.FDA for Nedosiran for Treatment of Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ Monotherapy Results in Skin Clearance and Itch in First Phase 3 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Almac Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-c165","moa":"RTK transmembrane receptor ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Almac Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Almac Group \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Almac Grou.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals to Discuss APEX\u2122 in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Submits Its First New Drug Application to National Medical Products Administration, for HQP1351","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HQP1351","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Biopharmaceuticals Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 S-Trimer vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s IPATential150 Study Testing Ipatasertib in Combination With Abiraterone & Prednisone\/Prednisolone Met Its Co-Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipatasertib","moa":"Serine\/threonine-protein kinase AKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Initiates the LIFT Study, a Phase 2a Clinical Trial of TERN-101 for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-101","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK\u2122 (tazemetostat) for Relapsed\/Refractory Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Prevention Pharmaceuticals Submits EU Marketing Authorization Application for CPP-1X\/sul to Treat Familial Adenomatous Polyposis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Pre.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forte Biosciences, Inc. Announces Issuance of New U.S. Patent","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY\u00ae (fremanezumab-vfrm) Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of XP-3924 in Adults with Type 1 DM","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pramlintide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces Initiation of Phase 1 Clinical Trials for Two Novel Antibody-Based Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SEA-TGT","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics to Host Scientific Seminar on Promising Preclinical Data from HPK1 Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen\u00ae for the Treatment of Dry AMD With Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinal pigment epithelial cells","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Announces Long-Term Efficacy and Safety Data for Fitusiran from Interim Analysis of Phase 2 Extension Study in Hemophilia A and B","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Givosiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology\u2019s Virtual Heart Failure Association Discoveries","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Danicamtiv","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gaboxadol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in A Phase 1b\/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI362","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Successfully Completes AM833 Phase 2 Trial and Phase 1 Combination Trial with AM833 and Semaglutide in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fleroxacin","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces EMA Acceptance of its Marketing Authorization Application for BRUKINSA for the Waldenstr\u00f6m\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Status to Chi-Med\u2019s Fruquintinib for Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH stops clinical trial of hydroxychloroquine to treat adults hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Discontinues Hydroxychloroquine Clinical Trial Based on Slow Enrollment, Remains Committed to Pandemic Research Efforts","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"University of South Australia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breakthrough Discovery to Transform Prostate Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"CYP17A1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of South Australia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of South Australia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces that V114 Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche, BioNTech Post 'Low' Response Rate in Cancer Vaccine Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces Priority Review and FDA Acceptance of NDA for Once-Daily, Oral Relugolix for Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences announces EDP1815 to advance into phase 2\/3 TACTIC-E COVID-19 trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ambrisentan","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMG 634","moa":"PDE4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ABM-1310","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therap.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Transgene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BT-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Colvis Oncology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alkermes Plc \/ Colvis Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Announces Intention to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dendritic Cell Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"twoXAR Pharmaceuticals Presents Positive Preclinical Safety and Efficacy Data for its Novel Investigational Cancer Treatment TXR-311","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TXR-311","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"twoXAR Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pha.."},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PH-804","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Phio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Phio Pharm.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jubilant Therapeutics Presents Preclinical Data at the American Association for Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JBI-802","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant T.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Reports News Preclinical Data Suggesting Synergy Between STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1\/2a Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Reports New Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FS222","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Presents Data from Four Preclinical XmAb\u00ae 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"XmAb30819","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Rgenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-104","moa":"Liver X receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenix \/ N.."},{"orgOrder":0,"company":"Rgenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-019","moa":"MerTK","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Rgenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rgenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rgenix \/ N.."},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Presents New Data Reinforcing Galectin-9 as a Compelling Therapeutic Target and Biomarker for a Range of Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LYT-200","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PureTech H.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NMBS-1","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics to Present Preclinical Data on SBT6050","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Presents Same Day Dosing Data for ROLONTIS\u00ae (eflapegrastim) at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GM-CSF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EMB-01","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EpimAb Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpimAb Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"EpimAb Bio.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Data from VBI-1901 Presented at AACR 2020: Partial Response Observed, Promising Biomarker Strategy Identified","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-1901","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"20-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Acceleron Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BT5528","moa":"Ephrin type A receptor 2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Completes Patient Enrollment Into the AUDREY Phase 2\/3 Clinical Trial of Voclosporin Ophthalmic Solution","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Preclinical Data Presentation at the 2020 American Association for Cancer Research Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TG-1701","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Presentation of Data on Genentech\u2019s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed\u2019s ROCK\u00ae Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM24","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"Shasqi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shasqi Demonstrates Chemistry-based Platform Produces Local and Systemic Anti-tumor Response in Preclinical Cancer Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SQL70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shasqi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shasqi \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Shasqi \/ N.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma's Drug Candidate VP01 Demonstrates Potential for Significant Benefit in Severe Pulmonary Hypertension","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RhoVac Receives Approval in Sweden to Start Clinical Phase IIb Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MRG-229","moa":"miR-29","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dracen Announces Two DRP-104 Presentations at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dracen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pha.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo\u00ae in Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1592","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PTX-35","moa":"TNFRSF25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces the Initiation of a Phase 1\/2a Study of Rigosertib Plus Nivolumab for KRAS+ Lung Adenocarcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"EOS-448","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLO-819","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allogene Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allogene T.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TG4050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"JTX-1811","moa":"CCR8","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Jounce Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MGC018","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AGEN1181","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AFP TCR T Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular B.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Templates\u2019 Presentations at the American Association of Cancer Research AACR Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MT-5111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mateon and GMP to Proceed to Clinical Development of OT-101 and Artemisin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"SINTX Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sintx Technologies Announces Sars-Cov-2 Testing Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Silicon Nitride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SINTX Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SINTX Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SINTX Tech.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covid\u201019 Infection in Psoriasis Patients Treated with Cyclosporin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Pennsylvania","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Pennsylvania \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Galecto","sponsor":"Pharmakea therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galecto to merge with onetime Celgene partner PharmAkea","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"PAT-1251","moa":"LOXL2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galecto \/ PharmAkea","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Aravive","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Biologics and Aravive Collaborate to Develop Novel Antibodies Targeting Cancer and Fibrosis Using the WuXiBody\u2122 Platform","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Aravive","highestDevelopmentStatusID":"2","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Hypoimmunogenic cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$72.5 million","newsHeadline":"Sarepta and Codiak BioSciences to develop rare disease therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Sarepta Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Linnaeus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Linnaeus Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"ITM","sponsor":"POINT Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM and POINT Biopharma Sign Two Supply Agreements for No-carrier-added Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ITM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ITM \/ POINT Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"ITM \/ POIN.."},{"orgOrder":0,"company":"Frontier Scientific","sponsor":"Renibus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Frontier Scientific, Renibus Therapuetics to develop Covid-19 therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Stannous protoporphyrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Frontier Scientific","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Frontier Scientific \/ Renibus Therapuetics","highestDevelopmentStatusID":"8","companyTruncated":"Frontier S.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Olivia Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Private Placement","leadProduct":"CTX-471","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Olivia Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"AsclepiX Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$35.0 million","newsHeadline":"AsclepiX Therapeutics Announces $35 Million Series A Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"AXT107","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"AsclepiX Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"AsclepiX Therapeutics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"AsclepiX T.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Replicate Bioscience and Immunomic Therapeutics Form Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RBI-5000","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Replicate Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$450.0 million","newsHeadline":"CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Etranacogene dezaparvovec","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":2.0499999999999998,"dosageForm":"","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Quest Products","sponsor":"Quest Products, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Quest Products, LLC. Acquires Summit Pharmaceuticals \/ Alliance Labs, Including Enemeez\u00ae and DocuSol\u00ae Brands","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Docusate Potassium","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Quest Products","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quest Products \/ Quest Products, LLC","highestDevelopmentStatusID":"12","companyTruncated":"Quest Prod.."},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Simcha debuts with $25M to advance custom-built IL-18 for cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"ST-067","moa":"IL-18","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Simcha Therapeutics \/ WuXi AppTec","highestDevelopmentStatusID":"7","companyTruncated":"Simcha The.."},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Toleranzia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"3P Bio and Toleranzia Enter Orphan Drug Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"TOL2","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"3P Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"3P Biopharmaceuticals \/ Toleranzia","highestDevelopmentStatusID":"4","companyTruncated":"3P Biophar.."},{"orgOrder":0,"company":"Edge Pharma","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Edge Pharma Completes Supplier Agreement with ANI Pharmaceuticals, Inc","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Edge Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edge Pharma \/ ANI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Edge Pharm.."},{"orgOrder":0,"company":"Enterome","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","amount":"$52.6 Million","upfrontCash":"Undisclosed","newsHeadline":"Enterome Completes \u20ac46.3 Million ($52.6 Million) Financing to Progress the Clinical Development of Its Therapeutic Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"EO2401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Enterome","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Enterome \/ SymBiosis, LLC","highestDevelopmentStatusID":"7","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna\u2019s COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Moderna","highestDevelopmentStatusID":"8","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied Biology in Collaboration with Corpometria Institute to Launch AntiAndrogen Clinical Study for the Treatment of COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$800.0 million","upfrontCash":"Undisclosed","newsHeadline":"SK Biopharmaceuticals Set to Make Historic IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Cenobamate","moa":"NaV Channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.80000000000000004,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"SK Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evelo Biosciences Announces Proposed Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"EDP1815","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Evelo Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Indegene Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharmaceuticals And Indegene Enter Into Probuphine\u00ae Co-Promotion Partnership","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Titan Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Indegene Inc","highestDevelopmentStatusID":"12","companyTruncated":"Titan Phar.."},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Symbiosis, AstraZeneca Sign Supply Agreement for Sterile Vaccine Manufacture","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Symbiosis Pharmaceutical Services \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Symbiosis .."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Yumanity Therapeutics Signs Drug Development Deal with Merck","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Yumanity Therapeutics","amount2":0.5,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"Yumanity Therapeutics \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"5AM Ventures","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"Undisclosed","newsHeadline":"Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series A Financing","leadProduct":"AB-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ 5AM Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Bio.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$414.0 million","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces Deliveries of Oral TPOXX\u00ae to HHS Valued at Approximately $32 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 1\/2 oncology biotech iTeos Therapeutics files for a $100 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"EOS-850","moa":"A2AR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Iteos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Ther.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics to Receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"12","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Signs Long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Immunotherapy","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ PharmAbcine","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces Development Agreement - Autoimmune Disease Treatments","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Hemogenyx .."},{"orgOrder":0,"company":"IBM Watson Health","sponsor":"iBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution to help Support clinical COVID-19 Vaccine Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"IBIO-200","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IBM Watson Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IBM Watson Health \/ iBio Inc.","highestDevelopmentStatusID":"4","companyTruncated":"IBM Watson.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"National Brain Tumor Society","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ National Brain Tumor Society","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Zelluna Immunotherapy","sponsor":"Lion TCR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zelluna Collaborates with Lion TCR to Develop TCR-NK Cell Therapies to Treat Virally Induced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"TCR based Natural Killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zelluna Immunotherapy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zelluna Immunotherapy \/ Lion TCR","highestDevelopmentStatusID":"1","companyTruncated":"Zelluna Im.."},{"orgOrder":0,"company":"Aldevron","sponsor":"Alaunos Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aldevron Announces Agreement with Ziopharm Oncology for neoGMP\u00ae Production of Sleeping Beauty Plasmid DNA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"DNA plasmids","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aldevron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aldevron \/ Ziopharm Oncology","highestDevelopmentStatusID":"1","companyTruncated":"Aldevron \/.."},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$69.3 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Pharmaceuticals Raises Approximately EUR 61.81 Million in Successful Initial Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Sotalol Hydrochloride","moa":"hREG","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hyloris Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intravenous Injection","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Hyloris Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Brazilian Health Ministry","pharmaFlowCategory":"D","amount":"$127.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brazil, AstraZeneca Sign $127 Million Deal To Produce Experimental COVID-19 Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"","sponsorNew":"AstraZeneca \/ Brazilian Health Ministry","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"EverInsight Therapeutics","pharmaFlowCategory":"D","amount":"$177.0 million","upfrontCash":"$5.0 million","newsHeadline":"VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.17999999999999999,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ EverInsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Burning Rock Dx","sponsor":"CStone Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Burning Rock and CStone Pharmaceuticals reached a strategic collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Burning Rock Dx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Burning Rock Dx \/ CStone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Burning Ro.."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Goldfinch Bio Secures $100 Million in Series B Financing","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series B Financing","leadProduct":"GFB-887","moa":"TRCP5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0.10000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Eventide Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Freeline Closes Major $120M Funding Round","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Series C Financing","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"9","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$42.6 million","upfrontCash":"Undisclosed","newsHeadline":"Ology Bioservices Gets $42.6M DoD Contract","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Anti-botulinum neurotoxin monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"CEL-SCI Corporation Receives $10 Million Through Warrant Exercises","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Interleukin 2","moa":"T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"University of Natural Resources","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avalon GloboCare to Develop Intranasal and Oral Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"S-layer COVID vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Avalon GloboCare \/ University of Natural Resources","highestDevelopmentStatusID":"1","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"PainReform","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Israeli Pain Relief Biotech PainReform Files for a $25 million US IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"PainReform","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Extended Release Solution","sponsorNew":"PainReform \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"PainReform.."},{"orgOrder":0,"company":"SparingVision","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfenex Announces Enters New Partnership in Latin America, and Provides CRM197 Business Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SparingVision \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"National Health Service (NHS)","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Successful Eloctaq Bid Should Widen Access to the Drug in the UK","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Efmoroctocog alfa","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ National Health Service (NHS)","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acceleron Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Sotatercept","moa":"INHBA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acceleron Pharma","amount2":0.45000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Acceleron Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Acceleron .."},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3,881.0 million\u202c","upfrontCash":"$16.0 million","newsHeadline":"Alteogen Enters into a Global License Agreement with a Top Ten Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ALT-B4","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":3.8799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":3.8799999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"$425.0 million","newsHeadline":"Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals' CRV431 Demonstrates Efficacy in Kidney Fibrosis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK\u2019s MHRA renews EAMS Scientific Opinion for Santhera\u2019s Idebenone in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Vecabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunesis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunesis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sunesis Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breztri Aerosphere Significantly Reduced Rate of Moderate or Severe COPD Exacerbations in Phase III ETHOS Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Budensonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Enrols First Patient in Pamrevlumab\u2019s Covid-19 Trial in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamrevlumab","moa":"CTGF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines begins patient dosing in phase1 trial of RMC-4630 in combo with pembrolizumab to treat solid tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces Pre-Clinical Data on GL0034 to Treat Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GL0034","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Released Research Data of \"FAK inhibitor IN10018 Overcomes Drug Resistance of KRAS G12C Inhibition\" at 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"Focal adhesion kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ N.."},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"REN001","moa":"PPAR gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Phar.."},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methadone","moa":"NMDA","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Relmada Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Relmada Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Relmada Th.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PL8177","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marker Therapeutics Receives USAN Approval for \"zelenoleucel\" as Nonproprietary Name for MT-401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Zelenoleucel","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Polynoma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Seviprotimut-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Polynoma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Polynoma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polynoma \/.."},{"orgOrder":0,"company":"Oppilan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OPL-002","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Oppilan Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oppilan Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oppilan Ph.."},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphivena Presents Translational Data for its Lead Clinical Candidate, AMV564 at the AACR 2020 Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMV564","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena .."},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SK1-I","moa":"Sphingosine kinase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzo Biochem \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Bioch.."},{"orgOrder":0,"company":"Praxis Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Praxis Bioresearch Announces Issuance of U.S. Patent on its Prodrug Stimulant PRX-P4-003","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PRX-P4-003","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Praxis Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Praxis Pha.."},{"orgOrder":0,"company":"RubrYc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RubrYc Therapeutics To Present at AACR Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-003","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"RubrYc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RubrYc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RubrYc The.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"Leukotriene receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Phase 2 Study of Arimoclomol In Gaucher Disease Demonstrates Marked Improvements in Key Clinical Markers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces First Patient Dosed in Phase 2 Trial With Long-Acting GLP-1\/Glucagon Dual Agonist in Obesity\/Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 456906","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Ph.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Nobilis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug\/Device Combination for Treatment of Panic Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Xenon","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Nobilis Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nobilis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nobilis Th.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Receives First Patent Approval for ATOR-1017","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1017","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Medigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigene Enters Phase I Clinical Development with its TCR-T Immunotherapy MDG1021 in Hematological Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MDG1021","moa":"Antigen HA-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/.."},{"orgOrder":0,"company":"Cassiopea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acne","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Clascoterone","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea .."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Final Data from Phase I PK\/PD Study of Intranasal Racemic Ketamine (SLS-002) and Clinical Development Plans","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Doses First Patient in Phase 1 Clinical Trial of KD033","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"KD033","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Doses First Patient in Phase 2 BRACELET-1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TYME-18","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumor","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Pirbright Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Studies at BBSRC-funded Pirbright Institute demonstrate two doses of Oxford University's COVID-19 vaccine boosts immune response in pigs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pirbright Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pirbright Institute \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pirbright .."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Announces Initial European Trial Sites Activated in AEROSURF\u00ae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucinactant","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Announces OCD Proof Of Concept Phase 2\/3 Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Troriluzole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Expands Clinical Pipeline to Evaluate NurOwn\u00ae for AZ","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Positive Pharmacokinetic (PK) \/ (PD) Study Results for PXL770","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"ImmunoMolecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IM Therapeutics Announces First Patient Dosed in Ph1 Study IMT-002","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IMT-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ImmunoMolecular Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoMolecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMole.."},{"orgOrder":0,"company":"Grid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grid Therapeutics Announces Enrollment of First Patient in Ph1 Study of GT103","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GT103","moa":"CFH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Grid Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Grid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Grid Thera.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono Initiates First Clinical Trial of TLR7 and 8 Inhibitor as a Potential Treatment for Severe Symptoms of Covid-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"M5049","moa":"TLR7\/8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TD-0903","moa":"JAK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moberg Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Therapeutics Announces Orphan Drug Designation Granted for the Treatment of T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Erlotinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ABI-H2158","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SLS-007","moa":"Alpha-synuclein Non-Amyloid component","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TTX-080","moa":"HLA-G","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Tizona Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tizona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tizona The.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Biopharma Announces the Formation of Scientific Advisory Board to Advance Autoimmune Disease Therapy AX-158","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artax Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"The Lundquist Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unique Clinical Trial Investigates a New Treatment Approach for Fatal \u2018Childhood Alzheimer\u2019s\u2019 and Continues Despite COVID-19 Pandemic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Anakinra","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"The Lundquist Institute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Lundquist Institute \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"The Lundqu.."},{"orgOrder":0,"company":"University of Wisconsin School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UW\u2013Madison and UW Health quickly launch a number of COVID-19 clinical trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Wisconsin School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Wisconsin School of Medicine \/ Novartis","highestDevelopmentStatusID":"10","companyTruncated":"University.."},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BC007","moa":"Coronavirus spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Berlin Cures","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Berlin Cures \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Berlin Cur.."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Announces Plans to Seek Regulatory Approval for Oxbryta\u00ae (voxelotor) to Treat Sickle Cell Patients in Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HemoShear Therapeutics Receives FDA Clearance of IND for Phase 2 Study of its Investigational Drug HST5040","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HST5040","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dar\u00e9 Bioscience Reports Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferrous Gluconate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"Dar\u00e9 Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Announces Initiation of 28-Day Phase 2 Razuprotafib Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nascent Biotech Appoints Chief Medical Consultant in Charge of COVID-19 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pritumumab","moa":"Vimentin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nascent Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Bi.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CCX559","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"University of the Witwatersrand","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trial of Oxford COVID-19 Vaccine in South Africa Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SOUTH AFRICA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ox1Cov-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of the Witwatersrand","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of the Witwatersrand \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Gets Ethics Approval for Lfenprodil\u2019s Covid-19 Trial in US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"UC San Francisco","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Researchers Trial Azithromycin to Treat Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Azithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UC San Francisco","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"UC San Francisco \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UC San Fra.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Secures Positive CHMP Opinion for Aybintio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Completes Enrollment in Phase 3 DOM-INNATE Trial of SGX942 to Treat Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dusquetide","moa":"p62 protein","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Aadi Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus for Advanced Malignant PEComa","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aadi Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Aadi Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aadi Biosc.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Reports COVID-19 Trial Program to Commence in Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"cGAS-STING signaling","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Simcha Therapeutics Shares Data at AACR Annual Meeting Highlighting Potent Preclinical Efficacy of Decoy-Resistant IL-18 Cytokine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"DR-18","moa":"Il-18","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Simcha Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Simcha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Simcha The.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Submission of Biologics License Application for TransCon\u2122 hGH in Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiViva Biopharma Announces Positive Data from Phase 1\/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AIV001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Bio.."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox\u00ae in Primary Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OPC1","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lineage Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Receives Positive CHMP Opinion for IdefirixTM (imlifidase) for Kidney Transplant in EU","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presented with upbeat Alzheimer's agitation data, FDA sees another 'breakthrough' in Axsome's AXS-05","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Receives FDA Response on Pre-Investigational New Drug Application for its Induced Mesenchymal Stem Cells","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"iPSC-derived MSCs","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Celltex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltex Therapeutics Receives FDA Approval: Phase II Clinical Trial Using Mesenchymal Stem Cells for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous adipose-derived stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Celltex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celltex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celltex Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pexidartinib","moa":"Stem Cell growth factor receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives positive CHMP opinion for new Xolair\u00ae indication to treat severe chronic rhinosinusitis with nasal polyps","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"IgE","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"Il-12","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Pfenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfenex Announces Positive European CHMP Opinion for PF708","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Pfenex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfenex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfenex \/ N.."},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics Announces First Patient Dosed in Phase IIa Study in Liver Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BO-112","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Highlight .."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bifikafusp alfa","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Begins Patient Dosing in Phase 1b\/2 Trial of NT-I7 in Combo with Keytruda to Treat r\/r Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Epitopoietic Research Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoiet.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Montreal Heart Institute Announces COLCORONA Trial in Patients COVID-19 Passes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech Announces Investigator Sponsored Ph 2 Trial Pelareorep","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AOBiome Reports Successful Clinical Trials in Pruritus Associated with Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"B244","moa":"IL-4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"AOBiome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Th.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Therapeutics Meeting with US FDA Provides Development Pathway for ATH434","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SFA Therapeutics Announces FDA Approval To Begin IND Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SFA002","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"SFA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"SFA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SFA Therap.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Orexo","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ No.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PEEL Therapeutics Announces Possible New Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Neutrophil targeting peptide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PEEL Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PEEL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PEEL Thera.."},{"orgOrder":0,"company":"ChemRar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data of Avifavir to Become Available to International Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ChemRar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ChemRar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ChemRar \/ .."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Corporation Highlights Orphazyme's Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces CHMP Recommendation of Translarna Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ataluren","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granules for Oral Suspension","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Cytocom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytocom, Inc. Announces Successful Completion of Type-B Pre-IND Meeting with FDA Regarding Phase 2 Trial of CYTO-201 in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CYTO-201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cytocom","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytocom \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cytocom \/ .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Announces Final Data Analysis from Phase II NASH Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"NuvOx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Allows COVID-19 Patients with Respiratory Failure to Be Given NuvOx Pharma's Oxygen Therapeutic in Phase IIa Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CAS 7632-00-0","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"NuvOx Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"NuvOx Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NuvOx Phar.."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VITRAC Therapeutics Initiated Global Clinical Development of VIC-1911, licensed from Taiho Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VIC-1911","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VITRAC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC The.."},{"orgOrder":0,"company":"GoLiver Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GoLiver Therapeutics Receives Scientific Advice from EMA on its Clinical Development and Biomanufacturing Strategy for Acute Liver Failure","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cell therapy products","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"GoLiver Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GoLiver Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GoLiver Th.."},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Prevention Pharmaceuticals Submits New Drug Application to the FDA for CPP-1X\/sul for Treatment of Familial Adenomatous Polyposis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Pre.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima\u00ae SC","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verrica Pharmaceuticals Provides Regulatory Update on VP-102","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"REVIMMUNE INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RevImmune Announces Phase II Trial of the T-Cell Growth Factor CYT107 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin-7","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"REVIMMUNE INC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"REVIMMUNE INC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"REVIMMUNE .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences Announces Publication of Trial Design Manuscript for Ongoing BLOCK CKD Phase 2b Study of KBP-5074","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Receives Approval for COVID-19 Phase 2\/3 Study with Opaganib in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma, Inc. Amends Definition of Primary Endpoint for Phase 3 Trial in Celiac Disease After Consultation with FDA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I\/II Study in Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ITI214","moa":"PDE1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Recardio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented at the 2020 Congress of the European Society of Cardiology","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dutogliptin Tartrate","moa":"DPP-4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recardio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Recardio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Recardio \/.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Receives Endari\u00ae Marketing Authorization from the Israeli Ministry of Health","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AVA-001","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Short-Acting Selective \u03b21 Blocker, Onoact\u00ae for Intravenous Infusion 50mg\/150mg Approved","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Landiolol Hydrochloride","moa":"Beta-1 adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunovant Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IMVT-1401","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptose Announces FDA Allowance of IND for Phase 1a\/b Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CG-806","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptose Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptose Bio.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel\u2122 (CBD Gel) in Fragile X Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-240","moa":"4-1BB ligand","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"University of Oxford","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"No Clinical Benefit From use of Lopinavir-Ritonavir in Hospitalised COVID-19 Patients Studied in RECOVERY, Reports University of Oxford Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lopinavir","moa":"HIV-1 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"University of Oxford \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"University.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study for INP105","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Submission of IND with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 pentaenoic acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Amniox Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amniox Announces Initiation for First of Two Phase 3 Clinical Trials of Cryopreserved Umbilical Cord TTAX01 Allograft","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TTAX01","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase III","graph3":"Amniox Medical","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amniox Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amniox Med.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b\/3 Trial of Belapectin","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Belapectin","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II\/ Phase III","graph3":"Galectin Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Galectin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Galectin T.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Provides Pipeline Update","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Stem Cell-Based Application for BeyondSpring\u2019s Plinabulin Presented at ISSCR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Mezzion Pharma Co Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mezzion Announces Submission of NDA for its Orphan Drug Udenafil","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Udenafil","moa":"PDE5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Mezzion Pharma Co Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mezzion Pharma Co Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mezzion Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selumetinib Granted Orphan Drug Designation in Japan for Neurofibromatosis Type 1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Selumetinib","moa":"MAP2K1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation (ODD) for Prestige BioPharma\u2019s PBP1510 Anti-PAUF Monoclonal Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PBP1510","moa":"PAUF protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Cambridge University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cambridge Launches Fast-Turnaround Experimental Drug Trial to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cambridge University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cambridge University \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Cambridge .."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Launches Cipremi the only U.S. FDA Approved Emergency Use Authorisation (EUA) Treatment for Patients with Severe COVID-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Hetero Drugs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hetero Announces the Approval and Launch of First Generic \u2018COVIFOR\u2019 (Remdesivir) in India for the Treatment of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hetero Drugs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hetero Drugs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hetero Dru.."},{"orgOrder":0,"company":"Vascular BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vascular BioSciences Announces New Preclinical Research Results Demonstrating Improved Pulmonary Hypertension and Sepsis Survival with CAR Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CAR Peptide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vascular BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vascular BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vascular B.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Becomes the First Pharmaceutical Company in India to Receive Regulatory Approval for Oral Antiviral Favipiravir, for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Quadrivalent Influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Presents New Preclinical Data on CAN04 at the 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Nidanilimab","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"CAL1 vaccinia virus","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Bio.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"AIMM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIMM Therapeutics Presents Preclinical Data on its Four Oncology Therapies at AACR\u2019s Annual Meeting Session on Antibody Technologies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AT1412","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AIMM Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AIMM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AIMM Thera.."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Data for PRGN-3005 UltraCAR-T\u00ae Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-3005","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"BeiGene","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifirafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Principia Announces First Patient Enrolled in Sanofi\u2019s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SAR442168","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Tecentriq in Combination With Chemotherapy Meets Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO\u2122 (fosfomycin) for injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosfomycin Sodium","moa":"UDP-N-acetylglucosamine 1-carboxyvinyltransferase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IMGN151","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"TEAD","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RAPT Therapeutics Highlights Early Results for RPT193 at Society for Investigative Dermatology Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"RPT193","moa":"CXCR4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rapt Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Thera.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Presents Biomarker Identification Strategies for Investigational Agents Alvocidib and TP-1287 at AACR Meeting II 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-1287","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Gamalei National Research Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia to Begin Clinical Trials of Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gamalei National Research Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gamalei National Research Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gamalei Na.."},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almirall Announces FDA Approval Of Updated Label For Seysara\u00ae (Sarecycline) Tablets","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Metastatic or Unresectable Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Completes Rolling Submission of New Drug Application for Umbralisib as a Treatment for Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Announces FDA Clearance of its IND Application for HB-202\/201 Clinical Trial to Treat HPV-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Receives Orphan Drug Designation for Tacrolimus Inhalation Powder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Piper Sandler & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ Piper Sandler & Co","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Cascade Chemistry","sponsor":"Renibus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cascade Chemistry Selected to Produce Active Pharmaceutical Ingredient for Clinical Trial Supplies of COVID-19 Investigational Drug RBT-9","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Stannous protoporphyrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cascade Chemistry","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cascade Chemistry \/ Renibus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cascade Ch.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"4D Molecular Therapeutics Announces New Agreement With Cystic Fibrosis Foundation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"4D-710","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"4D Molecular Therapeutics","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Oncologie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncologie Announces Key Updates and Planned Activities for its Clinical Programs and RNA-based Biomarker Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bavituximab","moa":"Phosphatidylserine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncologie","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncologie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncologie .."},{"orgOrder":0,"company":"Nagourney Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Identification of Alpelisib (BYL 719) as a Potential Treatment for Endometrial Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpelisib","moa":"PI3K p110-alpha subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nagourney Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nagourney Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nagourney .."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces Patent Issuances Covering AXA1665","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"MNPR-101","moa":"uPAR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ NorthStar Heathcare","highestDevelopmentStatusID":"4","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMPA Accepts Bio-Thera Solutions\u2019 Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"Amunix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AMX-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Amunix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amunix \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Amunix \/ N.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Presentation of Preclinical Data for TransCon IL-2 \u03b2\/\u03b3 at AACR Virtual Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon IL-2 \u03b2\/\u03b3","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Primary Peptides","sponsor":"Simcere Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcere Pharmaceutical Group and Primary Peptides Inc. Announce Exclusive China Partnership","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Partnership","leadProduct":"PP-001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Primary Peptides","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Primary Peptides \/ Simcere Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Primary Pe.."},{"orgOrder":0,"company":"Primary Peptides","sponsor":"Qingdao Primedicine Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qingdao Primedicine Pharmaceutical Co. Ltd and Primary Peptides Inc. Announce Exclusive China Partnership","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"PP-002","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Primary Peptides","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Primary Peptides \/ Qingdao Primedicine Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Primary Pe.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Dubermatinib","moa":"AXL receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Morningside","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amylyx Pharmaceuticals Raises $30 Million in Series B Funding","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Morningside","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","amount":"$93.5 million","upfrontCash":"Undisclosed","newsHeadline":"Bolt Biotherapeutics nabs $93.5M to Push Provenge Inventor's New Idea Deeper in the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"BDC-1001","moa":"TLR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bolt Biotherapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Bolt Biotherapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"7","companyTruncated":"Bolt Bioth.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Carmine Therapeutics","pharmaFlowCategory":"D","amount":"$900.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda Partners up with Carmine Therapeutics to Develop and Market Rare Disease Candidates","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"RBCEV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0.90000000000000002,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.90000000000000002,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Carmine Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"$407.5 million","upfrontCash":"$10.0 million","newsHeadline":"Hansa Biopharma Inks Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0.40999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"CF PharmTech","sponsor":"BioTrack Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series F Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"CF PharmTech","amount2":0.050000000000000003,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Aerosol","sponsorNew":"CF PharmTech \/ BioTrack Capital","highestDevelopmentStatusID":"1","companyTruncated":"CF PharmTe.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib + Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ex.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck and Ridgeback Bio Announce Closing of Collaboration and Licensing Transaction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Ridgeback Bio","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Celsius Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celsius Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"2","companyTruncated":"Celsius Th.."},{"orgOrder":0,"company":"EpicentRx","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"EpicentRx and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RRx-001","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"EpicentRx","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"EpicentRx \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"EpicentRx .."},{"orgOrder":0,"company":"Chiasma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0.070000000000000007,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ .."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Annexon Closes $100 Million Financing to Advance Broad Pipeline of Classical Complement Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"ANX005","moa":"C1q","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Annexon Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Redmile Group","highestDevelopmentStatusID":"7","companyTruncated":"Annexon Bi.."},{"orgOrder":0,"company":"Crestone","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$18.2 million","upfrontCash":"Undisclosed","newsHeadline":"Crestone, Inc. Secures NIH Funding for Development Through Phase 1 of Novel Antibiotic Candidate CRS0540","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"CRS0540","moa":"PolC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Crestone","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Crestone \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Crestone \/.."},{"orgOrder":0,"company":"ChemRar","sponsor":"Russian Direct Investment Fund (RDIF)","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RDIF and ChemRar Exceed Target Production of Avifavir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ChemRar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ChemRar \/ Russian Direct Investment Fund (RDIF)","highestDevelopmentStatusID":"12","companyTruncated":"ChemRar \/ .."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"$14.5 million","newsHeadline":"Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion Completes Acquisition of Portola","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Coagulation factor Xa (recombinant), inactivated-zhzo","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":1.3999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion Pharmaceuticals, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Intravacc","sponsor":"CimCure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc, CimCure Partner on Cancer, COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ CimCure","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Lysogene","sponsor":"Weizmann Institute of Science","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lysogene Enters Research Pact with Weizmann Institute of Science to Develop New AAV Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AAV gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lysogene \/ Weizmann Institute of Science","highestDevelopmentStatusID":"1","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"CureVac","sponsor":"Tesla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Taps Tesla for 'RNA Microfactories,' Elon Musk Says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"mRNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Tesla","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"DePuy Synthes Sales Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Termination","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ DePuy Synthes Sales Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Marker Therapeutics' New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"MultiTAA-Specific T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Marker Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Marker Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marker The.."},{"orgOrder":0,"company":"Eisai","sponsor":"The Global Coalition for Adaptive Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai to Investigate Eritoran in REMAP-COVID Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Eritoran","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ The Global Coalition for Adaptive Research","highestDevelopmentStatusID":"4","companyTruncated":"Eisai \/ Th.."},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Seltorexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Minerva Neurosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Minerva Neurosciences \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"Minerva Ne.."},{"orgOrder":0,"company":"Shionogi","sponsor":"StemRIM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shionogi Signs New Contract with StemRIM Toward Investigator-initiated Clinical Study Implementation of S-005151","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Redasemtide","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ StemRIM","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mission Raises $15m and Expands its Relationship with Pfizer","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"USP30","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Mission Therapeutics","amount2":0.02,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Mission Th.."},{"orgOrder":0,"company":"Biogen","sponsor":"Massachusetts Eye and Ear","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biogen Joins Harvard in Gene Therapy Pact to Fight Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AAV gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Massachusetts Eye and Ear","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ M.."},{"orgOrder":0,"company":"Novavax","sponsor":"Operation Warp Speed","pharmaFlowCategory":"D","amount":"$1,600.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax, maker of a Covid-19 vaccine, is backed by Operation Warp Speed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"NVX\u2011CoV2373","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novavax","amount2":1.6000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.6000000000000001,"dosageForm":"","sponsorNew":"Novavax \/ Operation Warp Speed","highestDevelopmentStatusID":"7","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Micro-cap Oncology Biotech Sun BioPharma Files for a $12 Million Nasdaq","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Sun BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$86.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rare Disease Biotech Inozyme Pharma Files for an $86 million IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0.089999999999999997,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Inozyme Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Ph.."},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical Oncology Biotech Nkarta Sets Terms for $150 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta The.."},{"orgOrder":0,"company":"CureVac","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Nets EU Funding to Ramp up Vaccine Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"mRNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ European Investment Bank","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"SciLifeLab","sponsor":"Medivir","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir and SciLifeLab Partner to Identify Covid-19 Drug Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"SARS CoV-2 protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SciLifeLab","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SciLifeLab \/ Medivir","highestDevelopmentStatusID":"2","companyTruncated":"SciLifeLab.."},{"orgOrder":0,"company":"Kiq","sponsor":"Unum Therapeutics","pharmaFlowCategory":"D","amount":"$104.4 million","upfrontCash":"Undisclosed","newsHeadline":"Unum Therapeutics Inc. Announces Acquisition of Kiq LLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"PLX9486","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kiq","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Kiq \/ Unum Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Kiq \/ Unum.."},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Fluconazole","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ascentage Pharma Collaborates with MSD to Evaluate APG-115 in Combo with Keytruda in Advanced Solid Tumours","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$55.0 million","newsHeadline":"Dragonfly Therapeutics Announces Collaboration with BMS to Develop Novel Therapeutic Candidates for M.S and Neuro-inflammation Targets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NK cell Engager Therapies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Levosimendan","moa":"Calcium dependent Cardiac Troponin C","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.01,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"WEP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA\u00ae (lefamulin)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ WEP","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lineage Cell Therapeutics Announces Extension of OpRegen\u00ae Development Grant From Israel Innovation Authority","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Retinal pigment epithelium cell transplant therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Lineage Cell Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Lineage Cell Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"7","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"HitGen","sponsor":"Morphic Therapeutic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Morphic Extend Drug Discovery Research Collaboration","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Morphic Therapeutic","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ M.."},{"orgOrder":0,"company":"89bio","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"89bio Announces Proposed Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"BIO89-100","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"89bio \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ Bo.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Shionogi","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"Livzon Pharmaceutical Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LTS and LIVZON Enter into License and Collaboration Agreement to Develop and Commercialize Asenapine TTS","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Asenapine Maleate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS - Lohmann Therapie Systeme","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"LTS - Lohmann Therapie Systeme \/ LIVZON","highestDevelopmentStatusID":"4","companyTruncated":"LTS - Lohm.."},{"orgOrder":0,"company":"American Regent","sponsor":"CytoDyn","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Announces Execution of Agreement with American Regent for Leronlimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"American Regent","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American Regent \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"American R.."},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Zentiva","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra to Commercialize Myring In France, Poland And UK","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Etonogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Mithra Pharmaceuticals \/ Zentiva","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pha.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Starts Regn-Cov2 Phase 3 Covid-19 Prevention Trial In Collaboration With National Institute of Allergy and Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"DynPort","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immune Regulation and DynPort to Trial Covid-19 Drug Candidate","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"ILR201104","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revolo Biotherapeutics \/ DynPort","highestDevelopmentStatusID":"4","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$15.5 million","upfrontCash":"$3.0 million","newsHeadline":"Entasis Therapeutics Awarded Contract from National Institutes of Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"ETX0462","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entasis Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Entasis Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Entasis Th.."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Proglumide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISA Pharmaceuticals Receives US Orphan-Drug Designation for ISA101b in HPV16-Positive Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Papillomavirus Vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ISA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISA Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ISA Pharma.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Presents Phase I\/II Data Testing Onivyde as an Investigational First-Line Combination Treatment for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DS-1062","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces Selection of T-VIVA-19\u2122 as Targeted Protein Vaccine Candidate for SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"T-VIVA-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antroquinonol","moa":"Nrf -2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Golden Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Golden Bio.."},{"orgOrder":0,"company":"MetVital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MetVital Gets FDA Fast Track Designation of Enol-Oxaloacetate for the Treatment of Patients with Newly Diagnosed Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Enol-oxaloacetate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"MetVital","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MetVital \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MetVital \/.."},{"orgOrder":0,"company":"NeurAegis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeurAegis Announces Publication of Preclinical Animal Data Supporting Calpain-2 as a Promising Therapeutic Target for Concussion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Calpain-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"NeurAegis","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeurAegis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NeurAegis .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Submits NDA to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Siltuximab","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eusa Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharm.."},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Napp Pharmaceuticals Announces European Commission Approval of Invokana\u00ae (canagliflozin) Label Update to Reflect Improved Renal Outcomes in Patients With Diabetic Kidney Disease and Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Napp Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napp Pharmaceuticals \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Napp Pharm.."},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Context Therapeutics Announces Publication of Onapristone Extended Release Safety Review Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Onapristone","moa":"PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Context Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces European Commission Approval for Janssen\u2019s Preventive Ebola Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.ZEBOV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNION Receives Approval From Danish Medicines Agency to Initiate Clinical Study With Niclosamide for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Moves Forward with Clinical Development of Neihulizumab in Steroid-Refractory Acute Graft-Vs-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces FUROSCIX\u00ae NDA Resubmission","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences to Present Clinical Data from Phase 1\/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Doses First Patient in EXCELLENCE Phase 2\/3 Clinical Trial of ANAVEX\u00ae2-73 (Blarcamesine) in Patients with Rett Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV for Endogenous Cushing\u2019s Syndrome","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbrid.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Announces All CONTROL Study Sites Open and Enrolling Patients with Moderate to Severe Congenital Ichthyosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Isotretinoin","moa":"RAR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Submitted Marketing Authorization Application to the EMA for Setmelanotide in POMC and LEPR Deficiency Obesities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KVD900","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Geron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ No.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Starts Patient Recruitment in Phase 2 Safety & Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Yuyuan BioScience Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nolasiban","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dispersible Tablet","sponsorNew":"ObsEva \/ Yuyuan BioScience Technology","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ Y.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Whole brain radiation therapy","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rhythm Rare Pediatric Disease Designation for Rare Obesities Drug","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Seeks US FDA Approval to Initiate Phase 1 Study of SYN-020 Intestinal Alkaline Phosphatase","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant bovine intestinal alkaline phosphatase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Tropical Infectious Diseases Research and Education Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TIDREC Laboratory Studies Confirm the Effectiveness of BETADINE\u00ae Gargle and Mouthwash Against COVID-19 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"MALAYSIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Povidone-Iodine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tropical Infectious Diseases Research and Education Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gargle And Mouthwash","sponsorNew":"Tropical Infectious Diseases Research and Education Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tropical I.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron and Sanofi Provide Update on Kevzara\u00ae (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostemsavir","moa":"HIV-1 attachment","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosmo Pharmaceuticals Announces US FDA Approval of BYFAVO\u2122 (remimazolam injection)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medici.."},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emcure Pharma Launches Generic Drug for Hyperphosphatemia in Chronic Kidney Disease Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Emcure Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Chewable Tablet","sponsorNew":"Emcure Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emcure Pha.."},{"orgOrder":0,"company":"Anivive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anivive Initiates Two Pre-Clinical Studies of Investigational Antiviral GC376 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GC376","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anivive","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anivive \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anivive \/ .."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare to Present New Data on Long-Acting Regimens for HIV Prevention and Treatment, Alongside Extensive Insights into the Evolving Needs of People Living with HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Ricerche Announces C-PRECISE-01, a New Phase Ib\/II Trial of MEN1611 in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MEN1611","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Na\u00efve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Study of MRx-4DP0004 in Patients Hospitalized with COVID-19 Open for Enrolment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx-4DP0004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus\u2019 Vaccine for COVID-19 (ZyCoV-D) Successfully Completes Preclinical\nDevelopment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viiv Healthcare Presents Positive Data from First-Ever Implementation Research Study on How Best to Integrate an Investigational Once-Monthly Injectable HIV Treatment In US Healthcare Practices","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"World Health Organization","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"WHO Discontinues Hydroxychloroquine and Lopinavir\/Ritonavir Treatment Arms for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"World Health Organization","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"World Health Organization \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"World Heal.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVYTM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis SA Says Melani-01 Trial has been Placed on Clinical Hold By U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"UCARTCS1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis .."},{"orgOrder":0,"company":"EspeRare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EspeRare Gets FDA Breakthrough Therapy Designation for ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ER-004","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"EspeRare","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-amniotic Injection","sponsorNew":"EspeRare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EspeRare \/.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Announces U.S FDA has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Announces Topline Results from its Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Additional Safety & Efficacy Data for Islatravir in Combination with Doravirine in Adults with HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Announces the Decision by the Investigator to Reduce the Number of Patients in the Ongoing Phase II Trial Evaluating lanifibranor in Type 2 Diabetes Patients with Non-Alcoholic Fatty Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Nyrada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nyrada Reveals Encouraging Cholesterol-Lowering Drug Study Results","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NYX-PCSK9i","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Nyrada","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nyrada \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nyrada \/ N.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Treats First Cancer Patients in Part B of Phase I\/II trial of MRx0518 in Combination with Keytruda\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Presents Additional Data on Relugolix Combination Therapy in Women with Uterine Fibroids and Ovulation Inhibition Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Limited Announces Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Celixir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celixir Provides Update on Ongoing Clinical Programme with Lead Therapeutic Candidate CLXR-001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"iMP cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Celixir","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celixir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Celixir \/ .."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong to Conduct Phase 1 trial of Covid-19 Treatment in Indonesia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DWP710","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX\u00ae3-71 (AF710B)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AF710B","moa":"S1R\/Muscarinic acetylcholine receptor M1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Reports Positive Top-Line Results from Phase 1\/2 Clinical Trial of OTO-313 in Patients with Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Gacyclidine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"LSU Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LSU Health New Orleans Discovers New Class of Safer Analgesics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"LSU Health","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LSU Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"LSU Health.."},{"orgOrder":0,"company":"Otonomy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otonomy Provides Update on OTIVIDEX\u00ae Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Otonomy","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Otonomy \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otonomy \/ .."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"OntoChem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa and OntoChem Announce Completion of Initial Screening Program and Identification of Additional Covid-19 Compounds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ OntoChem","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Positive Opinion from the Paediatric Committee of the EMA on the Agreement of a Paediatric Investigation Plan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune to Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"NasoVAX","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Malin-backed Poseida Therapeutics files for IPO on Nasdaq exchange","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Gene Therapies","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Poseida Therapeutics, Inc","amount2":0.11,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Poseida Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Poseida Th.."},{"orgOrder":0,"company":"University of St Andrews","sponsor":"ILC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ILC Therapeutics Announces Research Partnership with University of St Andrews to Fight Against COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Alfacyte","moa":"INF alpha 14","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of St Andrews","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of St Andrews \/ ILC Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai\u2019s Equfina receives South Korean marketing approval to treat Parkinson\u2019s disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Safinamide Mesylate","moa":"MAO-B","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Alector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"AL002","moa":"TREM2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Announces First Patient Enrolled in Clinical Study Conducted at The Ohio State University in R\/R AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnHeart Therapeutics Announces Acceptance of Taletrectinib Phase 1 Data for Publication in Clinical Cancer Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Completes Submission of NDA Seeking Approval of Casimersen for Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Casimersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Vivoryon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivoryon Develops New Phase IIa Alzheimer\u2019s Trial Design","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Varoglutamstat","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Vivoryon Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivoryon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vivoryon T.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Clears New Class of Anaemia Therapy from Bristol Myers Squibb","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Develops India\u2019s First DCGI-Approved Vaccine Candidate, Gets Nod for Human Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"ReNeuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReNeuron Announces Further Positive Data in Retinal Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Human retinal progenitor cell therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReNeuron","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReNeuron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReNeuron \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces MET Inhibitor Tabrecta\u2122 Approved in Japan for Advanced Non-Small Cell Lung Cancer with METex14","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC bio Announces First Patient Dosed in Second Zimura\u00ae Phase 3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces First Human Dosing With Tacrolimus Inhalation Powder and Topline Data for Voriconazole Inhalation Powder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Immutep","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Completes Recruitment for Part A of Phase II TACTI-002 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Millmount Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsca\u00aeApproved in Japan for Additional Indication of Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolvaptan","moa":"V2R","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Millmount Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rybelsus\u00ae approved in Japan for the treatment of type 2 diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osmotica Pharmaceuticals US LLC Submits Amended NDA for Arbaclofen Extended Release Tablets to U.S. Food and Drug Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Atriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Publication in PNAS Unveils Molecular Pathway Required for Influenza Virus Replication with Large Potential as an Antiviral Drug Target","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ATR-002","moa":"MEK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atriva The.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data presented at ISTH Virtual Congress highlights Sanofi\u2019s commitment to advancing treatments for people with rare blood disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Antihemophilic Factor","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Global Virus Network","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Virus Network Suggests Oral Polio Vaccine May Provide Temporary Protection Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Oral poliovirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Global Virus Network","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Global Virus Network \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Global Vir.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Lifts Partial Clinical Hold on Lacutamab TELLOMAK Trial in Advanced T-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Lacutamab","moa":"KIR3DL2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Analysts hail Akero's Midphase NASH Data as Best in Class","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Optinose","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optinose Announces Anti-COVID-19 Product Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"OPN-019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Optinose","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Optinose \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Optinose \/.."},{"orgOrder":0,"company":"RCSI University of Medicine and Health Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Irish Researchers Test Alpha-1-Antitrypsin for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpha-1-antitrypsin","moa":"Alpha-1 antiproteinase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"RCSI University of Medicine and Health Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RCSI University of Medicine and Health Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RCSI Unive.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Begins Phase 3 Trial for Aflibercept Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Meissa Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MV-014-210","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Meissa Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meissa Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Meissa Vac.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Submits a CTA for a Phase I\/IIa trial of BI-1808","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNF-1B","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Exelixis","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Roche","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Radiolabelled MNPR-101","moa":"uPAR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Monopar Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Monopar Therapeutics \/ NorthStar","highestDevelopmentStatusID":"1","companyTruncated":"Monopar Th.."},{"orgOrder":0,"company":"SparingVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"SPVN06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Enrolls First Patient in the Second Dose Cohort of Trial Combining NOX-A12 With Radiotherapy in Newly Diagnosed Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breast Cancer Drug Capivasertib Enters Major Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Capivasertib","moa":"Serine\/threonine-protein kinase AKT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"The Institute of Cancer Research \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Status to NeuroRx\u2019s Covid-19 Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Announces Presentations at the International Society on Thrombosis and Haemostasis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Marzeptacog alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Melior Discovery","sponsor":"SFA Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"SFA005","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Discovery","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Melior Discovery \/ SFA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Melior Dis.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participant Dosed in Phase 1 Clinical Study with VTP-300 Immunotherapeutic to Treat Chronically Infected Hepatitis B Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VTP-300","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent Enrolls First Patient in Phase I\/IIa Trial of BI-1206 in Combination With KEYTRUDA\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayne Pharma Announces FDA Filing Acceptance of New Drug Application for E4\/DRSP in the US","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imperial College London Begins Dosing in Covid-19 Vaccine Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"IgNova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IgNova Files Patent Application on Antibody Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IgY antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IgNova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IgNova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IgNova \/ N.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Reports IMBRUVICA\u00ae (ibrutinib) Seeks to Expand U.S. Label with Long-Term Data in Waldenstr\u00f6m's Macroglobulinemia (WM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics Receives FDA Fast Track Designation for RBT-9 Treatment in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Stannous protoporphyrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's Research Highlights Potential to Enhance Cancer Treatment by Combining Novel Costimulatory Bispecific Antibodies with Libtayo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"CD28","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sana Biotechnology Announces Completion of Initial Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Gene and Cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sana Biotechnology","amount2":0.69999999999999996,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Sana Biote.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA\u00ae 3PSP Smart Device","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 DNA Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"D","amount":"$59.0\u202c million","upfrontCash":"$43.0 million","newsHeadline":"La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"IBM Watson Health","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution for Phase II Clinical Trial of OT-101 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Trabedersen","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IBM Watson Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IBM Watson Health \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IBM Watson.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"ALX Oncology Holdings Raises $100.0 million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ALX Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"Canadian Institutes of Health Research (CIHR)","pharmaFlowCategory":"D","amount":"$4.2 million","upfrontCash":"Undisclosed","newsHeadline":"Entos Pharmaceuticals Announces Selection of Lead DNA Vaccine Candidates for COVID-19 and a $4.2M Award","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Fusogenix DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Entos Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ Canadian Institutes of Health Research (CIHR)","highestDevelopmentStatusID":"4","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$23.1 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Termination","leadProduct":"Sucrose Acetate Isobutyrate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Durect Corporation","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Durect Corporation \/ Gilead Sciences, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"STC Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Life Sciences Announces Agreement STC Biologics for GMP Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"TZLS-501","moa":"IL-6 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Tiziana Life Sciences \/ STC Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Temasek","pharmaFlowCategory":"D","amount":"$250.0 million","upfrontCash":"$139.0 million","newsHeadline":"Temasek Leads a $250M Raise for BioNTech as First Covid-19 mRNA Vaccine Data Looms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Funding","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0.25,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"BioNTech \/ Temasek","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Smerud Medical Research","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture Out-Licenses Clinical Assets to Smerud","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncology Venture","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Oncology Venture \/ Smerud Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Oncology V.."},{"orgOrder":0,"company":"University of Oslo","sponsor":"BioArctic AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"NORWAY","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Apolipoprotein E","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"University of Oslo","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Oslo \/ BioArctic","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Perrigo Company plc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Perrigo Company plc \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Perrigo Co.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"G1 Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Trilaciclib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ G1 Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"NHS England","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vertex Announces Expansion of Reimbursement Agreement With NHS England","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"NHS England","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"NHS England \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"NHS Englan.."},{"orgOrder":0,"company":"Bioasis","sponsor":"CHIESI USA INC","pharmaFlowCategory":"D","amount":"$141.0 million","upfrontCash":"$3.0 million","newsHeadline":"Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Transcend-peptide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Bioasis","amount2":0.14000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Bioasis \/ Chiesi Group","highestDevelopmentStatusID":"1","companyTruncated":"Bioasis \/ .."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pandion Therapeutics Raises $75 million IPO","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Public Offering","leadProduct":"PT101","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Pandion Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"GSK","sponsor":"Medicago","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK and Medicago Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Candidate Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CoVLP vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Medicago","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Medi.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regeneron Announces Manufacturing and Supply Agreement for Barda And U.S. DOD For Regn-Cov2 Anti-Viral Antibody Cocktaill","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"REGN10933","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Lipidor AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lipidor, Cadila to Conduct Ph III Study of Anti-Psoriasis Candidate","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Cadila Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cadila Pharmaceuticals \/ Lipidor","highestDevelopmentStatusID":"8","companyTruncated":"Cadila Pha.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"Undisclosed","newsHeadline":"Ology Bioservices Wins Three Department of Defense Awards Totaling More Than $16 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ology Bioservices","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"APEIRON Biologics and MaxCyte Enter Into Clinical and Commercial Licensing Agreement for APN401","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"APN401","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ APEIRON","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Osivax","sponsor":"European Innovation Council","pharmaFlowCategory":"D","amount":"$34.0 million","upfrontCash":"Undisclosed","newsHeadline":"Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"OVX836","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Osivax \/ European Innovation Council","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ E.."},{"orgOrder":0,"company":"CytoAgents","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"CytoAgents Receives Funding to Accelerate COVID-19 Clinical Trials for Cytokine Storm Treatment From Richard King Mellon Foundation","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"GP1681","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoAgents \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents.."},{"orgOrder":0,"company":"ProLynx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProLynx announces SBIR Arant Award to Develop Long-Ating Parathyroid Hormone for Hypo-Parathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"PTH(1-34)","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProLynx \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ .."},{"orgOrder":0,"company":"Gesynta Pharma","sponsor":"Hadean Ventures","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"Gesynta raises SEK 190M in Round Led by Hadean Ventures to Accelerate Development of First-in-Class mPGES-1 Inhibitor GS-248","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"GS-248","moa":"mPGES-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Gesynta Pharma","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Gesynta Pharma \/ Hadean Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Gesynta Ph.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Cybin Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntelGenx \/ Cybin Corp","highestDevelopmentStatusID":"1","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Multi-specific antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Numab Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"2","companyTruncated":"Numab Ther.."},{"orgOrder":0,"company":"Vor Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vor Biopharma Closes $110 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"VOR33","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vor Biopharma","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Vor Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Vor Biopha.."},{"orgOrder":0,"company":"Quantitative Medicine","sponsor":"Predictive Oncology","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"Predictive Oncology Completes Acquisition of Quantitative Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Quantitative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Quantitative Medicine \/ Predictive Oncology","highestDevelopmentStatusID":"2","companyTruncated":"Quantitati.."},{"orgOrder":0,"company":"Biothera Pharmaceuticals","sponsor":"HiberCell","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Imprime PGG","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biothera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biothera Pharmaceuticals \/ HiberCell","highestDevelopmentStatusID":"8","companyTruncated":"Biothera P.."},{"orgOrder":0,"company":"AlloVir","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Annexon, AlloVir Gun for $100M IPOs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"ALVR109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AlloVir \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foghorn\u00ae Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target\r\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0.42999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$66.0 million","newsHeadline":"CEPI to Invest $66 Million to Boost Clover's COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"S-Trimer COVID vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clover Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA\u00ae for the Treatment of Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Bentley University","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$6,500.0 million","upfrontCash":"Undisclosed","newsHeadline":"$6.5 billion in NIH Funding for Foundational Research Enabled Emergency Use Authorization of Remdesivir for Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bentley University","amount2":6.5,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":6.5,"dosageForm":"Intravenous Injection","sponsorNew":"Bentley University \/ Ntional Institute of Health","highestDevelopmentStatusID":"12","companyTruncated":"Bentley Un.."},{"orgOrder":0,"company":"Plakous Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Plakous Therapeutics Awarded $1.7 Million Fast-Track SBIR Grant from NIH to Develop Therapies for Necrotizing Enterocolitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Protego-PD","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Plakous Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Plakous Therapeutics \/ National Institute of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plakous Th.."},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"EDIT-301","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Grou.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$176.0 million","upfrontCash":"$25.0 million","newsHeadline":"Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0.17999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Turning Point Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Atreca","sponsor":"Xencor","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"T Cell Engaging Bispecific Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Atreca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ Xencor","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ X.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Taiba","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"VarmX","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$36.6 million","upfrontCash":"Undisclosed","newsHeadline":"VarmX Raises \u20ac32 Million to Develop Innovative Reversal Agent for the Treatment of Bleeding in Patients on Oral Anticoagulants","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"VMX-COO1","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"VarmX","amount2":0.040000000000000001,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VarmX \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"VarmX \/ Ys.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Professor Rikard Holmdahl","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyxone Signs Agreement With Professor Rikard Holmdahl as Senior Scientific Advisor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"T20K","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Professor Rikard Holmdahl","highestDevelopmentStatusID":"6","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Var2 Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VAR2 Pharmaceuticals Wins MilliporeSigma\u2019s Advance Biotech Grant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"rVAR2 Drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Var2 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Var2 Pharmaceuticals \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Var2 Pharm.."},{"orgOrder":0,"company":"SGS Life Sciences","sponsor":"Biophytis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biophytis and SGS Partner to Test Sarconeos in Covid-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"SGS Life Sciences","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"SGS Life Sciences \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"SGS Life S.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Thermo Fisher Signs CDx Agreement with Chugai Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Entrectinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead axes $445M Precision Biosciences Gene Therapy Hep B Pact","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Termination","leadProduct":"HBV gene therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna\u2019s COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Moderna","highestDevelopmentStatusID":"10","companyTruncated":"Laboratori.."},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology to Treating Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"TQS-168","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Tranquis Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis T.."},{"orgOrder":0,"company":"Zymeworks","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$891.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zymeworks Announces New Multispecific Antibody Collaboration with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0.89000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"","sponsorNew":"Zymeworks \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks .."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Kreos Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenSight Biologics Obtains a \u20ac7m Non-Dilutive Loan and Renegotiates the Bond Agreement With Kreos Capital Extending Runway to Mid-2021","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenSight Biologics \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"DynPort Vaccine Company","sponsor":"Altimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"DynPort Vaccine Company","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"DynPort Vaccine Company \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"DynPort Va.."},{"orgOrder":0,"company":"MolMed","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"OTL-200","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"MolMed","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MolMed \/ Orchard Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"MolMed \/ O.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$34.6 million","upfrontCash":"Undisclosed","newsHeadline":"Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration for COVID-19 Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Hyperimmune Globulin","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"KALEO INC","sponsor":"Optinose","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optinose Announces XHANCE Co-Promotion Agreement with Kal\u00e9o","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"KALEO INC","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"KALEO INC \/ Optinose","highestDevelopmentStatusID":"12","companyTruncated":"KALEO INC .."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takeda Teams up with Twist Bioscience to Boost Biologics R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Takeda","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Natco Pharma's Canadian Unit Signs Pact with Celgene for Cancer Treatment Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Lenalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Natco Pharma \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocumension Therapeutics Launches Initial Public Offering on Hong Kong Stock Exchange","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"OcuMension Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"5","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Kures","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ATAI Life Sciences Takes on Opioid Crisis by Acquiring Kures to Develop Novel Therapeutics for Opioid Abuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"KUR-101","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Kures","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kures \/ ATAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Kures \/ AT.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Times Pharmacy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B\u00ae Hepatitis B Vaccine to Customers Throughout Oahu","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Hepatitis B Vaccine (Recombinant) Adjuvanted","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Times Pharmacy","highestDevelopmentStatusID":"12","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Hudson Bay Capital","pharmaFlowCategory":"D","amount":"$102.8 million","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation Biologics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Hudson Bay Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Ardigen","sponsor":"CVC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ardigen, CVC Collaborate to Develop SARS-CoV-2 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Ardigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ardigen \/ CVC","highestDevelopmentStatusID":"3","companyTruncated":"Ardigen \/ .."},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orsini Pharmaceutical Services Expands Partnership With Ultragenyx To Provide Dojolvi\u2122 (triheptanoin)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Triheptanoin","moa":"Triglyceride","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orsini Specialty Pharmacy","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Orsini Specialty Pharmacy \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Orsini Spe.."},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Plex Pharmaceuticals Awarded $1.6 Million in Grant Funding from NIH to Advance Eye Drop Therapy for Cataracts","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"CAP4196","moa":"Alpha A crystallin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Plex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Plex Pharmaceuticals \/ National Institute of Health","highestDevelopmentStatusID":"5","companyTruncated":"Plex Pharm.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ Jefferies","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Immunomedics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunomedics Expands Collaboration with Roche Evaluating TrodelvyTM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Immunomedics","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Excivion","sponsor":"CPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CPI Partners with Excivion to Optimise and Scale up Production of Safe and Effective Zika Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Zika-HX antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Excivion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Excivion \/ CPI","highestDevelopmentStatusID":"1","companyTruncated":"Excivion \/.."},{"orgOrder":0,"company":"Alliance Pharmaceutical Company","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Licenses Canadian Rights to Ametop\u2122 Gel from Alliance Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tetracaine Hydrochloride","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Alliance Pharmaceutical Company","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alliance Pharmaceutical Company \/ Valeo Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Alliance P.."},{"orgOrder":0,"company":"Oncology Venture","sponsor":"2X Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncology Venture Acquires Full Ownership of its PARP Inhibitor (2X-121) Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Stenoparib","moa":"PARP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncology Venture","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncology Venture \/ 2X Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Oncology V.."},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai Enters Industry-Academia-Government Joint Research Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"E6742","moa":"TLR7\/8","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Un.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Antimicrobial Resistance Antibiotics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Rakuten Medical","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical Closes Deal with Merck KGaA, Darmstadt to Receive Cetuximab for Production of its ASP-1929 Antibody-Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Cetuximab-conjugated IRDye700DX","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Rakuten Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rakuten Medical \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Rakuten Me.."},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Premier Inc. ProvideGx\u2122 Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Propofol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Premier","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius .."},{"orgOrder":0,"company":"Undisclosed","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon Therapeutics to Fund Observational Studies of Artemisinin in Developing Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Undisclosed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Undisclosed \/ Mateon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Undisclose.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Reports superior efficacy of long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Launch In-House Developed New Anti-insomnia Drug in Japan","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemborexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Johns Hopkins University Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cord blood derived T-regulatory cell therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Johns Hopkins University Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johns Hopkins University Hospital \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopk.."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"7HP349","moa":"Integrin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"jCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"jCyte Announces Presentation of Phase 2b Results Evaluating jCell in Retinitis Pigmentosa at the American Society of Retina Specialists","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic human retinal progenitor cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ No.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Gets IRB Approval for Phase II trial of ANVS401","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring Evaluates Monoclonal Antibody in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Garadacimab","moa":"Factor XIIa","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"ILIAS Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ILB-202","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"ILIAS Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILIAS Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ILIAS Biol.."},{"orgOrder":0,"company":"Sinomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinomed Completes Enrollment in PIONEER-III pivotal US & Japanese Trial of the BuMA Supreme Coronary DES","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sinomed","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinomed \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sinomed \/ .."},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evive Biotech meets Promising Results at Global Ph III Trial for Neutropenia Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efbemalenograstim alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biot.."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Neurogene\u2019s Gene Therapy for the Treatment of CLN5 Batten Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-based engineered transgene","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSIR Seeks Regulatory Nod for Clinical Trials Using Combination of Antivirals and HDTs Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LAXAI Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LAXAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LAXAI Life.."},{"orgOrder":0,"company":"Biophytis","sponsor":"SGS Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Receives IND Clearance for COVA, a Phase 2\/3 Clinical Trial with Sarconeos for Treatment of COVID-19 Related Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ SGS","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CYT-0851","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir The.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Dosing Initiation in 2nd Phase 1 Trial with INM-755","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"TALLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TA-A001","moa":"CB receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"TALLC","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"TALLC \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TALLC \/ No.."},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarametyx Biosciences Published data in eBioMedicine Validates Novel Scientific Approach That Disarms Bacterial Defenses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Clarametyx Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clarametyx Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clarametyx.."},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reven Publishes New COVID-19 Related Articles Outlining Clinical Impact Potential of Its RJX Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Phar.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL\u2122 Study in RDEB after COVID-19 Related Pause","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Talaris Therapeutics\u2019 IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FCR001","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Biogen","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ E.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Initiates Phase 1\/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NC410","moa":"LAIR-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ANG-3777","moa":"HGF","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Bio.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Publish New Results in Journal of Alzheimer's Disease Support Masitinib\u2019s Potential Mode of Action in AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Seaver Autism Center for Research and Treatment","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seaver Autism Center For Research and Treatment at Mount Sinai Launches First Drug Trial for ADNP Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seaver Autism Center for Research and Treatment","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seaver Autism Center for Research and Treatment \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seaver Aut.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Awarded U.S. Composition of Matter Patent Covering Engineered Bacterial Strains for Treating Skin Conditions","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Staphylococcus epidermidis","moa":"SPINK5 gene","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Azitra","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Azitra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ N.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Submits Publication on StemVacs\u2122 Preclinical Data Supporting COVID-19 Indication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dendritic Cell Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection\n","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"In Vitro Testing of Innovation Pharmaceuticals\u2019 Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Files IND for International Phase 1b\/2b COVID-19 Clinical Program With TSC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Confirms Bioequivalence of New Tesamorelin Formulation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nasus Pharma Announces Data Demonstrating Efficacy of TaffiX\u00ae Intranasal Antiviral Protection Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Phar.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenava","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Publishes of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CA-4948","moa":"Interleukin-1 receptor-associated kinase 4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CPI-006","moa":"CD73","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Resumes CB4211 Phase 1b Clinical Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CB4211","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Cybrexa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cybrexa Therapeutics Completes Successful Pre-IND Meeting With FDA for CBX-12 (alphalex\u2122-exatecan), a Novel Treatment for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Alphalex-exatecan","moa":"DNA Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cybrexa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cybrexa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cybrexa Th.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Announces Simultaneous Regulatory Approvals by U.S. FDA and Health Canada of INQOVI","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cedazuridine","moa":"Cytidine deaminase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Doses First DIPG Patient in Phase 1\/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constant Therapeutics' TXA127 to be Tested in Multiple Clinical Trials for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Constant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant T.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PTC857","moa":"15-LOX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PL9643","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SARCLISA\u2122 (isatuximab for injection) Now Available in Canada for Patients with Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"University of Liverpool","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Trial Platform Launched to Accelerate COVID-19 Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Liverpool","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Liverpool \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"University.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EU Nod for Lynparza in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Erasmus University Medical Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stem Cell Gene Therapy Restores Glycogen Levels, Aids Movement in Mouse Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hematopoietic Stem Cell Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Erasmus University Medical Center","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Erasmus University Medical Center \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Erasmus Un.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Early Data Support Catalyst Biosciences\u2019 Potential Hemophilia B Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FIX-Gene Therapy","moa":"Factor IX","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laboratory Studies Confirm BETADINE(R) Antiseptic Products' Effectiveness Against COVID-19 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Povidone-Iodine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Gargle And Mouthwash","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data to be Presented at ISTH Virtual Congress Highlights Sobi's Commitment to Advancing Rare Haematology Treatments","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"rFVIIIFc-VWF-XTEN","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Renovion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renovion Announces Publication of Research Demonstrating the Impact of the Novel Treatment, Arina-1 on Mucus Transport in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ascorbic Acid","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Renovion","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Renovion \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovion \/.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Reports Positive Results of Preclinical Study of KB-0742","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KB-0742","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's BRILINTA Gets FDA Priority Review for the Reduction of Subsequent Stroke Acute Ischemic Stroke Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergy Therapeutics Announces Invalidation of the Birch MATA MPL Phase III Primary Endpoint Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tree MATA MPL","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Allergy Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allergy Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergy Th.."},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viracta Gets Notice of Allowance for U.S. Patent Application Covering its Combination Product Candidate for the Treatment of Viral or Virally-Induced Conditions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanatinostat","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viracta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Th.."},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JS InnoPharm Announces First Patient Dosed with JSI-1187","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"JSI-1187","moa":"ERK1\/2 Mapk","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"JS InnoPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPha.."},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal\/Provincial\/Territorial Public Drug Plan Formularies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Ph.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Announces Initiation of Phase 1\/2 Clinical Trial of NT219 in Advanced Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NT219","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Grifols International","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces Availability of TAVLESSE\u00ae (Fostamatinib Disodium Hexahydrate) in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Grifols S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients with Delirium and Agitation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Maruho\u2019s Phase III Study with Chugai\u2019s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Online","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Clinical Drug Candidate IRL752 Published in JPET","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IRL752","moa":"5-HT7 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Ricerche Announces the Latest Findings of Its Vaborem\u2122 and Quofenix\u2122 Clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Delafloxacin","moa":"Topoisomerse 4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq for Acquired Blepharoptosis (Droopy Eyelid) in Adults","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ABI-H2158","moa":"Viral core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Brown University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug treatment Could Improve Effectiveness of Immunotherapy for Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Navtemadlin","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Brown University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Brown University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Brown Univ.."},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Announces Patent Application for the First-Ever Powder for Oral Liquid Formulation of Duloxetine Hydrochloride for Major Depressive and Generalized Anxiety Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Duloxetine Hydrochloride","moa":"Serotonin transporter","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"OWP Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"OWP Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"OWP Pharma.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in Animal Model Advances NanoViricides\u2019 SARS-CoV-2 Therapeutics Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"APN","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cormedix inc. Reports Submission of Defencath\u2122 New Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-24","moa":"CEACAM1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Phar.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio Announces Orphan Drug Designation of Imsidolimab For Treatment of Generalized Pustular Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics Announces Potential COVID-19 Treatment EIDD-2801 Will Leverage Innovative Testing Platform AGILE for Phase 2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Aichi Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aichi Cancer Center, NEC study Advanced Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Neoantigen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Aichi Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aichi Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Aichi Canc.."},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indapta Therapeutics Provides Updates on Its G-NK cell Therapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic G-NK cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Th.."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TerraCoV2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Atox Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atox Bio Announces Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial in Necrotizing Soft Tissue Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Reltecimod","moa":"CD28","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atox Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atox Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Atox Bio \/.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Announces Updated Indication for Dysport\u00ae (abobotulinumtoxinA) for the Treatment of Spasticity in Children","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm's Avigan Inconclusive in COVID-19 Patients in Japan Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LZRSE-Col7A1 Engineered Autologous Epidermal Sheets","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Phoenix Tissue Repair","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s Phoenix Tissue Repair to Highlight Interim Phase 1\/2 Study Data","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PTR-01","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Phoenix Tissue Repair","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FT819","moa":"CAR19 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Fate Thera.."},{"orgOrder":0,"company":"Center Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CS02 Changes the Landscape of Diabetes Treatment: CenterLab Announces Positive Topline Results of Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CS02","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Center Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Center Laboratories \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Center Lab.."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Lab Gets USFDA Nod for Baclofen Tablets; Stock Ends Higher","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pankajakasthuri Announces Promising Interim Results for ZingiVir\u2013H Among COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Undisclosed","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zingivir-H","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pankajakasthuri Herbal Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pankajakasthuri Herbal Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pankajakas.."},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon\u2019s Breakthrough Drug Itolizumab Receives DCGI Nod for its\nUse in Moderate to Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Biocon","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ N.."},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Biosciences Presents Data at the International Society for Thrombosis and Haemostasis (ISTH) Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Marzeptacog alfa","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst B.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7-day Levofloxacin\/Dexamethasone Eye Drops as Effective as Standard Treatment After Cataract Surgery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Levofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Provides Business Update and Announces Preliminary First Quarter Fiscal 2021 Financial and Operating Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Authorization for Individual Patient Expanded Access Protocol for the use of Tradipitant for Gastroparesis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Freeline Presents New Haemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinigen's ALS Therapy Bags US Orphan Status","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse\u00ae Inhaled Nitric Oxide Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AVA-001","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension\/Switch Study of Investigational Once-Nightly FT218","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pha.."},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARS Pharmaceuticals Announces New Patent on ARS-1 (epinephrine nasal spray)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ARS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ARS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ARS Pharma.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amendments to ProtoKinetix AAGP\u00ae Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1\/2b Study Evaluating ARQ-252 in Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ARQ-252","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All Patients Have Completed their 15-month Visits in the European Phase IIb Trial with the Diabetes Vaccine Diamyd","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Files IND Application to FDA for Phase 2 Study of EC-18 in Preventing ARDS due to COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience AB (publ) Interim Report January-June 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1015","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-280","moa":"Arginase-1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel\u2019s Clinical Stage CDK2\/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclacel P.."},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ridinilazole","moa":"Cell Division","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Summit Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Summit The.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"JS016","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Commences 1000 Patients Post Marketing Surveillance Study With COVID-19 Who Are Administered FabiFlu\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"NextCure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1\/2 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NC318","moa":"S15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NextCure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NextCure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NextCure \/.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMAG Announces Presentation of Ciraparantag Data at the International Society on Thrombosis and Haemostasis","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciraparantag","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AMAG Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1\/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SPK-8011","moa":"Factor VIII","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Ther.."},{"orgOrder":0,"company":"Queensland University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia\u2019s Queensland University Begins Covid-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Queensland University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Queensland University \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Queensland.."},{"orgOrder":0,"company":"Sechenov University Center for Clinical Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russian University Completes Clinical Trials of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sechenov University Center for Clinical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Powder for the Preparation of an Intramuscular Solution","sponsorNew":"Sechenov University Center for Clinical Research \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sechenov U.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s Finerenone Meets Primary Endpoint in Phase III FIDELIO-DKD Renal Outcomes Study in Patients with Chronic Kidney Disease and T2D","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces U.S. FDA Acceptance of Biologics License Application for Tralokinumab for Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia May Start Phase III Tial of COVID-19 Vaccine in Mid-August: RIA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac Lyo","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"ExeGi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibiotics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ExeGi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExeGi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ExeGi \/ No.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Announces that the United Kingdom\u2019s MHRA Grants Early Access to Lumasiran","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From Phase IIIb Study Reinforces Safety Profile of Genentech\u2019s Hemlibra (emicizumab-kxwh) in People With Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immodulon Announces that IMM-101 will be Evaluated in World-First, Prophylactic Immuneboosting Strategy for COVID-19 in Cancer Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IMM-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Immodulon Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immodulon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immodulon .."},{"orgOrder":0,"company":"Archivel Farma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Archivel Farma\u2019s RUTI Vaccine to Start a Clinical Trial to Increase the Immunity of Healthcare Professionals Exposed to the Risk of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"RUTI vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archivel Farma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Archivel Farma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Archivel F.."},{"orgOrder":0,"company":"Zucero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucero Therapeutics Announces Promising Covid-19 Virus Laboratory Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Pixatimod","moa":"Spike protein S1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Zucero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zucero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Zucero The.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"CSIRO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceutical's RECCE\u00ae Compounds Selected by CSIRO\/Doherty Institute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral Screening Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Recce 327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ CSIRO","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"ICMR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ICMR Partners with Bharat Biotech to Launch COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ ICMR","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pracinostat","moa":"pan-HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MEI Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Helsinn Group","highestDevelopmentStatusID":"10","companyTruncated":"MEI Pharma.."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mundipharma Gets E.C Approval for Extended Invokana\u00ae (Canagliflozin) Indication to Cover Diabetic KD in Type 2 Diabetes","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mundipharma \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CSL Behring's IDELVION\u00ae Becomes First and Only Factor IX Therapy with 21-Day Prophylactic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Albutrepenonacog Alfa","moa":"Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty\u00ae for the Treatment of Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil\u2019s Regulator Approves Trial of Sinovac\u2019s Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second PhIII Study for Idorsia's Sleep Drug Returns Positive Results","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ\u00ae Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents Final Data From its Phase IIa Clinical Trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vafidemstat","moa":"Il-6","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies Completes Patient Dosing in Cohort 4 of OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm to Partner with Dr Reddy's to Sell Avigan Overseas as Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Toyama Chemical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Toyama Chemical \/ Dr Reddy's","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm T.."},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co., LLC","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Announces a \u20ac 6.1 Million Capital Increase Through Private Placement","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Biophytis \/ H.C. Wainwright & Co., LLC","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson\u2019s Lead COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Virbac","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Animal Health Acquires US Rights to Sentinel Flavor Tabs & Sentinel From Virbac","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Milbemycin Oxime","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Virbac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virbac \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Virbac \/ M.."},{"orgOrder":0,"company":"QurAlis","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"2 Months After Launch, QurAlis Nabs Early ALS Compounds from Eli Lilly","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"QurAlis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"QurAlis \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"QurAlis \/ .."},{"orgOrder":0,"company":"Citryll","sponsor":"BOM Brabant Ventures","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Citryll Completes \u20ac 18.5 M Fundraise to Develop CIT-013, an Antibody Targeting Neutrophil Extracellular Traps","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"CIT-013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Citryll","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Citryll \/ BOM Brabant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Citryll \/ .."},{"orgOrder":0,"company":"Revitope Oncology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Junshi Taps Revitope for Next-Gen Anticancer Bispecifics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Immunotherapy compound","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Revitope Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Revitope Oncology \/ Junshi Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Revitope O.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"CK-274","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cytokinetics","amount2":0.45000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ RTW Investments","highestDevelopmentStatusID":"8","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Educell","sponsor":"Orgenesis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis Enters Collaboration Agreement with Educell","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CAR-T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Educell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Educell \/ Orgenesis","highestDevelopmentStatusID":"1","companyTruncated":"Educell \/ .."},{"orgOrder":0,"company":"Lamassu Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Lamassu Pharma Receives Prestigious $1.5 Million NIH SBIRP Grant to Support Further Development of its Novel Therapy for Acute Pancreatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"RABI-767","moa":"Lipase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Lamassu Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lamassu Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Lamassu Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novocure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novocure Announces Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"Tumor growth","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Novocure","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Applied Biology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied Biology and Kintor to Collaborate on the Use of Proxalutamide for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen Receptors","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kintor Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kintor Pharmaceutical \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Kintor Pha.."},{"orgOrder":0,"company":"Versameb","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"Versameb Raises CHF 6 Million and Strengthens Team to Advance its VERSagile Technology Platform Towards Clinical Trials","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Financing","leadProduct":"RNA based therapies","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Versameb","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Versameb \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versameb \/.."},{"orgOrder":0,"company":"Vivasc Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"Vivasc Therapeutics Receives NIH Phase I STTR Grant to Utilize Novel Cardiac Targeting Peptides for Targeted Delivery of Amiodarone","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Funding","leadProduct":"CTP-Amio","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Vivasc Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivasc Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Vivasc The.."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sterling Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sterling Pharma Solutions \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Sterling P.."},{"orgOrder":0,"company":"Nurx","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD and Nurx Expand Access to ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Nurx","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravaginal Ring","sponsorNew":"Nurx \/ TherapeuticMD","highestDevelopmentStatusID":"12","companyTruncated":"Nurx \/ The.."},{"orgOrder":0,"company":"GSK","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orchard Licenses Gene Therapy Technology from GSK","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OTL-103","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Orchard Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Orch.."},{"orgOrder":0,"company":"Hackensack Meridian CDI","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hackensack Meridian Partners with Merck for Covid-19 Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Hackensack Meridian CDI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hackensack Meridian CDI \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Hackensack.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relay Passes the Baton from Private to Public Biotech for $400M","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"RLY-1971","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Kronos Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bischofberger's Kronos Buys SYK Inhibitors from Gilead","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Entospletinib","moa":"SYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Kronos Bio","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Imvax","sponsor":"HP WILD Holding AG","pharmaFlowCategory":"D","amount":"$112.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imvax Raises $112M to Advance Brain Cancer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"IGV-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imvax","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Inhalation","sponsorNew":"Imvax \/ HP WILD Holding AG","highestDevelopmentStatusID":"8","companyTruncated":"Imvax \/ HP.."},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Acacia Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acacia Pharma Assigned US License for BYFAVO\u2122 (remimazolam) by Cosmo Pharmaceuticals NV","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cosmo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cosmo Pharmaceuticals \/ Acacia Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cosmo Phar.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Invetx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Invetx","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Oncorus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncorus Announces Collaboration with Merck to Evaluate the Combination of Oncorus\u2019 ONCR-177 with Merck\u2019s KEYTRUDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"ONCR-177","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Oncorus","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Catalent Pharma Solutions \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"F-star Therapeutics: Merck KGaA, Darmstadt, Germany Takes an Early Option in Immuno-Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Tetravalent bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ Merck KGaA","highestDevelopmentStatusID":"4","companyTruncated":"F-star The.."},{"orgOrder":0,"company":"Virometix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virometix Announces Successful Closing of Series B Investment Round raising CHF 7.5 million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"V-306","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virometix","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Virometix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Virometix .."},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Mydecine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Leiden University Medical Center","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leiden University Medical Center \/ Mydecine","highestDevelopmentStatusID":"4","companyTruncated":"Leiden Uni.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Nantes Metropole","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"OSE Immunotherapeutics Receives Grant to Advance COVID-19 Vax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Covepit","moa":"SARS-CoV-2 spike protein inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Nantes Metropole","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"BioAtla","sponsor":"Soleus Capital","pharmaFlowCategory":"D","amount":"$72.5 million","upfrontCash":"Undisclosed","newsHeadline":"BioAtla Rakes in $72.5M Series D, Advancing Research for pH-Detecting Cancer Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series D Financing","leadProduct":"CAB-AXL-ADC","moa":"AXL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"BioAtla \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ .."},{"orgOrder":0,"company":"Partner International","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari\u00ae for Diverticulosis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Partner International","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Partner International \/ Emmaus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Partner In.."},{"orgOrder":0,"company":"Path BioAnalytics","sponsor":"Recce Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE\u00ae Compounds in Expanded SARS-CoV-2 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Recce 327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Path BioAnalytics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Path BioAnalytics \/ Recce Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Path BioAn.."},{"orgOrder":0,"company":"GSK","sponsor":"Foundation Consumer Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Consumer Healthcare to Add Seven Over-the-Counter Brands to Expanding Portfolio of Healthcare Products","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Brompheniramine Maleate","moa":"H1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Foundation Consumer Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Foun.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inozyme Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inozyme Pharma Acquires ENPP1 Deficiency Program Assets from Alexion Pharmaceuticals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"INZ-701","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Inozyme Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"PicnicHealth","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche, Genentech Employ PicnicHealth to Tap into MS Patient Data","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"PicnicHealth","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PicnicHealth \/ Roche","highestDevelopmentStatusID":"1","companyTruncated":"PicnicHeal.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Closes Series B Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Pharmapark","sponsor":"Pharmapark","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions Partners with Pharmapark to Market BAT2506 in Russia and other CIS Countries","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Golimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Pharmapark","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharmapark \/ Pharmapark","highestDevelopmentStatusID":"6","companyTruncated":"Pharmapark.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$183.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0.17999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.17999999999999999,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orphazyme to Collaborate with The Michael J. Fox Foundation on Parkinson\u2019s Disease Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Arimoclomol","moa":"HSF-1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chiesi Group and Bayer Announce Co-Promotion Agreement for Respiratory Treatments Clenil and Foster in China","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Beclomethasone Dipropionate","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Chiesi Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chiesi Group \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Chiesi Gro.."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO\u00ae (selinexor) Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Karyopharm Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Promethera Biosciences","sponsor":"Aceso Life Science Holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Promethera Plans to Form Joint Venture to Conduct Research and Develop Cell-Based and Biological Therapies to Treat Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"HepaStem","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Promethera Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Promethera Biosciences \/ Aceso Life Science Holding","highestDevelopmentStatusID":"8","companyTruncated":"Promethera.."},{"orgOrder":0,"company":"Columbia University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix to Focus on Precision Medicine Approaches for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccines","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Announces Participation in AMR Action Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Antimicrobial Resistance Antibiotics","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"NewG Lab","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"AnHeart Therapeutics Announces License Agreement with NewG Lab for Taletrectinib Rights in Korea","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ NewG Lab","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$540.0 million","upfrontCash":"$40.0 million","newsHeadline":"Assembly Biosciences and BeiGene Announce License and Collaboration Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"ABI-H0731","moa":"Core protein allosteric","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0.54000000000000004,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.54000000000000004,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Rilonacept","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Kiniksa Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Kiniksa Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"12","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Consonance Capital Management","pharmaFlowCategory":"D","amount":"$43.0 million","upfrontCash":"Undisclosed","newsHeadline":"Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"MT-3724","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Molecular Templates","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Molecular Templates \/ Consonance Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$650.0 million","upfrontCash":"$650.0 million","newsHeadline":"Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0.65000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.65000000000000002,"dosageForm":"Oral","sponsorNew":"PTC Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Asili Research Alliance","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Artemisinin","moa":"TGF beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Asili Research Alliance","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asili Research Alliance \/ Mateon","highestDevelopmentStatusID":"4","companyTruncated":"Asili Rese.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$18.9 million","upfrontCash":"Undisclosed","newsHeadline":"ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"CF-370","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ CARB-X","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Syracuse Biopharma","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics\u2019 Solid Tumor Technology in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"HONG KONG","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"T-cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Syracuse Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syracuse Biopharma \/ JW Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Syracuse B.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,680.0 million","upfrontCash":"$775.0 million","newsHeadline":"Roche Signs up to $1.7bn Cancer Drug Deal with Blueprint Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Pralsetinib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":1.6799999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":1.6799999999999999,"dosageForm":"Oral","sponsorNew":"Blueprint Medicines \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$986.0 million","upfrontCash":"$20.4 million","newsHeadline":"Kiadis Licenses Previously Undisclosed Pre-Clinical K-NK-cell Programs to Sanofi, with Total Potential Deal Value of \u20ac875 Million, Plus Royalties","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Isatuximab-irfc","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanofi","amount2":0.98999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.98999999999999999,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Vizient","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Vizient","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Establishes Manufacturing Network in Preparation for Its Ph 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"LP-300","moa":"ALK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lantern Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lantern Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lantern Ph.."},{"orgOrder":0,"company":"Fairhaven Pharmaceuticals","sponsor":"Liminal BioSciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program for Eosinophilic-Driven Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"OXE receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Fairhaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fairhaven Pharmaceuticals \/ Liminal BioSciences","highestDevelopmentStatusID":"4","companyTruncated":"Fairhaven .."},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 1\/2 Gene Therapy Biotech Freeline Therapeutics Files for a $100 million US IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Spur Thera.."},{"orgOrder":0,"company":"FHI Clinical","sponsor":"Leidos Biomedical Research, Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FHI Clinical Inc. Providing Clinical Operations Services for ACTT-1 Trial of Remdesivir for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"FHI Clinical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"FHI Clinical \/ Leidos Biomedical Research, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"FHI Clinic.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1068.5 million","upfrontCash":"$72.3 million","newsHeadline":"Basilea Reports Launch of Antifungal Cresemba\u00ae (isavuconazole) in Taiwan, Triggering the Second Milestone Payment Related to Asia-Pacific","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":1.0700000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.0700000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Invetx Announces Industry-Leading Antibody Discovery Platform to Develop Portfolio of Novel Therapeutics for Animal Health","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Monoclonal Antibodies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Curia","sponsor":"BioSig Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViralClear, Curia Enter COVID-19 Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curia \/ Biosig","highestDevelopmentStatusID":"8","companyTruncated":"Curia \/ Bi.."},{"orgOrder":0,"company":"Rosalind Franklin Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Researchers Engineer Antibodies from llamas Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanobodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rosalind Franklin Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rosalind Franklin Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rosalind F.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GSK Announces FDA Advisory Committee Votes in Favour of Positive Benefit\/Risk Profile for Belantamab Mafodotin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution for Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Hermann-Texas Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Hermann-Texas Medical Center","highestDevelopmentStatusID":"5","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Announces Clearance for Investigational New Drug Application of NT-I7 (efineptakin alfa) in Adults with Mild COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Medicago","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicago Begins Phase I Clinical Trials for its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Coronavirus Virus-Like Particle COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medicago","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medicago \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Medicago \/.."},{"orgOrder":0,"company":"Inflazome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation for Inflazome\u2019s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Inzomelid","moa":"NLRP3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome .."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Immutep","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Announces United States Patent Grant for IMP701 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IMP701","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution For Intravenous Infusion","sponsorNew":"Immutep \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KB-3061","moa":"Kv7.2\/7.3 potassium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Knopp Biosciences LLC \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Evox Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evox Therapeutics Expands Existing Exosome Patent Portfolio With Further Grant Covering Exosomes for RNA Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Exosome-mediated RNAi","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Evox Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evox Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Evox Thera.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s QED Therapeutics Doses First Child in Phase 2 Trial of the Investigational Medicine Infigratinib in Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Provides Updates on Its Cardiovascular Pipeline and Strategies to Build a Commercial Franchise","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Manuscript Describes How TLC\u2019s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit in Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenstr\u00f6m Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Plant-based COVID-19 antigen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ZYUS Life .."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President of Clinical Development","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab duocarmazine","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Starts Human Trials of ZyCoV-D, its COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Hebrew University of Jerusalem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hebrew U: Drug Could Turn Covid-19 Into Common Cold","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenofibrate","moa":"PPAR alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hebrew University of Jerusalem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hebrew University of Jerusalem \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hebrew Uni.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Rensselaer Polytechnic Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Researchers Say Heparin May Neutralise Covid-19 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Rensselaer Polytechnic Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rensselaer Polytechnic Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rensselaer.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ Unveils Detailed Data from THALES Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilteritinib Becomes First NICE-Approved Oral Therapy for Relapsed or Refractory Acute Myeloid Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Gilteritinib Fumarate","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Santa Lucia Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newly Published Study Funded by the Alzheimer's Drug Discovery Foundation Finds Dopamine Therapy Improves Cognitive Function in Mild-to-Moderate Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rotigotine","moa":"D2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Santa Lucia Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Santa Lucia Foundation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Santa Luci.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BOLD-100","moa":"GPCR 78","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma Reports Positive Data from octagam\u00ae Usage in Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Third Nintedanib Indication in Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Ribomic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical Trial for Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RBM-007","moa":"FGFR2\/3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ribomic","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribomic \/ .."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation AT-301","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DNV3837 Antibiotic Candidate: the Phase II Trial Continues in the US","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxaquin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SA.."},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2\/3 Study in the CHEST Journal","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Belleropho.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis\u2019 ARQ-151 for Chronic Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TREMFYA\u00ae Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Galt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals Approved by FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Orphenadrine","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Galt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galt Pharm.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's FARXIGA Granted Fast Track Designation for Heart Failure Following Acute Myocardial Infarction Leveraging an Innovative Registry-Based Trial Design","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Centivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centivax Antibody Effective in Reducing COVID-19 Lung Damage, Virus Levels and Symptoms in Immunocompromised Hamsters","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Centivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Centivax \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Centivax \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review to Merck\u2019s New Drug Application for Vericiguat","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Bayer","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces Filing Of Protocol For ENVASARC Pivotal Trial With The FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b\/3 Human Study of Ifenprodil for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI\u00ae for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aprepitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Receives Approval for Phase 2\/3 COVID-19 Study in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CAR-T Therapy","moa":"CD3 complex","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for Front-Line Treatment of TP53 Mutant AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aprea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J eyes September for Late-Stage Study of Potential COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilonacept","moa":"IL-1 beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora \u00ae Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Announces Data Showing Auxora\u2122 Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Advances Phospho-Tau Alzheimer\u2019s Vaccine in Phase 1b\/2a Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinomed Biotech AG Announces that Carragelose\u00ae has the Potential to Reduce the Risk of an Infection with SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Carrageenan API","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Marinomed Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Throat Sprays","sponsorNew":"Marinomed Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Marinomed .."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDEAYA Provides IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Ph 2 GNAQ\/11 Basket Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IDE196","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Ume\u00e5 University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swedish Trial to Assess Prostate Cancer Drug for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ume\u00e5 University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ume\u00e5 University \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ume\u00e5 Unive.."},{"orgOrder":0,"company":"Russian Defence Ministry","sponsor":"National Research Center for Epidemiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia finds Covid-19 Vaccine Candidate is Safe in Initial Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Russian Defence Ministry","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Russian Defence Ministry \/ National Research Center for Epidemiology","highestDevelopmentStatusID":"1","companyTruncated":"Russian De.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrollment, Dosing Underway in Sanfilippo Type A and B Trials of Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ABO-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Dosed First Patient in Pivotal Ph 2 Portion of LOTIS 3 Trial of Loncastuximab Tesirine in Combination With Ibrutinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Launches Human Clinical Trial of Potential COVID-19 Antiviral Antibody Treatment Following Positive Pre-Clinical Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 antiviral antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA and Takis Report Positive Preclinical Results from LineaDNA\u2122 Vaccine Candidates for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LineaDNA vaccine","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Applied DNA Sciences Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Applied DN.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"G42 Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"World\u2019s First Phase III Clinical Trial of COVID-19 Inactivated Vaccine Begins in UAE","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ G42 Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Gives the Go-Ahead for Human Trials of BioNTech's COVID Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates Bristol Myers Squibb\u2019s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Vaccine AZD1222 Showed Robust Immune Responses in all Participants in Phase I\/II Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD1222","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Starts Human Trial of its Anti-COVID Vaccine at PGI Rohtak: Minister Vij","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV2\/5-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Cancer Research UK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flagship Cancer Research UK Precision Medicine Trial Highlights the Need for a New Approach in Treating Genomically Complicated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD4547","moa":"FGFR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"University of Birmingham","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Birmingham \/ Cancer Research UK","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclerion Therapeutics Presentation at Biomarkers in Alzheimer\u2019s Disease Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IW-6463","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Cyclerion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclerion .."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplyx Touts Upbeat Readout from a Small PhII Study for Lead Antifungal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosmanogepix","moa":"Gwt1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Shares Soar on COVID-19 Treatment, but Caveats Abound","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Supplemental New Drug Application of ACADIA Pharmaceutical's NUPLAZID\u00ae to Treat Dementia-Related Psychosis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Sanford Burnham Prebys Medical Discovery Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Identify a New Drug Target for Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Vitronectin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Sanford Burnham Prebys Medical Discovery Institute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanford Burnham Prebys Medical Discovery Institute \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sanford Bu.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Reports a Publication on the Potential Benefits of Ampion for Treatment of a New COVID-19 Related Syndrome","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals\u2019 Brilacidin Inhibits COVID-19 by Almost 90% at the Lowest Concentration Tested to Date in a Human Lung Cell Line","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Biosceinces Provides Clinical Updates on Its Neoantigen Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Karyopharm\u2019s Supplemental New Drug Application for XPOVIO\u00ae for Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Vyriad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Vyriad","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vyriad \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vyriad \/ N.."},{"orgOrder":0,"company":"Belite Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Belite Bio Announces Positive Results from Phase 1 Clinical Trials of LBS-008","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tinlarebant","moa":"RBP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Belite Bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Belite Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Belite Bio.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo\u00ae (nivolumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Sanifit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanifit to Start New Clinical Development Program of SNF472 in End Stage Kidney Disease Patients with Peripheral Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SNF472","moa":"Calcification","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Sanifit","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ .."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GMcSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sonnet BioTherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Pharmaceuticals Reports Positive Phase 3 Study Results for TRIKAFTA\u00ae in People Ages 12 and Older With Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Starts CONTACT-03 Ph 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 as a Potential Treatment for Scalp Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Initiates Phase 2 Clinical Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Telotristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osmotica Pharmaceutical US LLC Announces FDA User Fee Goal Date of December 29, 2020 for Arbaclofen Extended Release Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Osmotica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Completion of Patient Enrolment into First Cohort of Phase 2 Study FIDES-01 With Derazantinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"University of Alabama","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BerGenBio Doses First Patient in Recurrent Glioblastoma Investigator Sponsored Ph I\/II Study Assessing Selective AXL Inhibitor Bemcentinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bemcentinib","moa":"AXL kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BerGenBio ASA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BerGenBio ASA \/ University of Alabama","highestDevelopmentStatusID":"7","companyTruncated":"BerGenBio .."},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imperial College Advances Covid-19 Vaccine into Next Phase","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Imperial College London","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imperial College London \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imperial C.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabis derived compounds","moa":"A3AR","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyfaquin\u00ae, a First-in-class Resuscitative Agent for Patients with Excessive Blood Loss, to be Launched in India","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Centhaquine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"Pharmazz","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/.."},{"orgOrder":0,"company":"LintonPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LintonPharm Gets Authorization From China Health Authority to Proceed With a Global Phase 3 Trial Evaluating Catumaxomab in Advanced Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Catumaxomab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"LintonPharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"LintonPharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"LintonPhar.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Completes Rolling Submission of New Drug Application to U.S. FDA for Arimoclomol for Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces a New Publication \u201cApoptotic Cell Therapy for Cytokine Storm Associated with Acute Severe Sepsis\u201d in Cell Death & Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Abicipar Pegol","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Ph 2\/3 Trial of RLF-100 for Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"60 Degrees Pharmaceuticals Announces Positive Results of Cell Culture Testing of ARAKODA\u00ae (tafenoquine) for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafenoquine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"60 Degrees Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"60 Degrees Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"60 Degrees.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HDT BIO\u2019s COVID-19 Vaccine Candidate HDT-301 Induces Neutralizing Antibody Responses After a Single Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"HDT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"IDBiologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IDBiologics Announces Nature Publication Highlighting Preclinical Results of Ultra-Potent Monoclonal Antibodies Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"IDB003","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IDBiologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IDBiologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IDBiologic.."},{"orgOrder":0,"company":"Vasopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vasopharm Announces Last Patient Last Visit in NOSTRA III Traumatic Brain Injury Clinical Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ronopterin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Vasopharm","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vasopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vasopharm .."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Doses First Patient in Phase 2b\/3 COVID-19 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"Viral replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Chiasma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Camargo Client Chiasma Receives FDA Approval for Novel Somatostatin Analog for Long-Term Maintenance Treatment of Acromegaly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ .."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Receives FDA IND Clearance for COVA Testing Sarconeos for the Treatment of Patients with COVID-19 Related Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces Completion of all Dosing in NurOwn\u00ae Phase 3 Clinical Trial in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The European Commission has Granted Orphan Medicinal Product Designation in the EU for Medivir's MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-818","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boryung Pharmaceutical Announces Superior Results for Plitidepsin (Aplidin\u00ae) Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"Protein synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ PharmaMar","highestDevelopmentStatusID":"6","companyTruncated":"Boryung Ph.."},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sedana Medical Announces Positive Top Line Result in Pivotal IsoConDa Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sedana Medical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sedana Med.."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DBV Technologies Publishes PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Pharma Announces Positive Results from Phase I\/II ARROW Trial of Pralsetinib in Chinese Patients with RET-Fusion NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Abliva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abliva receives positive FDA feedback on its KL1333 development plant","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KL1333","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Abliva","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Encapsulated Tablet","sponsorNew":"Abliva \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Abliva \/ N.."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Firibastat","moa":"APA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai\u2019s Hemlibra in Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Emicizumab","moa":"Factor IX\/Factor X","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"VelosBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$137.0 million","upfrontCash":"Undisclosed","newsHeadline":"VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"VLS-101","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"VelosBio \/ Matrix Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/.."},{"orgOrder":0,"company":"Kansas State University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Live Replicating Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kansas State University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kansas State University \/ Tonix Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kansas Sta.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Molecular Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin\u00ae Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"MP0420","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Molecular Partners","highestDevelopmentStatusID":"4","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"GHO Capital","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox Strengthens Cash Position With Divestment of its VISUfarma Shareholding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"NCX 470","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ GHO Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$305.0 million","newsHeadline":"Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint T.."},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"CombiGene AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cobra Biologics Delivers Plasmids for CombiGene's Epilepsy Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"DNA plasmids","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ CombiGene AB","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biol.."},{"orgOrder":0,"company":"Hubei Soundny Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soundny Presents a New Drug-based Alternative in Fight Against Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hubei Soundny Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hubei Soundny Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Hubei Soun.."},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIA Biotechnology Publishes in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"6-Thio-2-Deoxyguanosine","moa":"Telomere","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MAIA Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MAIA Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MAIA Biote.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sorafenib","moa":"Tyrosine protein kinase receptor RET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Senhwa Biosciences's Silmitasertib Receives Rare Pediatric Disease Designation from FDA for Treatment of Sonic Hedgehog Medulloblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Silmitasertib","moa":"CK2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Senhwa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Senhwa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Senhwa Bio.."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE for Treatment of Patients with Refractory MAC Lung Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Amikacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Liposome Inhalation Suspension","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunesis Reduces Workforce to Focus on Development of PDK1 inhibitor, SNS-510","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SNS-510","moa":"PDK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunesis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Ph.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma Canada Announces that Nova Scotia has Added the Company's Treatment for Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Croma-Pharma Announces Submission for Their Botulinum Toxin to Treat Glabellar (frown) Lines to the German Authority BfArM","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Croma-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Phar.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn\u2019s Leronlimab Prevents Transmission of SHIV in Macaque Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Photodynamic drug","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Begins Patient Enrollment in Phase 1 Trial of ANAVEX3-71 to Treat Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AF710B","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Announces Presentations on Phase I and Phase I\/II Trials using Trappsol\u00ae Cyclo\u2122 Intravenously to Treat Patients with Niemann-Pick Disease Type C1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in a Phase 1b Clinical Trial of Sintilimab plus Surufatinib in Advanced Malignancies in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Publishes Data Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within B7 Superfamily","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acer Therapeutics Administer ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Coated Formulation","sponsorNew":"Acer Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Thera.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The New England Journal of Medicine Publishes Final Results from Phase 1\/2 Study of Tofersen for a Genetic Form of ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofersen","moa":"SOD1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Advances HBV Candidate EDP-514 in Phase I Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP-514","moa":"HBV core protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"panCELLa","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"panCELLa Receives Research and Development Support for Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Funding","leadProduct":"Human embryonic stem cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"panCELLa","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"panCELLa \/ NRC IRAP","highestDevelopmentStatusID":"3","companyTruncated":"panCELLa \/.."},{"orgOrder":0,"company":"Antengene","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$97.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Antengene","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Antengene \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"12","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas is Awarded Grant from the U.S. National Institutes of Health (NIH) to Fund Early Clinical Studies of ASP8062","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"ASP8062","moa":"GABA B receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avance Clinical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Avance Clinical \/ Atossa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avance Cli.."},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Tenzing","pharmaFlowCategory":"D","amount":"$119.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenzing Acquisition and Reviva Pharmaceuticals Announce Execution of Definitive Agreement and Plan of Merger","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Merger","leadProduct":"Brilaroxazine","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Reviva Pharmaceuticals","amount2":0.12,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Reviva Pharmaceuticals \/ Tenzing","highestDevelopmentStatusID":"10","companyTruncated":"Reviva Pha.."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Aisling Capital","pharmaFlowCategory":"D","amount":"$32.5 million","upfrontCash":"Undisclosed","newsHeadline":"Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Seribantumab","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Aisling Capital","highestDevelopmentStatusID":"8","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"Selva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Selva Therapeutics Announces $3 Million Series A Financing to Advance a Novel Broad Spectrum Antiviral for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"SLV213","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Selva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Selva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Selva Ther.."},{"orgOrder":0,"company":"ImaginAb","sponsor":"ImaginAb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"67Cu-SARTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"","sponsorNew":"ImaginAb \/ ImaginAb","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/.."},{"orgOrder":0,"company":"AdaptVac","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$4.6 million","newsHeadline":"Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CLP based Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AdaptVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AdaptVac \/ Bavarian Nordic","highestDevelopmentStatusID":"4","companyTruncated":"AdaptVac \/.."},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"NIH Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"GPX-002","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"University of Pittsburgh","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aptevo Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"12","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"South Korea's SK Bioscience in Deal with AstraZeneca on Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"SK Bioscience \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Acentrus Specialty","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acentrus Specialty Partners with Puma Biotechnology to Bring Nerlynx\u00ae (neratinib) to Health Systems and Hospitals in the Acentrus Network","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Acentrus Specialty","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"European Cooperative Group","sponsor":"Groupe Francophone","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des My\u00e9lodysplasies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"European Cooperative Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"European Cooperative Group \/ Groupe Francophone","highestDevelopmentStatusID":"8","companyTruncated":"European C.."},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Panaxia's Agreement with International Pharma Neuraxpharm is Finalized","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Cannabis products","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Neuraxpharm","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuraxpharm \/ Panaxia","highestDevelopmentStatusID":"1","companyTruncated":"Neuraxphar.."},{"orgOrder":0,"company":"University of Louisville","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Louisville","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Louisville \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"BVF Partners L.P","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Announces $54 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series B Financing","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Olema Oncology \/ BVF Partners L.P","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"X-Chem","sponsor":"Orexia Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem Announces Achievement of Milestone In Orexia Collaboration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"X-Chem","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"X-Chem \/ Orexia Limited","highestDevelopmentStatusID":"2","companyTruncated":"X-Chem \/ O.."},{"orgOrder":0,"company":"Vesigen Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"Vesigen Therapeutics Launches with USD 28.5 Million Series A Investment Led by Leaps by Bayer and Morningside Ventures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"ARMMs based cell and gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Vesigen Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Vesigen Therapeutics \/ Bayer","highestDevelopmentStatusID":"3","companyTruncated":"Vesigen Th.."},{"orgOrder":0,"company":"Synaffix","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","amount":"$54.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Announces Expansion of Collaboration with ADC Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Antibody-drug conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Synaffix","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Synaffix \/ ADC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Synaffix \/.."},{"orgOrder":0,"company":"Genocea","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genocea Announces Private Placement Financing of Up to $80 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Genocea \/ Brookline Capital Markets","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Encoded Therapeutics","sponsor":"GV","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series D Financing","leadProduct":"ETX101","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Encoded Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Encoded Therapeutics \/ GV","highestDevelopmentStatusID":"4","companyTruncated":"Encoded Th.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"University of Connecticut","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ovid and UConn Enter Strategic Research Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Gaboxadol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ovid Therapeutics \/ University of Connecticut","highestDevelopmentStatusID":"1","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Humanetics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation Receives Funding from NIAID to Test Drug in COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Humanetics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Humanetics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics.."},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aumolertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hansoh Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ EQRx","highestDevelopmentStatusID":"12","companyTruncated":"Hansoh Pha.."},{"orgOrder":0,"company":"SarcoMed","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Protalix BioTherapeutics Inks Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Alidornase alfa","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"SarcoMed","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SarcoMed \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SarcoMed \/.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$3.0 million","newsHeadline":"Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"Radius Health \/ Menarini Group","highestDevelopmentStatusID":"10","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Norgine","pharmaFlowCategory":"D","amount":"$290.0 million","upfrontCash":"$30.0 million","newsHeadline":"AMAG Pharmaceuticals and Norgine B.V. Ink Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ciraparantag","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0.28999999999999998,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"AMAG Pharmaceuticals \/ Norgine B.V","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"NCCN Oncology Research Program","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NCCN Oncology Research Program to Get Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression Together with Taiho Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NCCN Oncology Research Program","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NCCN Oncology Research Program \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"NCCN Oncol.."},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alpine Immune Sciences Announces $60 Million Private Placement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"ALPN-101","moa":"ICOS","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Alpine Immune Sciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Alpine Imm.."},{"orgOrder":0,"company":"EpiPharm","sponsor":"CalciMedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CalciMedica Enters Research Pact with EpiPharma to Discover and Develop CRAC Channel Inhibitor Therapies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CM5480","moa":"CARC channel","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"EpiPharm","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiPharm \/ CalciMedica","highestDevelopmentStatusID":"4","companyTruncated":"EpiPharm \/.."},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento to Acquire SmartPharm","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"STI-1499","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SmartPharm Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SmartPharm Therapeutics \/ Sorrento","highestDevelopmentStatusID":"4","companyTruncated":"SmartPharm.."},{"orgOrder":0,"company":"National Institute of Neurological Disorders","sponsor":"MetVital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MetVital Joins National Institute of Neurological Disorders and Stroke (part of the NIH) in the Epilepsy Therapy Screening Program (ETSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Enol-oxaloacetate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute of Neurological Disorders","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Neurological Disorders \/ MetVital","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Pharma Provides Update on Proposed Acquisition of Altum and its Regulatory Guidance and Updated Clinical Development Plan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Interferon a2b","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"Altum Pharmaceuticals \/ Betterlife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Phar.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Israeli Ministry of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Israeli Ministry of Health","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Department of Biotechnology Provides seed Funding for Gennova Biopharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"HGCO19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gennova Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gennova Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Gennova Bi.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aurinia Closes US$200 Million Public Offering of Common Shares","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0.20000000000000001,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Global Stem Cell Technology","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Acquires GST to Strengthen its Stem Cell Capabilities in Animal Health","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Mesenchymal stem cell therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Global Stem Cell Technology","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Global Stem Cell Technology \/ Boehringer Ingelheim","highestDevelopmentStatusID":"12","companyTruncated":"Global Ste.."},{"orgOrder":0,"company":"Humanigen","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"National Institutes of Health Selects Humanigen\u2019s Lenzilumab for its COVID-19 Big Effect Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Tanner Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea\u00ae (paclitaxel micellar)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Elevar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Tanner Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Elevar The.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"$12.0 million","newsHeadline":"AMAG Pharmaceuticals Completes Divestment of Women\u2019s Health Assets","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Palatin Technologies","amount2":0.02,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Palatin Technologies \/ AMAG","highestDevelopmentStatusID":"12","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$34.6 million","upfrontCash":"Undisclosed","newsHeadline":"MBX Debuts with $35M to Bankroll Rare Endocrine Pipeline","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosci.."},{"orgOrder":0,"company":"Kobe University","sponsor":"Lynk Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lynk Pharmaceuticals Ink Licensing Agreements with Kobe University and RIKEN Research Institute to develop RAS inhibitors with a New MOA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Kobe University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kobe University \/ Lynk Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Kobe Unive.."},{"orgOrder":0,"company":"Cyclica","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cerevel Therapeutics and Cyclica Collaborate to Use Artificial Intelligence to Accelerate Discovery of Novel Medicines in Neuroscience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cyclica \/ Cerevel Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ .."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"NIAID","pharmaFlowCategory":"D","amount":"$44.2 million","upfrontCash":"Undisclosed","newsHeadline":"Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Non-beta-lactam antibiotic","moa":"PBP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"VenatoRx Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VenatoRx Pharmaceuticals \/ NIAID","highestDevelopmentStatusID":"2","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.6 million","upfrontCash":"Undisclosed","newsHeadline":"GT Biopharma Announces Completion of $5.6 Million Bridge Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"GTB-3550","moa":"IL-15","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"CorMedix","sponsor":"SunTrust Robinson Humphrey","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CorMedix Announces Proposed Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ SunTrust Robinson Humphrey","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tvardi\u2019s TTI-101 Receives $5 Million in Grant Funding to Support Clinical Trials and Translational Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"TTI-101","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tvardi Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Tvardi The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zentalis Enters Into Clinical Collaboration with Eli Lilly and Company to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Abemaciclib","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Zentalis Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alexion to Acquire Portola","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Coagulation factor Xa (recombinant), inactivated-zhzo","moa":"Factor Xa","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":1.3999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":1.3999999999999999,"dosageForm":"","sponsorNew":"Alexion Pharmaceuticals \/ Alexion","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$63,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Acquisition","leadProduct":"Brazikumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":63,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":63,"dosageForm":"","sponsorNew":"Allergan Aesthetics \/ AbbVie","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants fast track status to Hanmi\u2019s investigational fatty liver med","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"HM15211","moa":"GLP-1\/GIP\/Glucagon receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Pre-filled Syringes","sponsorNew":"Hanmi Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"India Begins Human Trials of its First Homegrown Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Indian Council of Medical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indian Council of Medical Research \/ Bharat Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Indian Cou.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm to Begin Clinical Trials Testing Avigan in COVID-19 Patients in Kuwait","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Doses Patients in Phase 1\/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"XC001","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XyloCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Th.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Receives Regulatory Approval to Commence a Phase II Clinical Trial for CM-101 as Treatment of Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Lilly at Alzheimer's Association International Conference 2020\u00ae (AAIC\u00ae 2020) to Showcase Clinical Advances in Alzheimer's Research","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Gantenerumab","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Araim Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Repair Activator Cibinetide Shows Potential for Efficacy in Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cibinetide","moa":"Innate repair receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Araim Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Araim Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Araim Phar.."},{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2B Study of ColonaryConcepts\u2019 Novel Colonoscopy Prep Confirms Excellent Efficacy & Safety Higher Patient Preference Over Standard Prep","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Macrogol","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ColonaryConcepts \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryCo.."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Colesevelam Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasugrel Hydrochloride","moa":"P2Y12","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino Vaccine Produces Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascletis Pharma completes pharmacokinetic bridging study of NASH drug candidate ASC40","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiadis Publishes Data in Blood Highlighting Proof-of-Concept to Enhance Potency of Anti-CD38 Antibodies with Kiadis\u2019 K-NK004","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Isatuximab-irfc","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Retrotope","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrotope Starts IND Enabling Studies for its Second D-PUFA Drug Candidate, Targeting the Treatment of AMD and Related Retinal Pathologies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DHA","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Retrotope","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Retrotope \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Retrotope .."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Latest Data on Pipeline Assets In the Area of Alzheimer\u2019s Disease and Dementia at The AAIC 2020 Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ban2401","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces FDA Approval of Wynzora\u00ae Cream (calcipotriene and betamethasone dipropionate) for Adults with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"MC2 Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MC2 Therap.."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Triplet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Triplet Therapeutics Selects Clinical Candidate for Novel Treatment of Repeat Expansion Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TTX-3360","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Triplet Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Triplet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Triplet Th.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial of CPI-613\u00ae for Relapsed or Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Provides Clinical Updates on its Phase III Critical Limb Ischemia (CLI) Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Receives FDA Authorization for Transfer of Investigational New Drug (IND) Application for its Sodium Nitrite Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ICER Publishes Evidence Report on Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma, Inc. Doses the First Patients in Phase 1b\/2a Clinical Trial in Short Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NM-002","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Provides Clarification Regarding Trial of SNG001 in Hospitalised COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Commercial Product Using Antares Pharma\u2019s Multi-Dose Pen Platform Launches in Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Antares Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Reports Final REALITY Natural History Study Results Confirming Poor Spontaneous Recovery for LHON Patients With ND4 Mutation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed with Taletrectinib in AnHeart Phase 2 Trial of Non-Small Cell Lung Cancer with ROS1 Fusion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dragonfly Therapeutics Initiates Phase 1\/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies In Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement factor C5a","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Immuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"IMM-124E","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immuron","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immuron \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immuron \/ .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Doses First Patient in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 to Treat Hematologic Malignancies in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupus Research Alliance Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Talaris Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of FCR001 in Living Donor Kidney Transplant Recipients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Talaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ERC-USA Announces Expansion of Glioblastoma Right-to-Try Treatment for ERC1671 with NYU Winthrop Hospital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Epitopoietic Research Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoiet.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Starts Patient Dosing in the LIFT Study, a Phase 2a Clinical Trial of TERN-101 in Development for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-101","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Nichi-Iko Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan Approves Dexamethasone as Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nichi-Iko Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Nichi-Iko Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nichi-Iko .."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RINVOQ\u2122 (upadacitinib) Monotherapy Meets All Primary and Secondary Endpoints in Second Phase 3 Study for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces REACH3 Trial of Ruxolitinib in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Initiates Phase 1\/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PIPE-505","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Contineum .."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobomarsen","moa":"miR-155","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Gets Breakthrough Therapy Designation for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Granted Access to PRIME Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4","moa":"MAGE-A4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Upcoming Data Presentations at the Alzheimer\u2019s Association International Conference 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Publication Of Preclinical Data Supporting Rigosertib\u2019s Mechanism Of Action As A Targeted Anticancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Receives EMA Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn\u00ae derived Exosome-Based Treatment for COVID-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Quadriga BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quadriga BioSciences Initiates Clinical Trial of Innovative, Targeted Treatment for Brain Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"QBS10072S","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Quadriga BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quadriga BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quadriga B.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Lifts All Clinical Holds on CymaBay Therapeutics' Seladelpar","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"ACRO Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACRO Biomedical to Conduct Trials on Acellular Cornea Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Collagen Ophthalmic Matrix","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ACRO Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ACRO Biomedical \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ACRO Biome.."},{"orgOrder":0,"company":"Benitec Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Benitec Begins Early Study of BB-301 Gene Therapy for OPMD","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BB-301","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Benitec Biopharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Benitec Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Benitec Bi.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Gets Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Receives Notice of US Patent Issuance for PT-112 as Therapeutic Agent for Treatment of Bone or Blood Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Milestone Pharmaceuticals Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Bags CHMP Positive Opinion for Expanded Use of IMBRUVICA\u00ae in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaginal Ring to Reduce the Risk of HIV Infection for Women in non-EU Countries with High Disease Burden","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapivirine","moa":"Reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Ring","sponsorNew":"International Partnership for Microbicides \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Internatio.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVrh74.MHCK7.micro-dystrophin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi will File for a Re-Examination of Emapalumab in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapalumab","moa":"INF gamma","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca COPD Drug Finally Gets OK From FDA, inching closer to GSK leader","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Budensonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Receives Positive CHMP Opinion for the Expanded Use of CRYSVITA\u00ae (burosumab) to Include Older Adolescents and Adults for the Treatment of X-Linked Hypophosphataemia (XLH)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dana-Farber to Offer First CAR T-cell Therapy for Mantle cell Lymphoma Following FDA Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Dana-Farber Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Intravenous Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dana-Farbe.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen to Present Data at Virtual 2020 Alzheimer\u2019s Association International Conference Highlighting Comprehensive Approach to treat AD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pieris Pharmaceuticals Announces Oral Presentation Of Phase 1 Data For 4-1bb\/Her2 Bispecific Prs-343 At ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TCR\u00b2 Therapeutics to Announce Interim Data from Phase 1\/2 Clinical Trial of TC-210 in Mesothelin-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TC-210","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TCR2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Thera.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Submits Marketing Authorization Application to European Medicines Agency for Vosoritide to Treat Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bimekizumab Shows Positive Phase 3b Results Against Cosentyx","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Adakveo\u00ae Receives Positive CHMP Opinion for the Prevention of Recurrent Vaso-Occlusive Crises in Patients with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Crizanlizumab","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Cipla","sponsor":"Indian Institute of Chemical Technology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Regulatory Approval for Launch of Ciplenza (Favipiravir 200 mg) in India to Treat Mild to Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cipla \/ Indian Institute of Chemical Technology","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ In.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites' Databases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Insmed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Amikacin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Insmed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Liposome Inhalation Suspension","sponsorNew":"Insmed \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Insmed \/ N.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF\u2122 (HTX-011) for the Management of Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Preclinical Results Generated with Sareum\u2019s TYK2\/JAK1 Inhibitors in a Disease Model of Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ N.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH to Start a Mass of Large Clinical Trials for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiviral monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"National I.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Kite\u2019s Tecartus\u2122, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"PolarityTE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE\u2122 Diabetic Foot Ulcer Trial","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SkinTE","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Undisclosed","graph3":"PolarityTE","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PolarityTE \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"PolarityTE.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med starts Phase I Hematological Malignancies Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"HMPL-306","moa":"Isocitrate dehydrogenase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SII Seeks Approval to Trial Oxford Covid-19 Vaccine in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Reports Topline Results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Choose Lead Mrna Vaccine Candidate Against Covid-19 And Commence Pivotal Phase 2\/3 Global Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BIONTECH","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PR006","moa":"Progranulin","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic's First Patient Enrolled in Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Boston University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Famotidine Doesn\u2019t Work as a COVID-19 Antiviral","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Famotidine","moa":"H2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boston University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Boston University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Boston Uni.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Grifols' AMBAR Clinical Trial Published in Alzheimer's & Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Perflutren","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"AxoProtego Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EQ-6","moa":"HSP90","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AxoProtego Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"AxoProtego Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AxoProtego.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Publishes Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Announces FDA Acceptance of FUROSCIX\u00ae New Drug Application Resubmission","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"4D-110","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Announces Receipt of IND Clearance to Conduct Window-of-Opportunity Trial of NT-I7 (efineptakin alfa) in Patients with Locally Recurrent Squamous Cell Carcinoma of Head and Neck","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkmate Pharma Gets FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade to Treat Types of Metastatic\/Unresectable Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Checkmate Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Checkmate Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"BCL11A gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Reports New Data of OPT-302 in Diabetic Macular Edema at the 2020 Annual Meeting of the American Society of Retina Specialists","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Destiny Pharma Provides Update on its Phase 2b Clinical Study of XF-73","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vicore Pharma Doses First COVID-19 Patient in the ATTRACT Study in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company\u2019s Pancreatic Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CypCaps","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"DalCor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DalCor Announces Dal-GenE Trial Continues with Final Data Expected in the First Half of 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dalcetrapib","moa":"CETP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"DalCor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"DalCor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"DalCor Pha.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharma Announces that Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Announces Multiple Presentations at the ASRS 2020 Virtual Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid to Present Phase 2 Results of D-PLEX\u2081\u2080\u2080 for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100)","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ethanol","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics to Present More Clinical Data from STEADFAST Study of Azeliragon at the Alzheimer's Association International Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CAS 603148-36-3","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals to Present Updated Data from Ongoing Phase 2 ACCURACY Trial of AL101 for the Treatment of R\/M Adenoid Cystic Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b\/2b COVID-19 Clinical Program with TSC","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"jCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic human retinal progenitor cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ No.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Submits Application For Rigosertib To Participate In Federally Funded Human Studies In COVID-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Rigosertib","moa":"PAR1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onconova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rezolute Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces Formation of Scientific Advisory Board","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CD377","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Versamune-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COLCORONA Trial Researchers Announce Increased U.S. Enrollment Options for this At-Home Study for Newly Diagnosed Patients\u00ad\u00ad\u00ad with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Montreal Heart Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priority Review Granted to BeiGene\u2019s New Drug Application of Pamiparib in Ovarian Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamiparib","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Imunon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Imunon \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ N.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Announces First Brain Cancer Patient From Second Dose Cohort Reaches 4 Weeks of Treatment With NOX-A12 Combined With Radiotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Columbia University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Identify Multiple Molecules tat Shut Down SARS-Cov-2 Polymerase Reaction","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofosbuvir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Entera Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Health Announces Approval of COVID-19 Clinical Trial using EnteraGam in Spain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bovine plasma derived immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Entera Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Entera Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Entera Hea.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVID-19 Fibroblast Based Cell Therapy Candidate Shown to\nReduce Lung Scarring in Aggressive Animal Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PneumoBlast","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Reports Positive Topline Results for AR-1105 Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"EXACT Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.9 million","upfrontCash":"Undisclosed","newsHeadline":"EXACT Therapeutics Raises NOK 155 Million and Lists on Oslo Stock Exchange's Merkur Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"ACT associated Chemotherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"EXACT Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"EXACT Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EXACT Ther.."},{"orgOrder":0,"company":"Sanofi","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi, MD Anderson Join Forces to Ramp up Cancer R&D","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ MD Anderson","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ M.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"ImmuneOncia Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics, ImmuneOncia Enter Into Manufacturing Development Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"IMC-002","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ ImmuneOncia","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"BaseLaunch","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bridge Biotherapeutics Becomes BaseLaunch's First Asia Pacific Partner","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"BBT-401","moa":"Pellino-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"BaseLaunch","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BaseLaunch \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BaseLaunch.."},{"orgOrder":0,"company":"NuGenerex","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"NuGenerex Immuno-Oncology Closes $50 Million Financing Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"AE37 Peptide","moa":"CD4 T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NuGenerex","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"NuGenerex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuGenerex .."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO\u00ae (tedizolid phosphate) in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Tedizolid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nabriva Therapeutics \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Invivyd","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adagio Therapeutics Launches With $50M Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Neutralizing Monoclonal Antibodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Invivyd","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intramuscular Injection","sponsorNew":"Invivyd \/ Polaris Partners","highestDevelopmentStatusID":"4","companyTruncated":"Invivyd \/ .."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Cediprof","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett and Cediprof Announce Exclusive Distribution Agreement for An Approved Levothyroxine","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lannett Company, Inc. \/ Cediprof","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"Exalys Therapeutics","sponsor":"Catalys Pacific","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"EP4 receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Exalys Therapeutics","amount2":0.02,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Exalys Therapeutics \/ Catalys Pacific","highestDevelopmentStatusID":"1","companyTruncated":"Exalys The.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"AT-GAA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amicus Therapeutics","amount2":0.40000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"GEMoaB","sponsor":"Intellia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"RevCAR-T 1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GEMoaB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GEMoaB \/ Intellia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"GEMoaB \/ I.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"U.K Governement","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"mRNA vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ U.K Governement","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Kedrion","sponsor":"Columbia University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kedrion Biopharma forms Partnership with Columbia University Irving Medical Center to Support Development of New IgG Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Anti-COVID IgG therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kedrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kedrion \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Kedrion \/ .."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$2,150.0 million","upfrontCash":"$150.0 million","newsHeadline":"Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":2.1499999999999999,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$22.1 million","upfrontCash":"Undisclosed","newsHeadline":"AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Private Placement","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"DSE Healthcare Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DSE Healthcare's VANQUISH Introduces Digital Headache Brand Pain Reliever For Modern Day Headaches","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"DSE Healthcare Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DSE Healthcare Solutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DSE Health.."},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PreveCeutical Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeuti.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of mRNA-1273","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation For DB102 in Patients with Newly-Diagnosed Glioblastoma (GBM)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzastaurin","moa":"PKC beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Denovo Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denovo Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Denovo Bio.."},{"orgOrder":0,"company":"DSG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DSG Supports PhaseBio Pharmaceuticals with Unified Clinical Trial Software Platform for COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"DSG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"DSG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DSG \/ Not .."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India to Apply for Local Trials on Oxford's Vaccine by August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ACADIA Announces Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for Adjunctive Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate to Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Abivertinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioniz Announces Positive Efficacy and Safety Data for BNZ-1 from Interim Analysis of Phase 1\/2 Study in Cutaneous T-cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BNZ-1","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioniz Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz The.."},{"orgOrder":0,"company":"Takis Biotech","sponsor":"Applied DNA Sciences Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied DNA, Takis Announce Positive Preclinical Results from LineaDNA Vaccine Candidates for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LineaDNA vaccine","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Takis Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takis Biotech \/ Applied DNA Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Takis Biot.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar has Filed Lurbinectedin for Temporary Marketing Authorisation with the Swiss Agency for Therapeutic Products","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Henlius Biotech, Inc. (2696 HK) \u2013 Expecting five NDA Approvals Within Two Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HLX71","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$9.0 billion","upfrontCash":"Undisclosed","newsHeadline":"Merck to Focus on Key Growth Pillars Through Spinoff of Women\u2019s Health, Trusted Legacy Brands and Biosimilars Products into New Company","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Demerger","leadProduct":"Etonogestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Merck & Co","amount2":0.01,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Committee Backs Terlipressin Approval for HRS-1","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's DUPIXENT Receives Positive Recommendation from INESSS for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Pivotal Phase 3 AMPOWER Study Results For Phexxi\u2122 in Contraception","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Announces the First Patient Visit in the International Phase II\/III REVERSE-IT Clinical Study on TOTUM-63","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Totum-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives USFDA SANDA Approval for Doxycycline Injection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhythm Pharmaceuticals Publishes Data from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pha.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XENLETA\u00ae (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shield Therapeutics PT20 Paper Publication","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric oxide adipate","moa":"Phosphate","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Shield Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shield Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shield The.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Early Breast Cancer Drug Now Approved in Malaysia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus gets Mexican Regulatory Approval to Conduct Trials of Pegylated IFN Alfa-2b, PegiHep in Patients COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"BANNER LIFE SCIENCES LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Banner Life Sciences Announces Commercial Launch of BAFIERTAM, a Novel Oral Fumarate Treatment for Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BANNER LIFE SCIENCES LLC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"BANNER LIFE SCIENCES LLC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BANNER LIF.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"U.K Government","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Innovate UK Awards Epsilogen Further Funding for Ovarian Cancer Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Mov18 IgE","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovate Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovate Biopharmaceuticals \/ U.K Government","highestDevelopmentStatusID":"6","companyTruncated":"Innovate B.."},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Forge Debuts with $40M and Tim Miller at the Helm","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"FBX-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biol.."},{"orgOrder":0,"company":"IRBM","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRBM to Collaborate with MSD to Develop Peptides Against Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IRBM","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRBM \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"IRBM \/ Mer.."},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$40.0 million","newsHeadline":"Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Solute carrier","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Jnana Therapeutics","amount2":1.04,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.04,"dosageForm":"","sponsorNew":"Jnana Therapeutics \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"Jnana Ther.."},{"orgOrder":0,"company":"Tubulis","sponsor":"BioMedPartners","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"Tubulis Raises \u20ac10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"TUB-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tubulis","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Tubulis \/ BioMedPartners","highestDevelopmentStatusID":"4","companyTruncated":"Tubulis \/ .."},{"orgOrder":0,"company":"Gustave Roussy","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo & Gustave Roussy Collaborate for Oncology Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"DS-1062","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gustave Roussy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gustave Roussy \/ Daiichi Sankyo","highestDevelopmentStatusID":"8","companyTruncated":"Gustave Ro.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"UNION therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNION Therapeutics Announces Acquisition of PDE4i Compound Class from LEO Pharma with Oral Lead Candidate (orismilast) in Phase 2","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Orismilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Leo Pharma \/ UNION therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centus Biotherapeutics Announces Positive CHMP Opinion for FKB238, Biosimilar Bevacizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Centus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Centus Bio.."},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clarity Pharmaceuticals opens SARTATE\u2122 neuroblastoma clinical trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"67Cu-SARTATE","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Ph.."},{"orgOrder":0,"company":"AbSci","sponsor":"Alpha Cancer Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alpha Cancer Technologies to License AbSci's SoluPro Strain for the Expression of Alpha-Fetoprotein","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant Human Alpha-fetoprotein","moa":"Alpha Fetoprotein receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AbSci","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbSci \/ Alpha Cancer Technologies","highestDevelopmentStatusID":"6","companyTruncated":"AbSci \/ Al.."},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$27.4 million","upfrontCash":"Undisclosed","newsHeadline":"T3 Pharma Raises 25M CHF to Advance Bacterial Cancer Therapy Through Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"T3P-Y058-739","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"T3 Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"T3 Pharma \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"T3 Pharma .."},{"orgOrder":0,"company":"Novavax","sponsor":"Fujifilm Diosynth Biotechnologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ FUJIFILM Diosynth Biotechnologies","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Galapagos","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead and Galapagos Gets Positive EU CHMP Opinion For Jyseleca\u00ae For The Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Galapagos","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ National Institute of Health","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Starts Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NGM621","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Vector State Virology Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocad discussing potential COVID-19 vaccine production in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Vesicular stomatitis virus-based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vector State Virology Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vector State Virology Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vector Sta.."},{"orgOrder":0,"company":"Staten Biotechnology","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Staten Biotechnology, In Collaboration with Novo Nordisk, Starts Dosing of Anti-ApoC3 Antibody SST-5058 in First-in-Human Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SST-5058","moa":"apoC3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Staten Biotechnology","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Staten Biotechnology \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Staten Bio.."},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dynavax and Medigen Partner to Develop Adjuvanted Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 adjuvanted vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medigen Vaccine Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medigen Vaccine Biologics \/ Dynavax Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Medigen Va.."},{"orgOrder":0,"company":"Rutgers University","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DuPont Nutrition & Biosciences Announces Research Collaboration with Rutgers University","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Gut-Microbiome","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Rutgers University","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rutgers University \/ DuPont","highestDevelopmentStatusID":"2","companyTruncated":"Rutgers Un.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"U.S Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ U.S Government","highestDevelopmentStatusID":"6","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,550.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"TTX-080","moa":"HLA-G","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":1.55,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.55,"dosageForm":"","sponsorNew":"Tizona Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Tizona The.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$421.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amgen Doubles Down on BeiGene Collaboration, Investing $421M More","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Financing","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lumos Pharma Announces Sale of Priority Review Voucher","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Live Ebola Zaire Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Lumos Pharma","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Lumos Pharma \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Lumos Phar.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Starts Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KB109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"Aravive","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500 in Platinum Resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AVB-S6-500","moa":"AXL\/GAS6 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Aravive","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aravive \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aravive \/ .."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Completes Enrollment in Controlled Ph 2 Trial of Relacorilant + Nab-Paclitaxel to Treat Metastatic Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Relacorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"ElsaLys Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ElsaLys Biotech Submits Biologics License Application to FDA for LEUKOTAC for the treatment of graft-versus-host disease in adult patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Inolimomab","moa":"IL-2 alpha receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"ElsaLys Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElsaLys Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ElsaLys Bi.."},{"orgOrder":0,"company":"Acurx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acurx Actively Enrolling Patients in Ph2 Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibezapolstat","moa":"DNA polymerase IIIC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acurx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Acurx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acurx Phar.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Vita Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vita Therapeutics Receives Orphan Drug Designation from FDA for New Novel Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"VTA-110","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vita Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vita Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vita Thera.."},{"orgOrder":0,"company":"Inotrem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inotrem to Initiate Phase IIa Study of Nangibotide for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nangibotide","moa":"TREM-1 pathway","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ .."},{"orgOrder":0,"company":"Columbia University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Say Newly Identified Antibodies can Neutralise SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Coronavirus-neutralising antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Columbia University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Columbia University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Columbia U.."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Updates Plan for Retinitis Pigmentosa Gene Therapy Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine\/Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LEAPS COVID 19 conjugate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Authorised Uses of Cancer Medicine Yondelis Unchanged Following Review of New Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer's Gene Therapy BAY 2599023 Showing Steady FVIII Activity, Safety in Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BAY2599023","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Ultragenyx Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Russian Ministry of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia to Vaccinate Medics for Coronavirus in August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Russian Ministry of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Russian Ministry of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Russian Mi.."},{"orgOrder":0,"company":"China's military-backed research unit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Covid-19 vaccine candidate shows some promise in animal tests","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"China's military-backed research unit","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"China's military-backed research unit \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"China's mi.."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"RIVOPHARM SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett Launches Mexiletine HCl Capsules","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lannett Company, Inc. \/ Rivopharm SA","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"Novocure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Novocure\u2019s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tumor Treating Fields","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Novocure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novocure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novocure \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Duke-NUS Medical School","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus and Duke-NUS to Trial Covid-19 Vaccine in Singapore","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Duke-NUS Medical School","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent's BI-1206 Could Improve Treatment In several cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Dana Solutions","sponsor":"Curi Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curi Bio Acquires Dana Solutions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Human iPSC-derived cardiomyocytes","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Dana Solutions","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dana Solutions \/ Curi Bio","highestDevelopmentStatusID":"2","companyTruncated":"Dana Solut.."},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AI Therapeutics Announces Start of Phase II Trial of LAM-002A (apilimod dimesylate) for Treatment of COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Apilimod mesylate","moa":"Il-12","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AI Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AI Therape.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Drops Hep B Antiviral as Late-Stage Pipeline Tests Largely on Track' Despite COVID-19 Disruption","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RG6217","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Favorable PhIII data for Roche\u2019s Port Delivery System with ranibizumab for neovascular ARMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$100.0 million","newsHeadline":"Sobi And Selecta Announce Closing of Previously Announced Strategic Licensing Agreement For Sel-212","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Announces $110 Million Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0.11,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Eventide Asset Management","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Bright Peak Therapeutics","sponsor":"Ridgeline Therapeutics Discovery","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Versant Ventures Launches Bright Peak Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"IL-2 conjugates","moa":"CD25 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bright Peak Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Bright Peak Therapeutics \/ Ridgeline Therapeutics Discovery","highestDevelopmentStatusID":"5","companyTruncated":"Bright Pea.."},{"orgOrder":0,"company":"Immunome","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$13.3 million","upfrontCash":"Undisclosed","newsHeadline":"Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Funding","leadProduct":"IMM-BCP-01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Immunome","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Immunome \/ U.S. Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Immunome \/.."},{"orgOrder":0,"company":"Schrodinger","sponsor":"Viva Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Schr\u00f6dinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Schrodinger","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Schrodinger \/ Viva Biotech","highestDevelopmentStatusID":"2","companyTruncated":"Schrodinge.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"TRN-000632","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Terns Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$33.1 million","upfrontCash":"Undisclosed","newsHeadline":"Enthera Pharmaceuticals Raises \u20ac28 Million in Series A Financing to Advance Restorative Therapy for Type 1 Diabetes and IBD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Ent001","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Ph.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chi-Med and Lilly to Collaborate in Commercializing Elunate\u00ae in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adalvo and AmbioPharm Partner on Development & Licensing for Key Peptide Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ A.."},{"orgOrder":0,"company":"MolMed","sponsor":"AGC Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC to Complete the Acquisition of MolMed on July 31, 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Zalmoxis","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MolMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MolMed \/ AGC Biologics","highestDevelopmentStatusID":"10","companyTruncated":"MolMed \/ A.."},{"orgOrder":0,"company":"Sera Labs","sponsor":"CURE Pharmaceutical","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"$20.0 million","newsHeadline":"CURE Pharmaceutical to Acquire Sera Labs in a $20 Million Transaction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sera Labs","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Controlled Substance","amount2New":0.040000000000000001,"dosageForm":"Topical Cream","sponsorNew":"Sera Labs \/ CURE Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Sera Labs .."},{"orgOrder":0,"company":"Sanofi","sponsor":"UK government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi\/GSK Sign Deal with UK Gov for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ UK government","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ U.."},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"VIDO-InterVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dalton, VIDO-InterVac Partner to Develop COVID-19 Vax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dalton Pharma Services","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dalton Pharma Services \/ VIDO-InterVac","highestDevelopmentStatusID":"1","companyTruncated":"Dalton Pha.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kodiak, Lonza Sign Long-Term Manufacturing Contract","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Lonza Group \/ Kodiak Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.9 million","newsHeadline":"Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis\u00ae U.S. Licensing Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Taro Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crescita T.."},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Ophthalmology Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ophthalmology Pharmaceutical and IACTA Pharmaceuticals Sign New Licensing Agreement for Dry Eye Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IC 265","moa":"SYK","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Phar.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$39.0 million","upfrontCash":"Undisclosed","newsHeadline":"ESSA Pharma Announces Pricing of Public Offering of Common Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Essa Pharma \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Agenus","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Balstilimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Agenus \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ B.."},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nura Bio Launches to Discover and Develop Neuroprotective Drugs, Backed by $73 Million Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SARM1","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nura Bio","amount2":0.070000000000000007,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"5","companyTruncated":"Nura Bio \/.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","amount":"$89.0 million","upfrontCash":"$25.0 million","newsHeadline":"Santen and RVL Pharmaceuticals Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0.089999999999999997,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harmony Biosciences Files for a $100 million IPO","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Harmony Biosciences \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"TrialSpark","sponsor":"resTORbio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"resTORbio and TrialSpark Collaborate to Investigate RTB-101 for COVID-19 on the Project Covalence Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"RTB-101","moa":"TORC1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TrialSpark","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TrialSpark \/ resTORbio","highestDevelopmentStatusID":"10","companyTruncated":"TrialSpark.."},{"orgOrder":0,"company":"BioTheryX","sponsor":"MSD Partners","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioTheryX Announces $35 Million Series D Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series D Financing","leadProduct":"BTX-A51","moa":"Multi-Kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ MSD Partners","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX .."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Citigroup","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Citigroup","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spectrum Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Eflapegrastim","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spectrum Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"TrueBinding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Horizon Discovery Licenses CHOSOURCE Platform to Truebinding for Development and Commercialization of Multiple Biotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Chinese Hamster Ovary K1 cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Horizon Discovery Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Horizon Discovery Group \/ TrueBinding","highestDevelopmentStatusID":"3","companyTruncated":"Horizon Di.."},{"orgOrder":0,"company":"BioMed Valley Discoveries","sponsor":"Strata Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strata Oncology Announces Partnership with BioMed Valley Discoveries to Accelerate Enrollment in ERK Inhibitor Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Ulixertinib","moa":"MAP kinase ERK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioMed Valley Discoveries","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BioMed Valley Discoveries \/ Strata Oncology","highestDevelopmentStatusID":"8","companyTruncated":"BioMed Val.."},{"orgOrder":0,"company":"Trobix Bio","sponsor":"Chartered Opus","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trobix Bio Completed Series A Funding by a Leading Japanese\/Singapore Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"TBX101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Trobix Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trobix Bio \/ Chartered Opus","highestDevelopmentStatusID":"4","companyTruncated":"Trobix Bio.."},{"orgOrder":0,"company":"Cancer Research","sponsor":"Touchlight","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"TGL-100","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Cancer Res.."},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sunesis Announces Pricing of $12 Million Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"SNS-510","moa":"PDK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Sunesis Pharmaceuticals \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Ph.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AMG 890","moa":"Apolipoprotein A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Omega Therapeutics Advances Controllable Epigenomic Programming Platform to Deliver a Pipeline of Novel Therapeutics with $85M in Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Omega Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Omega Ther.."},{"orgOrder":0,"company":"Celonic","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celonic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celonic \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"Celonic \/ .."},{"orgOrder":0,"company":"Poxel","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","amount":"$21.3 million","upfrontCash":"Undisclosed","newsHeadline":"Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Poxel","amount2":0.02,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Poxel \/ Su.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech, Regeneron join forces in I-O battle against melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"BNT111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioNTech \/ Regeneron","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$250.9 million","upfrontCash":"Undisclosed","newsHeadline":"Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Termination","leadProduct":"Tau and Alpha-synuclein vectorized antibody","moa":"Mapk tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0.25,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"PIPE","pharmaFlowCategory":"D","amount":"$445.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cerevel to Raise $445M in Merger with Blank-Check Company","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"CVL-231","moa":"Muscarinic M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevel Therapeutics","amount2":0.45000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Cerevel Therapeutics \/ PIPE","highestDevelopmentStatusID":"6","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$795.0 million","upfrontCash":"$75.0 million","newsHeadline":"Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"AAV based gene regulation therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Sangamo Therapeutics","amount2":0.80000000000000004,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.80000000000000004,"dosageForm":"","sponsorNew":"Sangamo Therapeutics \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Sangamo Th.."},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Life Science Partners","pharmaFlowCategory":"D","amount":"$31.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vico Therapeutics Raises $31 Million in Series A Financing Round","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Series A Financing","leadProduct":"Antisense OligoNucleotides","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vico Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Vico Therapeutics \/ Life Science Partners","highestDevelopmentStatusID":"4","companyTruncated":"Vico Thera.."},{"orgOrder":0,"company":"Worldwide Clinical Trials","sponsor":"Neurotrope","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Worldwide Clinical Trials","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Worldwide Clinical Trials \/ Neurotrope","highestDevelopmentStatusID":"8","companyTruncated":"Worldwide .."},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tanner Pharma Group and Domp\u00e9 Initiate Distribution Partnership for Oxervate\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Cenegermin","moa":"TrkA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tanner Pharma \/ Domp\u00e9 farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pha.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Completes Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share without Warrants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Financing","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"TerSera","pharmaFlowCategory":"D","amount":"$224.0 million","upfrontCash":"$159.0 million","newsHeadline":"Lexicon Pharmaceuticals Enters Into Agreement With Tersera Therapeutics For The Sale Of Xermelo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0.22,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.22,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ TerSera","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Sanofi","sponsor":"U.S Department of Health and Human Services","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK Land $2.1 Billion Deal With U.S. For Covid-19 Vaccine Development And 100 Million Doses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":2.1000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"Sanofi \/ U.S Department of Health and Human Services","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ U.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$276.2 million","upfrontCash":"Undisclosed","newsHeadline":"Allovir Raises $276M IPO to Run Broad Cell Therapy Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"ALVR105","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0.28000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"AlloVir \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Emery Pharma","sponsor":"Halodine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halodine Engages Emery Pharma for Next Generation Development of Oral and Nasal Antiseptics Active Against SARS-CoV-2 (COVID-19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"Povidone-Iodine","moa":"Inflammatory mediator","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emery Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Emery Pharma \/ Halodine","highestDevelopmentStatusID":"1","companyTruncated":"Emery Phar.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"$12.0 million","newsHeadline":"Sesen Bio Signs Exclusive License Agreement with Qilu Pharmaceutical for the Development and Commercialization of Vicineum\u2122 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Sesen Bio \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"Sanofi","sponsor":"European Union","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi, Glaxosmithkline in Talks with EU to Secure Covid-19 Vaccine Deal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ European Union","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ E.."},{"orgOrder":0,"company":"Xencor","sponsor":"MorphoSys","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi\u00ae (tafasitamab-cxix) in the United States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Xencor","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Xencor \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"Xencor \/ M.."},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Champalimaud Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immodulon, Champalimaud Foundation Team Up on \u2018Difficult To Treat\u2019 Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"IMM-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immodulon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immodulon Therapeutics \/ Champalimaud Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Immodulon .."},{"orgOrder":0,"company":"Wuxi Shuangliang Biotechnology","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Enter Into a Research Collaboration with Wuxi Shuangliang Biotechnology to Study a Combination Therapy to Treat NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"C-005","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wuxi Shuangliang Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wuxi Shuangliang Biotechnology \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Wuxi Shuan.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"OB-002","moa":"CCR5 pathway","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Biotechnology \/ National Research Council Industrial Research Assistance Program","highestDevelopmentStatusID":"4","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VistaGen Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Axovant Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Executes Licensing Agreement with Isoprene Pharmaceuticals of VNLG-152 for Treatment of Dermatological Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"BioCorRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Irisys to Manufacture BioCorRx's Opioid Use Disorder Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"IRISYS, LLC","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"IRISYS, LLC \/ BioCorRx","highestDevelopmentStatusID":"4","companyTruncated":"IRISYS, LL.."},{"orgOrder":0,"company":"Wockhardt","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wockhardt snags Covid-19 Vaccine Manufacturing Deal From the UK Govt","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Wockhardt \/ UK Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt .."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector\u00ae Platform for Next Generation CAR-T Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Lentiviral vector","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Beam Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"LUMICKS","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LUMICKS Enters Collaboration with Glycostem to Enhance NK cell-Mediated Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CAR-NK cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Glycostem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycostem Therapeutics \/ LUMICKS","highestDevelopmentStatusID":"4","companyTruncated":"Glycostem .."},{"orgOrder":0,"company":"Vigene Bioscience","sponsor":"Altimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altimmune Announces Manufacturing Agreement With Vigene Biosciences For AdCOVID\u2122, Its Single Dose Intranasal Vaccine Candidate For COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vigene Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Vigene Bioscience \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"Vigene Bio.."},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics\u2019 First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of Glioblastoma & Other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"CYT-101","moa":"Dual EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CytoImmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"CytoImmune Therapeutics \/ Cytovia Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"CytoImmune.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"SIT Laboratorio Farmaceutico","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIT Laboratorio Farmaceutico Acquires LOPRESSOR\u00ae, ICAZ\u00ae and MIOREL\u00ae from Daiichi Sankyo France","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Metoprolol Tartrate","moa":"Adrenergic beta-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ SIT Laboratorio Farmaceutico","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","amount":"$259.0 million","upfrontCash":"$5.0 million","newsHeadline":"TriSalus Life Sciences Acquires Dynavax\u2019s SD-101 Oncology Program in Purchase Agreement for up to $250 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"SD-101","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0.26000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ TriSalus Life Scineces","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"KYORIN PHARMACEUTICAL CO LTD","sponsor":"Otonomy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OTO-6XX","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"KYORIN PHARMACEUTICAL CO LTD","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KYORIN PHARMACEUTICAL CO LTD \/ Otonomy","highestDevelopmentStatusID":"4","companyTruncated":"KYORIN PHA.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$57.2 million","upfrontCash":"Undisclosed","newsHeadline":"Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Foralumab","moa":"T Cell surface glycoprotein CD3","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tiziana Life Sciences","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ ThinkEquity","highestDevelopmentStatusID":"1","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"IAVI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"CAT-5571","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"ExeVir Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$27.1 million","upfrontCash":"Undisclosed","newsHeadline":"ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Series A Financing","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ExeVir Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"ExeVir Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ExeVir Bio.."},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Human trials of second Russian Covid-19 vaccine to start July 27: TASS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Siberian Vector institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Siberian Vector institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Siberian V.."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayne Pharma Launches Chlorzoxazone Tablet in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Chlorzoxazone","moa":"Intermediate conductance calcium-activated potassium channel protein 4","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Phar.."},{"orgOrder":0,"company":"Adastra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adastra Pharmaceuticals to Present at LifeSci Partners' Summer Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zotiraciclib","moa":"CDK9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adastra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adastra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adastra Ph.."},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"HST5040","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"HemoShear Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HemoShear .."},{"orgOrder":0,"company":"ReAlta Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReAlta Life Sciences Announces U.S. FDA Clearance of First Investigational New Drug Application for RLS-0071","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RLS-0071","moa":"Inflammatory cascade","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"ReAlta Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ReAlta Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReAlta Lif.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Twist Bioscience Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-SARS-CoV-2 S1 Antibody","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FARXIGA Met All Primary and Secondary Endpoints in Groundbreaking Phase III DAPA-CKD Trial for the Treatment of Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recordati Reports Positive Results From the Phase III LINC-3 Study of Isturisa\u00ae (osilodrostat) for the Treatment of Cushing\u2019s Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Data Presentations at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of HER2 Mutated Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BDTX-189","moa":"EGFR\/ErbB2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Announces Initiation of Investigator-Sponsored Study Evaluating Bardoxolone for Complications Associated with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"PPAR gamma","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Third Pivotal Phase 3 Study Shows RINVOQ Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nipocalimab","moa":"Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Momenta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Larimar Therapeutics Gets Positive Opinion on Orphan Drug Designation Received from the EMA for CTI-1601","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CTI-1601","moa":"Frataxin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Th.."},{"orgOrder":0,"company":"Wake Forest Institute for Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Cell-Based Gene Therapy Approach to Better Treat Patients with Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cell-based gene therapy","moa":"Factor VIII transgene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wake Forest Institute for Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Wake Forest Institute for Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Wake Fores.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Breast cancer vaccine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Gets Breakthrough Therapy Designation for MK-6482 to Treat Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MK-6482","moa":"HIF-2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Dimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DIMERIX\u2019s DMX-200 Posts Strong Results in Kidney Disease Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Propagermanium","moa":"CCR2","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Dimerix","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dimerix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dimerix \/ .."},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repare Therapeutics Announces Dosing of First Patient in Phase 1\/2 Clinical Trial of RP-3500","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-3500","moa":"ATR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repare Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Repare Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Repare The.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Provides an Update on the Phase III COVACTA Trial of Actemra in Hospitalized Patients With Severe COVID-19 Associated Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Reports Results from Its Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-ENaC","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation of Nebulized Solution","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Topline Data from SER-109 Phase 3 Study in Recurrent C. Difficile Infection Expected in August 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Publication of Positive Pre-clinical Results for a Novel COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CiVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Begins Dosing Cohort 5 in an Ongoing Phase 1 Monotherapy Trial of CUE-101 in HPV+ Recurrent\/Metastatic Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CUE-101","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tegavivint","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iterion Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Iterion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iterion Th.."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"miRagen Together with Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MRG-110","moa":"MicroRNA-92a","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing\u2019s Syndrome of Adrenal Origin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Relacorilant","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"9 Meters Biopharma Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Larazotide Acetate","moa":"Nicotinic receptor alpha3\/beta4","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"9 Meters Biopharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"9 Meters Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"9 Meters B.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ivy Brain Tumor Center and QED Therapeutics Announce Dosing of First Patient in a Phase 0\/2 Trial of Infigratinib in Recurrent Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Infigratinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Apogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Asunercept","moa":"Apoptosis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apogenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339 for Acute Myeloid Leukemia and Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-5339","moa":"VCP\/p97","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cleave Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cleave The.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion\u2019s Phase 3 REFALS Trial Evaluating Oral Levosimendan in Treatment of ALS Patients Did Not Reach its Pre-Specified Endpoints","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE-3","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics To Present Step-1 Results of Phase 3 Clinical Trial of Tedopi\u00ae \u2018Atalante at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tedopi","moa":"Killer T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Beremagene geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Receives Scientific Advice From the EMA Regarding Xyndari\u2122","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Pharmaceuticals to Expand Clinical Program to Target Additional Sarcomas in Ewing Sarcoma Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melt Pharmaceuticals Enters the Clinical Stage of MELT-100 Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharm.."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Receives Orphan Drug Designation From for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-3107","moa":"HPV6","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DNL758","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ZEN003694","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Zenith Epigenetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zenith Epigenetics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zenith Epi.."},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"S. Korea's Green Cross seeks phase 2 trials of COVID-19 plasma drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GC5131A","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Green Cross Lab Cell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Green Cross Lab Cell \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Green Cros.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics LP Announces Priority Review of Biologics License Application for ansuvimab Ebola Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ansuvimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Receives FDA Approval to Initiate 'EXIT-COVID-19,' a Phase II Investigational New Drug Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bone marrow-derived extracellular vesicle and exosome product","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India Gets Approval to Start Human Trials for Oxford Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Atogepant","moa":"CGRPR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innate Pharma Announces Publication of Explore Covid-19 Translational Study Findings In Nature","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avdoralimab","moa":"C5aR1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS Reports Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Status to Regulus Therapeutics' Treatment for Common Type of PKD","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"RGLS4326","moa":"miR-17","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Constant Therapeutics Announces Start of Phase 2 Trial of Peptide Drug TXA127 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Angiotensin (1-7)","moa":"Proto-oncogene Mas","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Constant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant T.."},{"orgOrder":0,"company":"Samus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samus Therapeutics Presents Phase 1 PU-AD Study Data at AAIC 2020 Advancing the Company's Platform for Treating Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PU-AD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Samus Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Samus Ther.."},{"orgOrder":0,"company":"Helixmith","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1\/2a Trial of Gene Therapy Engensis for CMT1A Begins in Korea","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Donaperminogene seltoplasmid","moa":"HGF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Helixmith","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Helixmith \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Helixmith .."},{"orgOrder":0,"company":"Tychan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Study Demonstrates Safety and Efficacy of mAb to Treat Yellow Fever","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TY014","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tychan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tychan \/ N.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics\u2019 Aviptadil gets US FDA Expanded Access Protocol to Treat Respiratory Failure in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly Crashes Out of KRAS Race as it Ditches Phase 1 Effort","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Sinopharm to Test Potential COVID-19 Vaccine in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J Begins First Trial of Covid-19 Vaccine After Positive Preclinical Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Dumps ex-Achillion C3G Program After Seeing Phase 2 Data","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck, via Themis Starts New COVID-19 Trial with V591","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"V591","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-176 for Seasonal Influenza","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-176","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Provides Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Granted Access by European Medicines Agency to PRIME Scheme for IMG-7289 (Bomedemstat) in Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Receives MHRA Approval to Initiate Phase I Trial of Potential COVID-19 Antiviral Antibody Treatment, CT-P59, in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201 for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-201","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Denali Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Begins Dosing of DNL758 in Phase Ib Covid-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"DNL758","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Denali Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ D.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and Bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Files Japan NDA for Preventive Treatment of Migraines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Gets Breakthrough Therapy Designation for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pevonedistat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Waverley Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Waverley Pharma Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European Countries","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pemetrexed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Waverley Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"Waverley Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Waverley P.."},{"orgOrder":0,"company":"Duke-NUS Medical School","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Made-in-Singapore Cancer Drug ETC-159 Advances Further In Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ETC-159","moa":"Wnt Signalling Pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Duke-NUS Medical School","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duke-NUS Medical School \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Duke-NUS M.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Completes Phase 1 GvHD Clinical Trial Follow-up with Positive Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"MCA-derived mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG\/KG Level","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SIRP\u03b1-IgG1 Fc","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"AGT103-T","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American Gene Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"American G.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Files IND Application for Phase 2\/3 COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"EB05","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sound Pharmaceuticals Files IND to Test SPI-1005 in Phase 2 COVID-19 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gan & Lee Pharmaceuticals Initiates First-in Human Phase 1 Clinical Trial for New Anti-tumor Drug GLR2007","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GLR2007","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee .."},{"orgOrder":0,"company":"Aytu BioScience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zolpidem Tartrate","moa":"GABA A receptor alpha1\/beta1\/gamma2","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Aytu BioScience","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Aytu BioScience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioSc.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Endoxifen","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Presents New Phase IIIb ANJESO\u00ae Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Clinical Study (\"Study II\") Progress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TLD-1433","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Theralase Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theralase Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theralase .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves STELARA for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nirsevimab Reduced Respiratory Syncytial Virus Infections Requiring Medical Care in Healthy Premature Infants in Phase 2b Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nirsevimab","moa":"RSV fusion protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ A.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT111","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Eisai","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents the Latest Data from the Phase 2b Open-Label Extension Study of BAN2401 at AAIC 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ban2401","moa":"Amyloid beta plaque","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma Initiates Global Phase 2\/3 Study for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Two US Regulatory Milestones for KEYTRUDA\u00ae (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces FDA Clearance of Investigational New Drug Application for SYN-020 Intestinal Alkaline Phosphatase (IAP)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant bovine intestinal alkaline phosphatase","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpha37","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea To Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine Gen-009 In Combination With Checkpoint Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"Pharvaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Characterization of Novel B2-Receptor Antagonists Published in Frontiers in Pharmacology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PHA121","moa":"Bradykinin B2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pharvaris","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pharvaris \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharvaris .."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIGA Announces Marketing Authorization Filing for oral tecovirimat with the European Medicines Agency for Multiple Indications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisinicline Analogs","moa":"Nicotinic receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinity\u2019s COVID-19 Antibodies Ready for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BIOQUAL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BIOQUAL \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BIOQUAL \/ .."},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIOQUAL Publishes in Nature of Non-Human Primate Preclinical Viral Challenge Study of Single-shot Ad26 vaccine protects against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BIOQUAL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"BIOQUAL \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BIOQUAL \/ .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim\u2019s EMPEROR-Reduced phase II trial of empagliflozin in adults with heart failure meets primary endpoint","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Dynacure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynacure Gets Rare Pediatric Disease Designation from U.S. FDA for DYN101 for Myotubular and Centronuclear Myopathies","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dynamin 101","moa":"Dynamin 2 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynacure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives Piqray\u00ae approval in Europe \u2013 the first and only targeted medicine for HR+\/HER2- advanced breast cancer with a PIK3CA mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Alpelisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Monjuvi in Combination With Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JCR Pharmaceuticals Completes Phase 1\/2 Clinical Trial Notification of JR-171 for mucopolysaccharidosis type I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"alpha L Idosiduronase","moa":"Dermatan sulfate hydrolytic enzyme","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Backs Mercks's Bavencio Combo for Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Drug SCO-101 Potentiates the Effect of Chemotherapy in the First Cohort in Chemo-Resistant Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Endovion","moa":"Chloride channel","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2\/3 Trial of RLF-100 for Critical COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenicriviroc Sulfone","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Quantum Leap Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Leap Healthcare \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Quantum Le.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in the Phase 1 Clinical Trial of Anti-CD47\/PD-L1 Bispecific Antibody in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI322","moa":"CD47\/SIRPalpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pimavanserin Reduces Dementia-Related Psychosis Symptoms","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pha.."},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Xanomeline","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Karuna The.."},{"orgOrder":0,"company":"TB Alliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pretomanid","moa":"Mycolic acid biosynthesis","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"TB Alliance","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TB Allianc.."},{"orgOrder":0,"company":"IQWiG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Darolutamide in Prostate Cancer: Indication of Considerable Added Benefit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IQWiG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQWiG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IQWiG \/ No.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-TDP-43 antibody","moa":"TAR DNA binding protein 43","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Announces First Patients Enrolled in HEALEY ALS Platform Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Submits CTA Application In UK To Start Phase 1 Trial Of ALN-HSD To Treat NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALN-HSD","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Neutrolis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neutrolis Announces Development Of First-In-Class Treatment Targeting Neutrophil Extracellular Traps For Patients With Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NTR-441","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Neutrolis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neutrolis \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Neutrolis .."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Sonoran Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sonoran Biosciences Announces Qualified Infectious Disease Product Designation Granted by FDA for SBG003","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tobramycin","moa":"70s ribosome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sonoran Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sonoran Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sonoran Bi.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Completes Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Aivita Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AVOVA-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aivita Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aivita Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aivita Bio.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Publication of LPCN 1144 Liver Fat Study (\"LFS\") Results","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Homeostasis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Verdiperstat","moa":"Myeloperoxidase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Announces First Patient Dosed in Phase 1b\/2a Study of Tsquinimod Use in Treatment of Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Bio.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae Receives EU Approval for First-Line Systemic Treatment in Pediatric Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Secukinumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation for BCX9930 in PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Drugs in Dermatology Publishes Results from Phase 1\/2a Trial of Arcutis\u2019 ARQ-151 for the Treatment of Chronic Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"PolyPid","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolyPid Granted Fast Track Designation from FDA for D-PLEX\u2081\u2080\u2080 for Prevention of Surgical Site Infections in Abdominal Surgery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxycycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Powder","sponsorNew":"PolyPid \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ .."},{"orgOrder":0,"company":"Cerecor","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CERC-006","moa":"mTOR 1\/2 complex","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecor \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Personalized Stem Cells","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner: Personalized Stem Cells","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Adipose-derived MSCs","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Personalized Stem Cells","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Personalized Stem Cells \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Personaliz.."},{"orgOrder":0,"company":"Kadimastem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx\u00ae Phase 1\/2a Clinical Trial in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Human astrocytes","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kadimastem","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kadimastem \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kadimastem.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ\u00ae (tasimelteon) in the Treatment of Smith-Magenis Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Usona Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Usona Institute Publishes Breakthrough Development in Scalable Psilocybin Synthesis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Usona Institute","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral","sponsorNew":"Usona Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Usona Inst.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Reports Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"hAd5 vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen to Host Investor Conference Call to Discuss NIH\u2019s Selection of Lenzilumab for Big Effect Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vopec Pharma completes COVID-19 clinical trials of herbal formulation, Amrta Karuna","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amrta Karuna","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Vopec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Vopec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Vopec Phar.."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Cyprium Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fortress Biotech Gets Positive Opinion on Orphan Drug Designation Received from the EMA for CUTX-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Copper Histidine","moa":"Cu homeostasis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fortress Biotech \/ Cyprium Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fortress B.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly starts late-stage study of COVID-19 drug in nursing homes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic's Lead MS Drug Hits Primary and Key Secondary Endpoints in PhII, But Questions Remain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbCellera Provides COVID-19 Program Update with the Start of Phase 3 Clinical Trials and the Expansion of its COVID-19 Antibody Database","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbCellera \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Themis Bioscience","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mv-Sars-Cov-2 Vaccine Candidate: A New Partnership Between Institut Pasteur, Cepi, Th\u00e9mis And Msd","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"MV-SARS-CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Institut Pasteur","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Institut Pasteur \/ Th\u00e9mis","highestDevelopmentStatusID":"4","companyTruncated":"Institut P.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis\u2019 Ilaris [Canakinumab] Unexpectedly Slashes Need For Joint Replacements From Osteoarthritis In Key Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Canakinumab","moa":"IL-1 beta","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ono Reports Positive Phase III Data for Opdivo Combo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Inclisiran","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":2,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ Blackstone","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Financing","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.34999999999999998,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Blackstone","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$6,000.0 million","upfrontCash":"$1,000.0 million","newsHeadline":"AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"DS-1062","moa":"Trop2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":6,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":6,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ ASTRAZENECA","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"BioNTech","sponsor":"U.S. government","pharmaFlowCategory":"D","amount":"$1,950.0 million","upfrontCash":"Undisclosed","newsHeadline":"US signs $1.95bn deal for Pfizer and BioNTech\u2019s Covid-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":1.95,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.95,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ U.S. government","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$147.1 million","newsHeadline":"GSK and CureVac Announce Strategic mRNA Technology Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"CV7301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CureVac","amount2":1.1000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"CureVac \/ Glaxosmithkline","highestDevelopmentStatusID":"4","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$870.0 million","upfrontCash":"$10.0 million","newsHeadline":"Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Efinopegdutide","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0.87,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.87,"dosageForm":"","sponsorNew":"Hanmi Pharmaceutical \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Phar.."},{"orgOrder":0,"company":"IMV","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"DPX-COVID-19","moa":"SARS-CoV-2 spike protein inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"IMV \/ NRC .."},{"orgOrder":0,"company":"resTORbio","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Funding","leadProduct":"Dactolisib","moa":"TORC1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"resTORbio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"resTORbio .."},{"orgOrder":0,"company":"Somerset Pharmaceuticals Inc","sponsor":"Premier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Premier Inc. ProvideGx\u00ae Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole\/Trimethoprim","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Sulfamethoxazole","moa":"Dihydropteroate synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Somerset Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Somerset Pharmaceuticals Inc \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Somerset P.."},{"orgOrder":0,"company":"Transgene","sponsor":"Tasly BioPharmaceuticals","pharmaFlowCategory":"D","amount":"$22.2 million","upfrontCash":"Undisclosed","newsHeadline":"Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Flucytosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Tasly BioPharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Partner Therapeutics Announces $35 Million Deal with U.S. DOD for Advanced Development and Emergency Use of Leukine for COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Sargramostim","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Partner Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BARDA drafts Fujifilm Diosynth into its vaccine production effort, offering to also accelerate capacity expansion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ BARDA","highestDevelopmentStatusID":"7","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"Gero","sponsor":"Bulba Ventures","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"Undisclosed","newsHeadline":"Gero, a Singapore-based Biotech Startup raises $2.2M in Series A Funding","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"SINGAPORE","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Gero","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gero \/ Bulba Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Gero \/ Bul.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Achieve Life Sciences \/ Lake Street Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Suzhou GenHouse","sponsor":"HUYA Bioscience International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"HBI-2376","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Suzhou GenHouse","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Suzhou GenHouse \/ HUYA Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Suzhou Gen.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"EverInsight Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ EverInsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"National Yang-Ming University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vyripharm and the National Yang-Ming University Signed a MOU to Develop VYR-206 for Neurological Disorders Outcomes Following Treatments","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"VYR-206","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vyripharm Biopharmaceuticals \/ National Yang-Ming University","highestDevelopmentStatusID":"3","companyTruncated":"Vyripharm .."},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Monoclonal Antibodies biosimilar","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ Teva","highestDevelopmentStatusID":"1","companyTruncated":"Alvotech \/.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series B Financing","leadProduct":"TSHA-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 With National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BryoLogyx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"BryoLogyx .."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Seismic Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Seismic Bio","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adicet Bio Receives $10 Million Product Development Milestone From Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"ADI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Adicet Bio","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Adicet Bio \/ Regeneron","highestDevelopmentStatusID":"4","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Leerink","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Immunic Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Oral Tablet","sponsorNew":"Immunic Therapeutics \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Synthetic Lethality","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$100.0 million","newsHeadline":"IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IDE397","moa":"MAT2A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Synthetic Lethality","highestDevelopmentStatusID":"4","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Point Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma Announces Successful USD $20M Series A Financing to Bring Precision Radioligand Therapy to Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"PNT2002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Point Biopharma","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Point Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Point Biop.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"EyePoint Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for Dexycu","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ EyePoint Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"UWM Research Foundation","sponsor":"RespireRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"KRM-II-81","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"UWM Research Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UWM Research Foundation \/ RespireRx Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"UWM Resear.."},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bryn Pharma Raises $11 Million in Financing to Advance Bi-Dose Epinephrine Nasal Spray for Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharm.."},{"orgOrder":0,"company":"BostonGene","sponsor":"The Weinstock Laboratory","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BostonGene Announces Scientific Collaboration with Leading Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Duvelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"BostonGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"BostonGene \/ The Weinstock Laboratory","highestDevelopmentStatusID":"8","companyTruncated":"BostonGene.."},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"New Life Therapeutics","pharmaFlowCategory":"D","amount":"$40.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SON-081","moa":"IL-6","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Sonnet BioTherapeutics \/ New Life Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet Bio.."},{"orgOrder":0,"company":"Novavax","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and Serum Institute of India Announce Development and Commercial Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"LTL Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LTL Pharma to Take Over Sanofi\u2019s Diregura in Japan","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Fexofenadine Hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ LTL Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ L.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer, BioNTech Ink Deal To Supply Canada With Potential Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Government of Canada","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Matterhorn Biosciences","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Versant Ventures Launches Matterhorn Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"T cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Matterhorn Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Matterhorn Biosciences \/ Versant Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Matterhorn.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"ForDoz","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Gets Exclusive Rights to Market and Distribute 2 Complex Injectable Assets from ForDoz Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ForDoz","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ForDoz \/ Lupin","highestDevelopmentStatusID":"1","companyTruncated":"ForDoz \/ L.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Simcere","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$14.0 million","newsHeadline":"G1, Simcere to bring new cancer therapy in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trilaciclib","moa":"CDK4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.17000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Simcere","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Secarna, Evotec Form Strategic Antisense Alliance","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Antisense oligonucleotide therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Secarna Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Secarna Ph.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"$1,525.0 million","upfrontCash":"Undisclosed","newsHeadline":"Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":1.53,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.53,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ U.S. Government","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"VistaGen Therapeutics","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"10","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"W. L. Gore & Associates","sponsor":"ViaCyte Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Stem cell-derived pancreatic islet cell progenitors","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"W. L. Gore & Associates","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"W. L. Gore & Associates \/ ViaCyte","highestDevelopmentStatusID":"4","companyTruncated":"W. L. Gore.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"U.S. Department Of Defense","pharmaFlowCategory":"D","amount":"$35.6 million","upfrontCash":"Undisclosed","newsHeadline":"SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ U.S. Department Of Defense","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Belantamab mafodotin-blmf","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Seagen \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ G.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan in Combination with TAGRISSO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Osimertinib Mesylate","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"ARC Therapeutics","sponsor":"Eshelman Ventures","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"ARC Therapeutics Launches to Develop Novel CDK Inhibitors for the Treatment of Advanced and Resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ARC Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"ARC Therapeutics \/ Eshelman Ventures","highestDevelopmentStatusID":"4","companyTruncated":"ARC Therap.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Phage-based therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"$11.5 million","newsHeadline":"Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Verrica Pharmaceuticals","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$2,150.0 million","upfrontCash":"$560.0 million","newsHeadline":"Biogen and Denali to Collaborate on LRRK2 Program for Parkinson\u2019s Disease and TV Platform-Enabled Programs for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"DNL151","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":2.1499999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Corticotropin","moa":"ACTH","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AmbioPharm","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmbioPharm \/ Upsher-Smith Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"AmbioPharm.."},{"orgOrder":0,"company":"Veristat","sponsor":"PreveCeutical Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PreveCeutical Prepares for Clinical Trials for its Sol-Gel COVID-19 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veristat","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Veristat \/ PreveCeutical","highestDevelopmentStatusID":"4","companyTruncated":"Veristat \/.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$90.0 million","newsHeadline":"Editas Medicine Regains Full Global Rights to Ocular Medicines","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Termination","leadProduct":"EDIT-101","moa":"CEP290","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ AbbVie","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Cato Research","sponsor":"JanOne","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Cato Research","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cato Research \/ JanOne","highestDevelopmentStatusID":"5","companyTruncated":"Cato Resea.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"MidCap Financial Trust","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aptevo Therapeutics \/ MidCap Financial Trust","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Eversana","sponsor":"Zosano Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eversana","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Eversana \/ Zosano","highestDevelopmentStatusID":"10","companyTruncated":"Eversana \/.."},{"orgOrder":0,"company":"Mucokinetica","sponsor":"Covistat","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Covistat, Biopharmaceutical Company Developing Low-Cost COVID-19 Treatment, Acquires IP From World Leader in Respiratory Disease Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mucokinetica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mucokinetica \/ Covistat","highestDevelopmentStatusID":"1","companyTruncated":"Mucokineti.."},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"IOV-3001","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avid Bioservices","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avid Biose.."},{"orgOrder":0,"company":"Athenex","sponsor":"Sagard Healthcare Royalty Partners","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Sagard Healthcare Royalty Partners","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"RA Capital Incubator","pharmaFlowCategory":"D","amount":"$72.6 million","upfrontCash":"Undisclosed","newsHeadline":"Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding for Disease-Modifying Pulmonary Arterial Hypertension Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"Imatinib Mesylate","moa":"PDGF","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0.070000000000000007,"dosageForm":"Inhalation","sponsorNew":"Aerovate Therapeutics \/ RA Capital Incubator","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate T.."},{"orgOrder":0,"company":"T-knife","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"Undisclosed","newsHeadline":"T-knife Completes \u20ac66 Million Series AFinancing to Develop Next-Generation T-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"Humanized T-cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"T-knife","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"T-knife \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"T-knife \/ .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Pfizer Inc \/ Gilead Scinces","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Gavi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SII, Gavi and BMGF Collaborate to Boost Access to COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Gavi","highestDevelopmentStatusID":"8","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$450.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biohaven and Royalty Pharma Announce Funding Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Zavegepant","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0.45000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Novavax","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Japan in Deals with AstraZeneca, Novavax for COVID-19 Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UK's Hikma Making Gilead's COVID-19 Drug Remdesivir to Increase Supply","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Gilead Sciences \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"NIH Grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"CTT1403","moa":"PSMA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Targeted Technology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Targeted Technology \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Tar.."},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Amarin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amarin Supports Investigator-Initiated Trial at Kaiser","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kaiser Permanente Washington Health Research \/ AMARIN","highestDevelopmentStatusID":"11","companyTruncated":"Kaiser Per.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Ministry of Health, Labour and Welfare of Japan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo Selected as Provider for Japanese Government\u2019s \u201cEmergent Initiative to Build Production Capacity for COVID-19 Vaccines (First Round)\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Ministry of Health, Labour and Welfare of Japan","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Government of Switzerland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Swiss Government Signs Agreement with Moderna for COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Government of Switzerland","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"MODAG","sponsor":"The Michael J. Fox Foundation for Parkinson's Research.","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"MODAG Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Anle138b","moa":"Alpha synuclein protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"MODAG","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MODAG \/ The Michael J. Fox Foundation for Parkinson's Research.","highestDevelopmentStatusID":"6","companyTruncated":"MODAG \/ Th.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XORTX Partners with Mount Sinai\u2019s Icahn School of Medicine on US-based Clinical Trial in COVID-19","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"MTEC","pharmaFlowCategory":"D","amount":"$5.1 million","upfrontCash":"Undisclosed","newsHeadline":"Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for Treatment of ARDS in COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Razuprotafib","moa":"PTP","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ MTEC","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Celularity","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"Celularity Announces the Activation of First California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ CIRM","highestDevelopmentStatusID":"7","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"Gentbio","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Inks Licensing Agreement with Seattle Children\u2019s Research Institute to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Engineered Regulatory T cell therapy","moa":"T cell","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Seattle Children\u2019s Research Institute","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Seattle Children\u2019s Research Institute \/ Gentbio","highestDevelopmentStatusID":"3","companyTruncated":"Seattle Ch.."},{"orgOrder":0,"company":"Gavi","sponsor":"Bill and Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gavi Gets $150 million Funding From Bill & Melinda Gates Foundation to Support Collaboration With SII","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gavi","amount2":0.14999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Gavi \/ Bill and Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Gavi \/ Bil.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Independently Confirms and Extends Laboratory Findings and Expands Safety Profile of ATH434","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax\u2019s Covid-19 Vaccine Yields Positive Data in Phase I Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Long Journey for DBV Peanut Patch Ends in Rejection by FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Viaskin peanut","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"DBV Technologies","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"DBV Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"DBV Techno.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly initiates trial of neutralising antibody against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Singapore-MIT Alliance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Singapore develops potential antibody treatment for yellow fever","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"TY014","moa":"Viral envelope protein epitope","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Singapore-MIT Alliance","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Singapore-MIT Alliance \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Singapore-.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces First Two Patients Treated in Phase I\/II Clinical Trial of AMT-130 for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrastriatal Injection","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila's COVID-19 Vaccine Candidate found Safe in Early-Stage Human Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ZyCoV-D","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Starts the Phase 2 PORT Study Comparing Peripheral Versus Central Administration of Melflufen and Dexamethasone in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftansomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GB001","moa":"Prostaglandin D2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clovis Enrolls First Patient in Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucitanib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Clovis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Clovis Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Clovis Onc.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Gets U.S. FDA Fast Track Designation for delgocitinib Cream for the Treatment of Adults With Moderate-to-severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"ReViral","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sisunatovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReViral \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH-Moderna Investigational COVID-19 Vaccine Shows Promise in Mouse Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Institutes of Health \/ Moderna","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB'S CIMZIA is the First and Only Biologic Approved in Europe with the Option for a Reduced Maintenance Dose for Patients Across the Full Axial Spondyloarthritis Spectrum","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces NDA for Ripretinib Granted Priority Review by China\u2019s NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphan Drug Designation Granted to Mundipharma's Tinostamustine in EU for Very Rare form of Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tinostamustine","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharm.."},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANA Therapeutics Announces U.S. FDA Clearance Of IND Application To Initiate Clinical Trial Of Niclosamide In COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therap.."},{"orgOrder":0,"company":"Tarveda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"T-2143","moa":"pan-PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tarveda Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tarveda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tarveda Th.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-047","moa":"Alk2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 In Vitro Testing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Biosight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Designation to Aspacytarabine to Treat Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspacytarabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosight \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I\/II Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves GSK\u2019s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Fingolimod Capsules, 0.5 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"IMAC Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"IMAC Holdings","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IMAC Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IMAC Holdi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives EC approval for new Xolair\u00ae indication to treat severe chronic rhinosinusitis with nasal polyps","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"IgE","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Genentech","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Beroni Group","sponsor":"Tianjin University in China","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beroni Group Has Successfully Constructed and Purified 24 Types of Nanobodies for Detection and Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"nanobody","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beroni Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beroni Group \/ Tianjin University in China","highestDevelopmentStatusID":"4","companyTruncated":"Beroni Gro.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin, Concord, Receive US FDA Approval for Mycophenolate Mofetil Tablets USP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mycophenolate Mofetil","moa":"IMPDH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Audentes is Developing AT845 for the Treatment of Pompe Disease.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AT845","moa":"GAA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Audentes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Audentes T.."},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indoco Remedies Gets USFDA Nod for Schizophrenia, Bipolar Disorder Treatment Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indoco Remedies Limited","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indoco Remedies Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indoco Rem.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Introduces Higher Strength (400 mg) of FabiFlu\u00ae to Reduce Pill Burden of COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zenara Pharma Receives DCGI Approval to Manufacture, Sell Favipiravir Tablets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Zenara Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zenara Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zenara Pha.."},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amilo-5MER","moa":"Serum Amyloid A","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Galmed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galmed Pharmaceuticals \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"Galmed Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Maintained Pipeline Progress Over the Quarter","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Reduction of Inflammation Associated Memory Impairment by QuadraMune\u2122 Administration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diabetologia Publishes Results Highlighting Efficacy of the Diabetes Vaccine Diamyd\u00ae in Genetically Defined Subgroups of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Levo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Levo Therapeutics Announces Top-line Results from Phase 3 CARE-PWS Study of LV-101","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Levo Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Levo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Levo Thera.."},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maverick Therapeutics Announces First Peer-Reviewed Publication Describing the Design and Development of the COBRA\u2122 Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick T.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RG6346","moa":"HBsAg-mRNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciltacabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Legend Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Legend Bio.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Highlights Importance of T cell Immunity to Prevent COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX\u00ae2-73 (blarcamesine) for Alzheimer\u2019s Disease Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salarius Announces Issuance of New Patent for Seclidemstat by European Patent Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius P.."},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Rodatristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Altavant Sciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altavant S.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Formally Accepts PharmaCyte Biotech\u2019s Drug Master File for Company\u2019s Pancreatic Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lundbeck Discontinues Phase II Proof of Concept Study of Lu AF11167 in Patients with Negative Symptoms of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lu AF11167","moa":"PDE10A","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbec.."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Positive Oral Data on New RECCE\u00ae 435 Against Helicobacter Pylori in Animal Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RECCE 435","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Providence Therapeutics Reports Supportive Preclinical Data for its COVID-19 Vaccine Candidate (PTX-COVID19-B)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PTX-COVID19-B","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Providence Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Providence Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Providence.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Enrollment of First Patient in 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Griffith University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Aussie Drug Signals Breakthrough for Prostate Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"DpC","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Griffith University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Griffith University \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Griffith U.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pamiparib","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics plc Reports Clinical Eesults on OPTIC-X","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 'AMBITION' Clinical Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Soft Gel Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Liquidia Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaled Powder in Capsule","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liquidia C.."},{"orgOrder":0,"company":"Medicinova","sponsor":"UCLA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN\u2011166 (ibudilast) in Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medicinova \/ UCLA","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CANbridge Pharmaceuticals Receives Marketing Approval for NERLYNX\u00ae (neratinib) in Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CANbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CANbridge .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Provides Update on Phase III Study of Tecentriq in Combination with Paclitaxel for People with Metastatic Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Mountain Valley MD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mountain Valley MD Announces Successful Complexation of Ivermectin Drug in Quicksome(TM) Oral Strip and Commencement of Pre-Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mountain Valley MD","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mountain Valley MD \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mountain V.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals\u2019 Firdapse\u00ae (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baudax Bio Secures Permanent J-Code (J1738) for ANJESO\u00ae from Centers for Medicare and Medicaid Services","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Baudax Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Baudax Bio.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Achieves Target Enrollment of 500 Patients in Phase 3 AVENGER 500 Trial of CPI-613 for Patients with Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma\u2019s Phase 2\/3 COVID-19 Study Approved in Mexico","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Therapeutics Initiates Ph2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R\/R FL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu)-lilotomab satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Labs Receives US FDA Approval to Market Generic Detrol Tablets","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolterodine Tartrate","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem La.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Gets Positive CHMP Opinion for Avapritinib to Treat Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Bio Farma","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio Farma Begins Human Trials of Coronavirus Vaccine in Indonesia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio Farma \/ Sinovac Biotech Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces NEJM Publication of Phase III ASCLEPIOS Trials Demonstrating Superior Efficacy of Ofatumumab in Patients with Relapsing Multiple Sclerosis\n\nNovartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficac","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ofatumumab","moa":"CD20","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Announces That OmniAb-derived CS1001 Phase 3 Trial Met the Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"IDS","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces FDA Approval of Evrysdi for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Announces First Patient Dosed in a Phase 1b\/2 Study of FGF401 in Combination with Pembrolizumab for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Roblitinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Acceptance for Regulatory Review of Pfizer\u2019s Marketing Authorization Application for Antifungal Isavuconazole in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Isavuconazonium Sulfate","moa":"CYP51A1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jaguar Health Announces Activation of Investigational New Drug for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy\u2011Related Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Crofelemer","moa":"Anoctamin-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Jaguar Health","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield\u2122, a Single Dose Intranasal Anthrax Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NasoShield","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Nanyang Technological University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u200bNTU Singapore Develops Peptide that Makes Drug-Resistant Bacteria Sensitive to Antibiotics Again","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SINGAPORE","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CSM5-K5","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Nanyang Technological University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanyang Technological University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nanyang Te.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"DNL151","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Evrysdi (risdiplam) for Treatment of Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo Plus Yervoy Shows S Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Lampit\u00ae (nifurtimox) for the Treatment of Chagas Disease in Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nifurtimox","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Momelotinib","moa":"JAK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Reports Second Quarter 2020 Financial Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lisocabtagene maraleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Ther.."},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET\u2122 Immunotherapy Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DF-1001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dragonfly Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Dragonfly Therapeutics \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Dragonfly .."},{"orgOrder":0,"company":"IsoTherapeutics Group","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IsoTherapeutics Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IsoTherapeutics Group \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"2","companyTruncated":"IsoTherape.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Secura Bio","pharmaFlowCategory":"D","amount":"$381.0 million","upfrontCash":"$70.0 million","newsHeadline":"Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA\u00ae (duvelisib) Rights to Secura Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Verastem Oncology","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.38,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Secura Bio","highestDevelopmentStatusID":"12","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Onko Kocsel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar Signs a New Agreement with Onko to Commercialize Yondelis\u00ae in Turkey","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Onko Kocsel Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics Expands Partnership with Novavax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AGC Biologics \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"AnHeart Announces Entry into Series A+ Equity Financing Agreements","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"Taletrectinib","moa":"ROS1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"AnHeart Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"","sponsorNew":"AnHeart Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnHeart Th.."},{"orgOrder":0,"company":"KALEO INC","sponsor":"pan Canadian Pharmaceutical Alliance","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kal\u00e9o and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT\u00ae Auto-Injector","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"KALEO INC","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"KALEO INC \/ pan Canadian Pharmaceutical Alliance","highestDevelopmentStatusID":"12","companyTruncated":"KALEO INC .."},{"orgOrder":0,"company":"CureVac","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CureVac Announces Proposed Initial Public Offering of Common Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"mRNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Pieris Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pieris and Lilly Ink Clinical Trial Collaboration to Evaluate Combination of Prs-343 with Ramucirumab and Paclitaxel In Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Paclitaxel","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pieris Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Pieris Pha.."},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Vida Ventures","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dyne Therapeutics Announces $115M Financing to Ramp Up Muscle Disease Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Antibody-oligonucleotide conjugates","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0.12,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Dyne Therapeutics \/ Vida Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Thera.."},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$516.0 million","upfrontCash":"$438.0 million","newsHeadline":"Ligand to Acquire Pfenex Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0.52000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Pfenex \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ L.."},{"orgOrder":0,"company":"Kandy Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$875.0 million","upfrontCash":"$425.0 million","newsHeadline":"Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"NT-814","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Kandy Therapeutics","amount2":0.88,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.88,"dosageForm":"Capsule","sponsorNew":"Kandy Therapeutics \/ Bayer Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Kandy Ther.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$9.6 million","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$25.9 million","upfrontCash":"Undisclosed","newsHeadline":"TFF Pharmaceuticals Announces $25.9 Million in Financing to Further Advance Its Thin Film Freezing Technology Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therap.."},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","amount":"$26.5 million","upfrontCash":"Undisclosed","newsHeadline":"Scioto Biosciences Receives Series B Investment from Genome & Company","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series B Financing","leadProduct":"SB-121","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Bio.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVEO Oncology Announces Restructuring of Existing Term Loan with Closing of New Tranched, $35 Million Debt Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Tivozanib","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Guggenheim Securities, LLC","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiaMedica Announces Closing of $23 Million Public Offering of Common Shares","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"DM199","moa":"Kallikrein-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0.02,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"DiaMedica Therapeutics \/ Guggenheim Securities, LLC","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Brazilian Government","pharmaFlowCategory":"D","amount":"$356.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brazil's Bolsonaro Orders $360 million to Be Set Aside for AstraZeneca Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.35999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.35999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Brazilian Government","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$3,680.0 million","upfrontCash":"$3,680","newsHeadline":"Sanofi to acquire Principia Biopharma","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"SAR442168","moa":"BTK","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sanofi","amount2":3.6800000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":3.6800000000000002,"dosageForm":"Film Coated Tablet","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$377.0 million","upfrontCash":"Undisclosed","newsHeadline":"Redx Signs Out Licensing Agreement With Astrazeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RXC006","moa":"Porcupine","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0.38,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"Redx Pharma \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Swiss Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Molecular Partners Announces Agreement with Swiss Government, Securing Rights to Purchase Doses of First Anti-COVID-19 DARPin\u00ae Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"MP0420","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Partners \/ Swiss Government","highestDevelopmentStatusID":"4","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"LianBio","pharmaFlowCategory":"D","amount":"$187.0 million","upfrontCash":"Undisclosed","newsHeadline":"MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0.19,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.19,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","amount":"$113.5 million","upfrontCash":"Undisclosed","newsHeadline":"Verrica Pharmaceuticals Licenses LTX-315 from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lytix Biopharma","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Lytix Biop.."},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hemogenyx Pharmaceuticals PLC Announces CAR-T Agreement with University of Pennsylvania","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"CAR-T therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Pennsylvania \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Sapphire Biotech","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Sapphire Biotech Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"SPX-1009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sapphire Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sapphire Biotech \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Sapphire B.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Arctic Vision","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia and Arctic Vision Ink License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Arctic Vision","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","amount":"$60.8 million","upfrontCash":"Undisclosed","newsHeadline":"F2G Raises $61M for Late-Phase Antifungal R&D","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Olorofim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"F2G Limited \/ Cowen Healthcare Investments","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Celleron","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celleron Therapeutics Enters Into a Iicense Agreement with Roche to Improve the Lives of Patients Living with Tenosynovial Giant Cell Tumour","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Emactuzumab","moa":"CSF-1R positive macrophages depleter","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Celleron","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Perrigo Acquires Market-Leading OTC Self-Care Brands In Eastern Europe From Sanofi","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Azeloglycine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sanofi \/ Perrigo","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ P.."},{"orgOrder":0,"company":"Scipher Medicine","sponsor":"Galapagos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Scipher Medicine and Galapagos Sign Collaboration in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Scipher Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scipher Medicine \/ Galapagos","highestDevelopmentStatusID":"2","companyTruncated":"Scipher Me.."},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"NTN Buzztime","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Merger","leadProduct":"Cyclophosphamide","moa":"IL-2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ NTN Buzztime","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn I.."},{"orgOrder":0,"company":"Genkyotex","sponsor":"Genkyotex","pharmaFlowCategory":"D","amount":"$37.7 million","upfrontCash":"Undisclosed","newsHeadline":"Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Setanaxib","moa":"NOX4","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genkyotex","amount2":0.040000000000000001,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Genkyotex \/ Calliditas","highestDevelopmentStatusID":"8","companyTruncated":"Genkyotex .."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill and Cosmo Pharmaceuticals Expand Strategic Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"RedHill Biopharma","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Cosmo Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax, SK bioscience Collaborate for COVID-19 Vax Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SK Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"SK Bioscie.."},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"Beroni Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beroni Group Collaborates with Genscript Biotech Corporation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Nanobodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GenScript Biotech Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ Beroni Group","highestDevelopmentStatusID":"4","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Prometheus Biosciences","sponsor":"Dr. Falk Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"PR600","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Prometheus Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prometheus Biosciences \/ Dr. Falk Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Prometheus.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Solasia Pharma KK","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Isofol Enters Licensing Agreement with Solasia to Develop and Commercialize Arfolitixorin in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Isofol Medical \/ Solasia","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"QBiotics Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Tigilanol Tiglate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ QBiotics","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"MicuRx Announces CARB-X US$7.78 Million Financing for Development of MRX-8","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"MRX-8","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"MicuRx Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"MicuRx Pharmaceuticals \/ CARB-X","highestDevelopmentStatusID":"5","companyTruncated":"MicuRx Pha.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"J&J Strikes Covid Vaccine Supply Deal with Europe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Mexico Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca will Work with Mexico, Argentina on COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Mexico Government","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Novavax","sponsor":"Government of United Kingdom","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax\u2019 COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Government of United Kingdom","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"JN Nova Pharma","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Canadian Biotech JN Nova Pharma Inc. Partners with the Government of Canada to Develop Therapeutic Platform for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"KG2019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"JN Nova Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"JN Nova Pharma \/ Government of Canada","highestDevelopmentStatusID":"4","companyTruncated":"JN Nova Ph.."},{"orgOrder":0,"company":"Strata Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Adagrasib","moa":"KRAS","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Strata Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Strata Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Strata Onc.."},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"L-DOS47","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Moffitt Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moffitt Cancer Center \/ Helix BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Moffitt Ca.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Receives Eur 1.0 Million to Advance Ongoing JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"$3.0 million","newsHeadline":"Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ABO-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Abeona Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Taysha Gene Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$6,295.0 million","upfrontCash":"$125.0 million","newsHeadline":"Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tango Therapeutics","amount2":6.2999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":6.2999999999999998,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$635.8 million","upfrontCash":"$43.3 milllion","newsHeadline":"Bayer and Hua Medicine Announce Commercialization Agreement","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Dorzagliatin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0.64000000000000001,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0.64000000000000001,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Bayer","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medici.."},{"orgOrder":0,"company":"Tango Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tango Therapeutics Announces $50 Million Equity Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Tango Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tango Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"4","companyTruncated":"Tango Ther.."},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Dermin","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"WPD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WPD Pharmaceuticals \/ Dermin","highestDevelopmentStatusID":"4","companyTruncated":"WPD Pharma.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Union Therapeutics","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"Union Therapeutics Option Agreement to Acquire Worldwide Exclusive License for Covid-19 Technologies Developed By TFF Pharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TFF Pharmaceuticals","amount2":0.20999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ UNION therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Memo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG and Northway Biotechpharma Collaborate Fast-Track Manufacturing of a SARS-CoV-2-Neutralizing Antibody for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"MTX-COVAB","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Northway Biotechpharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Northway Biotechpharma \/ Memo Therapeutics AG","highestDevelopmentStatusID":"2","companyTruncated":"Northway B.."},{"orgOrder":0,"company":"Attwill Medical Solutions","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Attwill Medical Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Attwill Medical Solutions \/ Revive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Attwill Me.."},{"orgOrder":0,"company":"McKesson","sponsor":"Centers for Disease Control","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"McKesson to Distribute Future COVID-19 Vaccines in Support of Operation Warp Speed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"McKesson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"McKesson \/ Centers for Disease Control","highestDevelopmentStatusID":"1","companyTruncated":"McKesson \/.."},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm Diosynth Biotechnologies Expands Its Partnership with Novavax to Manufacture Covid-19 Vaccine Candidate at its Billingham Site","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Novavax","highestDevelopmentStatusID":"7","companyTruncated":"Fujifilm D.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Coronavirus Immunotherapy Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Mono & Bi-specific antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Coronavirus Immunotherapy Consortium","highestDevelopmentStatusID":"4","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Respirent Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lannett Signs Agreement with Respirent Pharmaceuticals for Exclusive Distributor Of Generic Flovent\u00ae Diskus\u00ae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lannett Company, Inc. \/ Respirent Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Co.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Queensland \/ CEPI","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Open Orphan","sponsor":"Codagenix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Open Orphan Awarded Contract from Codagenix Inc. New York USA for COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"CodaVax-COVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Open Orphan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Open Orphan \/ Codagenix","highestDevelopmentStatusID":"4","companyTruncated":"Open Orpha.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$3.4 million","upfrontCash":"Undisclosed","newsHeadline":"Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pivotal Phase 3 Trial Testing Topical Gene Therapy B-VEC Now Enrolling DEB Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Beremagene geperpavec","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Analyses of Ofev\u00ae Data in Patients with Chronic Fibrosing ILDs Available During American Thoracic Society Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Supports Investigator-Initiated Trial at Kaiser Permanente to Study VASCEPA\u00ae in Reducing Viral Upper Respiratory Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Release Clinical Trial Data of Sintilimab in Combination with ALIMTA and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen Publishes Data on New Recombinant Hyperimmune Drug GIGA-2050 as COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AG019","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr.Reddy\u2019S Launches Generic Version of Ciprodex","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Otic Suspension","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Sinopharm Starts Phase III Trial of COVID-19 Vaccine in Bahrain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury\u00ae (Remdesivir) for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX Administered in Suprachoroidal Space","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Axitinib","moa":"VEGF 1\/2\/3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Esperion Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Esperion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Esperion T.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb\/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Announces Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"UB-421","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"iBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iBio Provides Update on IBIO-201 COVID-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IBIO-201","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"iBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"iBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"iBio \/ Not.."},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Announces U.S. FDA Filing Acceptance of BLA for StrataGraft\u00ae Regenerative Skin Tissue for Deep Partial-thickness Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"StrataGraft skin tissue","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckro.."},{"orgOrder":0,"company":"Ocugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocugen Receives Fourth FDA Orphan Drug Designation for OCU400 Gene Therapy to Treat PDE6B Gene Mutation-Associated Retinal Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-hNR2E3","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ocugen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ocugen \/ N.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Expands Phase III Study of Lenzilumab in COVID-19 to Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Novocellbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novocellbio in Korea Confirms NOVO-NK\u2019s Promising Antiviral Effects Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NOVO-NK","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novocellbio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novocellbio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novocellbi.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Launches Ontruzant in Brazil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Initiated Dosing of its COVID-19 STARR\u2122 mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1\/2 study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Announces Enrolment of First Patient in Multinational Clinical Trial for the Treatment of COVID-19 with RUCONEST\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Conestat alfa","moa":"C1 esterase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LogicBio Therapeutics Announces SUNRISE Phase 1\/2 Clinical Design for LB-001 to Treat Methylmalonic Acidemia in Pediatric Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"LB-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Appili Therapeutics to Expand its Phase 2 Trial of Favipiravir for Prevention of COVID-19 at U.S. Long-Term Care Facilities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces FDA Approval of OLINVYK\u2122 (oliceridine) injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Purified Suspension","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from EMA\u2019s CHMP","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 for Treatment of Allergic Reactions Including Anaphylaxis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio's Etokimab Provides More Disappointing Results, Raising Questions About Compound's Future","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Etokimab","moa":"Interleukin-33","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in Treatment in RhoVac's Clinical Phase IIb Study in the USA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"Romark","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Romark Initiates New Phase 3 Clinical Trial Of NT-300 For The Treatment Of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Romark \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ N.."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene Announces FDA Orphan Drug Designation for CLN7 Batten Disease Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV-based engineered transgene","moa":"CLN7 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Announces Two Peer-Reviewed Publications Reporting Safety and Efficacy Results from the SAKURA 3 Open-Label Safety Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China National Medical Products Administration Approves Gilead's Truvada\u00ae for HIV Pre-Exposure Prophylaxis (PrEP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME Announces Outcome of Interim Futility Review for HopES Sarcoma Phase II Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Dosing Phase 1\/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-ENaC","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation of Nebulized Solution","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CheckMate -577 Evaluating Opdivo as Adjuvant Therapy for Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"BIOQUAL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BIOQUAL Announces Publication in NEJM of Non-Human Primate Preclinical Viral Challenge Study of an mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BIOQUAL","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BIOQUAL \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BIOQUAL \/ .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Launches Phase 3 Trial for COVID-19 Vaccine in Indonesia, Reports Phase 2 Details","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Emerald Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Emerald Bioscience","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emerald Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Emerald Bi.."},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Management Changes","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio .."},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Pharmaceuticals Welcomes Aziz Mottiwala as Chief Commercial Officer and Relocates to Larger Irvine Headquarters","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TP-03","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Tarsus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Tarsus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Tarsus Pha.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. FDA Acceptance of BLA for Pegunigalsidase Alfa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Global Rare Diseases","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atea Pharmaceuticals Appoints Janet Hammond, M.D., Ph.D., as Chief Development Officer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-527","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum\u2019s losmapimod Fails Interim Analysis in Muscle Wasting Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK\u2122","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Fennec Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fennec Pha.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotech to Begin Mid-to-Late Stage Study of Covid-19 Drug Candidate In August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"India Globalization Capital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Initiation of IGC\u2019s Cannabinoid Trial on Alzheimer\u2019s Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"INDIA","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinoid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"India Globalization Capital","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"India Globalization Capital \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"India Glob.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Reports Positive Interim Data From First Patient Cohort in Phase 2 Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for \"Methods of Administering 3,4-Diaminopyridine\"","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Catalyst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalyst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Catalyst P.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1536","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Provides Clinical Trial Update on Zevtera","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ceftobiprole","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Provides Update on the FDA Review of EM-100","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Deflazacort","moa":"CTGF","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Newron Pharmaceuticals Provides Clinical and Business Update","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pha.."},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fusion Pharmaceuticals Update Regarding FPI-1434 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"[225Ac]-FPI-1434","moa":"IGF-1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fusion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pha.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Completes Stable Formulation of JAN101 in Preparation for Its First GMP Manufacturing Batch to Support Upcoming Clinical Trials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"Hemoglobin subunit alpha oxidizer","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sustained-Release Oral Formulation","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cenobamate Designated Promising Innovative Medicine (PIM) by the UK\u2019s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Th.."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Destiny Pharma\u2019s Novel Antibiotic Asset XF-73 Clears Safety Review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Exeporfinium chloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Destiny Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SYD1875","moa":"5T4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Kymab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KY1005","moa":"OX40L","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymab","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kymab \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kymab \/ No.."},{"orgOrder":0,"company":"Saillant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saillant Therapeutics to Develop Generic Virus Inhibiting Therapy Based on Activation of a Cellular Master Regulator","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Saillant Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Saillant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Saillant T.."},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"National Institute of Allergy and Infectious Diseases Started Enrolling in Clinical Trials Of Monoclonal Antibodies To Prevent Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Regeneron Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"American Gene Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves American Gene Technologies (AGT) to Move Forward with Phase 1 Clinical Trial of HIV Cure Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AGT103-T","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"American Gene Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American Gene Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"American G.."},{"orgOrder":0,"company":"MANA RBM","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Potential Enhancement of Prostate Cancer Treatment Options: First Patient Randomized in Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MANA RBM","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MANA RBM \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MANA RBM \/.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Nykode Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1\/2a Study Arm Evaluating VB10.NEO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Vaccibody AS","highestDevelopmentStatusID":"7","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Evinacumab BLA for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Evinacumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Kahr Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"SIRP alpha\/41BBL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kahr Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kahr Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kahr Medic.."},{"orgOrder":0,"company":"LivaNova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Autonomic regulation therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"LivaNova","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LivaNova \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"LivaNova \/.."},{"orgOrder":0,"company":"Epirium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Epirium","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Announces TUKYSA\u00ae (tucatinib) Approved Within Months for All Countries Participating in FDA\u2019s Project Orbis Initiative","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IK-175","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Onco.."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of BLD-2660 in Treating Patients with COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BLD-2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anixa and OntoChem Announce Identification of Additional Covid-19 Compounds","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Anixa Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anixa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Anixa Bios.."},{"orgOrder":0,"company":"NS Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NS Pharma's VILTEPSO injection Now FDA-Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Viltolarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"NS Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NS Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NS Pharma .."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON to Present Data From the NOX-A12 \/ Keytruda\u00ae Combination Trial in Colorectal and Pancreatic Cancer at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Pharmaceuticals Resumes Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Orphan Designation for TransCon\u2122 CNP for the Treatment of Achondroplasia in Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon CNP","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KCP506","moa":"nAchR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201","therapeuticArea":"Hematology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Hematology","graph2":"Preclinical","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sapience Therapeutics Dosed First Patient with ST101 in Phase 1\/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ST101","moa":"CCAAT\/enhancer binding protein beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sapience Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience T.."},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyeGate Pharma Confirms Path Forward with FDA to Develop Combination Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kiora Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kiora Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kiora Phar.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431's Antiviral Properties","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elusys Therapeutics Receives Health Canada Approval For Anthim\u00ae For The Treatment Of Inhalation Anthrax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Obiltoxaximab","moa":"Protective antigen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elusys The.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PneumoBlast","moa":"Tissue factor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Starts Phase 2 Study of CFI-400945 and Durvalumab in Patients with Advanced\/Metastatic Triple Negative Breast Cancer (TNBC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-400945","moa":"PLK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Reports End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study of Nomacopanfor for Bullous Pemphigoid","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutics Receives FDA Fast Track Designation for 4D-310 Gene Therapy for Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"4D-310","moa":"GLA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gyroscope Therapeutics Starts Phase II Programme Evaluating Its Gene Therapy, GT005, for Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT\u00ae (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"ChemDiv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemDiv Created Unique KATO TM Platform for Development of Innovative Drugs Against Coronavirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ChemDiv","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ChemDiv \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ChemDiv \/ .."},{"orgOrder":0,"company":"Antengene","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australian Therapeutic Goods Administration Approves First Phase I Trial of ATG-017 for Advanced Solid Tumors and Hematological Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ATG-017","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing ARDS due to COVID-19 Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem L.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Reports that SRK-015 has Received Rare Pediatric Disease Designation from U.S. FDA for the Treatment of Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"KYORIN PHARMACEUTICAL CO LTD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Kyorin Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinopharm Shares Phase 2 Data On Inactivated Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Minnesota Trials Stem Cell Therapy for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Minnesota \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Presents Phase 3 Data for Solosec\u00ae (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Secnidazole","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral Granules","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer\u2019s Disease Has Reached Enrollment Milestone of 500 Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Gets FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Marginal Zone Lymphoma and Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Holdings Dosed First Patient in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daridorexant Phase 3 Results In Insomnia to be Presented at Sleep 2020","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CERC-002","moa":"LIGHT","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm\u2019S IAP Antagonist Significantly Improves Overall Survival Of High-Risk Head & Neck Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Patent Granted Covering INmune Bio\u2019s XPro1595","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aleor Dermaceuticals Receives USFA Tentative Approval for Antifungal Medication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavaborole","moa":"Leucine-tRNA ligase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aleor Dermaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Derm.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Submits Investigational New Drug (IND) Application for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TLC Therap.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Genentech\u2019s Enspryng for Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tempol","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Adamis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Adamis Pha.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Begins Plonmarlimab Dosing In Rheumatoid Arthritis Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Plonmarlimab","moa":"GM-CSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"7\u00d721 CAR-T cells","moa":"IL-7 expression","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai\u2019s Enspryng (Satralizumab) Receives Regulatory Approval from FDA for Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unity Biotechnology Announces 12-Week Data From Ubx0101 Phase 2 Clinical Study In Patients With Painful Osteoarthritis Of The Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biot.."},{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u2018AeroNabs\u2019 Promise Powerful, Inhalable Protection Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Nanobodies","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Unveils Publication of QINLOCK Phase 1 Study Results in Gastrointestinal Stromal Tumor in Journal of Clinical Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech\u2019S Kb407 Granted Orphan Drug Designation by The FDA to Treat Patients with Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KB407","moa":"CFTR gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Balticgruppen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Balticgruppen Bio Starts Bridging Pharmacokinetic & Safety Clinical Trial of a Novel Solid Pharmaceutical Composition of AMPK Activator O304","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Balticgruppen Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Balticgruppen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Balticgrup.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's First Trastuzumab Biosimilar Approved by NMPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for First-in-Class Cystic Fibrosis Therapy ETD002","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ETD002","moa":"TMEM16A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Enterprise Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics sNDA Application For Tyvaso \u00ae For Pulmonary Hypertension Associated with Interstitial Lung Disease Accepted by U.S. FDA","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"United The.."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin to Present New Study Evaluating VASCEPA in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions Announces FDA Approval of NARCAN\u00ae (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon Published Data Supporting First Wave of Disease-Modifying Alzheimer\u2019s Treatments with Aducanumab, Gantenerumab, BAN2401 and ALZ-801","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Announces FDA Clearance of ENVASARC Pivotal Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-107","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Axcella\u2019s AXA1665-001 Clinical Study Published in Clinical and Translational Gastroenterology","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1665","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Neuroptika","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuroptika Completes Enrollment In Phase 2 Clinical Trial For Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NRO-1","moa":"Semaphorin-3A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Neuroptika","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuroptika \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuroptika.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi for the Treatment of Spinal Muscular Atrophy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"GNI Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydronidone","moa":"TGF beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"GNI Group","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GNI Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GNI Group .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio to Present Data from Elivaldogene Autotemcel Gene Therapy Trial for Cerebral Adrenoleukodystrophy EBMT Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Elivaldogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MAU868","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Will Attempt to Use Leronlimab During Bone Marrow Transplant for 5 HIV Patients Who also have Cancer","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precigen Dosed First Patient in Phase I\/II Study of First-in-Class PRGN-2009 AdenoVerse\u2122 Immunotherapy to Treat HPV-associated Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PRGN-2009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BOLD-100","moa":"GPCR 78","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19 related ARDS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Bill & Melinda Gates Medical Research Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 to treat Tuberculosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"CAT-5571","moa":"Autophagy","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catabasis Pharmaceuticals \/ Bill & Melinda Gates Medical Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":1,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"7HP349","moa":"Integrin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"7 Hills Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"7 Hills Ph.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leo Lens Pharma Expands Its Scientific Advisory Board","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Mediprint Ophthalmics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Contact Lens","sponsorNew":"Mediprint Ophthalmics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mediprint .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Shanghai Fosun Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AZ\u2019s Fasenra Study Confirms Robust Efficacy in Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYR Pharmaceuticals Receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bulevirtide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MYR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MYR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MYR Pharma.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-001","moa":"CD74","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Aims to Make 1 Billion Doses of COVID-19 Vaccine Candidate in 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Panacea Biotec Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panacea Biotec Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Panacea Bi.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Inhaled Use IND for RLF-100 (Aviptadil) to Treat Patients With Moderate and Severe COVID-19 Aiming to Prevent Progression to Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics Holdings","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkem Labs launches Alfluenza for Coronavirus Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Alkem Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkem Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkem Labo.."},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BDR Pharmaceuticals Launches Favipiravir Under Brand name 'BDFAVI' at Rs 63 per Tablet in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BDR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BDR Pharma.."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND\u2122 Phase 3 open-label, safety trial of STS101","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Japan Confirms Daridorexant Dose Response in Japanese Patients with Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine, COVID-19 Preventive Vaccine, GX-19, clinical 1\/2 Phase Approval","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Starts the First Study with Melflufen Outside Multiple Myeloma and Enrolls First Patient in Phase 1\/2 AL Amyloidosis Study","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Gets FDA Approval of an Expanded Indication for Dovato (dolutegravir\/lamivudine)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"HIV-1 integrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Expedited Review to Biogen's Alzheimer's Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aducanumab","moa":"Amyloid beta aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces Health Canada Approval of DARZALEX\u00ae* SC for the Treatment of Patients with Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Seeks UK Approval of Leronlimab for HIV and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Highly active anti-retroviral therapy","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Blade Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blade Therapeutics Appoints Accomplished Biopharmaceutical Executive, Mark Timney, as Chairman of the Board","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BLD-2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Blade Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Blade Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Blade Ther.."},{"orgOrder":0,"company":"Merus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merus Announces That Lead program Zenocutuzumab Remains on Track for Zenocutuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Zenocutuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merus \/ No.."},{"orgOrder":0,"company":"Pankajakasthuri Herbal Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pankajakasthuri Declares Final Clinical Trials of ZingiVir-H as Adjunct Therapy for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Undisclosed","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Zingivir-H","moa":"RNA-dependent DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pankajakasthuri Herbal Research Foundation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pankajakasthuri Herbal Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Pankajakas.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$433.5 million","upfrontCash":"$25.0 million","newsHeadline":"AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Tivozanib","moa":"VEGF","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Aveo Oncology","amount2":0.42999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Kyowa Kirin","highestDevelopmentStatusID":"5","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Government of Singapore","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Singapore Will Get First Claim to Any Successful Arcturus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Funding","leadProduct":"Starr mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Government of Singapore","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Avoro Capital","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"PMV Pharma Raises $70M for Tumor Suppressor Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Series D Financing","leadProduct":"Undisclosed","moa":"p53 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"PMV Pharma","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"PMV Pharma \/ Avoro Capital","highestDevelopmentStatusID":"2","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"Neurasic Therapeutic","sponsor":"McGill University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurasic Therapeutic Launched to Advance Research into Made-in-Canada Therapy for Patients with Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Acid-sensing ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Neurasic Therapeutic","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurasic Therapeutic \/ McGill University","highestDevelopmentStatusID":"2","companyTruncated":"Neurasic T.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Shanghai Pharma","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Intratumoral Oncolytic Virus Immunotherapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"oHSV-1","moa":"IL 12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Shanghai Pharma","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's Mirikizumab Superior to Cosentyx\u00ae (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Tsinghua University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tsinghua University, 3rd People\u2019s Hospital of Shenzhen and Brii Biosciences Enter Partnership to Develop Antibodies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BRII-196","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Brii Biosciences \/ Tsinghua University","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosc.."},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem Life Sciences and TransThera Biosciences Ink License Agreement for Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"TT-01025","moa":"VAP-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"TransThera Biosciences","amount2":0.34999999999999998,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"TransThera Biosciences \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"TransThera.."},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","amount":"$453.5 million","upfrontCash":"Undisclosed","newsHeadline":"Avacta and LG Chem Life Sciences Expand Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"AVA6000","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0.45000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Avacta Group \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Gro.."},{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"AV-001","moa":"Angiopoietin 1","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vasomune Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vasomune Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Vasomune T.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$200.0 million","newsHeadline":"Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":1.03,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.03,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Foundation for Angelman Syndrome Therapeutics","sponsor":"Lixte Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Foundation for Angelman Syndrome Therapeutics and Lixte Biotechnology Collaborate to Support the Preclinical Study of LB-100","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"LB-100","moa":"Protein phosphatase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Foundation for Angelman Syndrome Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foundation for Angelman Syndrome Therapeutics \/ Lixte Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"KYE Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse\u00ae Available to LEMS Patients in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"KYE Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"KYE Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"KYE Pharma.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Israeli Ministry of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Israeli Ministry of Health","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Therapure Biomanufacturing","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Therapure Signs Manufacturing Deal with VBI Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"VBI-2901","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapure Biomanufacturing","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapure Biomanufacturing \/ VBI Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Therapure .."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"NIH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharm Abcine Executes of a Material Cooperative Research and Development Agreement with NIH to Evaluate Efficacy of P-403 to Treat SCLS","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"PMC-403","moa":"Tie2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$6,500.0 million","upfrontCash":"$6,500.0 million","newsHeadline":"Momenta Enters Definitive Agreement with Johnson & Johnson","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":6.5,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":6.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"Medlight SA","sponsor":"Rakuten Medical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rakuten Medical Announces Acquisition of Medlight SA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Cetuximab-conjugated IRDye700DX","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Medlight SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medlight SA \/ Rakuten Medical","highestDevelopmentStatusID":"10","companyTruncated":"Medlight S.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$106.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Announces $106 Million Private Placement Financing to Advance Precision Medicines for Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Private Placement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.11,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Minakem (formerly Delmar Chemicals)","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$19.6 million","upfrontCash":"Undisclosed","newsHeadline":"DelMar Announces $19.6 Million Private Placement Priced at-the-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Private Placement","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Minakem (formerly Delmar Chemicals)","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Minakem (formerly Delmar Chemicals) \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minakem (f.."},{"orgOrder":0,"company":"Dualogics","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"IgG-like bispecific antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Dualogics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dualogics \/ AbCellera","highestDevelopmentStatusID":"3","companyTruncated":"Dualogics .."},{"orgOrder":0,"company":"Alzheon","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Valiltramiprosate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Novavax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Novavax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Cipla","sponsor":"Stempeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla and Stempeutics Collaborate for Launch of\nStempeucel\u00ae, First \u2018Made in India\u2019 Cell Therapy to\nTreat Critical Limb Ischemia (CLI)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Bone marrow-derived allogeneic mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ Stempeutics","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ St.."},{"orgOrder":0,"company":"Evotec","sponsor":"Centogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Centogene Expand Collaboration into Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Expanded Collaboration","leadProduct":"Induced pluripotent stem cell","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ CENTOGENE","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ C.."},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Monopar Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aragen Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aragen Life Sciences \/ Monopar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Aragen Lif.."},{"orgOrder":0,"company":"Pharmaceutics International","sponsor":"Humanetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanetics Corporation and Pharmaceutics International Announce Partnership in Support of BIO 300 Clinical Trials in COVID-19 Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Genistein","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pharmaceutics International","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pharmaceutics International \/ Humanetics Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Pharmaceut.."},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Oragenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Terra CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avid Bioservices","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Avid Biose.."},{"orgOrder":0,"company":"GID BIO","sponsor":"Richard King Mellon Foundation","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Gid Bio Wins Funding from Richard King Mellon Foundation to Study Regenerative Medicine to Treat Severe Respiratory Distress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Autologous stromal vascular fraction cell therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"GID BIO","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GID BIO \/ Richard King Mellon Foundation","highestDevelopmentStatusID":"1","companyTruncated":"GID BIO \/ .."},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Proteostasis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yumanity Therapeutics \/ Proteostasis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity T.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"$155.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kronos Bio Announces $155 Million Private Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Entospletinib","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kronos Bio","amount2":0.16,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.16,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Jefferies LLC","highestDevelopmentStatusID":"7","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Vantage Outsourcing","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraocular Suspension","sponsorNew":"EyePoint Pharmaceuticals \/ Vantage Outsourcing","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint P.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series C Financing","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.12,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.12,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin\u00ae (Bevacizumab) Biosimilar BAT1706 in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MC2 Therapeutics Announces Collaboration with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA\u00ae Cream, in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"EPI Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EPI Health.."},{"orgOrder":0,"company":"RNAimmune","sponsor":"Terra Magnum Capital Partners","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"RNAimmune Closed Seed Funding of $2.35m for Development of mRNA Therapeutics and Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"RV1730","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"RNAimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RNAimmune \/ Terra Magnum Capital Partners","highestDevelopmentStatusID":"5","companyTruncated":"RNAimmune .."},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Cancer Prevention and Research Institute\nof Texas","pharmaFlowCategory":"D","amount":"$15.5 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGenesis Awarded $15.5 M Grant from Cancer Prevention and Research Institute of Texas (CPRIT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"IMGS-001","moa":"PD1 pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"ImmunoGenesis \/ Cancer Prevention and Research Institute\nof Texas","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGene.."},{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Confirms Advanced Discussions with EU to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Divestment","leadProduct":"Fursultiamine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":2.2999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":2.2999999999999998,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Blackstone Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Catalent P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kiadis collaborates with premier Dutch institutions to apply K-NK-cell technology for the development of a novel COVID-19 therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"K-NK-ID101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ U.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Reports Early Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Treatment benefits from Tradipitant in COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AKCEA-APOCIII-LRx","moa":"Apolipoprotein C-III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Ther.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Announces New Research Showing Veyonda\u00ae Cancer Survival Rates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Caspase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-HIF2","moa":"HIF2-alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs ASA Announces Completion of Patient Enrollment in Phase I Trial in Malignant Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"QBECO SSI","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qu Biologics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Granted FDA Priority Review for Less-Frequent, Fixed-Dose Use","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD\/NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Elobixibat","moa":"IBAT","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Ceapro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Yeast beta-glucans","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ceapro \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ N.."},{"orgOrder":0,"company":"Sentien Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sentien Biotechnologies Announces Open IND in Phase 1\/2 Trial of SBI-101 for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal stromal cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sentien Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sentien Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sentien Bi.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Doses First Subject in Phase 1 Proof of Concept Study of Oligonucleotide Drug Candidate ALG-010133","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeted Therapy Combination Effective for Patients with Advanced Cholangiocarcinoma and Braf Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mylan Brings Critical Access to the M.S Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Viatris","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ .."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB (publ) Announces Update on Survival Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study of Aldafermin in Patients with NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldafermin","moa":"Bile acid synthesis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acepodia Initiates a Phase 1 Clinical Trial Evaluating Allogeneic NK Cell Therapy ACE1702 for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/.."},{"orgOrder":0,"company":"MaxCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CARMA Cell Therapies\u2122 Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MCY-M11","moa":"T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ .."},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Glutamine","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Emmaus Life Sciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emmaus Lif.."},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CalciMedica Reports Publication of COVID-19 Data and Initiation of Clinical Trial of Auxora\u2122 in Patients with Severe COVID-19 Pneumonia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Auxora","moa":"CRAC","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Emulsion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedic.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA202","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"Intravacc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intravacc Reports Positive Data from Phase I Trial of RSV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RSVDG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Intravacc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intravacc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azur Rx Launches Option 2 Cystic Fibrosis Trialinn Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Enteric Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elicio\u2019s Lymph Node Targeting Covid-19 Vaccine Candidate Induces Up To 25-Fold More T Cells Over Benchmark Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ELI-005","moa":"T cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac\u00ae Abstracts Accepted for Oral and Poster Presentations at EASL 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Third-generation hepatitis B vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enanta Pharmaceuticals Announces Data Presentations at the EASL Digital International Liver Congress\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP-305","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pha.."},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Puma Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Puma Biote.."},{"orgOrder":0,"company":"Maverick Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maverick Therapeutics Reveals Preclinical Data from COBRA\u2122 Program, MVC-280, at Virtual Cell Engager Summit 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVC-101","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Maverick Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Maverick Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Maverick T.."},{"orgOrder":0,"company":"Trefoil Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TTHX1114","moa":"FGF-1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Trefoil Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Trefoil Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trefoil Th.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Eagle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Eagle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of AVIGAN\u00ae (Favipiravir) in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Institute of Technology on Immunobiologicals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergex and Bio-Manguinhos\/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Yellow fever vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Emergex Vaccines Holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emergex Vaccines Holding \/ Institute of Technology on Immunobiologicals","highestDevelopmentStatusID":"4","companyTruncated":"Emergex Va.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"AmideBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Rare Pediatric Disease Designation to Amide Bio's Glucagon Analog for the Treatment of Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-G023","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"AmideBio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/.."},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viking Therapeutics to Present Data from Phase 2 Study of VK2809 in Non-Alcoholic Fatty Liver Disease Patients with Elevated LDL-Cholesterol","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VK2809","moa":"TR beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking The.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMU-856","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Hackensack Meridian CDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hackensack Meridian Health Observational Study Identifies Drug that Improves Survival in Sickest COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hackensack Meridian CDI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hackensack Meridian CDI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NW Bio Announces Completion of Further Data Gathering For Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Initiates Phase 2 Study to Evaluate Clinical and Immunologic Activity of ALKS 4230 in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline Announces First Participant Vaccinated in Phase 3 Clinical Trials of Its 5-in-1, Meningitis Abcwy Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Men ABCWY vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Receives Health Canada Approval for Dupixent to Treat Severe Chronic Rhinosinusitis with Nasal Polyposis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Announces Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Evinacumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Z Factor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Z Factor Doses First Subject with ZF874, a Potential Disease-Modifying Treatment for Alpha-1-Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ZF874","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Z Factor","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Z Factor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Z Factor \/.."},{"orgOrder":0,"company":"Nuformix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuformix Reports Results from Pre-clinical Pilot Study in IPF for NXP004 Programme","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NXP004","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Nuformix","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuformix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuformix \/.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-R18","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2\/3 Trial Suggests that Amzell\u2019s New Topical Treatment (AMZ001) for the Treatment of Knee Osteoarthritis Symptoms Is Effective","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"COX","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Amzell B.V","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amzell B.V \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amzell B.V.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Provides Update on COVID-19 Clinical Trial Activities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-1499","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virtual FDA Advisory Committee Meeting to Review Alkermes' New Drug Application for ALKS 3831 in Schizophrenia and Bipolar I Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Approval for Additional Indication of Kadcyla for Adjuvant Therapy of HER2-Positive Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab Emtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Approved in Japan for the Treatment of Extensive-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Blood coagulation factor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Neurogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurogene\u2019s CLN7 Gene Therapy Granted FDA Orphan Drug Designation","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Neurogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurogene \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neurogene .."},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-linked Myotubular Myopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Resamirigene bilparvovec","moa":"MTM1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Audentes Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Audentes T.."},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with MDR HIV-1 infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"UB-421","moa":"CD4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"United BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United Bio.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Completes Successful Meetings with FDA and EMA for OPT-302 Phase 3 Clinical Program in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SAB Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of SAB-185 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Announces Results from the Next Evaluable Chemo-Resistant Colorectal Cancer Patient Treated with SCO-101 and Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Endovion","moa":"Chloride channel","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Molecular Therapeutic Doses First Patient in Phase 1\/2 Clinical Trial of 4D-125 for the Treatment of X-Linked Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"4D-125","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecul.."},{"orgOrder":0,"company":"HK inno.N","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hk Inno.N Publishes P3 Trial Results of Drug on Gastric Ulcers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"HK inno.N","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HK inno.N .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on Phase III Study Evaluating Investigational Spartalizumab in Combination with Tafinlar\u00ae + Mekinist\u00ae in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabrafenib Mesylate","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Positive Topline Results from Phase 3 Clinical Study of Freeze-dried Smallpox Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MVA-BN","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Bavarian Nordic","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Freeze-Dried Formulation","sponsorNew":"Bavarian Nordic \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bavarian N.."},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"CHOP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PEEL Therapeutics Developing Cancer Drug from Plant Toxin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SN22","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PEEL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PEEL Therapeutics \/ CHOP","highestDevelopmentStatusID":"4","companyTruncated":"PEEL Thera.."},{"orgOrder":0,"company":"Spago Nanomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spago Nanomedical Appoints Candidate Drug in the Tumorad Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tumorad-Lu177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Spago Nanomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Spago Nanomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Spago Nano.."},{"orgOrder":0,"company":"Akcea Therapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (RX) ) at ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vupanorsen","moa":"ANGPTL3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Akcea Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akcea Therapeutics \/ Ionis Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Akcea Ther.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InDex Pharmaceuticals Presentst Positive Results of the Conduct Study at Two Leading Medical Conferences","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Initiates Phase 2 Portion of Phase 1\/2 Clinical Trial of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"ReiThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReiThera's COVID-19 Vaccine Candidate Enters Phase 1 Clinical Study with First Healthy Volunteer Dosed in Italy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GRAd-COV2","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ReiThera","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ReiThera \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ReiThera \/.."},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Editas Medicine Receives Rare Pediatric Disease Designation For EDIT-301 For The Treatment Of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"EDIT-301","moa":"CD34+ gene","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Editas Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Med.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protalix BioTherapeutics Completes Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa in Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of EBMT","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Submitts Supplemental New Drug Application to U.S. FDA for CABOMETYX\u00ae in Combination With Opdivo\u00ae for Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"American BriVision","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PDC-1421","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Gelatin Capsule","sponsorNew":"American BriVision \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"American B.."},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec\u2019s RAMQ List of Medications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Medexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medexus Ph.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Submits Clinical Trial Application for Chronic Hepatitis B Capsid Assembly Modulator Candidate ALG-000184","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kazia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Ther.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals' Covid-19 Drug Candidate Brilacidin Achieves a Selectivity Index Among the Highest Reported, Exhibiting Potent Anti-Sars-Co V-2 Activity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name \u2018sumifilam\u2019 by USAN","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sumifilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Announces an Investigator-Initiated Study of DSUVIA\u00ae in Orthopedic Patients in the Perioperative Setting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atai Life Sciences Launches Empath Bio to Treat Post-Traumatic Stress Disorder with Novel Mdma Product","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Serotonin","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"ATAI Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ATAI Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ATAI Life .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical Reports that Clinical Trial with Remygen[\u00ae] is Expanded to Evaluate Prevention of Hypoglycaemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Medicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicure Announces AGGRASTAT\u00ae Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tirofiban","moa":"Integrin alpha-IIb\/beta-3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medicure","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicure \/.."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adlai Nortye Doses First Patient in Phase 1b Clinical Trial of AN0025 in Combination with Merck's KEYTRUDA for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AN0025","moa":"EP4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adlai Nortye \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nort.."},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tiziana Granted a Patent on Methods and Use of Anti-Il-6\/il-6 Receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for Covid-19 and Other Pulmonary Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TZLS-501","moa":"IL-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tiziana Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Li.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona Announces Poster Presentation at the European Congress of Endocrinology Virtual Annual Meeting","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Receives Two New Approvals in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1b Study of NT-I7 and Kymriah in Relapsed\/Refractory Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Efineptakin alfa","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NeoImmuneTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NeoImmuneT.."},{"orgOrder":0,"company":"Trevena","sponsor":"Imperial College London","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Imperial College London","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-527","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odonate Therapeutics Announces Positive Top-line Results from CONTESSA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Th.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces Enrollment Has Resumed For The Global Phase 3 Study Of Oral Edaravone For ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valeo Pharma Files Natural Product License with Health Canada for Bioflavonoid Formulation, Hesperco","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hesperidin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valeo Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valeo Pharma \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Valeo Phar.."},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expression Therapeutics Announces Success in Developing a Stem Cell Lentiviral Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH)","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lentivirus-Hematopoietic Stem Cell","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Expression Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Expression Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Expression.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"26S proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX-2026","moa":"BTN3A","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Compass Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Ingenza","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ingenza Meets a Key Milestone in the Deployment of Novel Cost-Effective Covid-19 Vaccine Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ingenza","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ingenza \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ingenza \/ .."},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabies Immune Globulin [Human]","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"11","companyTruncated":"Kamada \/ K.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Fast Track Disease Designation from U.S. FDA for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biogen to Initiate Phase 4 Respond Study Evaluating Benefit of Spinraza in Patients Treated with Zolgensma","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Kimera Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kimera\u00ae Labs Files First FDA Investigational New Drug (IND) Application Using XoGlo\u00ae for Treatment of ARDS Secondary to COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell- Derived Exosomes","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Kimera Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kimera Labs \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kimera Lab.."},{"orgOrder":0,"company":"Adrenomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeting Endothelial Barrier Function in Critically Ill Covid-19 Patients: Adrecizumab Shows Beneficial Effects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Adrecizumab","moa":"Adrenomedullin receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adrenomed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Adrenomed .."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cymerus mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"ExCellThera","sponsor":"IRICoR","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRICoR Makes Additional Investment in ExCellThera","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ECT-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ExCellThera","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ExCellThera \/ IRICoR","highestDevelopmentStatusID":"4","companyTruncated":"ExCellTher.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim's Empagliflozin Meets Primary Endpoint in Reducing Risk of Cardiovascular Death or Hospitalization","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Provides Update on Phase III Studies of Etrolizumab In People with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"Beta-7 integrin Ligand binding","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino to Start Phase III Trial of COVID-19 Vaccine in Saudi","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Federal Biomedical Agency of Russia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russian Drug Given Patent for Dalargin for the Treatment of Coronavirus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Leitragin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Federal Biomedical Agency of Russia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Federal Biomedical Agency of Russia \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Federal Bi.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional Analysis of Real-World Data Confirms Sequential Gilotrif\u00ae Followed By Osimertinib Imporved Survival","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Afatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Report Promising Phase I\/Ii Data of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162b1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Application for Xolair (Omalizumab) Prefilled Syringe for Self-Administration Across All Indications","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutic Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibiotic","moa":"Staphylococcal biofilm formation","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anti-Pd-1\/Ctla-4 Bi-Specific Antibody (Ak104) of Akeso Granted FDA Fast Track Designation For Recurrent And Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AK104","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Akeso","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akeso \/ No.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Resumes the Phase 3 Clinical Trials Investigating Concizumab (Anti-Tfpi Mab) In Haemophilia A and B With or without Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Concizumab","moa":"Tissue factor pathway","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Advisory Committee Votes in Favor of Ryoncil for Efficacy in Children With Steroid-Refractory Acute Graft Versus Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Wockhardt","sponsor":"U.S Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"India's Wockhardt Strikes Deal to Supply COVID-19 Vaccines to UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Wockhardt \/ U.S Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt .."},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Rusalatide Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chrysalis BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chrysalis BioTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Chrysalis .."},{"orgOrder":0,"company":"Biological E","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biological E Inks Agreement with Janssen Pharmaceutica NV for Coronavirus Vaccine Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biological E","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biological E \/ Janssen Pharmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"Biological.."},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Biological E","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baylor College of Medicine and Biological E ink Licensing Agreement to Develop Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Covid 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Baylor College of Medicine \/ Biological E","highestDevelopmentStatusID":"1","companyTruncated":"Baylor Col.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review for OS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ofranergene obadenovec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Novateur Ventures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novateur Study Points Toward Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Zileuton","moa":"5-LOX","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novateur Ventures","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Formulation","sponsorNew":"Novateur Ventures \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novateur V.."},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carisma Therapeutics Enters Into Scientific Research AND Licensing Agreement with Nyu Langone Health","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Vpx Lentiviral Vector","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NYU Langone Health \/ CARISMA Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langon.."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Diaprost","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Diaprost AB Acquires Rights to use of PSA Antibodies from Memorial Sloan Kettering Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"h5A10","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Diaprost","highestDevelopmentStatusID":"4","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"Therapyx","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Intravacc and Therapyx Jointly Develop the World's First Prophylactic Gonorrhea Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"NGoXIM","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Therapyx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapyx \/ Intravacc","highestDevelopmentStatusID":"4","companyTruncated":"Therapyx \/.."},{"orgOrder":0,"company":"Elixiron Immunotherapeutics","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elixiron Immunotherapeutics Awarded Alzheimer's Association Grant to Target Microglia in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"EI1071","moa":"CSF1R","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Elixiron Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elixiron Immunotherapeutics \/ Alzheimer's Association","highestDevelopmentStatusID":"6","companyTruncated":"Elixiron I.."},{"orgOrder":0,"company":"CerSci Therapeutics","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","amount":"$939.5 million","upfrontCash":"Undisclosed","newsHeadline":"ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"ACP-044","moa":"Muscarinic M1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"CerSci Therapeutics","amount2":0.93999999999999995,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.93999999999999995,"dosageForm":"Oral","sponsorNew":"CerSci Therapeutics \/ ACADIA Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"CerSci The.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"NewAmsterdam Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Amsterdam Pharma Acquires Obicetrapib from Amgen","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Obicetrapib","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ NewAmsterdam Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"CohBar","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"CB4211","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"CohBar","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"CohBar \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ R.."},{"orgOrder":0,"company":"ReViral","sponsor":"CR-CP Life Science Fund","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"Undisclosed","newsHeadline":"ReViral Raises $44 Million in Series C Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series C Financing","leadProduct":"Sisunatovir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReViral","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"ReViral \/ CR-CP Life Science Fund","highestDevelopmentStatusID":"8","companyTruncated":"ReViral \/ .."},{"orgOrder":0,"company":"Premier","sponsor":"Baudax Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Premier","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Baudax Bio","highestDevelopmentStatusID":"12","companyTruncated":"Premier \/ .."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Bio Farma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Bio Farma","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Contrafect Announces Funding Agreement with the Cystic Fibrosis Foundation","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Exebacase","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ContraFect Corporation \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"$100.0 million","newsHeadline":"Morphic Announces that Abbvie Exercises License Option to \u0391v\u03b26 Integrin Inhibitor Program, Including Morf-720, for Fibrotic Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"MORF-720","moa":"Alpha5Beta6 Integrin","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Morphic Therapeutic","amount2":0.12,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"EpiVax","sponsor":"EpiVax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EpiVax Announces Licensing of COVID-19 Vaccine Candidate to EpiVax Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"EPV-CoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"EpiVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EpiVax \/ EpiVax Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"EpiVax \/ E.."},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kinnate Biopharma Closes $98 Million Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kinnate Biopharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Kinnate Bi.."},{"orgOrder":0,"company":"Propeller Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Propeller Health Enters Japan with Digital Health Sensor for New Enerzair\u00ae and Atectura\u00ae Breezhaler\u00ae Asthma Medications","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Propeller Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Propeller Health \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Propeller .."},{"orgOrder":0,"company":"iVeena","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IVeena Closes Series B Financing to Advance Multiple Programs in Clinical Development","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series B Financing","leadProduct":"IVMED-80","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"iVeena \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ N.."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"M1231","moa":"MUC1-EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sutro Biopharma \/ Merck KGaA","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"U.S Department of Defense","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Adaptive Phage Therapeutics \/ U.S Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive P.."},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ivy Brain Tumor Center and Vivace Therapeutics Collaborate to Test Targeted Agent in Glioblastoma and Meningioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"VT-01","moa":"TEAD palmitoylation","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vivace Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vivace Therapeutics \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"4","companyTruncated":"Vivace The.."},{"orgOrder":0,"company":"Seagen","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ G.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Novit LP","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Cyclo Therapeutics Closes $2.8 Million Private Placement Led by Novit LP With $1.0 Million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Private Placement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Novit LP","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"Singlomics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"DXP-593","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Singlomics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Singlomics \/ BeiGene","highestDevelopmentStatusID":"4","companyTruncated":"Singlomics.."},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series A Financing","leadProduct":"TAC01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Triumvira Immunologics \/ Bayer","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira .."},{"orgOrder":0,"company":"Sarah Cannon","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sarah Cannon and Lyell Immunopharma Announce Collaboration to Advance Development and Patient Access to T-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"CAR T-Cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sarah Cannon","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sarah Cannon \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sarah Cann.."},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Odonate Therapeutics Announces Public Offering of Shares of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Tesetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Th.."},{"orgOrder":0,"company":"Harvard University","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Harvard University","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Harvard University \/ AbbVie","highestDevelopmentStatusID":"1","companyTruncated":"Harvard Un.."},{"orgOrder":0,"company":"Scancell","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"Scancell Led Consortium Awarded Funding by Innovate UK to Progress Second Generation Covid-19 Vaccine Into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Covid 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scancell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scancell \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Scancell \/.."},{"orgOrder":0,"company":"Mapp Biopharmaceutical","sponsor":"Avid Bioservices","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Human monoclonal antiviral antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Mapp Biopharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mapp Biopharmaceutical \/ Avid Bioservices","highestDevelopmentStatusID":"5","companyTruncated":"Mapp Bioph.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"U.S. Army Contracting Command","pharmaFlowCategory":"D","amount":"$106.3 million","upfrontCash":"$53.1 million","newsHeadline":"U.S. Army Contracting Command Awards Ology Bioservices Contract to Reserve Production Capacity IN Support of Operation Warp Speed","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.11,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Ology Bioservices \/ U.S. Army Contracting Command","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"SymBiosis II, LLC","pharmaFlowCategory":"D","amount":"$42.5 million","upfrontCash":"Undisclosed","newsHeadline":"Clene Nanomedicine Raises Series D Financing of $42.5 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Series D Financing","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.040000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.040000000000000001,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ SymBiosis II, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ADX10061","moa":"D1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Addex Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Addex Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"2","companyTruncated":"Addex Ther.."},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"UK Research and Innovation","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaccitech Receives Government Grant for Covid-19 Vaccine Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Barinthus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ UK Research and Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Barinthus .."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Cirmtuzumab","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncternal Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Vitanova Biomedical","sponsor":"National Science Foundation","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"Vitanova Biomedical Awarded Competitive Grant from the National Science Foundation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"VNBp-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vitanova Biomedical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vitanova Biomedical \/ National Science Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Vitanova B.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"TRACON Pharmaceuticals Announces $5.0 Million Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Private Placement","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Exeltis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intelgenx and Exeltis Healthcare S.L. Expand Rizaport\u00ae Commercialization Agreement to Include the European Union","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Rizatriptan Benzoate","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Film","sponsorNew":"IntelGenx \/ Exeltis","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"Natera","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Natera Enters Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Natera \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ M.."},{"orgOrder":0,"company":"T3D Therapeutics","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"T3D Therapeutics Receives a Research Award from the Alzheimer\u2019s Association Part the Cloud-Gates Partnership Grant Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"T3D-959 Sodium","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"T3D Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"T3D Therapeutics \/ Alzheimer's Association","highestDevelopmentStatusID":"8","companyTruncated":"T3D Therap.."},{"orgOrder":0,"company":"Elion Oncology","sponsor":"Processa Pharmaceuticals","pharmaFlowCategory":"D","amount":"$103.1 million","upfrontCash":"$88.0 million","newsHeadline":"Processa Pharmaceutical Enters Licensing Agreement with Elion Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Eniluracil","moa":"DPD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Elion Oncology","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Elion Oncology \/ Processa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Elion Onco.."},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$490.0 million","upfrontCash":"$30.0 million","newsHeadline":"PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi\u2122 (risdiplam)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"PTC Therapeutics","amount2":0.48999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.48999999999999999,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Roche","highestDevelopmentStatusID":"12","companyTruncated":"PTC Therap.."},{"orgOrder":0,"company":"Jacobson Pharma","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jacobson Pharma Collaborates with Fosun Pharma Group to Supply BioNTech SE\u2019s COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jacobson Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Jacobson Pharma \/ Fosun Pharma Group","highestDevelopmentStatusID":"9","companyTruncated":"Jacobson P.."},{"orgOrder":0,"company":"Planet Biotechnology","sponsor":"iBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ACE2-Fc","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Planet Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Planet Biotechnology \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"Planet Bio.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fibromyalgia biotech Virios Therapeutics files for a $35 million IPO","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JanOne Selects Partner for Bottling and Labeling of JAN101 for Peripheral Artery Disease and Potential Covid-19 Clinical Trials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ U.."},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$50.1 million","upfrontCash":"$29.5 million","newsHeadline":"Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Termination","leadProduct":"AUT00206","moa":"Kv3 potassium channel","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Autifony Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Autifony Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"6","companyTruncated":"Autifony T.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","amount":"$1,930.0 million","upfrontCash":"$1,930.0 million","newsHeadline":"Nestl\u00e9 to Acquire Aimmune Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":1.9299999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.9299999999999999,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Nestl\u00e9","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$357.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leo Pharma Sells Portfolio of Four Products to Cheplapharm","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Divestment","leadProduct":"Alfacalcidol","moa":"Vitamin D receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Leo Pharma \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Seneca Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Seneca Therapeutics, Inc. Licenses Tumor Endothelial Marker 8 (TEM8) to Enable Better Patient Selection for SVV-001 Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Seneca Valley virus-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Seneca Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Beximco Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beximco Pharma and Serum Institute of India Announce Intention to Cooperate on A Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Beximco Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Alcami","sponsor":"Trevena","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alcami Providing Commercial Manufacturing for Trevena\u2019s Recently FDA Approved OLINVYK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Alcami","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alcami \/ Trevena","highestDevelopmentStatusID":"12","companyTruncated":"Alcami \/ T.."},{"orgOrder":0,"company":"ForwardVue","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ForwardVue Pharma Secures Funding to Advance Pre-Clinical Development Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Caroboxyamidotriazole","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ForwardVue","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ForwardVue \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ForwardVue.."},{"orgOrder":0,"company":"HitGen","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HitGen and Almirall Announce Achievement of Milestoneinn their Strategic Collaboration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ A.."},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Fosun Pharma to Supply 10 Million Doses of BioNTech\u2019s BNT162 mRNA-based Vaccine Candidate Against SARS-CoV-2 to Hong Kong SAR and Macao SAR","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Fosun Pharma","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Financing","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"PDL BioPharma","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"$4.3 million","newsHeadline":"PDL BioPharma Announces Sale of Kybella\u00ae, Zalviso\u00ae and Coflex\u00ae Royalties to SWK Holdings Corporation","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Divestment","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"PDL BioPharma","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"PDL BioPharma \/ SWK Holdings Corporation","highestDevelopmentStatusID":"12","companyTruncated":"PDL BioPha.."},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Sotio","pharmaFlowCategory":"D","amount":"$11.5 million","upfrontCash":"$8.1 million","newsHeadline":"SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"BOXR1030","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Unum Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Unum Therapeutics \/ SOTIO","highestDevelopmentStatusID":"4","companyTruncated":"Unum Thera.."},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Engages IRISYS LLC as GMP Manufacturer for AS1411 Drug Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"IRISYS, LLC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IRISYS, LLC \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"IRISYS, LL.."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$17.2 million","upfrontCash":"Undisclosed","newsHeadline":"Cocrystal Pharma Closed $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"Antiviral therapy","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal .."},{"orgOrder":0,"company":"University of Cambridge","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Cambridge University Aims for Autumn Trials of Coronavirus Vaccine After Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"DIOS-CoVax2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Cambridge","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Cambridge \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Selects Syneos Health as Commercialization Partner to Launch Daridorexant in the United States","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Syneos Health","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"12","companyTruncated":"Syneos Hea.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"Undisclosed","newsHeadline":"NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Galidesivir","moa":"RNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCryst Pharmaceuticals \/ National Institute of Health","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Asalyxa Bio","sponsor":"Orange Grove Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Asalyxa Bio Launches with Novel Neutrophil-Targeting Drug Delivery Platform Technology and Lead Candidate, ASX-100","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"ASX-100","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Asalyxa Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Asalyxa Bio \/ Orange Grove Bio","highestDevelopmentStatusID":"4","companyTruncated":"Asalyxa Bi.."},{"orgOrder":0,"company":"Verndari","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verndari, Inc. Announces Funding from U.S. Government Agency BARDA to Accelerate Development of VaxiPatch\u2122 Dermal Patch Vaccine Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"VaxiPatch","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Verndari","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Verndari \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Verndari \/.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Union Therapeutics A\/s Completes Dosing of Healthy Volunteers with UNI911 (inhaled Niclosamide) for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO\u2122 (lemborexant) CIV, at the SLEEP 2020 Virtual Conference","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemborexant","moa":"OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Byondis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Byondis Initiates Phase I Study of ADC [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ .."},{"orgOrder":0,"company":"Agtc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agtc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Not.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Filing of NDA for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tepotinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Application to FDA for RINVOQ\u2122 (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Provides FDA Update on IND Filing for Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis (MS)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"University of Kentucky","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanders-Brown Study Leads to Potential for a New Treatment Approach to Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AL002","moa":"TREM2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Kentucky","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Kentucky \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress\u2122","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cilofexor","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen to Present Results from Move, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (fop), at Asbmr 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Immunovant","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ligand OmniAb\u00ae Partner Immunovant Announced Positive Topline Results from Phase 2a Trial of IMVT-1401 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMVT-1401","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Immunovant","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunovant \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunovant.."},{"orgOrder":0,"company":"Bonac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bonac to Begin Human Clinical Tests for Covid-19 Drug in 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BNC-1322","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bonac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bonac \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bonac \/ No.."},{"orgOrder":0,"company":"Bolder BioTechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bolder BioTechnology Announces Positive Preclinical Data for Use of BBT-032 to Inhibit Growth of the SARS-CoV-2 Virus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BBT-032","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bolder BioTechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bolder BioTechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bolder Bio.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Autophagy","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"Starpharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Starpharma Provides Development Update on Spl7013 Nasal Spray for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Astodrimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Starpharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Starpharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Starpharma.."},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lidocaine Hydrochloride","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical patch","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pha.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Desmoglein 3 Chimeric AutoAntibody Receptor T cells","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cabaletta .."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech Announces Initiation of Phase 1 Study Evaluating KB301 in Aesthetic Indications","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KB301","moa":"COL3A1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine\u00ae (rhuGM-CSF, sargramostim) in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sargramostim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Partner Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Partner Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Partner Th.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Positioned to Launch Prestige Aesthetics Portfolio with the RHA\u00ae Collection of Dermal Fillers","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Cytovia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytovia Therapeutics and NYSCF File Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells For Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"iPSC CAR-NK cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cytovia Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cytovia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cytovia Th.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Announces FDA Acceptance of Casimersen (SRP-4045) NDA for Duchenne Muscular Dystrophy Amenable to Skipping Exon 45","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Casimersen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mind Med Announces First-Ever Clinical Trial Combining MDMA and LSD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Serotonin","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mind Medicine","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mind Medic.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine Announces MET409 Receives FDA Fast Track Designation for the Treatment of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MET409","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves CYSTADROPS\u00ae 0.37%, A New Practical Treatment Option for the Ocular Manifestations of Cystinosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cysteamine Hydrochloride","moa":"Cystine reducing agent","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for Diabetic Retinopathy Using Suprachoroidal Delivery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Altimmune","sponsor":"University of Alabama","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune and the University of Alabama at Birmingham Announce Potent Respiratory Mucosal T Cell Responses in Preclinical Study of Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ University of Alabama","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Mitotech","sponsor":"Essex Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 \u2013 a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Essex Bio","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Enasidenib","moa":"Isocitrate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2 ELEKTRA Study of Soticlestat Meets Primary Endpoint","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Soticlestat","moa":"CH24H","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Ovid Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents the Clinical Project Portfolio at Virtual R & D Day August 27, 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitazalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tricida sinks as FDA rejection raises prospect of new trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, I.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Translate Bio, Sanofi Covid-19 Vaccine Candidate Produces Immune Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Melbourne\u2019s Walter and Eliza Hall Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Melbourne\u2019s Walter and Eliza Hall Institute's Coronavirus Antibody Therapy Aims for Trial in Early 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibody therapy","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Melbourne\u2019s Walter and Eliza Hall Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Melbourne\u2019s Walter and Eliza Hall Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Melbourne\u2019.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Receives Korean MFDS Approval to Initiate Phase I Trial of COVID-19 Antiviral Antibody Treatment Candidate, CT-P59, in Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at ACIP Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"HFB30132A","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Silverback Therapeutics Initiates Phase 1 Clinical Study of SBT6050","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Preclinical Coronavirus Program Data and Selection of Clinical Candidates with Potential as One-Dose Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-2901","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME\u2019s Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bile Salts","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Reports Positive Phase 3 Results for Tapinarof Cream in Adult Patients with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha\u00ae (evolocumab) Efficacy In High-Risk Patient Populations","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b\/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Alvelestat","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Discovers Key Pathway and Identifies Promising Phase 2 Ready Drug to Treat and Reverse Immune Aging","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BGE-175","moa":"Prostaglandin D2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Lab.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase I Clinical Trial Initiated for Monoclonal Antibody Combination for the Prevention and Treatment of Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Receives FDA Fast Track Designation for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L401","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Receives European Orphan Drug Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Therapeutics Announces First Commercial Launch of VAFSEO\u2122 (vadadustat tablets)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm\u2019s New Generation Radionuclide Therapy Advances Into Clinical Research in the Fight Against Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Minigastrin-Lu177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience: Encouraging Interim Safety Data in Ator-1017 Clinical Phase I Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1017","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enrolment Initiated in World's First Rct with Sirolimus Coated Balloon for the Treatment of Below-the-Knee (btk) Peripheral Artery Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma Releases Preclinical Results of IAP Antagonist APG-1387 in an Oral Presentation at EASL ILC 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-1387","moa":"Apoptosis protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laurent Pharmaceuticals Receives Approval from FDA to Initiate its COVID-19 Phase 2 Clinical Trial in the United States","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenretinide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Laurent Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laurent Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Laurent Ph.."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Starts a Phase 2 Study at the Moffitt Cancer Center to Evaluate Combination of TAVO plus OPDIVO\u00ae as Neoadjuvant Therapy for Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UroGen Provides Update on a Phase 2 Trial of an RTGel\u2122 Hydrogel Formulation and BOTOX\u00ae Combo for Overactive Bladder and Urinary Incontinence","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OnabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"UroGen Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pha.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Receives Orphan Drug Designation and Rare Pediatric Disease Designation for TSHA-101 for GM2 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TSHA-101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex\u2019s Kaftrio Approved for Use in Europe and Made Accessible on the NHS","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Elexacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Northwestern University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targeted Drug Combo Attacks Breast Cancer Brain Metastases in Mice","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Molibresib","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Northwestern University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Northwestern University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Northweste.."},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassiopea Receives FDA Approval for Winlevi\u00ae (clascoterone Cream 1%)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Clascoterone","moa":"Androgen receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Conditional Approval for Hansa's Idefirix[tm] (imlifidase) in Highly Sensitized Kidney Transplant Patients in the European Union","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Pharma Launches Enspryng Subcutaneous Injection 120 Mg Syringe for Prevention of Relapses of NMOSD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Trishula Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trishula Therapeutics Established to Advance Novel TTX-030, an Anti-CD39 Antibody, Being Evaluated in Phase 1\/1B Study in Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ttx-030","moa":"CD39","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Trishula Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Trishula Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trishula T.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals Announces Peer-Reviewed Publication of Positive Study Results of Oteseconazole in Acute Vulvovaginal Candidiasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP51","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"STK-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Immunocore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunocore Publishes Preclinical Data in Hepatology Showing the Potential of Imm Tav\u00ae Bispecific Molecules to Cure Chronic Hepatitis B","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMC-I109V","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Immunocore","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Immunocore \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunocore.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Farxiga Phase III DAPA-CKD Trial Paradigm-Shifting Data to Be Presented at ESC 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Announces ESMO Oral Presentation of Two Clinical Trials of Balstilimab Alone and in Combination with Zalifrelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ N.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Non-Clinical Research Results of Chugai\u2019s Switch Antibody STA551 Published in Cancer Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"STA551","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Announces Data Presentation on ALT-801","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-801","moa":"GCGR\/GLP-1R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncolytics Biotech\u00ae Doses First Patient in Phase 2 IRENE Study of Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pelareorep","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics.."},{"orgOrder":0,"company":"Cerecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CERC-002","moa":"LIGHT","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Cerecor","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cerecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerecor \/ .."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital ILC 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference in October","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Comprehensive Clinical Benefit Data from Part a Of Combination Trial of M Rx051 and Keytruda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg) from NORSE 1","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Akers Biosciences","sponsor":"Premas Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akers, Premas Note Positive Proof-Of-Concept Data of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PRAK-03202 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Akers Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Akers Biosciences \/ Premas Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Akers Bios.."},{"orgOrder":0,"company":"University of Queensland","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Queensland's Covid-19 Vaccine Shows Effectiveness in Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"University of Queensland","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Queensland \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"University.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Expands Patent Portfolio for TIGIT Inhibitor COM902 with New US Composition of Matter Patent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"COM701","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at EBMT 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MaaT013","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharm.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Expands Cohorts in Ongoing Phase 1 Study of Oral CFI-402257, in Patients with Breast Cancer and Additional Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-402257","moa":"Tyrosine threonine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ N.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa\u00ae","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 pentaenoic acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital EASL 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KB174","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients at the Digital International Liver Congress\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MET409","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CT1812","moa":"Amyloid beta","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition .."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces Issuance of U.S. Patent Providing Composition of Matter Protection for SRK-015","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GB0139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Molecular Transport Announces First Patient Dosed in Phase 2 Study of Oral AMT-101 in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Mo.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The \n Digital ILC 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Present New Data from the Interim Analysis of Regenerate Show that Oca Helped Patients with Liver Fibrosis Due to NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella\u2019s Late-Breaker Data from AXA1125-003 Clinical Study Presented at the EASL Digital International Liver Congress","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ammendments to ProtoKinetix AAGP\u00ae Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinet.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos to Present Nonclinical Data for All Components of Chronic Hep B Combination Therapy at EASL Digital International Liver Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Publishes Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA\u2122 in Advanced Solid Tumors in the British Journal of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava\u2122 to Treat Complicated Intra-Abdominal Infections in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Me.."},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University of Illinois Chicago","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 Human Trials Suggest Uic-Developed Breast Cancer Drug Is Safe, Effective","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TTC-352","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TTC Oncology \/ University of Illinois Chicago","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncolo.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline Presents Promising Phase 2A Data for Chronic Hepatitis B Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"GSK3228836","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead and Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"JNJ-3989","moa":"HBV gene","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Filing of NDA for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tepotinib","moa":"HGF receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Vericiguat for Marketing Authorization in China for the Treatment of Chronic Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vericiguat","moa":"sGC","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Assembly Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data from Assembly Biosciences\u2019 HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Vebicorvir","moa":"Core protein allosteric","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Assembly Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assembly Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Assembly B.."},{"orgOrder":0,"company":"Liquidia Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with Dry Powder Treprostinil","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Liquidia Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"Liquidia Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liquidia C.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune\u2122 and Minocycline","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Pterostilbene","moa":"NLRP3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Therapeutics Presents Promising Data from Phase 1 Trial with ADP-A2 Afpinn Liver Cancer at the International Liver Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Ridgeback Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ridgeback Biotherapeutics LP Announces Initiation of Expanded Access Protocol for Ebola Treatment Ansuvimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ansuvimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ridgeback Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ridgeback Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ridgeback .."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Provides Regulatory Update for TLANDO\u2122","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadila Pharmaceuticals Launches Cadalimab\u2122 (Adalimumab biosimilar) for India","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Cadila Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cadila Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cadila Pha.."},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbrium Therapeutics Presents First Data and Describes Novel Mechanism of Action For IMB-115","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"IMB-115","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imbrium Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NILEMDO\u00ae Delivers Significant Cholesterol Lowering in Addition to Statin Therapy Which is Maintained During 2.5 Years of Treatment","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempedoic Acid","moa":"ACLY","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac's Coronavirus Vaccine Candidate Approved for Emergency Use in China- Source","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review of Melflufen for Patients with Triple-Class Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital ILC 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actelion P.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead\u2019s Investigational Antiviral Veklury\u00ae (Remdesivir) Receives FDA Emergency Use Authorization for Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of Cerebral Aneurysms","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BA-1049","moa":"Rho-associated protein kinase 2","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone B.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Farxiga Improves Survivalinn Kidney Disease Patients Study Shows","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R\/R ENKTL","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Can-Fite to Commence Phase II Study of Piclidenoson COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis New Analysis Shows High Consistency in Lowering LDL-C in Individual Response with Investigational Inclisiran","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Presents Positive New Phase 1\/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at the ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-APOC3","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight The.."},{"orgOrder":0,"company":"Kannalife","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kannalife, Inc. Receives Patent Grants for KLS-13019 in Additional European Territories","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KLS-13019","moa":"CB1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Kannalife","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kannalife \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kannalife .."},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology and Gsk Start Phase 2\/3 Study of Covid-19 Antibody Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"GSK \/ Vir .."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVAXX Announces First Multitope Peptide-Based Vaccine to Enter Human Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Multitope Peptide-based Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Expands Development of Covid-19 Vaccine Azd1222 Into Us Phase III Clinical Trial Across All Adult Age Groups","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Subsidiary Orpheris Enrolls First Patients in Phase 2 PRANA Clinical Study Evaluating OP-101 for Severe COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OP-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces First Patient Dosed in Phase I China Trial of Claudin18.2 Targeting Monoclonal Antibody TST001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"TST001","moa":"CLDN18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae Reduced the Combined Relative Risk of Cardiovascular Death and Hospitalization for Heart Failure by 25% in Adults with and Without Diabetes Who Had Heart Failure with Reduced Ejection Fraction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Gene Therapy Shows Sustained Benefit in Rare Metabolic Disorder","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Elivaldogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Glaxo Smith Kline's Blenrep for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Belantamab mafodotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Kaken Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"NKMax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKMax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NKMax \/ No.."},{"orgOrder":0,"company":"GtreeBNT","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Joint Venture GtreeBNT Expects to Complete Phase 3 Dry Eye Trial in November 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"GtreeBNT \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shattuck Labs Announces Initiation of Phase 1 Clinical Trial of SL-172154 (SIRP\u03b1-Fc-CD40L) for the Treatment of Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SL-172154","moa":"CD47\/SIRPalpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shattuck Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck L.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the HFSA Annual Scientific Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-207","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"SPR720","moa":"DNA gyrase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"VelosBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VelosBio Announces FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VLS-101","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VelosBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 Investigational New Drug Application for OMS906 Cleared by FDA","therapeuticArea":"Hematology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OMS906","moa":"MBL-associated serine protease","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Mindset Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mindset Pharma Announces Promising Test Results of its Novel and Proprietary Psilocybin-Inspired Compounds","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocin","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mindset Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mindset Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mindset Ph.."},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2 Study of EMB-001 in Cocaine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Metyrapone","moa":"CYP450","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Embera NeuroTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Embera Neu.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"PRV-015","moa":"IL-15","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Provention.."},{"orgOrder":0,"company":"CorMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Defencath","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Taurolidine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"CorMedix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Solution","sponsorNew":"CorMedix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CorMedix \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation for BCX9930 in PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Files U.S. FDA Pre-IND Meeting Request for XRx-101 (Oxypurinol) COVID-19 Program and Pre-IND Meeting Submission Potential of Acute Kidney Injury Emerging as a Serious Consequence of COVID-19","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmascience Reiterates Its Support to the Montreal Heart Institute's Colchicine Repurposing Research Studies in Cardiovascular Medicine and Covid-19","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Colchicine","moa":"Tubulin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience","highestDevelopmentStatusID":"10","companyTruncated":"Montreal H.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rodeo Therapeutics Nominates First-in-Class Oral Development Candidate for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-1688","moa":"15-Hydroxyprostaglandin dehydrogenase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Results of the Phase 1\/2 Clinical Study of PCSK9 Antibody Tafolecimab at the ESC Annual Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tafolecimab","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Innocoll Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves XARACOLL\u00ae (bupivacaine HCl) Implant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine Hydrochloride","moa":"Sodium channel protein 4 subunit alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Innocoll Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Innocoll Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innocoll P.."},{"orgOrder":0,"company":"Allied Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allied Corp. Strengthens IP and Pharma Strategy by Filing Provisional Patent for ALID-10 and ALID-11","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ALID-10","moa":"CB receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Allied Corp","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allied Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Allied Cor.."},{"orgOrder":0,"company":"Acasti Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 phospholipid","moa":"PPAR gamma","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Acasti Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acasti Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Acasti Pha.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astex Pharmaceuticals Announces That Tolinapant Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolinapant","moa":"X-linked apoptosis proteins","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Astex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study at Digital ILC 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Peginterferon Alfa 2A","moa":"Interferon alpha\/beta receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Data on UCB's Vimpat\u00ae CV in Primary Generalized Tonic-Clonic Seizures Published in Journal of Neurology, Neurosurgery & Psychiatry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears SPI\u2019s Ebselen for Phase II COVID-19 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sound Phar.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's Covid-19 Vaccine Selected by Japanese Drug Discovery Body","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Presents Phase 3 Sci-B-Vac\u00ae Data at EASL 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Third-generation hepatitis B vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Chiasma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer\u2019s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BARHEMSYS\u00ae (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of PONV","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Hercules Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hercules' AHR Inhibitor Hp163 Blocks Viral Replicationinn Zika Infection and Potentially in Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"HP163","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hercules Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hercules Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hercules P.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn\u00ae Mechanism in ALS, Progressive MS and Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Collaborates with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Vir Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Alternative Research Associates","sponsor":"Organicell Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Organicell Partnered With Alternative Research Associates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Zofin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Alternative Research Associates","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alternative Research Associates \/ Organicell","highestDevelopmentStatusID":"7","companyTruncated":"Alternativ.."},{"orgOrder":0,"company":"Kentucky BioProcessing","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bat Working on Potential Covid-19 Vaccine Through Us Bio-Tech Subsidiary","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kentucky BioProcessing","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kentucky BioProcessing \/ ","highestDevelopmentStatusID":"4","companyTruncated":"Kentucky B.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Approves Human Trials for Potential Johnson & Johnson Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"CombiGene","sponsor":"Cobra Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cobra Biologics Completes Production of Master Cell Banks for CombiGene\u2019s Epilepsy Gene Therapy Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"CG01","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"CombiGene","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CombiGene \/ Cobra Biologics","highestDevelopmentStatusID":"4","companyTruncated":"CombiGene .."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Highmark","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Highmark Forges Outcomes-Based Contract with UCB for Anti-Inflammatory Drug CIMZIA\u00ae (certolizumab pegol)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Highmark","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highmark \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Highmark \/.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PCI Biotech: Publication of Case Report Series from the Phase I Study in Bile Duct Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NORWAY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Fimaporfin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$337.0 million","upfrontCash":"Undisclosed","newsHeadline":"Medtronic Announces a $337 Million Product Investment from Blackstone Life Sciences to Expand Development of Future Diabetes Technologies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Funding","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0.34000000000000002,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.34000000000000002,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Boston Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BOS-580","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Boston Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"WestRiver Management","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"LMN-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lumen Bioscience","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Lumen Bioscience \/ WestRiver Management","highestDevelopmentStatusID":"8","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"ImmProNano","sponsor":"Emergex Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Emergex Vaccines Forms US Subsidiary by Acquisition of Laboratories, Technology and Assets of US-Based T Cell Specialist Biotech ImmProNano","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Set-point vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ImmProNano","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmProNano \/ Emergex Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"ImmProNano.."},{"orgOrder":0,"company":"Cornell University","sponsor":"reVision Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"reVision Therapeutics, Inc. Announces License with Cornell to Develop Treatment for Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"REV-0100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Cornell University","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cornell University \/ reVision Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cornell Un.."},{"orgOrder":0,"company":"H&T Presspart","sponsor":"Bilim Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bilim Pharmaceuticals, H&T Presspart and Hovione Technology Unveil Collaboration for New Asthma Product: Ventofor Combi Fix","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"H&T Presspart","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Dry Powder Inhaler","sponsorNew":"H&T Presspart \/ Bilim Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"H&T Pressp.."},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Avomeen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dar\u00e9 Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Dar\u00e9\u2019s Novel Pipeline of Women\u2019s Health Programs","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Ferrous Gluconate","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Dar\u00e9 Bioscience","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravaginal","sponsorNew":"Dar\u00e9 Bioscience \/ Avomeen","highestDevelopmentStatusID":"12","companyTruncated":"Dar\u00e9 Biosc.."},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$805.0 million","upfrontCash":"$85.0 million","newsHeadline":"Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"JTX-1811","moa":"CCR8","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Jounce Therapeutics","amount2":0.81000000000000005,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.81000000000000005,"dosageForm":"","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Jounce The.."},{"orgOrder":0,"company":"The National Comprehensive Cancer Network","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NCCN Oncology Research Program, with Taiho Oncology, to Explore New Research into Oral Medication Targeting Tumor Suppression Genes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"The National Comprehensive Cancer Network","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The National Comprehensive Cancer Network \/ Taiho Oncology","highestDevelopmentStatusID":"1","companyTruncated":"The Nation.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$64.9 million","upfrontCash":"$19.4 million","newsHeadline":"Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Oxford Biomedica","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Flaskworks","sponsor":"Northwest Biotherapeutics","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"$1.6 million","newsHeadline":"Northwest Biotherapeutics Acquires Flaskworks","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Flaskworks","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Flaskworks \/ Northwest Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Flaskworks.."},{"orgOrder":0,"company":"AskBio","sponsor":"Scottish Enterprise","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"AskBio Awarded \u00a32m Scottish Enterprise R&D Grant to Help Reduce Barriers to Mainstream Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"AAV2\/8LSPhGAA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AskBio \/ Scottish Enterprise","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ S.."},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Craig-Hallum Capital Group","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sun BioPharma, Inc. Closes $10.5 Million Public Offering of Common Stock and Warrants","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Diethyl dihydroxyhomospermine","moa":"Polyamine metabolic","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Sun BioPharma \/ Craig-Hallum Capital Group","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPha.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"SternAegis Ventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Private Placement","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Kintara Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ SternAegis Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Australian Government Department of Industry, Science, Energy and Resources","pharmaFlowCategory":"D","amount":"$0.02 million","upfrontCash":"Undisclosed","newsHeadline":"Recce Pharmaceuticals Receives Entrepreneurs\u2019 Programme Innovation Connections Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Recce 327","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Australian Government Department of Industry, Science, Energy and Resources","highestDevelopmentStatusID":"4","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"LUCA Science","sponsor":"Axil Capital Partners","pharmaFlowCategory":"D","amount":"$9.8 million","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Announces $9.8 Million Series A Financing to Support Research and Development of Functional Mitochondria as Therapeutic Agents","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Mitochondria therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"LUCA Science","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"LUCA Science \/ Axil Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"LUCA Scien.."},{"orgOrder":0,"company":"Binex","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Signs a CMO Contract with Binex so Binex Can Produce Olinvacimab at Its New 5,000 L Production Line","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Binex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Binex \/ PharmAbcine","highestDevelopmentStatusID":"6","companyTruncated":"Binex \/ Ph.."},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"$19.4 million","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Announces the Closing of Its Acquisition of SmartPharm","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"STI-2020dna","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SmartPharm Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"SmartPharm Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SmartPharm.."},{"orgOrder":0,"company":"Fred Hutchinson Cancer Research Center","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$14.6 million","upfrontCash":"Undisclosed","newsHeadline":"Gene Therapy Research for Hiv Awarded $14.6 Million Nih Grant","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fred Hutchinson Cancer Research Center","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Fred Hutchinson Cancer Research Center \/ National Institute of Health","highestDevelopmentStatusID":"1","companyTruncated":"Fred Hutch.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","amount":"$11.4 million","upfrontCash":"Undisclosed","newsHeadline":"Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.01,"dosageForm":"","sponsorNew":"Idorsia Pharmaceuticals \/ Santhera","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orca Bio and Lyell Immunopharma Announce Research Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"T cell therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orca Bio \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Pocono Coated Product","sponsor":"Nutriband","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nutriband Acquires Transdermal and Health Product Manufacturing Business","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Acquisition","leadProduct":"Opioid based transdermal medications","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Pocono Coated Product","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"Pocono Coated Product \/ Nutriband","highestDevelopmentStatusID":"1","companyTruncated":"Pocono Coa.."},{"orgOrder":0,"company":"SHINE Technologies","sponsor":"Fidelity Management and Research Company LLC","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Shine Closes $80-Million Series C Financing Supported by Fidelity Management and Research Company Llc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"Lutetium-177","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"SHINE Technologies","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"SHINE Technologies \/ Fidelity Management and Research Company LLC","highestDevelopmentStatusID":"1","companyTruncated":"SHINE Tech.."},{"orgOrder":0,"company":"AEON Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Financing","leadProduct":"PrabotulinumtoxinA","moa":"SNAP-25","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AEON Biopharma","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"AEON Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"AEON Bioph.."},{"orgOrder":0,"company":"Option Care Health","sponsor":"NS Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Option Care Health Selected as a Limited Distribution Provider of VILTEPSO\u2122 Injection for Patients with Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Viltolarsen","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Option Care Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Option Care Health \/ NS Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Option Car.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Preclinical Protein Degrader Biotech Kymera Therapeutics Files for A $100 Million Ipo","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Rain Oncology","sponsor":"Boxer Capital","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rain Therapeutics Closes $63 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"RAIN-32","moa":"MDM2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rain Oncology","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Rain Oncology \/ Boxer Capital","highestDevelopmentStatusID":"8","companyTruncated":"Rain Oncol.."},{"orgOrder":0,"company":"Curia","sponsor":"Tryp Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tryp Therapeutics Partners with Curia to Manufacture a Proprietary Psilocybin-based Drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Partnership","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curia \/ Tryp Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Curia \/ Tr.."},{"orgOrder":0,"company":"Hibiskus BioPharma","sponsor":"Lodo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lodo Therapeutics Acquires Hibiskus Biopharma AND Licenses Rights to Novel Proteasome Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"TIR-199","moa":"Syrbactin proteasome","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Hibiskus BioPharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hibiskus BioPharma \/ Lodo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hibiskus B.."},{"orgOrder":0,"company":"CannaGlobal Wellness","sponsor":"Sansero Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CannaGlobal, Sansero Life Sciences and Rise Wellness Complete Merger, Announce Formation of CannaGlobal Wellness","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Merger","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"CannaGlobal Wellness","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CannaGlobal Wellness \/ Sansero Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"CannaGloba.."},{"orgOrder":0,"company":"Xencor","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb\u00ae Drug Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Vibecotamab","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ MD Anderson","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ M.."},{"orgOrder":0,"company":"Charcot Marie Tooth Association","sponsor":"Pharnext","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMTA and Pharnext Enter Biomarker Research Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Charcot Marie Tooth Association","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Charcot Marie Tooth Association \/ Pharnext","highestDevelopmentStatusID":"10","companyTruncated":"Charcot Ma.."},{"orgOrder":0,"company":"Curia","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curia Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Curia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curia \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Curia \/ As.."},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite and Hifibio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Anti-AML specific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"HiFiBiO Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Kite","highestDevelopmentStatusID":"2","companyTruncated":"HiFiBiO Th.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","amount":"$418.0 million","upfrontCash":"Undisclosed","newsHeadline":"I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Private Placement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"I-Mab Biopharma","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Hillhouse Capital Group","highestDevelopmentStatusID":"1","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,940.0 million","upfrontCash":"$180.0 million","newsHeadline":"AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":1.9399999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.9399999999999999,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Sinopharm","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Shanghai Fosun Pharma, Sinopharm Group Sign Deal to Supply BioNTech Coronavirus Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinopharm \/ Shanghai Fosun Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Sinopharm .."},{"orgOrder":0,"company":"CureVac","sponsor":"German Federal Ministry of Education and Research","pharmaFlowCategory":"D","amount":"$297.8 million","upfrontCash":"Undisclosed","newsHeadline":"CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"mRNA based vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CureVac","amount2":0.29999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"CureVac \/ German Federal Ministry of Education and Research","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"U.S. Government Exercises Option To Purchase Additional RAPIVAB\u00ae from BioCryst for Delivery to Strategic National Stockpile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Peramivir","moa":"Neuraminidase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"BioCryst Pharmaceuticals \/ U.S. Government","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Relation Therapeutics Teams up With Mila in Coalition to Identify Covid-19 Therapeutic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Relation Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Relation Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Relation T.."},{"orgOrder":0,"company":"InxMed","sponsor":"Ennovation Ventures","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Cobimetinib","moa":"Focal adhesion kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"InxMed \/ Ennovation Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ E.."},{"orgOrder":0,"company":"University of Wisconsin","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"University of Wisconsin","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Wisconsin \/ Revive Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"State of Pennsylvania","pharmaFlowCategory":"D","amount":"$0.3 million","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ State of Pennsylvania","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Pharmaceuticals Tumbles on Possible FDA Approval Delay of Omaveloxolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces that the First Phase I Clinical Study of Anti-Il-23 Monoclonal Antibody Ibi112 Has Been Administered to A Subject","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IBI112","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ITI Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ITI-1000","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunomic Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immunomic Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunomic .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Proceedings Journal","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Antios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antios Therapeutics Announces Publication Describing Preclinical Profile of ATI-2173","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-2173","moa":"Protein P","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Antios Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Antios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antios The.."},{"orgOrder":0,"company":"Isofol Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strengthened Patent Protection for Arfolitixorin in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Arfolitixorin","moa":"Thymidylate synthase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isofol Medical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Isofol Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isofol Med.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo phase 3 ELDERCARE AF study of anticoagulant, edoxaban in non-valvular atrial fibrillation & high bleeding risk meets primary endpoint","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nocion Therapeutics Advances to Clinical Stage and Expands Leadership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NTX-1175","moa":"Sodium channel","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nocion Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nocion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nocion The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Onureg\u00ae, a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Launch for Novo's New Diabetes Pill","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Final Approval from the Usfda for Cisatracurium Besylate Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisatracurium Besylate","moa":"Nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"APVO436","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo The.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio and Quantum Leap Doses First Patients with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"PTP","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aerpio Pharmaceuticals \/ Quantum Leap Healthcare Collaborative","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Radboud University","sponsor":"Hellenic Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elderly People Protected Against Respiratory Infections by Bcg Vaccine Reveals Radboud University Research","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"NETHERLANDS","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Radboud University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Radboud University \/ Hellenic Institute","highestDevelopmentStatusID":"11","companyTruncated":"Radboud Un.."},{"orgOrder":0,"company":"Universities of Liverpool","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Identify Promising New ALS Drug Candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ebselen","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Universities of Liverpool","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Universities of Liverpool \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Universiti.."},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clear Creek Bio Doses First Patient in Clinical Study of Brequinar in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Brequinar","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Clear Creek Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Clear Creek Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Clear Cree.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor\u2122 for Immune Mediated Complications in COVID19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Fujita Health University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elixirgen Therapeutics Planning to Begin Phase I\/II Clinical Trials of Its Covid-19 Vaccine Candidate Exg-5003 at Fujita Health University","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elixirgen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Elixirgen Therapeutics \/ Fujita Health University","highestDevelopmentStatusID":"4","companyTruncated":"Elixirgen .."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Vertex\u2019s Supplemental New Drug Applications for TRIKAFTA\u00ae , SYMDEKO\u00ae and KALYDECO\u00ae for Additional CFTR Mutations","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Successfully Completes Multiple Dose Toxicity and Toxicokinetic Studies Of ALT-801 For The Treatment Of NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALT-801","moa":"GCGR\/GLP-1R","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical's Analysis of Prevention Trials and Intralymphatic Pilot Trial with the Diabetes Vaccine Diamyd\u00ae Support a Positive Trend in Genetically Defined Subgroups of Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IVERIC Bio Publishes GATHER1 Phase 3 Clinical Trial Results for Zimura\u00ae in Geographic Atrophy Secondary to Age-related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacincaptad Pegol","moa":"Completent C5","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"IVERIC bio","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"IVERIC bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IVERIC bio.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer\u2019s and Parkinson\u2019s Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Pharmaceuticals Provides Update on Tradipitant Development Program","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Phar.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imfinzi Approved in the EU for the Treatment of Extensive-Stage Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oxurion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxurion NV Reports First Patient Dosed in Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oxurion","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Oxurion \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxurion \/ .."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx\u2019s Neuron-Protecting Drug Slows ALS Decline in Nejm Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Presents New Data on Efficacy of MS Treatment Ocrevus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono to Showcase New Data at ACTRIMS-ECTRIMS MS Virtual 2020 Meeting, Furthering Innovation in Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Advantages of the CiVax\u2122 Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CiVax","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces Oral Presentation of Phase 1b Combination Study of PT-112 Plus Avelumab at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia in CKD Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Libtayo\u00ae (cemiplimab) Pivotal Data in Advanced Non-Small Cell Lung Cancer and Basal Cell Carcinoma to Be Presented at Esmo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published in Blood Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu) lilotomab satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANVISA Authorizes Domp\u00e9's REPAVID-19, a Phase 2 Clinical Trial for Treatment of Severe Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Reparixin","moa":"IL-8","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farm.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces Nejm Publication of Pivotal Study of Tabrecta\u2122 in Patients with ME Tex14 Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Ionis Pharmaceuticals' Study Results Evaluating Ionis Antisense Therapy in Treatment of Patients with Hereditary Angioedema","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IONIS-PKK-LRx","moa":"Prekallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"STRO-002","moa":"Folate receptor alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biop.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Cansino Kicks Off Phase III Vaccine Clinical Trials in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Enrollment of 50th Patient in Multinational 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Issued Key Patent on Combination Platform Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HS-130","moa":"T-Cell mediated immune response","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmabcine Is Presenting on Olinivacimab Plus Pembrolizuamb Study at the KSMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek\u00ae National Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Ph.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides to Present COVID-19 Drug Update at The LD 500 Virtual Conference","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Announces First Patient Treated in Higher Dose Cohort in Phase 1 Clinical Trial of RP-A501 for Danon Disease","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-A501","moa":"AAV9.LAMP2B","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Announces Initiation of Patient Dosing in TWT-101, a Phase 1\/2 Study CFI-402411, in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-402411","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in \u2018Blood\u2019","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott\u2019s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"Pulmonem","sponsor":"McGill University Health Centre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New COVID-19 Drug Therapy Developed by Canadian Biotech Start-up Headed for Phase III Clinical Trial Sponsored by the RI-MUHC Fran\u00e7ais","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pulmonem \/ McGill University Health Centre","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/.."},{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xellia Pharmaceuticals expands approved doses of VANCO READY\u2122 (Ready-to-use Premixed Vancomycin bags)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Xellia Pharmaceuticals ApS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xellia Pharmaceuticals ApS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xellia Pha.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Orphan Drug Designation for MB-107 to Treat X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-107","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Umecrine Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Presents Data from Clinical Phase 2a Study at AALSD International Liver Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Golexanolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Umecrine Cognition","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Umecrine Cognition \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Umecrine C.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pioglitazone","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Provides Update on U.S. Development Program for the Subcutaneous Formulation of ENTYVIO\u00ae for Moderate to Severe Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corning Jerry's Bispecific Antibody Kn046 Was Granted Orphan Drug Designation by the Us FDA for the Treatment of Thymic Epithelial Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KN046","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alphamab Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Alphamab Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alphamab O.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Announces that Janssen\u2019s COVID-19 Vaccine Candidate Prevents Severe Clinical Disease in Pre-clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Savara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for NTM Lung Infection in People Living With Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Molgramostim","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Savara","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Savara \/ N.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Additional Doses of Trulicity\u00ae (dulaglutide) for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Peptide","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mexico Eyes October Start for Gamaleya Research Institute of Epidemiology and Microbiology's Phase 3 Trials of Russian Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"The Gamale.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX\u00ae to Treat HER2-Positive Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight The.."},{"orgOrder":0,"company":"Abivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abivax Reports Long-Lasting Two-Year Efficacy and Safety Data from ABX464 Ulcerative Colitis Phase 2a Maintenance Study","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Obefazimod","moa":"miR-124","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Abivax","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Abivax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abivax \/ N.."},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Lyra Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Steroid","amount2New":0,"dosageForm":"","sponsorNew":"Lyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lyra Thera.."},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RLY-4008","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Relay Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Relay Ther.."},{"orgOrder":0,"company":"BANNER LIFE SCIENCES LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Banner Life Sciences Announces BAFIERTAM for Relapsing Forms of Multiple Sclerosis, is Now Available in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Monomethyl Fumarate","moa":"Nrf2","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"BANNER LIFE SCIENCES LLC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"BANNER LIFE SCIENCES LLC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BANNER LIF.."},{"orgOrder":0,"company":"CeleCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CeleCor Announces Publication of Positive Clinical Results of RUC-4 (zalanfiban) for Subcutaneous Point-of-Care STEMI Therapy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RUC-4","moa":"GPIIb\/IIIa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CeleCor Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CeleCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CeleCor Th.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Prednisone Tablets","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Steroid","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Novan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Berdazimer sodium","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ No.."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune\u2122 Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Natural killer cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara\u00ae (Ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera .."},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeoVax Announces Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MVA-MARV-VLP vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GeoVax Labs","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GeoVax Lab.."},{"orgOrder":0,"company":"Neumentum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neumentum Announces Two Poster Presentations for Novel Non-opioid, Non-NSAID Analgesic Drug Candidate at PAINWeek 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NTM-006","moa":"A3AR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neumentum","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neumentum \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neumentum .."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Announces US Drug Manufacturing Milestones","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vutrisiran","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"FGF21","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Final Approval from the Usfda for Cisatracurium Besylate Injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Midodrine","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"4-Chlorokynurenine","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VistaGen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen T.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich\u2019s Ataxia at AAN","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces NMPA Granted Marketing Approval for SULINNO\u00ae (Adalimumab Injection) in China","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma Launches Phase 3 Superiority Study for Pediatric Acute-onset Neuropsychiatric Syndrome","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Immune globulin, human - ifas","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lianhua Qingwen Receives First International Approval for Covid-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lianhua Qingwen","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Yiling Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yiling Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yiling Pha.."},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concept Medical Announces Enrolment of Index Patient in the Crucial Transform -1 RCT Using Magic Touch Sirolimus Coated Balloon for Small Coronary Vessels","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Concept Medical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Concept Me.."},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in Phase 1 Gene Therapy Study in Ireland","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BIIB078","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ N.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Completes Enrollment for Intravenous Covid-19 Clinical Trial & Provides Update on Osteoarthritis of the Knee Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kite Submits Supplemental Biologics License Application to U.S. FDA for Yescarta\u00ae in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Completes the Extended Enrollment for the Pivotal Phase 3 Ocean Study in Relapsed Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents Positive Biomarker Data Demonstrating Proof of Mechanism in Mitazalimab Clinical Phase I Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitazalimab","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at ESE","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca to Begin Phase 1\/2 Clinical Trials of Coronavirus Vaccine in Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAegis Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant human plasma gelsolin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis T.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces FDA Approval of Gavreto for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech and Pfizer Receive Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2\/3 Trial for COVID-19 Vaccine Candidate BNT162b2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ Pfizer","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Provides Update on Kevzara\u00ae (sarilumab) Phase 3 Trial in Severe and Critically Ill Covid-19 Patients Outside the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarilumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medtronic Announces FDA Approval for Minimed\u2122 770G Insulin Pump System with Smartphone Connectivity for People with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharma Provides Updated Guidance on Its Clinical Programs","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"Viela Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Inebilizumab","moa":"CD19","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Viela Bio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viela Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viela Bio .."},{"orgOrder":0,"company":"Syntekabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syntekabio Found Repurposable Covid-19 Drug Candidates Stronger than Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Syntekabio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Syntekabio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Syntekabio.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GB001","moa":"Prostaglandin D2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma\u2019s BCL-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"APG-2575","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Phase 2\/3 Neurodegeneration Biotech Athira Pharma Files for a $100 Million IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0.10000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Goldman Sachs","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"NellOne Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nell One Therapeutics Secures Key Patent to Revolutionize Large-Scale Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"NV1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NellOne Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NellOne Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NellOne Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Lademirsen","moa":"miR-21","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces Agreement in Principle with Government of Canada to Supply its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Government of Canada","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Engitix Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"Engitix Signs Collaboration and Licensing Agreement with Takeda to Develop Anti-Fibrotic Therapies in Advanced Liver Diseases","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Engitix Therapeutics","amount2":0.5,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"Engitix Therapeutics \/ Takeda Pharmaceutical Company","highestDevelopmentStatusID":"3","companyTruncated":"Engitix Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Investigational Novel Stamp Inhibitor Asciminib (ABL001) Meets Primary Endpoint of Phase III Chronic Myeloid Leukemia Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Asciminib","moa":"Bcr\/Abl","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Washington University School of Medicine's Experimental Nasal Vaccine Protects Upper and Lower Respiratory Tracts Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAd-SARS-CoV-2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Washington University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Washington.."},{"orgOrder":0,"company":"Novavax","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax to Supply 76M Doses of COVID-19 Vax to Canada","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novavax \/ Government of Canada","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"SHENZHEN SALUBRIS PHARMACEUTICALS","sponsor":"Carlyle","pharmaFlowCategory":"D","amount":"$260.0 million","upfrontCash":"Undisclosed","newsHeadline":"Carlyle to Acquire 5% Stake in Salubris, a Leading Biopharmaceutical Company in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"JK07","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"SHENZHEN SALUBRIS PHARMACEUTICALS","amount2":0.26000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"SHENZHEN SALUBRIS PHARMACEUTICALS \/ Carlyle","highestDevelopmentStatusID":"6","companyTruncated":"SHENZHEN S.."},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"SporeGen","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"SporeGen\u00ae Announces Collaboration with Destiny Pharma Supported by an Innovate UK grant award for a Preventative Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"SPOR-COV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Destiny Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Destiny Pharma \/ SporeGen","highestDevelopmentStatusID":"4","companyTruncated":"Destiny Ph.."},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai to Take Over Manufacturing and Marketing Approval for Equfina\u00ae 50 Mg Tablets (safinamide Mesilate)INn Japan from Meiji Seika Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Safinamide Mesylate","moa":"MAO-B","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Meiji Seika Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Meiji Seika Pharma \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Meiji Seik.."},{"orgOrder":0,"company":"Intravacc","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$9.4 million","upfrontCash":"Undisclosed","newsHeadline":"Intravacc Receives US NIH\/NIAID Contract to Develop Enterovirus D68 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Inactivated EV D68 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Intravacc","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Intravacc \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Intravacc .."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oncology Biotech Prelude Guns for $100 M IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"PRT543","moa":"PRMT5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astex Pharmaceuticals and MD Anderson Collaborate to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Decitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Astex","highestDevelopmentStatusID":"1","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Biopharma","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta\u00ae (voxelotor) in Six Middle Eastern Countries","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Biopharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biopharma \/ Global Blood Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biopharma .."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inversago Pharma Closes US$35 M Series B Financing Round and Expands Board of Directors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"INV-101","moa":"CB1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$420.0 million","upfrontCash":"$10.0 million","newsHeadline":"Redx Announces New Research Collaboration with Jazz Pharmaceuticals to Discover and Develop Two Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Redx Pharma","amount2":0.41999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Redx Pharma \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Redx Pharm.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Galmed Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galmed and Ascletis Subsidiary Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Aramchol","moa":"TR-Beta","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Galmed","highestDevelopmentStatusID":"8","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Exscientia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Huadong Medicine and Exscientia Enter Co-Development Partnership to Accelerate Oncology Drug Discovery Through Artificial Intelligence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Hangzhou Z.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"European Union","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer and Biontech to Potentially Supply the EU with 200 Million Doses of mRNA-Based Vaccine Candidate Against SARS-Cov-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ European Union","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AnGes","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AnGes Anoounces Collaboration Agreement with Brickell Biotech","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AG0302-COVID19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AnGes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnGes \/ Brickell Biotech","highestDevelopmentStatusID":"7","companyTruncated":"AnGes \/ Br.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"HM Capital","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Onco Immune, Inc. Raises $56 Million Series B Financing for Novel Cancerandd Covid-19 Therapeutics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"MK-7110","moa":"CD24","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ HM Capital","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Napo EU","sponsor":"Oasis Capital","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to Purchase Agreement with Oasis Capital, LLC","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Napo EU","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napo EU \/ Oasis Capital","highestDevelopmentStatusID":"12","companyTruncated":"Napo EU \/ .."},{"orgOrder":0,"company":"Bioclinica","sponsor":"Direct Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioclinica Partners with Direct Biologics to Provide Interactive Response Technology (IRT) Solution for COVID-19 Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"DB-001","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Bioclinica","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioclinica \/ Direct Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Bioclinica.."},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"$7.0 million","newsHeadline":"Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ABO-202","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Abeona Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Abeona Therapeutics \/ Taysha Gene Therapies","highestDevelopmentStatusID":"5","companyTruncated":"Abeona The.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$21,000.0 million","upfrontCash":"$15,000.0 million","newsHeadline":"Gilead Sciences to Acquire Immunomedics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":21,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":21,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Gilead","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Valneva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Dynavax Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynavax Technologies \/ Valneva","highestDevelopmentStatusID":"4","companyTruncated":"Dynavax Te.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Molteni Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Accord Healthcare Enters Exclusive Distribution Agreement with Molteni Farmaceutici for First Buprenorphine Implant Approved in Europe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Narcotic","amount2New":0,"dosageForm":"Implant","sponsorNew":"Accord healthcare \/ Molteni Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Myotonic Dystrophy Clinical Research Network","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AOC 1001","moa":"TfR1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ Myotonic Dystrophy Clinical Research Network","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Bi.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai and Takeda Ink Clinical Collaboration for Global Phase III Studies for the Combination Therapy with Multiple Tumor Types in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"CMAB Biopharma Inc","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMAB Biopharma and Laekna Therapeutics Enter Strategic Agreement for LAE005 Global Development and Commercialization Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Afuresertib","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CMAB Biopharma Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CMAB Biopharma Inc \/ Laekna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CMAB Bioph.."},{"orgOrder":0,"company":"Korro Bio","sponsor":"Wu Capital","pharmaFlowCategory":"D","amount":"$91.5 million","upfrontCash":"Undisclosed","newsHeadline":"Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"RNA editing therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Korro Bio","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Korro Bio \/ Wu Capital","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio .."},{"orgOrder":0,"company":"Casma Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Casma Therapeutics Announces $50 Million Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"TRPML1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Casma Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Casma Therapeutics \/ The Column Group","highestDevelopmentStatusID":"4","companyTruncated":"Casma Ther.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"CAP ALTER PHARMA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Signs Two Agreements in Latin America, Global Business System for Seroquel Continues to Grow Rapidly","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ CAP ALTER PHARMA","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Corpometria Institute","sponsor":"Applied Biology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied Biology in Collaboration with Corpometria Institute to Launch ANDROCOV TRIAL for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"BRAZIL","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Dutasteride","moa":"Steroid 5-alpha reductase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Corpometria Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corpometria Institute \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Corpometri.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"National Institute of Allergy and Infectious Diseases.","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"Undisclosed","newsHeadline":"HDT BIO Receives NIH Contract to Advance Novel RNA\/LION\u2122 COVID-19 Vaccine Into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"HDT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HDT Biotech","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ National Institute of Allergy and Infectious Diseases.","highestDevelopmentStatusID":"4","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"ImmunoBrain Checkpoint","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoBrain Checkpoint Awarded Alzheimer\u2019s Association Grant to Support Phase II Trial Investigating Novel Immunotherapeutic Approach to Treat Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"IBC-Ab002","moa":"PD-L1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"ImmunoBrain Checkpoint","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoBrain Checkpoint \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoBrai.."},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Bluestem Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"CSF-1","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Eye Drop","sponsorNew":"Orasis Pharmaceuticals \/ Bluestem Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pha.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Biodesix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVEO Oncology Regains Full Global Rights to Ficlatuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Cetuximab","moa":"HGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aveo Oncology \/ Biodesix","highestDevelopmentStatusID":"8","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"Anelixis Therapeutics","sponsor":"Novus Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novus Therapeutics Announces Acquisition of Anelixis Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"AT-1501","moa":"CD40","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anelixis Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anelixis Therapeutics \/ Novus Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Anelixis T.."},{"orgOrder":0,"company":"ABL Bio","sponsor":"HiFiBiO Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HiFiBiO Therapeutics Announces a Global Strategic Partnership with ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"HFB30132A","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ABL Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ABL Bio \/ HiFiBiO Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ABL Bio \/ .."},{"orgOrder":0,"company":"Attralus","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"AT-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Attralus \/ venBio Partners","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/.."},{"orgOrder":0,"company":"Saptagir Laboratories","sponsor":"Jubilant Generics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Saptagir Labs Signs Manufacturing Deal with Jubilant Generics for Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Saptagir Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Saptagir Laboratories \/ Jubilant Generics","highestDevelopmentStatusID":"12","companyTruncated":"Saptagir L.."},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Monash University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Partners with Monash University to Support Development of Inhaled Oxytocin to Prevent Postpartum Haemorrhage","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Oxytocin","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Monash University","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Lt.."},{"orgOrder":0,"company":"Neogene","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Neo-Antigen TCR Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Neo-Antigen T Cell Receptor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Neogene","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Neogene \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Neogene \/ .."},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$4,200.0 million","upfrontCash":"$600.0 million","newsHeadline":"Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Ladiratuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":4.2000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":4.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ M.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics and Janssen to Evaluate Nirogacestat in Combination with Teclistamab for Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Escape Bio","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","amount":"$73.0 million","upfrontCash":"Undisclosed","newsHeadline":"Escape Bio Closes $73 Million to Advance Clinical Development of Precision Neurology Medicines for Genetic Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"ESB1609","moa":"S1P5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Escape Bio","amount2":0.070000000000000007,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Escape Bio \/ Wellington Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Escape Bio.."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurodegeneration Biotech Athira Pharma Sets Terms for $160 Million IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0.16,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.16,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Tracer","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tracer to Support Akston Biosciences\u2019 Phase 1 Clinical Study of AKS-452, an Innovative Anti-Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AKS-452","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tracer","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tracer \/ Akston Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Tracer \/ A.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Nebraska Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UNMC, COVAXX Sign Agreement Paving Way for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"UB-612","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ University of Nebraska Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Spy Biotech and Serum Institute of India Announce Dosed First Subjects in \nPhase I\/II Trial of a Novel Virus-Like Particle Vaccine Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Virus-like-particle vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"SpyBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ Serum Institute of India","highestDevelopmentStatusID":"7","companyTruncated":"SpyBiotech.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Presentations for TransCon\u2122 PTH and Hypoparathyroidism at ASBMR 2020 Virtual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Initiates Pilot Study with PMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PGI Rohtak to Start Phase-2 Trial of Bharat Biotech's COVAXIN","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"Zion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zion Pharma Announces Initiation of Phase 1 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ZN-A-1041","moa":"RTK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zion Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharm.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in China Enrolled in Clinical Phase 3 Study NefIgArd with Lead Candidate Nefecon","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statement on Astra Zeneca Oxford SARS-CO V-2 Vaccine, AZD1222, Covid-19 Vaccine Trials Temporary Pause","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s Gefapixant Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Refractory or Unexplained Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Submits Marketing Authorisation Application to the EMA for TransCon\u2122 hGH for Pediatric Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Kadmon's Belumosudil for the Treatment of Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Humantakinogene hadenovec","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Flexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"Biomica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BMC128","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Launches Development of Drug-Free Nasal Spray for Protection Against Airborne Pathogens and Allergens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AM-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Center for International Blood and Marrow Transplant Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CIBMTR Completes Enrollment in Yescarta\u00ae Long-Term Post-Marketing Safety Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV","graph3":"Center for International Blood and Marrow Transplant Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Center for International Blood and Marrow Transplant Research \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Center for.."},{"orgOrder":0,"company":"LIPAC Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipac Oncology Announces Completion of Phase 2a Clinical Trial of LiPainin Patients with Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"LIPAC Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravesical Instillation","sponsorNew":"LIPAC Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LIPAC Onco.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CYNK-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Celularity.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health: Enrollment Completed for Phase 3 wearABLe Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Trabsdermal Patch","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Announces Publication of Independent Research on Kevetrin, the Company\u2019s p53 Drug Candidate, in Oncology Reports","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Kevetrin","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma\u2019s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Biotherapeutics to Accelerate ARQ-151 into Phase 3 Trials for Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Announces The Lancet Publishes Detailed Vosoritide Phase 3 Data in Children with Achondroplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vosoritide","moa":"FGFR3","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Approves Athena Bioscience's New Drug Application (NDA) for QDOLO\u2122 (tramadol hydrochloride) Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Athena Bioscience","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Athena Bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Athena Bio.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 to Advance in Oncology and Rare Disease Indications","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Kleo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KP1237","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kleo Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kleo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Kleo Pharm.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces U.S. Commercial Launch of Phexxi\u2122, the First and Only Non-Hormonal, Prescription Contraceptive Vaginal Gel","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Announces Positive Results on CorVax\u2122 in In-Vivo Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CorVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxil Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clene Nanomedicine Completes Enrollment in Rescue-ALS Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis with CNM-Au8","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spero Therapeutics Announces Topline Results from its Phase 3 ADAPT-PO Trial of Tebipenem HBr in Complicated UTI and Acute Pyelonephritis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Spero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spero Ther.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer to Showcase New Data from Evolving Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Regorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caribou Biosciences Announces FDA Clearance of its IND for CB-010","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-010","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Bi.."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Goldfinch Bio Initiates Phase 2 Clinical Trial Evaluating GFB-887 as a Precision Medicine for Patients with Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-601","moa":"MOSPD2","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Data From a Phase 1 Trial With Transgene\u2019s Oncolytic Virus TG6002","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Flucytosine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271 to Treat Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA2271","moa":"Mesothelin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Doses First Patient in Phase 1\/2 Triple Combination Study\nof COM701 with Bristol Myers Squibb\u2019s Opdivo\u00ae and Anti-TIGIT\nAntibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Hea.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synairgen Announces Positive Data from Analysis of Trial in COPD Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cymerus mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Cynata Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cynata The.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science to Present Results from Its AB07015 Study in Severe Asthma at the Annual European Respiratory Society International Congress","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune Regulation Ltd Receives Notice of Allowance for New U.S. Patent for Its Novel Protein \"1805\" with Anti-Inflammatory Properties","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IRL201805","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Revolo Biotherapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeyondSpring Gets Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin for Chemotherapy-Induced Neutropenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Announces Resubmission of Biologics License Application to USFDA for Ryplazim\u00ae (plasminogen)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India to Halt Trial of the Astrazeneca Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Precision BioSciences Receives Fast Track Designation from USFDA for PBCAR269A for Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMPIO Reports Positive Results For Ampion Treatment in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Regenxbio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical\u2019s Licensing Partner REGENXBIO Doses First Patient in its Phase 2 Gene Therapy Trial Using SCS Microinjector\u00ae for Suprachoroidal Delivery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-314","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ REGENXBIO","highestDevelopmentStatusID":"8","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and GSK Initiate Phase 1\/2 Clinical Trial of Covid-19 Adjuvanted Recombinant Protein-Based Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Adjuvanted COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ GlaxoSmithKline","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 1 Drug Candidate GLR2007 Developed by Gan & Lee has been Granted Orphan Drug Designation by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GLR2007","moa":"CDK-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Peptilogics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Peptilogics Receives FDA Orphan Drug Designation for Novel Peptide Therapy for the Treatment of Prosthetic Joint Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PLG0206","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Peptilogics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Peptilogics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Peptilogic.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart\u2019s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces Positive Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy for Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cell.."},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMRYT Announces Positive Top Line Results from Pivotal Phase 3 \"ease\" Trial of Filsuvez\u00ae in Epidermolysis Bullosa","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Episalvan","moa":"Transient receptor potential channel stimulant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Amryt Pharma","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amryt Phar.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Expands Its M.S Portfolio with Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenebrutinib","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Trials of Sinovac Covid-19 Vaccine Show Promising Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose\n(SLS-005)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Trehalose API","moa":"Amyloid beta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VBL Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Th.."},{"orgOrder":0,"company":"Immatics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immatics Provides Update on IMA204 ACTengine\u00ae Cell Therapy Program Targeting the Tumor Microenvironment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IMA204","moa":"COL6A3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immatics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immatics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immatics \/.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dosing Underway for Diffusion Pharma's Lead Asset in Early-Stage COVID-19 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Trans Sodium Crocetinate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zogenix Announces Positive Top-Line Results from its Third Pivotal Phase 3 Clinical Trial of FINTEPLA\u00ae in Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fenfluramine Hydrochloride","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Satsuma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satsuma Pharmaceuticals Announces Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Satsuma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Powder","sponsorNew":"Satsuma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Satsuma Ph.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biohaven's Oral Zavegepant Receives Authorization to Proceed from FDA and Achieves First in Human Dosing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zavegepant","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Announces NMPA Approval of ZEJULA\u00ae for First-Line Maintenance Treatment of Ovarian Cancer in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Completion of ANAVEX\u00ae2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum DIsorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Fasenra Met Both Co-Primary Endpoints of Reduced Nasal Polyp Size and Blockage in the Ostro Phase III Trial","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Benralizumab","moa":"IL-5 alpha receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Positive Final Results from Phase 1\/2a Study of BIVV001 in People with Severe Hemophilia A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"rFVIIIFc-VWF-XTEN","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ S.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Provides Program Update for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVrh74.MHCK7.micro-dystrophin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"GigaGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GigaGen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GigaGen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"GigaGen \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s ENSPRYNG (satralizumab) Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Satralizumab-mwge","moa":"IL-6R alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS\u2019 Multidisciplinary NET Medical Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tidutamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NEJM Publishes Data for NUBEQA\u00ae Plus Androgen Deprivation Therapy for Men with Non-Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Darolutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Orion Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Propose Expansion of Pivotal Covid-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Receives UK MHRA Approval to Resume Covid-19 Vaccine AZD1222 Clinical Trials in UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Dupixent\u00ae (dupilumab) Granted Breakthrough Therapy Designation for Eosinophilic Esophagitis By FDA","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck (Finally) Starts a Clinical Trial of its Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"V591","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"89bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"89bio to Announce Topline Results from Phase 1b\/2a Study of BIO89-100 in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BIO89-100","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"89bio","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"89bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"89bio \/ No.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Presents Phase 2B\/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Showcases Commitment to Patient-Centric Advances in Oncology with Record Number of Abstracts to Be Presented at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"EMD Serono","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMD Serono Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"EMD Serono","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EMD Serono \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EMD Serono.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Dosed First Patient in Phase 3 Clinical Trial of Dextenza\u00ae for Post-Surgical Ocular Inflammation and Pain in Children","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I\/IIa EVICTION Trial for ICT01","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ICT01","moa":"BTN3A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Haoma Medica to Present Scientific Data on NaQuinate, a Potential New Treatment for Osteoporosis, at ASBMR 2020 Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NaQuinate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haoma Medica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medi.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen To Present New Insights at ASBMR For Potential Treatment of Ultra-Rare Disease Fibrodysplasia Ossificans Progressiva, Including Global Phase III MOVE Trial Results","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Palovarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Announces First Patient Dosed in Phase I\/II Trial of Bicycle\u00ae Toxin Conjugate BT8009 for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BT8009","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Greenwich Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich Biosciences to Present Safety and Efficacy Data of Nabiximols in MS-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Greenwich Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oromucosal Spray","sponsorNew":"Greenwich Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies Announces FDA Acceptance for Filing of NDA for Epsolay\u00ae for the Treatment of Inflammatory Lesions of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Te.."},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbor Presents Data from Pivotal Study of AR19 to Resist Physical Manipulation form Nonmedical Misuse or Abuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Arbor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arbor Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arbor Phar.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Activ Initiative Launches Adaptive Clinical Trials of Blood-Clotting Treatments for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Heparin Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"NaviFUS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NaviFUS Launches Clinical Trial of a Combination FUS-Bevacizumab Therapy in rGBM Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"NaviFUS","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NaviFUS \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NaviFUS \/ .."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces that BioComo\u2019s Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Announces Positive Phase 3 Study for TRIKAFTA\u00ae in Children Ages 6-11 Years With Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Advances Novel Bi-specific TRAILR2\/CDH17 Antibody to Phase 1 Clinical Trial for Gastrointestinal Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 905711","moa":"TRAILR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Powder for Solution for Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals Receives Fast Track Designation for TERN-201 as a Treatment for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-201","moa":"SSAO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59, an Anti-COVID-19 Monoclonal Antibody Treatment Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's REYVOW\u2122 (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits Application Seeking USFDA Approval of DARZALEX FASPRO\u2122 for the Treatment of Patients with Light Chain Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS\u00ae in Patients with Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Opicapone","moa":"COMT","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term 3 Year Data on an Investigational Gene Therapy for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurocrine Biosciences \/ Voyager Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics Announces Positive Results of Phase 1a Study of ATA188 in MS Patients with Sustained Disability","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Prevention Pharmaceuticals Publishes Landmark Phase 3 Clinical Trial Data for Treatment of Familial Adenomatous Polyposis in NEJM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Pre.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at ASBMR 2020","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-012","moa":"ACVR2A","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Its First Complex Injectable Approval from USFDA for Doxorubicin Hydrochloride Liposome Injection","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Liposomal Injection","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LB Pharmaceuticals Inc Announces Results of LB-102 Phase 1 First-in-Human Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmac.."},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI\u2019s Platform-Derived Hypothesis For COVID-19 Treatment Validated In US NIAID Randomised Control Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"BenevolentAI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Benevolent.."},{"orgOrder":0,"company":"Immunity Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunity Pharma Announces Promising Interim Results of its Phase 1\/2a Study with IPL344 in ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IPL344","moa":"Akt signaling pathway","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Immunity Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunity Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Immunity P.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TOTUM-070","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase IIb Topline Results Demonstrate a Significant Treatment Effect of Diamyd\u00ae in Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Med.."},{"orgOrder":0,"company":"PharmAbcine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olinvacimab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PharmAbcine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmAbcine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmAbcin.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad-RTS-hIL-12","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Alaunos Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alaunos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alaunos Th.."},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Once Daily Dosing Option for NITYR (nitisinone) Tablets for HT-1 Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitisinone","moa":"HPDD","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Phar.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's MDM2-p53 Inhibitor APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim's Phase II Trial Results Demonstrated Improvement in Cognition with BI 425809 in Adult Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 425809","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Indoco Receives USFDA Approval for Apixaban Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Apixaban","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Indoco Remedies Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indoco Remedies Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indoco Rem.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Reports Positive Topline Results from the First Phase III Trial of Beovu\u00ae Vs Aflibercept in Patients with Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ National Institute of Health","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Research Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Angiopoietin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA\u00ae in Waldenstr\u00f6m\u2019s Macroglobulinemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zanubrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Announces Registration of HONEDRA\u00ae Trademark and New Patent in Japan","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CLBS12","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Transfusion","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinuvel Progresses Innovative DNA Repair Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Clinuvel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Clinuvel P.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 20th Annual SRNT-E Virtual Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes in Usage or Dosage for Anticoagulant Edoxaban","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Edoxaban Tosylate","moa":"Factor Xa","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Tikomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tikomed's ILB\u00ae Restores Brain Energy Metabolism Following Severe Traumatic Brain Injury in the Rat","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dextrans","moa":"MMP","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Tikomed","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tikomed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tikomed \/ .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recovery Covid-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Identified GC376 and Boceprevir Can Inhibit SARS-Co V-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Boceprevir","moa":"HCV proteases\/NS3-4A serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Chinese Academy of Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chinese Academy of Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Chinese Ac.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Plans to Initiate a Phase 2 Clinical Trial with Rabeximod in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Descartes 30","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Cartesian Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cartesian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cartesian .."},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Identify Nanobody that May Prevent Covid-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ty1","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Karolinska Institutet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Karolinska Institutet \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Karolinska.."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Experimental Covid-19 Vaccine Prevents Severe Disease in Mice","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"VSV-SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Washington University School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Washington.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$239.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recursion Pharmaceuticals Raises $239 Million And Partners With Bayer","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series D Financing","leadProduct":"REC-994","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0.23999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Supports Latest Clinical Research Evaluating VASCEPA\u00ae in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ N.."},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Announces Start of Trial to Evaluate the New Esprit\u2122 BTK Drug-Eluting Resorbable Scaffold","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Lab.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck\u2019s Commitment to Advancing Cancer Research and Care","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive MS at MSVirtual2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biot.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics Dosed First Patient in Oxurion\u2019s Phase II Trial Using a Novel Bicycle\u00ae-based Plasma Kallikrein Inhibitor for DME","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"THR-149","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Aptorum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptorum Group Announces Further Positive Data on ALS-4 Against MRSA Wound Infection and MRSA Bacteraemia Against Linezolid and Vancomycin Respectively in In Vivo Models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALS-4","moa":"Dehydrosqualene desaturase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Aptorum","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptorum \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Enrolls First Patient in COVA, Phase 2\/3 Clinical Trial with Sarconeos for the Treatment of COVID-19 Related Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Ponce De Leon Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Reveals Longevity Benefits of Calcium Alpha-Ketoglutarate in Scientific Journal Cell Metabolism","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium Alpha-Ketoglutarate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Ponce De Leon Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ponce De Leon Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ponce De L.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals Initiates Rolling Submission of an NDA for Maralixibat for Cholestatic Pruritus in Patients with Alagille Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chong Kun Dang Proceeds to Phase 2 Trial in Russia to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"Serine protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Chong Kun Dang Pharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun .."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Research UK and AstraZeneca\u2019s New Antibody Maturation Technique Yields High-Affinity Arginase 2 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"C0021158","moa":"Arginase 2","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Clene Nanomedicine","sponsor":"Tottenham Acquisition I Limited","pharmaFlowCategory":"D","amount":"$542.5 million","upfrontCash":"$25.0 million","newsHeadline":"Clene Nanomedicine, Inc. to Go Public Through Merger with Tottenham Acquisition I Limited","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Merger","leadProduct":"CNM-Au8","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Clene Nanomedicine","amount2":0.54000000000000004,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.54000000000000004,"dosageForm":"Suspension","sponsorNew":"Clene Nanomedicine \/ Tottenham Acquisition I Limited","highestDevelopmentStatusID":"10","companyTruncated":"Clene Nano.."},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanford Health Is First in Nation to Dose Patient with Promising Novel Therapeutic Candidate for Covid-19, SAB-185","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SAB-185","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SAB Biotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"SAB Biothe.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science New Independent Research Reveals that Masitinib Has Direct Anti-Viral Activity Against the SARS-CoV-2 Virus in Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen to Discontinue Pimodivir Influenza Development Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pimodivir","moa":"PB2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"University of Chicago Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U Chicago Medicine Begins Clinical Trial Testing the Efficacy of Antibody Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Chicago Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Chicago Medicine \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NBIb-1817","moa":"Aromatic-L-amino-acid decarboxylase","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"JanOne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janone Confirms Stability Data of JAN101 Development Batch and Prepares for Commercial GMP Production to Support the Upcoming Pad and Potential Covid-19 Clinical Trials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ N.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Alkahest","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$146.0 million","upfrontCash":"Undisclosed","newsHeadline":"Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Plasma-based therapies","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Alkahest","amount2":0.14999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Alkahest \/ Grifols","highestDevelopmentStatusID":"2","companyTruncated":"Alkahest \/.."},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"Enesi Pharma to Develop Thermostable Solid Dose DNA Vaccine Targeting Zika Virus Under New Partnership with the University of Adelaide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Adelaide","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Transcutaneous","sponsorNew":"University of Adelaide \/ Enesi Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","amount":"$232.0 million","upfrontCash":"$20.0 million","newsHeadline":"Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Gaboxadol","moa":"GABA A receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ovid Therapeutics","amount2":0.23000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Ovid Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Taw Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ema Begins Review of Taw Pharma's Dexamethasone Taw for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Taw Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taw Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Taw Pharma.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Safety Monitoring Board Recommends Continuation of Remestemcel-L Phase 3 Trial in COVID-19 Patients With ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lexicon Pharmaceuticals Commences Patient Dosing in Relief-DPN-1 Phase 2 Clinical Study of LX9211 for Diabetic Peripheral Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LX9211","moa":"AAK-1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Discontinues Development of BI 467335 for Diabetic Retinopathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 1467335","moa":"AOC3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis\u2019 phase III IRIDIUM study shows high-dose once-daily Enerzair Breezhaler reduces severe asthma exacerbation rates","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Melior Pharmaceuticals Awarded Grant for Advancing Pulmonary Therapeutic in COVID-19 Phase 2 Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Tolimidone","moa":"Lyn kinase","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Melior Pharmaceuticals \/ Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Melior Pha.."},{"orgOrder":0,"company":"Viralgen","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"AXO-AAV-GM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Viralgen","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viralgen \/ Axovant Gene Therapie","highestDevelopmentStatusID":"7","companyTruncated":"Viralgen \/.."},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"China National Biotech Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Croma Establishes New Joint Venture in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Croma-Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Gel Implant","sponsorNew":"Croma-Pharma \/ China National Biotech Group","highestDevelopmentStatusID":"12","companyTruncated":"Croma-Phar.."},{"orgOrder":0,"company":"PharmaJet","sponsor":"Genexine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"International Pharmaceutical Development Consortium to Partner With PharmaJet for Delivery of COVID-19 DNA Vaccine, GX-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"GX-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"PharmaJet","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"PharmaJet \/ Genexine","highestDevelopmentStatusID":"7","companyTruncated":"PharmaJet .."},{"orgOrder":0,"company":"Pascal Biosciences","sponsor":"SORSE Technology","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Biotech Company Pascal Biosciences and SORSE Technology Announce Partnership for Cannabinoid Drug Development and Cancer Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Cannabinoid-based therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pascal Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pascal Biosciences \/ SORSE Technology","highestDevelopmentStatusID":"6","companyTruncated":"Pascal Bio.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"8","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"BioNTech","sponsor":"German Federal Ministry of Education and Research","pharmaFlowCategory":"D","amount":"$438.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioNTech to Receive up to \u20ac375M in Funding from German Federal Ministry of Education and Research to Support BNT162","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0.44,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.44,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ German Federal Ministry of Education and Research","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RDIF and Dr. Reddy\u2019s to Cooperate on Clinical Trials and Supply of 100 million Doses of Sputnik V Vaccine to India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Russian Direct Investment Fund","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Russian Direct Investment Fund \/ Dr. Reddy\u2019s Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Russian Di.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"BB Pureos Bioventures","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of $64 million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"ICT01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ BB Pureos Bioventures","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Systems Oncology","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$370.0 million","upfrontCash":"$25.0 million","newsHeadline":"Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ErSO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Systems Oncology","amount2":0.37,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.37,"dosageForm":"Oral","sponsorNew":"Systems Oncology \/ Bayer Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"Systems On.."},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elicio Therapeutics and Moffitt Collaborate to Study AMP-CD19 in Combination with CD19 CART Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AMP-CD19","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elicio Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Elicio Therapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Elicio The.."},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Novo Ventures","pharmaFlowCategory":"D","amount":"$83.0 million","upfrontCash":"Undisclosed","newsHeadline":"LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"V\u03b39V\u03b42 T cells based antibodies","moa":"5 Gamma 9V Delta 2 T Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lava Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Lava Therapeutics \/ Novo Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Lava Thera.."},{"orgOrder":0,"company":"World Health Organization","sponsor":"Japanese Government","pharmaFlowCategory":"D","amount":"$165.0 million","upfrontCash":"Undisclosed","newsHeadline":"Japan Commits $165 Million to WHO's Global Coronavirus Vaccine Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0.17000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"World Health Organization \/ Japanese Government","highestDevelopmentStatusID":"1","companyTruncated":"World Heal.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"$25.0 million","newsHeadline":"Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"mRNA Therapeutics","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Moderna Therapeutics","amount2":0.42999999999999999,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$455.0 million","upfrontCash":"$75.0 million","newsHeadline":"Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"LNP based mRNA Therapeutics","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Moderna Therapeutics","amount2":0.46000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.46000000000000002,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Vertex","highestDevelopmentStatusID":"2","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Levoketoconazole","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Strongbrid.."},{"orgOrder":0,"company":"Wigen Biomedicine Technology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","amount":"$69.2 million","upfrontCash":"$5.2 million","newsHeadline":"Junshi Biosciences and Wigen Biomedicine Enter Global Development and Commercialization Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"WJ1075","moa":"XPO1","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wigen Biomedicine Technology","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Wigen Biomedicine Technology \/ Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Wigen Biom.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Corza","pharmaFlowCategory":"D","amount":"$427.0 million","upfrontCash":"427.0 million","newsHeadline":"Takeda to Divest TachoSil\u00ae to Corza Health for \u20ac350 Million","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Divestment","leadProduct":"Human Fibrinogen","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.42999999999999999,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"Patch","sponsorNew":"Takeda Pharmaceutical \/ Corza","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$562.0 million","upfrontCash":"$562.0 million","newsHeadline":"Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","year":"2020","type":"Divestment","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.56000000000000005,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.56000000000000005,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"INmune Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"Undisclosed","newsHeadline":"INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"INmune Bio \/ National Institute of Health","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Children\u2019s Oncology Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics Announces Collaboration with Children\u2019s Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Children\u2019s Oncology Group","highestDevelopmentStatusID":"12","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Dogma Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca Acquires Dogma Therapeutics\u2019 PCSK9 Inhibitor Programme","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Dogma Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dogma Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Dogma Ther.."},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"$74.0 million","upfrontCash":"$27.0 million","newsHeadline":"Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RZL 012","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ Fosun Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Raziel The.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Baupost Group","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Finch Therapeutics Announces $90 Million Financing to Advance Pipeline of Investigational Oral Microbiome Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series D Financing","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Baupost Group","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Mirati Therapeutics Announce Clinical Collaboration to Study BI1701963","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"BI 1701963","moa":"SOS1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mirati Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Synthekine","sponsor":"Canaan Partners","pharmaFlowCategory":"D","amount":"$82.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"STK-012","moa":"Interleukin-2 partial","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Synthekine \/ Canaan Partners","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine.."},{"orgOrder":0,"company":"Proniras","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$12.3 million","upfrontCash":"Undisclosed","newsHeadline":"Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Tezampanel","moa":"Glutamate receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Proniras","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Proniras \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"1","companyTruncated":"Proniras \/.."},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Graphite Bio Launches with $45 Million Series A Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Graphite Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Graphite B.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech to Acquire GMP Manufacturing Site of Novartis to Expand COVID-19 Vaccine Production Capacity in First Half 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"LY-CoV-555","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Amgen","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Servier","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and Servier Expand CART Oncology Development Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"CAR T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Precision BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Servier","highestDevelopmentStatusID":"1","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Huntington Study Group","sponsor":"Prilenia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Huntington Study Group Announces a Partnership with Prilenia Therapeutics to Conduct a Global Phase 3 Clinical Study of Pridopidine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Huntington Study Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Huntington Study Group \/ Prilenia Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Huntington.."},{"orgOrder":0,"company":"Humanigen","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol \u201cHGEN\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0.070000000000000007,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"XWPharma","sponsor":"Panacea Venture","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"XWPharma Announces $40 Million Financing and Appoints Leonard Blum as Chief Executive Officer","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"XW10172","moa":"GABA B receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I","graph3":"XWPharma","amount2":0.040000000000000001,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"XWPharma \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"XWPharma \/.."},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne\u00aeCDx and FoundationOne\u00aeLiquid CDx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Mobocertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Foundation Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Foundation Medicine \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Foundation.."},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Adimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JHL Biotech to Develop and Manufacture GMP-grade Antigen for Taiwan\u2019s Leading Covid-19 Vaccine Produced by Adimmune","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Eden Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eden Biologics \/ Adimmune","highestDevelopmentStatusID":"1","companyTruncated":"Eden Biolo.."},{"orgOrder":0,"company":"Sanofi","sponsor":"European Union","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK Will Provide Up To 300 Million Doses of COVID-19 Vaccine to the European Union","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Adjuvanted COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ European Union","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ E.."},{"orgOrder":0,"company":"Grunenthal","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Closes a Deal with Teva to Market Teriparatide","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Grunenthal","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grunenthal \/ Teva Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal.."},{"orgOrder":0,"company":"Valneva","sponsor":"U.K. Government","pharmaFlowCategory":"D","amount":"$1,611.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Valneva","amount2":1.6100000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.6100000000000001,"dosageForm":"","sponsorNew":"Valneva \/ U.K. Government","highestDevelopmentStatusID":"4","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"List Biological Laboratories","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Scales up Manufacturing of AP-003 (Interferon Alpha 2b) to Prepare for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"AP-003","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"List Biological Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"List Biological Laboratories \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"List Biolo.."},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Medical Research Future Fund","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Australia Invests $6M in New COVID-19 Vaccine Projects","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Protein vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Melbourne","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Melbourne \/ Medical Research Future Fund","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Inflazome","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$441.9 million","newsHeadline":"Inflazome Announces its Acquisition by Roche","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Inzomelid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Inflazome","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Roche","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome .."},{"orgOrder":0,"company":"Allegro Ophthalmics","sponsor":"Bausch Health","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$10.0 million","newsHeadline":"Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Risuteganib","moa":"Integrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allegro Ophthalmics","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"Allegro Ophthalmics \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Allegro Op.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"$42.2 million","upfrontCash":"Undisclosed","newsHeadline":"VBI Vaccines Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Agreement","leadProduct":"VBI-2900","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VBI Vaccines","amount2":0.040000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VBI Vaccines \/ Government of Canada","highestDevelopmentStatusID":"4","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","amount":"$53.4 million","upfrontCash":"Undisclosed","newsHeadline":"Immune Regulation Limited raises \u00a340.6 million \/ $53.4 million Series B Equity Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"IRL201805","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Revolo Biotherapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Revolo Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Revolo Bio.."},{"orgOrder":0,"company":"Novellus","sponsor":"Pontifax","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novellus Closes $57M Series C Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"Plixorafenib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novellus","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Novellus \/ Pontifax","highestDevelopmentStatusID":"7","companyTruncated":"Novellus \/.."},{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bristol Myers Squibb Completes Acquisition of Forbius","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ .."},{"orgOrder":0,"company":"City of Hope","sponsor":"Chimeric","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CART Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"CLTX-CAR T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"City of Hope \/ Chimeric","highestDevelopmentStatusID":"6","companyTruncated":"City of Ho.."},{"orgOrder":0,"company":"JanOne","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JanOne Announces Strategic Plan to Divest its Legacy Businesses","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Divestment","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"JanOne","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"JanOne \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JanOne \/ U.."},{"orgOrder":0,"company":"Enzolytics","sponsor":"BioClonetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzolytics, Inc. Announces Execution of Letter of Intent with BioClonetics Immunotherapeutics, Inc","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Merger","leadProduct":"Anti-HIV recombinant monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enzolytics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzolytics \/ BioClonetics","highestDevelopmentStatusID":"1","companyTruncated":"Enzolytics.."},{"orgOrder":0,"company":"Histogen","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"HST-003","moa":"Hyaline cartilage","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$375.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0.38,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.38,"dosageForm":"","sponsorNew":"Scenic Biotech \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Bio.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"J&J Unit to Start Mid-Stage Covid-19 Vaccine Trials in Spain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2.S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Vector virology institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia Completes Early Trials of Second Potential Covid-19 Vaccine - IFAX","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EpiVacCorona","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vector virology institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vector virology institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vector vir.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laboratory Testing of Brilacidin for COVID-19 in Combination with Remdesivir Reduces Viral Load by Nearly 100 Percent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tivozanib","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Aveo Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aveo Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aveo Oncol.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ\u00ae Gene Therapy for Leber Hereditary Optic Neuropathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Curevo Vaccine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine for Shingles CRV-101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CRV-101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Curevo Vaccine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Curevo Vaccine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Curevo Vac.."},{"orgOrder":0,"company":"Taiho Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taiho Oncology to Present Futibatinib (TAS-120) Data in Advanced Intrahepatic Cholangiocarcinoma at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Futibatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Taiho Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taiho Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Onco.."},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arbutus Announces AB-729 90 mg Single-Dose in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AB-729","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arbutus Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arbutus Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arbutus Bi.."},{"orgOrder":0,"company":"Tyme Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TYME\u2019s Phase II Prostate Cancer Study of SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published in Investigational New Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Tyme Technologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyme Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyme Techn.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates Bristol Myers Squibb\u2019s Type II Variation Application for Opdivo Plus Yervoy for First-line Treatment of Malignant Pleural Mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead\u2019s Magrolimab Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Azacitidine","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces FDA Acceptance for Filing of its NDA of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Filovirus vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"VE-PTP","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Galecto","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galecto\u2019s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific Conferences","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GB1211","moa":"Galectin-3","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Galecto","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Hard Capsule","sponsorNew":"Galecto \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab for Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for BPX-01 and BPX-04","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Timber Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Timber Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Timber Pha.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Investor Day Features Significant Number of Pipeline Advances for Covid-19 Programs and Across Numerous Therapeutic Areas","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PF-07304814","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Designation to Jardiance\u00ae (empagliflozin) to Improve Outcomes following a Heart Attack","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Canadian Cancer Society","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Trial Tests Common Diabetes Drug to Enhance Brain Function in Childhood Brain Cancer Survivors","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Metformin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Canadian Cancer Society","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canadian Cancer Society \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"10","companyTruncated":"Canadian C.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Plus Therapeutics Receives Fast Track Designation from FDA for Its Novel Glioblastoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcifediol","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Healt.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Omega-3 pentaenoic acid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Announces Topline Results of Voriconazole Inhalation Powder Phase 1 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Approves Label Update for HYQVIA\u00ae Expanding its Use to a Broader Group of Patients with Secondary Immunodeficiencies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Immunoglobulin G 285-292","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Corino Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corino Therapeutics Announces Presentation of New Clinical Research Finding at the XVII International Symposium on Amyloidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolcapone","moa":"COMT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Corino Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corino Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corino The.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Launches Novel Antibiotic Fetcroja in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Begins Patient Dosing in Phase 2 Study of Patritumab Deruxtecan to Treat Advanced\/Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute Gets DCGI Nod to Resume Clinical Trial of Oxford AstraZeneca COVID-19 Vaccine Candidate in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Arimoclomol for Niemann-Pick Disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Announces Proof of Concept Data for Neutralizing Antibody LY-CoV555 in the COVID-19 Outpatient Setting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Biontech Announce Data from Preclinical Studies of mRNA-Based Vaccine Candidate Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Institute of Cancer Research's Test if Combining Two Precision Medicines Can Treat Drug-Resistant Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Granted Pediatric Disease Designation for OXi-4503","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Combretastatin A1 Diphosphate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mateon Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mateon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mateon The.."},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Trials Evaluating ARQ-151 as a Treatment for Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Bi.."},{"orgOrder":0,"company":"Theris Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theris Medical Launches Patient Enrollment for \u201cOrphan Drug\u201d Clinical Trial to Help African-Americans Suffering from Sickle Cell Ulcers","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Deferoxamine Mesylate","moa":"Fe","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Theris Medical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Theris Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Theris Med.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics Announces Publication of Results of Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Transgene","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipapkinogen sovacivec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Transgene \/ Merck KGaA","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle AVM Biotechnology Announces Second IND for AVM0703","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Genelux","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genelux to Present Data from Phase 2 Trial of Olvi-Vec in Heavily Pre-treated Platinum-Resistant\/Refractory Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Genelux \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Highlights Start of Recruitment Incorporating Ampligen in the Treatment of Cancer Patients with Mild or Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Data and Safety Monitoring Board Recommends the Continuation of Multinational 2b\/3 Human Study of Ifenprodil for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Unveils Clinical Follow-Up Results of 'Abincio'","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen To Showcase Data From Oncology Pipeline During ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verastem Oncology Announces Presentation of Updated Phase 1\/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-6766","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Verastem Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Verastem Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IO-202","moa":"LILRB4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Presents Promising Interim Results from Ongoing Phase 1b\/2 Trial of Cavrotolimod at Virtual KOL Event Today","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ARO-AAT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexpramipexole","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Knopp Biosciences LLC","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Knopp Biosciences LLC \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Provides Update on the FDA Review of EM-100","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HOOKIPA Pharma\u2019s LCMV-based Immunotherapy for HPV16+ Cancers Demonstrates High Immunogenicity, According to Peer Reviewed Article","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HB-201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hookipa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Hookipa Ph.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pitt Scientists Discover Tiny Antibody Component That is Highly Effective in Preventing and Treating SARS-CoV-2 Infection in Animal Models","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ab8","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PBFT02","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Announces Filing of U.S. Provisional Patent Application for the Use of AS1411 to Prevent Viral Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Etrasimod","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYR Pharmaceuticals launches HEPCLUDEX\u00ae in Germany, France and Austria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bulevirtide Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"MYR Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MYR Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MYR Pharma.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Support Strong Clinical Profile of Vitrakvi\u00ae for Adult and Pediatric Patients with TRK Fusion Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Larotrectinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin\u00ae at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOXXON Presents Clinical Data From Phase 1\/2 NOX-A12 \/ Keytruda\u00ae Combination Trial in Colorectal and Pancreatic Cancer at the ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Presents Data from Rebastinib at the European Society for Medical Oncology (ESMO) Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rebastinib","moa":"ABL1 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Presents Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine in Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Patent and Trademark Office Allows Reven\u2019s Patent Application to Issue as a New Patent","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Phar.."},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Successfully Completes Phase 1 Study in Lead Program for Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxybutynin","moa":"Muscarinic M2 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apnimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ .."},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Patient Recruitment Starts for the International PRO-SID study Evaluating Panzyga\u00ae for Primary Prophylaxis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Immune globulin, human - ifas","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Octapharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma.."},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBI Vaccines Announces Biomarker Data From VBI-1901 Phase 1\/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VBI-1901","moa":"GB\/pp65 antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VBI Vaccines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VBI Vaccines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VBI Vaccin.."},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX\u00ae (furosemide) for subcutaneous administration","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmace.."},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb\u2019s Yervoy\u00ae in a Phase 2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Intensity .."},{"orgOrder":0,"company":"Virometix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virometix Announces Completion of Initial Vaccination of the First Dose Cohort in Phase 1 Study with V-306","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"V-306","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Virometix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virometix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Virometix .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Receives Korean MFDS Approval to Initiate Phase II\/III Pivotal Trial of CT-P59","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CLN-081","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cullinan Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cullinan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cullinan T.."},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ryvu Begins Patient Dosing in Europe for Phase I\/II DIAMOND-01 Trial of SEL24\/MEN1703 to Treat AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MEN1703","moa":"PIM","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini Group","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Thera.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 Neutralizing Antibody in COVID-19 Positive Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"STI-1499","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brainstorm Announces Grant of a New Japanese Patent for NurOwn\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Laboratories Launches Over-the-Counter Eye Allergy Drop, the Store-Brand\nEquivalent of Pataday\u00ae, in US","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olopatadine Hydrochloride","moa":"5-HT1","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna to Seek Limited Emergency Use of Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rigel Announces NIH\/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac\u2019s Coronavac\u2122, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I\/II Clinical Trial in Adolescents and Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray for COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Atossa Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Atossa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atossa The.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Hepion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rencofilstat","moa":"CyPA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hepion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Soft Gel Capsule","sponsorNew":"Hepion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hepion Pha.."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"GreenLight Clinical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ GreenLight Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"RhoVac AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Sweden","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RV001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RhoVac AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RhoVac AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RhoVac AB .."},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210\/TJ210 in Patients with Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MorphoSys \/ I-Mab","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys .."},{"orgOrder":0,"company":"Menarini","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MEN1611","moa":"PI3K","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Menarini","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Menarini \/.."},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AMTX-100","moa":"SRTFs","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amytrx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx The.."},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the ERS International Congress 2020","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the AAN Science Committee as Featured Presentation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Cebina","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEBINA Reports Positive Findings on the Potency of Azelastine, a Widely Used Anti-Histamine, as Anti-Covid-19 Approach","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Azelastine Hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cebina","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cebina \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cebina \/ N.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces the FDA Clearance of Investigational New Drug Application for ALVR109 for the Treatment of High-Risk COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALVR109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Oncology Presents Data Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Presents Preclinical Data for BLU-945 Showing Robust Anti-Tumor Activity for Resistant EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BLU-945","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"eXIthera Announces Publication of EP-7041 Data Demonstrating Safe Antithrombotic Activity in ECMO","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EP-7041","moa":"Factor XIa","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera P.."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze\u00ae In Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Halozyme Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artax Biopharma Announces Issuance of U.S. Composition of Matter Patent for Autoimmune Disease Program AX-158","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AX-158","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Artax Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artax Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Artax Biop.."},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Biopharmaceuticals Presents 2-Year Landmark Data from Combination Therapy Trial of PV-10\u00ae and KEYTRUDA\u00ae for Checkpoint-Na\u00efve Advanced Cutaneous Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rose Bengal Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rilzabrutinib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Presents Efficacy and Safety Results of its CLEPSIDRA Trial with Iadademstat in ED-SCLC Patients at ESMO-2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Iadademstat","moa":"LSD1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at European Association for the Study of Diabetes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Grapiprant","moa":"Aldose reductase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces GALACTIC-HF Accepted for Presentation In Late Breaking Clinical Trial Session At AHA Scientific Sessions","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Autolus Therapeutics Presents Additional Data on AUTO3 in DLBCL During the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AUTO3","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Th.."},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen's Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline\u00ae Autogel\u00ae Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 months","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanreotide Acetate","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ No.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Patritumab Deruxtecan","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Shows Interim Results from Registration-Enabling Trial of Cosibelimab in Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cosibelimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Checkpoint Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkpoint Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Checkpoint.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Pivotal Data for Libtayo\u00ae (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"CEL-SCI","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CEL-4000","moa":"Il-17 alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"CEL-SCI","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CEL-SCI \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"CEL-SCI \/ .."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi's Orfadin\u00ae (nitisinone) Receives Positive Opinion from CHMP for Treatment of AKU","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nitisinone","moa":"HPDD","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"MEDIMETRIKS PHARMS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medimetriks' MM36 (difamilast) Atopic Dermatitis Development Program Streamlined Following FDA Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Difamilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"MEDIMETRIKS PHARMS","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"MEDIMETRIKS PHARMS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"MEDIMETRIK.."},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spectrum Pharmaceuticals Presents Results in HER2 Exon 20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum P.."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Results from Evaluation of Cytisinicline Vs Chantix\u00ae in 5-HT3 Receptor Binding Assay Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces Results from Phase 1b Dose Escalation Study of PT-112 Plus Avelumab in Patients with Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Merck KGaA","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sitravatinib","moa":"TYRO3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Oncologie","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bavituximab","moa":"Phosphatidylserine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oncologie","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncologie \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncologie .."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Status to Junshi\u2019s Toripalimab to Treat Soft Tissue Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline Receives CHMP Positive Opinion Recommending Approval of Zejula (niraparib) as First-Line Monotherapy Maintenance Treatment for Women with Platinum-Responsive Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALKS 4230","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Deciphera Presents Data from QINLOCK Program in Patients with Gastrointestinal Stromal Tumor at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera .."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensei Biotherapeutics Reports Early Data from Phase 1\/2 Clinical Trial of SNS-301 Pembrolizumab Combo in Advanced Head and Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sensei Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for Recurrent\/Metastatic Adenoid Cystic Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AL101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Agenus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent\/Metastatic Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Balstilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Agenus \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ N.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Reports Improving Results from INSIGHT-004 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftilagimod Alpha","moa":"APC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IO102","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"IO Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IO Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IO Biotech.."},{"orgOrder":0,"company":"BeiGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BeiGene Presents Data on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeiGene \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Plus Yervoy Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab for the Treatment of Advanced Squamous Cell Carcinoma of Anal Canal","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Receives Positive CHMP Opinion for Tecentriq in Combination with Avastin for the Treatment of Most Common form of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven\u00ae at Esmo Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eribulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedic's Trodelvy\u2122 Encouraging Early-Stage Clinical Results","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira Receives Positive CHMP Opinion for EXPAREL\u00ae for Postsurgical Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pacira Bio.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Highlight Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Highlight Therapeutics Announces Second Collaboration with MSD to Evaluate Combination of BO-112 and Keytruda\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"BO-112","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Merck & Co \/ Highlight Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$1,030.0 million","upfrontCash":"$30.0 million","newsHeadline":"Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Recursion Pharma","amount2":1.03,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":1.03,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Bayer","highestDevelopmentStatusID":"2","companyTruncated":"Recursion .."},{"orgOrder":0,"company":"Valneva","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"VLA2001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DB-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Direct Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Direct Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Direct Bio.."},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seneca Biopharma, Inc. Announces Completion of Phase II Clinical Study in China for the Treatment of Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NSI-566","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intracranial Injection","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade B.."},{"orgOrder":0,"company":"SanBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SanBio Announces Additional Results of the US-Based Phase 2b Clinical Trial of Regenerative Cell Medicine SB623 for Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SB623","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"SanBio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ N.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC42","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Government of Australia","pharmaFlowCategory":"D","amount":"$1,700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Australia Secures Onshore Manufacturing Deal for Two Covid-19 Vaccines Developed By Oxford\/AstraZeneca and University of Queensland\/CSL","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":1.7,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":1.7,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Government of Australia","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Exosome Biotech Codiak Bio Sciences Refiles for a $100 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"exoSTING","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Codiak BioSciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CanSino Phase 3 Covid-19 Vaccine Trialinn Pakistan Expected to Begin This Month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad5-nCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CanSino Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Bi.."},{"orgOrder":0,"company":"Abigail Wexner Research Institute","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FDA Approves Abigail Wexner Research Institute's IND for A Covid-19 Clinical Trial with Off-the-Shelf K-NK Cells Using Kiadis\u2019 Platforms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"K-NK-cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Abigail Wexner Research Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abigail Wexner Research Institute \/ Kiadis","highestDevelopmentStatusID":"5","companyTruncated":"Abigail We.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Approves Safety Label Update for Novartis Beovu\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Data Show Early Treatment with Mayzent\u00ae Show Benefits in Cognitive Performance in Patients with Secondary Progressive MS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Siponimod fumarate","moa":"S1PR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Janssen Pharmaceutical's TREMFYA\u00ae, a First-In-Class Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"National Institute of Immunology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NII\u2019s Covid-19 Vaccine Candidate Exhibits Positive Results in Immunogenicity Study on Mice","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institute of Immunology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institute of Immunology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Foscarbidopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PANTHERx\u00ae Rare Pharmacy Selected by Blueprint Medicines to Distribute GAVRETO\u2122 for Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PANTHERx Rare Pharmacy","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"PANTHERx Rare Pharmacy \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"PANTHERx R.."},{"orgOrder":0,"company":"Taurus Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"$5.0 million","newsHeadline":"Ligand Expands Omniab\u00ae Antibody Discovery Platform Through the Acquisitions of Taurus Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Mono- and Bispecific human antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Taurus Biosciences","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Taurus Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Taurus Bio.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Primary Endpoint Achieved with Ziritaxestat in Novesa Trial in Systemic Sclerosis Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Xcella Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ligand Expands Omni AB\u00ae Antibody Discovery Platform Through the Acquisitions of XCella Biosciences and Taurus Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Mono- and Bispecific human antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcella Biosciences","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Xcella Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Xcella Bio.."},{"orgOrder":0,"company":"Valneva","sponsor":"US Government","pharmaFlowCategory":"D","amount":"$166.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valneva Announces New Ixiaro\u00ae Supply Contract with the US Government Worth up to $166 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Inactivated aluminum-adjuvanted JE vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Valneva","amount2":0.17000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ US Government","highestDevelopmentStatusID":"12","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics to Present Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at 2020 ESMO Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"XMT-1536","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Sanofi Ventures","pharmaFlowCategory":"D","amount":"$77.5 million","upfrontCash":"Undisclosed","newsHeadline":"Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1\/1b Clinical Trial Of EP547","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"EP547","moa":"MRGPRX4","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0.080000000000000002,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Escient Pharmaceuticals \/ Sanofi Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Escient Ph.."},{"orgOrder":0,"company":"SPARC","sponsor":"Tripoint Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sparc Licenses Commercialization Rights of Elepsia Drug to Tripoint Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Levetiracetam","moa":"SV2A","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SPARC","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SPARC \/ Tripoint Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"SPARC \/ Tr.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"OnKure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Binimetinib","moa":"Class I HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ OnKure","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"T-knife","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"T-cell receptor-based cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"T-knife","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"T-knife \/ Catalent","highestDevelopmentStatusID":"1","companyTruncated":"T-knife \/ .."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Precision Oncology Biotech PMV Pharmaceuticals Sets Terms for $125 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"PC14586","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0.13,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.13,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Goldman Sachs","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","amount":"$766.4 million","upfrontCash":"Undisclosed","newsHeadline":"Zai Lab Announces Pricing of Hong Kong Secondary Listing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0.77000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.77000000000000002,"dosageForm":"Capsule","sponsorNew":"Zai Lab \/ J.P. Morgan Securities","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"Impilo Therapeutics","sponsor":"Cend Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cend Therapeutics Announces Acquisition of Impilo Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Impilo Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Impilo Therapeutics \/ Cend Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Impilo The.."},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"TARA-002","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Protara Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protara Therapeutics \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Protara Th.."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Stevanato Group","sponsor":"Bexson Biomedical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stevanato Group And Bexson Biomedical Announce Collaboration To Develop A Customized Wearable Ketamine Delivery Device","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Stevanato Group","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Stevanato Group \/ Bexson Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Stevanato .."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","amount":"$900.0 million","upfrontCash":"$150.0 million","newsHeadline":"MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"MacroGenics","amount2":0.90000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.90000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Expands Partnership with Samsung Biologics for PMC-403","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"PMC-403","moa":"Tie2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100\u2122 and Selection of Commercial Partners","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Relief Therapeutics \/ NeuroRx","highestDevelopmentStatusID":"9","companyTruncated":"Relief The.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision BioSciences and SpringWorks Therapeutics Collaborate to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SpringWorks Therapeutics \/ Precision BioSciences","highestDevelopmentStatusID":"1","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Canadian Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Canadian Government","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"SymBio Pharmaceuticals","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"$12.5 million","newsHeadline":"Eagle Pharmaceuticals\u2019 Licensing Partner, SymBio, Gets Approval of TREAKISYM Ready-To-Dilute Formulation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Liquid","sponsorNew":"Eagle Pharmaceuticals \/ SymBio Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"U.S. Army","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Awarded U.S. Army Contract for DSUVIA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Sufentanil Citrate","moa":"Mu opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"AcelRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"AcelRx Pharmaceuticals \/ U.S. Army","highestDevelopmentStatusID":"12","companyTruncated":"AcelRx Pha.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"KAN-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Anokion SA \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Beyond Celiac","sponsor":"Provention Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beyond Celiac Partners with Provention Bio on Phase 2 Clinical Trial for Promising Celiac Disease Therapeutic","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Beyond Celiac","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Beyond Celiac \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Beyond Cel.."},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Biotech Inks Licensing Deal with Washington University School of Medicine to advance COVID-19 Intranasal Vaccine Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Covid 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Washington University School of Medicine \/ Bharat Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Washington.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Spur Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Freeline Announces Supply Agreement for Haemophilia B Program With Thermo Fisher Scientific","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"FLT180a","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Thermo Fisher Scientific \/ Freeline Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Thermo Fisher Scientific \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fis.."},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3-kinase class I","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farbe.."},{"orgOrder":0,"company":"Fox Chase Cancer Center","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Announces Inks Pact with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Fox Chase Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fox Chase Cancer Center \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Fox Chase .."},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"STMC-103H","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Siolta Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Siolta Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Siolta The.."},{"orgOrder":0,"company":"Nutcracker Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nutcracker Therapeutics Radies $60M Series B Financing for an mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"mRNA therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nutcracker Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Nutcracker Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Nutcracker.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Vivet Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet\u2019s Investigational Gene Therapy for Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"VTX-801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Vivet Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Fenfluramine Hydrochloride","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0.20000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.20000000000000001,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"IAG, Image Analysis Group","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IAG, Image Analysis Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IAG, Image Analysis Group \/ CNS Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"IAG, Image.."},{"orgOrder":0,"company":"Sixfold Bioscience","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sixfold Bioscience and Medicines Discovery Catapult Awarded Innovate Uk Grant to Pursue Ground-Breaking Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"siRNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sixfold Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sixfold Bioscience \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Sixfold Bi.."},{"orgOrder":0,"company":"Hovione","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury\u00ae for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Modified Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hovione","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hovione \/ Ligand","highestDevelopmentStatusID":"12","companyTruncated":"Hovione \/ .."},{"orgOrder":0,"company":"Immetas Therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immetas Therapeutics Announces Series A Financing for its Research on Inflammation Pathways in Aging and Develop Anti-Inflammatory Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Bi-specific antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immetas Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Immetas Therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Immetas Th.."},{"orgOrder":0,"company":"ImmVira","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"oHSV-1","moa":"IL 12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ .."},{"orgOrder":0,"company":"InSysBio","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InSys Bio Announces Its Collaboration with Genmab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"GEN1042","moa":"CD40","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InSysBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"InSysBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"InSysBio \/.."},{"orgOrder":0,"company":"KYAN Therapeutics","sponsor":"Georgetown University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"KYAN-001","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KYAN Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KYAN Therapeutics \/ Georgetown University","highestDevelopmentStatusID":"4","companyTruncated":"KYAN Thera.."},{"orgOrder":0,"company":"Libra Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"Libra Therapeutics Launches with $29 Million Series A to Develop Novel Therapeutics for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Libra Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Libra Therapeutics \/ Boehringer Ingelheim Venture Fund","highestDevelopmentStatusID":"2","companyTruncated":"Libra Ther.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Kanaph Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Signs Strategic Partnership with Kanaph Therapeutics to Develop Treatment for Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"KNP-301","moa":"C3b","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Biologics \/ Kanaph Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"UMass Medical School","sponsor":"Johns Hopkins University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"UMass Medical School and Johns Hopkins Team up For COVID Plasma Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Anti- SARS-CoV-2 Plasma","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"UMass Medical School","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UMass Medical School \/ Johns Hopkins University","highestDevelopmentStatusID":"8","companyTruncated":"UMass Medi.."},{"orgOrder":0,"company":"GSK","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK Sign Agreements with the Government of Canada to Supply up To 72 Million Doses of Adjuvanted Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Adjuvanted COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Government of Canada","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Gove.."},{"orgOrder":0,"company":"BioVie","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioVie Announces Closing of Public Offering of Common Stock","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Terlipressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"BioVie","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.02,"dosageForm":"Continuous Infusion","sponsorNew":"BioVie \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"BioVie \/ T.."},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive Promotions","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"SBT6050","moa":"TLR8","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Silverback Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"6","companyTruncated":"Silverback.."},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Permira Funds","pharmaFlowCategory":"D","amount":"$1,880.0 million","upfrontCash":"Undisclosed","newsHeadline":"Permira Funds to Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neuraxpharm","amount2":1.8799999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.8799999999999999,"dosageForm":"Oral prefilled syringe","sponsorNew":"Neuraxpharm \/ Permira Funds","highestDevelopmentStatusID":"12","companyTruncated":"Neuraxphar.."},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas, University of Pittsburgh Enter Research Collaboration for Dry Age-Related Macular Degeneration Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA and Pfizer Expand Clinical Trial Collaboration to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Darovasertib","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ IDEAYA Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"USAMRDC","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lumen Bioscience Awarded Federal Grant to Rapidly Develop Nanobody-based Covid-19 Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Camelid antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lumen Bioscience","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lumen Bioscience \/ USAMRDC","highestDevelopmentStatusID":"4","companyTruncated":"Lumen Bios.."},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Jupiter Orphan Announces Federal Grant to ADVANCE JOTROL\u2122 to Phase I Clinical Trial for Alzheimer's","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Resveratrol","moa":"Angiogenesis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Or.."},{"orgOrder":0,"company":"AbCellera","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IgM antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ IGM Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Opthea Files for a $150 Million US IPO","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0.14999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ U.."},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics Sets Terms for $30 million IPO","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios The.."},{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GRAM Partners with Johnson & Johnson on Manufacturing in Fight Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grand River Aseptic Manufacturing","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Grand River Aseptic Manufacturing \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Grand Rive.."},{"orgOrder":0,"company":"Galecto","sponsor":"Soleus Capital","pharmaFlowCategory":"D","amount":"$64.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Seeds Portfolio Company Galecto Raises USD 64 Million to Accelerate Development of Clinical Pipeline","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"GB0139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0.059999999999999998,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Inhalation","sponsorNew":"Galecto \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"LB Pharmaceuticals Inc Secures $10.0 Million in Additional Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"N-methyl amisulpride","moa":"Dopamine","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmac.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics preparing $100M IPO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"ALG-010133","moa":"S-antigen transport","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aligos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"MyoKardia","pharmaFlowCategory":"D","amount":"$465.0 million","upfrontCash":"$12.5 million","newsHeadline":"MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Fulcrum Therapeutics","amount2":0.46999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"","sponsorNew":"Fulcrum Therapeutics \/ MyoKardia","highestDevelopmentStatusID":"2","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MyoKardia Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Public Offering","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb's Opdivo\u00ae and CABOMETYX\u00ae Combo Shows Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Presents Trial Data Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Amivantamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA\u00ae Plus LENVIMA\u00ae in Seven Different Tumor Types","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's Abemaciclib Improves OS In Combination With Tamoxifen In HR-Positive, HER2-Negative Metastatic Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Reports No Improvement In Survival With Avelumab Added To CRT In Locally Advanced SCCHN","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Merck","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy\u2122 in Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The Lancet Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lisinopril","moa":"ACE","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Yiling Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yiling Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yiling Pha.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MGD019","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Data From Full Phase 1 Cohort Of Investigational Sotorasib Published In New England Journal Of Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Shanghai SIMR Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai SIMR Biotechnology's First Patient Successfully Dosed with the Candidate Drug SR419 for Peripheral Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SR419","moa":"Ion channel","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Shanghai SIMR Biotechnology","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Shanghai SIMR Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai S.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Release Biomarker Results of TYVYT\u00ae, ALIMTA\u00aeand Platinum Chemotherapy Combo as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Jointly Release Phase 3 Results of TYVYT\u00ae, GEMZAR\u00aeand Platinum Chemotherapy Combo as First-Line Treatment for Squamous Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Receives CHMP Positive Opinion for New Advanced Formulation of ULTOMIRIS\u00ae (ravulizumab) with Significantly Reduced Infusion Time","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Selected to Present 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Totum-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Algiax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algiax Pharmaceuticals Enrolles First Patient in Phase IIa Multi-center Proof-of-Concept Study Evaluating AP-325 in Chronic Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AP-325","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Algiax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Algiax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Algiax Pha.."},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics Submits BLA to the U.S FDA for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Loncastuximab Tesirine","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"ADC Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ADC Therap.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb's Opdivo Shows Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Lynparza Recommended for Approval in the EU by CHMP for Brca-Mutated Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Olaparib","moa":"PARP 1\/2\/3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tagrisso Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Seagen","sponsor":"Genmab","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Metastatic Cervical Cancer at ESMO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tisotumab Vedotin","moa":"Microtubule protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravitreous","sponsorNew":"Seagen \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Seagen \/ G.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae Doubled Five-Year Survival Rate Versus Chemotherapy in Some Patients With Metastatic Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's ESMO Presentation Shows Libtayo\u00ae Monotherapy Increases Overall Survival in First-Line Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IH201","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"XBiotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"XBiotech \/.."},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provectus Biopharmaceuticals Highlights Stage IV M1C Patient Outcome from Combination Therapy Trial of PV-10\u00ae and KEYTRUDA\u00ae for Checkpoint-Na\u00efve Advanced Cutaneous Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rose Bengal Sodium","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Provectus .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Gets Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Beximco Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Flecainide","moa":"SCN5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Beximco Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beximco Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Beximco Ph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gene Signatures and Tumour Microenvironments were Identified that Associate with Nivolumab Outcomes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Calcilytix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma\u2019s Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1 (ADH1)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Encaleret","moa":"CaSR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calcilytix Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Calcilytix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calcilytix.."},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Agios Reports Final OS Data from Phase 3 ClarIDHy Study of TIBSOVO\u00ae in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivosidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Agios Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Agios Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Agios Phar.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the at the EORTC-NCI-AACR Symposium 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyclacel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclacel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyclacel P.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of Wisconsin-Madison","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revive Therapeutics \/ University of Wisconsin-Madison","highestDevelopmentStatusID":"6","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H\/dMMR Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Envafolimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"TRACON Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"HanX Biopharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Narazaciclib","moa":"ARK5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Onconova Therapeutics \/ HanX Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Onconova T.."},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CRN04777","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics .."},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sojournix Announces Publication of Results from SJX-653 Proof-of-Mechanism Study in The Journal of Clinical Endocrinology & Metabolism","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SJX-653","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix .."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics and BeiGene Dosed First Patient in Study of DKN-01 and Tislelizumab Combo for Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"Homeostasis","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Provides Update on Progress on BLA for Ryplazim\u00ae(plasminogen)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Plasminogen","moa":"Plasminogen","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal Bi.."},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspartyl-alanyl-diketopiperazine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ampio Phar.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Presents Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed\/Refractory Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TK216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Launches Two Digital Inhalers in the U.S., AirDuo\u00ae Digihaler\u00ae (fluticasone propionate and salmeterol) Inhalation Powder","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Trevena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TRV027","moa":"AT1 receptor selective","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Trevena","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ .."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Reboxetine Mesylate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"GC Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GC Pharma Speeds Up Developing Covid-19 Plasma Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyper-immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GC Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GC Pharma .."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves INREBIC\u00ae (fedratinib), First New Treatment in Nearly a Decade for Patients Living with Myelofibrosis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fedratinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Butalbital, Acetaminophen, and Caffeine Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Butalbital","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Kisqali Receives Highest Rating of any CDK4\/6 Inhibitor on the ESMO Magnitude of Clinical Benefit Scale","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ribociclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"TherapeuticsMD","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Knight Therapeutics \/ TherapeuticsMD","highestDevelopmentStatusID":"12","companyTruncated":"Knight The.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo Sowed Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck\u2019s KEYTRUDA\u00ae Plus Chemotherapy Reduced Risk of Death by 27% as First-Line Treatment for Locally Advanced Esophageal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi\u00ae in NSCLC at the ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tedopi","moa":"Killer T-Cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Micreos Initiates Clinical Trial to Evaluate World\u2019s First Endolysin-Drug as a Therapy for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"XZ.700","moa":"Cell wall","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Micreos Human Health \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Hu.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society of Medical Oncology Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Berg Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BERG To Present Discovery\/Validation Of Biomarkers Associated With Survival In Pancreatic Ductal Adenocarcinoma Treated With BPM 31510-IV","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Nanosuspension for Intravenous Injection","sponsorNew":"Berg Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Healt.."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech\u2019s Phase III EMPACTA Study Showed Actemra Reduced Odds of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Seagen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Genetics and Astellas Announce PADCEV\u00ae (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Astellas","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ A.."},{"orgOrder":0,"company":"The Chumakov Federal Scientific Center","sponsor":"Vektor State Research Center of Virology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ministry of Health Allows Human Trials of Another Vaccine Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Whole-virion vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Chumakov Federal Scientific Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Chumakov Federal Scientific Center \/ Vektor State Research Center of Virology","highestDevelopmentStatusID":"1","companyTruncated":"The Chumak.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verzenio\u00ae Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Abemaciclib","moa":"CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb and Bluebird Bio Gets U.S. FDA Priority for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Idecabtagene vicleucel","moa":"B-Cell maturation antigen","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ bluebird bio","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Afimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Afimmune Initiates Epeleuton Phase IIb TRIAGE Study in Patients With High Triglycerides and Type 2 Diabetes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Epeleuton","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Afimmune","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Afimmune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Erasmus University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Erasmus University Medical Center","highestDevelopmentStatusID":"1","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces 50% Enrollment in Multinational 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Biology and Corpometria Institute Receive National IRB Approval to Study a Potential Breakthrough Therapy for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Proxalutamide","moa":"Androgen receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"AXIM Biotechnologies","sponsor":"Sapphire Biotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AXIM\u00ae Biotechnologies Gets Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SBI-183","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AXIM Biotechnologies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AXIM Biotechnologies \/ Sapphire Biotech","highestDevelopmentStatusID":"4","companyTruncated":"AXIM Biote.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer\u2019s Aflibercept Injection (EyleaTM) for Intravitreal use Receives DCGI Approval for Diabetic Macular Edema Indication","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio\u2019s Lenti Globin\u2122 for Sickle Cell Disease Gene Therapy (bb1111) Granted PRIME Designation by European Medicines Agency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"LentiGlobin","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brazil Approves RedHill Biopharma\u2019s Phase 2\/3 COVID-19 Study with Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Holds a Company Briefing on the Development of New Drug Candidates for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BBT-401","moa":"Pellino-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Rectal","sponsorNew":"Bridge Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Bio.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Gets CHMP Nod for MenQuadfi\u00ae for Active Immunization Against Invasive Meningococcal ACWY Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Meningococcal (Groups A, C, Y, W) Conjugate Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution for Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Sanofi's Supemtek\u00ae for the Prevention of Influenza in Adults Aged 18 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Quadrivalent recombinant influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Clearside Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clearside Biomedical Presents Clinical Trial Data at The Retina Society 2020 and Reports XIPERE\u2122 Data in Diabetic Macular Edema in Ophthalmology Retina","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Clearside Biomedical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Clearside Biomedical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Clearside .."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics and Vertex Pharmaceuticals' CTX001\u2122 Gets PRIME Designation Granted by the EMA for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271, Company Advances Second Cardiac Myosin Inhibitor","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CK-3772271","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Receives Positive Opinion from EMA\u2019S CHMP on Use of Antiepileptic Agent Fycompa\u00ae in Pediatric Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Emmecell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emmecell Announces FDA Acceptance of IND Application for EO2002 in Corneal Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"EO2002","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Emmecell","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Emmecell \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Emmecell \/.."},{"orgOrder":0,"company":"Enterome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enterome Announces First Patient Dosed in Phase 2a Trial of Sibofimloc in Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sibofimloc","moa":"E coli fimH protein blocker","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Enterome","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enterome \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterome \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Supplemental New Drug Application for Pfizer\u2019s XALKORI\u00ae for Pediatric ALK-Positive Anaplastic Large Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Crizotinib","moa":"ALK tyrosine kinase receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Athersys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MultiStem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athersys \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/.."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Randomized in Sobi's Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm's Anti-Influenza drug Avigan\u00ae Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Toyama Chemical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm T.."},{"orgOrder":0,"company":"Geneva Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Geneva Biotech Announces SARS-CoV-2 Antiviral Pipeline Based on Ground-Breaking Discovery Published in Science Magazine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Linoleic Acid","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Geneva Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Geneva Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Geneva Bio.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Announces FDA Acceptance of Gen-011 IND Application","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-011","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"GW Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GW Pharmaceuticals Gets Australian TGA Approval for Epidyolex for Seizures in Patients with Two Rare Forms of Childhood-Onset Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"GW Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GW Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GW Pharmac.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb's Opdivo Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 in Patients with Myelodysplastic Syndromes\/Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"JSP191","moa":"CD117","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper The.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen\u2019s COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MGA012","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Publication of Flotetuzumab Interim Phase 1\/2 Clinical Trial Results in Blood","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medeor Therapeutics\u2019 Transplant Immune Tolerance Therapy Receives Regenerative Medicine Advanced Therapy Designation from FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MDR-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor The.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova's COVID-19 Vaccine Induces Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 Using BC-PIV Vector Technology","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BC-PIV vaccine","moa":"SARS-CoV-2 S1 antigen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio's MB-207 Gets Orphan Drug Designation to Treat X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-207","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Onasemnogene abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis to Present Significant Corporate and Clinical Development Progress at Upcoming Biotech and Ophthalmology Conferences","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"Rutgers University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rutgers University's New Smart Drug Delivery System May Help Treatment for Neurological Disorders","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Rutgers University","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Rutgers University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rutgers Un.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Serum Institute of India Initiates Manufacturing of Codagenix's Intranasal Live-Attenuated COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-005","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Codagenix","highestDevelopmentStatusID":"4","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics Reports Positive Results of Phase 1B Trial of Resiniferatoxin Epidural in Cancer Patients with Intractable Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virginia Commonwealth University Study Shows the Experimental Drug AR-12 Could be a Promising COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-12","moa":"PDK-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Virginia Commonwealth University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Virginia Commonwealth University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Virginia C.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma Announces the Launch of ILUMYA\u00ae (tildrakizumab) for Treatment of Plaque Psoriasis in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tildrakizumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Switching to Novo Nordisk's Investigational Insulin Icodec Found to be Efficacious in People with Type 2 Diabetes in Phase 2 Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"TPG Capital IP","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Esophagitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ellodi Pharmaceuticals \/ TPG Capital IP","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's Trulicity\u00ae, Now Indicated as an Adjunct to Diet, Exercise, and Standard of Care Therapy to Reduce Risk of Stroke in T2DM","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Peptide","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Vaccinex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Top-Line Results of Phase 2 SIGNAL Study in Huntington\u2019s Disease Support Potential for Cognitive Benefit of Pepinemab","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pepinemab","moa":"SEMA4D","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/.."},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pha.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSig Subsidiary ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Semorinemab","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune .."},{"orgOrder":0,"company":"American CryoStem Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"American Cryo Stem Announces: FDA Has Cleared Its Investigational New Drug (IND) for Post-Concussion Syndrome for PhaseII Clinical Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal stem cell","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"American CryoStem Corporation","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"American CryoStem Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"American C.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma Files Clinical Trial Notification for Phase 3 Trial of TransCon\u2122 hGH for Pediatric Growth Hormone Deficiency in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Durect Corporation Doses First Patient in Phase 2 Safety & Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DUR-928","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Durect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Durect Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Durect Cor.."},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Dermatology Publishes Results from Verrica\u2019s Two \n Pivotal Phase III CAMP (Cantharidin Application in Molluscum \n Patients) Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verrica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Verrica Ph.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune Launches First-in-human Clinical Trial for ONC-392","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Onc-392","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panacea Biotec Successfully completes Phase I\/II Study of Its Novel, Tetravalent Recombinant Chimeric Dengue Candidate Vaccine, DengiAll","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetravalent recombinant chimeric Dengue vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Panacea Biotec Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Panacea Biotec Limited \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Panacea Bi.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th EASD Annual Meeting","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor .."},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TCRT-ESO-A2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Athenex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Athenex \/ .."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the \nWMS 2020 Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cardiosphere-derived cells","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor T.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB Achieves Important Regulatory Milestone for Bimekizumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada approves Merck\u2019s etanercept biosimilar for new indications","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces Program To Investigate The Safety And Pharmacokinetics Of VALTOCO\u00ae (Diazepam Nasal Spray) In Children Aged 2 To 5","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx Submits Request for Emergency Use Authorization for RLF-100\u2122 for Patients with Critical Covid-19 and Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Completes Dosing of First Cohort in Phase 1\/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NEXI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Expands Clinical Trials to Test Convalescent Plasma Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Convalescent plasma","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"vTv Therapeutics Presents Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therap.."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month \n Mercury 3 Clinical Trial in Europe","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Netarsudil Mesylate","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences Starts KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Telaglenastat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Comments on Animal Studies in the Development of High Potency Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Dry Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Final Approval from USFDA for Dimethyl Fumarate Delayed-Release Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 S-Trimer vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"Spirovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SPIRO-2101","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Spirovant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Spirovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Spirovant .."},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ N.."},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenScript ProBio Congratulates XLifeSc on FDA Allowance of IND Application for TCR-T Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"TAEST16001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ GenScript","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue L.."},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo to Present Qwo\u2122 (Collagenase Clostridium Histolyticum-Aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals Announces Publication of Clinical Data from the Phase I\/Ib study of Tenalisib in Patients with Relapsed\/Refractory T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenalisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rhizen Pha.."},{"orgOrder":0,"company":"Innova Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innova Therapeutics Receives Rare Pediatric Disease Designation from the FDA for IVT-8086 for the Treatment of Osteosarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IVT-8086","moa":"SFRP2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Innova Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Innova Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Innova The.."},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MLE-301","moa":"NK3R","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Millendo T.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the \n Journal Cell","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GlaxoSmithKline","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Leap Therapeutics \/ BeiGene","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reports High Response Rates with CAN04 Combination Therapy in Nsclc and Presents Next Development Steps","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"IL-1 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cantargia AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia .."},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hansa Biopharm Announces Positive High-Level Data from Investigator-Initiated Phase 2 Trial with Imlifidase to Treat Anti-GBM Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"IgG-mediated immune response","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biop.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Biotechnologies Announces Presentation of Positive Phase 2b Data for Next Generation Pertussis Vaccine at World Vaccine Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinol","moa":"CB2\/CB1","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"InMed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"InMed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InMed Phar.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Gavorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EC Grants Marketing Authorization for Gilead's Jyseleca\u00ae for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Eisai","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KSQ Therapeutics to Present Data from its USP1 Inhibitor Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KSQ-4279","moa":"USP1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KSQ Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"KSQ Therap.."},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Publishes Promising Data of Apeiron's APN01 (rhsACE2) to Treat COVID-19 in Named Patient Use","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Alunacedase alfa","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Bi.."},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer\u2019s Disease Has Exceeded Study Enrollment Target of 570 Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Atuzaginstat","moa":"Lysine gingipain","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Quince Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quince Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Quince The.."},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Announces FDA Clearance of IND Application for ANK-700 for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ANK-700","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Anokion SA","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Anokion SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Anokion SA.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Receives European Medicines Agency PRIME Designation for CLN6 Batten Disease Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-GTX-501","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ganaxolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Ph.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health & Menarini Group Provide Elacestrant Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Elacestrant","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radius Health \/ Menarini Group","highestDevelopmentStatusID":"10","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-504","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Grants Market Authorization to Polivy\u2122 (polatuzumab vedotin) for the Treatment of Adult Patients with Relapsed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Polatuzumab Vedotin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Revises the Development Plan for Rabeximod","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Rabeximod","moa":"TNF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Cyxone AB","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyxone AB .."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Begins Patient Dosing in PHEARLESS Phase 1\/2 Study of BMN 307 to Treat Phenylketonuria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BMN 307","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Posts Interim Results from Phase 1\/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Japanese Approval for Additional Indication of Tecentriq and Avastin to Treat Unresectable Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Glaxosmithkline's Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mepolizumab","moa":"IL-5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Aquestive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant\u2122 (diazepam) Buccal Film for Management of Seizure Clusters","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aquestive Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Aquestive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aquestive .."},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiol Therapeutics Receives FDA Approval for Investigational New Drug (IND) Application for Phase II\/III COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cardiol Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardiol Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Cardiol Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves KALYDECO\u00ae (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivacaftor","moa":"CFTR","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Kaken Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Kaken Pharmaceuticals \/ Brickell Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Kaken Phar.."},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth .."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Applies for the Additional Indication in Japan of Bipolar Disorder for ABILIFY MAINTENA for Suspended Release Injectable Suspension","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pha.."},{"orgOrder":0,"company":"Adial Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adial Pharmaceuticals Files For Expedited Review Of AD04 with The FDA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ondansetron","moa":"5-HT3A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Adial Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adial Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adial Phar.."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ULTOMIRIS\u00ae (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UniQure Gets Recommendations from Data Safety Monitoring Board of Phase I\/II Clinical Trial of AMT-130 for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Stereotaxic Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab at 2020 CSCO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FTX-6058","moa":"EED","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo's ENHERTU\u00ae Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"DNA topoisomerase 1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ono Pharmaceutical's Opdivo and Yervoy Combination Therapy Approved in Japan to Expand Use for the Treatment of MSI-High Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ono Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Bristol-Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Ono Pharma.."},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"GlycoMimetics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Uproleselan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Apollomics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apollomics Inc \/ GlycoMimetics","highestDevelopmentStatusID":"10","companyTruncated":"Apollomics.."},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharmaceuticals Expands ArtemiC\u2122 Phase II Clinical Trial on COVID-19 Patients in Israel and India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Artemisinin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"MGC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MGC Pharma.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent's TYVYT\u00ae in Combination with BYVASDA\u00ae in ORIENT-32 Study Met Its Primary Endpoints","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"OLX10010","moa":"CTGF","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Sojournix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sojournix Presents Data at NAMS Showing SJX-653 Exhibits Potent NK3 Antagonist Profile Across Nonclinical and Initial Clinical Studies in Men and Postmenopausal Women","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SJX-653","moa":"NK-3 receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Sojournix","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sojournix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sojournix .."},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NYX-2925","moa":"NMDA receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ .."},{"orgOrder":0,"company":"Ensysce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"COVISTAT, a Subsidiary of Ensysce Biosciences Is Commencing Phase 1 Study of Novel COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Nafamostat","moa":"TMPRSS2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ensysce Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ensysce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ensysce Bi.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals Presents Information on Edasalonexent at the Virtual 25th International Congress of the World Muscle Society","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"Avrobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVROBIO Receives Orphan Drug Designation from the EMA for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AVR-RD-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avrobio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Completes Final Patient Treatment in AUDREY Phase 2\/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves HAEGARDA\u00ae for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Human C1 Esterase Inhibitor","moa":"C1 esterase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Receives Final Approval for Generic Version of Biogen IDEC Inc.'s Tecfidera\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica's itMSC Therapy for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ischemic-tolerant mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Stemedica Cell Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Stemedica Cell Technologies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Stemedica .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 \/ 3 Trial of COVID-19 Vaccine Candidate INO-4800","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Receives Orphan Drug and Fast Track Designations from the U.S FDA for Elezanumab for the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Elezanumab","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion; Intravenous","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Peginterferon Lambda-1a","moa":"Type III IFN receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 Monotherapy Adult T-cell Leukemia-Lymphoma ATL in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Chidamide","moa":"HDAC","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HUYA Bioscience International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Biosc.."},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell\u2122 Universal Donor Stem Cell Therapy for Brain Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Idera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Idera Phar.."},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aligos Therapeutics Receives Clinical Trial Application Approval for Chronic Hepatitis B Capsid Assembly Modulator Candidate ALG-000184","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALG-000184","moa":"Capsid assembly","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Aligos Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aligos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aligos The.."},{"orgOrder":0,"company":"Altimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune Presents Data from Intranasal COVID-19 Vaccine and Therapeutic Programs \u2013 AdCOVID\u2122 and T-COVID\u2122 at the World Vaccine Congress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AdCOVID","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SRP-9003","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Th.."},{"orgOrder":0,"company":"Scandion Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scandion Oncology Receives Final Approval from the Danish Medicines Agency and Ethical Committee for Start of a Clinical Trial in Patients with Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SCO-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Scandion Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scandion Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scandion O.."},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka Has Filed an Application in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Difamilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pha.."},{"orgOrder":0,"company":"ENA Respiratory","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ena Respiratory Announces an Extension of its Series A and Positive COVID-19 Ferret Challenge Study Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"INNA-051","moa":"TLR2\/TLR6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ENA Respiratory","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"ENA Respiratory \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ENA Respir.."},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heron Therapeutics\u2019 Zynrelef Receives European Marketing Approval to Treat Postoperative Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bupivacaine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Heron Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Solution","sponsorNew":"Heron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Heron Ther.."},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taro Pharmaceutical Launches Generic Deferiprone in U.S","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Deferiprone","moa":"Iron","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Taro Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharm.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Danicamtiv","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia's Mavacamten Treatment Significantly Reduced Biomarkers of Cardiac Injury In Hypertrophic Cardiomyopathy Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for 69th ACC Annual Scientific Session","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"MyoKardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"Koligo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Koligo Therapeutics to Develop Personalized Cell Therapy for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"KT-PC-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Koligo Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Koligo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Koligo The.."},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"MAN-19","moa":"Tie2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Q BioMed \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Q BioMed \/.."},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NanoViricides","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NanoVirici.."},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$757.2 million","upfrontCash":"$310.4 million","newsHeadline":"Divestment of Aspen\u2019s European Thrombosis Business to Mylan and Withdrawal of Cautionary","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Fondaparinux Sodium","moa":"Antithrombin III","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.76000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.76000000000000001,"dosageForm":"","sponsorNew":"Aspen Pharmacare Holdings \/ Mylan","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Phar.."},{"orgOrder":0,"company":"Protagenic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"PT00114","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Protagenic Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Protagenic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Protagenic.."},{"orgOrder":0,"company":"Imunon","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Carboplatin","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imunon","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Imunon \/ Lincoln Park Capital","highestDevelopmentStatusID":"7","companyTruncated":"Imunon \/ L.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Trillium Therapeutics Announces $25 Million Equity Investment From Pfizer Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Rituximab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lonza Group","sponsor":"Humanigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Horizon Therapeutics's Study Results Show 79% of Patients Achieved Complete Response Using KRYSTEXXA\u00ae with Methotrexate","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"REMD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript Biotech Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ REMD","highestDevelopmentStatusID":"3","companyTruncated":"GenScript .."},{"orgOrder":0,"company":"Lonza Group","sponsor":"LamKap Bio Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"NILK-2301","moa":"CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lonza Group \/ LamKap Bio Group","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Grou.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Panolos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Signs Development Agreement with Panolos for Solid Tumor Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"PB101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Panolos","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"University of Montana","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$33.4 million","upfrontCash":"Undisclosed","newsHeadline":"University of Montana Receives $33.4 million for Development and Clinical Trials of Opioid Vaccines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Opioid vaccines","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"University of Montana","amount2":0.029999999999999999,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"University of Montana \/ National Institute of Health","highestDevelopmentStatusID":"7","companyTruncated":"University.."},{"orgOrder":0,"company":"Palleon Pharmaceuticals","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"Sialidase-Fc","moa":"Sialoglycan","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Palleon Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Palleon Pharmaceuticals \/ Matrix Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Palleon Ph.."},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Papyrus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Papyrus Therapeutics Inc. Signs Research Collaboration With Oxford Biomedica","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"PYTX-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Papyrus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Reports Data From Study 211 Supporting 24 Mg As the Appropriate Starting Dose for Lenvima to treat Differentiated Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenvatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Presents Data from Phase 1 Clinical Study of Dubermatinib in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Dubermatinib","moa":"AXL receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison .."},{"orgOrder":0,"company":"LiberaTx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u200bSingapore Start-Up, LiberaTx, Plans Clinical Trial of a Single Daily Pill Replacing Multiple Pills for Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"LiberaTx","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"LiberaTx \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"LiberaTx \/.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,890.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Announces Second Novel Drug Candidate from Its Multi-Target Drug Discovery Collaboration with Pfizer has Started Clinical Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sosei Heptares","amount2":1.8899999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.8899999999999999,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"CytRx Corporation","pharmaFlowCategory":"D","amount":"$83.7 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Issues Statement Regarding Orphazyme\u2019s Global Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ CytRx","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Locus Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$144.0 million","upfrontCash":"$77.0 million","newsHeadline":"Locus Biosciences Signs Contract with BARDA to Advance $144 Million Precision Medicine Program to Develop LBP-EC01","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"LBP-EC01","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Locus Biosciences","amount2":0.14000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Locus Biosciences \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Locus Bios.."},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Luminarie","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TaiGen Out-Licensed Taigexyn\u00ae to Luminarie Canada for Canada, Australia and New Zealand","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Nemonoxacin","moa":"Topoisomerase II","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"TaiGen Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"TaiGen Biotechnology \/ Luminarie","highestDevelopmentStatusID":"12","companyTruncated":"TaiGen Bio.."},{"orgOrder":0,"company":"Koligo Therapeutics","sponsor":"Orgenesis","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"Undisclosed","newsHeadline":"Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Autologous pancreatic islets cells","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Koligo Therapeutics","amount2":0.02,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Koligo Therapeutics \/ Orgenesis","highestDevelopmentStatusID":"12","companyTruncated":"Koligo The.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100\u2122 (aviptadil)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharm-Olam Selected as a CRO for Department of Defense Support to Operation Warp Speed Vaccine Trials, Partnering with Geneva Foundation","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm-Olam","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pharm-Olam \/ U.S. Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Pharm-Olam.."},{"orgOrder":0,"company":"Progreso y Salud Foundation","sponsor":"Amarna Therapeutics","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Amarna Announces Research Join Hands with Progreso y Salud Foundation for Testing MS Gene Therapy Platform","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"SV40 vector based gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Progreso y Salud Foundation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Progreso y Salud Foundation \/ Amarna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Progreso y.."},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Drugs for Neglected Disease Initiative","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"CpG-D35","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Bio-Pharma \/ Drugs for Neglected Disease Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto .."},{"orgOrder":0,"company":"Aclipse Therapeutics","sponsor":"FightMND","pharmaFlowCategory":"D","amount":"$0.7 million","upfrontCash":"Undisclosed","newsHeadline":"Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"M102","moa":"Nrf2","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Aclipse Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclipse Therapeutics \/ FightMND","highestDevelopmentStatusID":"4","companyTruncated":"Aclipse Th.."},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vor Biopharma and Arbor Biotechnologies to Collaborate on Engineered Hematopoietic Stem-Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Engineered hematopoietic stem cell","moa":"CD33","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Arbor Biotechnologies, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Vor Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Arbor Biot.."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$480.0 million","upfrontCash":"Undisclosed","newsHeadline":"CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0.47999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.47999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"ABEC","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute Selects ABEC for Large-Scale, Single-Use COVID-19 Vaccine Manufacturing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ABEC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ABEC \/ Serum Institute of India","highestDevelopmentStatusID":"8","companyTruncated":"ABEC \/ Ser.."},{"orgOrder":0,"company":"Invetx","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$25.5 million","upfrontCash":"Undisclosed","newsHeadline":"Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"Antibody therapeutics","moa":"GPCR","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Invetx","amount2":0.029999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Invetx \/ Casdin Capital","highestDevelopmentStatusID":"2","companyTruncated":"Invetx \/ C.."},{"orgOrder":0,"company":"DSG","sponsor":"Reven Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Reven Selects\u200c E-Clinical Services\u200c Provider\u200c DSG for Clinical Data Management Services","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"DSG","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DSG \/ Reven","highestDevelopmentStatusID":"6","companyTruncated":"DSG \/ Reve.."},{"orgOrder":0,"company":"Verastem Oncology","sponsor":"Secura Bio","pharmaFlowCategory":"D","amount":"$381.0 million","upfrontCash":"$70.0 million","newsHeadline":"Verastem Oncology Announces Closing of COPIKTRA\u00ae (duvelisib) Sale to Secura Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Verastem Oncology","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.38,"dosageForm":"Oral","sponsorNew":"Verastem Oncology \/ Secura Bio","highestDevelopmentStatusID":"12","companyTruncated":"Verastem O.."},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Synairgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synairgen and Clinigen Sign Managed Access Program Agreement with SNG001 for Treatment of Hospitalised Patients with Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Clinigen Group","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Clinigen Group \/ SYNAIRGEN","highestDevelopmentStatusID":"8","companyTruncated":"Clinigen G.."},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$77.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dewpoint Therapeutics raises $77 million to go after \u2018undruggable\u2019 diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ ARCH Venture Partners","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint T.."},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Dextromethorphan","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Axsome The.."},{"orgOrder":0,"company":"Applied BioMath","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied BioMath, LLC Announces Collaboration with Cullinan Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"CLN-049","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Applied BioMath","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Applied BioMath \/ Cullinan Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Applied Bi.."},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","amount":"$10.4 million","upfrontCash":"Undisclosed","newsHeadline":"CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"CNCT19","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Juventas Cell Therapy","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Juventas Cell Therapy \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Juventas C.."},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moksha8 Pharmaceuticals Announces Strategic Partnership with Janssen for Selected CNS Portfolio in Mexico","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Ph.."},{"orgOrder":0,"company":"US Oncology Network","sponsor":"Elevation Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elevation Oncology and US Oncology Research Ink Collaboration in Support of Phase 2 CRESTONE Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Seribantumab","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"US Oncology Network","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"US Oncology Network \/ Elevation Oncology","highestDevelopmentStatusID":"8","companyTruncated":"US Oncolog.."},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Accord healthcare","pharmaFlowCategory":"D","amount":"$565.0 million","upfrontCash":"$27.0 million","newsHeadline":"Henlius Granted Exclusive Development and Commercialisation Rights of HLX02 in the US and Canada to Accord","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0.56999999999999995,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ ACCORD HEALTHCARE","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai H.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"HLS Therapeutics","pharmaFlowCategory":"D","amount":"$49.3 million","upfrontCash":"$30.8 million","newsHeadline":"HLS Therapeutics Acquires Portfolio of Four Royalty Interest, Gains Takeda's Obizur","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Porcine recombinant Factor VIII","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ HLS Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Exactis Innovation","sponsor":"Sermonix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Lasofoxifene","moa":"Selective estrogen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exactis Innovation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exactis Innovation \/ Sermonix","highestDevelopmentStatusID":"8","companyTruncated":"Exactis In.."},{"orgOrder":0,"company":"LogicBio Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LogicBio Therapeutics Announces Proposed Public Offering of Common Stock","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"LB-001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"LogicBio Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LogicBio Therapeutics \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"LogicBio T.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Kreos","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"$5.9 million","newsHeadline":"Kiadis Announces the Placement of \u20ac5 Million Convertible Bonds with Kreos","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Financing","leadProduct":"K-NK cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Sanofi \/ Kreos","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ K.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioSig Technologies \/ Sorrento Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute to Produce up to Additional 100 mn COVID-19 Vaccine Doses for India and LMIC in 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Serum Inst.."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"VLP Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm Signs Manufacturing Contract with VLP Therapeutics for Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID 19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm holding \/ VLP Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Carmot Therapeutics Closes $47 Million Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"CT-868","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Carmot The.."},{"orgOrder":0,"company":"FibroGenesis","sponsor":"R4D Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FibroGenesis Expands Fight Against COVID-19 In Brazil with International Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"PneumoBlast","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"FibroGenesis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"FibroGenesis \/ R4D Biotech","highestDevelopmentStatusID":"4","companyTruncated":"FibroGenes.."},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Bial","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BIAL and Recipharm Expand Long-Term Supply Agreement for Opicapone API","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Opicapone","moa":"COMT","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Recipharm AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recipharm AB \/ BIAL","highestDevelopmentStatusID":"12","companyTruncated":"Recipharm .."},{"orgOrder":0,"company":"University of Louisville","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AS1411-GNP","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Louisville","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Louisville \/ Qualigen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Antares Pharma","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$5.0 million","newsHeadline":"Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna\u00ae in U.S.","therapeuticArea":"Urology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","url1":"","url2":"","graph1":"Urology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","productSubType":"Hormone","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Ferring Pharmaceuticals \/ Antares Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$715.0 million","upfrontCash":"$200.0 million","newsHeadline":"Vaccibody Enters into Worldwide License and Collaboration Agreement with Genentech to Develop Individualized Neoantigen Cancer Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"VB10.NEO","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nykode Therapeutics","amount2":0.71999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.71999999999999997,"dosageForm":"","sponsorNew":"Nykode Therapeutics \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Nykode The.."},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$647.0 million","upfrontCash":"$647.0 million","newsHeadline":"Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.65000000000000002,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.65000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharm.."},{"orgOrder":0,"company":"Radius Health","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Radius Health Divests RAD 140 Program to Ellipses Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Divestment","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Radius Health \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Radius Hea.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Aduro Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"Georgetown University","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Hydroxyureamethylacylfulvene","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Georgetown University","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Georgetown University \/ Lantern Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Georgetown.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SpringWorks Therapeutics and Pfizer Join Hands to Evaluate Nirogacestat and PF\u201006863135 Combo in Relapsed or Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SpringWorks Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"Lysosomal Therapeutics","sponsor":"BIAL","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"BIAL Goes Global With New US Research Center and Acquisition of Promising Parkinson's Disease Programs","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"LTI-291","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lysosomal Therapeutics","amount2":0.13,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.13,"dosageForm":"Oral","sponsorNew":"Lysosomal Therapeutics \/ BIAL","highestDevelopmentStatusID":"6","companyTruncated":"Lysosomal .."},{"orgOrder":0,"company":"Safi Biosolutions","sponsor":"iBio","pharmaFlowCategory":"D","amount":"$1.5 million","upfrontCash":"Undisclosed","newsHeadline":"iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming\u00ae System","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Blood cell therapy","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Safi Biosolutions","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Safi Biosolutions \/ iBio","highestDevelopmentStatusID":"1","companyTruncated":"Safi Bioso.."},{"orgOrder":0,"company":"The University of Manchester","sponsor":"Avrobio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Lentiviral gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"The University of Manchester","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Manchester \/ Avrobio","highestDevelopmentStatusID":"4","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"MyoKardia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$13,100.0 million","upfrontCash":"$13,100.0 million","newsHeadline":"Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"MyoKardia","amount2":13.1,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":13.1,"dosageForm":"Capsule","sponsorNew":"MyoKardia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"MyoKardia .."},{"orgOrder":0,"company":"ViroVax","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bharat Biotech to Use ViroVax\u2019s Adjuvant for Longer-Lasting Immunity by Covaxin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Alhydroxiquim-II","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ViroVax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ViroVax \/ Bharat Biotech","highestDevelopmentStatusID":"8","companyTruncated":"ViroVax \/ .."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Gets FDA Acceptance of IND Application for a Phase 2 Clinical Trial of KL4 Surfactant in Acute Lung Injury in Adults with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lucinactant","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centaur Pharma Launches Novel Topical Solution WoxHeal for the Treatment of Diabetic Foot Ulcer","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Diperoxochloric Acid","moa":"","url1":"","url2":"","graph1":"Podiatry","graph2":"Approved","graph3":"Centaur Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Podiatry","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Centaur Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Centaur Ph.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma and Origin Biosciences Gets FDA Acceptance Of Its New Drug Application For Fosdenopterin For The Treatment Of MoCD Type A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosdenopterin","moa":"cPMP","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharma Reports Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-15512","moa":"TRPM8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forte Biosciences Dosed First Patient in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sabizabulin","moa":"Alpha tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Veru","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Not.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intellia Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR\/Cas9-Based Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NTLA-2001","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma to Submit NDA for Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharma Gets FDA Approval of Orphan Drug ALKINDI\u00ae SPRINKLE as Replacement Therapy in Children with Adrenocortical Insufficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Submits NDA for UPTRAVI\u00ae Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prelude Therapeutics Doses First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for Relapsed\/Refractory Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PRT1419","moa":"Mcl-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Th.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Infinity Gets Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy to Treat Advanced TNBC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Infinity P.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves REBLOZYL\u00ae (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Luspatercept","moa":"TGF beta","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Organicell Expanded Access To Treat COVID-19 Patients With ZofinTM","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zofin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Organicell Regenerative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Organicell Regenerative Medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Organicell.."},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CAR-NKT Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kuur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Thera.."},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company\u2019s Lead Peripheral CB1 Blocker","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"INV-101","moa":"CB1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago .."},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Colesevelam Hydrochloride","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ironwood Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ironwood P.."},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MedinCell Initiates the First Clinical Trial of its Covid-19 \n Prevention Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ivermectin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"MedinCell","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MedinCell .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Publication in NEJM of Interim Results From Phase 1 Study of its mRNA Vaccine Against COVID-19 in Older Age Group","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Doses First Patient in Clinical Study of Microbiome Metabolic Therapy KB295 to treat Mild to Moderate Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KB295","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ZT-01","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara The.."},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Announces Enrollment of 100 Patients in Multinational 2b\/3 Human Study of Ifenprodil for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Algernon P.."},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Plinabulin","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BeyondSpring \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpri.."},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I\/II Clinical Study of ART27.13","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ART27.13","moa":"CB receptor","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Artelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Bio.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Announces Update for its HST-002 Dermal Filler Program","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HST-002","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bucillamine","moa":"Glutathione","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revive The.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliX Pharmaceuticals to Present New Data in Liver and Ophthalmic Areas at 16th Annual Meeting of the Oligonucleotide Therapeutics Society","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"OLX301A","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Galapagos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galapagos Announces First Dosing with Toledo Compound GLPG3970 in Psoriasis Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GLPG3970","moa":"TOL2\/3","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Galapagos \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos .."},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Plans to Complete Phase 3 RELIEF Study of TNX-102 SL to Manage Fibromyalgia Based on Results of Interim Analysis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Phar.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIAID Stops Enrollment of Severely Ill COVID-19 Participants in Clinical Trial of Investigational Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pha.."},{"orgOrder":0,"company":"Creative Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz\u00ae Immunotherapy Product in Rheumatoid Arthritis Model","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ImmCelz","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Creative Medical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative M.."},{"orgOrder":0,"company":"Field Trip Psychedelics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Field Trip Psychedelics Successfully Synthesizes GLP, Results From Initial Preclinical Testing for FT-104, its First Molecule in Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"FT-104","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Field Trip Psychedelics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Field Trip Psychedelics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Field Trip.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1096","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Neihulizumab","moa":"PSGL-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"AltruBio","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AltruBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AltruBio \/.."},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PXL770","moa":"AMPK","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Poxel","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Poxel \/ No.."},{"orgOrder":0,"company":"IRLAB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IRLAB's Mesdopetam IND Accepted by the US FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesdopetam","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"IRLAB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IRLAB \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"IRLAB \/ No.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis' Zolgensma\u00ae Demonstrate Therapeutic Benefit, Including Increased Motor Function and Milestone Achievement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Onasemnogene Abeparvovec","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zosano Pharma Receives Preliminary FDA Communication on Qtrypta\u2122 NDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Zosano Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pha.."},{"orgOrder":0,"company":"Baylx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baylx Receives US FDA Clearance of Covid-19 IND Application for Umbilical Cord Tissue Mesenchymal Stem Cells Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Human umbilical cord tissue mesenchymal stem cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Baylx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Baylx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylx \/ No.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson\u2019s Treatment of NASH at AASLD 2020 Virtual Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Namodenoson","moa":"Adenosine A3 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Cassava Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cassava Sciences\u2019 Phase 2b Clinical Results in Alzheimer\u2019s Selected as Late-Breaking News at CTAD 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Sumifilam","moa":"Filamin A","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cassava Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cassava Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cassava Sc.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Melanoma Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenacapavir","moa":"HIV-1 capsid","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi Pasteur launches Tetraxim, the first full-dose DTaP booster vaccine in India for preschoolers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"DTaP-IPV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio Reports Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta to Present Preliminary Phase I\/II Clinical Data on Temferon\u2122 in Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Temferon","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Sc.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eisai Initiates Phase 3 MOMENTUM 1 Clinical Trial (Study 304) of Lorcaserin in Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lorcaserin HCl","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Genexine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Eftansomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Genexine","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ovid Therapeutics Provides Soticlestat (OV935\/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Soticlestat","moa":"CH24H","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ovid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Thera.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Doses First Patients in Two Phase II Clinical Studies of Batoclimab to Treat Myasthenia Gravis and Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Medeor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medeor Therapeutics Announces Data Presentation at the American Society of Nephrology Kidney Week 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MDR-101","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Medeor Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medeor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Medeor The.."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REGENXBIO Continues Progress and Expansion of Clinical Development Program for RGX-121 to Treat Mucopolysaccharidosis Type II (MPS II)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"RGX-121","moa":"IDS gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal","sponsorNew":"Regenxbio \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIDDS Announces Data on Liproca Depot from Open Label Extension Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"2-Hydroxyflutamide","moa":"Testosterone congener","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Lidds","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lidds \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lidds \/ No.."},{"orgOrder":0,"company":"xCures","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"xCures launches compassionate use programme for ulixertinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ulixertinib","moa":"MAP kinase ERK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"xCures","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"xCures \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"xCures \/ N.."},{"orgOrder":0,"company":"Scripps Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Discover Small Molecule that Targets, Destroys RNA Sequence of Virus that Causes COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"C5-RIBOTAC","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scripps Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scripps Re.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts Sanofi's Regulatory Submission for Avalglucosidase Alfa for Pompe Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for Primary Hyperoxaluria Type 1 in Children Aged 6","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi and Selecta Biosciences Announce Topline Data of SEL-212 From the Phase 2 COMPARE Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Belumosudil","moa":"Rho-associated coiled-coil kinase 2","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Treatment for Alexander Disease Receives Orphan Drug Designation from U.S. FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Golimumab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCryst\u2019s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-na\u00efve PNH Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BCX9930","moa":"Complement Factor D","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin\u2019s Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"IGM-8444","moa":"DR5","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IGM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosci.."},{"orgOrder":0,"company":"Kinderfarms","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinderfarms Announces the Launch of Kinderlyte\u00ae Sleep and Immunity","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Kinderfarms","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kinderfarms \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kinderfarm.."},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Tanabe Pharma America Announces Presentations At Northeast Amyotrophic Lateral Sclerosis 19th Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Edaravone","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Mitsubishi Tanabe Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Pharmaceutical's SIMPONI ARIA\u00ae Approved by the U.S. FDA for Active Polyarticular Juvenile Idiopathic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Golimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication Highlights Therapeutic Potential of Endogenous Metabolic Modulators (EMMs)","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Axcella He.."},{"orgOrder":0,"company":"Centus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centus Biotherapeutics Receives European Marketing Authorization for Equidacent\u00ae, Biosimilar Avastin\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Centus Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Centus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Centus Bio.."},{"orgOrder":0,"company":"Irvine School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study by Irvine School of Medicine finds Antidepressant Drug Effective in Treating \"Lazy Eye\" in Adults","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Irvine School of Medicine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Irvine School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Irvine Sch.."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazoxide","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Controlled Release Tablet","sponsorNew":"Soleno Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno The.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated D-serine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Powder for Oral Solution","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord-UK Launches Pelgraz\u00ae Pre-filled Injector and Patient App, Supporting Patients to Self-Inject at Home","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegfilgrastim","moa":"GCSF","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Injector","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord hea.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Accepts Regulatory Submission for Avalglucosidase Alfa, a Potentially new Standard of Care Enzyme Replacement Therapy for Pompe disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avalglucosidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Farxiga Granted Breakthrough Therapy Designation in US for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Metacrine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metacrine to Present New Data from MET409 Program in NASH at AASLD\u2019s The Liver Meeting Digital Experience\u2122","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MET409","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Metacrine","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metacrine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Metacrine .."},{"orgOrder":0,"company":"Acticor Biotech SAS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Glenzocimab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Acticor Biotech SAS","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acticor Biotech SAS \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Acticor Bi.."},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Debiopharm Launches TrilynX - A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head & Neck Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Xevinapant","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Debiopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm.."},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx-99 an Experimental Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Phosphorylated hexaacylated disaccharide","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation.."},{"orgOrder":0,"company":"Aegle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AGLE-102","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aegle Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aegle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aegle Ther.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Olorinab","moa":"CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Windtree Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Windtree Doses First Patient in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Istaroxime","moa":"SERCA2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Windtree Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Windtree Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Windtree T.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1066","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces ZILXI\u2122 (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"VYNE Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VYNE Thera.."},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rhenium-186","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Plus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Plus Thera.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. Market","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cinacalcet Hydrochloride","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"CiVi Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CiVi Biopharma Resumes AURORA Phase 3 Clinical Trial of CIVI030 to Treat Systemic Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"CiVi Biopharma","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CiVi Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CiVi Bioph.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teneobio Reports US FDA Clearance of its IND Application for TNB-486 and the Initiation of Phase I Clinical Studies for B-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TNB-486","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Athira Pharma Starts Patient Dosing for the LIFT-AD Study, a Phase 2\/3 Clinical Trial to Evaluate ATH-1017 for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH-1017","moa":"HGF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Athira Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled syringe","sponsorNew":"Athira Pharma \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Athira Pha.."},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imago BioSciences Doses First Patient in Phase 2b Study of Bomedemstat (IMG-7289) in Essential Thrombocythemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II","graph3":"Imago BioSciences","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imago BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imago BioS.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces First Patient Dosed in Multicenter Phase 1\/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Relmapirazin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Completes Scientific Advice Meeting with EMA for a Pivotal Phase III Study of Nomacopan to treat Bullous Pemphigoid","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck to Present New Data from the Company\u2019s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Madrigal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Madrigal Pharmaceuticals' Three Abstracts Accepted by The Liver Meeting Digital Experience, including Data on Phase 3 MAESTRO-NAFLD-1 Trial","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Resmetirom","moa":"TR beta-1","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved","graph3":"Madrigal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Madrigal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Madrigal P.."},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$11.7 million","upfrontCash":"Undisclosed","newsHeadline":"Biophytis Announces a \u20ac 10 Million Capital Increase Through Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Private Placement","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Biophytis \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Reliance Life Sciences Private Limited","sponsor":"Medicure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medicure Announces an Agreement with Reliance Life Sciences for the Marketing Rights of a Cardiovascular Biosimilar","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Reliance Life Sciences Private Limited","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Reliance Life Sciences Private Limited \/ Medicure","highestDevelopmentStatusID":"1","companyTruncated":"Reliance L.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b\/3 Clinical Trial Design Based On FDA Written Guidance","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Ministry of Health and Welfare, Taiwan","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"UB-612","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxxinity","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Vaxxinity \/ Ministry of Health and Welfare, Taiwan","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity .."},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"JPMorgan Chase Bank","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.16,"dosageForm":"Intranasal","sponsorNew":"Eagle Pharmaceuticals \/ JPMorgan Chase Bank","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Phar.."},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$62.5 million","upfrontCash":"$41.0 million","newsHeadline":"Lexicon Pharmaceuticals Reaches Agreements To Exchange Convertible Notes, Reduce Outstanding Indebtedness","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"TPH","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Lexicon pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Lexicon ph.."},{"orgOrder":0,"company":"Liechti Lab","sponsor":"Mind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Liechti Lab","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Liechti Lab \/ MindMed","highestDevelopmentStatusID":"6","companyTruncated":"Liechti La.."},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","amount":"$78.0 million","upfrontCash":"Undisclosed","newsHeadline":"Minoryx Therapeutics and Sperogenix Therapeutics Sign License Pact to Develop and Commercialize Leriglitazone in Mainland China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Leriglitazone","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Minoryx Therapeutics \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Th.."},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Brain Trust Accelerator Fund II","pharmaFlowCategory":"D","amount":"$8.8 million","upfrontCash":"Undisclosed","newsHeadline":"NeuroTherapia Closes $8.8M Series A Financing Led By Brain Trust Accelerator Fund II","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series A Financing","leadProduct":"NTRX-07","moa":"CB2 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Brain Trust Accelerator Fund II","highestDevelopmentStatusID":"6","companyTruncated":"NeuroThera.."},{"orgOrder":0,"company":"Biocytogen","sponsor":"CMB International","pharmaFlowCategory":"D","amount":"$142.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Raised 142 Million Dollars (USD) in Support of Project Integrum","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Series D Financing","leadProduct":"Human antibodies","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biocytogen","amount2":0.14000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Biocytogen \/ CMB International","highestDevelopmentStatusID":"4","companyTruncated":"Biocytogen.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoImmune\u2019s SACCOVID\u2122 (CD24Fc) Exhibits Superb Therapeutic Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"MK-7110","moa":"CD24","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-003","moa":"TLR2","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Thera.."},{"orgOrder":0,"company":"NeoMatrix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cP12","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NMT-cP12","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"NeoMatrix Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeoMatrix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoMatrix .."},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RemeGen Announces US FDA Has Granted Breakthrough Therapy Designation for Disitamab Vedotin (RC48) in Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Disitamab vedotin","moa":"HER2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ .."},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Robust Effects of VP01 in Human Idiopathic Pulmonary Fibrosis Lung Tissue","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VP01","moa":"Angiotensin II type 2 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pha.."},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"REX Health Ventures","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Rediscovery Life Sciences Completes $4.5M Series B Financing","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Rediscovery Life Sciences","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rediscovery Life Sciences \/ REX Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Rediscover.."},{"orgOrder":0,"company":"Palladio Zannini Industrie","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Palladio Completes $20 Million Series B Financing","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"Lixivaptan","moa":"V2R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Zannini Industrie","amount2":0.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Palladio Zannini Industrie \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Z.."},{"orgOrder":0,"company":"Genelux","sponsor":"Woodward Diversified Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genelux Announces Closing of a Strategic Financing Transaction","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Genelux","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Genelux \/ Woodward Diversified Capital","highestDevelopmentStatusID":"10","companyTruncated":"Genelux \/ .."},{"orgOrder":0,"company":"InventisBio","sponsor":"GL Ventures","pharmaFlowCategory":"D","amount":"$147.0 million","upfrontCash":"Undisclosed","newsHeadline":"InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series D Financing","leadProduct":"D-0502","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"InventisBio","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"InventisBio \/ GL Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InventisBi.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicine Files for a $100 million IPO","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0.10000000000000001,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"MEDUNIK CANADA","sponsor":"Jacobus Pharmaceutical Company, Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"M\u00e9dunik Canada's Ruzurgi\u00ae Now Available to Canadian Lambert-Eaton Myasthenic Syndrome Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"MEDUNIK CANADA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MEDUNIK CANADA \/ Jacobus Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"MEDUNIK CA.."},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paradigm Biopharmaceuticals has Clear Path Towards Zilosul\u00ae OA Phase 3 Clinical Trial and Product Registration in Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR2\/3","url1":"","url2":"","graph1":"Rheumatology","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm B.."},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IONTAS and FairJourney Biologics Discover SARS-CoV2 Neutralizing Antibodies with Picomolar Potency","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV2 neutralizing antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Iontas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Iontas \/ F.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Announces Korea's First-Ever SGLT2 Inhibitor for Diabetes Treatment","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Enavogliflozin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Xeljanz approved by the FDA for the treatment of children with arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Fosaprepitant for Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosaprepitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Oncology Venture","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncology Venture\u2019s Novel PARP Inhibitor Stenoparib Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Stenoparib","moa":"PARP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oncology Venture","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncology Venture \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncology V.."},{"orgOrder":0,"company":"Peking University","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China Isolates Potent Neutralizing Abs Against Sars-Co V-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"BD-368-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Peking University","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Peking University \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Peking Uni.."},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,040.0 million","upfrontCash":"$300.0 million","newsHeadline":"Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 \r\n Antitrypsin-Associated Liver Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"ARO-AAT","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":1.04,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.04,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead .."},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$96.8 milion","newsHeadline":"Enterprise Therapeutics\u2019 TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"ETD002","moa":"TMEM16A","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enterprise Therapeutics \/ Roche","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise.."},{"orgOrder":0,"company":"Zogenix","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$222.7 million","upfrontCash":"Undisclosed","newsHeadline":"Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $30.0 Million","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Fenfluramine Hydrochloride","moa":"Sigma opioid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0.22,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.22,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ .."},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE\u00ae Technology","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Efgartigimod","moa":"Neonatal Fc receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Argenx","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme T.."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Zoic Capital","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"HDT Bio Announces Completion of Seed Financing Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"HDT-301","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"HDT Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Zoic Capital","highestDevelopmentStatusID":"4","companyTruncated":"HDT Biotec.."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Ciforadenant","moa":"Adenosine A2A receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Engineered Antibodies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Argenx","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$526.7 million","upfrontCash":"$58.6 million","newsHeadline":"Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"M6495","moa":"ADAMTS5","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Merck & Co","amount2":0.53000000000000003,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"BostonGene","sponsor":"Transgene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TG4050","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BostonGene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BostonGene \/ Transgene","highestDevelopmentStatusID":"6","companyTruncated":"BostonGene.."},{"orgOrder":0,"company":"Sansero Life Sciences","sponsor":"University of Toronto","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sansero Life Sciences Announces Joint Study With the University of Toronto to Advance Clinical Research of Psychedelic Medications","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Sansero Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sansero Life Sciences \/ University of Toronto","highestDevelopmentStatusID":"4","companyTruncated":"Sansero Li.."},{"orgOrder":0,"company":"Kao Corporation","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Lead Optimization trial for Soil-transmitted\n helminths Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Cry5B protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kao Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kao Corporation \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Kao Corpor.."},{"orgOrder":0,"company":"MILLENNIUM PHARMS","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Hit Identification trial for Malaria\n Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"MILLENNIUM PHARMS","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MILLENNIUM PHARMS \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"MILLENNIUM.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.07 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Hit Identification trial for Chagas disease,\n Leishmaniasis Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"$2,830.0 million","upfrontCash":"$175.0 million","newsHeadline":"Bridgebio Pharma and Eidos Therapeutics Announce Merger Agreement","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":2.8300000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":2.8300000000000001,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Bridgebio Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Ther.."},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Recipharm Signs Agreement with Arcturus Therapeutics to Support the Manufacture of LUNAR[\u00ae]-COV19 (ARCT-021) Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"ARCT-021","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Recipharm AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Recipharm AB \/ Arcturus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Recipharm .."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$200.0 million","newsHeadline":"Innovent Announces Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Sintilimab","moa":"PD-1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"GT Biopharma Announces Expanded TriKe(tm) Partnership with Cytovance Biologics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovance Biologics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Cytovance .."},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Mustang Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mustang Bio Licenses LentiBOOST\u2122 Technology from SIRION Biotech","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"MB-207","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sirion Biotech","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirion Biotech \/ Mustang Bio","highestDevelopmentStatusID":"7","companyTruncated":"Sirion Bio.."},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"Talaris Therapeutics Closes $115 Million Series B Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Cryopreserved Allogeneic Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Talaris Therapeutics","amount2":0.12,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.12,"dosageForm":"Intravenous infusion","sponsorNew":"Talaris Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"Talaris Th.."},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,800.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dyno Therapeutics Join Hands With Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"AAV vectors based gene therapies","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Dyno Therapeutics","amount2":1.8,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.8,"dosageForm":"","sponsorNew":"Dyno Therapeutics \/ Roche","highestDevelopmentStatusID":"3","companyTruncated":"Dyno Thera.."},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aro Collaboration with Ionis Advances with Option Exercise","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ASO-Centyrin drug conjugates","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Aro Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aro Biotherapeutics \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Aro Biothe.."},{"orgOrder":0,"company":"Atomwise","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/.."},{"orgOrder":0,"company":"A2 Biotherapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","amount":"$71.5 million","upfrontCash":"Undisclosed","newsHeadline":"A2 Biotherapeutics Closes $71.5M Series B To Begin Clinical Development Of Its Potentially Transformative Selective Tumor Cell Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Tmod-engineered T cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"A2 Biotherapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"A2 Biotherapeutics \/ The Column Group","highestDevelopmentStatusID":"2","companyTruncated":"A2 Biother.."},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRISYS LLC Signs a Third Contract with TFF Pharma to Produce Medication to Treat Lung Conditions, Including COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IRISYS, LLC","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IRISYS, LLC \/ TFF Pharma","highestDevelopmentStatusID":"1","companyTruncated":"IRISYS, LL.."},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Curon Biopharmaceutical","pharmaFlowCategory":"D","amount":"$149.5 million","upfrontCash":"Undisclosed","newsHeadline":"Rhizen Pharmaceuticals and Curon Biopharmaceutical Limited Announce an Exclusive License Agreement to Develop and Commercialize Tenalisib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tenalisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Rhizen Pharmaceuticals","amount2":0.14999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Rhizen Pharmaceuticals \/ Curon Biopharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Rhizen Pha.."},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Cambrian Biopharma","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage\u2122 Platform Targeting Multiple Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"SNS-301","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sensei Biotherapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Sensei Biotherapeutics \/ Cambrian Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Sensei Bio.."},{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Urovant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Vibegron","moa":"ADRB3","url1":"","url2":"","graph1":"Urology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sunovion Pharmaceuticals \/ Urovant Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion P.."},{"orgOrder":0,"company":"Luminera","sponsor":"Innovative Luminera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Luminera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Gel","sponsorNew":"Luminera \/ Innovative Luminera","highestDevelopmentStatusID":"12","companyTruncated":"Luminera \/.."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$2,150.0 million","upfrontCash":"$560.0 million","newsHeadline":"Denali Therapeutics Announces Closing of Collaboration and Share Purchase Agreements with Biogen","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"DNL151","moa":"LRRK2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Denali Therapeutics","amount2":2.1499999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Denali Therapeutics \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$10.3 million","newsHeadline":"OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Th\u00e9a to Develop siRNA Therapeutics for Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OLX301A","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Laboratoires Th\u00e9a","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharm.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"The European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury\u00ae (remdesivir)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Gilead Sciences \/ The European Commission","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"$6,500.0 million","upfrontCash":"$6,500.0 million","newsHeadline":"Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":6.5,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":6.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Ph.."},{"orgOrder":0,"company":"BioNTech","sponsor":"New Zealand government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Zealand signs deal with Pfizer, BioNTech for COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"BioNTech \/ New Zealand government","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kamada Provides Update on 2021 GLASSIA Supply to Takeda","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Alpha1-Proteinase Inhibitor (Human)","moa":"Alpha-1 antitrypsin protein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kamada","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Solution For Infusion","sponsorNew":"Kamada \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Kamada \/ T.."},{"orgOrder":0,"company":"Janpix","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Janpix Announces $10 Million Series B Financing to Advance STAT Protein Degrader Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"STAT3 protein","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Janpix","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Janpix \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Janpix \/ M.."},{"orgOrder":0,"company":"Federation Bio","sponsor":"Horizons Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies","therapeuticArea":"Nephrology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Human gut microbiome","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Federation Bio","amount2":0.050000000000000003,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Federation Bio \/ Horizons Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Federation.."},{"orgOrder":0,"company":"Rentschler Biopharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Joining forces against SARS-CoV-2, Rentschler Biopharma contributes to manufacturing of COVID-19 mRNA vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rentschler Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rentschler Biopharma \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Rentschler.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Government of Brazil","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Brazil's Sao Paulo Signs Agreement with Sinovac for COVID Vaccine Doses","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0.089999999999999997,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Government of Brazil","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Geron","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Geron Secures up to $75M Non-Dilutive Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Imetelstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Geron","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Geron \/ Hercules Capital","highestDevelopmentStatusID":"10","companyTruncated":"Geron \/ He.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Seladelpar","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"CymaBay Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CymaBay Th.."},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CD19-CAR-T cells","moa":"4-1BB","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon Glo.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Receives FDA Fast Track Designation For Duchenne Muscular Dystrophy Investigational Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PF-06939926","moa":"Dystrophin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lovastatin Lactone","moa":"HMG-CoA reductase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theriva Biologics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Theriva Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theriva Bi.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canada joins countries in real-time AstraZeneca COVID vaccine review","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia to begin Phase III trials of second COVID-19 vaccine in Nov-Dec: TASS","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Siberian Vector institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Siberian Vector institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Siberian V.."},{"orgOrder":0,"company":"IDT Biologika GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Germany Approves Third Trial of COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MVA-SARS-2-S vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IDT Biologika GmbH","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IDT Biologika GmbH \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IDT Biolog.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IMGN632","moa":"CD123","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients At The Liver Meeting\u00ae 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"MEI Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin and MEI Pharma Dosed First Patient in Japanese Pivotal Phase 2 Study of Zandelisib for Indolent B-cell non-Hodgkin's Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zandelisib","moa":"PI3-kinase p110-delta subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyowa Kirin \/ MEI Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AiViva Biopharma Initiates Phase 1\/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AIV001","moa":"VEGF","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"AiViva Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Bio.."},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cytokinetics Announces Publication Of Manuscript Detailing Baseline Characteristics Of Galactic-HF inEuropean Journal Of Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Cytokinetics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cytokinetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cytokineti.."},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Brilacidin","moa":"Il-6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Innovation Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Innovation Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovation.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Confirms that REGN-COV2 Antibody Cocktail Provided to \n President Trump Under Compassionate Use Request","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CPI-006","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Corvus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pha.."},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FTX-6058","moa":"EED","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Th.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Orphan Therapeutics Announces U.S. Patent for Its Resveratrol Formulation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Resveratrol","moa":"Angiogenesis","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Or.."},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Clemizole hydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Epygenix Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Epygenix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epygenix T.."},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioMarin Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BMN 307","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin P.."},{"orgOrder":0,"company":"BioCurity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCurity Pharma Gets Issuance of European Patent for Reduction of Side Effects Caused by Radiation Therapy Combined with Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cerium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BioCurity Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCurity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCurity .."},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bluebird Bio Announces EMA Acceptance of Marketing Authorization Application for Elivaldogene Autotemcel Gene Therapy for Cerebral Adrenoleukodystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Elivaldogene autotemcel","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Bluebird Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bluebird B.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb to Host Virtual Investor Event to Discuss Results from Phase 3 True North Trial of Zeposia\u00ae in Ulcerative Colitis at UEG Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"Sphingosine 1-phosphate receptor Edg-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces Lenzilumab in COVID-19 Program Updates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA\u00ae and ATRIPLA\u00ae Tablets in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Emtricitabine","moa":"HIV-1 reverse transcriptase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at HFSA Annual Scientific Meeting","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Ther.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS\u2019 Multidisciplinary NET Medical Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tidutamab","moa":"SSTR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech\u2019s Investigational New Drug Application Placed on Hold by the U. S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Encapsulated Live Cells Converting Ifosamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaCyte Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaCyte Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmaCyte.."},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the U.S for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegunigalsidase alfa","moa":"Alpha-galactosidase A","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Protalix BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Protalix B.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsius Pharma Achieves Positive Results In Proof Of Concept Study For TRS01 Targeting Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TRS01","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotorasib","moa":"KRAS-G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Kaneka Nutrients","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results Evaluating The Effect Of Kaneka Nutrients' Ubiquinol On Endothelial Function Published In Nutrients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Coenzyme Q10","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Kaneka Nutrients","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaneka Nutrients \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Nut.."},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Announces EC Approval of CRYSVITA\u00ae for the Treatment of X-Linked Hypophosphataemia (XLH) in Older Adolescents and Adults","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kiri.."},{"orgOrder":0,"company":"Eyevensys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EYS611","moa":"Human transferrin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Eyevensys","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eyevensys \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eyevensys .."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eureka Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS\u00ae T Cell Therapy in Hepatocellular Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ET140203","moa":"Alpha fetoprotein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eureka Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eureka Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eureka The.."},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Canada Announces Availability of Aermony RespiClick\u2122, an Innovative New Device for the Treatment of Bronchial Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharm.."},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ARCT-810","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus T.."},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Odonate Therapeutics Results of CONTESSA in the Treatment of Patients with Metastatic Breast Cancer, to Be Presented at the 2020 SABCS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Th.."},{"orgOrder":0,"company":"Arch Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1\/2 Trial in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AO-176","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arch Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arch Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arch Oncol.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa\u00ae in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivipansel","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"InDex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals\u2019 results of the phase IIb study with cobitolimod","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobitolimod","moa":"TLR9","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"InDex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"InDex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InDex Phar.."},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB (publ) Announces Next Safety and Enrollment Update for Phase Ib\/II ILIAD Combination Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ilixadencel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mendus","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Mendus \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mendus \/ N.."},{"orgOrder":0,"company":"Aeglea BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ACN00177","moa":"Homocysteine","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aeglea BioTherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection","sponsorNew":"Aeglea BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aeglea Bio.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"131I-omburtamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobomarsen","moa":"miR-155","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Miragen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Miragen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lifileucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva to Present the Results of its NATIVE Phase IIb Clinical Trial with Lanifibranor in NASH The Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline's ZEJULA is approved in Canada for first-line maintenance treatment of women with advanced ovarian cancer Fran\u00e7ais","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"INmune Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer\u2019s Drug Discovery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"XPro1595","moa":"TNF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G \/ IC-MPGN and ALS, Rare Diseases with High Unmet Need","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Presentation of Positive Results from Phase 2 Trial of OCS-01 in Patients with DME at EURETINA 2020 Virtual","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oculis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Oculis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oculis \/ N.."},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Designation to CARsgen\u2019s CT041 CLDN18.2 CAR-T Cells to Treat Gastric and Gastroesophageal Junction Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Humanized anti-claudin18.2 autologous Chimeric Antigen Receptor T Cells","moa":"Claudin18.2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CARsgen Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CARsgen Th.."},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Receives Approval for Dimethyl Fumarate Delayed-Release Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Provides Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"LY-CoV555","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Breezhaler\u00ae Approval in the European Union as a Treatment for Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Approval in Japan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation Powder for Capsule","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes that Enerzair\u00ae Breezhaler\u00ae has Been Recommended for Approval in the E.U for treating Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Indacaterol Acetate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Sosei Heptares","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Sosei Heptares \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trillium Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's seeks DCGI nod to conduct phase-3 clinical trial of Russian COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-Lenti-PD","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine Sulfate","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar .."},{"orgOrder":0,"company":"Gamida Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel for Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omidubicel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gamida Cell","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamida Cell \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Gamida Cel.."},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis and Biogen Announce EMA Filing Acceptance OF SB11, a Proposed Biosimilar Referencing Lucentis\u00ae (RANIBIZUMAB)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biogen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Biogen \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ S.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Laboratories to submit a revised protocol for conducting clinical trials of Russian COVID-19 vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology and GSK Announce Global Expansion to Phase 3 of COMET-ICE Study Evaluating VIR-7831 for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-7831","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vir Biotechnology \/ GlaxoSmithKline","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune First Patient Dosed in NexImmune Phase 1\/2 Clinical Trial of NEXI-002 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NEXI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"Karyopharm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Selinexor","moa":"Exportin-1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Karyopharm Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Karyopharm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karyopharm.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acacia Pharma Announces BYFAVO its Newly Approved Product for Procedural Sedation","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remimazolam Besylate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acacia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"Elorac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elorac Biotherapeutics Announces Amendment to Naloxone Lotion Phase III Study For Increased Access to Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Elorac","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Elorac \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Elorac \/ N.."},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Taiwan Liposome Company","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Taiwan Lip.."},{"orgOrder":0,"company":"Neurotrope","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neurotrope","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neurotrope \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Neurotrope.."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Doses First Patient in Phase 1 Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13-NK cells","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NantKwest","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"NantKwest .."},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome.."},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 'Long Haulers' in the AMP-511 ME\/CFS Clinical Trial of Ampligen","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim Immuno.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Rega Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces New Antiviral Drug Candidates Demonstrate In Vitro Activity Against HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"WP1096","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moleculin Biotech \/ Rega Institute","highestDevelopmentStatusID":"4","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Oragenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Broadly Supports Oragenics\u2019 Pre-IND Development Program for its SARS-CoV-2 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Terra CoV-2","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Oragenics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oragenics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oragenics .."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Shows Reduction of Mortality and Potent Therapeutic Activity of Anti-COVID-19 DARPin\u00ae Candidates in Advanced COVID-19 Disease Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MP0420","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Molecular Partners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Molecular Partners \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Molecular .."},{"orgOrder":0,"company":"Oncternal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncternal Therapeutics Gets Rare Pediatric Disease Designation from U.S. FDA for TK216 for Treatment of Ewing Sarcoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TK216","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oncternal Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncternal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncternal .."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bentracimab","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium\u00ae, December 9 \u2013 11","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell T.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals Announces Clinical Trial Site Expansion in its Multi-Center Phase 1\/2 Actimab-A Venetoclax Combination Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"AbFero Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abfero Announces PK Study Results For SP-420 in\n Transfusional Iron Overload -- Proceeds With\n PHASE 1-2 Trial Of Iron Chelator","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SP-420","moa":"Iron","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbFero Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbFero Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AbFero Pha.."},{"orgOrder":0,"company":"Greenwich LifeSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Greenwich LifeSciences, Inc. Announces Completion of Manufacturing of Drug for its Planned Phase III Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GP2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Greenwich LifeSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Greenwich LifeSciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Greenwich .."},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Trac.."},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"RespireRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"RespireRx .."},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sagimet To Present Data From Phase 2 Fascinate-1 Trial Of TVB-2640 in NASH at AASLD\u2019S the Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sagimet Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Bi.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Topiramate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zai Lab Dosed First Patient in Greater China in the Global Phase 2\/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Zai Lab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zai Lab \/ .."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO\u2122 and Its Gene Delivery Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavokinogene Telseplasmid","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite B.."},{"orgOrder":0,"company":"Kaleido Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kaleido Biosciences Provides Update on KB109 Clinical Data Timeline","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KB109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kaleido Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kaleido Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kaleido Bi.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Institute of Cancer Research's New Drug Targeting High-Risk Children\u2019s Cancer is Ready for Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fadraciclib","moa":"N-Myc","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Institute of Cancer Research \/ Cyclacel","highestDevelopmentStatusID":"6","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cerevel Therapeutics Dosed First Patient in Phase 2 Trial of CVL-865 for the Treatment of Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CVL-865","moa":"GABA-A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cerevel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Th.."},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Initiates a Combined Phase I\/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NMD670","moa":"ClC-1","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"NMD PHARMA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NMD PHARMA \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NMD PHARMA.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Expands its Phase II COVID-19 European Clinical \n Trial to Israel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pluri \/ No.."},{"orgOrder":0,"company":"GemVax & KAEL","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promising Phase II Results Underpin GemVax Decision to Apply for Expanded Access IND for GV1001 in Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tertomotide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"GemVax & KAEL","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GemVax & KAEL \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GemVax & K.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA\u00ae Collection During the ASDS Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Propella Therapeutics Granted U.S. Patent for New Treatment for Metastatic Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Abiraterone decanoate","moa":"Androgen receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Propella Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Propella Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Propella T.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces Presentations on Phexxi and EVO100 at Key Medical Society Meetings","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILC Therapeutics Announces \u2018Significant\u2019 COVID-19 Drug Breakthrough","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IFN Alpha-14","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ILC Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ILC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ILC Therap.."},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1\/2a MONARCH Study for Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"STK-001","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Stoke Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Stoke Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Stoke Ther.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opdivo Plus Chemotherapy Improves Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Epizyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epizyme Announces Two Lancet Oncology Publications on TAZVERIK\u00ae (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tazemetostat","moa":"EZH2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Epizyme","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Epizyme \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Epizyme \/ .."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals to Publish Results From Phase 1b Study of Waldenstrom's Macroglobulinemia in H1, 2021 - (Fidelity via NewsPoints Desk)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in Combination With Neutralizing Antibodies Against COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Salicyn-30","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Karolinska Development AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development's portfolio company Aprea Therapeutics receives FDA clearance to initiate Phase 1 study of APR-548","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"APR-548","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aprea Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Karolinska Development AB","highestDevelopmentStatusID":"5","companyTruncated":"Aprea Ther.."},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biolo.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs\u2019 Nivatrotamab for the Treatment of Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivatrotamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renibus Therapeutics\u2019 COVID-19 Treatment, RBT-9, Shows Antiviral Activity Against SARS-CoV-2 In Vitro","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Stannous protoporphyrin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Th.."},{"orgOrder":0,"company":"ARCA Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"rNAPc2","moa":"Tissue factor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ARCA Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ARCA Biopharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ARCA Bioph.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Bristol Myers Squibb's ZEPOSIA, an Oral Treatment for Relapsing Remitting Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1PR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arch Biopartners Gets Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopa.."},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calithera Biosciences\u2019 CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CB-280","moa":"Arginase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calithera Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera .."},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Gets IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for Schizophrenia and Bipolar Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Liquid Oral Suspension","sponsorNew":"OWP Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharma.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics' Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TPX-0022","moa":"CSF1R","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin-MLL","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb to Host Virtual Investor Event Focusing on Phase 3 True North Trial of Zeposia\u00ae in Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ozanimod Hydrochloride","moa":"S1P receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Samidorphan L-Malate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Alkermes Plc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alkermes P.."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Voyager Therapeutics Provides Regulatory Update On VY-HTT01 Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VY-HTT01","moa":"HTT gene expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Th.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Cytokinetics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Cytokinetics","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sobi Announces Topline Phase 3 Data of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avatrombopag Maleate","moa":"Thrombopoietin receptor","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Swedish Orphan Biovitrum AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Swedish Or.."},{"orgOrder":0,"company":"Intercept Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intercept Receives Complete Response Letter From FDA For Obeticholic Acid For the Treatment OF Fibrosis Due To NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Obeticholic Acid","moa":"FXR","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Intercept Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intercept Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Intercept .."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GB001","moa":"Prostaglandin D2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytisine","moa":"nAChR Alpha4Beta2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Film Coated Oral Tablet","sponsorNew":"Achieve Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Li.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Positive Results from Phase II BHT-II-002 Trial of Blautix in Irritable Bowel Syndrome","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Blautia Hydrogenotrophica","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Announces Expects to Complete Enrollment on its SP-102 (SEMDEXA\u2122) Phase 3 Pivotal Trial Program in 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SP-102","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals receives ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dimethyl Fumarate","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia a Gene Therapy Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Giroctocogene fitelparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Completes Patient Dosing in Phase 1b\/2a Trial of HST-001 to Treat Androgenic Alopecia in Men","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"HST-001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Histogen \/.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Results of National Institute of Allergy and Infectious Diseases\u2019 ACTT-1 Trial Published in NEJM Expand Clinical Benefits of Veklury\u00ae for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Cerecin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Rare Pediatric Disease Designation to Cerecin\u2019s Investigational Drug Tricaprilin for the Treatment of Infantile Spasms","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tricaprylin","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerecin","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerecin \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerecin \/ .."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascentage Pharma's Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Alrizomadlin","moa":"MDM2-p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces NDA for CAMCEVI\u2122 42MG Accepted for Review by the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leuprolide Mesylate","moa":"GnRH receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Foresee Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Foresee Ph.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Evaluating KRYSTEXXA\u00ae With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Noxopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noxopharm Announces First COVID-19 Patient Treated in Veyonda\u00ae Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Idronoxil","moa":"Caspase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm .."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Topline Phase 1 Clinical Trial Results of OTX-CSI","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Islatravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavorixafor","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"X4 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"X4 Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"X4 Pharmac.."},{"orgOrder":0,"company":"Elusys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elusys Therapeutics Receives Positive CHMP Opinion For Obiltoxaximab SFL For The Treatment Of Inhalation Anthrax","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Obiltoxaximab","moa":"Protective antigen","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Elusys Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elusys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elusys The.."},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US Patent Allowance for Sareum\u2019s SDC-1802 TYK2\/JAK1 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ N.."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Ther.."},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xenon Pharmaceuticals Gets FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ezogabine","moa":"KCNQ","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xenon Phar.."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nicotinamide Riboside","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ChromaDex, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ChromaDex,.."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Revs up for Xolair Biosimilar\u2019s Phase 3 Clinical Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Impel Neuropharma Presents Data from Pivotal Phase 3 Registration Study of INP104 for the Treatment of Acute Migraine at 2020 Migraine Trust Virtual Symposium","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D alpha receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Impel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Impel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Impel Phar.."},{"orgOrder":0,"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All patients included in Follicum\u2019s Phase II Study with FOL-005 for Stimulation of Hair Growth","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FOL-005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Follicum A.."},{"orgOrder":0,"company":"Philogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Philogen Announces Publication of Malignant Brain Tumor Study Results in Science Translational Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"L19TNF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Philogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/.."},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nordic Nanovector Publishes Results of Preclinical Study Demonstrating Betalutin Reverses Tumour Resistance to Rituximab in NHL Disease Models","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu) lilotomab satetraxetan","moa":"CD37","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nan.."},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Phase I\/II Study of a New Gene Therapy for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OTQ923","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Memorial S.."},{"orgOrder":0,"company":"CervoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Neflamapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"CervoMed","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CervoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CervoMed \/.."},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BOLD-100","moa":"GRP78 upregulation pathway","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Thera.."},{"orgOrder":0,"company":"CNS Pharmaceuticals","sponsor":"BSP Pharmaceuticals S.p.A","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CNS Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CNS Pharmaceuticals \/ BSP Pharmaceuticals S.p.A","highestDevelopmentStatusID":"8","companyTruncated":"CNS Pharma.."},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Inter.."},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patients Enrolled in Rigel's NIH\/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Rigel Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Rigel Phar.."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Grifols' anti-SARS-CoV-2 Hyperimmune Globulin Begins Clinical Trial in Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hyperimmune globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols In.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics to Present Data from its Positive PRISM3 Trial of CP101","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Gossamer Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GB004","moa":"HIF-1 alpha","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Gossamer Bio","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gossamer Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gossamer B.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Aurigene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis and Aurigene Announce Promising Preclinical Data to Be Presented at the ENA Symposium Back Development of a Novel CDK7 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AUR102","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Aurigene","highestDevelopmentStatusID":"4","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Canada and BioNTech Initiate Rolling Submission to Health Canada for SARS-CoV-2 Vaccine Candidate BNT162b2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Th.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark's Antiviral Combination for Moderate COVID-19 Shows no Clinical Benefit","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed with Tp-1454 IN Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ipilimumab","moa":"PK M1\/M2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo P.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-3434","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ORIC-101","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ORIC Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharm.."},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AXO-AAV-GM1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene T.."},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Italfarmaco Gets FDA Rare Pediatric Disease Designation for Givinostat in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Givinostat","moa":"HDAC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfa.."},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesofensine","moa":"Serotonin transporter","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Received European Medicines Agency (EMA) PRIME Designation for Iptacopan (LNP) in C3 Glomerulopathy (C3G)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Penelope-B Trial of Ibrance\u00ae (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Palbociclib","moa":"CDK4\/Cyclin D1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav\u2122 Oral Solution for Idiopathic Hypersomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"University of Exeter Medical School","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Study Tests if BCG Vaccine Protects Against COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BCG vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Exeter Medical School","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Exeter Medical School \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Begins Phase 1 Trial of Niclosamide as COVID-19 Drug in Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong P.."},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA\u00ae (Rituximab Injection) in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent B.."},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Junshi\u2019s Phase III JUPITER-02 Study of Toripalimab and Gemcitabine Combo to Treat Recurrent Nasopharyngeal Carcinoma Meets Endpoints","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Toripalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai J.."},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Farmalider SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspargo Laboratories, Inc. Acquires International Rights to Sildenafil Oral Spray for the Treatment of Erectile Dysfunction","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Farmalider","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo La.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Vivo Capital","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Raises $85 Million in Series C Financing to Advance Clinical Development of OP-1250 in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series C Financing","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Olema Oncology \/ Vivo Capital","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Shionogi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Positive NICE Recommendation for Rizmoic\u00ae (naldemedine) for OIC","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Naldemedine Tosylate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Film Coated Tablet","sponsorNew":"Sandoz B2B \/ Shionogi","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B.."},{"orgOrder":0,"company":"Jaguar Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Jaguar Health Inks Financing Transaction Pact Involving the Sale of Royalty Rights Related to Future Mytesi Revenue Stream for $5 Million","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Jaguar Health","amount2":0.02,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Jaguar Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jaguar Hea.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Announces EU Decision for Expanded Use of IMBRUVICA\u00ae in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Initiates Subject Dosing in a Phase 1 Clinical Trial of exoIL-12\u2122 for the Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"exoIL-12","moa":"IL-12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Blueprint Medicines Reports ARROW Trial Data at ESMO Virtual Congress 2020 Demonstrating Durable Clinical Benefits of GAVRETO\u2122 in Patients with Advanced RET-Mutant Medullary Thyroid Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pralsetinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Blueprint Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Blueprint Medicines \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Blueprint .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Mobocertinib","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Announces FDA Approval of Fetroja\u00ae for Hospital-Acquired Bacterial Pneumonia AND Ventilator-Associated Bacterial Pneumonia","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefiderocol","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"LUCA Science","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LUCA Science Announces Joint Research with the University of Oxford, Nuffield Department of Women's & Reproductive Health","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"Mitochondrial therapy","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"LUCA Science \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Scien.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$76.9 million","upfrontCash":"$7.4 million","newsHeadline":"Vedanta Biosciences Awarded Up to $76.9 Million from BARDA to Advance the Development of VE303","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"VE303","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vedanta Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Institute of Cancer Research's New Drug Targeting DNA Repair Shows Promise in Range of Advanced Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"BAY1895344","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"The Instit.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mesoblast Receives Complete Response Letter From the FDA for its BLA for Steroid-Refractory Acute Graft Versus Host Disease in Children","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Initiates Patient Dosing in Phase 1\/2 Clinical Trial of exoSTING\u2122 for the Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"exoSTING","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Imvaq Therapeutics","sponsor":"Hanne Capital","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Imvaq Therapeutics Raises $15 Million in Series B Financing to Fund IND and Phase 1 Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series B Financing","leadProduct":"MQ710","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Imvaq Therapeutics","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Imvaq Therapeutics \/ Hanne Capital","highestDevelopmentStatusID":"4","companyTruncated":"Imvaq Ther.."},{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"The Pirbright Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enesi Pharma's ImplaVax\u00ae-Enabled Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"PRRSV vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Enesi Pharma Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enesi Pharma Limited \/ The Pirbright Institute","highestDevelopmentStatusID":"2","companyTruncated":"Enesi Phar.."},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"$516.0 million","upfrontCash":"$438.0 million","newsHeadline":"Ligand Completes Acquisition of Pfenex Inc","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0.52000000000000002,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Pfenex \/ Ligand","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ L.."},{"orgOrder":0,"company":"Aegle Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aegle Therapeutics Announces Award of Grant by U.S. DOD Congressionally Directed Medical Research Programs for Development of AGLE-102","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"AGLE-102","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aegle Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aegle Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Aegle Ther.."},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences and IGAN Biosciences Collaborate to Study ImmTOR\u2122 Immune Tolerance Platform in Combination with IgA Protease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IGAN Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGAN Biosciences \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"IGAN Biosc.."},{"orgOrder":0,"company":"Vincera Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vincera Pharma Announces Exclusive License Agreement with Bayer for Oncology Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"VIP152","moa":"PTEFb","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vincera Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vincera Pharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Vincera Ph.."},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Launches to Transform the Treatment of Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"suPAR","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Walden Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Walden Biosciences \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Walden Bio.."},{"orgOrder":0,"company":"Federal Emergency Management Agency","sponsor":"US WorldMeds","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"US WorldMeds Advances Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Federal Emergency Management Agency","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Federal Emergency Management Agency \/ US WorldMeds","highestDevelopmentStatusID":"12","companyTruncated":"Federal Em.."},{"orgOrder":0,"company":"Novellus","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for ARDS in COVID","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"NC-iMSCs therapy","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Novellus \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/.."},{"orgOrder":0,"company":"Celiac Disease Foundation","sponsor":"Provention Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celiac Disease Foundation Partners with Provention Bio on Its Phase 2b Study of Celiac Disease Therapeutic PRV-015","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"PRV-015","moa":"IL-15","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Celiac Disease Foundation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Celiac Disease Foundation \/ Provention Bio","highestDevelopmentStatusID":"8","companyTruncated":"Celiac Dis.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Announces EC Approval of Agreement to Supply 200 Million Doses of Janssen\u2019s COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Vinnova","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Oblique Therapeutics Together with Collaborators at Sahlgrenska University Hospital and Karolinska Institutet Granted 5MSEK by Vinnova","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"\u03b1SARS-CoV-2 antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oblique Therapeutics \/ Vinnova","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Th.."},{"orgOrder":0,"company":"Berkeley Lights","sponsor":"Abveris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abveris Announces Antibody Discovery Agreement with Immunitas Using the Berkeley Lights Beacon\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Berkeley Lights","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Berkeley Lights \/ Abveris","highestDevelopmentStatusID":"2","companyTruncated":"Berkeley L.."},{"orgOrder":0,"company":"Almirall","sponsor":"University of Dundee","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Almirall","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Almirall \/ University of Dundee","highestDevelopmentStatusID":"2","companyTruncated":"Almirall \/.."},{"orgOrder":0,"company":"VirTrial","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BetterLife Announces VirTrial, as Clinical Trial Patient Monitoring Partner","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"AP-003","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VirTrial","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"VirTrial \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VirTrial \/.."},{"orgOrder":0,"company":"Kineta","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"KCP-506","moa":"nAchR","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ G.."},{"orgOrder":0,"company":"CSL Behring","sponsor":"Commonwealth of Australia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSL Finalises Agreement to Supply 51 Million Doses of UQ Covid-19 Vaccine Candidate to Australia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"V451","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CSL Behring \/ Commonwealth of Australia","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behrin.."},{"orgOrder":0,"company":"Galecto","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fibrosis Biotech Galecto Files for a $100 Million IPO","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"GB0139","moa":"Galectin-3","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Galecto","amount2":0.10000000000000001,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Inhalation","sponsorNew":"Galecto \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ .."},{"orgOrder":0,"company":"Lobsor Pharmaceuticals","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STADA Expands Specialty Footprint Through Acquisition of Innovative Therapy for Treating Advanced Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Lobsor Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lobsor Pharmaceuticals \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"Lobsor Pha.."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SIGA Announces Public Health Agency of Canada Intent to Purchase Up To 33,300 Courses of Oral TPOXX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Techn.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$632.0 million","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Announces Capital Increase to Prepare for the Launch of Daridorexant and Further Fund Its Diversified Pipeline","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0.63,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0.63,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Adds Israel Rights to Movantik\u00ae From AstraZeneca","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Naloxegol Oxalate","moa":"Mu-opioid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic ","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ RedHill Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"$125.0 million","newsHeadline":"Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trastuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0.28000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Oral","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ M.."},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Affamed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Licensing Agreement with Affamed for KDT-3594, a Novel Investigational Drug for Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"KDT-3594","moa":"Dopamine receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kissei Pharmaceutical \/ Affamed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pha.."},{"orgOrder":0,"company":"Mid-Atlantic BioTherapeutics","sponsor":"Connectyx Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Connectyx Technologies Holdings Group Announces Agreement with Mid-Atlantic BioTherapeutics for Treatment of Symptomatic Rabies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"IMT504","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mid-Atlantic BioTherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mid-Atlantic BioTherapeutics \/ Connectyx Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Mid-Atlant.."},{"orgOrder":0,"company":"Rezolute","sponsor":"Cam Capital","pharmaFlowCategory":"D","amount":"$41.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-List to Nasdaq","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Private Placement","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Cam Capital","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/.."},{"orgOrder":0,"company":"Acacia Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acacia Pharma Completes Drawdown from \u20ac25 million Loan Facility from Cosmo Pharmaceuticals to Support US Launches of BARHEMSYS\u00ae and BYFAVO\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Acacia Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Acacia Pharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acacia Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$486.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's COVID-19 Long-Acting AntiBody Combination AZD7442 Rapidly Advances into Phase III Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"AstraZeneca","amount2":0.48999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.48999999999999999,"dosageForm":"","sponsorNew":"AstraZeneca \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"World Health Organization","sponsor":"Governemnt of Mexico","pharmaFlowCategory":"D","amount":"$159.8 million","upfrontCash":"Undisclosed","newsHeadline":"Mexico Makes Nearly $160 Million Down Payment for COVAX Vaccine Plan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0.16,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"World Health Organization \/ Governemnt of Mexico","highestDevelopmentStatusID":"1","companyTruncated":"World Heal.."},{"orgOrder":0,"company":"Priothera","sponsor":"Fountain Healthcare","pharmaFlowCategory":"D","amount":"$35.4 million","upfrontCash":"Undisclosed","newsHeadline":"Priothera Closes \u20ac30 Million Series A Financing to Develop Highly Promising Therapies for Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Mocravimod","moa":"S1PR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Priothera","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"Priothera \/ Fountain Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Priothera .."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Bausch Health","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$10.0 million","newsHeadline":"Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"EdiGene","sponsor":"3H Health Investment","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"ET-01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"EdiGene","amount2":0.070000000000000007,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"EdiGene \/ 3H Health Investment","highestDevelopmentStatusID":"6","companyTruncated":"EdiGene \/ .."},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Omega Funds","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chord Therapeutics Launches with USD 16 million Series A Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Cladribine","moa":"DNA polymerase","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Chord Therapeutics","amount2":0.02,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Omega Funds","highestDevelopmentStatusID":"1","companyTruncated":"Chord Ther.."},{"orgOrder":0,"company":"University of Houston","sponsor":"AuraVax Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AuraVax Therapeutics Enters into Exclusive License Option Agreement with the University of Houston for Intranasal Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Houston","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"University of Houston \/ AuraVax Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Sidero Bioscience","sponsor":"SRS Life Sciences Pte ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sidero Bioscience Announces Agreement with SRS Life Sciences for Commercialization of BioFe for Iron Deficiency","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"FTH1","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed","graph3":"Sidero Bioscience","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sidero Bioscience \/ SRS Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Sidero Bio.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Mirvetuximab Soravtansine","moa":"Tubulin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Sickle Cell Disease Association of America","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"ARU-1801","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Sickle Cell Disease Association of America","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sc.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Regains RSV Vaccine Programme from Merck","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1172","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Hunan Warrant Chiral Pharmaceutical","sponsor":"CytoDyn","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA Approval in Philippines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hunan Warrant Chiral Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hunan Warrant Chiral Pharmaceutical \/ CytoDyn","highestDevelopmentStatusID":"10","companyTruncated":"Hunan Warr.."},{"orgOrder":0,"company":"Knopp Biosciences LLC","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Knopp Biosciences NIH-Funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Kv7.2\/Kv7.3 cellular potassium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Knopp Biosciences LLC","amount2":0.01,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Knopp Biosciences LLC \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Knopp Bios.."},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Lademirsen","moa":"miR-21","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Th.."},{"orgOrder":0,"company":"Novellus","sponsor":"NoveCite","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"$5.0 million","newsHeadline":"Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) and Other Acute Respiratory Conditions","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Induced Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0.059999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Novellus \/ NoveCite","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/.."},{"orgOrder":0,"company":"Rappta Therapeutics","sponsor":"Novo Seeds","pharmaFlowCategory":"D","amount":"$10.6 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Seeds Co-Leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"PTPA","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Rappta Therapeutics","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Rappta Therapeutics \/ Novo Seeds","highestDevelopmentStatusID":"1","companyTruncated":"Rappta The.."},{"orgOrder":0,"company":"University of Goettingen","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iksuda Therapeutics Enters License Agreement With University of Goettingen to Develop a New Generation of Antibody Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of Goettingen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Goettingen \/ Iksuda Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"Hospital Clinic of Barcelona","sponsor":"Immuneel Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immuneel, HCB and IDIBAPS Enter into a Collaboration and Licensing Agreement for CAR T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Autologous T-cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hospital Clinic of Barcelona","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hospital Clinic of Barcelona \/ Immuneel Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Hospital C.."},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Vaxart","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KindredBio Expands Manufacturing Agreement with Vaxart","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"VXA-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Centaur Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centaur Pharmaceuticals \/ Vaxart","highestDevelopmentStatusID":"6","companyTruncated":"Centaur Ph.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Israel's Redhill Biopharma Signs Manufacturing Deal for Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$8.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Tosatoxumab","moa":"Staphylococcus aureus alpha toxin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Polyphor","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$18.4 million","upfrontCash":"Undisclosed","newsHeadline":"Polyphor Receives CARB-X Award of up to USD 18.44 Million to Support Development of New Antibiotic Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Thanatin-derivative antibiotic","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Polyphor","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Polyphor \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Polyphor \/.."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"EverInsight Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AffaMed Therapeutics Announces Merger with EverInsight Therapeutics and Appoints Dayao Zhao, M.D., Ph.D. as CEO","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Fasedienol","moa":"Chemoreceptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"AffaMed Therapeutics \/ EverInsight Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Takara Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Merck Licenses CRISPR Genome-Editing Technology to PanCELLa and Takara Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Takara Bio","highestDevelopmentStatusID":"3","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nimbus Therapeutics Announces $60 Million Private Financing From New Investors to Advance Expanded Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"TYK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Nimbus Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$57.6 million","upfrontCash":"Undisclosed","newsHeadline":"Cedilla Therapeutics Announces $57.6 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cedilla Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Cedilla Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"4","companyTruncated":"Cedilla Th.."},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Neogene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"CAR-T cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Neogene","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bios.."},{"orgOrder":0,"company":"University of Massachusetts Medical School","sponsor":"Foundation to Fight H-ABC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foundation to Fight H-ABC, University of Massachusetts Medical School and Yale University Initiate Gene Therapy Study Targeting Cure for Rare Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AAV-based gene","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"University of Massachusetts Medical School","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Massachusetts Medical School \/ Foundation to Fight H-ABC","highestDevelopmentStatusID":"2","companyTruncated":"University.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirona Biochem Signs Agreement with Global Pharmaceutical Company for Clinical Trial of its Novel Skincare Compound TFC-1067","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"TFC-1067","moa":"Tyrosinase activity","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"$506.0 million","upfrontCash":"$47.0 million","newsHeadline":"SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"SK Biopharmaceuticals","amount2":0.51000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.51000000000000001,"dosageForm":"Tablet","sponsorNew":"SK Biopharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"SK Biophar.."},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Axis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"PharmaEssentia","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaEssentia \/ Axis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"PharmaEsse.."},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Bio.."},{"orgOrder":0,"company":"Azitra","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company Azitra","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"ATR-01","moa":"Filaggrin","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Azitra","amount2":0.02,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Azitra \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Azitra \/ L.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncopeptides Signs \u20ac 40 Million Loan Agreement with the EIB","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ European Investment Bank","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"XOMA","sponsor":"Rezolute","pharmaFlowCategory":"D","amount":"$1.9 million","upfrontCash":"Undisclosed","newsHeadline":"XOMA Earns $1.9 Million Associated with Two Partner Developments","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"RZ358","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"XOMA","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XOMA \/ Rezolute","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Rez.."},{"orgOrder":0,"company":"Lactiga","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Lactiga Announces NIH-Funded Partnership with Mount Sinai to Advance its Patented Biologic for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"LCTG-001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lactiga \/ Icahn School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ .."},{"orgOrder":0,"company":"Gemini Therapeutics","sponsor":"FS Development Corp","pharmaFlowCategory":"D","amount":"$216.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"GEM103","moa":"Complement Factor H","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gemini Therapeutics","amount2":0.22,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.22,"dosageForm":"Intravitreal Injection","sponsorNew":"Gemini Therapeutics \/ FS Development Corp","highestDevelopmentStatusID":"8","companyTruncated":"Gemini The.."},{"orgOrder":0,"company":"Greenteaspoon","sponsor":"PanTheryx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PanTheryx Acquires Goodgut\u00ae and Preliva\u00ae Brands from Greenteaspoon Inc.","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Prebiotics","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Greenteaspoon","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Greenteaspoon \/ PanTheryx","highestDevelopmentStatusID":"12","companyTruncated":"Greenteasp.."},{"orgOrder":0,"company":"Enzolytics","sponsor":"BioClonetics Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzolytics, Inc. Announces Execution of Binding Letter of Intent for Merger with BioClonetics Immunotherapeutics, Inc.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Anti-HIV recombinant monoclonal antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enzolytics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enzolytics \/ BioClonetics Immunotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Enzolytics.."},{"orgOrder":0,"company":"Yale Cancer Center","sponsor":"Alliance for Cancer Gene Therapy","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Yale Cancer Center Receives ACGT Grant To Advance Strategies For Treating Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"MAEGI","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Yale Cancer Center","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Yale Cancer Center \/ Alliance for Cancer Gene Therapy","highestDevelopmentStatusID":"1","companyTruncated":"Yale Cance.."},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","amount":"$190.0 million","upfrontCash":"Undisclosed","newsHeadline":"Praxis Precision Medicines Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Praxis Precision Medicines","amount2":0.19,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.19,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"9","companyTruncated":"Praxis Pre.."},{"orgOrder":0,"company":"Eversana","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eversana","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eversana \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eversana \/.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Financing","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Adjuvant Capital","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Levosimendan","moa":"PDE3","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Orion Corporation \/ Tenax Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar signs an agreement with Jazz Pharmaceuticals for lurbinectedin in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"The National Comprehensive Cancer Network","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Neratinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"The National Comprehensive Cancer Network","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The National Comprehensive Cancer Network \/ Puma Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"The Nation.."},{"orgOrder":0,"company":"Aptorum","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aptorum Group Announces Closing of $9.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"SACT-1","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Aptorum","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Aptorum \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"5","companyTruncated":"Aptorum \/ .."},{"orgOrder":0,"company":"Antengene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Antengene signs MoU with WuXi Biologics to advance development of innovative oncology medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Antengene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antengene \/ WuXi Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Antengene .."},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Initiates Post-Exposure Prophylaxis Clinical Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CT-P59","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion .."},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Human Trials of Russian Covid-19 Vaccine Abroad, in UAE, Have Launched","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Siberian Vector institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Siberian Vector institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Siberian V.."},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Glycostem\u2019s oNKord\u00ae Orphan Drug Designation for Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"oNKord","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Glycostem Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycostem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Glycostem .."},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avenue Therapeutics Receives Complete Response Letter from USFDA for IV Tramadol","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Avenue Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avenue Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avenue The.."},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gannex a Wholly Owned Subsidiary of Ascletis Pharma Received US IND Approval for its NASH Drug Candidate ASC42","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASC42","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"IND Enabling","graph3":"Ascletis Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Ascletis P.."},{"orgOrder":0,"company":"University of Glasgow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Glasgow Research Details Promising Precision Medicine Approach in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"University of Glasgow","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Glasgow \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amicus Therapeutics Announces Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AT-GTX-501","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Amicus Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Amicus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amicus The.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Takeda Announces Safety and Efficacy of Subcutaneous Entyvio Sustained During Long-term Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Pooled Efficacy Data for Derazantinib in iCCA Patients with FGFR2 Gene Mutations and Amplifications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Targovax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Targovax Announces that the Oncos-102 and Durvalumab Trial Successfully Completes Part 1 in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Targovax \/ Astrazeneca","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"With the Priority Review Underway at FDA, Oncopeptides Moves Forward with Intent to File for Conditional Approval of Melflufen with EMA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Melphalan Flufenamide","moa":"DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Pharmaceutical Present STELARA\u00ae Five-Year Results from Long-term Extension Study of Clinical Response and Remission in Patients with Moderate to Severe Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's TREMFYA\u00ae Induces Clinical and Endoscopic Improvements in Patients with Moderately to Severely Active Crohn's Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS\u00ae (ravulizumab-cwvz) with Significantly Reduced Infusion Time","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ravulizumab","moa":"Completent C5","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Alexion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alexion Ph.."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunomedics Announces FDA Orphan Drug Designation of Trodelvy\u2122 for Adult and Pediatric Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Phase III FIDELIO-DKD Study Presented at the American Society of Nephrology (ASN)\u2019s Kidney Week 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"Morphic Therapeutic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MORF-057","moa":"Integrin alpha-4\/beta-7","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Morphic Therapeutic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Morphic Therapeutic \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Morphic Th.."},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunesis Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SNS-510","moa":"PDPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sunesis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Ph.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's Mirikizumab Shows Improved Symptom and Reduces Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mirikizumab","moa":"IL-23p19 subunit","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured at EORTC-NCI-AACR Annual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Th.."},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VE202","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Vedanta Biosciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"6","companyTruncated":"Vedanta Bi.."},{"orgOrder":0,"company":"Oxular","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OXU-003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxular","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxular \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oxular \/ N.."},{"orgOrder":0,"company":"Altimmune","sponsor":"UAB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altimmune and UAB Announce Publication of Compelling Pre-clinical Data for AdCOVID\u2122 Intranasal COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AdCOVID","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Altimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altimmune \/ UAB","highestDevelopmentStatusID":"4","companyTruncated":"Altimmune .."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revolution Medicines to Present Interim Data from Phase 1b\/2 Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cobimetinib","moa":"SHP2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Revolution Medicines","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Revolution.."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor to be Presented at ASN's Kidney Week 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GBT Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders for Development of Oxbryta\u00ae Tablets","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Voxelotor","moa":"HbA positive","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Global Blood Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Global Blood Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Global Blo.."},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kuur Therapeutics Announces Publication of Interim Phase 1 Data for CAR-NKT Cell Therapy KUR-501 in Nature Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kuur Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Thera.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FR104","moa":"CD28","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"PPAR gamma","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Reports Interim Results from Phase 1\/2 Study Fides-02 Exploring Derazantinib in Patients with Advanced Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Prestige BioPharma Pte Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prestige Biopharma Receives Positive EMA Opinion on Orphan Designation for PBP1510 for Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PBP1510","moa":"PAUF protein","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prestige BioPharma Pte Ltd","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Prestige BioPharma Pte Ltd \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prestige B.."},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuroRx and Relief Announce Efficacy Data from Patients Treated with RLF-100\u2122 Under the U.S. FDA Expanded Access Protocol Authorization","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aviptadil Acetate","moa":"VIP receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NRx Pharmaceuticals \/ Relief Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharma.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Pharmaceuticals' Dupixent\u00ae Reduced Severe Asthma Attacks in Children","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanobiotix Injects First Patient with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ UNIV TX MD ANDERSON","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SER-109","moa":"Microbiome","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Seres Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seres Ther.."},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Buntanetap","moa":"APP","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bi.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis' Inhaled Antisense Medicine Demonstrates Potential as a Novel Treatment for Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IONIS-ENAC-2.5Rx","moa":"ENaC","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid\u2019s Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CytRx Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Funapide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Flexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Flexion Th.."},{"orgOrder":0,"company":"Osmotica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JAMA Ophthalmology Publishes Pooled Analysis of Data from two Phase 3 Clinical Trials of Osmotica's Upneeq\u2122 for Acquired Ptosis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Osmotica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Osmotica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Osmotica P.."},{"orgOrder":0,"company":"Linnaeus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Linnaeus Therapeutics Dosed First Patient in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA\u00ae for Treatment of Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"LNS8801","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Linnaeus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Linnaeus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Linnaeus T.."},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix\u2122 Intranasal Antiviral Protection Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypromellose","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nasus Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Nasus Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nasus Phar.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvation Bio Announces FDA Acceptance of IND Application for NUV-422 for Treatment of Patients with High-grade Gliomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NUV-422","moa":"CDK2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Radiation therapy","moa":"p-STAT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTI BioPharma Initiates Rolling Submission of NDA for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"CTI BioPharma Corp","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTI BioPha.."},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure gets abstract on the NeuroRestore platform against Alzheimer's accepted for poster presentation at CTAD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure P.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"National Institutes of Health Launches its ACTIV-5 \u201cBig Effect Trial\u201d Evaluating Humanigen\u2019s Lenzilumab\u2122 as Potential COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VAC2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research UK","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Ce.."},{"orgOrder":0,"company":"CytoAgents","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoAgents Launches Clinical Trials for GP1681, Treatment of COVID-19 Cytokine Storm","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GP1681","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoAgents \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents.."},{"orgOrder":0,"company":"BryoLogyx Inc","sponsor":"Curia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BryoLogyx Announces Completion of World\u2019s First GMP Synthesis of Bryostatin-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bryostatin-1","moa":"PKC","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"BryoLogyx Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BryoLogyx Inc \/ Albany Molecular Research Inc.","highestDevelopmentStatusID":"4","companyTruncated":"BryoLogyx .."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aliqopa\u2122 (copanlisib) in Combination With Rituximab Meets Primary Endpoint in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Copanlisib","moa":"PI3K p110-alpha subunit","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"Vaxart","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VXA-CoV2-1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vaxart","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vaxart \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxart \/ N.."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoceutics Expands IP Portfolio With Additional Patents for ONC201 and ONC212","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC212","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma Intends to Submit a Registration Application in Europe in 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Moberg Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moberg Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Moberg Pha.."},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD\/NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tesamorelin Acetate","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Theratechnologies","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Hormone","amount2New":0,"dosageForm":"","sponsorNew":"Theratechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theratechn.."},{"orgOrder":0,"company":"Apogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apogenix Advances Clinical Development of CD95L Inhibitor Asunercept in European COVID-19 Phase II Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Asunercept","moa":"CD95","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apogenix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apogenix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/.."},{"orgOrder":0,"company":"Passage Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Passage Bio Announces Publication of Preclinical Data Supporting Advancement of PBGM01 into Clinic","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PBGM01","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intra-cisterna Magna Injection","sponsorNew":"Passage Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bi.."},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"ACE2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Taiwan Liposome Company","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Taiwan Liposome Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiwan Lip.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics\u2019 Allogeneic Cell Therapy Product, Allob, Shows 90% Fusion Rate at 24 Months in Phase II A Studyinn Lumbar Spinal Fusion","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALLOB","moa":"","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Introduces NINDANIB for the Treatment of Pulmonary Fibrosis in India","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nabriva\u2019s XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lefamulin Acetate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nabriva Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nabriva Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nabriva Th.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi Announces Publication of Two Studies in the Lancet Infectious Diseases Highlighting the Efficacy and Safety of Fetroja\u00ae For the Treatment of Infections Due To Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Medicinova","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediciNova Announces Positive Findings on MN-001 in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience\u2122 2020","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipelukast","moa":"5-LO","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Medicinova","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicinova \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Biomica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BMC128","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Biomica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biomica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biomica \/ .."},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CDX-0159","moa":"Tyrosine kinase KIT","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Celldex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Th.."},{"orgOrder":0,"company":"Vaxil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxil Initiates Pre-Clinical Study in New Oncology Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MUC1-SP-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Vaxil Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxil Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vaxil Bio .."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"PMV Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PC14586","moa":"p53","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PMV Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"PMV Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PMV Pharma.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaptysBio Reports Positive Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Altamira T.."},{"orgOrder":0,"company":"Uniqure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"uniQure Announces Enrollment of Next Two Patients in Phase I\/II Clinical Trial of AMT-130 for the Treatment of Huntington\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV5-miHTT","moa":"Huntingtin mRNA","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Stereotaxic Infusion","sponsorNew":"Uniqure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ .."},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Goldfinch Bio Announces Presentation of Phase 1 Clinical Data for Lead Precision Kidney Therapeutic Candidate, Gfb-887","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch .."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israeli Ministry of Health Authorizes Initiation of Enlivex's Phase II Clinical Trial of Allocetra in COVID-19 Severe and Critical Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuGenerex Immuno-Oncology Publishes Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2) Immunotherapeutic Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AE37 Peptide","moa":"Helper T lymphocyte","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Bi.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science' Results from Masitinib Study AB07015 in Severe Asthma Have Been Selected at an American Thoracic Society symposium Symposium","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparc Reports Positive Top-Line Results of Phase 3 Clinical Trial of SDN-037","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SDN-037","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"Orca Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orca Bio Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Orca-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TregGraft","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Orca Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orca Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orca Bio \/.."},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia Approves Second Covid-19 Vaccine After Preliminary Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EpiVacCorona","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Siberian Vector institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Siberian Vector institute \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Siberian V.."},{"orgOrder":0,"company":"Northwest Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Northwest Biotherapeutics Announces Data Lock of Phase III Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"DCVax-L","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Northwest Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Northwest Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Northwest .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KT-474","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera The.."},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio\u2019s Expanded Phase 2 Study of Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aldoxorubicin HCl","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"CytRx Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"CytRx Corporation \/ ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"CytRx Corp.."},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"University of Notre Dame","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advancement of Anticancer Compounds for B Cell Cancer Therapy Targeting a Cellular Stress Response Mechanism","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"B-I09","moa":"IRE-1 RNAse","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"The Wistar Institute","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The Wistar Institute \/ University of Notre Dame","highestDevelopmentStatusID":"4","companyTruncated":"The Wistar.."},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CpG 1018","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medigen Vaccine Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medigen Vaccine Biologics \/ Dynavax Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Medigen Va.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iovance Biotherapeutics to Present Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"LN-145","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Bi.."},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"STING","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Mersana Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mersana Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mersana Th.."},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genocea Announces Upcoming Data Presentations at Virtual SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GEN-009","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genocea","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genocea \/ .."},{"orgOrder":0,"company":"GNT Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz for Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nelonemdaz","moa":"NMDA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"GNT Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GNT Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GNT Pharma.."},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CFTX-1554","moa":"Angiotensin II receptor type 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Confo Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Confo Ther.."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Announces Abstract for CI-8993 Accepted for Presentation at SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CI-8993","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"ImCheck Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ICT01","moa":"BTN3A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImCheck Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImCheck Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ImCheck Th.."},{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astex and Otsuka Announce Results of Phase 3 ASTRAL-2 and ASTRAL-3 Studies of Guadecitabine in Patients with Previously Treated AML and Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Guadecitabine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Astex Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Astex Phar.."},{"orgOrder":0,"company":"Xencor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xencor to Present Data from the Phase 1 Study of XmAb\u00ae20717 and Three Research Programs at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"XmAb20717","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ N.."},{"orgOrder":0,"company":"Bicycle Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BT7480","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bicycle Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bicycle Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bicycle Th.."},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VX-814","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pha.."},{"orgOrder":0,"company":"Qihan Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qihan Biotech Unveils its Program to Develop Immunologically Privileged Human Stem Cells for Allogeneic Cell Therapies","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Allogeneic cell therapies","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Qihan Biotech","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Qihan Biotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Qihan Biot.."},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Reports Positive Results from ASPEN-1 Phase 3 Trial of DaxibotulinumtoxinA for Injection in Cervical Dystonia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Th.."},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Taysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-102 as a Treatment for Rett Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TSHA-102","moa":"MECP2 gene","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Taysha Gene Therapies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gen.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's New First-in-Class Phase 3 Data Demonstrate TREMFYA Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Guselkumab","moa":"IL-23","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KVD824","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"KalVista Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista P.."},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sage Therapeutics Announces Positive Interim, Zuranolone Safety and Tolerability Data from SHORELINE Study in Patients with MDD","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Thera.."},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tevogen Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Thomas Jefferson University","highestDevelopmentStatusID":"5","companyTruncated":"Tevogen Bi.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARISE-3 Phase 3 Trial Completion Expected by End of 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX For The Treatment Of Cataplexy In Adult Patients With Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Harmony Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC\u2122 ODT For The Preventive Treatment Of Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rimegepant Sulfate","moa":"CGRP receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Biohaven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Biohaven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biohaven P.."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVrh10-h.SGSH","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Authorizes Phase 1 Trial of ImmunityBio\u2019s Novel COVID-19 Vaccine Candidate hAd5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anavex Life Sciences Announces Positive Results from Phase 2 Clinical Trial Evaluating ANAVEX\u00ae2-73 in Parkinson\u2019s Disease Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Blarcamesine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Lif.."},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"CDK4\/CDK6","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"G1 Therapeutics, Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"G1 Therape.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Present Phase 1 Data of Lemzoparlimab at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lemzoparlimab","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MS1819","moa":"Dietary triglyceride ester bond hydrolysis","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"First Wave BioPharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave.."},{"orgOrder":0,"company":"Shasqi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shasqi Announces Click Chemistry Breakthrough with First-Ever Human Application in Launch of Clinical Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SQL70","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Shasqi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shasqi \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shasqi \/ N.."},{"orgOrder":0,"company":"Arvinas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arvinas Announces Pipeline Programs Targeting Validated and Classically \u201cUndruggable\u201d Disease-Causing Proteins","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Arvinas","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arvinas \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Arvinas \/ .."},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/.."},{"orgOrder":0,"company":"Replimune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Replimune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Replimune .."},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANVISA Authorizes Sorrento Therapeutics\u2019 Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Abivertinib","moa":"BTK","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento T.."},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recipharm\u2019s Proprietary Molecule Erdosteine has been Positively Tested As Part of COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Erdosteine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Recipharm AB","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recipharm AB \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Recipharm .."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"4D Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4D Pharma Announces Three Presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MRx0518","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"4D Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma .."},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affimed Announces Presentation of Preclinical Data on AFM13-Targeted NK Cells at the SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ .."},{"orgOrder":0,"company":"BioNTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT311","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioNTech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioNTech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioNTech \/.."},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NL-201","moa":"Il-2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin .."},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"Alivio Therapeutics Awarded $3.3 Million from U.S. Department of Defense","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"ALV-304","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alivio Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Alivio The.."},{"orgOrder":0,"company":"Zenith Epigenetics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Ipilimumab","moa":"BET","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Zenith Epigenetics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zenith Epigenetics \/ National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Zenith Epi.."},{"orgOrder":0,"company":"Dexcom","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lilly and Dexcom Team Up on New Program to Help Improve Diabetes Management","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Insulin Lispro","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Dexcom","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dexcom \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Dexcom \/ E.."},{"orgOrder":0,"company":"NuGenerex","sponsor":"Bintai Kinden","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"NuGenerex Closes Licensing & Distribution Agreement with Bintai Kinden to Advance Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ii-Key-SARS-CoV-2 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NuGenerex","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NuGenerex \/ Bintai Kinden","highestDevelopmentStatusID":"1","companyTruncated":"NuGenerex .."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamond Supports GenSight Biologics in LUMEVOQ MAA Submission","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Requests Emergency Approval for COVID-19 Therapy Given to Trump","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Krystal Biotech to Present Pre-clinical Data Highlighting KB301 for Aesthetic Indications at the ASDS 2020 Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KB301","moa":"COL3A1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Krystal Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Bi.."},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emergent BioSolutions\u2019 COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Emergent BioSolutions \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Emergent B.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MB-105","moa":"PSCA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CLBS119","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata The.."},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Xenon Pharmaceuticals Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NBI-921352","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Xenon Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine.."},{"orgOrder":0,"company":"Zydus Cadila","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus launches India\u2019s first pressurized Metered Dose Inhaler for patients suffering from Chronic Obstructive Pulmonary Disease","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Formoterol Fumarate","moa":"ADRB2","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Zydus Cadila","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Zydus Cadila \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Cadi.."},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$409.0 million","upfrontCash":"$32.0 million","newsHeadline":"Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"GPCR","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0.40999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40999999999999998,"dosageForm":"","sponsorNew":"Sosei Heptares \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Hept.."},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santhera to Discontinue Phase 3 SIDEROS Study and Development of\n Puldysa\u00ae in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Idebenone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera P.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead Phase 2b\/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Filgotinib","moa":"JAK1","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Filed U.S IND for Its Influenza Antiviral TG-1000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TaiGen Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"TaiGen Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TaiGen Bio.."},{"orgOrder":0,"company":"Quest Products","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Announces Agreement For a Fundraising of Approximately $50 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Ridinilazole","moa":"Cell Division","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Quest Products","amount2":0.050000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.050000000000000003,"dosageForm":"Oral","sponsorNew":"Quest Products \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quest Prod.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biontech and Pfizer Initiate Rolling Submission to European Medicines Agency For Sars-Cov-2 Vaccine Candidate BNT162B2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Biontech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SY-5609","moa":"CDK7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Phar.."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Johnson & Johnson \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Next-generation Wet AMD Therapy Beovu\u00ae, Now Available in Canada, Receives Positive Recommendation from CADTH Drug Expert Committee","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Brolucizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"$415.0 million","upfrontCash":"$15.0 million","newsHeadline":"Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"CRISPR based gene therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Scribe Therapeutics","amount2":0.41999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.41999999999999998,"dosageForm":"","sponsorNew":"Scribe Therapeutics \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Scribe The.."},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinovac Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sinovac Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinovac Bi.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed\/Refractory AML Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Lintuzumab-Ac225","moa":"Alpha radiation","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Mesoblast","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients with Crohn\u2019s Disease AND Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remestemcel-L","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Mesoblast","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Mesoblast .."},{"orgOrder":0,"company":"Meabco","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Meabco Gets $5.9 M US Government Contract to Advance Its Bp-C2 Compound for Cutaneous Radiation Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Funding","leadProduct":"BP-C2","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0.01,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Meabco \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ N.."},{"orgOrder":0,"company":"Dren Bio","sponsor":"Taiho Ventures","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dren Bio Announces a $60M Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"DR-01","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dren Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Dren Bio \/ Taiho Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dren Bio \/.."},{"orgOrder":0,"company":"Essex Biotechnology","sponsor":"Henlius","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$10.0 million","newsHeadline":"Essex and Henlius Ink Global Co-Development and License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Essex Biotechnology","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Essex Biotechnology \/ Henlius","highestDevelopmentStatusID":"10","companyTruncated":"Essex Biot.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Connectyx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibody-drug conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Connectyx","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"AnGes","sponsor":"Er-Kim","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AnGes and Er-Kim Enter Into an Agreement for the Commercialization of Collategene\u00ae in Turkey","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Beperminogene Perplasmid","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AnGes","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnGes \/ Er-Kim","highestDevelopmentStatusID":"12","companyTruncated":"AnGes \/ Er.."},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kazia Executes Agreement with GCAR To Commence GBM Agile Pivotal Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Paxalisib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Global Coalition for Adaptive Research \/ Kazia","highestDevelopmentStatusID":"8","companyTruncated":"Global Coa.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"$100.0 million","newsHeadline":"Vifor Pharma and Cara Therapeutics Sign US License Agreement for IV Korsuva\u2122* to Treat Dialysis Patients with Pruritus","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0.14999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"BioEleven","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Partners with BioEleven for Cancer Immunotherapy Development and Manufacturing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"BN-101A","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ BioEleven","highestDevelopmentStatusID":"4","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland BioLabs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cytocom and Cleveland BioLabs Announce Definitive Merger Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"Noroxymorphone analogs","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Narcotic","amount2New":0,"dosageForm":"","sponsorNew":"Cytocom \/ Cleveland BioLabs","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ .."},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec Biologics Receives Grant to Enable an Antibody Product for the Prevention of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Anti-SARS-CoV-2 antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ B.."},{"orgOrder":0,"company":"Immunogen","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","amount":"$305.0 million","upfrontCash":"$40.0 million","newsHeadline":"ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Mirvetuximab Soravtansine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Immunogen","amount2":0.31,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.31,"dosageForm":"","sponsorNew":"Immunogen \/ Huadong Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen .."},{"orgOrder":0,"company":"Cardinal Health","sponsor":"Sesen Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sesen Bio Ink Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharma Distribution Services for Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cardinal Health","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cardinal Health \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Cardinal H.."},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Synairgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Akron Biotech Signs Agreement With Synairgen plc to Supply Interferon-Beta for COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Interferon Beta-1A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Akron Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akron Biotech \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Akron Biot.."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$50.0 million","newsHeadline":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Quantum Genomics \/ qilu pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"VectivBio","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Apraglutide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.11,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Peptide","amount2New":0.11,"dosageForm":"","sponsorNew":"VectivBio \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio .."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"RGN-259","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Disarm Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,360.0 million","upfrontCash":"$135.0 million","newsHeadline":"Lilly Announces Agreement to Acquire Disarm Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"SARM1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Disarm Therapeutics","amount2":1.3600000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":1.3600000000000001,"dosageForm":"","sponsorNew":"Disarm Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Disarm The.."},{"orgOrder":0,"company":"Axis Therapeutics","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"TCRT-ESO-A2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Axis Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axis Therapeutics \/ PharmaEssentia","highestDevelopmentStatusID":"5","companyTruncated":"Axis Thera.."},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz Canada","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pha.."},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amryt and Swixx Sign Distribution Deal for Lojuxta","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Lomitapide","moa":"MTP","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Swixx BioPharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Swixx BioPharma \/ Amryt","highestDevelopmentStatusID":"12","companyTruncated":"Swixx BioP.."},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$28.6 million","upfrontCash":"Undisclosed","newsHeadline":"EIB Provides Immunic With up to \u20ac24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Vidofludimus calcium anhydrous","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immunic Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Immunic Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"8","companyTruncated":"Immunic Th.."},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Nevakar","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nevakar and Zhaoke Ophthalmology Enter into Licensing Agreement for NVK-002 (Atropine to Treat Progression of Myopia in Children)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke Ophthalmology","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Zhaoke Ophthalmology \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke Oph.."},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Credit Suisse","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Immuno-Oncology Biotech Compass Therapeutics Files for a $50 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"CTX-471","moa":"CD137","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Compass Therapeutics \/ Credit Suisse","highestDevelopmentStatusID":"6","companyTruncated":"Compass Th.."},{"orgOrder":0,"company":"Cevec","sponsor":"Rznomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cevec and Rznomics Sign License Agreement for THE Use of CAP\u00ae Technology inManufacturing of Adenoviral Vectors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RCA-free adenoviral vectors","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cevec","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cevec \/ Rznomics","highestDevelopmentStatusID":"1","companyTruncated":"Cevec \/ Rz.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Enters into a License Agreement for Chugai\u2019s Antibody Engineering Technologies with Novo Nordisk","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Circuit Clinical","sponsor":"Intrommune Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intrommune Therapeutics Strikes Deal with Circuit Clinical\u00ae","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"INT301","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Circuit Clinical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Circuit Clinical \/ Intrommune Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Circuit Cl.."},{"orgOrder":0,"company":"Regenerative Care Network","sponsor":"Organicell Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin\u2122 for Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Zofin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Regenerative Care Network","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenerative Care Network \/ Organicell","highestDevelopmentStatusID":"5","companyTruncated":"Regenerati.."},{"orgOrder":0,"company":"NKMax","sponsor":"Affimed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"AFM24","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NKMax","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NKMax \/ Affimed","highestDevelopmentStatusID":"4","companyTruncated":"NKMax \/ Af.."},{"orgOrder":0,"company":"Parexel Biotech","sponsor":"Synairgen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Parexel Biotech Collaborates with Synairgen on Pivotal Phase III Trial for Study of Inhaled COVID-19 Treatment","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Parexel Biotech","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Parexel Biotech \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Parexel Bi.."},{"orgOrder":0,"company":"University of Georgia","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunshine Biopharma and University Of Georgia Team Up To Develop A New Anti-Coronavirus Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"SBFM-PL4","moa":"Protease","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Georgia","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Georgia \/ Sunshine Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Symvivo","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Symvivo Corporation Receives Funding for COVID-19 Vaccine Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"bacTRL-Spike vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ National Research Council Industrial Research Assistance Program","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ .."},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"European Commission","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EU Signs Supply Deal with J&J on Potential COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2-S","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"InCarda Therapeutics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"InCarda Therapeutics \/ Innoviva","highestDevelopmentStatusID":"8","companyTruncated":"InCarda Th.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"The University Of Colorado Anschutz Medical Campus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Pharma and The University Of Colorado Anschutz Medical Campus Collaborate To Advance Medicines For Genetically Driven Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus","highestDevelopmentStatusID":"3","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Lubrizol Life Science Health","sponsor":"Population Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lubrizol Expands Partnership with the Population Council","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Segesterone Acetate","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Lubrizol Life Science Health","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lubrizol Life Science Health \/ Population Council","highestDevelopmentStatusID":"1","companyTruncated":"Lubrizol L.."},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Broad Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"PARG","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ideaya Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ideaya Biosciences \/ Broad Institute","highestDevelopmentStatusID":"2","companyTruncated":"Ideaya Bio.."},{"orgOrder":0,"company":"Kintara Therapeutics","sponsor":"Global Coalition for Adaptive Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Dianhydrogalactitol","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Kintara Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kintara Therapeutics \/ Global Coalition for Adaptive Research","highestDevelopmentStatusID":"9","companyTruncated":"Kintara Th.."},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actinium Pharmaceuticals Awarded an NIH Grant to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"131-I Apamistamab","moa":"CD45","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium p.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharma Signs a License Agreement with Diurnal for the Registration and Commercialization of Alkindi\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ EffRx","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoImmuneTech Ink 2nd Collaboration with Roche to Evaluate NT-I7 in Combination with PD-L1 Checkpoint Inhibitor in First-line Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"IL-7","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"F. Hoffmann-La Roche \/ NeoImmuneTech","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"University of Sydney","sponsor":"Medicinova","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 in Chemotherapy-Induced Peripheral Neuropathy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Ibudilast","moa":"MIF","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"University of Sydney","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Sydney \/ MediciNova","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"IAVI","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAVI, Merck KGaA, Serum Institute join hands to develop monoclonal antibodies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"SARS-CoV-2 neutralising monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IAVI","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IAVI \/ Merck KGaA","highestDevelopmentStatusID":"2","companyTruncated":"IAVI \/ Mer.."},{"orgOrder":0,"company":"ProteoNic","sponsor":"Immunomedics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant protein","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ProteoNic","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProteoNic \/ Immunomedics","highestDevelopmentStatusID":"1","companyTruncated":"ProteoNic .."},{"orgOrder":0,"company":"Lassogen","sponsor":"Playground Global","pharmaFlowCategory":"D","amount":"$4.5 million","upfrontCash":"Undisclosed","newsHeadline":"Lassogen Raises Seed Round to Develop Novel Therapeutics for Challenging Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"LAS-103","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Lassogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Lassogen \/ Playground Global","highestDevelopmentStatusID":"4","companyTruncated":"Lassogen \/.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioInvent to Present Data on BI-1808, an Anti-TNFR2 Antibody, at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNFR2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche Writes Off Ulcerative Colitis Portion of Etrolizumab Program, Days After Dissecting Phase III Setback","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"Beta-7 integrin Ligand binding","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Bios.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron's Antibody Cocktail REGN-EB3 (INMAZEB\u00ae) Is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atoltivimab","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi's Sarclisa Bags NICE Recommendation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Status to RedHill\u2019s RHB-204 to Treat Nontuberculous Mycobacteria Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Clarithromycin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"RedHill Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives US FDA Approval to Market Fingolimod Capsules & Verapamil HCl Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fingolimod Hydrochloride","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Files a New Drug Application for Risdiplam as the First Oral Drug for Spinal Muscular Atrophy in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Risdiplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pha.."},{"orgOrder":0,"company":"Inserm","sponsor":"World Health Organization","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Solidarity Therapeutics Trial Produces Conclusive Evidence on the Effectiveness of Repurposed Drugs for COVID-19 in Record Time","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inserm","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Inserm \/ World Health Organization","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ W.."},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Castle Creek Biosciences Announces First Patient Dosed in Phase 1\/2 Clinical Trial of FCX-013 Gene Therapy","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FCX-013","moa":"MMP-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Castle Creek Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Castle Cre.."},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genomic Study of 6000 NCI-MATCH Cancer Patients Leads to New Clinical Trial Benchmarks","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Afatinib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ECOG-ACRIN.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar Plans Phase III Trial of Cancer Drug for COVID-19, Shares Jump","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Plitidepsin","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fujifilm Filed an Application for Partial Changes to the Manufacturing and Marketing Approval Matters of Anti-Influenza Drug Avigan\u00ae Tablet in Japan to Include Additional Indication for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm holding","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm holding \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm h.."},{"orgOrder":0,"company":"Beijing Institute of Biological Products","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Coronavirus Vaccine Candidate from China's CNBG Shows Promise in Human Test","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BBIBP-CorV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Beijing Institute of Biological Products","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Beijing Institute of Biological Products \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Beijing In.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Neurelis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurelis Announces Four Poster Presentations For The Joint Meeting Of The International Child Neurology Association And Child Neurology Society","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Neurelis","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Neurelis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurelis \/.."},{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Respira to Present Clinical Data on RT234-PAH Patient-Controlled Treatment to Acutely Improve Episodic Symptoms in PAH Patients","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vardenafil Hydrochloride","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Respira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Respira Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fosmanogepix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Ther.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics to Present New Tyvaso\u00ae Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United The.."},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Peginterferon Lambda-1a","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eiger BioPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioP.."},{"orgOrder":0,"company":"Seattle Gummy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seattle Gummy Company Secures The First (IND) Gummy Drug Approval From FDA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetirizine Dihydrochloride","moa":"H1 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Seattle Gummy","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seattle Gummy \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Gu.."},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Armata Pharmaceuticals Gets Clearance of IND Application to Initiate Phase 1b\/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AP-PA02","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Armata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pha.."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amylyx Pharmaceuticals Announces Publication of CENTAUR Survival Data Showing Statistically Significant Survival Benefit of AMX0035 for People with ALS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pha.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European CHMP Adopts Positive Opinion for Kite\u2019s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"Checkmate Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkmate Pharmaceuticals Announces Data Presentations for CMP-001 at SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vidutolimod","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Checkmate Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Checkmate Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Checkmate .."},{"orgOrder":0,"company":"Meabco","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meabco's Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in Mice","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BP-C2","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Meabco","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Meabco \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Meabco \/ N.."},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GT Biopharma Announces Selection of GTB-3550 Interim Results for Presentation at 62nd (ASH) American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GTB-3550","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GT Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GT Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GT Biophar.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MacroGenics Announces Flotetuzumab Publication in Blood Advances","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Flotetuzumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MacroGenics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MacroGenic.."},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zynerba Pharmaceuticals Presents New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with ASD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Ph.."},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ADP-A2M4CD8","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmun.."},{"orgOrder":0,"company":"Mirati Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Adagrasib","moa":"KRAS G12C","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mirati Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mirati Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mirati The.."},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Publishes Paper in Journal of Clinical Oncology Demonstrating Relevance of Iadademstat in Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iadademstat","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Oryzon Genomics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Gen.."},{"orgOrder":0,"company":"Leap Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leap Therapeutics to Present Esophagogastric Cancer Data at SITC 2020 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"DKN-01","moa":"||DNA cross-linking","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Leap Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leap Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Leap Thera.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis to Present Data from Ongoing ADXS-503 Phase 1\/2 Clinical Trial at SITC 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apexigen's APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sotigalimab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Pyxis Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pyxis Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pyxis Onco.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zonisamide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Sermonix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company\u2019s Abemaciclib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lasofoxifene","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sermonix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Sermonix Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Sermonix P.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"APL-9","moa":"Complement C3 inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis Antisense Medicine Being Evaluated in an investigator-Initiated Clinical Study of COVID-19 Patients in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IONIS-PKK-LRx","moa":"Prekallikrein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biomarkers Associated With Clinical Response in Patients With r\/r DLBCL Treated With DPX-Survivac Combination Therapy to be Presented by IMV at the Upcoming SITC Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not .."},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Denali Therapeutics to Highlight Progress Across Broad Biotherapeutics Portfolio for Neurodegeneration Enabled by Its Blood-Brain Barrier","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Recombinant Iduronate 2-sulfatase","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali The.."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-240","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orion Biotechnology Successfully Completes Phase 1 Clinical Trial of a First-in-Class Precision Engineered Ligand Analog for HIV Prevention","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OB-002","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Orion Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orion Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Orion Biot.."},{"orgOrder":0,"company":"OS Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Transfers OS Therapies' IND Application OST-HER2 (Listeria monocytogenes) to OS Therapies in Record Time","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OST-HER2","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OS Therapies \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapi.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Farudodstat","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer Seek Approval for Covid-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Receives Positive CHMP Opinion on PALFORZIA\u00ae for the Treatment of Patients with Peanut Allergy in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Th.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Study Aims to Identify Promising COVID-19 Treatments for Larger Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"National I.."},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China NMPA Accepts Eisai\u2019s sNDA for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures, Paediatric Indication for Partial Onset Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Perampanel","moa":"AMPA receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ No.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie's VENCLEXTA\u00ae (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Approval of Regeneron's Dupixent\u00ae (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Venetoclax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Presents 3-years Survival Data for KEYTRUDA\u00ae in Combination With Chemotherapy and Updated Phase 1\/2 Data for MK-1308 and KEYTRUDA Combo in Advanced Non\u2011Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces British Journal of Dermatology Publication of Three Pivotal Ph 3 Trials of Tralokinumab","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mometasone furoate","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros\u2019 OMS906 Data Presented at Complement-based Drug Development Summit","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OMS906","moa":"","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Prolonged-release Suspension for Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & .."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Avalyn Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Avalyn Pharma","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Avalyn Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Avalyn Pha.."},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Y-mAbs Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Y-mAbs Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Y-mAbs The.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipella Pharmaceuticals Initiates Its Phase-2a Clinical Trial of LP-10 for Hemorrhagic Cystitis","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Ph.."},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy\u2122 for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Libmeldy","moa":"ARSA gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Orchard Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Orchard Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orchard Th.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives Positive CHMP Opinion for Leqvio\u00ae, a Potential First-in-Class siRNA for the Treatment of High Cholesterol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Inclisiran","moa":"PCSK9","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Imara","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tovinontrine","moa":"PDE9","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ No.."},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rocket Pharmaceuticals Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the ESID 2020 Meeting","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"RP-L201","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Pharma India will Launch Calquence in India on Oct 21","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Acalabrutinib","moa":"BTK","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MRT5500","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Translate Bio","highestDevelopmentStatusID":"5","companyTruncated":"Sanofi \/ T.."},{"orgOrder":0,"company":"VelosBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VLS-101","moa":"ROR1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"VelosBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VelosBio \/.."},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncopeptides Submitts Investigational New Drug Application to FDA for the Second Drug Candidate from the PDC Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OPD5","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oncopeptides","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncopeptides \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Oncopeptid.."},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-MOSPD2 monoclonal antibodies","moa":"MOSPD2","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therap.."},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Cadila Receives Tentative Approval from USFDA for Tofacitinib Extended-Release Tablets","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Life.."},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European CHMP Adopts Positive Opinion for Kite\u2019s KTE-X19 for THE Treatment of Relapsed or Refractory Mantle Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Suspension for Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharm.."},{"orgOrder":0,"company":"OncoMyx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoMyx Announces Presentation of Preclinical Data for Novel Oncolytic Virotherapy at AACR Tumor Immunology and Immunotherapy Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Immune checkpoint inhibitor","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OncoMyx Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OncoMyx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoMyx Th.."},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ .."},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GM-CSF","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ultimovacs","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Ultimovacs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultimovacs.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ\u2122 (upadacitinib) in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-711","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released by Astellas Pharma at the ASN Kidney Week 2020 Reimagined","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Astellas Pharma \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"AmacaThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AmacaThera to Commence Phase 1 Clinical Trial for Non-Opioid, Post-Operative Pain Management","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AMT-143","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"AmacaThera","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmacaThera \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AmacaThera.."},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Reaches 50% Treated Patients in Ongoing JTA-004 Phase III Pivotal Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Thera.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals\u2019 Lead Compound CPI-613\u00ae\ufe0f for Patients With Pancreatic Cancer in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aclaris Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777 for the Treatment of Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Aclaris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Th.."},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stealth BioTherapeutics Announces Poster Presentation at American Society of Human Genetics (ASHG) Virtual Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Elamipretide","moa":"Cardiolipin","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Bi.."},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-050","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Keros Ther.."},{"orgOrder":0,"company":"Abpro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ABP 300","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Abpro","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Abpro \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Abpro \/ No.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sulopenem Etzadroxil","moa":"Cell wall","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nolasiban","moa":"Oxytocin receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Dispersible Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glenmark Pharmaceuticals Receives ANDA Approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Steroid","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas.."},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cue Biopharma Announces Upcoming Scientific Presentations at the SITC 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CUE-101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopha.."},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chemomab Announces Late-Breaking Presentation of CM-101 First Evidence of Anti-Fibrotic Activity in NAFLD Patients","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"Solution For Infusion","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Announces Upcoming Presentations at the EORTC-NCI-AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Treos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine That Shows Broad T Cell Response","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Montanide ISA 51VG","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Treos Bio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Treos Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Treos Bio .."},{"orgOrder":0,"company":"IntraBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IntraBio Reports Further Detail on Positive Data from IB1001 Multinational Clinical Trial for the Treatment of Niemann-Pick disease Type C","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"N-Acetyl-L-Leucine","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"IntraBio","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"IntraBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/.."},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Receives Ethics Approval to Start Phase I\/II Study Evaluating Topical Spray-On Synthetic Antibiotic RECCE\u00ae 327 on Chronic Burn Wounds","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Recce 327","moa":"Bacterial cell wall","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Recce Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Recce Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Recce Phar.."},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Midatech Pharma PLC Announces Headline Results of MTX110 Phase I DIPG Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Panobinostat lactate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Midatech Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Midatech Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Midatech P.."},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Receives Approval to Initiate COVID-19 Study in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EB05","moa":"TLR4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biot.."},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 for Cryptococcal Meningitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphotericin B","moa":"Ergosterol","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Matinas BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Matinas Bi.."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Accepts for Bristol Myers Squibb's Priority Review Applications for OPDIVO\u00ae in Combination with CABOMETYX\u00ae in Advanced Renal Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol My.."},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b\/2 study for Etigilimab (Anti-TIGIT)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mereo BioPharma Group","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mereo BioP.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trixeo Aerosphere recommended for approval in the EU by CHMP for the maintenance treatment of COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Budensonide","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Steroid","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Forxiga Recommended for Approval in the EU by CHMP for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"World Health Organization","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gilead's remdesivir has 'little or no effect' on COVID-19 recovery or mortality: WHO","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ World Health Organization","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis\u2019 Mayzent Receives Approval from the Scottish Medicines Consortium as the First Recommended Treatment in Scotland for Patients Living with Secondary Progressive Multiple Sclerosis (SPMS) with Active Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Siponimod fumarate","moa":"S1PR","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"AskBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ImmTOR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Selecta Biosciences \/ Asklepios BioPharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Bi.."},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventiva Receives FDA Fast Track Designation in MPS VI for its Clinical-Stage Asset Odiparci","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Odiparcil","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inventiva Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva .."},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NGM707","moa":"ILT2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NGM Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NGM Biopha.."},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olema Oncology to Present Preclinical Data on OP-1250, Lead Program in Breast Cancer, at ENA 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OP-1250","moa":"Complete estrogen receptor ant","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Olema Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Olema Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Olema Onco.."},{"orgOrder":0,"company":"Cardiff Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cardiff Presents Positive Efficacy and Biomarker Data from mCRPC Trial Showing Ability of Onvansertib to Overcome Zytiga\u00ae Resistance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Onvansertib","moa":"PLK1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Cardiff Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardiff Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardiff On.."},{"orgOrder":0,"company":"Kineta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kineta Presents New Preclinical Data on its VISTA Antagonist Antibodies at the AACR Virtual Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Anti-VISTA antibodies","moa":"VISTA","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kineta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kineta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kineta \/ N.."},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravaginal Gel","sponsorNew":"Evofem Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Bio.."},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav\u2122 Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharm.."},{"orgOrder":0,"company":"NeuClone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NeuClone Announces Positive Results from Phase I Study of Stelara\u00ae (ustekinumab) Biosimilar Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"IL-23","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"NeuClone","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuClone \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuClone \/.."},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TFF Pharmaceuticals Updates Progress of Human Clinical Trial with Tacrolimus Inhalation Powder","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharma.."},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neuraptive Therapeutics Announces Activation of First Clinical Site in Phase 2 Study of NTX-001 for the Treatment of Nerve Repair","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NTX-001","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"15-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Sinovac Vaccine is Safe, Brazil Institute Says","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CoronaVac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Butantan Institute \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Butantan I.."},{"orgOrder":0,"company":"Chumakov Federal Scientific Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia\u2019s Chumakov Center Begins Clinical Trials of its COVID-19 Vaccine in St. Petersburg","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"RUSSIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chumakov Federal Scientific Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chumakov Federal Scientific Center \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Chumakov F.."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GlaxoSmithKline Presents Positive Clinical Data on Maternal and Older Adults RSV Candidate Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GSK3888550A","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Ethacrynic Acid Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ethacrynic Acid","moa":"Sodium\/potassium\/chloride cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Ph.."},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Priority Review Granted to Ascentage Pharma's NDA for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Ascentage Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascentage .."},{"orgOrder":0,"company":"Nanoform","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform Initiates GMP Campaign for First-in-Human Trial of Nanoformed Drug by year End","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Nanoform","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nanoform \/ Quotient Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nanoform \/.."},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the IDSA IDWeek Conference 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BX002","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ No.."},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TScan Therapeutics Announces Publication of Study in Immunity Highlighting the Discovery of Novel T Cell Targets in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"T Cell","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"TScan Ther.."},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient who Previously Experienced Liver Toxicity with Tolvaptan During the American Society of Nephrology Kidney Week 2020 Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lixivaptan","moa":"V2R","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio B.."},{"orgOrder":0,"company":"Prothena","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Prasinezumab","moa":"Alpha synuclein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Prothena","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Prothena \/.."},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Phar.."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences to Present Positive Results from Phase 2b Study of Oral JAK\/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gusacitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis receives US FDA Orphan Drug Designation for branaplam (LMI070) in Huntington\u2019s disease (HD)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Branaplam","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharming Receives Orphan Drug Designation from EC for Leniolisib for the Treatment of Activated Phosphoinositide 3-Kinase Delta Syndrome","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leniolisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharming \/ Novartis","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/.."},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valneva Announces Positive Initial Results for Second Phase 2 Study of Lyme Disease Vaccine Candidate VLA15","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valneva \/ Pfizer","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Actemra May Curb Covid Deaths in Critical Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"IncellDx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IncellDx to Study Maraviroc in a COVID-19 Phase 2 Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Maraviroc","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IncellDx","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IncellDx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IncellDx \/.."},{"orgOrder":0,"company":"Treadwell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Treadwell Announces Initiation of New Clinical Trial of CFI-400945 in Patients with Metastatic Castrate-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CFI-400945","moa":"PLK4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Treadwell Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Treadwell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Treadwell .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astrazeneca Tagrisso Granted Priority Review in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"ErbB1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CIN-107","moa":"Aldosterone synthase","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pha.."},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV.7m8-Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Adverum Biotechnologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adverum Bi.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytoDyn Receives Positive DSMC Recommendation after Interim Analysis for Leronlimab Phase 2b\/3 COVID-19 Registrational Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Cipla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cipla Launches Nintib to Treat Idiopathic Pulmonary Fibrosis, in Continuation of its Fight Against Rare Lung Diseases","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"VEGFR","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Cipla","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cipla \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cipla \/ No.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. FDA Grants Fast Track Designation to Astellas Pharma's ASP0367\/MA-0211","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASP0367","moa":"PARP delta","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"Brigham and Women\u2019s Hospital","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brigham and Women\u2019s Hospital's Study Shows Rheumatoid Arthritis Drug Tocilizumab Advances as a COVID Treatment, as Other Regimens Fall Back","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tocilizumab","moa":"IL-6 alpha receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brigham and Women\u2019s Hospital","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brigham and Women\u2019s Hospital \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brigham an.."},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110\u2122 in Relapsed or Refractory CD19+ B-cell Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX110","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR The.."},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma to Present Amphetamine Extended-Release Tablet Data at the American Academy of Child and Adolescent Psychiatry Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharm.."},{"orgOrder":0,"company":"Salix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Plecanatide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Salix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Salix Phar.."},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Treprostinil Sodium","moa":"Prostanoid IP receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"United Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation Solution","sponsorNew":"United Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"United The.."},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Seagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Astellas and Seagen Announce Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV\u00ae in Advanced Urothelial Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Enfortumab vedotin-ejfv","moa":"Nectin-4","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Astellas Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Seagen","highestDevelopmentStatusID":"12","companyTruncated":"Astellas P.."},{"orgOrder":0,"company":"RayzeBio","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Actinium-225","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"RayzeBio","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"RayzeBio \/ venBio Partners","highestDevelopmentStatusID":"1","companyTruncated":"RayzeBio \/.."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer Submits Supplemental New Drug Application to FDA for Intrauterine Device Mirena\u00ae 52 mg","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Levonorgestrel","moa":"PR","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0,"dosageForm":"Sterile Inserter","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/.."},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PCI Biotech: Preclinical Research Collaboration with Big Pharma Ended","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Nucleic acid therapeutics","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"PCI Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"PCI Biotec.."},{"orgOrder":0,"company":"AavantiBio","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"$107.0 million","upfrontCash":"Undisclosed","newsHeadline":"AavantiBio Launches with $107 Million Series A Financing Perceptive Advisors Including Sarepta Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Gene therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AavantiBio","amount2":0.11,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"AavantiBio \/ Sarepta Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"AavantiBio.."},{"orgOrder":0,"company":"Arixa Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arixa Pharmaceuticals Announces Acquisition by Pfizer\u2019s Hospital Business","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"ARX-1796","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Arixa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arixa Pharmaceuticals \/ Pfizer","highestDevelopmentStatusID":"6","companyTruncated":"Arixa Phar.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"BioInvent Receives \u20ac2 million Milestone from Daiichi Sankyo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"DS-1055","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"InCarda Therapeutics","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series C Financing","leadProduct":"Flecainide","moa":"SCN5A","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"InCarda Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"InCarda Therapeutics \/ Deerfield Management","highestDevelopmentStatusID":"10","companyTruncated":"InCarda Th.."},{"orgOrder":0,"company":"Neumentum","sponsor":"Nuance Biotech","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"$3.0 million","newsHeadline":"Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ketorolac Trometamol","moa":"COX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Neumentum","amount2":0.050000000000000003,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Neumentum \/ Nuance Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Neumentum .."},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$350.0 million","newsHeadline":"Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"AT-527","moa":"RNA polymerase inhibitor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Atea Pharmaceuticals","amount2":0.34999999999999998,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Atea Pharm.."},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"AZR-MD-001","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Azura Ophthalmics \/ OrbiMed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Opht.."},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Longwood Fund","pharmaFlowCategory":"D","amount":"$52.0 million","upfrontCash":"Undisclosed","newsHeadline":"Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Engineer B cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Be Biopharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Be Biopharma \/ Longwood Fund","highestDevelopmentStatusID":"1","companyTruncated":"Be Biophar.."},{"orgOrder":0,"company":"Orphan Technologies","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","amount":"$517.0 million","upfrontCash":"$90.0 million","newsHeadline":"Retrophin Announces Agreement to Acquire Orphan Technologies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"OT-58","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orphan Technologies","amount2":0.52000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Orphan Technologies \/ Retrophin","highestDevelopmentStatusID":"7","companyTruncated":"Orphan Tec.."},{"orgOrder":0,"company":"Epsilogen","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Epsilogen Announces Further Uk Government Funding for Further Development of A Novel Ig E Antibody Cancer Immunotherapeutic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"EPS 201","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Epsilogen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epsilogen \/ Innovate UK","highestDevelopmentStatusID":"4","companyTruncated":"Epsilogen .."},{"orgOrder":0,"company":"BrainStorm Cell Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"MSC-NTF cells","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"BrainStorm Cell Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"BrainStorm Cell Therapeutics \/ Catalent","highestDevelopmentStatusID":"10","companyTruncated":"BrainStorm.."},{"orgOrder":0,"company":"ProBioGen","sponsor":"Heidelberg Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Heidelberg Pharma contracts ProBioGen for Cell Line Development and Manufacturing Services","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Antibody-targeted Amanitin-Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ProBioGen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ProBioGen \/ Heidelberg Pharma","highestDevelopmentStatusID":"4","companyTruncated":"ProBioGen .."},{"orgOrder":0,"company":"Milestone Pharmaceuticals","sponsor":"Jefferies and Piper Sandler","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares\n and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Etripamil","moa":"Calcium channel","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Milestone Pharmaceuticals","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.050000000000000003,"dosageForm":"Nasal Spray","sponsorNew":"Milestone Pharmaceuticals \/ Jefferies and Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Milestone .."},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Rotating Boulder Fund","pharmaFlowCategory":"D","amount":"$105.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sirnaomics Sealed US$105M Series D Financing to Fund RNAi Therapeutics for Cancers, Fibrotic Diseases and Viral Infections Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series D Financing","leadProduct":"Cotsiranib","moa":"TGF beta-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Sirnaomics \/ Rotating Boulder Fund","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics.."},{"orgOrder":0,"company":"Synairgen","sponsor":"Aerogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor 1","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Synairgen","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Synairgen .."},{"orgOrder":0,"company":"Immunomedics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$21,000.0 million","upfrontCash":"$15,000.0 million","newsHeadline":"Gilead Sciences Completes Acquisition of Immunomedics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Sacituzumab Govitecan","moa":"Topoisomerase I","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Immunomedics","amount2":21,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":21,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Immunomedi.."},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"NRC IRAP","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entos Pharmaceuticals Awarded Funding to Conduct Phase I Clinical Trial of COVID-19 DNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Covigenix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Entos Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Entos Pharmaceuticals \/ NRC IRAP","highestDevelopmentStatusID":"6","companyTruncated":"Entos Phar.."},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"$18.2 million","upfrontCash":"Undisclosed","newsHeadline":"Precision NanoSystems Will Receive $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"COVID-19 mRNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Precision NanoSystems \/ Government of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Precision .."},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Eflornithine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Orbus Therapeutics \/ Longitude Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Ther.."},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Sulopenem Etzadroxil","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Iterum The.."},{"orgOrder":0,"company":"Voronoi","sponsor":"ORIC Pharmaceuticals","pharmaFlowCategory":"D","amount":"$621.0 million","upfrontCash":"$5.0 million","newsHeadline":"Oric Pharma Teams up With Korean firm to Expand Precision Oncology Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"ORIC-114","moa":"Irreversible EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Voronoi","amount2":0.62,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.62,"dosageForm":"Oral","sponsorNew":"Voronoi \/ ORIC Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Voronoi \/ .."},{"orgOrder":0,"company":"Carelink","sponsor":"Fujifilm holding","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fujifilm Partners with Chinese Pharmaceutical Company Carelink in Deploying Anti-influenza Drug Avigan\u00ae Tablets in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Carelink","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Carelink \/ Fujifilm","highestDevelopmentStatusID":"10","companyTruncated":"Carelink \/.."},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","amount":"$295.0 million","upfrontCash":"$40.0 million","newsHeadline":"Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"SGT-001","moa":"Dystrophin gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0.29999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Solid Biosciences \/ Ultragenyx","highestDevelopmentStatusID":"7","companyTruncated":"Solid Bios.."},{"orgOrder":0,"company":"PAO Group","sponsor":"Undiaclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PAOG Announces CRO Agreement To Advance Respiratory Cannabis Treatment Through Regulatory Approval","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"PAO Group","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"PAO Group \/ Undiaclosed","highestDevelopmentStatusID":"5","companyTruncated":"PAO Group .."},{"orgOrder":0,"company":"hVIVO","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"$9.0 million","upfrontCash":"$13.1 million","newsHeadline":"UK Government Invests in Human Challenge Trials for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"hVIVO","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"hVIVO \/ UK Government","highestDevelopmentStatusID":"4","companyTruncated":"hVIVO \/ UK.."},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Opaganib","moa":"SPHK2","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Bi.."},{"orgOrder":0,"company":"Surrozen","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"$1.0 million","newsHeadline":"Surrozen Awarded NIH Grant to Support Development of SZN-043","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"SZN-043","moa":"Hepatocyte-targeted R-spondin","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Surrozen","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Surrozen \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Surrozen \/.."},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NOXXON Announces Three Additional Clinical Centers to Recruit Patients for NOX-A12 Brain Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma.."},{"orgOrder":0,"company":"Focus Fund GP","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"MD Anderson Establishes new $50M+ Biotech Fund to Choose the Next Promising Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Cancer therapies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Focus Fund GP","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Focus Fund GP \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Focus Fund.."},{"orgOrder":0,"company":"George Mason University NCBID","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"ARDS-003","moa":"CB2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"George Mason University NCBID","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"George Mason University NCBID \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"4","companyTruncated":"George Mas.."},{"orgOrder":0,"company":"IntelGenx","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa\u00ae Mucoadhesive Delivery Technology for Dronabinol","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IntelGenx \/ Tetra Bio-Pharma","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx .."},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$4,000.0 million","upfrontCash":"$2,000.0 million","newsHeadline":"Bayer Acquires Asklepios Bio Pharmaceutical to Broaden Innovation Base in Cell and Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"AAV2\/8LSPhGAA","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Bayer","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ B.."},{"orgOrder":0,"company":"Vallon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CNS Pharmaceutical Developer Vallon Pharmaceuticals Files for a $17 million IPO","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Amphetamine","moa":"VMAT","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Vallon Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vallon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vallon Pha.."},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$35.0 million","newsHeadline":"Jazz Pharmaceuticals Acquires Spring Works Therapeutics' Faah Inhibitor Program","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"PF-04457845","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0.40999999999999998,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"Small molecule","amount2New":0.40999999999999998,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"SpringWork.."},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Solid Tumor Biotech SQZ Biotechnologies Sets Terms for $75 Million IPO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SQZ Biotechnologies","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"SQZ Biotechnologies \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"SQZ Biotec.."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"GEO-CM01","moa":"Spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"National Institutes of Health \/ GeoVax","highestDevelopmentStatusID":"4","companyTruncated":"National I.."},{"orgOrder":0,"company":"USAMRIID","sponsor":"Vaxil Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxil Enters Into a Cooperative Research and Development Agreement With USAMRIID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"CorVax","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"USAMRIID","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"USAMRIID \/ Vaxil","highestDevelopmentStatusID":"4","companyTruncated":"USAMRIID \/.."},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$1,340.0 million","upfrontCash":"$1,175.0 million","newsHeadline":"Anaptysbio and Glaxosmithkline Amend Strategic Immuno-Oncology Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":1.3400000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3400000000000001,"dosageForm":"","sponsorNew":"AnaptysBio \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Ministry of Public Health of Qatar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Ministry of Public Health of Qatar","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"ISOThrive","sponsor":"Virginia Catalyst","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"ISOThrive Awarded $800K Virginia Catalyst Grant to address major unmet need in gastroesophageal reflux disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Maltosyl-isomaltooligosaccharide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"ISOThrive","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ISOThrive \/ Virginia Catalyst","highestDevelopmentStatusID":"5","companyTruncated":"ISOThrive .."},{"orgOrder":0,"company":"Regenxbio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Regenxbio to Receive $80.0 Million Milestone Payment from Novartis Ag","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"NAV AAV9 vector","moa":"SMN1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Regenxbio","amount2":0.080000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Regenxbio .."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oncolytics Biotech\u00ae Collaborates with Roche and AIO to Initiate a Phase 1\/2 Gastrointestinal Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Atezolizumab","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Oncolytics Biotech","highestDevelopmentStatusID":"1","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"BioInvent","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"$5.0 million","newsHeadline":"BioInvent Licenses Anti-Fc\u03b3RllB Antibody BI-1206 to CASI Pharmaceuticals for Greater China Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BI-1206","moa":"CD32B","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0.089999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"EQRx","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"$150.0 million","newsHeadline":"CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: Sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Sugemalimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":1.3,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.3,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ EQRx","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pha.."},{"orgOrder":0,"company":"University of California","sponsor":"Releviate Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"RLVT-9-01","moa":"MMP-9","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of California \/ Releviate Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"Appili Therapeutics Announces Additional Funding for Its ATI-1701 Biodefense Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Appili Therapeutics","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Appili Therapeutics \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"4","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$56.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"LP352","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.059999999999999998,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Longboard Pharmaceuticals \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Longboard .."},{"orgOrder":0,"company":"Arvelle Therapeutics","sponsor":"European Medicines Agency","pharmaFlowCategory":"D","amount":"$207.8 million","upfrontCash":"Undisclosed","newsHeadline":"Arvelle Announces Closing of Final Tranche of Series A Financing Round","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Cenobamate","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Arvelle Therapeutics","amount2":0.20999999999999999,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Arvelle Therapeutics \/ European Medicines Agency","highestDevelopmentStatusID":"12","companyTruncated":"Arvelle Th.."},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinese Rare Disease Player inks First Deal Around Narcolepsy Drug Wakix After Grabbing $80M to Build an Ecosystem","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Pitolisant Hydrochloride","moa":"H3 receptor","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Harmony Biosciences","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harmony Biosciences \/ Citrine Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Harmony Bi.."},{"orgOrder":0,"company":"Immutep","sponsor":"University Hospital Pilsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immutep Announces the Start of an Investigator-Initiated\n Phase II Study in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Immutep \/ University Hospital Pilsen","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PTG-300","moa":"Hepcidin","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Protagonist Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Mycovia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Global Phase 3 \u201cVIOLET Studies\u201d for Oteseconazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Oteseconazole","moa":"CYP51","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mycovia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mycovia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mycovia Ph.."},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Noveome Biotherapeutics, Inc. Announces Publication of Preclinical Results Demonstrating the Neuroprotective Properties of Amnion-derived Multipotent Progenitor Cells in Spinal Cord and Retinal Ganglion Cells","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ST266","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Bi.."},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Affinivax Announces the Presentation of Phase 1 Clinical Data for its MAPS\u2122 Vaccine for Streptococcus pneumoniae at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASP3772","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax .."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"Immunotolerance","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enlivex Th.."},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hypericin","moa":"Oxygen radical","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Soligenix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Soligenix .."},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics to Present New Data on Novel HPK1 Inhibitors at Upcoming Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"HPK1","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nimbus Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nimbus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nimbus The.."},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio.."},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CARA Thera.."},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TERN-101","moa":"Farnesoid X receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Terns Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Terns Phar.."},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Phar.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Dosed First Patient in the Phase 1\/2 GRECO-1 Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GC4711","moa":"SOD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin-associated serine protease 2","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III","graph3":"Omeros","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ N.."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Presentation of Tapinarof Pivotal Phase 3 PSOARING Data at Fall Clinical Dermatology Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences to Present Clinical Data on Oral ASN007, A Novel ERK1\/2 Inhibitor, at the 32nd EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ASN007","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Asana BioS.."},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lumasiran","moa":"Glycolate oxidase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Alnylam Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alnylam Ph.."},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Offers Insights on Treatment with KRYSTEXXA\u00ae Among Kidney Transplant Patients for the Management of Uncontrolled Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegloticase","moa":"","url1":"","url2":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Horizon Therapeutics","amount2":0,"therapeuticAreaNew":"Rheumatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Horizon Th.."},{"orgOrder":0,"company":"Synlogic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SYNB8802","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/.."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal of Allergy and Clinical Immunology Publishes Results from BioCryst\u2019s APeX-2 Pivotal Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Berotralstat","moa":"Plasma kallikrein","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"BioCryst Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioCryst P.."},{"orgOrder":0,"company":"Kronos Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 Inhibitor KB-0742 in Cell Chemical Biology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KB-0742","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Kronos Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kronos Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kronos Bio.."},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"STORM Therapeutics Selects First-in-Class Clinical Candidate Targeting METTL3","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"STC-15","moa":"METTL3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Storm Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Storm Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Storm Ther.."},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"DS-1055","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sa.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Focuses on ATOR-1017 and Mitazalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mitazalimab","moa":"4-1BB receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"F2G Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Olorofim","moa":"DHODH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F2G Limited","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"F2G Limite.."},{"orgOrder":0,"company":"ObsEva","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Linzagolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"ObsEva","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ObsEva \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ObsEva \/ N.."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB\u2019s Anti-Epileptic Drug Vimpat[\u00ae] (lacosamide) Receives EU CHMP Positive Opinion for Primary Generalised Tonic-Clonic Seizures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Continued Positive Findings From First-Ever Implementation Science Study on Integrating an Investigational Once-Monthly Injectable HIV Treatment into US Healthcare Practices","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ViiV Healthcare Presents Positive New Findings from Two Studies of its Investigational, Long-Acting Regimen of Cabotegravir and Rilpivirine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabotegravir","moa":"HIV-1 integrase strand transfer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"ViiV Healthcare","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Extended Release Intramuscular Suspension","sponsorNew":"ViiV Healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ViiV Healt.."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Announces Presentations for its Endocrinology Rare Disease Clinical Programs at Upcoming Medical Conferences","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Hormone","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with ENIGMA in the NEJM","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Genmab","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genmab \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Genmab \/ J.."},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rezafungin","moa":"Glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cidara The.."},{"orgOrder":0,"company":"ILiAD Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILiAD Biotechnologies Announces Upcoming Presentation at the European Society for Paediatric Infectious Diseases 2020 Virtual Meeting","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BPZE1","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ILiAD Biotechnologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"ILiAD Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ILiAD Biot.."},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Danish Biotech UNION Therapeutics A\/S Adds Program to Prevent COVID-19 With Intranasal Delivery of Niclosamide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Union Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Union Ther.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rbx2660","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Cyclo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Cyclo Therapeutics","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cyclo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cyclo Ther.."},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cefepime","moa":"Peptidoglycan synthesis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"VenatoRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx P.."},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Pivotal","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Highlight Therapeutics & Pivotal Advance into a Phase IIa Trial to Examine Gastro-Intestinal Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BO-112","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Highlight Therapeutics \/ Pivotal","highestDevelopmentStatusID":"8","companyTruncated":"Highlight .."},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TG Therapeutics Gets Fast Track Designation by the FDA to Ublituximab in Combination with Umbralisib for Chronic Lymphocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Umbralisib","moa":"PI3K delta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"TG Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TG Therape.."},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vir Biotechnology Presents New Data on VIR-2482 at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VIR-2482","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Vir Biotechnology","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vir Biotec.."},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Repotrectinib","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Turning Po.."},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immutep Secures New European Patent for IMP761","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IMP761","moa":"LAG-3","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Immutep","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immutep \/ .."},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Annamycin","moa":"DNA","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin .."},{"orgOrder":0,"company":"Curis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CA-4948","moa":"Interleukin-1 receptor-associated kinase 4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Curis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ No.."},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/.."},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Provides Clinical Trial Updates for Haduvio\u2122","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Trevi Ther.."},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zosano Pharma Receives Complete Response Letter from FDA for Qtrypta\u2122","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zolmitriptan","moa":"5-HT1D receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Zosano Pharma","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Zosano Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zosano Pha.."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MF59-adjuvanted trivalent influenza vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seqirus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ .."},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Paratek Pharmaceuticals Presenting New Data on NUZYRA\u00ae (Omadacycline) at IDWeek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omadacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Ph.."},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxeia Biopharmaceuticals, Inc. Announces Initiation Of Phase 2 Trial For OXE103 For The Treatment Of Concussions","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Ghrelin","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxeia Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biop.."},{"orgOrder":0,"company":"Myovant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Relugolix","moa":"GnRH receptor","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Myovant Sciences","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Myovant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myovant Sc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Pfizer\u2019s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at Idweek 2020","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"20-valent pneumococcal conjugate vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bharat Biotech Gets CDSCO Nod to Conduct Phase III Covid-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BBV152","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bharat Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bharat Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bharat Bio.."},{"orgOrder":0,"company":"ImmunityBio","sponsor":"NantKwest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Novel COVID-19 Vaccine Candidate hAd5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"hAd5-S-Fusion+N-ETSD Vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ImmunityBio \/ NantKwest","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBi.."},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Receives US FDA Approval for Generic Ofirmev Injection","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo .."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Gilead\u2019s Antiviral Veklury\u00ae (remdesivir) for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sci.."},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SOM Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotec.."},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ionis' Third Novel Antisense Medicine for ALS, its First Designed to Treat a Broad ALS Population, Begins Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ION541","moa":"Ataxin 2","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Phar.."},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life.."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Vycellix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vycellix CEO to Present its Universal Cell Program (VY-UC) for Off-the-Shelf NK Cell Therapy at Allogeneic Cell Therapies Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NK Cell","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Vycellix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vycellix \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Vycellix \/.."},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dicerna Presents New Interim Data From PHYOX\u21223 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nedosiran","moa":"LDH","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Dicerna Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dicerna Ph.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Farxiga Reduced Worsening of Kidney Function, Risk of Cardiovascular or Renal Death in Patients with Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Interim Data from First Cohort of Patients in Pilot Phase 1\/2 Clinical Trial of GC4419 in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ansun Biopharm","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ansun Biopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ansun Biop.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Announces European Medicines Agency (EMA) has Granted Orphan Drug Designation for Iptacopan (LNP023) in IgA Nephropathy (IgAN)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Provides Update on Dovitinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dovitinib","moa":"FLT3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Sumitomo Chemical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dubermatinib","moa":"AXL receptor tyrosine kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Chemical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Chemical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo C.."},{"orgOrder":0,"company":"CureVac","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CVnCoV","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CureVac","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CureVac \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CureVac \/ .."},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S Receives Orphan Designation for TransCon\u2122 PTH for Treatment of Hypoparathyroidism in Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis P.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim's and Lilly's New Jardiance\u00ae Findings Showed Improved Cardio-Renal Outcomes in Adults with Heart Failure with Reduced Ejection Fraction Regardless of CKD status","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Odevixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Albireo Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Albireo Ph.."},{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PhaseBio Provides Pemziviptadil (PB1046) Program Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vasomera","moa":"VPAC2 receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PhaseBio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio P.."},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Proglumide","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Imm.."},{"orgOrder":0,"company":"Orphazyme","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphazyme Accelerates Arimoclomol Pre-Launch Activities and Updates Financial Outlook for 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Arimoclomol","moa":"Molecular chaperones","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orphazyme","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Orphazyme \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Orphazyme .."},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"INO-4800","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Inovio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Inovio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inovio Pha.."},{"orgOrder":0,"company":"Nevakar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-To-Use Vials","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ephedrine","moa":"Adrenergic receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Nevakar","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nevakar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nevakar \/ .."},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of Tenapanor at ASN's Kidney Week 2020","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ .."},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm\u2019s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/.."},{"orgOrder":0,"company":"TrippBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TrippBio Completes Enrollment in a Proof of Concept Trial Evaluating the Efficacy of TD213 in Treating Patients with Confirmed COVID-19 Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TD213","moa":"SARS-CoV-2 virus replication","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"TrippBio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Doses First Patient in Phase 2 Study of PT-112 in Metastatic Castration Resistant Prostate Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chinook Therapeutics Presents Data Across Kidney Disease Pipeline During the ASN Kidney Week 2020 Reimagined","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Th.."},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OSE Immunotherapeutics Publishes Data Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRP\u03b1 BI 765063","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OSE-172","moa":"Checkpoint","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immuno.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Receives Notice of Intent to Grant a New Patent Enhancing THE Protection IN Europe of Asidna\u2122 Combined with Parp Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Sanifit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sanifit Presents New Data for SNF472 in Treatment of Vascular Calcification at ASN Kidney Week 2020","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SNF472","moa":"Calcification","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sanifit","amount2":0,"therapeuticAreaNew":"Rare Diseases and Disorders","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanifit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanifit \/ .."},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosci.."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Announces U.S. FDA Approval for Enstilar\u00ae (Calcipotriene and Betamethasone Dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-Term Use in Plaque Psoriasis Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Reven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reven Pharmaceuticals Wins FDA Approval of Its IND Application for Treatment of COVID-19 With Rejuveinix (RJX)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rejuveinix","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Reven Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Reven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reven Phar.."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"Ribosome activity","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"FibroGen","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"12","companyTruncated":"FibroGen \/.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flublok Vaccine Given Authorisation for Temporary Supply in the UK to Meet Public Health Need","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Flublok Quadrivalent","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ N.."},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd\n EORTC-NCI-AACR Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"EPI-7386","moa":"Androgen receptor N-terminal domain","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Essa Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Essa Pharm.."},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Feinstein Institutes Researchers Find Effective COVID-19 \u2018Cytokine Storm\u2019 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Feinstein Institutes","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Feinstein Institutes \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Feinstein .."},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia's European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aurinia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Aurinia Ph.."},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Prexigebersen","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bio-Path Holdings","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Path Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Path H.."},{"orgOrder":0,"company":"Onxeo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Onxeo Announces Enrollment of First Patient in Phase Ib\/II Study Revocan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AsiDNA","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onxeo","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Onxeo \/ No.."},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2 receptor","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pha.."},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the ASHG 2020 Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gavorestat","moa":"Aldose reductase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Th.."},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to CKD in Adult Patients","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia The.."},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Positive Top-Line Olutasidenib Data From A Planned Interim Analysis Of A Registrational Phase 2 Clinical Trial In AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Olutasidenib","moa":"IDH-1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Forma Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Forma Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forma Ther.."},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dupixent\u00ae (Dupilumab) Late-Breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dupilumab","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Regeneron","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ R.."},{"orgOrder":0,"company":"Alterity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alterity Commences Enrolling Multiple System Atrophy Patients in bioMUSE Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATH434","moa":"Alpha synuclein aggregation","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alterity Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alterity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alterity T.."},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis - First US Patient Enrolled in COVA, a Multinational\n Phase 2\/3 Clinical Trial with Sarconeos (BIO101) for the\n Treatment of COVID-19 Related Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis .."},{"orgOrder":0,"company":"Lysogene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lysogene Provides Update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AAVrh10-h.SGSH","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/.."},{"orgOrder":0,"company":"GeneTx Biotherapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeneTx and Ultragenyx Announce Positive Interim Phase 1\/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GTX-102","moa":"UBE3A-AS expression","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneTx Biotherapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GeneTx Biotherapeutics \/ Ultragenyx","highestDevelopmentStatusID":"7","companyTruncated":"GeneTx Bio.."},{"orgOrder":0,"company":"Aerpio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerpio Dosed First Patient with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Razuprotafib","moa":"Tie2 activator\/Vascular endothelial protein tyrosine phosphatase","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aerpio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Aerpio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aerpio Pha.."},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Edasalonexent","moa":"NFkB","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis .."},{"orgOrder":0,"company":"CohBar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CB5138 Analog peptides","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"CohBar","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CohBar \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CohBar \/ N.."},{"orgOrder":0,"company":"Beat AML, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Beat AML, LLC Study in Nature Medicine Shows Superior Outcomes for Patients in The Leukemia & Lymphoma Society's Paradigm-Shifting Beat AML Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cytarabine","moa":"CD200","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beat AML, LLC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beat AML, LLC \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Beat AML, .."},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa's New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at ACR Convergence","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mavrilimumab","moa":"GCSF","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Ph.."},{"orgOrder":0,"company":"TRACON Pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TRACON Announces FDA Orphan Drug Designation For TRC102 In Malignant Glioma, Including Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Methoxyamine","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"TRACON Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"TRACON Pharmaceuticals \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"TRACON Pha.."},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advaxis\u2019 ADXS-503 Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1\/2 Lung Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ADXS-503","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ayala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Ayala Phar.."},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Forte Bios.."},{"orgOrder":0,"company":"Flatley Discovery Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vatiquinone","moa":"15-LOX","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Flatley Discovery Lab","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Flatley Discovery Lab \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Flatley Di.."},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Second Publication Shortlists Resverlogix's Apabetalone for Its Potential Covid-19 Effectiveness Including Reducing Cytokine Storms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"BET","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Resverlogix","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Resverlogi.."},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Maralixibat","moa":"IBAT","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Mirum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mirum Phar.."},{"orgOrder":0,"company":"University of Maryland School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Landmark Study at UM School of Medicine Finds Aspirin Use Reduces Risk of Death in Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Aspirin","moa":"COX","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Maryland School of Medicine","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Maryland School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University.."},{"orgOrder":0,"company":"PDS Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDS Biotech Initiates Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PDS0101","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"PDS Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PDS Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PDS Biotec.."},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bi.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Presents Promising Preclinical Data on IL-2 and IL-13 Superkines at the EORTC-NCI-AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA11","moa":"Il-2 beta receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at ASCAT Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rivipansel","moa":"P-selectin","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GlycoMimetics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GlycoMimet.."},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib for Cholangiocarcinoma Fran\u00e7ais","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"FGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Cor.."},{"orgOrder":0,"company":"Nitric Oxide Innovations","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NOi Receives FDA Approval to Begin the Trial on its New Drug NOviricid to Treat COVID 19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Sodium Nitrite","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nitric Oxide Innovations","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Nitric Oxide Innovations \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nitric Oxi.."},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem Announces Acceptance of Clinical Study for TFC-1067 in the Journal of Cosmetic Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TFC-1067","moa":"Tyrosinase activity","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Bio.."},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP\u00ae Biomarker Patents","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dovitinib","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Allarity Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Allarity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allarity T.."},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seelos Therapeutics Announces Issuance of Composition of Matter Patent for SLS-007","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SLS-007","moa":"Alpha-synuclein Non-Amyloid component","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Seelos Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seelos The.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leronlimab Shows Early, but Promising Clinical Responses in First Two Patients Recovering from Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CXCR5 receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Evoke Pharma","sponsor":"Eversana","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evoke and Eversana Announce Commercial Launch of Gimoti\u2122","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Metoclopramide","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Evoke Pharma","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Evoke Pharma \/ Eversana","highestDevelopmentStatusID":"12","companyTruncated":"Evoke Phar.."},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kura Oncology Reports Antitumor Activity of Tipifarnib in Combination with PI3K\u03b1 Inhibitor in Head and Neck Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipifarnib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncol.."},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SHR0302","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Reistone B.."},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TYK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Santen Announces U.S. FDA Filing Acceptance of NDA for Cyclosporine Topical Ophthalmic Emulsion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"BioSig Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viral Clear Halts Its Phase 2 Hospitalized Covid-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Merimepodib","moa":"IMPDH","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioSig Technologies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioSig Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioSig Tec.."},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Announces Successful Pre-Submission Meeting with the European Medicines Agency for Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio .."},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Exebacase","moa":"Cell wall peptidoglycan","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ContraFect Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect.."},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medicenna Presents Late Breaking Abstract Updating Results from Phase 2b Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MDNA55","moa":"IL-4 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicenna Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicenna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medicenna .."},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Elevation Oncology Announces the Presentation of Preclinical Data on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Seribantumab","moa":"HER3","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Elevation Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Elevation .."},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in Critical COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATYR1923","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"aTyr Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"aTyr Pharm.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results from Allakos' Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BDTX-189","moa":"EGFR","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Black Diamond Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Black Diam.."},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allakos","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allakos \/ .."},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"BioXcel Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioXcel Th.."},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Shows Improvement in HF Patients Measured by Exercise Outcomes and Cardiac Function","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CardiAMP cell therapy","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia .."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Presents Preclinical Data on Anti-Angiogenic Activity of Derazantinib at ENA 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Derazantinib","moa":"panFGFR kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents Promising Interim Phase II Data of Potential First-in-Class Oral Therapy Iptacopan in Rare Renal Disease C3 Glomerulopathy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis P.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NANOBIOTIX Provides Updates on Global Clinical Development Plan for First-in-class Radioenhancer NBTXR3 at ASTRO 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hafnium Oxide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Nanobiotix","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanobiotix.."},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Israel to Start COVID-19 Vaccine Human Trials on Nov. 1","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Israel Institute for Biological Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Israel Institute for Biological Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Israel Ins.."},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syntrix Completes Initial SX-682 Dosing in Broad Phase 1\/2 Cancer Trial Campaign","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SX-682","moa":"CXCR1\/CXCR2","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syntrix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Syntrix Ph.."},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"MorphoSys","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"MOR210","moa":"Complement C5a receptor","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"I-Mab Biopharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"I-Mab Biopharma \/ MorphoSys","highestDevelopmentStatusID":"5","companyTruncated":"I-Mab Biop.."},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phosplatin Therapeutics Announces Data Revealing Novel Mechanistic Attributes for PT-112 at the 32nd EORTC-NCI-AACR Virtual Symposium","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Imifoplatin","moa":"Immunogenic Cell death","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Phosplatin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin.."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Upadacitinib","moa":"JAK1","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer\u2019s Abrocitinib","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Alkido Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"DHA-dFdC","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Alkido Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alkido Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alkido Pha.."},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at EADV Virtual Congress October 29","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Ther.."},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ALX Oncology Dosed First Patient in ASPEN-02","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ALX148","moa":"CD47","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ALX Oncology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ALX Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"ALX Oncolo.."},{"orgOrder":0,"company":"Alzheon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Valiltramiprosate","moa":"Amyloid beta protein","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alzheon","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alzheon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alzheon \/ .."},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Global Coalition for Adaptive Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Global Coalition for Adaptive Research \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Global Coa.."},{"orgOrder":0,"company":"KYE Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Amifampridine Phosphate","moa":"KV Channel","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"KYE Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KYE Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KYE Pharma.."},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANA Therapeutics Begins Phase 2\/3 Clinical Trial of Proprietary Oral Niclosamide Formulation to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therap.."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Appili Therapeutics to Present at TSX Life Sciences Investor Day","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aridis Pharmaceuticals, Inc. to Present at the ROTH Capital Healthcare Event \"COVID-19 Therapeutics in Development\"","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-711","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Aridis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aridis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aridis Pha.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca's Enhertu Granted Priority Review in the US for the Treatment of HER2-Positive Metastatic Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Deruxtecan","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Forxiga Cardiovascular Outcomes Benefit Approved in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Neuronasal","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ATAI Life Sciences Announces Neuronasal Completes Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Acetylcysteine","moa":"","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Neuronasal","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neuronasal \/ ATAI","highestDevelopmentStatusID":"5","companyTruncated":"Neuronasal.."},{"orgOrder":0,"company":"Genome & Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genome & Company Announces First Patient Dosed in Phase 1\/1b Study of GEN-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avelumab","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genome & Company \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & C.."},{"orgOrder":0,"company":"Eisai","sponsor":"BioArctic AB","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioArctic\u2019s Partner Eisai to Present Latest Data on BAN2401 at CTAD Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lecanemab","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eisai","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ BioArctic","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ Bi.."},{"orgOrder":0,"company":"BioInvent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CTA Approval of BioInvent\u2019s BI-1808, a First-in-Class Anti-TNFR2 Antibody, Sets Stage for Phase I\/IIa Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BI-1808","moa":"TNFR2 alpha","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioInvent","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioInvent .."},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BI 764198","moa":"TRPC6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer.."},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Pharmaceuticals to Share New Reproductive Medicine Data at ASRM 2020 Scientific Congress & Expo","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Menotropins","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Ph.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NICE Draft Guidance Recommends Eli Lilly's Galcanezumab for Preventing Migraines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"National I.."},{"orgOrder":0,"company":"Versantis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versantis Receives FDA Rare Pediatric Disease Designation for VS-01 for the Treatment of Urea Cycle Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"VS-01","moa":"Ammonia clearance","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Versantis","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Versantis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Versantis .."},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Participants Dosed in Appili Therapeutics\u2019 Phase 2 Clinical Trial Evaluating Favipiravir for COVID-19 Outbreak Control in Canadian Long-Term Care Homes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Favipiravir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Appili Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Appili The.."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"FibroGen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AstraZeneca Advances Leadership in Renal Disease with More Than 80 Abstracts at ASN Kidney Week 2020 Reimagined","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Roxadustat","moa":"HIF-PH","url1":"","url2":"","graph1":"Hematology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"therapeuticAreaNew":"Hematology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ FibroGen","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Kamada","sponsor":"Israeli Health Authorities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kamada Signs a Supply Agreement with the Israeli Health Authorities for the Investigational Anti-COVID-19 Plasma-Derived Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"COVID-19 IgG Therapy","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Israeli Health Authorities","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ I.."},{"orgOrder":0,"company":"University of Alberta","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University of Alberta Study Shows Targeted Delivery of Anti-Inflammatory Therapy Shows Promise in Slowing Progression of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Belnacasan","moa":"Caspase-1","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Alberta","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Alberta \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"AB Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AB Science Announces Positive Top-Line Phase 3 Results for Oral Masitinib in Severe Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Masitinib Mesylate","moa":"FGFR3 gene","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"AB Science","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AB Science \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AB Science.."},{"orgOrder":0,"company":"University Medical Center Utrecht","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"University Medical Center Utrecht Study Shows that Crushed Prasugrel Prehospital Fails to Improve STEMI Reperfusion vs. Integral Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ticagrelor","moa":"P2Y12 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University Medical Center Utrecht","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Medical Center Utrecht \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"University.."},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Moderate-to-Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Bi.."},{"orgOrder":0,"company":"Anagram Therapeutics","sponsor":"CF Foundation","pharmaFlowCategory":"D","amount":"$22.5 Million","upfrontCash":"$14.0 million","newsHeadline":"Synspira Therapeutics Announces Expanded Agreement with Cystic Fibrosis Foundation to Advance Promising Treatments for Cystic Fibrosis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"SNSP003","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Anagram Therapeutics","amount2":0.02,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Anagram Therapeutics \/ CF Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anagram Th.."},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Dinona","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Inks Development Partnership with Dinona for Potential COVID-19 Treatment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"DNP-019","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Biologics \/ Dinona","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"SparingVision","sponsor":"4BIO Capital","pharmaFlowCategory":"D","amount":"$51.9 million","upfrontCash":"Undisclosed","newsHeadline":"SparingVision Raises \u20ac44.5 Million and Appoints St\u00e9phane Boissel\n as Chief Executive Officer","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"SPVN06","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0.050000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ 4BIO Capital","highestDevelopmentStatusID":"7","companyTruncated":"SparingVis.."},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$592.3 million","upfrontCash":"Undisclosed","newsHeadline":"Idorsia Successfully Completes Capital Increase with Gross Proceeds of CHF 535.5 Million","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Daridorexant","moa":"OX1R\/OX2R","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Idorsia Pharmaceuticals","amount2":0.58999999999999997,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0.63,"dosageForm":"Film Coated Tablet","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Idorsia Ph.."},{"orgOrder":0,"company":"Amerimmune","sponsor":"Histogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Histogen and Amerimmune Enter into a Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Emricasan","moa":"Caspase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Amerimmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amerimmune \/ Histogen","highestDevelopmentStatusID":"5","companyTruncated":"Amerimmune.."},{"orgOrder":0,"company":"Viridian Therapeutics","sponsor":"Miragen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Viridian Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Viridian Therapeutics \/ miRagen Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Viridian T.."},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$280.0 million","upfrontCash":"$150.0 million","newsHeadline":"Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vedere Bio","amount2":0.28000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"Intravitreal Injection","sponsorNew":"Vedere Bio \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Vedere Bio.."},{"orgOrder":0,"company":"Nuvation Bio","sponsor":"Panacea Acquisition","pharmaFlowCategory":"D","amount":"$850.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Merger","leadProduct":"NUV-422","moa":"CDK","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nuvation Bio","amount2":0.84999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.84999999999999998,"dosageForm":"","sponsorNew":"Nuvation Bio \/ Panacea Acquisition","highestDevelopmentStatusID":"7","companyTruncated":"Nuvation B.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foghorn Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"FHD-286","moa":"Allosteric ATPase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Foghorn Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"4","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50 M Payment from Astrazeneca","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Monalizumab","moa":"NKG2A","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Innate Pharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Innate Pha.."},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"ImStem Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IMS001","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AgeX Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AgeX Therapeutics \/ ImStem Biotechnology","highestDevelopmentStatusID":"5","companyTruncated":"AgeX Thera.."},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus\u2019s Novel Anti-TIGIT Antibody, Plus Imfinzi\u00ae in Stage III NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Domvanalimab","moa":"TIGIT","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Bios.."},{"orgOrder":0,"company":"Insitro","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"$50.0 million","newsHeadline":"Insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery","graph3":"Insitro","amount2":2.1000000000000001,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"Insitro \/ Bristol Myers Squibb","highestDevelopmentStatusID":"2","companyTruncated":"Insitro \/ .."},{"orgOrder":0,"company":"Sanofi","sponsor":"Gavi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi and GSK to Support COVAX with 200 Million Doses of Adjuvanted, Recombinant Protein-Based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Adjuvanted COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Gavi","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ G.."},{"orgOrder":0,"company":"Axplora","sponsor":"Sensorion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"AAV vectors","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axplora","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Axplora \/ Sensorion","highestDevelopmentStatusID":"4","companyTruncated":"Axplora \/ .."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$1,245.0 million","upfrontCash":"$250.0 million","newsHeadline":"Sobi and Apellis Enter Collaboration for Global Co-Development and Ex-Us Commercialisation of Systemic Pegcetacoplan in Rare Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":1.25,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.25,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"CAM Capital","pharmaFlowCategory":"D","amount":"$27.4 million","upfrontCash":"Undisclosed","newsHeadline":"Primmune Therapeutics Announces $27.4 Million Series A Financing","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"PRTX007","moa":"TLR7","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ CAM Capital","highestDevelopmentStatusID":"6","companyTruncated":"Primmune T.."},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for Ramucirumab in the Ongoing Fides-03 Study with Derazantinib in Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Ramucirumab","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Basilea Pharmaceutica","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"12","companyTruncated":"Basilea Ph.."},{"orgOrder":0,"company":"LianBio","sponsor":"RA Capital","pharmaFlowCategory":"D","amount":"$310.0 million","upfrontCash":"Undisclosed","newsHeadline":"LianBio Announces $310 Million Crossover Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"Mavacamten","moa":"Cardiac Myosin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"LianBio","amount2":0.31,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.31,"dosageForm":"Capsule","sponsorNew":"LianBio \/ RA Capital","highestDevelopmentStatusID":"12","companyTruncated":"LianBio \/ .."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","amount":"$149.0 million","upfrontCash":"$50.0 million","newsHeadline":"Santen and Aerie Conclude Exclusive License Agreement for Rhopressa\u00ae and Rocklatan\u00ae in Japan and Several Other Asian Countries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.14999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Merck & Co","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Teams Up with Merck to Pair Keytruda with a Next-Gen IL-2 Candidate from the Synthorx Buyout","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"THOR-707","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co.."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Government of Japan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Takeda Pharmaceutical \/ Government of Japan","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"JT Pharmaceuticals","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"JT-09","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"JT Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JT Pharmaceuticals \/ Titan Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"JT Pharmac.."},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"AB2 Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Tadekinig alfa","moa":"IL-18","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ AB2 Bio","highestDevelopmentStatusID":"10","companyTruncated":"WuXi Biolo.."},{"orgOrder":0,"company":"XOMA","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$517.0 million","upfrontCash":"$37.0 million","newsHeadline":"XOMA Earns $25 Million Milestone Payment as Anti-TGF\u03b2 Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Gemcitabine Hydrochloride","moa":"TGF-beta","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"XOMA","amount2":0.52000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.52000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Novartis","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Nov.."},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Multiple Myeloma Research Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics Announce Investment to Advance Clinical Development of Natural Killer Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Allogeneic G-NK cell therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Indapta Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ Multiple Myeloma Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Indapta Th.."},{"orgOrder":0,"company":"Prokarium","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prokarium Closes $21M Series B Financing Round and Strengthens Board","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"Vesibax","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prokarium","amount2":0.02,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Prokarium \/ Korea Investment Partners","highestDevelopmentStatusID":"4","companyTruncated":"Prokarium .."},{"orgOrder":0,"company":"CellCentric","sponsor":"Morningside Venture Investments","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"CellCentric Raises $33m to Broaden Clinical Trials of its First-in-Class p300\/CBP Inhibitor, CCS1477","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"CCS1477","moa":"Acetyltransferases p300\/CBP","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CellCentric","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"CellCentric \/ Morningside Venture Investments","highestDevelopmentStatusID":"7","companyTruncated":"CellCentri.."},{"orgOrder":0,"company":"OncoBeta","sponsor":"NanoMab Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NanoMab and OncoBeta Outline the Pathway to a Strategic Alliance and Supply Agreement Focused on the Secure Supply of Rhenium-188","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Rhenium-188","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"OncoBeta","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoBeta \/ NanoMab","highestDevelopmentStatusID":"1","companyTruncated":"OncoBeta \/.."},{"orgOrder":0,"company":"Quantum Genomics","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$11.3 million","newsHeadline":"Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Firibastat","moa":"APA","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Quantum Genomics","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Quantum Genomics \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Ge.."},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"DOD Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"ATI-1701","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ology Bioservices","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Ology Bios.."},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"ADX-914","moa":"IL-7R","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0.059999999999999998,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Q32 Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ .."},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT-1 receptor","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"AstraZeneca","amount2":0.40000000000000002,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"AstraZenec.."},{"orgOrder":0,"company":"Oscine","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sana Biotechnology Announces Acquisition of Oscine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Acquisition","leadProduct":"Glial progenitor cell therapy","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oscine","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oscine \/ Sana Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Oscine \/ S.."},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series C Financing","leadProduct":"GC012F","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gracell Biotechnologies","amount2":0.10000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Gracell Biotechnologies \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Gracell Bi.."},{"orgOrder":0,"company":"Icosavax","sponsor":"Bill & Melinda Gates Foundation and Open Philanthropy","pharmaFlowCategory":"D","amount":"$16.5 million","upfrontCash":"Undisclosed","newsHeadline":"Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"IVX-411","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0.02,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Icosavax \/ Bill & Melinda Gates Foundation and Open Philanthropy","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"D","amount":"$103.0 million","upfrontCash":"$12.0 million","newsHeadline":"Ocular Therapeutix\u2122 and Affamed Therapeutics Announce License Agreement and Collaboration for Dextenza\u00ae AND Otx-Tic IN Asia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocular Therapeutix","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.10000000000000001,"dosageForm":"Ophthalmic Insert","sponsorNew":"Ocular Therapeutix \/ AffaMed Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Rugen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The McQuade Center for Strategic Research and Development Enters Collaboration Agreement with Rugen Holdings (Cayman) Limited","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"McQuade Center for Strategic Research and Development \/ Rugen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Ce.."},{"orgOrder":0,"company":"Genmab","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Agreement","leadProduct":"Camidanlumab tesirine","moa":"CD25","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Genmab","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genmab \/ ADC Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Genmab \/ A.."},{"orgOrder":0,"company":"Advanced Chemotherapy Technologies","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","amount":"$5.5 million","upfrontCash":"Undisclosed","newsHeadline":"Advanced Chemotherapy Technologies, Inc. Announces $5.5M Series A Financing Round led by Khosla Ventures","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"ACT-IOP-003","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Advanced Chemotherapy Technologies","amount2":0.01,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Advanced Chemotherapy Technologies \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Advanced C.."},{"orgOrder":0,"company":"Elpis Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elpis Biopharmaceuticals Debuts with Series A Funding and Establishment of Scientific Advisory Board","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"EPIM-001","moa":"IL-2R beta","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Elpis Biopharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Elpis Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Elpis Biop.."},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AGC Biologics and Horizon Therapeutics plc Expand Partnership","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Teprotumumab","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"AGC Biologics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AGC Biologics \/ Horizon Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"AGC Biolog.."},{"orgOrder":0,"company":"University of Campinas","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"BRAZIL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"WP1122","moa":"Glycolysis","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"University of Campinas","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"University of Campinas \/ Moleculin Biotech","highestDevelopmentStatusID":"4","companyTruncated":"University.."},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"$40.0 million","newsHeadline":"Fochon Pharmaceuticals Announces Licensing Agreement with Eli Lilly and Company for Novel Selective BCL-2 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"FCN-338","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fosun Pharmaceutical","amount2":0.44,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.44,"dosageForm":"","sponsorNew":"Fosun Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Fosun Phar.."},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Niclosamide","moa":"DNA","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tufts Medical Center","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Tufts Medical Center \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Tufts Medi.."},{"orgOrder":0,"company":"Synedgen","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synedgen Receives Supplemental NEI Funding To Identify Lead Development Candidate for Ocular Mustard Gas Injury Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Synedgen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synedgen \/ National Eye Institute","highestDevelopmentStatusID":"2","companyTruncated":"Synedgen \/.."},{"orgOrder":0,"company":"Minoryx Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"$29.0 million","upfrontCash":"Undisclosed","newsHeadline":"EIB Provides Minoryx with up to \u20ac25 Million to Support Development of Breakthrough Therapies in Orphan Neurodegenerative Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Leriglitazone","moa":"PPAR-gamma","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Minoryx Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Minoryx Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"Minoryx Th.."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Biotechnology Industry Research Assistance Council","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Partners with Department of Biotechnology - BIRAC for Sputnik V Vaccine Clinical Trials in India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Biotechnology Industry Research Assistance Council","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Mebias Discovery","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","amount":"$7.1 million","upfrontCash":"Undisclosed","newsHeadline":"Mebias Discovery Receives Grant from NIDA to Advance MEB-1170 as an Analgesic Drug Candidate for Prevention of Opioid Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Funding","leadProduct":"MEB-1170","moa":"Mu opoid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Mebias Discovery","amount2":0.01,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Mebias Discovery \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"Mebias Dis.."},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Indivior","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Partnership","leadProduct":"Nalmefene Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aptar Pharma","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Aptar Pharma \/ Opiant Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Aptar Phar.."},{"orgOrder":0,"company":"AbCellera","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Kodiak Sciences Enter Second Antibody Discovery Collaboration for Ophthalmology Targets","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Kodiak Sciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eli Lilly and Daiichi Sankyo Enter Commercialization Collaboration in Japan for Anti-CGRP Antibody Galcanezumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$990.0 million","upfrontCash":"$50.0 million","newsHeadline":"Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"PN-235","moa":"IL-23 receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Protagonist Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Protagonis.."},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","amount":"$91.0 million","upfrontCash":"Undisclosed","newsHeadline":"miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"VRDN-001","moa":"IGF-1R","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Miragen Therapeutics","amount2":0.089999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"Intravenous Injection","sponsorNew":"Miragen Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"5","companyTruncated":"Miragen Th.."},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of Debcoemagene Autoficel (D-Fi) Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dabocemagene Autoficel","moa":"COL7A1","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Castle Creek Biosciences","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Castle Creek Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Castle Cre.."},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc .."},{"orgOrder":0,"company":"Compugen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BMS-986207","moa":"PVRIG","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Compugen","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Compugen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Compugen \/.."},{"orgOrder":0,"company":"CytoDyn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Leronlimab","moa":"CCR5","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ .."},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant\u2019s Pivotal Phase 3 PSOARING Data for Tapinarof Cream in Adults with Plaque Psoriasis Selected at the 29th EADV Virtual Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant .."},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr Reddy's Plans to Complete Phase 3 Trial of Sputnik V Covid Vaccine by March End","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Gam-COVID-Vac","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"Dracen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dracen Pharmaceutical\u2019s DRP-104 Granted U.S. FDA Fast Track Designation for the treatment of Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"6-Diazo-5-oxo-L-norleucine","moa":"Glutamine","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dracen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dracen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dracen Pha.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data for Lilly's Bamlanivimab (LY-CoV555) in COVID-19 Outpatients Published in New England Journal of Medicine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bamlanivimab","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX\u00ae in Combination with OPDIVO\u00ae for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cabozantinib","moa":"VEGFR2","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pha.."},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Finch Therapeutics Presents Data from Its PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"CP101","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Finch Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Finch Ther.."},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galera Therapeutics Announces Interim Data from Pilot Phase 1\/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Galera Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Galera The.."},{"orgOrder":0,"company":"Gyroscope Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gyroscope's First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I\/II FOCUS Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"GT005","moa":"Complement Factor I production","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Gyroscope Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gyroscope Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Gyroscope .."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma to Highlight New Data in Medical Dermatology at EADV Virtual 2020","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bromelain","moa":"Prostaglandins","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"MediWound","amount2":0,"therapeuticAreaNew":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MediWound .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moderna on Track to Report Late-Stage COVID-19 Vaccine Data Next Month","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bempegaldesleukin","moa":"IL-2 beta receptor","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nektar Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nektar The.."},{"orgOrder":0,"company":"Novavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Novavax \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ .."},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ONC206","moa":"D2 receptor","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoceutics Inc","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoceutic.."},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oramed to Present Phase 2b Oral Insulin Data at American Association of Pharmaceutical Scientists 2020 PharmSci 360 Conference","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pha.."},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PT001","moa":"PD-L1","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Th.."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Late-Stage Coronavirus Vaccine Trial is Near Complete Enrollment with 42,000 Volunteers","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc.."},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Methylprednisolone","moa":"GBA1 gene","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Th.."},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington\u2019s Disease in the United States","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Pridopidine","moa":"Sigma-1 receptor","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Prilenia therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia t.."},{"orgOrder":0,"company":"Cornerstone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial of CPI-613\u00ae (Devimistat) for Relapsed or Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Devimistat","moa":"Pyruvate dehydrogenase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Cornerstone Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornerstone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Cornerston.."},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EXSCALATE4COV: Italian Medicines Agency (AIFA) authorizes Raloxifene Clinical Trial for Paucisymptomatic Covid-19 Patients treated at Home and in Medical Facilities","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor beta","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dompe Farmaceutici","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Dompe Farm.."},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree .."},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic\u2122 Oncology Product Candidate for HPV-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"RTX-321","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Rubius Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rubius Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Rubius The.."},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Japan's Shionogi Readies COVID-19 Vaccine for December Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Covid-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shionogi","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shionogi \/.."},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tipapkinogen sovacivec","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transgene","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transgene \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transgene .."},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, Starts Phase II Clinical Study HEART","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"TOTUM-070","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis .."},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna\u2019s mRNA Vaccine Against COVID-19 (mRNA-1273)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-1273","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Th.."},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Apitegromab","moa":"Myostatin activation","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Ro.."},{"orgOrder":0,"company":"Ellodi Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ellodi Pharmaceuticals Presents Phase 2b Data at ACG 2020 on the Safety and Efficacy of Maintenance Treatment Following Induction of Remission in Eosinophilic Esophagitis with APT-1011","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Ellodi Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"Steroid","amount2New":0,"dosageForm":"Orally Disintegrating Tablet","sponsorNew":"Ellodi Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ellodi Pha.."},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Dapansutrile","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Olatec Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Olatec Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Olatec The.."},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Convalescent Plasma Misses the Mark in Phase 2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Convalescent plasma","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Indian Council of Medical Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Indian Council of Medical Research \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Indian Cou.."},{"orgOrder":0,"company":"reVision Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"reVision Therapeutics Announces US FDA Grant of Rare Pediatric Disease and Orphan-Drug Designation for REV-0100 for Stargardt Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"REV-0100","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"reVision Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"reVision Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"reVision T.."},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Phoenix Tissue Repair","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BBP-589","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BridgeBio Pharma","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Phoenix Tissue Repair","highestDevelopmentStatusID":"8","companyTruncated":"BridgeBio .."},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It\u2019s ERSG Library In Two Leading Journals","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ELX-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eloxx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Phar.."},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expected Therapeutic Dose Levels Achieved in Phase I Study with ATOR-1017","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ATOR-1017","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alligator Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator .."},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ashvattha Therapeutics Selected to Present Virtual Poster at ACR Convergence 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxyl dendrimer","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha .."},{"orgOrder":0,"company":"iVeena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"iVeena Announces Positive Topline Results; IVMED-80 Advancing to Phase 3 Clinical Trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"IVMED-80","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"iVeena","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"iVeena \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"iVeena \/ N.."},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Reata Announces Publication of Results From Pivotal Moxie Trial of Omaveloxolone in Patients with Friedreich\u2019s Ataxia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Omaveloxolone","moa":"Nrf2","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Reata Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Reata Phar.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharmaceuticals Announces FDA Approval of EYSUVIS\u2122 for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic suspension","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BetterLife Provides Important Update on its Australian Clinical Study Design","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alfa-2b","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BetterLife Pharma","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Metered-Dose Inhaler","sponsorNew":"BetterLife Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BetterLife.."},{"orgOrder":0,"company":"Qualigen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Qualigen Therapeutics Receives Positive Pre-IND Response from FDA for the Clinical Development of AS1411 as a Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AS1411","moa":"Nucleolin","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Qualigen Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Qualigen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Qualigen T.."},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MeiraGTx to Present Data from Ongoing Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa at AAO 2020 Virtual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AAV2\/5-RPGR","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"MeiraGTx","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"MeiraGTx \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MeiraGTx \/.."},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"JadiCell\u2122 Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double Blind FDA Clinical Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"Stem Cell proliferation","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Therapeutic Solutions","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Therapeuti.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts For Priority Review LIBTAYO\u00ae (cemiplimab-RWLC) For Advanced Non-Small Cell Lung Cancer With PD-L1 Expression Of \u226550%","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cemiplimab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Kangtai Starts Mid-Stage Trial of its COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shenzhen Kangtai Biological Products \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen K.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Tecentriq in Combination with Avastin Approved in China for People with the Most Common form of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China's Clover Applies for Philippines COVID-19 Vaccine Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 S-Trimer vaccine","moa":"S-Trimer","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Clover Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Bio.."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data at EADV 2020 Confirm Lilly's Taltz\u00aeDemonstrates Sustained Long-Term Efficacy in Patients with Psoriasis and Psoriatic Arthritis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Ixekizumab","moa":"IL-17A","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asieris Announces Approval for Ph 1 Trial of Bladder Cancer Drug in Australia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"APL-1501","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Asieris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Ph.."},{"orgOrder":0,"company":"Equillium","sponsor":"Biocontrolled","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Equillium","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"12","companyTruncated":"Equillium .."},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EU Approves GlaxoSmithKline's Zejula as a First-Line Monotherapy Maintenance Treatment in Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Niraparib Tosylate","moa":"PARP1","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"GSK","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not .."},{"orgOrder":0,"company":"OncoSec Immunotherapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 spike protein plasmid DNA vaccine","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OncoSec Immunotherapies","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"OncoSec Immunotherapies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoSec Im.."},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regeneron Announces that Independent Monitoring Committee Recommends Halting REGN-COV2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"REGN10933","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron .."},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bellicum Announces Interim BPX-601 Data and Corporate Restructuring","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"BPX-601","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum P.."},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novo Nordisk Completed the Phase 2b Trial with Ziltivekimab in Cardiovascular Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","productSubType":"Peptide","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordi.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Osimertinib Mesylate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ .."},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Reports Results of Phase 2b Dose-Finding Study with Delgocitinib cream in Patients with Mild-to-Severe Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma.."},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia During Late-Breaking Session at EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Ph.."},{"orgOrder":0,"company":"Oligomerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oligomerix to Present at Clinical Trials on Alzheimer\u2019s Disease Conference & Life Sciences Summit","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Tau protein","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Oligomerix","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oligomerix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Oligomerix.."},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Humanigen Announces First Patient Dosed in NIH ACTIV-5\/Big Effect Trial Evaluating Lenzilumab\u2122 for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenzilumab","moa":"GCSF","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Humanigen","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humanigen .."},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"FX-322","moa":"","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Frequency Therapeutics","amount2":0,"therapeuticAreaNew":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Frequency Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Frequency .."},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"AR-15512","moa":"TRPM8","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Alcon Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alcon Inc .."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly .."},{"orgOrder":0,"company":"Promentis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promentis Pharmaceuticals to Present at the 11th Anniversary CNS Summit","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SXC-2023","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Promentis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Promentis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Promentis .."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UCB'S Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira\u00ae in Moderate-to-Severe Psoriasis Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Pre-filled Syringe Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma.."},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx .."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"Antibiotic","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"AnaBios","sponsor":"Orion Biotechnology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AnaBios and Orion Publish Scientific Article Describing Novel Cardiac Compound","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"ORM-11372","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"AnaBios","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AnaBios \/ Orion","highestDevelopmentStatusID":"4","companyTruncated":"AnaBios \/ .."},{"orgOrder":0,"company":"Seqirus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza Vaccine (QIVc) Efficacy in Children \u22652 to <
Market Place